1	By	O
2	contrast	O
3	,	O
4	secretory	O
5	HI	O
6	antibodies	O
7	were	O
8	not	O
9	demonstrated	O
10	at	O
11	the	O
12	onset	O
13	of	O
14	illness	O
15	in	O
16	any	O
17	of	O
18	the	O
19	patients	O
20	,	O
21	but	O
22	their	O
23	formation	O
24	started	O
25	early	O
26	and	O
27	the	O
28	antibodies	O
29	reached	O
30	maximal	O
31	levels	O
32	about	O
33	10	O
34	days	O
35	after	O
36	onset	O
37	of	O
38	illness	O
39	.	O
1	Gamma	O
2	glutamyl	O
3	transpeptidase	O
4	(	O
5	GGTP	O
6	)	O
7	activity	O
8	in	O
9	the	O
10	seminal	O
11	fluid	O
1	Abstracts	O
2	.	O
1	Removal	O
2	of	O
3	thick	O
4	,	O
5	permanently	O
6	altered	O
7	mucoas	O
8	is	O
9	recommended	O
10	even	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	squamous	O
16	epithelium	O
17	.	O
1	Sings	O
2	which	O
3	are	O
4	indicative	O
5	of	O
6	metaplastic	O
7	erythropoiesis	O
8	are	O
9	absent	O
10	.	O
1	Only	O
2	17	O
3	%	O
4	of	O
5	all	O
6	patients	O
7	admitted	O
8	it	O
9	at	O
10	all	O
11	times	O
12	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	cynomolgus	O
6	monkeys	O
7	are	O
8	either	O
9	less	O
10	sensitive	O
11	or	O
12	respond	O
13	differently	O
14	than	O
15	rhesus	O
16	monkeys	O
17	to	O
18	some	O
19	of	O
20	the	O
21	pharmacological	O
22	effects	O
23	of	O
24	norcocaine	O
25	.	O
1	The	O
2	effect	O
3	of	O
4	CBZ	O
5	and	O
6	DPH	O
7	can	O
8	be	O
9	explained	O
10	by	O
11	interference	O
12	with	O
13	thyroid	O
14	hormone	O
15	binding	O
16	to	O
17	TBG	O
18	combined	O
19	with	O
20	enzyme	O
21	-	O
22	induced	O
23	increased	O
24	metabolic	O
25	clearance	O
26	rate	O
27	of	O
28	thyroid	O
29	hormones	O
30	without	O
31	homeostatic	O
32	maintenance	O
33	of	O
34	premedication	O
35	levels	O
36	of	O
37	FT4	O
38	and	O
39	FT3	O
40	.	O
1	Variability	O
2	within	O
3	Down	O
4	'	O
5	s	O
6	syndrome	O
7	(	O
8	trisomy	O
9	-	O
10	21	O
11	):	O
12	empirically	O
13	observed	O
14	sex	O
15	differences	O
16	in	O
17	IQs	O
18	.	O
1	Radioimmunoassays	O
2	of	O
3	pregnenolone	O
4	,	O
5	progesterone	O
6	,	O
7	dehydroepiandrosterone	O
8	(	O
9	DHA	O
10	)	O
11	16	O
12	alpha	B
13	-	O
14	hydroxy	O
15	-	O
16	DHA	O
17	,	O
18	estriol	O
19	,	O
20	and	O
21	cortisol	O
22	were	O
23	performed	O
24	on	O
25	a	O
26	total	O
27	of	O
28	0	O
29	;	O
30	1	O
31	ml	O
32	;	O
33	of	O
34	fetal	O
35	plasma	O
36	,	O
37	collected	O
38	during	O
39	the	O
40	course	O
41	of	O
42	normal	O
43	vaginal	O
44	delivery	O
45	.	O
1	In	O
2	only	O
3	two	O
4	patients	O
5	were	O
6	we	O
7	able	O
8	to	O
9	demonstrate	O
10	changes	O
11	suggestive	O
12	of	O
13	pulmonary	O
14	metastases	O
15	any	O
16	earlier	O
17	with	O
18	a	O
19	99mTc	O
20	-	O
21	EHDP	O
22	scan	O
23	than	O
24	with	O
25	chest	O
26	radiographs	O
27	and	O
28	one	O
29	of	O
30	these	O
31	resolved	O
32	spontaneously	O
33	.	O
1	Accepting	O
2	arbitrarily	O
3	chosen	O
4	limits	O
5	of	O
6	maximized	O
7	errors	O
8	of	O
9	+/-	O
10	10	O
11	%,	O
12	it	O
13	could	O
14	be	O
15	shown	O
16	that	O
17	the	O
18	system	O
19	did	O
20	not	O
21	work	O
22	acceptably	O
23	when	O
24	the	O
25	mean	O
26	carbon	O
27	dioxide	O
28	concentration	O
29	was	O
30	below	O
31	1	O
32	.	O
33	5	O
34	vol	O
35	.%	O
36	within	O
37	the	O
38	fresh	O
39	gas	O
40	flow	O
41	rates	O
42	(	O
43	2	O
44	.	O
45	2	O
46	--	O
47	7	O
48	.	O
49	7	O
50	1	O
51	min	O
52	-	O
53	1	O
54	)	O
55	and	O
56	the	O
57	range	O
58	of	O
59	minute	O
60	ventilation	O
61	(	O
62	4	O
63	--	O
64	10	O
65	1	O
66	min	O
67	-	O
68	1	O
69	)	O
70	employed	O
71	.	O
1	The	O
2	carcass	O
3	of	O
4	a	O
5	great	O
6	horned	O
7	owl	O
8	(	O
9	Bubo	O
10	virginianus	O
11	),	O
12	which	O
13	had	O
14	been	O
15	found	O
16	moribund	O
17	in	O
18	southern	O
19	Ontario	O
20	,	O
21	was	O
22	presented	O
23	for	O
24	necropsy	O
25	.	O
1	The	O
2	incidence	O
3	of	O
4	hepatitis	O
5	B	O
6	antigen	B
7	following	O
8	transfusion	O
9	was	O
10	about	O
11	2	O
12	.	O
13	8	O
14	per	O
15	cent	O
16	.	O
1	The	O
2	decline	O
3	in	O
4	the	O
5	activity	O
6	of	O
7	cytochrome	O
8	oxidase	O
9	,	O
10	peroxidase	O
11	and	O
12	in	O
13	the	O
14	lipid	O
15	content	O
16	of	O
17	peripheral	O
18	neutrophils	O
19	was	O
20	followed	O
21	by	O
22	a	O
23	decrease	O
24	in	O
25	the	O
26	phagocytic	O
27	activity	O
28	.	O
1	XXI	O
2	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	serum	O
6	alpha1AT	O
7	quantitation	O
8	,	O
9	newborn	O
10	infants	O
11	may	O
12	be	O
13	separated	O
14	into	O
15	two	O
16	groups	O
17	,	O
18	characterized	O
19	respectively	O
20	by	O
21	concentrations	O
22	above	O
23	or	O
24	below	O
25	150	O
26	mg	O
27	%.	O
1	Changes	O
2	in	O
3	body	O
4	weight	O
5	and	O
6	agonistic	O
7	behavior	O
8	were	O
9	also	O
10	recorded	O
11	.	O
1	Use	O
2	of	O
3	radioactive	O
4	isotopes	O
5	in	O
6	the	O
7	chemistry	O
8	of	O
9	proteins	O
1	Antenatal	O
2	diagnosis	O
3	of	O
4	haematological	O
5	disorders	O
6	--'	O
7	1978	O
8	'.	O
1	Hepatic	O
2	oxygen	O
3	supply	O
4	and	O
5	selected	O
6	blood	O
7	parameters	O
8	were	O
9	recorded	O
10	in	O
11	fasted	O
12	male	O
13	rates	O
14	given	O
15	20	O
16	--	O
17	30	O
18	mg	O
19	/	O
20	kg	O
21	Escherichia	O
22	coli	O
23	endotoxin	O
24	intraperitoneally	O
25	.	O
1	A	O
2	study	O
3	of	O
4	the	O
5	comparative	O
6	efficacy	O
7	of	O
8	diflucortolone	O
9	valerate	O
10	0	O
11	.	O
12	3	O
13	%	O
14	ointment	O
15	and	O
16	clobetasol	O
17	propionate	O
18	0	O
19	.	O
20	05	O
21	%	O
22	ointment	O
23	.	O
1	Thus	O
2	,	O
3	the	O
4	inhibition	O
5	of	O
6	pepsin	O
7	in	O
8	human	O
9	gastric	O
10	juice	O
11	does	O
12	not	O
13	appear	O
14	to	O
15	have	O
16	a	O
17	major	O
18	influence	O
19	on	O
20	the	O
21	healing	O
22	of	O
23	duodenal	O
24	ulcer	O
25	.	O
1	Changes	O
2	in	O
3	tissue	O
4	PCO2	O
5	were	O
6	less	O
7	dramatic	O
8	and	O
9	did	O
10	not	O
11	vary	O
12	significantly	O
13	from	O
14	those	O
15	recorded	O
16	in	O
17	venous	O
18	blood	O
19	.	O
1	Recognition	O
2	of	O
3	emphysema	O
4	was	O
5	poor	O
6	when	O
7	radiographs	O
8	of	O
9	inadequate	O
10	quality	O
11	were	O
12	included	O
13	(	O
14	anteroposterior	O
15	films	O
16	or	O
17	films	O
18	from	O
19	patients	O
20	with	O
21	acute	O
22	or	O
23	chronic	O
24	lung	O
25	disease	O
26	).	O
1	A	O
2	total	O
3	of	O
4	57	O
5	patients	O
6	with	O
7	Hodgkin	O
8	'	O
9	s	O
10	disease	O
11	limited	O
12	to	O
13	above	O
14	the	O
15	diaphragm	O
16	(	O
17	Stages	O
18	I	O
19	and	O
20	II	O
21	,	O
22	A	O
23	and	O
24	B	O
25	)	O
26	were	O
27	treated	O
28	with	O
29	radiation	O
30	therapy	O
31	alone	O
32	at	O
33	the	O
34	University	O
35	of	O
36	Florida	O
37	between	O
38	1964	O
39	and	O
40	1974	O
41	.	O
1	Biliary	O
2	-	O
3	enteric	O
4	fistulas	O
1	Plasma	O
2	ion	O
3	changes	O
4	in	O
5	venous	O
6	blood	O
7	incubated	O
8	with	O
9	beta	B
10	receptor	I
11	blockers	O
12	and	O
13	subjected	O
14	to	O
15	tonometry	O
16	in	O
17	vitro	O
18	.	O
1	A	O
2	prospective	O
3	trail	O
4	comparing	O
5	hysterectomy	O
6	,	O
7	hysterectomy	O
8	plus	O
9	vaginal	O
10	radium	O
11	,	O
12	and	O
13	uterine	O
14	radium	O
15	plus	O
16	hysterectomy	O
17	in	O
18	stage	O
19	I	O
20	endometrial	O
21	carcinoma	O
22	.	O
1	Effect	O
2	of	O
3	intraventricular	O
4	administration	O
5	of	O
6	streptolysin	O
7	O	O
8	on	O
9	the	O
10	electroencephalogram	O
11	of	O
12	rabbits	O
13	.	O
1	The	O
2	biochemistry	O
3	of	O
4	amniotic	O
5	fluid	O
6	with	O
7	poor	O
8	fetal	O
9	growth	O
10	.	O
1	It	O
2	is	O
3	concluded	O
4	that	O
5	opiate	O
6	receptors	O
7	bordering	O
8	the	O
9	fourth	O
10	cerebral	O
11	ventricle	O
12	mediate	O
13	the	O
14	cardiovascular	O
15	and	O
16	hypnotic	O
17	action	O
18	of	O
19	fentanyl	O
20	.	O
1	Their	O
2	conduction	O
3	velocity	O
4	ranged	O
5	from	O
6	0	O
7	.	O
8	23	O
9	to	O
10	0	O
11	.	O
12	98	O
13	m	O
14	/	O
15	sec	O
16	(	O
17	group	O
18	C	O
19	).	O
1	The	O
2	major	O
3	urinary	O
4	metabolites	O
5	were	O
6	3	O
7	-(	O
8	3	O
9	-	O
10	carboxyphenyl	O
11	)-	O
12	5	O
13	-	O
14	hydroxymethyl	O
15	-	O
16	2	O
17	-	O
18	oxazolidinone	O
19	and	O
20	a	O
21	glucuronide	O
22	of	O
23	toloxatone	O
24	.	O
1	These	O
2	characteristics	O
3	indicated	O
4	the	O
5	pronounced	O
6	activity	O
7	of	O
8	collagenous	O
9	fiber	O
10	synthesis	O
11	and	O
12	the	O
13	matrix	O
14	of	O
15	the	O
16	osteoid	O
17	tissue	O
18	.	O
1	The	O
2	ventilation	O
3	did	O
4	not	O
5	increase	O
6	when	O
7	PACO2	O
8	was	O
9	increased	O
10	.	O
1	Study	O
2	on	O
3	re	O
4	-	O
5	establishment	O
6	of	O
7	ovulation	O
8	after	O
9	termination	O
10	of	O
11	sex	O
12	-	O
13	steroidal	O
14	treatment	O
15	--	O
16	compared	O
17	with	O
18	re	O
19	-	O
20	appearance	O
21	of	O
22	ovulation	O
23	after	O
24	abortion	O
25	and	O
26	premature	O
27	delivery	O
28	.	O
1	In	O
2	the	O
3	duodenum	O
4	a	O
5	small	O
6	part	O
7	of	O
8	the	O
9	administered	O
10	dose	O
11	was	O
12	transformed	O
13	to	O
14	3H	O
15	-	O
16	alpha	B
17	-	O
18	acetyldigoxin	O
19	.	O
1	One	O
2	-	O
3	third	O
4	of	O
5	the	O
6	men	O
7	with	O
8	azoospermia	O
9	and	O
10	with	O
11	sperm	O
12	density	O
13	of	O
14	less	O
15	than	O
16	10	O
17	million	O
18	had	O
19	marked	O
20	FSH	O
21	elevation	O
22	and	O
23	our	O
24	experience	O
25	confirms	O
26	the	O
27	work	O
28	of	O
29	others	O
30	that	O
31	this	O
32	indicates	O
33	a	O
34	poor	O
35	prognosis	O
36	.	O
1	Experimental	O
2	ischemic	O
3	heart	O
4	disease	O
5	induced	O
6	by	O
7	thromboxane	O
8	A2	O
9	in	O
10	rabbits	O
11	.	O
1	To	O
2	study	O
3	the	O
4	sensitivity	O
5	of	O
6	some	O
7	central	O
8	brain	O
9	structures	O
10	to	O
11	the	O
12	action	O
13	of	O
14	an	O
15	electromagnetic	O
16	field	O
17	of	O
18	decimeter	O
19	waves	O
20	(	O
21	EMF	O
22	of	O
23	DW	O
24	)	O
25	a	O
26	dynamic	O
27	investigation	O
28	of	O
29	single	O
30	unit	O
31	activity	O
32	was	O
33	undertaken	O
34	.	O
1	This	O
2	implies	O
3	that	O
4	the	O
5	groups	O
6	do	O
7	not	O
8	just	O
9	differ	O
10	along	O
11	one	O
12	dimension	O
13	,	O
14	but	O
15	along	O
16	three	O
17	dimensions	O
18	.	O
1	These	O
2	responses	O
3	were	O
4	compared	O
5	with	O
6	others	O
7	in	O
8	the	O
9	same	O
10	subjects	O
11	under	O
12	the	O
13	same	O
14	conditions	O
15	and	O
16	it	O
17	was	O
18	concluded	O
19	that	O
20	the	O
21	antihypertensive	O
22	effect	O
23	of	O
24	labetalol	O
25	is	O
26	explained	O
27	by	O
28	concurrent	O
29	blockade	O
30	of	O
31	alpha	B
32	-	O
33	and	O
34	beta	B
35	-	O
36	adrenoceptors	O
37	.	O
1	Action	O
2	of	O
3	strontium	O
4	-	O
5	90	O
6	and	O
7	metaphos	O
8	on	O
9	Cyprinus	O
10	carpio	O
1	Diagnosis	O
2	and	O
3	differential	O
4	diagnosis	O
1	Experimental	O
2	studies	O
3	on	O
4	virus	O
5	excretion	O
6	and	O
7	non	O
8	-	O
9	arthropod	O
10	transmission	O
11	.	O
1	Increased	O
2	urinary	O
3	riboflavin	O
4	excretion	O
5	resulting	O
6	from	O
7	boric	O
8	acid	O
9	ingestion	O
10	.	O
1	Looming	O
2	detectors	O
3	in	O
4	the	O
5	human	O
6	visual	O
7	pathway	O
8	.	O
1	Procion	O
2	yellow	O
3	dye	O
4	was	O
5	injected	O
6	intracellularly	O
7	into	O
8	large	O
9	auditory	O
10	fibers	O
11	of	O
12	goldfish	O
13	to	O
14	investigate	O
15	the	O
16	relationship	O
17	between	O
18	the	O
19	response	O
20	type	O
21	of	O
22	these	O
23	fibers	O
24	and	O
25	their	O
26	site	O
27	of	O
28	termination	O
29	in	O
30	the	O
31	saccular	O
32	macula	O
33	.	O
1	Silicosis	O
2	mortality	O
1	Pentane	O
2	and	O
3	ethane	O
4	,	O
5	which	O
6	arise	O
7	during	O
8	lipid	O
9	peroxidation	O
10	in	O
11	vivo	O
12	,	O
13	were	O
14	measured	O
15	by	O
16	gas	O
17	chromatography	O
18	in	O
19	breath	O
20	samples	O
21	of	O
22	rats	O
23	fed	O
24	for	O
25	8	O
26	weeks	O
27	a	O
28	vitamin	O
29	E	O
30	-	O
31	deficient	O
32	diet	O
33	to	O
34	which	O
35	had	O
36	been	O
37	added	O
38	0	O
39	,	O
40	11	O
41	,	O
42	or	O
43	40	O
44	IU	O
45	vitamin	O
46	E	O
47	acetate	O
48	per	O
49	kg	O
50	.	O
1	Althoug	O
2	RBF	O
3	tended	O
4	to	O
5	increase	O
6	after	O
7	the	O
8	therapy	O
9	,	O
10	there	O
11	was	O
12	no	O
13	statistically	O
14	significant	O
15	change	O
16	in	O
17	RBF	O
18	,	O
19	GFR	O
20	and	O
21	cardiac	O
22	output	O
23	.	O
1	Synovial	O
2	cysts	O
3	of	O
4	the	O
5	hip	O
6	joint	O
1	Because	O
2	decreases	O
3	in	O
4	the	O
5	disfluency	O
6	rates	O
7	of	O
8	stutterers	O
9	were	O
10	observed	O
11	during	O
12	the	O
13	presentation	O
14	of	O
15	all	O
16	three	O
17	stimulus	O
18	words	O
19	,	O
20	the	O
21	data	O
22	failed	O
23	to	O
24	support	O
25	the	O
26	operant	O
27	model	O
28	.	O
1	It	O
2	was	O
3	postulated	O
4	that	O
5	persistent	O
6	challenge	O
7	by	O
8	M	O
9	.	O
10	leprae	O
11	or	O
12	its	O
13	antigens	O
14	to	O
15	the	O
16	IgA	O
17	immunocytes	O
18	of	O
19	the	O
20	intestinal	O
21	epithelium	O
22	might	O
23	have	O
24	induced	O
25	tolerance	O
26	leading	O
27	to	O
28	IgA	O
29	deficiency	O
30	and	O
31	subsequent	O
32	subtotal	O
33	atrophy	O
34	of	O
35	the	O
36	intestinal	O
37	villi	O
38	in	O
39	the	O
40	patients	O
41	with	O
42	lepromatous	O
43	leprosy	O
44	.	O
1	The	O
2	histochemistry	O
3	and	O
4	ultrastructure	O
5	of	O
6	calcified	O
7	cerebellar	O
8	deposits	O
9	described	O
10	by	O
11	Tonge	O
12	et	O
13	al	O
14	.	O
1	As	O
2	expected	O
3	,	O
4	the	O
5	heparin	O
6	did	O
7	produce	O
8	increased	O
9	recalcification	O
10	times	O
11	and	O
12	the	O
13	development	O
14	of	O
15	occasional	O
16	subcutaneous	O
17	hematomas	O
18	.	O
1	Dietetics	O
2	of	O
3	childhood	O
4	-	O
5	and	O
6	juvenile	O
7	diabetes	O
1	The	O
2	December	O
3	armed	O
4	revolt	O
5	in	O
6	Moscow	O
7	and	O
8	the	O
9	paramedical	O
10	personnel	O
1	39	O
2	-	O
3	47	O
4	.	O
1	Absorption	O
2	varied	O
3	between	O
4	65	O
5	and	O
6	95	O
7	per	O
8	cent	O
9	,	O
10	with	O
11	a	O
12	mean	O
13	absorption	O
14	of	O
15	80	O
16	per	O
17	cent	O
18	,	O
19	in	O
20	both	O
21	pregnant	O
22	and	O
23	non	O
24	-	O
25	pregnant	O
26	subjects	O
27	.	O
1	Dialyzable	O
2	transfer	O
3	factor	O
4	.	O
1	Up	O
2	to	O
3	now	O
4	the	O
5	number	O
6	of	O
7	patients	O
8	examined	O
9	is	O
10	about	O
11	300	O
12	,	O
13	additionally	O
14	6	O
15	persons	O
16	who	O
17	underwent	O
18	binephrectomy	O
19	.	O
1	Treatment	O
2	with	O
3	heparin	O
4	,	O
5	plasminogen	O
6	activators	O
7	and	O
8	fibrinogenolytic	O
9	agents	O
10	was	O
11	disappointing	O
12	although	O
13	renal	O
14	function	O
15	has	O
16	stabilized	O
17	in	O
18	one	O
19	patient	O
20	on	O
21	long	O
22	term	O
23	oral	O
24	anticoagulant	O
25	therapy	O
26	.	O
1	Amikacin	O
2	was	O
3	used	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	56	O
9	serious	O
10	gram	O
11	-	O
12	negative	O
13	infections	O
14	in	O
15	54	O
16	patients	O
17	of	O
18	whom	O
19	47	O
20	survived	O
21	.	O
1	In	O
2	the	O
3	control	O
4	preparation	O
5	before	O
6	weight	O
7	was	O
8	allowed	O
9	to	O
10	increase	O
11	,	O
12	isogravimetric	O
13	capillary	O
14	pressure	O
15	(	O
16	Pci	O
17	)	O
18	averaged	O
19	8	O
20	mmHg	O
21	lower	O
22	than	O
23	colloid	O
24	osmotic	O
25	pressure	O
26	of	O
27	the	O
28	plasma	O
29	(	O
30	IIp	O
31	).	O
1	The	O
2	length	O
3	scales	O
4	of	O
5	the	O
6	turbulence	O
7	were	O
8	also	O
9	estimated	O
10	:	O
11	at	O
12	a	O
13	Reynolds	O
14	number	O
15	near	O
16	4	O
17	,	O
18	000	O
19	the	O
20	macroscale	O
21	is	O
22	about	O
23	1	O
24	.	O
25	25	O
26	mm	O
27	,	O
28	the	O
29	Taylor	O
30	microscale	O
31	is	O
32	about	O
33	0	O
34	.	O
35	85	O
36	mm	O
37	,	O
38	and	O
39	the	O
40	Kolmogoroff	O
41	scale	O
42	is	O
43	near	O
44	0	O
45	.	O
46	075	O
47	mm	O
48	.	O
1	Well	O
2	-	O
3	visualised	O
4	arteriograms	O
5	of	O
6	the	O
7	limbs	O
8	can	O
9	be	O
10	obtained	O
11	by	O
12	xeroradiography	O
13	after	O
14	rapid	O
15	manual	O
16	injection	O
17	of	O
18	contrast	O
19	-	O
20	medium	O
21	into	O
22	an	O
23	arm	O
24	vein	O
25	,	O
26	as	O
27	demonstrated	O
28	in	O
29	28	O
30	patients	O
31	.	O
1	The	O
2	mechanism	O
3	by	O
4	which	O
5	large	O
6	molecules	O
7	,	O
8	such	O
9	as	O
10	the	O
11	diphosphonate	O
12	99mTc	O
13	-	O
14	labeled	O
15	EHDP	O
16	or	O
17	99mTc	O
18	-	O
19	labeled	O
20	pyrophosphate	O
21	,	O
22	pass	O
23	through	O
24	capillaries	O
25	in	O
26	bone	O
27	is	O
28	by	O
29	passive	O
30	diffusion	O
31	.	O
1	Thus	O
2	analysis	O
3	indicated	O
4	no	O
5	reliable	O
6	evidence	O
7	that	O
8	conscious	O
9	presleep	O
10	suggestions	O
11	become	O
12	incorporated	O
13	into	O
14	dream	O
15	content	O
16	.	O
1	Levels	O
2	of	O
3	both	O
4	PGF	O
5	and	O
6	PGFM	O
7	were	O
8	significantly	O
9	higher	O
10	during	O
11	early	O
12	spontaneous	O
13	labour	O
14	,	O
15	at	O
16	a	O
17	cervical	O
18	dilatation	O
19	of	O
20	less	O
21	than	O
22	4	O
23	cm	O
24	,	O
25	than	O
26	before	O
27	the	O
28	onset	O
29	of	O
30	labour	O
31	.	O
1	The	O
2	most	O
3	common	O
4	cause	O
5	of	O
6	renal	O
7	deterioration	O
8	in	O
9	the	O
10	spinal	O
11	cord	O
12	injured	O
13	patient	O
14	is	O
15	irreversible	O
16	vesicoureteral	O
17	reflux	O
18	.	O
1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	the	O
6	rat	O
7	larynx	O
8	to	O
9	be	O
10	an	O
11	important	O
12	organ	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	irritancy	O
18	of	O
19	inhaled	O
20	materials	O
21	.	O
1	These	O
2	observed	O
3	drug	O
4	interactions	O
5	,	O
6	plus	O
7	the	O
8	known	O
9	effect	O
10	of	O
11	probenecid	O
12	to	O
13	block	O
14	secretion	O
15	of	O
16	PZA	O
17	,	O
18	have	O
19	to	O
20	be	O
21	considered	O
22	in	O
23	evaluating	O
24	the	O
25	effect	O
26	of	O
27	the	O
28	two	O
29	drugs	O
30	given	O
31	together	O
32	,	O
33	compared	O
34	to	O
35	the	O
36	effect	O
37	of	O
38	each	O
39	drug	O
40	given	O
41	separately	O
42	.	O
1	Circulatory	O
2	arrest	O
3	in	O
4	the	O
5	operating	O
6	room	O
7	.	O
1	Extramedullary	O
2	plasmacytoma	O
3	of	O
4	the	O
5	parotid	O
6	gland	O
1	Preflight	O
2	,	O
3	inflight	O
4	,	O
5	and	O
6	postflight	O
7	exercise	O
8	response	O
9	tests	O
10	were	O
11	conducted	O
12	on	O
13	the	O
14	astronauts	O
15	of	O
16	the	O
17	second	O
18	Skylab	O
19	mission	O
20	(	O
21	Skylab	O
22	3	O
23	)	O
24	as	O
25	part	O
26	of	O
27	an	O
28	evaluation	O
29	of	O
30	physiological	O
31	adaptation	O
32	to	O
33	long	O
34	-	O
35	term	O
36	weightlessness	O
37	.	O
1	Since	O
2	myoglobin	O
3	is	O
4	co	O
5	-	O
6	extracted	O
7	with	O
8	the	O
9	hemoglobin	O
10	,	O
11	the	O
12	2	O
13	heme	O
14	pigments	O
15	are	O
16	separated	O
17	in	O
18	one	O
19	portion	O
20	of	O
21	the	O
22	extract	O
23	by	O
24	precipitating	O
25	the	O
26	hemoglobin	O
27	in	O
28	an	O
29	85	O
30	%	O
31	(	O
32	NH4	O
33	)	O
34	2SO4	O
35	solution	O
36	.	O
1	With	O
2	the	O
3	help	O
4	of	O
5	a	O
6	nomogram	O
7	one	O
8	can	O
9	read	O
10	off	O
11	the	O
12	refraction	O
13	,	O
14	when	O
15	axis	O
16	length	O
17	and	O
18	corneal	O
19	curvature	O
20	are	O
21	known	O
22	.	O
1	Compared	O
2	to	O
3	controls	O
4	,	O
5	both	O
6	UB	O
7	and	O
8	OCS	O
9	rats	O
10	showed	O
11	a	O
12	small	O
13	but	O
14	significant	O
15	post	O
16	-	O
17	operative	O
18	reduction	O
19	in	O
20	the	O
21	nocturnality	O
22	of	O
23	drinking	O
24	.	O
1	Certain	O
2	characteristics	O
3	of	O
4	eye	O
5	changes	O
6	in	O
7	patients	O
8	with	O
9	pheochromocytoma	O
10	including	O
11	Sipple	O
12	'	O
13	s	O
14	syndrome	O
1	It	O
2	was	O
3	found	O
4	that	O
5	under	O
6	the	O
7	selected	O
8	conditions	O
9	a	O
10	linear	O
11	dependence	O
12	exists	O
13	between	O
14	the	O
15	betaI	O
16	%	O
17	value	O
18	and	O
19	lgC	O
20	within	O
21	the	O
22	range	O
23	of	O
24	0	O
25	.	O
26	5	O
27	--	O
28	10	O
29	mug	O
30	ruscogenin	O
31	.	O
1	Who	O
2	says	O
3	'	O
4	National	O
5	Health	O
6	Dis	O
7	-	O
8	service	O
9	'.	O
1	After	O
2	90	O
3	d	O
4	a	O
5	subsurface	O
6	,	O
7	radiolucent	O
8	caries	O
9	-	O
10	like	O
11	lesion	O
12	was	O
13	observed	O
14	in	O
15	two	O
16	specimens	O
17	only	O
18	.	O
1	Evidence	O
2	is	O
3	presented	O
4	that	O
5	Leber	O
6	'	O
7	s	O
8	military	O
9	aneurysm	O
10	retinitis	O
11	is	O
12	not	O
13	a	O
14	separate	O
15	entity	O
16	but	O
17	a	O
18	special	O
19	form	O
20	of	O
21	Coats	O
22	'	O
23	disease	O
24	.	O
1	The	O
2	authors	O
3	describe	O
4	the	O
5	technique	O
6	of	O
7	transverse	O
8	axial	O
9	tomography	O
10	of	O
11	the	O
12	spine	O
13	and	O
14	give	O
15	a	O
16	detailed	O
17	description	O
18	of	O
19	the	O
20	axial	O
21	anatomy	O
22	of	O
23	the	O
24	normal	O
25	lumbar	O
26	spine	O
27	from	O
28	L	O
29	-	O
30	4	O
31	to	O
32	the	O
33	sacrum	O
34	.	O
1	A	O
2	clinically	O
3	useful	O
4	diagnostic	O
5	method	O
6	has	O
7	been	O
8	developed	O
9	for	O
10	detecting	O
11	and	O
12	quantitating	O
13	periods	O
14	of	O
15	apnea	O
16	in	O
17	pediatric	O
18	patients	O
19	.	O
1	The	O
2	other	O
3	hypoglycaemic	O
4	patient	O
5	showed	O
6	an	O
7	exaggerated	O
8	insulin	B
9	release	O
10	in	O
11	response	O
12	to	O
13	tolbutamide	O
14	.	O
1	Risk	O
2	of	O
3	infection	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	fractures	O
1	Prolonged	O
2	heavy	O
3	work	O
4	effected	O
5	an	O
6	increase	O
7	of	O
8	10	O
9	.	O
10	3	O
11	plus	O
12	or	O
13	minus	O
14	0	O
15	.	O
16	9	O
17	mmHg	O
18	in	O
19	in	O
20	vivo	O
21	P50	O
22	(	O
23	7	O
24	.	O
25	30	O
26	PH	O
27	-	O
28	v	O
29	,	O
30	41	O
31	degrees	O
32	C	O
33	-	O
34	v	O
35	,	O
36	and	O
37	45	O
38	Pv	O
39	-	O
40	CO2	O
41	);	O
42	due	O
43	entirely	O
44	to	O
45	the	O
46	additive	O
47	effects	O
48	of	O
49	increased	O
50	venous	O
51	temperature	O
52	and	O
53	[	O
54	H	O
55	+].	O
1	A	O
2	clinical	O
3	,	O
4	serological	O
5	and	O
6	prognostic	O
7	study	O
1	At	O
2	the	O
3	very	O
4	high	O
5	dose	O
6	levels	O
7	used	O
8	,	O
9	sodium	O
10	saccharin	O
11	and	O
12	sodium	O
13	cyclamate	O
14	were	O
15	weak	O
16	solitary	O
17	carcinogens	O
18	producing	O
19	4	O
20	/	O
21	253	O
22	and	O
23	3	O
24	/	O
25	228	O
26	bladder	O
27	tumours	O
28	respectively	O
29	,	O
30	and	O
31	the	O
32	first	O
33	of	O
34	these	O
35	tumours	O
36	did	O
37	not	O
38	appear	O
39	for	O
40	more	O
41	than	O
42	80	O
43	weeks	O
44	.	O
1	Glucose	O
2	-	O
3	6	O
4	-	O
5	phosphate	O
6	dehydrogenase	O
7	(	O
8	G	O
9	-	O
10	6	O
11	-	O
12	PD	O
13	)	O
14	deficiency	O
15	in	O
16	the	O
17	newborn	O
18	.	O
1	Prostaglandins	O
2	F	O
3	(	O
4	PGF	O
5	)	O
6	were	O
7	measured	O
8	in	O
9	uterine	O
10	vein	O
11	,	O
12	ovarian	O
13	artery	O
14	,	O
15	and	O
16	jugular	O
17	vein	O
18	plasma	O
19	and	O
20	in	O
21	the	O
22	endometrial	O
23	tissues	O
24	at	O
25	various	O
26	times	O
27	during	O
28	the	O
29	bovine	O
30	estrous	O
31	cycle	O
32	,	O
33	and	O
34	were	O
35	compared	O
36	to	O
37	peripheral	O
38	plasma	O
39	progesterone	O
40	levels	O
41	.	O
1	The	O
2	attainment	O
3	of	O
4	sexual	O
5	maturity	O
6	in	O
7	terms	O
8	of	O
9	secondary	O
10	sexual	O
11	characteristics	O
12	,	O
13	the	O
14	production	O
15	of	O
16	spermatozoa	O
17	in	O
18	the	O
19	male	O
20	,	O
21	and	O
22	the	O
23	cyclical	O
24	female	O
25	pattern	O
26	with	O
27	release	O
28	of	O
29	ova	O
30	are	O
31	end	O
32	-	O
33	points	O
34	of	O
35	the	O
36	developmental	O
37	process	O
38	.	O
1	Following	O
2	retransfusion	O
3	,	O
4	the	O
5	affected	O
6	epithelial	O
7	lining	O
8	appeared	O
9	greatly	O
10	distended	O
11	over	O
12	the	O
13	oedematous	O
14	lamina	O
15	propria	O
16	,	O
17	with	O
18	almost	O
19	complete	O
20	loss	O
21	of	O
22	structural	O
23	detail	O
24	.	O
1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	4	O
7	groups	O
8	receiving	O
9	NLA	O
10	II	O
11	with	O
12	or	O
13	without	O
14	nalorphine	O
15	,	O
16	morphine	O
17	or	O
18	Micoren	O
19	.	O
1	The	O
2	alterations	O
3	of	O
4	5	O
5	-	O
6	HT	O
7	and	O
8	5	O
9	-	O
10	HIAA	O
11	levels	O
12	in	O
13	several	O
14	regions	O
15	of	O
16	the	O
17	brain	O
18	under	O
19	the	O
20	conditions	O
21	examined	O
22	may	O
23	indicate	O
24	that	O
25	IDPN	O
26	'	O
27	s	O
28	neurotoxicity	O
29	primarily	O
30	affects	O
31	5	O
32	-	O
33	HT	O
34	-	O
35	containing	O
36	neurones	O
37	.	O
1	(	O
2	5	O
3	)	O
4	An	O
5	increase	O
6	in	O
7	leukocyte	O
8	-	O
9	counts	O
10	occurred	O
11	on	O
12	the	O
13	administration	O
14	of	O
15	serum	O
16	obtained	O
17	from	O
18	rabbit	O
19	during	O
20	phase	O
21	-	O
22	2	O
23	.	O
1	Reduction	O
2	in	O
3	dosage	O
4	restored	O
5	normal	O
6	taste	O
7	sense	O
8	in	O
9	all	O
10	three	O
11	,	O
12	but	O
13	in	O
14	two	O
15	the	O
16	drug	O
17	had	O
18	to	O
19	be	O
20	discontinued	O
21	because	O
22	of	O
23	persisting	O
24	high	O
25	transaminase	O
26	levels	O
27	.	O
1	Her	O
2	serum	O
3	FT3	O
4	concentration	O
5	was	O
6	,	O
7	however	O
8	,	O
9	much	O
10	higher	O
11	than	O
12	the	O
13	ranges	O
14	in	O
15	normal	O
16	pregnancy	O
17	or	O
18	in	O
19	GTD	O
20	patients	O
21	without	O
22	clinical	O
23	hyperthyroidism	O
24	.	O
1	Biohydrogenation	O
2	of	O
3	linoleic	O
4	acid	O
5	into	O
6	octadecenoic	O
7	acid	O
8	was	O
9	observed	O
10	.	O
1	Prospects	O
2	for	O
3	controlled	O
4	-	O
5	delivery	O
6	systems	O
7	.	O
1	The	O
2	mean	O
3	(+/-	O
4	SD	O
5	)	O
6	PaO2	O
7	increased	O
8	from	O
9	80	O
10	.	O
11	8	O
12	+/-	O
13	26	O
14	.	O
15	9	O
16	mmHg	O
17	before	O
18	to	O
19	89	O
20	.	O
21	8	O
22	+/-	O
23	27	O
24	.	O
25	3	O
26	mmHg	O
27	after	O
28	the	O
29	infusion	O
30	(	O
31	P	O
32	<	O
33	0	O
34	.	O
35	05	O
36	)	O
37	and	O
38	the	O
39	PaCO2	O
40	decreased	O
41	from	O
42	42	O
43	.	O
44	4	O
45	+/-	O
46	8	O
47	.	O
48	3	O
49	to	O
50	39	O
51	.	O
52	6	O
53	+/-	O
54	7	O
55	.	O
56	9	O
57	mmHg	O
58	(	O
59	P	O
60	<	O
61	0	O
62	.	O
63	05	O
64	).	O
1	A	O
2	statistically	O
3	significant	O
4	improvement	O
5	due	O
6	to	O
7	the	O
8	administration	O
9	of	O
10	Bromergon	O
11	was	O
12	observed	O
13	in	O
14	symptoms	O
15	associated	O
16	with	O
17	overreactiveness	O
18	to	O
19	normal	O
20	prolactin	O
21	levels	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	abdominal	O
28	tension	O
29	,	O
30	edema	O
31	,	O
32	weight	O
33	gain	O
34	and	O
35	breast	O
36	tenderness	O
37	.	O
1	In	O
2	the	O
3	absence	O
4	of	O
5	histological	O
6	criteria	O
7	,	O
8	which	O
9	it	O
10	is	O
11	difficult	O
12	to	O
13	demand	O
14	in	O
15	view	O
16	of	O
17	the	O
18	variability	O
19	of	O
20	results	O
21	and	O
22	potential	O
23	dangers	O
24	of	O
25	endomyocardial	O
26	biopsy	O
27	involving	O
28	such	O
29	thin	O
30	and	O
31	fragile	O
32	ventricular	O
33	walls	O
34	,	O
35	the	O
36	diagnosis	O
37	of	O
38	ACRV	O
39	is	O
40	based	O
41	upon	O
42	the	O
43	concomitant	O
44	existence	O
45	of	O
46	:	O
47	(	O
48	1	O
49	)	O
50	electrophysiological	O
51	criteria	O
52	:	O
53	ventricular	O
54	arrhythmias	O
55	,	O
56	in	O
57	particular	O
58	sustained	O
59	monomorphous	O
60	VT	O
61	,	O
62	with	O
63	the	O
64	particular	O
65	feature	O
66	of	O
67	a	O
68	very	O
69	high	O
70	degree	O
71	of	O
72	sensitivity	O
73	to	O
74	adrenergic	O
75	stimulation	O
76	(	O
77	exercise	O
78	),	O
79	the	O
80	existence	O
81	of	O
82	late	O
83	potentials	O
84	on	O
85	the	O
86	high	O
87	amplification	O
88	ECG	O
89	,	O
90	a	O
91	highly	O
92	specific	O
93	sign	O
94	,	O
95	though	O
96	unfortunately	O
97	of	O
98	poor	O
99	sensitivity	O
100	in	O
101	localized	O
102	froms	O
103	,	O
104	those	O
105	which	O
106	are	O
107	most	O
108	difficult	O
109	to	O
110	identify	O
111	(	O
112	2	O
113	);	O
114	segmentary	O
115	morphological	O
116	and	O
117	kinetic	O
118	RV	O
119	abnormalities	O
120	,	O
121	most	O
122	often	O
123	resulting	O
124	in	O
125	localized	O
126	akinetic	O
127	or	O
128	dyskinetic	O
129	parietal	O
130	vaulting	O
131	,	O
132	with	O
133	stasis	O
134	""""	O
135	in	O
136	situ	O
137	"""."	O
1	The	O
2	target	O
3	contained	O
4	between	O
5	positions	O
6	-	O
7	403	O
8	and	O
9	-	O
10	125	O
11	acts	O
12	independently	O
13	of	O
14	orientation	O
15	,	O
16	in	O
17	different	O
18	cell	O
19	types	O
20	and	O
21	species	O
22	,	O
23	and	O
24	in	O
25	the	O
26	context	O
27	of	O
28	a	O
29	heterologous	O
30	promoter	O
31	.	O
1	These	O
2	studies	O
3	show	O
4	that	O
5	UCRBP	O
6	binds	O
7	to	O
8	various	O
9	target	O
10	motifs	O
11	that	O
12	are	O
13	distinct	O
14	from	O
15	the	O
16	UCR	O
17	motif	O
18	:	O
19	the	O
20	adeno	O
21	-	O
22	associated	O
23	virus	O
24	P5	O
25	promoter	O
26	and	O
27	elements	O
28	in	O
29	the	O
30	immunoglobulin	O
31	light	O
32	-	O
33	and	O
34	heavy	O
35	-	O
36	chain	O
37	genes	O
38	,	O
39	as	O
40	well	O
41	as	O
42	elements	O
43	in	O
44	ribosomal	O
45	protein	O
46	genes	O
47	.	O
1	Drosophila	O
2	UbcD1	O
3	encodes	O
4	a	O
5	highly	O
6	conserved	O
7	ubiquitin	O
8	-	O
9	conjugating	O
10	enzyme	O
11	involved	O
12	in	O
13	selective	O
14	protein	O
15	degradation	O
16	.	O
1	Comparison	O
2	with	O
3	the	O
4	sequence	O
5	databanks	O
6	show	O
7	that	O
8	Tactile	O
9	is	O
10	a	O
11	member	O
12	of	O
13	the	O
14	immunoglobulin	O
15	gene	O
16	superfamily	O
17	,	O
18	with	O
19	similarity	O
20	to	O
21	Drosophila	O
22	amalgam	O
23	,	O
24	the	O
25	melanoma	O
26	Ag	O
27	MUC	O
28	-	O
29	18	O
30	,	O
31	members	O
32	of	O
33	the	O
34	carcinoembryonic	O
35	Ag	O
36	family	O
37	,	O
38	the	O
39	poliovirus	O
40	receptor	B
41	,	O
42	and	O
43	the	O
44	neural	O
45	cell	O
46	adhesion	O
47	molecule	O
48	.	O
1	Analysis	O
2	of	O
3	nucleotide	O
4	sequence	O
5	of	O
6	the	O
7	rightmost	O
8	43	O
9	kbp	O
10	of	O
11	herpesvirus	O
12	saimiri	O
13	(	O
14	HVS	O
15	)	O
16	L	O
17	-	O
18	DNA	O
19	:	O
20	general	O
21	conservation	O
22	of	O
23	genetic	O
24	organization	O
25	between	O
26	HVS	O
27	and	O
28	Epstein	O
29	-	O
30	Barr	O
31	virus	O
32	.	O
1	Two	O
2	points	O
3	are	O
4	indicated	O
5	:	O
6	first	O
7	,	O
8	the	O
9	photosensitized	O
10	damage	O
11	of	O
12	YHPD	O
13	is	O
14	interrelated	O
15	to	O
16	not	O
17	only	O
18	1O2	O
19	,	O
20	but	O
21	also	O
22	free	O
23	radicals	O
24	(	O
25	O2	O
26	-.	O
27	.	O
28	OH	O
29	and	O
30	YHPD	O
31	-.);	O
32	second	O
33	,	O
34	although	O
35	the	O
36	photosensitized	O
37	damage	O
38	of	O
39	YHPD	O
40	is	O
41	stronger	O
42	than	O
43	that	O
44	of	O
45	BHPD	O
46	,	O
47	yet	O
48	the	O
49	photosensitized	O
50	damage	O
51	is	O
52	negatively	O
53	correlated	O
54	to	O
55	the	O
56	yield	O
57	of	O
58	1O2	O
59	but	O
60	positively	O
61	correlated	O
62	to	O
63	those	O
64	of	O
65	O2	O
66	-.	O
67	and	O
68	OH	O
69	.	O
1	After	O
2	the	O
3	first	O
4	28	O
5	patients	O
6	vincristine	O
7	was	O
8	replaced	O
9	by	O
10	teniposide	O
11	(	O
12	VM	O
13	-	O
14	26	O
15	)	O
16	due	O
17	to	O
18	neurotoxicity	O
19	.	O
1	Possible	O
2	roles	O
3	of	O
4	RAD5	O
5	putative	O
6	ATPase	B
7	/	O
8	DNA	O
9	helicase	O
10	activity	O
11	in	O
12	DNA	O
13	repair	O
14	and	O
15	in	O
16	the	O
17	maintenance	O
18	of	O
19	wild	O
20	-	O
21	type	O
22	rates	O
23	of	O
24	instability	O
25	of	O
26	simple	O
27	repetitive	O
28	sequences	O
29	are	O
30	discussed	O
31	.	O
1	Susceptibilities	O
2	of	O
3	540	O
4	anaerobic	O
5	gram	O
6	-	O
7	negative	O
8	bacilli	O
9	to	O
10	amoxicillin	O
11	,	O
12	amoxicillin	O
13	-	O
14	BRL	O
15	42715	O
16	,	O
17	amoxicillin	O
18	-	O
19	clavulanate	O
20	,	O
21	temafloxacin	O
22	,	O
23	and	O
24	clindamycin	O
25	.	O
1	In	O
2	rats	O
3	anaesthetized	O
4	with	O
5	+-	O
6	chloralose	O
7	the	O
8	changes	O
9	in	O
10	extracellular	O
11	pH	O
12	and	O
13	K	O
14	+	O
15	in	O
16	spinal	O
17	cord	O
18	dorsal	O
19	horn	O
20	were	O
21	studied	O
22	using	O
23	pH	O
24	and	O
25	K	O
26	+	O
27	ion	O
28	-	O
29	selective	O
30	electrodes	O
31	.	O
1	Truncation	O
2	variants	O
3	of	O
4	peptides	O
5	isolated	O
6	from	O
7	MHC	O
8	class	O
9	II	O
10	molecules	O
11	suggest	O
12	sequence	O
13	motifs	O
14	.	O
1	Intermediate	O
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	TnI	O
10	enhancers	O
11	containing	O
12	E	O
13	-	O
14	boxes	O
15	derived	O
16	from	O
17	the	O
18	MCK	O
19	left	O
20	E	O
21	-	O
22	box	O
23	site	O
24	or	O
25	from	O
26	the	O
27	Ig	O
28	kappa	B
29	E2	O
30	E	O
31	-	O
32	box	O
33	.	O
1	The	O
2	basal	O
3	promoter	O
4	elements	O
5	of	O
6	murine	O
7	cytochrome	O
8	c	B
9	oxidase	O
10	subunit	O
11	IV	O
12	gene	O
13	consist	O
14	of	O
15	tandemly	O
16	duplicated	O
17	ets	O
18	motifs	O
19	that	O
20	bind	O
21	to	O
22	GABP	O
23	-	O
24	related	O
25	transcription	O
26	factors	O
27	.	O
1	A	O
2	total	O
3	of	O
4	281	O
5	patients	O
6	were	O
7	divided	O
8	into	O
9	groups	O
10	according	O
11	to	O
12	their	O
13	clinical	O
14	diagnosis	O
15	and	O
16	were	O
17	examined	O
18	using	O
19	capnography	O
20	,	O
21	spirometry	O
22	and	O
23	blood	O
24	-	O
25	gas	O
26	analysis	O
27	.	O
1	Characterization	O
2	of	O
3	the	O
4	regulon	O
5	controlled	O
6	by	O
7	the	O
8	leucine	O
9	-	O
10	responsive	O
11	regulatory	O
12	protein	O
13	in	O
14	Escherichia	O
15	coli	O
16	.	O
1	Mutational	O
2	studies	O
3	revealed	O
4	that	O
5	it	O
6	was	O
7	the	O
8	homeodomain	O
9	binding	O
10	site	O
11	II	O
12	sequence	O
13	that	O
14	was	O
15	required	O
16	for	O
17	this	O
18	regulation	O
19	.	O
1	The	O
2	pulmonary	O
3	effects	O
4	observed	O
5	,	O
6	became	O
7	more	O
8	pronounced	O
9	with	O
10	increasing	O
11	NO2	O
12	concentrations	O
13	(	O
14	0	O
15	,	O
16	25	O
17	,	O
18	75	O
19	,	O
20	125	O
21	,	O
22	175	O
23	or	O
24	200	O
25	ppm	O
26	,	O
27	1	O
28	ppm	O
29	NO2	O
30	=	O
31	1	O
32	.	O
33	88	O
34	mg	O
35	m	O
36	-	O
37	3	O
38	NO2	O
39	)	O
40	and	O
41	exposure	O
42	times	O
43	(	O
44	5	O
45	,	O
46	10	O
47	,	O
48	20	O
49	or	O
50	30	O
51	min	O
52	).	O
1	The	O
2	subunit	O
3	protein	O
4	of	O
5	curli	O
6	was	O
7	highly	O
8	homologous	O
9	at	O
10	its	O
11	amino	O
12	terminus	O
13	to	O
14	SEF	O
15	-	O
16	17	O
17	,	O
18	the	O
19	subunit	O
20	protein	O
21	of	O
22	thin	O
23	,	O
24	aggregative	O
25	fimbriae	O
26	of	O
27	Salmonella	O
28	enteritidis	O
29	27655	O
30	strain	O
31	3b	O
32	,	O
33	suggesting	O
34	that	O
35	these	O
36	fibres	O
37	form	O
38	a	O
39	novel	O
40	class	O
41	of	O
42	surface	O
43	organelles	O
44	on	O
45	enterobacteria	O
46	.	O
1	Substitution	O
2	of	O
3	the	O
4	DR1	O
5	beta	B
6	chain	O
7	with	O
8	H	O
9	-	O
10	2E	O
11	beta	B
12	k	O
13	led	O
14	to	O
15	a	O
16	dramatic	O
17	loss	O
18	of	O
19	recognition	O
20	;	O
21	alpha	B
22	chain	O
23	substitution	O
24	had	O
25	a	O
26	less	O
27	marked	O
28	effect	O
29	.	O
1	These	O
2	sites	O
3	are	O
4	also	O
5	potential	O
6	keratan	O
7	sulfate	O
8	attachment	O
9	sites	O
10	.	O
1	We	O
2	propose	O
3	that	O
4	plasmids	O
5	of	O
6	the	O
7	pLS1	O
8	family	O
9	(	O
10	pE194	O
11	,	O
12	pADB201	O
13	,	O
14	and	O
15	pLB4	O
16	)	O
17	share	O
18	functional	O
19	and	O
20	structural	O
21	characteristics	O
22	for	O
23	the	O
24	regulation	O
25	of	O
26	their	O
27	copy	O
28	numbers	O
29	.	O
1	Between	O
2	acoR	O
3	and	O
4	acoXABC	O
5	,	O
6	two	O
7	different	O
8	types	O
9	of	O
10	sequences	O
11	with	O
12	dual	O
13	rotational	O
14	symmetry	O
15	[	O
16	CAC	O
17	-(	O
18	N11	O
19	to	O
20	N18	O
21	)-	O
22	GTG	O
23	and	O
24	TGT	O
25	-(	O
26	N10	O
27	to	O
28	N14	O
29	)-	O
30	ACA	O
31	]	O
32	were	O
33	found	O
34	;	O
35	these	O
36	sequences	O
37	are	O
38	similar	O
39	to	O
40	NtrC	O
41	and	O
42	NifA	O
43	upstream	O
44	activator	O
45	sequences	O
46	,	O
47	respectively	O
48	.	O
1	Although	O
2	the	O
3	effects	O
4	of	O
5	the	O
6	calcium	O
7	supplement	O
8	or	O
9	calcium	O
10	antagonist	O
11	alone	O
12	were	O
13	significant	O
14	,	O
15	such	O
16	hypotensive	O
17	responses	O
18	were	O
19	not	O
20	optimal	O
21	or	O
22	predictable	O
23	or	O
24	clearly	O
25	dose	O
26	-	O
27	dependent	O
28	.	O
1	Furthermore	O
2	it	O
3	was	O
4	suggested	O
5	that	O
6	FK506	O
7	plasma	O
8	levels	O
9	were	O
10	concerned	O
11	with	O
12	the	O
13	appearance	O
14	of	O
15	side	O
16	effect	O
17	.	O
1	The	O
2	ARG	O
3	SH2	O
4	domain	O
5	exhibited	O
6	relatively	O
7	weak	O
8	affinity	O
9	for	O
10	BCR	O
11	and	O
12	was	O
13	determined	O
14	to	O
15	bind	O
16	about	O
17	10	O
18	-	O
19	fold	O
20	less	O
21	strongly	O
22	than	O
23	the	O
24	ABL	O
25	SH2	O
26	domain	O
27	.	O
1	We	O
2	report	O
3	the	O
4	successful	O
5	use	O
6	of	O
7	electroconvulsive	O
8	therapy	O
9	for	O
10	treatment	O
11	of	O
12	severe	O
13	depression	O
14	in	O
15	a	O
16	young	O
17	man	O
18	with	O
19	adult	O
20	GM2	O
21	gangliosidosis	O
22	.	O
1	Entry	O
2	of	O
3	yeast	O
4	cells	O
5	into	O
6	the	O
7	mitotic	O
8	cell	O
9	cycle	O
10	(	O
11	Start	O
12	)	O
13	involves	O
14	a	O
15	form	O
16	of	O
17	the	O
18	CDC28	O
19	kinase	B
20	that	O
21	associates	O
22	with	O
23	G1	O
24	-	O
25	specific	O
26	cyclins	O
27	encoded	O
28	by	O
29	CLN1	O
30	and	O
31	CLN2	O
32	(	O
33	ref	O
34	.	O
1	Again	O
2	residue	O
3	Glu	O
4	-	O
5	381	O
6	of	O
7	beta	B
8	was	O
9	notably	O
10	reduced	O
11	and	O
12	no	O
13	missing	O
14	residue	O
15	from	O
16	the	O
17	epsilon	O
18	peptide	O
19	could	O
20	be	O
21	identified	O
22	,	O
23	but	O
24	the	O
25	peptide	O
26	sequence	O
27	limited	O
28	the	O
29	possible	O
30	choices	O
31	to	O
32	Ser	O
33	-	O
34	106	O
35	,	O
36	Ser	O
37	-	O
38	107	O
39	,	O
40	or	O
41	Ser	O
42	-	O
43	108	O
44	.	O
1	From	O
2	all	O
3	clinically	O
4	important	O
5	yeasts	O
6	species	O
7	,	O
8	a	O
9	total	O
10	of	O
11	96	O
12	%	O
13	were	O
14	identified	O
15	by	O
16	ATB	O
17	method	O
18	according	O
19	to	O
20	conventional	O
21	methods	O
22	.	O
1	The	O
2	RNase	B
3	MRP	O
4	RNA	O
5	gene	O
6	was	O
7	deleted	O
8	by	O
9	insertional	O
10	replacement	O
11	and	O
12	found	O
13	to	O
14	be	O
15	essential	O
16	for	O
17	cellular	O
18	viability	O
19	,	O
20	indicating	O
21	a	O
22	critical	O
23	nuclear	O
24	role	O
25	for	O
26	RNase	B
27	MRP	O
28	.	O
1	In	O
2	humans	O
3	,	O
4	four	O
5	AMP	O
6	deaminase	O
7	variants	O
8	,	O
9	termed	O
10	M	O
11	(	O
12	muscle	O
13	),	O
14	L	O
15	(	O
16	liver	O
17	),	O
18	E1	O
19	,	O
20	and	O
21	E2	O
22	(	O
23	erythrocyte	O
24	)	O
25	can	O
26	be	O
27	distinguished	O
28	by	O
29	a	O
30	variety	O
31	of	O
32	biochemical	O
33	and	O
34	immunological	O
35	criteria	O
36	.	O
1	Western	O
2	blot	O
3	analyses	O
4	detect	O
5	anti	B
6	-	O
7	E	O
8	-	O
9	specific	O
10	immunoreactivity	O
11	in	O
12	affinity	O
13	-	O
14	purified	O
15	extracts	O
16	derived	O
17	from	O
18	the	O
19	bacterial	O
20	expression	O
21	of	O
22	a	O
23	truncated	O
24	AMPD3	O
25	cDNA	O
26	.	O
1	Chronic	O
2	hepatitis	O
3	B	O
4	in	O
5	adopted	O
6	Romanian	O
7	children	O
8	.	O
1	Autopsy	O
2	demonstrated	O
3	good	O
4	survival	O
5	of	O
6	the	O
7	transplanted	O
8	cells	O
9	with	O
10	good	O
11	integration	O
12	with	O
13	the	O
14	brain	O
15	of	O
16	the	O
17	recipient	O
18	and	O
19	traces	O
20	of	O
21	positive	O
22	immunocytochemical	O
23	reaction	O
24	for	O
25	tyrosine	O
26	hydroxylase	O
27	.	O
1	The	O
2	effect	O
3	of	O
4	sodium	O
5	18	O
6	beta	B
7	-	O
8	glycyrrhetate	O
9	(	O
10	SGA	O
11	)	O
12	on	O
13	experimental	O
14	arrhythmia	O
15	was	O
16	investigated	O
17	.	O
1	Substitution	O
2	of	O
3	either	O
4	Val33	O
5	(	O
6	by	O
7	Gly	O
8	)	O
9	or	O
10	Gly28	O
11	(	O
12	by	O
13	Ser	O
14	),	O
15	two	O
16	of	O
17	the	O
18	most	O
19	conserved	O
20	residues	O
21	in	O
22	all	O
23	protein	O
24	kinases	B
25	,	O
26	resulted	O
27	in	O
28	enzyme	O
29	with	O
30	marginally	O
31	detectable	O
32	activity	O
33	.	O
1	The	O
2	highest	O
3	prevalence	O
4	of	O
5	reported	O
6	pet	O
7	allergy	O
8	,	O
9	chronic	O
10	cough	O
11	,	O
12	wheeze	O
13	,	O
14	attacks	O
15	of	O
16	shortness	O
17	of	O
18	breath	O
19	with	O
20	wheezing	O
21	,	O
22	and	O
23	doctor	O
24	-	O
25	diagnosed	O
26	asthma	O
27	was	O
28	found	O
29	in	O
30	children	O
31	who	O
32	had	O
33	pets	O
34	in	O
35	the	O
36	past	O
37	but	O
38	not	O
39	anymore	O
40	.	O
1	The	O
2	shift	O
3	to	O
4	the	O
5	nonpermissive	O
6	temperature	O
7	is	O
8	accompanied	O
9	by	O
10	the	O
11	loss	O
12	of	O
13	guanyl	O
14	nucleotide	O
15	-	O
16	dependent	O
17	activity	O
18	of	O
19	adenylylcyclase	O
20	in	O
21	vitro	O
22	.	O
1	Clin	O
2	.	O
1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	minimal	O
7	catalytic	O
8	domain	O
9	of	O
10	Nmt1p	O
11	is	O
12	located	O
13	between	O
14	Ile59	O
15	-->	O
16	Phe96	O
17	and	O
18	Gly451	O
19	-->	O
20	Leu455	O
21	.	O
1	Disruption	O
2	of	O
3	microtubules	O
4	did	O
5	not	O
6	affect	O
7	the	O
8	fidelity	O
9	or	O
10	kinetics	O
11	of	O
12	vacuolar	O
13	protein	O
14	sorting	O
15	,	O
16	indicating	O
17	that	O
18	Vps1p	O
19	function	O
20	is	O
21	not	O
22	dependent	O
23	on	O
24	microtubules	O
25	.	O
1	In	O
2	order	O
3	to	O
4	investigate	O
5	the	O
6	blood	O
7	compatibility	O
8	of	O
9	autogenous	O
10	vein	O
11	graft	O
12	(	O
13	AVG	O
14	),	O
15	changes	O
16	in	O
17	prostacyclin	O
18	(	O
19	PGI2	O
20	)	O
21	production	O
22	following	O
23	harvesting	O
24	and	O
25	arterial	O
26	implantation	O
27	were	O
28	studied	O
29	experimentally	O
30	.	O
1	Nonreplicating	O
2	vaccinia	O
3	vector	O
4	efficiently	O
5	expresses	O
6	recombinant	O
7	genes	O
8	.	O
1	No	O
2	other	O
3	changes	O
4	in	O
5	hematopoietic	O
6	differentiation	O
7	status	O
8	were	O
9	observed	O
10	in	O
11	association	O
12	with	O
13	Id	O
14	-	O
15	SCL	O
16	expression	O
17	.	O
1	To	O
2	study	O
3	the	O
4	significance	O
5	of	O
6	these	O
7	domains	O
8	and	O
9	the	O
10	overall	O
11	evolutionary	O
12	conservation	O
13	of	O
14	the	O
15	gene	O
16	,	O
17	the	O
18	homolog	O
19	from	O
20	Drosophila	O
21	melanogaster	O
22	was	O
23	isolated	O
24	by	O
25	low	O
26	stringency	O
27	hybridizations	O
28	using	O
29	two	O
30	flanking	O
31	probes	O
32	of	O
33	the	O
34	human	O
35	ERCC3	O
36	cDNA	O
37	.	O
1	GAL4	O
2	-	O
3	VP16	O
4	-	O
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O
1	Abstracts	O
2	.	O
1	Since	O
2	CENP	O
3	-	O
4	B	O
5	gene	O
6	is	O
7	conserved	O
8	in	O
9	mammalian	O
10	species	O
11	and	O
12	CENP	O
13	-	O
14	B	O
15	boxes	O
16	are	O
17	found	O
18	also	O
19	in	O
20	mouse	O
21	centromere	O
22	satellite	O
23	DNA	O
24	(	O
25	minor	O
26	satellite	O
27	),	O
28	this	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	-	O
34	protein	O
35	interaction	O
36	may	O
37	be	O
38	important	O
39	for	O
40	some	O
41	kind	O
42	of	O
43	common	O
44	centromere	O
45	function	O
46	.	O
1	Interestingly	O
2	,	O
3	a	O
4	portion	O
5	of	O
6	the	O
7	tail	O
8	domain	O
9	(	O
10	aa	O
11	,	O
12	1	O
13	,	O
14	094	O
15	-	O
16	1	O
17	,	O
18	830	O
19	)	O
20	shares	O
21	58	O
22	%	O
23	amino	O
24	acid	O
25	sequence	O
26	identity	O
27	with	O
28	a	O
29	723	O
30	-	O
31	aa	O
32	protein	O
33	from	O
34	mouse	O
35	brain	O
36	reported	O
37	to	O
38	be	O
39	a	O
40	glutamic	O
41	acid	O
42	decarboxylase	O
43	.	O
1	Green	O
2	pepper	O
3	significantly	O
4	inhibited	O
5	N	O
6	-	O
7	nitrosothiazolidine	O
8	-	O
9	carboxylic	O
10	acid	O
11	formation	O
12	relative	O
13	to	O
14	ascorbic	O
15	acid	O
16	alone	O
17	.	O
1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	O
12	serum	O
13	prolactin	O
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O
1	One	O
2	phage	O
3	clone	O
4	contains	O
5	a	O
6	junction	O
7	between	O
8	alpha	B
9	satellite	O
10	DNA	O
11	and	O
12	a	O
13	novel	O
14	low	O
15	-	O
16	copy	O
17	repeated	O
18	sequence	O
19	.	O
1	The	O
2	CEM	O
3	receives	O
4	registration	O
5	updates	O
6	via	O
7	an	O
8	HL7	O
9	message	O
10	and	O
11	evaluates	O
12	data	O
13	dependencies	O
14	in	O
15	rules	O
16	via	O
17	an	O
18	interface	O
19	to	O
20	the	O
21	relational	O
22	database	O
23	.	O
1	Dopamine	O
2	neurons	O
3	in	O
4	subjects	O
5	that	O
6	received	O
7	6	O
8	-	O
9	OHDA	O
10	were	O
11	protected	O
12	by	O
13	pre	O
14	-	O
15	treatment	O
16	with	O
17	GBR	O
18	-	O
19	12909	O
20	.	O
1	The	O
2	case	O
3	described	O
4	is	O
5	that	O
6	of	O
7	a	O
8	72	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	with	O
15	ochronosis	O
16	who	O
17	suffered	O
18	a	O
19	hyperextension	O
20	injury	O
21	to	O
22	his	O
23	spine	O
24	in	O
25	a	O
26	fall	O
27	,	O
28	resulting	O
29	in	O
30	a	O
31	fracture	O
32	through	O
33	an	O
34	ankylosed	O
35	L2	O
36	-	O
37	L3	O
38	disk	O
39	space	O
40	.	O
1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	neither	O
7	phosphate	O
8	buffered	O
9	saline	O
10	injection	O
11	into	O
12	the	O
13	ES	O
14	nor	O
15	primary	O
16	KLH	O
17	challenges	O
18	of	O
19	the	O
20	ES	O
21	were	O
22	capable	O
23	of	O
24	elevating	O
25	the	O
26	threshold	O
27	level	O
28	and	O
29	changing	O
30	the	O
31	latency	O
32	.	O
1	A	O
2	newly	O
3	developed	O
4	broad	O
5	-	O
6	spectrum	O
7	fluoroquinolone	O
8	,	O
9	levofloxacin	O
10	(	O
11	LVFX	O
12	,	O
13	DR	O
14	-	O
15	3355	O
16	),	O
17	was	O
18	evaluated	O
19	in	O
20	vitro	O
21	and	O
22	in	O
23	vivo	O
24	in	O
25	comparison	O
26	with	O
27	ciprofloxacin	O
28	(	O
29	CPFX	O
30	),	O
31	ofloxacin	O
32	(	O
33	OFLX	O
34	)	O
35	and	O
36	norfloxacin	O
37	(	O
38	NFLX	O
39	).	O
1	NE	O
2	and	O
3	PR3	O
4	assist	O
5	in	O
6	the	O
7	destruction	O
8	of	O
9	phagocytosed	O
10	microorganisms	O
11	,	O
12	cleave	O
13	the	O
14	important	O
15	connective	O
16	-	O
17	tissue	O
18	protein	O
19	elastin	O
20	,	O
21	and	O
22	generate	O
23	chemotactic	O
24	activities	O
25	by	O
26	forming	O
27	alpha	B
28	1	O
29	-	O
30	proteinase	O
31	inhibitor	O
32	complexes	O
33	and	O
34	elastin	O
35	peptides	O
36	.	O
1	Factors	O
2	associated	O
3	with	O
4	afterdrop	O
5	included	O
6	age	O
7	,	O
8	end	O
9	-	O
10	of	O
11	-	O
12	surgery	O
13	temperature	O
14	(	O
15	both	O
16	positively	O
17	)	O
18	and	O
19	body	O
20	mass	O
21	(	O
22	negatively	O
23	).	O
1	Differentiating	O
2	among	O
3	renal	O
4	stones	O
5	.	O
1	Switching	O
2	FDC	O
3	-	O
4	P1	O
5	/	O
6	MAC	O
7	cells	O
8	from	O
9	growth	O
10	in	O
11	M	O
12	-	O
13	CSF	B
14	to	O
15	GM	O
16	-	O
17	CSF	B
18	caused	O
19	the	O
20	selective	O
21	degradation	O
22	of	O
23	c	B
24	-	O
25	fms	O
26	mRNA	O
27	within	O
28	6	O
29	h	O
30	after	O
31	factor	O
32	switching	O
33	.	O
1	The	O
2	gene	O
3	encoding	O
4	IFN	O
5	-	O
6	gamma	B
7	was	O
8	previously	O
9	found	O
10	to	O
11	contain	O
12	an	O
13	intronic	O
14	enhancer	O
15	element	O
16	that	O
17	was	O
18	not	O
19	tissue	O
20	-	O
21	specific	O
22	in	O
23	its	O
24	activity	O
25	,	O
26	despite	O
27	the	O
28	restricted	O
29	expression	O
30	of	O
31	the	O
32	intact	O
33	IFN	O
34	-	O
35	gamma	B
36	-	O
37	encoding	O
38	gene	O
39	.	O
1	Within	O
2	the	O
3	human	O
4	enhancer	O
5	,	O
6	these	O
7	two	O
8	sites	O
9	are	O
10	located	O
11	within	O
12	the	O
13	previously	O
14	defined	O
15	DNase	B
16	I	O
17	footprints	O
18	,	O
19	NFAT	O
20	-	O
21	1	O
22	and	O
23	NFIL	O
24	-	O
25	2B	O
26	,	O
27	respectively	O
28	.	O
1	The	O
2	cardiac	O
3	myosin	O
4	light	O
5	chain	O
6	-	O
7	2	O
8	(	O
9	MLC	O
10	-	O
11	2	O
12	)	O
13	gene	O
14	promoter	O
15	contains	O
16	several	O
17	positive	O
18	and	O
19	negative	O
20	cis	O
21	-	O
22	acting	O
23	sequences	O
24	that	O
25	are	O
26	involved	O
27	in	O
28	the	O
29	regulation	O
30	of	O
31	its	O
32	expression	O
33	.	O
1	Using	O
2	a	O
3	degenerate	O
4	oligodeoxyribonucleotide	O
5	(	O
6	oligo	O
7	)	O
8	based	O
9	on	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	aa	O
15	sequence	O
16	,	O
17	plus	O
18	an	O
19	internal	O
20	oligo	O
21	homologous	O
22	to	O
23	a	O
24	conserved	O
25	region	O
26	within	O
27	the	O
28	portion	O
29	of	O
30	CYP1	O
31	and	O
32	CYP2	O
33	that	O
34	had	O
35	been	O
36	deleted	O
37	in	O
38	the	O
39	genome	O
40	,	O
41	a	O
42	CYP3	O
43	-	O
44	specific	O
45	DNA	O
46	fragment	O
47	was	O
48	generated	O
49	by	O
50	the	O
51	polymerase	B
52	chain	O
53	reaction	O
54	(	O
55	PCR	O
56	)	O
57	using	O
58	GL81	O
59	genomic	O
60	DNA	O
61	as	O
62	a	O
63	substrate	O
64	.	O
1	The	O
2	level	O
3	of	O
4	carboxyl	O
5	-	O
6	terminal	O
7	parathyroid	O
8	hormone	O
9	in	O
10	the	O
11	patients	O
12	with	O
13	thyroid	O
14	carcinoma	O
15	was	O
16	higher	O
17	than	O
18	that	O
19	in	O
20	the	O
21	patients	O
22	without	O
23	thyroid	O
24	carcinoma	O
25	(	O
26	P	O
27	less	O
28	than	O
29	0	O
30	.	O
31	05	O
32	).	O
1	The	O
2	functions	O
3	of	O
4	isolated	O
5	portions	O
6	of	O
7	the	O
8	insulin	B
9	,	O
10	IAPP	O
11	,	O
12	and	O
13	beta	B
14	GK	O
15	promoters	O
16	were	O
17	studied	O
18	by	O
19	using	O
20	transient	O
21	expression	O
22	and	O
23	DNA	O
24	binding	O
25	assays	O
26	.	O
1	Electromagnetic	O
2	blood	O
3	flow	O
4	(	O
5	BF	O
6	)	O
7	probe	O
8	was	O
9	applied	O
10	on	O
11	the	O
12	left	O
13	anterior	O
14	descending	O
15	artery	O
16	(	O
17	LAD	O
18	).	O
1	Control	O
2	Tmuscle	O
3	was	O
4	35	O
5	.	O
6	8	O
7	+/-	O
8	0	O
9	.	O
10	7	O
11	degrees	O
12	C	O
13	,	O
14	with	O
15	control	O
16	Wi	O
17	,	O
18	max	O
19	being	O
20	51	O
21	.	O
22	6	O
23	(	O
24	SD	O
25	8	O
26	.	O
27	7	O
28	)	O
29	W	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	.	O
1	Eight	O
2	of	O
3	14	O
4	infectious	O
5	or	O
6	inflammatory	O
7	lesions	O
8	could	O
9	be	O
10	detected	O
11	in	O
12	the	O
13	early	O
14	scan	O
15	(	O
16	4	O
17	-	O
18	6	O
19	h	O
20	p	O
21	.	O
22	i	O
23	.).	O
1	Similar	O
2	observations	O
3	have	O
4	been	O
5	made	O
6	previously	O
7	for	O
8	other	O
9	genes	O
10	.	O
1	Overproduction	O
2	,	O
3	purification	O
4	and	O
5	characterization	O
6	of	O
7	M	O
8	.	O
9	HinfI	O
10	methyltransferase	O
11	and	O
12	its	O
13	deletion	O
14	mutant	O
15	.	O
1	Various	O
2	companies	O
3	produce	O
4	this	O
5	type	O
6	of	O
7	lens	O
8	.	O
1	Keck	O
2	,	O
3	C	O
4	.	O
5	J	O
6	.	O
1	A	O
2	possible	O
3	mechanism	O
4	is	O
5	that	O
6	elevated	O
7	alveolar	O
8	pressure	O
9	and	O
10	decreased	O
11	cardiac	O
12	output	O
13	eliminate	O
14	blood	O
15	flow	O
16	from	O
17	corner	O
18	vessels	O
19	in	O
20	nondependent	O
21	high	O
22	VA	O
23	/	O
24	Q	O
25	regions	O
26	.	O
1	Computer	O
2	-	O
3	aided	O
4	""""	O
5	FRAME	O
6	""""	O
7	analysis	O
8	revealed	O
9	four	O
10	possible	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	),	O
17	three	O
18	in	O
19	one	O
20	direction	O
21	and	O
22	one	O
23	in	O
24	the	O
25	opposite	O
26	direction	O
27	.	O
1	In	O
2	the	O
3	last	O
4	20	O
5	years	O
6	,	O
7	the	O
8	therapeutic	O
9	uses	O
10	of	O
11	botulinum	O
12	toxin	O
13	,	O
14	a	O
15	potent	O
16	neurotoxin	O
17	,	O
18	have	O
19	been	O
20	investigated	O
21	.	O
1	Allagille	O
2	'	O
3	s	O
4	syndrome	O
5	associated	O
6	with	O
7	antenatal	O
8	ascites	O
1	Dimerization	O
2	of	O
3	Myf	O
4	-	O
5	5	O
6	with	O
7	the	O
8	ubiquitously	O
9	expressed	O
10	bHLH	O
11	protein	O
12	E12	O
13	not	O
14	only	O
15	increases	O
16	the	O
17	affinity	O
18	for	O
19	DNA	O
20	but	O
21	also	O
22	stimulates	O
23	transactivation	O
24	independently	O
25	of	O
26	DNA	O
27	binding	O
28	.	O
1	SEA	O
2	was	O
3	recorded	O
4	with	O
5	bidirectional	O
6	filters	O
7	at	O
8	25	O
9	-	O
10	250	O
11	HZ	O
12	and	O
13	40	O
14	-	O
15	250	O
16	Hz	O
17	using	O
18	Simson	O
19	method	O
20	.	O
1	The	O
2	decay	O
3	curves	O
4	of	O
5	chlorophyll	O
6	fluorescence	O
7	showed	O
8	a	O
9	superposition	O
10	of	O
11	three	O
12	exponentially	O
13	decaying	O
14	components	O
15	with	O
16	time	O
17	constants	O
18	of	O
19	T1	O
20	=	O
21	100	O
22	-	O
23	200	O
24	ps	O
25	,	O
26	T2	O
27	=	O
28	300	O
29	-	O
30	500	O
31	ps	O
32	and	O
33	T3	O
34	=	O
35	2	O
36	.	O
37	0	O
38	-	O
39	3	O
40	.	O
41	5	O
42	ns	O
43	.	O
1	Coronary	O
2	flow	O
3	was	O
4	reduced	O
5	by	O
6	10	O
7	%	O
8	in	O
9	the	O
10	phosphocreatine	O
11	and	O
12	by	O
13	18	O
14	%	O
15	in	O
16	the	O
17	control	O
18	group	O
19	.	O
1	Three	O
2	pyridoxine	O
3	derivatives	O
4	have	O
5	been	O
6	isolated	O
7	from	O
8	the	O
9	fresh	O
10	stem	O
11	bark	O
12	of	O
13	Albizzia	O
14	julibrissin	O
15	DURAZZ	O
16	..	O
1	Argatroban	O
2	may	O
3	be	O
4	more	O
5	effective	O
6	under	O
7	low	O
8	HC	O
9	II	O
10	conditions	O
11	because	O
12	of	O
13	its	O
14	potent	O
15	inhibition	O
16	of	O
17	thrombin	O
18	activity	O
19	at	O
20	sites	O
21	of	O
22	vascular	O
23	wall	O
24	damage	O
25	.	O
1	These	O
2	results	O
3	support	O
4	the	O
5	diagnostic	O
6	validity	O
7	of	O
8	NFPD	O
9	in	O
10	CP	O
11	/	O
12	NCA	O
13	patients	O
14	,	O
15	because	O
16	such	O
17	patients	O
18	had	O
19	a	O
20	family	O
21	history	O
22	of	O
23	panic	O
24	disorder	O
25	similar	O
26	to	O
27	patients	O
28	with	O
29	a	O
30	more	O
31	classical	O
32	panic	O
33	disorder	O
34	presentation	O
35	.	O
1	FDA	O
2	regulations	O
3	for	O
4	growth	O
5	factors	O
6	and	O
7	related	O
8	products	O
9	.	O
1	The	O
2	mean	O
3	minimum	O
4	steady	O
5	-	O
6	state	O
7	concentration	O
8	after	O
9	the	O
10	oral	O
11	regimen	O
12	(	O
13	23	O
14	micrograms	O
15	.	O
16	l	O
17	-	O
18	1	O
19	)	O
20	was	O
21	78	O
22	%	O
23	of	O
24	that	O
25	after	O
26	the	O
27	intramuscular	O
28	regime	O
29	(	O
30	29	O
31	micrograms	O
32	.	O
33	l	O
34	-	O
35	1	O
36	).	O
1	Whole	O
2	blood	O
3	serotonin	O
4	levels	O
5	were	O
6	investigated	O
7	in	O
8	a	O
9	control	O
10	group	O
11	(	O
12	n	O
13	=	O
14	35	O
15	)	O
16	and	O
17	in	O
18	a	O
19	group	O
20	of	O
21	chronic	O
22	renal	O
23	failure	O
24	patients	O
25	(	O
26	n	O
27	=	O
28	127	O
29	)	O
30	on	O
31	various	O
32	treatment	O
33	regimen	O
34	i	O
35	.	O
36	e	O
37	.	O
38	conservative	O
39	treatment	O
40	(	O
41	n	O
42	=	O
43	39	O
44	),	O
45	maintenance	O
46	haemodialysis	O
47	(	O
48	n	O
49	=	O
50	35	O
51	)	O
52	and	O
53	after	O
54	renal	O
55	transplantation	O
56	(	O
57	n	O
58	=	O
59	53	O
60	).	O
1	Two	O
2	cDNAs	O
3	encoding	O
4	casein	O
5	kinase	B
6	-	O
7	1	O
8	have	O
9	been	O
10	isolated	O
11	from	O
12	a	O
13	yeast	O
14	cDNA	O
15	library	O
16	and	O
17	termed	O
18	CKI1	O
19	and	O
20	CKI2	O
21	.	O
1	The	O
2	observed	O
3	sequence	O
4	variation	O
5	disrupts	O
6	the	O
7	first	O
8	ORF	O
9	in	O
10	many	O
11	Y	O
12	'	O
13	s	O
14	while	O
15	most	O
16	of	O
17	the	O
18	second	O
19	ORF	O
20	including	O
21	the	O
22	putative	O
23	helicase	O
24	region	O
25	is	O
26	unaffected	O
27	.	O
1	We	O
2	identified	O
3	a	O
4	protein	O
5	,	O
6	termed	O
7	NFIL	O
8	-	O
9	1	O
10	beta	B
11	A	O
12	(	O
13	NF	B
14	beta	I
15	A	O
16	),	O
17	that	O
18	binds	O
19	to	O
20	a	O
21	highly	O
22	conserved	O
23	12	O
24	-	O
25	bp	O
26	DNA	O
27	sequence	O
28	(-	O
29	49	O
30	to	O
31	-	O
32	38	O
33	)	O
34	located	O
35	upstream	O
36	of	O
37	the	O
38	TATA	O
39	box	O
40	motif	O
41	in	O
42	both	O
43	the	O
44	human	O
45	and	O
46	murine	O
47	IL	B
48	-	O
49	1	O
50	beta	B
51	genes	O
52	.	O
1	Cardiovascular	O
2	risk	O
3	factors	O
4	were	O
5	measured	O
6	by	O
7	standardized	O
8	techniques	O
9	.	O
1	The	O
2	modalities	O
3	for	O
4	using	O
5	reference	O
6	values	O
7	for	O
8	individual	O
9	subjects	O
10	as	O
11	well	O
12	as	O
13	for	O
14	groups	O
15	are	O
16	then	O
17	discussed	O
18	and	O
19	the	O
20	main	O
21	points	O
22	of	O
23	research	O
24	which	O
25	must	O
26	be	O
27	faced	O
28	in	O
29	the	O
30	near	O
31	future	O
32	regarding	O
33	reference	O
34	values	O
35	are	O
36	highlighted	O
37	.	O
1	Altogether	O
2	these	O
3	results	O
4	indicate	O
5	that	O
6	the	O
7	Syn	O
8	5	O
9	locus	O
10	segregates	O
11	from	O
12	the	O
13	gene	O
14	specifying	O
15	gH	O
16	,	O
17	to	O
18	a	O
19	region	O
20	encompassing	O
21	portions	O
22	of	O
23	the	O
24	TK	O
25	and	O
26	UL	O
27	24	O
28	genes	O
29	,	O
30	and	O
31	that	O
32	the	O
33	syn	O
34	mutation	O
35	does	O
36	not	O
37	affect	O
38	the	O
39	expression	O
40	or	O
41	activity	O
42	of	O
43	TK	O
44	.	O
1	The	O
2	reason	O
3	that	O
4	nitrous	O
5	oxide	O
6	does	O
7	not	O
8	produce	O
9	hydroxyl	O
10	radicals	O
11	readily	O
12	might	O
13	be	O
14	that	O
15	the	O
16	one	O
17	-	O
18	electron	O
19	reduction	O
20	proceeds	O
21	through	O
22	an	O
23	N2O	O
24	-	O
25	intermediate	O
26	which	O
27	is	O
28	energetically	O
29	very	O
30	unfavourable	O
31	:	O
32	EO	O
33	(	O
34	N2O	O
35	/	O
36	N2O	O
37	-)	O
38	=	O
39	-	O
40	1	O
41	.	O
42	1	O
43	V	O
44	.	O
1	All	O
2	mutant	O
3	JCV	O
4	T	O
5	antigens	O
6	bound	O
7	to	O
8	JCV	O
9	and	O
10	SV40	O
11	origins	O
12	of	O
13	DNA	O
14	replication	O
15	.	O
1	In	O
2	patients	O
3	with	O
4	limited	O
5	disease	O
6	,	O
7	the	O
8	survival	O
9	in	O
10	the	O
11	alternating	O
12	arm	O
13	was	O
14	significantly	O
15	superior	O
16	to	O
17	the	O
18	survival	O
19	in	O
20	the	O
21	CAV	O
22	arm	O
23	(	O
24	P	O
25	=	O
26	.	O
27	014	O
28	)	O
29	or	O
30	the	O
31	survival	O
32	in	O
33	the	O
34	PE	O
35	arm	O
36	(	O
37	P	O
38	=	O
39	.	O
40	023	O
41	).	O
1	Plasma	O
2	vitamin	O
3	E	O
4	,	O
5	total	O
6	lipids	O
7	and	O
8	myeloperoxidase	O
9	levels	O
10	during	O
11	spinal	O
12	surgery	O
13	.	O
1	Two	O
2	putative	O
3	12	O
4	-	O
5	O	O
6	-	O
7	tetradecanoyl	O
8	-	O
9	phorbol	O
10	-	O
11	13	O
12	-	O
13	acetate	O
14	(	O
15	TPA	O
16	)	O
17	response	O
18	elements	O
19	,	O
20	that	O
21	might	O
22	serve	O
23	as	O
24	binding	O
25	sites	O
26	for	O
27	the	O
28	transcription	O
29	factor	O
30	AP	B
31	-	O
32	1	O
33	and	O
34	a	O
35	consensus	O
36	sequence	O
37	of	O
38	a	O
39	transforming	O
40	growth	O
41	factor	O
42	beta	B
43	1	O
44	(	O
45	TGF	O
46	-	O
47	beta	B
48	1	O
49	)	O
50	inhibitory	O
51	element	O
52	were	O
53	found	O
54	in	O
55	the	O
56	promoter	O
57	region	O
58	.	O
1	They	O
2	were	O
3	almost	O
4	regularly	O
5	excited	O
6	by	O
7	pressure	O
8	to	O
9	the	O
10	ipsilateral	O
11	cornea	O
12	or	O
13	to	O
14	both	O
15	corneas	O
16	at	O
17	a	O
18	strength	O
19	well	O
20	above	O
21	the	O
22	human	O
23	corneal	O
24	pain	O
25	threshold	O
26	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	a	O
9	region	O
10	that	O
11	complements	O
12	the	O
13	exoenzyme	O
14	S	O
15	-	O
16	deficient	O
17	phenotype	O
18	of	O
19	strain	O
20	388	O
21	exs1	O
22	::	O
23	Tn1	O
24	,	O
25	a	O
26	chromosomal	O
27	Tn1	O
28	insertional	O
29	mutation	O
30	.	O
1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	to	O
8	occur	O
9	66	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	initiating	O
15	Met	O
16	.	O
1	Recombination	O
2	between	O
3	feline	O
4	leukemia	O
5	virus	O
6	subgroup	O
7	B	O
8	or	O
9	C	O
10	and	O
11	endogenous	O
12	env	O
13	elements	O
14	alters	O
15	the	O
16	in	O
17	vitro	O
18	biological	O
19	activities	O
20	of	O
21	the	O
22	viruses	O
23	.	O
1	A	O
2	third	O
3	is	O
4	a	O
5	partial	O
6	element	O
7	terminating	O
8	at	O
9	a	O
10	probable	O
11	internal	O
12	restriction	O
13	site	O
14	used	O
15	for	O
16	cloning	O
17	.	O
1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	RNA14	O
7	and	O
8	RNA15	O
9	or	O
10	between	O
11	RNA14	O
12	and	O
13	other	O
14	proteins	O
15	contained	O
16	in	O
17	data	O
18	banks	O
19	.	O
1	No	O
2	such	O
3	benefits	O
4	were	O
5	seen	O
6	for	O
7	children	O
8	with	O
9	CD4	O
10	+	O
11	counts	O
12	below	O
13	0	O
14	.	O
15	2	O
16	x	O
17	10	O
18	(	O
19	9	O
20	)	O
21	per	O
22	liter	O
23	at	O
24	entry	O
25	.	O
1	The	O
2	95	O
3	%	O
4	confidence	O
5	values	O
6	(	O
7	2SD	O
8	)	O
9	for	O
10	the	O
11	change	O
12	in	O
13	Ros	O
14	required	O
15	to	O
16	exclude	O
17	natural	O
18	variability	O
19	were	O
20	0	O
21	.	O
22	39	O
23	,	O
24	0	O
25	.	O
26	50	O
27	and	O
28	0	O
29	.	O
30	53	O
31	cmH2O	O
32	l	O
33	-	O
34	1	O
35	s	O
36	,	O
37	respectively	O
38	.	O
1	Biochemical	O
2	studies	O
3	revealed	O
4	the	O
5	expected	O
6	loss	O
7	of	O
8	ChAT	O
9	activity	O
10	in	O
11	the	O
12	dorsal	O
13	and	O
14	ventral	O
15	hippocampi	O
16	of	O
17	lesioned	O
18	animals	O
19	along	O
20	with	O
21	elevated	O
22	levels	O
23	of	O
24	norepinephrine	O
25	(	O
26	NE	O
27	)	O
28	in	O
29	the	O
30	dorsal	O
31	hippocampus	O
32	of	O
33	MS	O
34	/	O
35	HSI	O
36	animals	O
37	.(	O
38	ABSTRACT	O
39	TRUNCATED	O
40	AT	O
41	250	O
42	WORDS	O
43	)	O
1	The	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	mediating	O
7	glucocorticoid	O
8	inducibility	O
9	of	O
10	the	O
11	chicken	O
12	glutamine	O
13	synthetase	O
14	gene	O
15	has	O
16	been	O
17	identified	O
18	.	O
1	Diagnostic	O
2	value	O
3	of	O
4	cerebrospinal	O
5	fluid	O
6	immunoglobulin	O
7	G	O
8	(	O
9	IgG	O
10	)	O
11	in	O
12	pediatric	O
13	neurological	O
14	diseases	O
15	.	O
1	This	O
2	exon	O
3	,	O
4	here	O
5	named	O
6	exon	O
7	0	O
8	,	O
9	contained	O
10	the	O
11	entire	O
12	5	O
13	'	O
14	untranslated	O
15	region	O
16	and	O
17	the	O
18	N	O
19	-	O
20	terminal	O
21	signal	O
22	sequence	O
23	of	O
24	the	O
25	polypeptide	O
26	.	O
1	A	O
2	new	O
3	,	O
4	flexible	O
5	fiberoptic	O
6	ventriculoscope	O
7	for	O
8	observation	O
9	of	O
10	the	O
11	ventricles	O
12	and	O
13	major	O
14	cisterns	O
15	is	O
16	reported	O
17	.	O
1	Wnt	O
2	-	O
3	1	O
4	(	O
5	int	O
6	-	O
7	1	O
8	)	O
9	is	O
10	a	O
11	cellular	O
12	oncogene	O
13	often	O
14	activated	O
15	by	O
16	insertion	O
17	of	O
18	proviral	O
19	DNA	O
20	of	O
21	the	O
22	mouse	O
23	mammary	O
24	tumor	O
25	virus	O
26	.	O
1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	the	O
6	promoter	O
7	for	O
8	the	O
9	cytotactin	O
10	gene	O
11	.	O
1	Polyadenylation	O
2	of	O
3	B4	O
4	RNA	O
5	,	O
6	which	O
7	occurs	O
8	very	O
9	early	O
10	during	O
11	maturation	O
12	,	O
13	is	O
14	limited	O
15	to	O
16	150	O
17	residues	O
18	,	O
19	and	O
20	it	O
21	is	O
22	this	O
23	number	O
24	that	O
25	is	O
26	required	O
27	for	O
28	polysomal	O
29	recruitment	O
30	.	O
1	The	O
2	murine	O
3	mutation	O
4	dominant	O
5	white	O
6	spotting	O
7	(	O
8	W	O
9	)	O
10	is	O
11	in	O
12	the	O
13	proto	O
14	-	O
15	oncogene	O
16	,	O
17	c	B
18	-	O
19	kit	O
20	.	O
1	The	O
2	SH2	O
3	and	O
4	SH3	O
5	domains	O
6	of	O
7	pp60src	O
8	direct	O
9	stable	O
10	association	O
11	with	O
12	tyrosine	O
13	phosphorylated	O
14	proteins	O
15	p130	O
16	and	O
17	p110	O
18	.	O
1	The	O
2	C5	O
3	alpha	B
4	-	O
5	chain	O
6	was	O
7	encoded	O
8	by	O
9	49	O
10	kilobases	O
11	containing	O
12	26	O
13	exons	O
14	;	O
15	the	O
16	beta	B
17	-	O
18	chain	O
19	was	O
20	encoded	O
21	by	O
22	29	O
23	kilobases	O
24	containing	O
25	16	O
26	exons	O
27	.	O
1	Comparison	O
2	of	O
3	the	O
4	nucleotide	O
5	sequences	O
6	between	O
7	the	O
8	human	O
9	and	O
10	bovine	O
11	DNA	O
12	showed	O
13	that	O
14	the	O
15	sequence	O
16	similarity	O
17	extended	O
18	2400	O
19	bp	O
20	downstream	O
21	from	O
22	the	O
23	coding	O
24	region	O
25	.	O
1	An	O
2	approximately	O
3	2	O
4	-	O
5	kilobase	O
6	B2	O
7	transcript	O
8	was	O
9	expressed	O
10	in	O
11	all	O
12	alfalfa	O
13	organs	O
14	tested	O
15	.	O
1	These	O
2	risk	O
3	factors	O
4	can	O
5	be	O
6	divided	O
7	into	O
8	2	O
9	groups	O
10	:	O
11	local	O
12	vessel	O
13	wall	O
14	-	O
15	related	O
16	factors	O
17	,	O
18	and	O
19	local	O
20	(	O
21	focal	O
22	action	O
23	)	O
24	systemic	O
25	factors	O
26	.	O
1	The	O
2	tissue	O
3	specificity	O
4	of	O
5	gene	O
6	expression	O
7	was	O
8	identical	O
9	to	O
10	that	O
11	described	O
12	previously	O
13	for	O
14	the	O
15	CaMV	O
16	35S	O
17	domain	O
18	B	O
19	enhancer	O
20	element	O
21	.	O
1	In	O
2	some	O
3	early	O
4	B	O
5	cells	O
6	and	O
7	Abelson	O
8	murine	O
9	leukemia	O
10	virus	O
11	-	O
12	transformed	O
13	pre	O
14	-	O
15	B	O
16	-	O
17	cell	O
18	lines	O
19	,	O
20	LT	O
21	mRNA	O
22	is	O
23	constitutively	O
24	expressed	O
25	.	O
1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	RAP74	O
7	protein	O
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	RAP30	O
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O
1	The	O
2	size	O
3	of	O
4	the	O
5	mutant	O
6	molecule	O
7	corresponds	O
8	to	O
9	the	O
10	unprocessed	O
11	cytoplasmic	O
12	precursor	O
13	(	O
14	pre	O
15	-	O
16	super	O
17	-	O
18	pro	O
19	-	O
20	PrB	O
21	),	O
22	as	O
23	detected	O
24	in	O
25	sec61	O
26	mutants	O
27	,	O
28	when	O
29	translocation	O
30	into	O
31	the	O
32	endoplasmic	O
33	reticulum	O
34	is	O
35	blocked	O
36	.	O
1	Heat	O
2	-	O
3	inducible	O
4	CAT	O
5	activity	O
6	was	O
7	detectable	O
8	when	O
9	additional	O
10	sequences	O
11	from	O
12	the	O
13	native	O
14	promoter	O
15	containing	O
16	three	O
17	CCAAT	O
18	boxes	O
19	and	O
20	a	O
21	single	O
22	HSE	O
23	were	O
24	present	O
25	in	O
26	the	O
27	constructions	O
28	.	O
1	Patients	O
2	with	O
3	moderate	O
4	PDDAT	O
5	were	O
6	impaired	O
7	on	O
8	all	O
9	serial	O
10	positions	O
11	for	O
12	both	O
13	spatial	O
14	order	O
15	and	O
16	spatial	O
17	recognition	O
18	memory	O
19	.	O
1	The	O
2	constraints	O
3	of	O
4	primase	O
5	recognition	O
6	sequences	O
7	,	O
8	nucleotide	O
9	substrate	O
10	requirements	O
11	,	O
12	and	O
13	the	O
14	effects	O
15	of	O
16	additional	O
17	proteins	O
18	on	O
19	oligoribonucleotide	O
20	synthesis	O
21	by	O
22	the	O
23	63	O
24	-	O
25	kDa	O
26	gene	O
27	4	O
28	protein	O
29	have	O
30	been	O
31	examined	O
32	using	O
33	templates	O
34	of	O
35	defined	O
36	sequence	O
37	.	O
1	When	O
2	both	O
3	lesions	O
4	were	O
5	complete	O
6	lateral	O
7	hemisections	O
8	in	O
9	weanling	O
10	operates	O
11	,	O
12	little	O
13	behavioral	O
14	recovery	O
15	was	O
16	observed	O
17	,	O
18	similar	O
19	to	O
20	complete	O
21	spinal	O
22	cord	O
23	transection	O
24	(	O
25	N	O
26	=	O
27	3	O
28	).	O
1	Cardiac	O
2	output	O
3	(	O
4	CO	O
5	)	O
6	was	O
7	significantly	O
8	higher	O
9	(	O
10	p	O
11	less	O
12	than	O
13	0	O
14	.	O
15	0005	O
16	)	O
17	in	O
18	the	O
19	MBBF	O
20	group	O
21	.	O
1	We	O
2	obtained	O
3	quantitative	O
4	evidence	O
5	on	O
6	the	O
7	coding	O
8	of	O
9	interaural	O
10	time	O
11	differences	O
12	(	O
13	ITDs	O
14	)	O
15	of	O
16	click	O
17	stimuli	O
18	by	O
19	40	O
20	single	O
21	neurons	O
22	in	O
23	the	O
24	auditory	O
25	cortex	O
26	of	O
27	anesthetized	O
28	albino	O
29	rats	O
30	.	O
1	Airway	O
2	pressure	O
3	and	O
4	air	O
5	flow	O
6	were	O
7	measured	O
8	at	O
9	the	O
10	endotracheal	O
11	tube	O
12	in	O
13	13	O
14	children	O
15	on	O
16	a	O
17	variety	O
18	of	O
19	ventilators	O
20	.	O
1	Substituting	O
2	a	O
3	Ser	O
4	for	O
5	Gly69	O
6	or	O
7	a	O
8	Glu	O
9	for	O
10	Lys	O
11	71	O
12	in	O
13	the	O
14	conserved	O
15	TGEK	O
16	tetrapeptide	O
17	in	O
18	finger	O
19	II	O
20	of	O
21	TFIIIA	O
22	resulted	O
23	in	O
24	the	O
25	loss	O
26	of	O
27	DNA	O
28	binding	O
29	.	O
1	In	O
2	Xenopus	O
3	laevis	O
4	,	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	elongation	O
10	factor	O
11	1	O
12	-	O
13	alpha	B
14	variant	O
15	EF	O
16	-	O
17	1	O
18	alpha	B
19	O	O
20	,	O
21	where	O
22	O	O
23	stands	O
24	for	O
25	oocyte	O
26	,	O
27	is	O
28	expressed	O
29	in	O
30	oocytes	O
31	and	O
32	early	O
33	embryos	O
34	.	O
1	Two	O
2	potential	O
3	regulatory	O
4	sequences	O
5	for	O
6	DNA	O
7	binding	O
8	proteins	O
9	were	O
10	found	O
11	in	O
12	the	O
13	non	O
14	-	O
15	coding	O
16	5	O
17	'	O
18	region	O
19	:	O
20	a	O
21	HAP2	O
22	/	O
23	HAP3	O
24	consensus	O
25	recognition	O
26	sequence	O
27	at	O
28	nucleotide	O
29	-	O
30	154	O
31	and	O
32	a	O
33	BAF1	O
34	consensus	O
35	recognition	O
36	sequence	O
37	at	O
38	nucleotide	O
39	-	O
40	136	O
41	.	O
1	Plasma	O
2	lipid	O
3	and	O
4	lipoprotein	O
5	profiles	O
6	were	O
7	compared	O
8	in	O
9	elderly	O
10	female	O
11	runners	O
12	(	O
13	RU	O
14	:	O
15	n	O
16	=	O
17	15	O
18	,	O
19	aged	O
20	66	O
21	+/-	O
22	5	O
23	years	O
24	,	O
25	body	O
26	fat	O
27	20	O
28	+/-	O
29	4	O
30	%,	O
31	training	O
32	distance	O
33	35	O
34	+/-	O
35	15	O
36	km	O
37	week	O
38	-	O
39	1	O
40	,	O
41	VO2max	O
42	36	O
43	+/-	O
44	4	O
45	ml	O
46	kg	O
47	-	O
48	1	O
49	min	O
50	-	O
51	1	O
52	,	O
53	mean	O
54	+/-	O
55	SD	O
56	)	O
57	and	O
58	age	O
59	-	O
60	matched	O
61	untrained	O
62	women	O
63	(	O
64	UT	O
65	:	O
66	n	O
67	=	O
68	28	O
69	,	O
70	66	O
71	+/-	O
72	4	O
73	years	O
74	,	O
75	body	O
76	fat	O
77	26	O
78	+/-	O
79	6	O
80	%,	O
81	VO2max	O
82	26	O
83	+/-	O
84	3	O
85	ml	O
86	kg	O
87	-	O
88	1	O
89	min	O
90	-	O
91	1	O
92	).	O
1	The	O
2	alcoholic	O
3	patient	O
4	,	O
5	his	O
6	work	O
7	and	O
8	the	O
9	subjectivity	O
10	of	O
11	the	O
12	period	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	combined	O
7	treatment	O
8	with	O
9	a	O
10	thromboxane	O
11	synthetase	O
12	inhibitor	O
13	and	O
14	a	O
15	thromboxane	O
16	receptor	B
17	antagonist	O
18	provides	O
19	a	O
20	better	O
21	protection	O
22	against	O
23	digoxin	O
24	intoxication	O
25	than	O
26	with	O
27	either	O
28	agent	O
29	alone	O
30	.	O
1	A	O
2	330	O
3	-	O
4	kb	O
5	YAC	O
6	,	O
7	A148A7	O
8	,	O
9	spanned	O
10	from	O
11	the	O
12	HLA	O
13	-	O
14	DQA1	O
15	locus	O
16	through	O
17	the	O
18	Y3	O
19	/	O
20	Ring	O
21	4	O
22	locus	O
23	and	O
24	extended	O
25	at	O
26	least	O
27	130	O
28	kb	O
29	centromeric	O
30	of	O
31	YAC	O
32	B1D12	O
33	.	O
1	The	O
2	EPO	O
3	levels	O
4	were	O
5	distinctly	O
6	increased	O
7	before	O
8	transfusion	O
9	;	O
10	they	O
11	did	O
12	not	O
13	significantly	O
14	change	O
15	just	O
16	after	O
17	transfusion	O
18	,	O
19	but	O
20	subsequently	O
21	decreased	O
22	.	O
1	However	O
2	,	O
3	it	O
4	was	O
5	synthesized	O
6	at	O
7	both	O
8	temperatures	O
9	after	O
10	addition	O
11	of	O
12	A23187	O
13	.	O
1	Relatively	O
2	little	O
3	is	O
4	known	O
5	regarding	O
6	the	O
7	role	O
8	of	O
9	5	O
10	-	O
11	HT2	O
12	receptor	B
13	activity	O
14	in	O
15	male	O
16	rat	O
17	sexual	O
18	behavior	O
19	.	O
1	So	O
2	far	O
3	15	O
4	children	O
5	have	O
6	been	O
7	studied	O
8	.	O
1	Regional	O
2	cerebral	O
3	blood	O
4	flow	O
5	(	O
6	rCBF	O
7	)	O
8	measurements	O
9	and	O
10	psychiatric	O
11	ratings	O
12	were	O
13	performed	O
14	on	O
15	seven	O
16	schizophrenic	O
17	patients	O
18	(	O
19	mean	O
20	age	O
21	=	O
22	41	O
23	.	O
24	4	O
25	years	O
26	)	O
27	who	O
28	had	O
29	been	O
30	examined	O
31	18	O
32	years	O
33	previously	O
34	in	O
35	a	O
36	study	O
37	that	O
38	used	O
39	similar	O
40	psychiatric	O
41	ratings	O
42	and	O
43	a	O
44	comparable	O
45	rCBF	O
46	technique	O
47	.	O
1	Different	O
2	doses	O
3	of	O
4	15	O
5	-	O
6	methyl	O
7	-	O
8	PGF2	O
9	alpha	B
10	(	O
11	0	O
12	.	O
13	125	O
14	-	O
15	10	O
16	mg	O
17	)	O
18	were	O
19	used	O
20	to	O
21	induce	O
22	luteolysis	O
23	and	O
24	oestrus	O
25	in	O
26	7	O
27	heifers	O
28	with	O
29	28	O
30	treatments	O
31	on	O
32	day	O
33	8	O
34	-	O
35	12	O
36	of	O
37	the	O
38	oestrous	O
39	cycle	O
40	.	O
1	Review	O
2	of	O
3	the	O
4	literature	O
5	and	O
6	report	O
7	of	O
8	a	O
9	case	O
10	of	O
11	a	O
12	dermoid	O
13	cyst	O
14	.	O
1	In	O
2	all	O
3	instances	O
4	the	O
5	apparent	O
6	alcohol	O
7	responses	O
8	were	O
9	very	O
10	small	O
11	and	O
12	never	O
13	exceeded	O
14	a	O
15	reading	O
16	of	O
17	1	O
18	microgram	O
19	/	O
20	100ml	O
21	for	O
22	breath	O
23	samples	O
24	more	O
25	than	O
26	10min	O
27	post	O
28	-	O
29	exposure	O
30	.	O
1	Human	O
2	GATA	O
3	-	O
4	3	O
5	:	O
6	a	O
7	lineage	O
8	-	O
9	restricted	O
10	transcription	O
11	factor	O
12	that	O
13	regulates	O
14	the	O
15	expression	O
16	of	O
17	the	O
18	T	O
19	cell	O
20	receptor	B
21	alpha	I
22	gene	O
23	.	O
1	Thus	O
2	,	O
3	the	O
4	positive	O
5	effect	O
6	of	O
7	NS1	O
8	on	O
9	the	O
10	steady	O
11	-	O
12	state	O
13	levels	O
14	of	O
15	P4	O
16	transcripts	O
17	depends	O
18	on	O
19	the	O
20	amplification	O
21	of	O
22	gene	O
23	copy	O
24	number	O
25	and	O
26	the	O
27	integrity	O
28	of	O
29	the	O
30	terminal	O
31	repeats	O
32	.	O
1	The	O
2	minus	O
3	-	O
4	end	O
5	-	O
6	directed	O
7	microtubule	O
8	motors	O
9	,	O
10	the	O
11	dyneins	O
12	,	O
13	may	O
14	also	O
15	constitute	O
16	a	O
17	superfamily	O
18	of	O
19	force	O
20	-	O
21	generating	O
22	proteins	O
23	with	O
24	distinct	O
25	attachment	O
26	domains	O
27	.	O
1	It	O
2	is	O
3	transparent	O
4	,	O
5	cheap	O
6	to	O
7	be	O
8	made	O
9	,	O
10	and	O
11	easy	O
12	to	O
13	empty	O
14	and	O
15	was	O
16	tested	O
17	in	O
18	118	O
19	animals	O
20	for	O
21	two	O
22	and	O
23	four	O
24	weeks	O
25	.	O
1	The	O
2	spectrum	O
3	of	O
4	histologically	O
5	diagnosed	O
6	malignant	O
7	neoplasms	O
8	in	O
9	Sabah	O
10	,	O
11	1983	O
12	-	O
13	1988	O
14	.	O
1	A	O
2	vector	O
3	containing	O
4	a	O
5	transcriptionally	O
6	inactive	O
7	neomycin	O
8	phosphotransferase	O
9	II	O
10	gene	O
11	was	O
12	used	O
13	to	O
14	select	O
15	promoter	O
16	sequences	O
17	from	O
18	a	O
19	pool	O
20	of	O
21	random	O
22	genomic	O
23	DNA	O
24	fragments	O
25	.	O
1	The	O
2	second	O
3	transcriptional	O
4	unit	O
5	,	O
6	designated	O
7	UL26	O
8	.	O
9	5	O
10	,	O
11	predicted	O
12	to	O
13	specify	O
14	a	O
15	protein	O
16	of	O
17	329	O
18	amino	O
19	acids	O
20	,	O
21	encodes	O
22	the	O
23	family	O
24	35	O
25	proteins	O
26	;	O
27	it	O
28	is	O
29	transcribed	O
30	by	O
31	an	O
32	mRNA	O
33	which	O
34	initiates	O
35	at	O
36	approximately	O
37	nucleotide	O
38	+	O
39	1000	O
40	of	O
41	the	O
42	UL26	O
43	transcription	O
44	initiation	O
45	site	O
46	and	O
47	is	O
48	translated	O
49	from	O
50	the	O
51	methionine	O
52	initiation	O
53	codon	O
54	located	O
55	at	O
56	position	O
57	+	O
58	1099	O
59	of	O
60	the	O
61	UL26	O
62	transcriptional	O
63	unit	O
64	.	O
1	This	O
2	study	O
3	tested	O
4	the	O
5	hypothesis	O
6	that	O
7	sodium	O
8	channel	O
9	blocking	O
10	drugs	O
11	selectively	O
12	prolong	O
13	the	O
14	late	O
15	potential	O
16	,	O
17	or	O
18	terminal	O
19	low	O
20	amplitude	O
21	signal	O
22	,	O
23	portion	O
24	of	O
25	the	O
26	signal	O
27	-	O
28	averaged	O
29	QRS	O
30	complex	O
31	and	O
32	that	O
33	prolongation	O
34	of	O
35	the	O
36	late	O
37	potential	O
38	would	O
39	correlate	O
40	with	O
41	slowing	O
42	of	O
43	ventricular	O
44	tachycardia	O
45	.	O
1	Stable	O
2	association	O
3	of	O
4	U2	O
5	snRNP	O
6	with	O
7	the	O
8	branchpoint	O
9	sequence	O
10	of	O
11	mammalian	O
12	pre	O
13	-	O
14	mRNAs	O
15	requires	O
16	binding	O
17	of	O
18	a	O
19	non	O
20	-	O
21	snRNP	O
22	protein	O
23	to	O
24	the	O
25	polypyrimidine	O
26	tract	O
27	.	O
1	The	O
2	promoter	O
3	activity	O
4	of	O
5	the	O
6	gene	O
7	encoding	O
8	Alzheimer	O
9	beta	B
10	-	O
11	amyloid	O
12	precursor	O
13	protein	O
14	(	O
15	APP	O
16	)	O
17	is	O
18	regulated	O
19	by	O
20	two	O
21	blocks	O
22	of	O
23	upstream	O
24	sequences	O
25	.	O
1	Dd	O
2	PK1	O
3	RNA	O
4	decreases	O
5	after	O
6	6	O
7	h	O
8	of	O
9	starvation	O
10	to	O
11	re	O
12	-	O
13	accumulate	O
14	once	O
15	the	O
16	cells	O
17	have	O
18	aggregated	O
19	.	O
1	The	O
2	across	O
3	-	O
4	fiber	O
5	pattern	O
6	of	O
7	the	O
8	responses	O
9	to	O
10	hypotonic	O
11	NaCl	O
12	solutions	O
13	correlated	O
14	strongly	O
15	to	O
16	that	O
17	elicited	O
18	by	O
19	distilled	O
20	H2O	O
21	.(	O
22	ABSTRACT	O
23	TRUNCATED	O
24	AT	O
25	400	O
26	WORDS	O
27	)	O
1	Thigh	O
2	girth	O
3	correlated	O
4	positively	O
5	with	O
6	HDL	O
7	and	O
8	HDL2	O
9	-	O
10	C	O
11	and	O
12	mass	O
13	,	O
14	and	O
15	with	O
16	LDL	O
17	particle	O
18	size	O
19	among	O
20	women	O
21	.	O
1	The	O
2	cDNA	O
3	contained	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	1392	O
10	bp	O
11	that	O
12	predicted	O
13	a	O
14	protein	O
15	of	O
16	464	O
17	amino	O
18	acids	O
19	and	O
20	a	O
21	molecular	O
22	mass	O
23	of	O
24	52	O
25	kDa	O
26	;	O
27	this	O
28	protein	O
29	has	O
30	97	O
31	%	O
32	identity	O
33	to	O
34	rat	O
35	liver	O
36	glucokinase	O
37	.	O
1	Identification	O
2	of	O
3	Ets	O
4	-	O
5	and	O
6	notch	O
7	-	O
8	related	O
9	subunits	O
10	in	O
11	GA	O
12	binding	O
13	protein	O
14	.	O
1	The	O
2	enzymatic	O
3	response	O
4	of	O
5	neutrophils	O
6	and	O
7	monocytes	O
8	was	O
9	similar	O
10	although	O
11	the	O
12	magnitude	O
13	of	O
14	the	O
15	NADPH	O
16	oxidase	O
17	activity	O
18	was	O
19	significantly	O
20	higher	O
21	in	O
22	neutrophils	O
23	than	O
24	in	O
25	monocytes	O
26	.	O
1	Uptake	O
2	of	O
3	ofloxacin	O
4	by	O
5	Escherichia	O
6	coli	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	beta	B
6	-	O
7	1	O
8	may	O
9	act	O
10	as	O
11	a	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	trans	O
17	-	O
18	acting	O
19	regulator	O
20	of	O
21	the	O
22	expression	O
23	of	O
24	the	O
25	beta	B
26	-	O
27	zein	O
28	gene	O
29	in	O
30	developing	O
31	maize	O
32	endosperm	O
33	.	O
1	This	O
2	study	O
3	examines	O
4	the	O
5	effects	O
6	of	O
7	hypovolemia	O
8	on	O
9	the	O
10	extracellular	O
11	ptO2	O
12	and	O
13	ptH	O
14	distributions	O
15	at	O
16	multiple	O
17	tissue	O
18	sites	O
19	using	O
20	a	O
21	recently	O
22	developed	O
23	multipoint	O
24	microelectrode	O
25	,	O
26	that	O
27	provides	O
28	simultaneous	O
29	measurements	O
30	of	O
31	ptO2	O
32	and	O
33	ptH	O
34	.	O
1	Information	O
2	on	O
3	conserved	O
4	noncoding	O
5	sequences	O
6	will	O
7	help	O
8	in	O
9	studies	O
10	on	O
11	the	O
12	regulation	O
13	of	O
14	the	O
15	pro	O
16	alpha	B
17	1	O
18	(	O
19	II	O
20	)	O
21	collagen	O
22	gene	O
23	.	O
1	Increasing	O
2	mean	O
3	arterial	O
4	pressure	O
5	by	O
6	phenylephrine	O
7	infusion	O
8	to	O
9	levels	O
10	much	O
11	greater	O
12	than	O
13	produced	O
14	by	O
15	NMA	O
16	and	O
17	NNA	O
18	caused	O
19	only	O
20	small	O
21	reductions	O
22	in	O
23	cardiac	O
24	output	O
25	.	O
1	DNA	O
2	hybridization	O
3	analysis	O
4	revealed	O
5	that	O
6	both	O
7	pigmented	O
8	and	O
9	nonpigmented	O
10	cells	O
11	of	O
12	Y	O
13	.	O
14	pestis	O
15	possess	O
16	a	O
17	DNA	O
18	locus	O
19	homologous	O
20	to	O
21	the	O
22	Escherichia	O
23	coli	O
24	fur	O
25	gene	O
26	.	O
1	Determinants	O
2	of	O
3	recurrent	O
4	ischaemia	O
5	and	O
6	revascularisation	O
7	procedures	O
8	after	O
9	thrombolysis	O
10	with	O
11	recombinant	O
12	tissue	O
13	plasminogen	O
14	activator	O
15	in	O
16	primary	O
17	coronary	O
18	occlusion	O
19	.	O
1	UDP	O
2	-	O
3	Gal	O
4	:	O
5	Gal	O
6	beta	B
7	1	O
8	----	O
9	4GlcNAc	O
10	alpha	B
11	1	O
12	----	O
13	3	O
14	-	O
15	galactosyltransferase	O
16	is	O
17	a	O
18	terminal	O
19	glycosyltransferase	O
20	that	O
21	is	O
22	widely	O
23	expressed	O
24	in	O
25	a	O
26	variety	O
27	of	O
28	mammalian	O
29	species	O
30	,	O
31	with	O
32	the	O
33	notable	O
34	exception	O
35	of	O
36	man	O
37	,	O
38	apes	O
39	,	O
40	and	O
41	Old	O
42	World	O
43	monkeys	O
44	.	O
1	Anti	O
2	-	O
3	HBc	O
4	production	O
5	of	O
6	PBMC	O
7	was	O
8	enhanced	O
9	remarkably	O
10	in	O
11	this	O
12	case	O
13	.	O
1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	sMtCK	O
6	genomic	O
7	upstream	O
8	sequences	O
9	reveals	O
10	a	O
11	typical	O
12	TATAA	O
13	box	O
14	within	O
15	the	O
16	80	O
17	base	O
18	pairs	O
19	(	O
20	bp	O
21	)	O
22	that	O
23	,	O
24	by	O
25	transfection	O
26	experiments	O
27	,	O
28	are	O
29	sufficient	O
30	to	O
31	promote	O
32	expression	O
33	of	O
34	chimeric	O
35	plasmids	O
36	with	O
37	the	O
38	chloramphenicol	O
39	acetyltransferase	O
40	reporter	O
41	.	O
1	Lipoprotein	O
2	lipase	O
3	(	O
4	LPL	O
5	),	O
6	a	O
7	key	O
8	enzyme	O
9	in	O
10	normal	O
11	lipoprotein	O
12	metabolism	O
13	,	O
14	has	O
15	a	O
16	complex	O
17	pattern	O
18	of	O
19	regulation	O
20	and	O
21	tissue	O
22	-	O
23	specific	O
24	expression	O
25	.	O
1	An	O
2	ASSEMBLER	O
3	routine	O
4	for	O
5	on	O
6	-	O
7	line	O
8	graphic	O
9	display	O
10	and	O
11	averaging	O
12	of	O
13	data	O
14	acquired	O
15	on	O
16	a	O
17	personal	O
18	microcomputer	O
19	.	O
1	Habituation	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	edible	O
9	snail	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O
1	Blood	O
2	flow	O
3	velocity	O
4	waveforms	O
5	were	O
6	recorded	O
7	by	O
8	pulsed	O
9	Doppler	O
10	examination	O
11	of	O
12	the	O
13	fetal	O
14	internal	O
15	carotid	O
16	and	O
17	middle	O
18	cerebral	O
19	arteries	O
20	using	O
21	the	O
22	established	O
23	transabdominal	O
24	route	O
25	as	O
26	well	O
27	as	O
28	a	O
29	new	O
30	transvaginal	O
31	approach	O
32	.	O
1	In	O
2	the	O
3	yeast	O
4	Saccharomyces	O
5	cerevisiae	O
6	,	O
7	copper	O
8	levels	O
9	exert	O
10	some	O
11	control	O
12	over	O
13	the	O
14	level	O
15	of	O
16	SOD1	O
17	expression	O
18	.	O
1	Evaluation	O
2	of	O
3	antiepileptic	O
4	drug	O
5	effect	O
6	on	O
7	membrane	O
8	fluidity	O
9	.	O
1	The	O
2	examinations	O
3	were	O
4	performed	O
5	on	O
6	two	O
7	groups	O
8	of	O
9	20	O
10	(	O
11	using	O
12	AmF	O
13	/	O
14	SnF2	O
15	)-,	O
16	resp	O
17	.	O
1	The	O
2	construct	O
3	was	O
4	introduced	O
5	into	O
6	BW2001	O
7	(	O
8	xth	O
9	-	O
10	11	O
11	,	O
12	nfo	O
13	-	O
14	2	O
15	)	O
16	strain	O
17	cells	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O
1	Neither	O
2	model	O
3	,	O
4	as	O
5	applied	O
6	,	O
7	provided	O
8	a	O
9	satisfactory	O
10	account	O
11	of	O
12	the	O
13	effects	O
14	of	O
15	the	O
16	main	O
17	variables	O
18	of	O
19	number	O
20	of	O
21	tones	O
22	and	O
23	amount	O
24	of	O
25	perturbation	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	400	O
31	WORDS	O
32	)	O
1	Determination	O
2	of	O
3	an	O
4	RNA	O
5	structure	O
6	involved	O
7	in	O
8	splicing	O
9	inhibition	O
10	of	O
11	a	O
12	muscle	O
13	-	O
14	specific	O
15	exon	O
16	.	O
1	The	O
2	original	O
3	technique	O
4	was	O
5	developed	O
6	in	O
7	the	O
8	1960	O
9	'	O
10	s	O
11	to	O
12	analyze	O
13	the	O
14	inner	O
15	ear	O
16	fluid	O
17	as	O
18	a	O
19	diagnostic	O
20	procedure	O
21	(	O
22	i	O
23	.	O
24	e	O
25	.,	O
26	diagnostic	O
27	labyrinthotomy	O
28	)	O
29	in	O
30	acoustic	O
31	neuroma	O
32	suspects	O
33	.	O
1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	seizure	O
7	,	O
8	the	O
9	patient	O
10	was	O
11	asked	O
12	to	O
13	read	O
14	a	O
15	test	O
16	phrase	O
17	aloud	O
18	until	O
19	it	O
20	was	O
21	read	O
22	correctly	O
23	and	O
24	clearly	O
25	.	O
1	Echinococcus	O
2	granulosus	O
3	was	O
4	diagnosed	O
5	by	O
6	fine	O
7	-	O
8	needle	O
9	aspiration	O
10	cytology	O
11	of	O
12	a	O
13	lung	O
14	cyst	O
15	in	O
16	a	O
17	6	O
18	-	O
19	yr	O
20	-	O
21	old	O
22	white	O
23	female	O
24	in	O
25	central	O
26	Missouri	O
27	.	O
1	Fortunately	O
2	DDT	O
3	-,	O
4	HCH	O
5	-	O
6	and	O
7	HCB	O
8	-	O
9	levels	O
10	decreased	O
11	in	O
12	breast	O
13	milk	O
14	during	O
15	the	O
16	last	O
17	years	O
18	.	O
1	A	O
2	herpesvirus	O
3	proteinase	O
4	activity	O
5	has	O
6	been	O
7	identified	O
8	and	O
9	partially	O
10	characterized	O
11	by	O
12	using	O
13	the	O
14	cloned	O
15	enzyme	O
16	and	O
17	substrate	O
18	genes	O
19	in	O
20	transient	O
21	transfection	O
22	assays	O
23	.	O
1	Following	O
2	treatment	O
3	,	O
4	serum	O
5	estradiol	O
6	levels	O
7	were	O
8	higher	O
9	in	O
10	groups	O
11	E	O
12	+	O
13	T	O
14	and	O
15	E	O
16	than	O
17	in	O
18	group	O
19	C	O
20	.	O
1	DNA	O
2	sequence	O
3	and	O
4	evolution	O
5	of	O
6	the	O
7	CPS	O
8	domain	O
9	of	O
10	the	O
11	Syrian	O
12	hamster	O
13	multifunctional	O
14	protein	O
15	CAD	O
16	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	these	O
6	synthetic	O
7	binding	O
8	sites	O
9	have	O
10	a	O
11	more	O
12	restricted	O
13	and	O
14	specific	O
15	ability	O
16	to	O
17	enhance	O
18	transcription	O
19	when	O
20	assayed	O
21	in	O
22	transformed	O
23	embryos	O
24	.	O
1	A	O
2	bovine	O
3	abomasum	O
4	lambda	O
5	gt11	O
6	cDNA	O
7	library	O
8	was	O
9	screened	O
10	with	O
11	a	O
12	monoclonal	O
13	antibody	O
14	raised	O
15	against	O
16	the	O
17	rabbit	O
18	H	O
19	,	O
20	K	O
21	-	O
22	ATPase	B
23	beta	I
24	subunit	O
25	.	O
1	Judicious	O
2	use	O
3	of	O
4	laboratory	O
5	testing	O
6	,	O
7	including	O
8	monitoring	O
9	of	O
10	CD4	O
11	cell	O
12	counts	O
13	,	O
14	is	O
15	recommended	O
16	.	O
1	Initial	O
2	screening	O
3	of	O
4	a	O
5	rat	O
6	liver	O
7	cDNA	O
8	library	O
9	with	O
10	an	O
11	oligonucleotide	O
12	probe	O
13	derived	O
14	from	O
15	the	O
16	rat	O
17	SCP2	O
18	protein	O
19	sequence	O
20	revealed	O
21	an	O
22	825	O
23	-	O
24	base	O
25	pair	O
26	cDNA	O
27	clone	O
28	coding	O
29	for	O
30	the	O
31	complete	O
32	SCP2	O
33	protein	O
34	sequence	O
35	.	O
1	Radiation	O
2	-	O
3	induced	O
4	changes	O
5	in	O
6	the	O
7	area	O
8	of	O
9	alveoli	O
10	and	O
11	septa	O
12	as	O
13	well	O
14	as	O
15	collagen	O
16	content	O
17	were	O
18	seen	O
19	11	O
20	weeks	O
21	after	O
22	irradiation	O
23	.	O
1	Landsberg	O
2	(	O
3	La	O
4	-	O
5	O	O
6	)	O
7	and	O
8	cv	O
9	.	O
1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	report	O
7	a	O
8	detailed	O
9	study	O
10	of	O
11	the	O
12	structure	O
13	and	O
14	the	O
15	functional	O
16	role	O
17	of	O
18	the	O
19	MalT	O
20	binding	O
21	sites	O
22	located	O
23	in	O
24	the	O
25	adjacent	O
26	and	O
27	divergent	O
28	pulAp	O
29	and	O
30	pulCp	O
31	promoters	O
32	.	O
1	I	O
2	propose	O
3	that	O
4	their	O
5	gene	O
6	products	O
7	bind	O
8	to	O
9	the	O
10	chromatin	O
11	to	O
12	establish	O
13	or	O
14	maintain	O
15	a	O
16	proper	O
17	higher	O
18	order	O
19	structure	O
20	as	O
21	a	O
22	prerequisite	O
23	for	O
24	a	O
25	regulated	O
26	gene	O
27	expression	O
28	.	O
1	The	O
2	C4BP	O
3	alpha	B
4	gene	O
5	is	O
6	organized	O
7	as	O
8	follows	O
9	:	O
10	the	O
11	first	O
12	exon	O
13	codes	O
14	for	O
15	the	O
16	first	O
17	198	O
18	nucleotides	O
19	of	O
20	the	O
21	5	O
22	'	O
23	UTR	O
24	.	O
1	The	O
2	CDC7	O
3	gene	O
4	has	O
5	two	O
6	in	O
7	-	O
8	frame	O
9	AUG	O
10	codons	O
11	as	O
12	possible	O
13	translation	O
14	start	O
15	sites	O
16	,	O
17	which	O
18	would	O
19	produce	O
20	58	O
21	-	O
22	and	O
23	56	O
24	-	O
25	kDa	O
26	proteins	O
27	,	O
28	respectively	O
29	.	O
1	We	O
2	purified	O
3	a	O
4	Ca2	O
5	+/	O
6	calmodulin	O
7	(	O
8	CaM	O
9	)-	O
10	dependent	O
11	protein	O
12	kinase	B
13	(	O
14	CaM	O
15	kinase	B
16	)	O
17	from	O
18	the	O
19	yeast	O
20	Saccharomyces	O
21	cerevisiae	O
22	with	O
23	properties	O
24	similar	O
25	to	O
26	mammalian	O
27	type	O
28	II	O
29	CaM	O
30	kinases	B
31	.	O
1	Two	O
2	patients	O
3	had	O
4	immediate	O
5	adverse	O
6	effects	O
7	from	O
8	NMF	O
9	;	O
10	one	O
11	had	O
12	a	O
13	grand	O
14	mal	O
15	seizure	O
16	and	O
17	the	O
18	other	O
19	developed	O
20	severe	O
21	abdominal	O
22	pain	O
23	.	O
1	Serum	O
2	TNF	O
3	concentrations	O
4	were	O
5	elevated	O
6	at	O
7	diagnosis	O
8	and	O
9	gradually	O
10	decreased	O
11	toward	O
12	the	O
13	reference	O
14	limits	O
15	by	O
16	week	O
17	16	O
18	.	O
1	Genomic	O
2	clones	O
3	encompassing	O
4	the	O
5	human	O
6	ETS1	O
7	gene	O
8	were	O
9	isolated	O
10	and	O
11	utilized	O
12	to	O
13	define	O
14	its	O
15	molecular	O
16	organization	O
17	.	O
1	Polymerase	O
2	chain	O
3	reaction	O
4	analysis	O
5	of	O
6	ETS1	O
7	cDNA	O
8	identified	O
9	several	O
10	amplified	O
11	products	O
12	,	O
13	indicating	O
14	alternative	O
15	splicing	O
16	.	O
1	Eight	O
2	patients	O
3	with	O
4	ARC	O
5	and	O
6	renal	O
7	failure	O
8	were	O
9	recently	O
10	evaluated	O
11	.	O
1	Hydrophobicity	O
2	analysis	O
3	indicated	O
4	that	O
5	the	O
6	KlaA	O
7	and	O
8	KlaB	O
9	polypeptides	O
10	are	O
11	likely	O
12	to	O
13	be	O
14	soluble	O
15	,	O
16	whereas	O
17	the	O
18	KlaC	O
19	polypeptide	O
20	was	O
21	predicted	O
22	to	O
23	have	O
24	four	O
25	potential	O
26	membrane	O
27	-	O
28	spanning	O
29	domains	O
30	.	O
1	To	O
2	facilitate	O
3	the	O
4	availability	O
5	of	O
6	important	O
7	new	O
8	therapeutic	O
9	agents	O
10	,	O
11	the	O
12	Food	O
13	and	O
14	Drug	O
15	Administration	O
16	(	O
17	FDA	O
18	)	O
19	in	O
20	the	O
21	mid	O
22	-	O
23	1970s	O
24	began	O
25	assigning	O
26	therapeutic	O
27	ratings	O
28	to	O
29	investigational	O
30	new	O
31	drugs	O
32	and	O
33	holding	O
34	end	O
35	-	O
36	of	O
37	-	O
38	phase	O
39	II	O
40	conferences	O
41	with	O
42	drug	O
43	sponsors	O
44	.	O
1	The	O
2	remainder	O
3	(	O
4	18	O
5	.	O
6	4	O
7	%)	O
8	was	O
9	with	O
10	IgA	O
11	nephropathy	O
12	,	O
13	which	O
14	was	O
15	histologically	O
16	mild	O
17	.	O
1	Grossly	O
2	,	O
3	the	O
4	experimental	O
5	vulvitis	O
6	was	O
7	identical	O
8	to	O
9	the	O
10	field	O
11	condition	O
12	,	O
13	and	O
14	bacteria	O
15	indistinguishable	O
16	from	O
17	the	O
18	inoculated	O
19	strains	O
20	were	O
21	reisolated	O
22	.	O
1	3	O
2	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	levels	O
7	of	O
8	oxygen	O
9	free	O
10	radicals	O
11	were	O
12	increased	O
13	in	O
14	hepatocytes	O
15	and	O
16	mitochondria	O
17	.	O
1	The	O
2	sequence	O
3	of	O
4	the	O
5	pMxL1	O
6	plasmid	O
7	containing	O
8	the	O
9	invertible	O
10	region	O
11	contains	O
12	a	O
13	perfect	O
14	tandem	O
15	repeat	O
16	of	O
17	19	O
18	bp	O
19	in	O
20	the	O
21	orientation	O
22	1	O
23	nonexpressed	O
24	pilin	O
25	gene	O
26	at	O
27	the	O
28	middle	O
29	of	O
30	the	O
31	recombination	O
32	junction	O
33	site	O
34	.	O
1	When	O
2	given	O
3	the	O
4	choice	O
5	between	O
6	an	O
7	estrous	O
8	female	O
9	and	O
10	a	O
11	sexually	O
12	active	O
13	male	O
14	in	O
15	the	O
16	AOF	O
17	,	O
18	flutamide	O
19	females	O
20	,	O
21	as	O
22	well	O
23	as	O
24	controls	O
25	,	O
26	preferred	O
27	the	O
28	male	O
29	partner	O
30	.	O
1	A	O
2	method	O
3	for	O
4	establishing	O
5	stimulus	O
6	control	O
7	of	O
8	ethanol	O
9	responding	O
10	was	O
11	developed	O
12	.	O
1	Furthermore	O
2	,	O
3	plasma	O
4	fibrinogen	O
5	levels	O
6	increased	O
7	by	O
8	a	O
9	mean	O
10	of	O
11	17	O
12	.	O
13	6	O
14	%,	O
15	a	O
16	potentially	O
17	adverse	O
18	effect	O
19	of	O
20	gemfibrozil	O
21	that	O
22	has	O
23	not	O
24	been	O
25	previously	O
26	reported	O
27	.	O
1	The	O
2	authors	O
3	evaluate	O
4	the	O
5	clinical	O
6	efficacy	O
7	of	O
8	EMB	O
9	AZS	O
10	in	O
11	recurrent	O
12	ulcer	O
13	after	O
14	operation	O
15	on	O
16	the	O
17	stomach	O
18	caused	O
19	by	O
20	a	O
21	high	O
22	level	O
23	of	O
24	acid	O
25	production	O
26	and	O
27	ulcerative	O
28	gastroduodenal	O
29	bleeding	O
30	.	O
1	To	O
2	investigate	O
3	the	O
4	regulation	O
5	of	O
6	Spec	O
7	gene	O
8	activity	O
9	,	O
10	the	O
11	region	O
12	around	O
13	the	O
14	Spec1	O
15	transcriptional	O
16	initiation	O
17	site	O
18	was	O
19	analyzed	O
20	for	O
21	sites	O
22	of	O
23	protein	O
24	-	O
25	DNA	O
26	interaction	O
27	.	O
1	The	O
2	encoded	O
3	sequence	O
4	revealed	O
5	a	O
6	typical	O
7	signal	O
8	peptide	O
9	,	O
10	a	O
11	predominantly	O
12	hydrophilic	O
13	707	O
14	amino	O
15	acid	O
16	residue	O
17	domain	O
18	with	O
19	8	O
20	N	O
21	-	O
22	glycosylation	O
23	sites	O
24	,	O
25	a	O
26	transmembrane	O
27	domain	O
28	,	O
29	and	O
30	a	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	of	O
36	52	O
37	amino	O
38	acids	O
39	.	O
1	A	O
2	new	O
3	method	O
4	for	O
5	the	O
6	in	O
7	vitro	O
8	transfer	O
9	of	O
10	delayed	O
11	hypersensitivity	O
12	by	O
13	dialysed	O
14	transfer	O
15	factor	O
16	.	O
1	The	O
2	5	O
3	'	O
4	regions	O
5	of	O
6	these	O
7	two	O
8	soybean	O
9	actin	O
10	genes	O
11	contain	O
12	many	O
13	unusual	O
14	features	O
15	including	O
16	(	O
17	CT	O
18	)	O
19	repeats	O
20	and	O
21	long	O
22	stretches	O
23	of	O
24	pyrimidine	O
25	-	O
26	rich	O
27	DNA	O
28	.	O
1	Maternal	O
2	seizures	O
3	had	O
4	occurred	O
5	during	O
6	pregnancy	O
7	in	O
8	52	O
9	per	O
10	cent	O
11	.	O
1	It	O
2	encodes	O
3	a	O
4	protein	O
5	with	O
6	three	O
7	zinc	O
8	fingers	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	transcription	O
15	factor	O
16	Sp1	B
17	.	O
1	The	O
2	interindividual	O
3	variability	O
4	of	O
5	the	O
6	parameters	O
7	is	O
8	taken	O
9	into	O
10	consideration	O
11	by	O
12	interactively	O
13	determining	O
14	the	O
15	threshold	O
16	levels	O
17	.	O
1	Further	O
2	,	O
3	they	O
4	are	O
5	consistent	O
6	with	O
7	the	O
8	suggestion	O
9	that	O
10	sites	O
11	homologous	O
12	to	O
13	the	O
14	CAR1	O
15	URS	O
16	may	O
17	be	O
18	situated	O
19	in	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	regions	O
25	of	O
26	multiple	O
27	unrelated	O
28	yeast	O
29	genes	O
30	.	O
1	Critical	O
2	residues	O
3	required	O
4	for	O
5	repression	O
6	are	O
7	located	O
8	within	O
9	the	O
10	C	O
11	-	O
12	terminal	O
13	27	O
14	amino	O
15	acids	O
16	of	O
17	c	B
18	-	O
19	Fos	O
20	,	O
21	since	O
22	v	O
23	-	O
24	Fos	O
25	and	O
26	C	O
27	-	O
28	terminal	O
29	truncations	O
30	of	O
31	c	B
32	-	O
33	Fos	O
34	did	O
35	not	O
36	down	O
37	regulate	O
38	.	O
1	Thirty	O
2	minutes	O
3	of	O
4	supine	O
5	restraint	O
6	decreased	O
7	DOPAC	O
8	concentrations	O
9	in	O
10	the	O
11	median	O
12	eminence	O
13	of	O
14	female	O
15	rats	O
16	that	O
17	were	O
18	not	O
19	exposed	O
20	to	O
21	ether	O
22	,	O
23	and	O
24	brief	O
25	exposure	O
26	to	O
27	ether	O
28	enhanced	O
29	this	O
30	effect	O
31	.	O
1	Five	O
2	of	O
3	10	O
4	scars	O
5	studied	O
6	decreased	O
7	at	O
8	least	O
9	50	O
10	%	O
11	in	O
12	linear	O
13	dimensions	O
14	.	O
1	A	O
2	second	O
3	isotype	O
4	of	O
5	Raja	O
6	immunoglobulin	O
7	heavy	O
8	chain	O
9	genes	O
10	has	O
11	been	O
12	detected	O
13	by	O
14	screening	O
15	a	O
16	spleen	O
17	cDNA	O
18	library	O
19	with	O
20	homologous	O
21	Raja	O
22	VH	O
23	-	O
24	and	O
25	CH1	O
26	-	O
27	specific	O
28	probes	O
29	complementing	O
30	the	O
31	respective	O
32	regions	O
33	of	O
34	the	O
35	mu	O
36	-	O
37	like	O
38	isotype	O
39	.	O
1	Disruption	O
2	of	O
3	ARF2	O
4	causes	O
5	no	O
6	detectable	O
7	phenotype	O
8	.	O
1	Additionally	O
2	,	O
3	although	O
4	c	B
5	-	O
6	fos	O
7	and	O
8	egr	O
9	-	O
10	1	O
11	mRNAs	O
12	are	O
13	expressed	O
14	at	O
15	elevated	O
16	levels	O
17	in	O
18	stimulated	O
19	liver	O
20	cells	O
21	,	O
22	fos	O
23	-	O
24	B	O
25	,	O
26	fra	O
27	-	O
28	1	O
29	,	O
30	and	O
31	egr	O
32	-	O
33	2	O
34	are	O
35	not	O
36	,	O
37	which	O
38	suggests	O
39	that	O
40	factors	O
41	in	O
42	addition	O
43	to	O
44	the	O
45	serum	O
46	response	O
47	factor	O
48	participate	O
49	in	O
50	the	O
51	regulation	O
52	of	O
53	immediate	O
54	-	O
55	early	O
56	gene	O
57	induction	O
58	.	O
1	The	O
2	experimental	O
3	group	O
4	consisted	O
5	of	O
6	61	O
7	examinees	O
8	class	O
9	II	O
10	/	O
11	2	O
12	orthodontic	O
13	anomalies	O
14	.	O
1	Teicoplanin	O
2	was	O
3	given	O
4	most	O
5	often	O
6	because	O
7	of	O
8	persistent	O
9	fever	O
10	or	O
11	initial	O
12	Gram	O
13	-	O
14	positive	O
15	bacteraemia	O
16	and	O
17	only	O
18	one	O
19	-	O
20	third	O
21	of	O
22	these	O
23	cases	O
24	responded	O
25	.	O
1	Luteinizing	O
2	hormone	O
3	-	O
4	releasing	O
5	hormone	O
6	analog	O
7	therapy	O
8	of	O
9	uterine	O
10	fibroid	O
11	:	O
12	analysis	O
13	of	O
14	results	O
15	obtained	O
16	with	O
17	buserelin	O
18	administered	O
19	intranasally	O
20	and	O
21	goserelin	O
22	administered	O
23	subcutaneously	O
24	as	O
25	a	O
26	monthly	O
27	depot	O
28	.	O
1	In	O
2	Experiments	O
3	1	O
4	and	O
5	2	O
6	,	O
7	infants	O
8	,	O
9	like	O
10	adults	O
11	,	O
12	initially	O
13	categorized	O
14	novel	O
15	objects	O
16	on	O
17	the	O
18	basis	O
19	of	O
20	physical	O
21	appearance	O
22	,	O
23	but	O
24	only	O
25	if	O
26	trained	O
27	with	O
28	multiple	O
29	exemplars	O
30	,	O
31	after	O
32	delays	O
33	of	O
34	1	O
35	and	O
36	7	O
37	days	O
38	.	O
1	The	O
2	clinical	O
3	picture	O
4	of	O
5	the	O
6	disease	O
7	was	O
8	significantly	O
9	different	O
10	from	O
11	anthropogenic	O
12	cutaneous	O
13	leishmaniasis	O
14	caused	O
15	by	O
16	L	O
17	.	O
18	tropica	O
19	but	O
20	similar	O
21	to	O
22	cutaneous	O
23	patterns	O
24	caused	O
25	by	O
26	L	O
27	.	O
28	infantum	O
29	which	O
30	was	O
31	a	O
32	prevalent	O
33	pattern	O
34	in	O
35	the	O
36	southern	O
37	France	O
38	.	O
1	In	O
2	comparison	O
3	with	O
4	the	O
5	16	O
6	introns	O
7	reported	O
8	in	O
9	AHA3	O
10	,	O
11	AHA2	O
12	is	O
13	missing	O
14	one	O
15	intron	O
16	in	O
17	the	O
18	5	O
19	'-	O
20	untranslated	O
21	region	O
22	and	O
23	a	O
24	second	O
25	intron	O
26	in	O
27	the	O
28	C	O
29	-	O
30	terminal	O
31	coding	O
32	region	O
33	.	O
1	A	O
2	needs	O
3	assessment	O
4	of	O
5	these	O
6	families	O
7	was	O
8	also	O
9	done	O
10	.	O
1	The	O
2	3	O
3	'	O
4	stem	O
5	-	O
6	loop	O
7	is	O
8	highly	O
9	divergent	O
10	in	O
11	structure	O
12	among	O
13	species	O
14	and	O
15	lies	O
16	immediately	O
17	upstream	O
18	of	O
19	the	O
20	binding	O
21	site	O
22	for	O
23	Sm	O
24	proteins	O
25	.	O
1	The	O
2	deleted	O
3	nucleotide	O
4	sequence	O
5	corresponded	O
6	to	O
7	sequences	O
8	that	O
9	,	O
10	by	O
11	analogy	O
12	to	O
13	the	O
14	organization	O
15	of	O
16	the	O
17	type	O
18	I	O
19	collagen	O
20	genes	O
21	,	O
22	should	O
23	be	O
24	precisely	O
25	encoded	O
26	by	O
27	exon	O
28	41	O
29	of	O
30	the	O
31	COL3A1	O
32	gene	O
33	.	O
1	The	O
2	4	O
3	days	O
4	dexamethasone	O
5	suppression	O
6	test	O
7	showed	O
8	more	O
9	than	O
10	80	O
11	%	O
12	suppression	O
13	of	O
14	dehydroepiandrosterone	O
15	-	O
16	sulphate	O
17	and	O
18	a	O
19	variable	O
20	(	O
21	40	O
22	-	O
23	60	O
24	%)	O
25	reduction	O
26	of	O
27	testosterone	O
28	and	O
29	androstenedione	O
30	levels	O
31	.	O
1	This	O
2	result	O
3	indicates	O
4	that	O
5	separate	O
6	complexes	O
7	exist	O
8	containing	O
9	ankyrin	O
10	and	O
11	fodrin	O
12	with	O
13	either	O
14	uvomorulin	O
15	or	O
16	Na	O
17	+,	O
18	K	O
19	+-	O
20	ATPase	B
21	.	O
1	The	O
2	PC2	O
3	protein	O
4	also	O
5	shows	O
6	great	O
7	similarity	O
8	to	O
9	the	O
10	incomplete	O
11	NH2	O
12	-	O
13	terminal	O
14	sequence	O
15	of	O
16	the	O
17	human	O
18	furin	O
19	gene	O
20	product	O
21	,	O
22	a	O
23	putative	O
24	membrane	O
25	-	O
26	inserted	O
27	receptor	B
28	-	O
29	like	O
30	molecule	O
31	.	O
1	Whether	O
2	or	O
3	not	O
4	there	O
5	are	O
6	sequences	O
7	conferring	O
8	cAMP	O
9	responsiveness	O
10	which	O
11	are	O
12	common	O
13	both	O
14	to	O
15	P	O
16	-	O
17	450scc	O
18	and	O
19	the	O
20	other	O
21	steroidogenic	O
22	P	O
23	-	O
24	450	O
25	genes	O
26	remains	O
27	to	O
28	be	O
29	established	O
30	.	O
1	The	O
2	zta	O
3	transactivator	O
4	involved	O
5	in	O
6	induction	O
7	of	O
8	lytic	O
9	cycle	O
10	gene	O
11	expression	O
12	in	O
13	Epstein	O
14	-	O
15	Barr	O
16	virus	O
17	-	O
18	infected	O
19	lymphocytes	O
20	binds	O
21	to	O
22	both	O
23	AP	B
24	-	O
25	1	O
26	and	O
27	ZRE	O
28	sites	O
29	in	O
30	target	O
31	promoter	O
32	and	O
33	enhancer	O
34	regions	O
35	.	O
1	Constructs	O
2	were	O
3	made	O
4	in	O
5	which	O
6	an	O
7	AATAAA	O
8	and	O
9	the	O
10	GT	O
11	-	O
12	rich	O
13	region	O
14	were	O
15	separated	O
16	by	O
17	various	O
18	distances	O
19	ranging	O
20	from	O
21	7	O
22	to	O
23	43	O
24	bp	O
25	.	O
1	We	O
2	show	O
3	that	O
4	cytR	O
5	expression	O
6	is	O
7	negatively	O
8	controlled	O
9	by	O
10	the	O
11	CytR	O
12	protein	O
13	and	O
14	positively	O
15	affected	O
16	by	O
17	the	O
18	cAMP	O
19	/	O
20	CAP	O
21	complex	O
22	.	O
1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	the	O
7	deduced	O
8	amino	O
9	acid	O
10	sequence	O
11	of	O
12	the	O
13	3T3	O
14	-	O
15	L1	O
16	adipocyte	O
17	insulin	B
18	receptor	I
19	of	O
20	the	O
21	mouse	O
22	was	O
23	determined	O
24	.	O
1	It	O
2	is	O
3	likely	O
4	that	O
5	the	O
6	sequence	O
7	similarities	O
8	reflect	O
9	a	O
10	common	O
11	molecular	O
12	architecture	O
13	of	O
14	the	O
15	two	O
16	heme	O
17	binding	O
18	sites	O
19	and	O
20	of	O
21	a	O
22	copper	O
23	binding	O
24	site	O
25	in	O
26	these	O
27	enzymes	O
28	.	O
1	To	O
2	characterize	O
3	the	O
4	O7	O
5	-	O
6	LPS	O
7	region	O
8	,	O
9	the	O
10	recombinant	O
11	cosmids	O
12	pJHCV31	O
13	and	O
14	pJHCV32	O
15	were	O
16	mutagenized	O
17	by	O
18	transposon	O
19	mutagenesis	O
20	with	O
21	Tn3HoHo1	O
22	,	O
23	which	O
24	carries	O
25	a	O
26	promoterless	O
27	lac	O
28	operon	O
29	and	O
30	can	O
31	therefore	O
32	generate	O
33	lacZ	O
34	transcriptional	O
35	fusions	O
36	with	O
37	target	O
38	DNA	O
39	sequences	O
40	.	O
1	To	O
2	determine	O
3	whether	O
4	vanadate	O
5	could	O
6	inhibit	O
7	PEPCK	O
8	gene	O
9	transcription	O
10	,	O
11	a	O
12	series	O
13	of	O
14	chimeric	O
15	genes	O
16	containing	O
17	several	O
18	deletions	O
19	in	O
20	the	O
21	P	O
22	-	O
23	enolypyruvate	O
24	carboxykinase	O
25	promoter	O
26	between	O
27	-	O
28	550	O
29	and	O
30	-	O
31	68	O
32	was	O
33	linked	O
34	to	O
35	the	O
36	structural	O
37	genes	O
38	for	O
39	either	O
40	amino	O
41	-	O
42	3	O
43	-	O
44	glycosyl	O
45	phosphotransferase	O
46	(	O
47	neo	O
48	)	O
49	or	O
50	chloramphenicol	O
51	acetyltransferase	O
52	and	O
53	introduced	O
54	into	O
55	hepatoma	O
56	cells	O
57	using	O
58	three	O
59	methods	O
60	:	O
61	(	O
62	a	O
63	)	O
64	infection	O
65	with	O
66	a	O
67	Moloney	O
68	murine	O
69	leukemia	O
70	virus	O
71	-	O
72	based	O
73	retrovirus	O
74	,	O
75	(	O
76	b	O
77	)	O
78	transfection	O
79	and	O
80	stable	O
81	selection	O
82	for	O
83	neo	O
84	expression	O
85	,	O
86	or	O
87	(	O
88	c	B
89	)	O
90	transient	O
91	expression	O
92	of	O
93	chloroamphenicol	O
94	acetyltransferase	O
95	.	O
1	In	O
2	order	O
3	to	O
4	characterize	O
5	the	O
6	functional	O
7	elements	O
8	of	O
9	the	O
10	promoter	O
11	that	O
12	in	O
13	some	O
14	way	O
15	must	O
16	respond	O
17	to	O
18	these	O
19	regulatory	O
20	signals	O
21	,	O
22	a	O
23	number	O
24	of	O
25	promoter	O
26	mutations	O
27	were	O
28	constructed	O
29	,	O
30	including	O
31	a	O
32	set	O
33	of	O
34	linker	O
35	-	O
36	scanning	O
37	mutations	O
38	across	O
39	the	O
40	entire	O
41	promoter	O
42	region	O
43	.	O
1	A	O
2	DNA	O
3	motif	O
4	related	O
5	to	O
6	the	O
7	cAMP	O
8	-	O
9	responsive	O
10	element	O
11	and	O
12	an	O
13	exon	O
14	-	O
15	located	O
16	activator	O
17	protein	O
18	-	O
19	2	O
20	binding	O
21	site	O
22	in	O
23	the	O
24	human	O
25	tissue	O
26	-	O
27	type	O
28	plasminogen	O
29	activator	O
30	gene	O
31	promoter	O
32	cooperate	O
33	in	O
34	basal	O
35	expression	O
36	and	O
37	convey	O
38	activation	O
39	by	O
40	phorbol	O
41	ester	O
42	and	O
43	cAMP	O
44	.	O
1	The	O
2	transcripts	O
3	were	O
4	equally	O
5	active	O
6	with	O
7	or	O
8	without	O
9	a	O
10	5	O
11	'	O
12	methylated	O
13	capstructure	O
14	as	O
15	expected	O
16	,	O
17	since	O
18	EMCV	O
19	-	O
20	RNA	O
21	is	O
22	one	O
23	of	O
24	the	O
25	mRNAs	O
26	capable	O
27	of	O
28	internal	O
29	initiation	O
30	.	O
1	The	O
2	electrically	O
3	induced	O
4	motile	O
5	responses	O
6	were	O
7	not	O
8	suppressed	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	dinitrophenol	O
14	or	O
15	cytochalasin	O
16	B	O
17	.	O
1	Blood	O
2	flow	O
3	and	O
4	velocity	O
5	(	O
6	measured	O
7	using	O
8	Doppler	O
9	ultrasound	O
10	)	O
11	gradually	O
12	decreased	O
13	during	O
14	diastole	O
15	and	O
16	ultimately	O
17	reversed	O
18	in	O
19	direction	O
20	as	O
21	cotyledon	O
22	resistance	O
23	was	O
24	increased	O
25	up	O
26	to	O
27	14	O
28	fold	O
29	.	O
1	The	O
2	ANB1	O
3	locus	O
4	of	O
5	Saccharomyces	O
6	cerevisiae	O
7	encodes	O
8	the	O
9	protein	O
10	synthesis	O
11	initiation	O
12	factor	O
13	eIF	O
14	-	O
15	4D	O
16	.	O
1	Therapeutic	O
2	effects	O
3	of	O
4	cefpirome	O
5	(	O
6	HR	O
7	810	O
8	)	O
9	on	O
10	experimental	O
11	mixed	O
12	infections	O
13	with	O
14	Enterococcus	O
15	faecalis	O
16	and	O
17	Escherichia	O
18	coli	O
19	in	O
20	mice	O
21	.	O
1	Homozygous	O
2	individuals	O
3	usually	O
4	develop	O
5	purpura	O
6	fulminans	O
7	as	O
8	newborns	O
9	;	O
10	heterozygous	O
11	protein	O
12	C	O
13	-	O
14	deficient	O
15	individuals	O
16	are	O
17	at	O
18	increased	O
19	risk	O
20	for	O
21	venous	O
22	thrombosis	O
23	and	O
24	pulmonary	O
25	embolism	O
26	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	5	O
6	KE	O
7	X	O
8	3	O
9	/	O
10	W	O
11	may	O
12	be	O
13	the	O
14	optimal	O
15	regimen	O
16	to	O
17	augment	O
18	the	O
19	antitumor	O
20	immunity	O
21	of	O
22	RNL	O
23	.	O
1	Analysis	O
2	of	O
3	various	O
4	deletion	O
5	mutants	O
6	indicates	O
7	that	O
8	the	O
9	sequence	O
10	requirements	O
11	for	O
12	binding	O
13	by	O
14	QBP	O
15	in	O
16	vitro	O
17	are	O
18	indistinguishable	O
19	from	O
20	those	O
21	necessary	O
22	for	O
23	Q	O
24	activity	O
25	in	O
26	vivo	O
27	,	O
28	strongly	O
29	suggesting	O
30	that	O
31	QBP	O
32	is	O
33	required	O
34	for	O
35	the	O
36	function	O
37	of	O
38	this	O
39	TATA	O
40	-	O
41	independent	O
42	promoter	O
43	.	O
1	Yeast	O
2	Gal11	O
3	protein	O
4	mediates	O
5	the	O
6	transcriptional	O
7	activation	O
8	signal	O
9	of	O
10	two	O
11	different	O
12	transacting	O
13	factors	O
14	,	O
15	Gal4	O
16	and	O
17	general	O
18	regulatory	O
19	factor	O
20	I	O
21	/	O
22	repressor	O
23	/	O
24	activator	O
25	site	O
26	binding	O
27	protein	O
28	1	O
29	/	O
30	translation	O
31	upstream	O
32	factor	O
33	.	O
1	The	O
2	juxtamembrane	O
3	region	O
4	of	O
5	the	O
6	insulin	B
7	receptor	I
8	(	O
9	IR	O
10	)	O
11	beta	B
12	-	O
13	subunit	O
14	contains	O
15	an	O
16	unphosphorylated	O
17	tyrosyl	O
18	residue	O
19	(	O
20	Tyr960	O
21	)	O
22	that	O
23	is	O
24	essential	O
25	for	O
26	insulin	B
27	-	O
28	stimulated	O
29	tyrosyl	O
30	phosphorylation	O
31	of	O
32	some	O
33	endogenous	O
34	substrates	O
35	and	O
36	certain	O
37	biological	O
38	responses	O
39	(	O
40	White	O
41	,	O
42	M	O
43	.	O
44	F	O
45	.,	O
46	Livingston	O
47	,	O
48	J	O
49	.	O
50	N	O
51	.,	O
52	Backer	O
53	,	O
54	J	O
55	.	O
56	M	O
57	.,	O
58	Lauris	O
59	,	O
60	V	O
61	.,	O
62	Dull	O
63	,	O
64	T	O
65	.	O
66	J	O
67	.,	O
68	Ullrich	O
69	,	O
70	A	O
71	.,	O
72	and	O
73	Kahn	O
74	,	O
75	C	O
76	.	O
77	R	O
78	.	O
1	Pups	O
2	placed	O
3	into	O
4	the	O
5	novel	O
6	environment	O
7	with	O
8	their	O
9	mothers	O
10	exhibited	O
11	an	O
12	intermediate	O
13	level	O
14	of	O
15	DA	O
16	turnover	O
17	.	O
1	The	O
2	efficacy	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	novel	O
8	percutaneous	O
9	anaesthetic	O
10	preparation	O
11	based	O
12	on	O
13	amethocaine	O
14	has	O
15	been	O
16	investigated	O
17	in	O
18	the	O
19	paediatric	O
20	clinical	O
21	environment	O
22	.	O
1	The	O
2	grandfather	O
3	and	O
4	the	O
5	granddaughter	O
6	both	O
7	had	O
8	microtia	O
9	and	O
10	meatal	O
11	atresia	O
12	,	O
13	whereas	O
14	the	O
15	daughter	O
16	had	O
17	a	O
18	normal	O
19	outer	O
20	ear	O
21	except	O
22	for	O
23	a	O
24	narrow	O
25	meatus	O
26	and	O
27	auricular	O
28	appendages	O
29	.	O
1	Abnormal	O
2	intrapulmonary	O
3	shunting	O
4	(	O
5	IPS	O
6	),	O
7	which	O
8	was	O
9	proved	O
10	in	O
11	4	O
12	cases	O
13	by	O
14	whole	O
15	-	O
16	body	O
17	radionuclide	O
18	scanning	O
19	with	O
20	99mTc	O
21	-	O
22	MAA	O
23	,	O
24	is	O
25	suggested	O
26	as	O
27	the	O
28	major	O
29	cause	O
30	of	O
31	cyanosis	O
32	in	O
33	liver	O
34	cirrhosis	O
35	.	O
1	The	O
2	urinary	O
3	protein	O
4	,	O
5	serum	O
6	albumin	O
7	,	O
8	BUN	O
9	and	O
10	SCr	O
11	all	O
12	had	O
13	very	O
14	significant	O
15	improvement	O
16	.	O
1	More	O
2	generally	O
3	,	O
4	Ets1	O
5	and	O
6	Ets2	O
7	could	O
8	regulate	O
9	transcription	O
10	of	O
11	cellular	O
12	genes	O
13	.	O
1	Horseradish	O
2	peroxidase	O
3	as	O
4	a	O
5	permeability	O
6	marker	O
7	in	O
8	injured	O
9	rat	O
10	caudal	O
11	and	O
12	iliac	O
13	arteries	O
14	.	O
1	2	O
2	.	O
1	Chick	O
2	brain	O
3	actin	O
4	depolymerizing	O
5	factor	O
6	(	O
7	ADF	O
8	)	O
9	is	O
10	a	O
11	19	O
12	-	O
13	kDa	O
14	protein	O
15	that	O
16	severs	O
17	actin	O
18	filaments	O
19	and	O
20	binds	O
21	actin	O
22	monomers	O
23	.	O
1	Initial	O
2	experience	O
3	with	O
4	a	O
5	serotonin	O
6	agonist	O
7	.	O
1	Primer	O
2	extension	O
3	analysis	O
4	and	O
5	RNA	O
6	sequencing	O
7	demonstrates	O
8	that	O
9	the	O
10	transcription	O
11	start	O
12	point	O
13	of	O
14	rat	O
15	ODC	O
16	mRNA	O
17	is	O
18	located	O
19	303	O
20	nt	O
21	upstream	O
22	from	O
23	the	O
24	A	O
25	residue	O
26	in	O
27	the	O
28	start	O
29	codon	O
30	.	O
1	Patients	O
2	with	O
3	detectable	O
4	serum	O
5	TNF	O
6	levels	O
7	had	O
8	significantly	O
9	lower	O
10	serum	O
11	T3	O
12	concentrations	O
13	compared	O
14	to	O
15	those	O
16	with	O
17	undetectable	O
18	levels	O
19	[	O
20	1	O
21	.	O
22	072	O
23	+/-	O
24	0	O
25	.	O
26	588	O
27	vs	O
28	.	O
1	Each	O
2	parent	O
3	interacted	O
4	with	O
5	their	O
6	4	O
7	-	O
8	or	O
9	5	O
10	-	O
11	year	O
12	-	O
13	old	O
14	son	O
15	or	O
16	daughter	O
17	in	O
18	each	O
19	of	O
20	two	O
21	conversations	O
22	--	O
23	unstructured	O
24	(	O
25	social	O
26	conversation	O
27	)	O
28	and	O
29	structured	O
30	(	O
31	task	O
32	activity	O
33	).	O
1	As	O
2	in	O
3	mammals	O
4	,	O
5	considerable	O
6	nucleotide	O
7	diversity	O
8	was	O
9	observed	O
10	at	O
11	the	O
12	junctions	O
13	of	O
14	the	O
15	variable	O
16	,	O
17	diversity	O
18	,	O
19	and	O
20	joining	O
21	elements	O
22	in	O
23	chicken	O
24	TCR	O
25	beta	B
26	cDNAs	O
27	.	O
1	The	O
2	protooncogene	O
3	c	B
4	-	O
5	myb	O
6	encodes	O
7	a	O
8	nuclear	O
9	transcription	O
10	factor	O
11	that	O
12	binds	O
13	to	O
14	DNA	O
15	in	O
16	a	O
17	sequence	O
18	-	O
19	specific	O
20	manner	O
21	and	O
22	transactivates	O
23	transcription	O
24	of	O
25	several	O
26	viral	O
27	and	O
28	cellular	O
29	genes	O
30	.	O
1	We	O
2	have	O
3	now	O
4	identified	O
5	,	O
6	after	O
7	21	O
8	serial	O
9	undiluted	O
10	passages	O
11	of	O
12	MHV	O
13	,	O
14	a	O
15	small	O
16	DI	O
17	RNA	O
18	,	O
19	DIssF	O
20	,	O
21	which	O
22	is	O
23	efficiently	O
24	packaged	O
25	into	O
26	virions	O
27	.	O
1	The	O
2	TUP1	O
3	gene	O
4	was	O
5	isolated	O
6	in	O
7	a	O
8	screen	O
9	for	O
10	genes	O
11	that	O
12	regulate	O
13	mating	O
14	type	O
15	(	O
16	V	O
17	.	O
18	L	O
19	.	O
1	Interestingly	O
2	,	O
3	disruption	O
4	of	O
5	the	O
6	VPS34	O
7	locus	O
8	resulted	O
9	in	O
10	a	O
11	temperature	O
12	-	O
13	sensitive	O
14	growth	O
15	defect	O
16	,	O
17	indicating	O
18	that	O
19	the	O
20	VPS34	O
21	gene	O
22	is	O
23	essential	O
24	for	O
25	vegetative	O
26	growth	O
27	only	O
28	at	O
29	elevated	O
30	growth	O
31	temperatures	O
32	.	O
1	This	O
2	interaction	O
3	occurs	O
4	over	O
5	a	O
6	wide	O
7	range	O
8	of	O
9	both	O
10	parameters	O
11	;	O
12	for	O
13	charge	O
14	density	O
15	from	O
16	at	O
17	least	O
18	10	O
19	to	O
20	800	O
21	microC	O
22	/	O
23	cm2	O
24	and	O
25	,	O
26	for	O
27	charge	O
28	per	O
29	phase	O
30	,	O
31	from	O
32	at	O
33	least	O
34	0	O
35	.	O
36	05	O
37	to	O
38	5	O
39	.	O
40	0	O
41	microC	O
42	per	O
43	phase	O
44	.	O
1	Results	O
2	have	O
3	surprisingly	O
4	revealed	O
5	the	O
6	presence	O
7	of	O
8	three	O
9	U14	O
10	snRNA	O
11	-	O
12	homologous	O
13	regions	O
14	positioned	O
15	within	O
16	introns	O
17	5	O
18	,	O
19	6	O
20	,	O
21	and	O
22	8	O
23	of	O
24	the	O
25	mouse	O
26	cognate	O
27	hsc70	O
28	heat	O
29	shock	O
30	gene	O
31	.	O
1	The	O
2	Mauriceville	O
3	and	O
4	Varkud	O
5	mitochondrial	O
6	plasmids	O
7	are	O
8	closely	O
9	related	O
10	,	O
11	closed	O
12	-	O
13	circular	O
14	DNAs	O
15	(	O
16	3	O
17	.	O
18	6	O
19	and	O
20	3	O
21	.	O
22	7	O
23	kb	O
24	,	O
25	respectively	O
26	)	O
27	that	O
28	have	O
29	characteristics	O
30	of	O
31	mtDNA	O
32	introns	O
33	and	O
34	retroid	O
35	elements	O
36	.	O
1	Finally	O
2	,	O
3	a	O
4	complementary	O
5	footprinting	O
6	analysis	O
7	of	O
8	the	O
9	upstream	O
10	region	O
11	of	O
12	the	O
13	constitutively	O
14	expressed	O
15	HSC82	O
16	gene	O
17	reveals	O
18	the	O
19	presence	O
20	of	O
21	three	O
22	discrete	O
23	protein	O
24	complexes	O
25	.	O
1	Pathophysiology	O
2	of	O
3	bone	O
4	loss	O
5	in	O
6	castrated	O
7	animals	O
8	.	O
1	First	O
2	,	O
3	each	O
4	lung	O
5	was	O
6	cut	O
7	into	O
8	slices	O
9	,	O
10	from	O
11	which	O
12	primary	O
13	disectors	O
14	were	O
15	sampled	O
16	systematically	O
17	with	O
18	a	O
19	known	O
20	sampling	O
21	fraction	O
22	.	O
1	Common	O
2	foot	O
3	pathologies	O
4	are	O
5	heel	O
6	pain	O
7	,	O
8	metatarsalgia	O
9	,	O
10	hammertoes	O
11	and	O
12	clawtoes	O
13	,	O
14	bunions	O
15	,	O
16	hallux	O
17	rigidus	O
18	,	O
19	corns	O
20	and	O
21	calluses	O
22	,	O
23	nail	O
24	pathologies	O
25	,	O
26	arthritis	O
27	,	O
28	and	O
29	neuropathies	O
30	.	O
1	Ultrastructural	O
2	and	O
3	morphometric	O
4	study	O
5	of	O
6	the	O
7	myeloid	O
8	parenchyma	O
9	cells	O
10	of	O
11	mice	O
12	prior	O
13	and	O
14	after	O
15	X	O
16	-	O
17	ray	O
18	exposure	O
1	Using	O
2	an	O
3	audiotape	O
4	cassette	O
5	and	O
6	headphones	O
7	the	O
8	duration	O
9	of	O
10	the	O
11	hallucinations	O
12	decreased	O
13	significantly	O
14	.	O
1	Very	O
2	good	O
3	accuracy	O
4	(	O
5	r	O
6	greater	O
7	than	O
8	0	O
9	.	O
10	9	O
11	)	O
12	was	O
13	found	O
14	when	O
15	except	O
16	comparing	O
17	H	O
18	*	O
19	2	O
20	with	O
21	the	O
22	other	O
23	machine	O
24	and	O
25	the	O
26	reference	O
27	methods	O
28	,	O
29	except	O
30	for	O
31	MCHCH	O
32	and	O
33	basophil	O
34	count	O
35	.	O
1	Interlimb	O
2	coordination	O
3	during	O
4	fictive	O
5	locomotion	O
6	in	O
7	the	O
8	thalamic	O
9	cat	O
10	.	O
1	By	O
2	introducing	O
3	a	O
4	series	O
5	of	O
6	deletions	O
7	in	O
8	the	O
9	vimentin	O
10	promoter	O
11	,	O
12	we	O
13	further	O
14	restrict	O
15	these	O
16	sequences	O
17	to	O
18	30	O
19	base	O
20	pairs	O
21	,	O
22	located	O
23	between	O
24	241	O
25	and	O
26	210	O
27	base	O
28	pairs	O
29	upstream	O
30	of	O
31	the	O
32	mRNA	O
33	cap	O
34	site	O
35	.	O
1	To	O
2	determine	O
3	the	O
4	effects	O
5	on	O
6	the	O
7	pulmonary	O
8	barrier	O
9	of	O
10	several	O
11	surface	O
12	active	O
13	agents	O
14	,	O
15	a	O
16	series	O
17	of	O
18	metered	O
19	dose	O
20	inhalers	O
21	(	O
22	MDIs	O
23	)	O
24	was	O
25	prepared	O
26	and	O
27	used	O
28	to	O
29	dose	O
30	aerosolized	O
31	surfactant	O
32	to	O
33	the	O
34	airways	O
35	of	O
36	isolated	O
37	perfused	O
38	rat	O
39	lungs	O
40	.	O
1	The	O
2	therapeutic	O
3	protocole	O
4	used	O
5	at	O
6	the	O
7	Gustave	O
8	Roussy	O
9	Institute	O
10	for	O
11	invasive	O
12	epithelioma	O
13	of	O
14	the	O
15	uterine	O
16	cervix	O
17	rests	O
18	,	O
19	for	O
20	limited	O
21	forms	O
22	(	O
23	T1B	O
24	-	O
25	T2	O
26	proximal	O
27	),	O
28	on	O
29	combined	O
30	radiology	O
31	and	O
32	surgery	O
33	.	O
1	In	O
2	the	O
3	first	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	Sprague	O
9	-	O
10	Dawley	O
11	male	O
12	rats	O
13	were	O
14	implanted	O
15	unilaterally	O
16	with	O
17	guide	O
18	cannulas	O
19	aimed	O
20	at	O
21	the	O
22	lateral	O
23	ventricle	O
24	.	O
1	The	O
2	persistence	O
3	of	O
4	members	O
5	of	O
6	the	O
7	prostigmatid	O
8	families	O
9	Tydeidae	O
10	,	O
11	Nanorchestidae	O
12	and	O
13	Tarsonemidae	O
14	in	O
15	the	O
16	moisture	O
17	-	O
18	deficient	O
19	90	O
20	%-	O
21	concentration	O
22	treatments	O
23	supports	O
24	previous	O
25	evidence	O
26	of	O
27	adaptations	O
28	to	O
29	low	O
30	-	O
31	water	O
32	-	O
33	content	O
34	habitats	O
35	.	O
1	The	O
2	coding	O
3	sequences	O
4	of	O
5	the	O
6	Crry	O
7	gene	O
8	encompass	O
9	over	O
10	25	O
11	kb	O
12	of	O
13	DNA	O
14	,	O
15	whereas	O
16	the	O
17	Crry	O
18	-	O
19	ps	O
20	sequences	O
21	are	O
22	included	O
23	within	O
24	a	O
25	single	O
26	5	O
27	.	O
28	6	O
29	-	O
30	kb	O
31	Eco	O
32	-	O
33	R1	O
34	fragment	O
35	.	O
1	The	O
2	abscess	O
3	was	O
4	debrided	O
5	and	O
6	the	O
7	septum	O
8	was	O
9	patched	O
10	with	O
11	a	O
12	single	O
13	layer	O
14	of	O
15	autologous	O
16	pericardium	O
17	.	O
1	In	O
2	18	O
3	%	O
4	lymphography	O
5	was	O
6	clearly	O
7	positive	O
8	and	O
9	CT	O
10	negative	O
11	.	O
1	Senior	O
2	systems	O
3	--	O
4	45	O
5	;	O
6	Mental	O
7	health	O
8	and	O
9	illness	O
10	in	O
11	old	O
12	age	O
13	--	O
14	3	O
15	.	O
1	The	O
2	clinical	O
3	relevance	O
4	of	O
5	these	O
6	findings	O
7	is	O
8	strengthened	O
9	by	O
10	the	O
11	observation	O
12	that	O
13	similar	O
14	results	O
15	were	O
16	obtained	O
17	when	O
18	P	O
19	.	O
20	HCl	O
21	was	O
22	given	O
23	by	O
24	the	O
25	intravenous	O
26	route	O
27	.	O
1	The	O
2	procedure	O
3	has	O
4	been	O
5	applied	O
6	to	O
7	three	O
8	materials	O
9	:	O
10	particle	O
11	board	O
12	with	O
13	carpet	O
14	;	O
15	gypsum	O
16	board	O
17	with	O
18	wallpaper	O
19	;	O
20	and	O
21	plywood	O
22	with	O
23	polyurethane	O
24	lacquer	O
25	,	O
26	for	O
27	which	O
28	the	O
29	steady	O
30	-	O
31	state	O
32	emission	O
33	factors	O
34	(	O
35	mg	O
36	m	O
37	-	O
38	2	O
39	h	O
40	-	O
41	1	O
42	)	O
43	of	O
44	several	O
45	compounds	O
46	are	O
47	given	O
48	.	O
1	After	O
2	4	O
3	h	O
4	,	O
5	lesions	O
6	in	O
7	the	O
8	secretory	O
9	part	O
10	of	O
11	the	O
12	stomach	O
13	were	O
14	scored	O
15	and	O
16	mucosal	O
17	prostaglandin	O
18	E2	O
19	synthesis	O
20	was	O
21	determined	O
22	by	O
23	the	O
24	ex	O
25	vivo	O
26	prostaglandin	O
27	generation	O
28	technique	O
29	.	O
1	A	O
2	second	O
3	,	O
4	novel	O
5	C	O
6	subunit	O
7	(	O
8	CeCAT	O
9	alpha	B
10	',	O
11	374	O
12	residues	O
13	)	O
14	has	O
15	a	O
16	unique	O
17	56	O
18	-	O
19	residue	O
20	carboxyl	O
21	-	O
22	terminal	O
23	region	O
24	that	O
25	is	O
26	generated	O
27	by	O
28	the	O
29	alternative	O
30	splicing	O
31	of	O
32	the	O
33	C	O
34	pre	O
35	-	O
36	mRNA	O
37	.	O
1	The	O
2	alternative	O
3	exon	O
4	introduces	O
5	the	O
6	novel	O
7	carboxyl	O
8	terminus	O
9	and	O
10	a	O
11	new	O
12	translation	O
13	stop	O
14	signal	O
15	,	O
16	while	O
17	simultaneously	O
18	converting	O
19	the	O
20	coding	O
21	sequence	O
22	for	O
23	40	O
24	carboxyl	O
25	-	O
26	terminal	O
27	residues	O
28	in	O
29	CeCAT	O
30	alpha	B
31	into	O
32	3	O
33	'-	O
34	untranslated	O
35	nucleotides	O
36	.	O
1	Methods	O
2	used	O
3	include	O
4	Cobb	O
5	angle	O
6	and	O
7	a	O
8	segmental	O
9	evaluation	O
10	(	O
11	T7	O
12	-	O
13	T12	O
14	)	O
15	of	O
16	each	O
17	of	O
18	convex	O
19	and	O
20	concave	O
21	rib	O
22	-	O
23	vertebra	O
24	angles	O
25	(	O
26	RVAs	O
27	),	O
28	rib	O
29	-	O
30	vertebra	O
31	angle	O
32	differences	O
33	(	O
34	RVADs	O
35	),	O
36	vertebral	O
37	rotation	O
38	,	O
39	tilt	O
40	and	O
41	displacement	O
42	.	O
1	In	O
2	a	O
3	stepwise	O
4	logistic	O
5	regression	O
6	analysis	O
7	of	O
8	SPT	O
9	and	O
10	RAST	O
11	data	O
12	,	O
13	the	O
14	occurrence	O
15	of	O
16	serum	O
17	IgE	O
18	antibodies	O
19	to	O
20	P	O
21	.	O
22	orbiculare	O
23	had	O
24	the	O
25	highest	O
26	explanatory	O
27	value	O
28	for	O
29	current	O
30	eczema	O
31	.	O
1	Effect	O
2	of	O
3	hyperglycemia	O
4	on	O
5	pain	O
6	threshold	O
7	in	O
8	alloxan	O
9	-	O
10	diabetic	O
11	rats	O
12	.	O
1	Basing	O
2	on	O
3	experimental	O
4	toxicity	O
5	research	O
6	it	O
7	was	O
8	established	O
9	that	O
10	,	O
11	out	O
12	of	O
13	50	O
14	atmosphere	O
15	metal	O
16	corrosion	O
17	inhibitors	O
18	,	O
19	some	O
20	14	O
21	per	O
22	cent	O
23	were	O
24	found	O
25	extremely	O
26	hazardous	O
27	,	O
28	42	O
29	per	O
30	cent	O
31	--	O
32	of	O
33	high	O
34	level	O
35	hazardous	O
36	,	O
37	33	O
38	percent	O
39	--	O
40	of	O
41	moderate	O
42	and	O
43	11	O
44	per	O
45	cent	O
46	--	O
47	of	O
48	low	O
49	hazardous	O
50	.	O
1	Dermal	O
2	toxicity	O
3	and	O
4	carcinogenicity	O
5	of	O
6	4	O
7	-	O
8	vinyl	O
9	-	O
10	1	O
11	-	O
12	cyclohexene	O
13	diepoxide	O
14	in	O
15	Fischer	O
16	rats	O
17	and	O
18	B6C3F1	O
19	mice	O
20	.	O
1	MK	O
2	-	O
3	927	O
4	:	O
5	a	O
6	topically	O
7	active	O
8	ocular	O
9	hypotensive	O
10	carbonic	O
11	anhydrase	O
12	inhibitor	O
13	.	O
1	100	O
2	of	O
3	the	O
4	patients	O
5	who	O
6	would	O
7	have	O
8	died	O
9	survive	O
10	.	O
1	Thus	O
2	adaptation	O
3	to	O
4	continuous	O
5	mild	O
6	stress	O
7	has	O
8	a	O
9	potent	O
10	antiarrhythmic	O
11	effect	O
12	which	O
13	occurs	O
14	due	O
15	to	O
16	the	O
17	increased	O
18	vagal	O
19	tone	O
20	.	O
1	The	O
2	RF	O
3	values	O
4	correlated	O
5	well	O
6	with	O
7	the	O
8	angiographic	O
9	semiquantitative	O
10	scale	O
11	of	O
12	severity	O
13	of	O
14	aortal	O
15	insufficiency	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	805	O
22	;	O
23	p	O
24	less	O
25	than	O
26	0	O
27	.	O
28	001	O
29	),	O
30	although	O
31	they	O
32	enabled	O
33	the	O
34	authors	O
35	only	O
36	to	O
37	make	O
38	a	O
39	partial	O
40	differentiation	O
41	of	O
42	haemodynamically	O
43	severe	O
44	regurgitations	O
45	and	O
46	mild	O
47	or	O
48	insignificant	O
49	ones	O
50	.	O
1	Results	O
2	of	O
3	the	O
4	long	O
5	-	O
6	term	O
7	observation	O
8	and	O
9	treatment	O
10	of	O
11	patients	O
12	with	O
13	arterial	O
14	hypertension	O
1	Comparison	O
2	of	O
3	propofol	O
4	and	O
5	thiopentone	O
6	as	O
7	anaesthetic	O
8	agents	O
9	for	O
10	electroconvulsive	O
11	therapy	O
12	.	O
1	All	O
2	ABFI	O
3	-	O
4	binding	O
5	sites	O
6	,	O
7	regardless	O
8	of	O
9	origin	O
10	,	O
11	provided	O
12	weak	O
13	UAS	O
14	function	O
15	in	O
16	vivo	O
17	when	O
18	examined	O
19	in	O
20	test	O
21	plasmids	O
22	.	O
1	These	O
2	characteristics	O
3	of	O
4	N22	O
5	/	O
6	P22	O
7	indicate	O
8	that	O
9	it	O
10	is	O
11	a	O
12	localized	O
13	synaptically	O
14	dependent	O
15	event	O
16	conforming	O
17	to	O
18	a	O
19	transverse	O
20	dipole	O
21	with	O
22	dorsal	O
23	negativity	O
24	and	O
25	a	O
26	simultaneous	O
27	anterior	O
28	positivity	O
29	.	O
1	The	O
2	levels	O
3	of	O
4	both	O
5	MAP1	O
6	-	O
7	specific	O
8	and	O
9	MAP2	O
10	-	O
11	specific	O
12	mRNAs	O
13	decline	O
14	in	O
15	the	O
16	postnatal	O
17	developing	O
18	brain	O
19	;	O
20	the	O
21	level	O
22	of	O
23	MAP1	O
24	-	O
25	specific	O
26	mRNA	O
27	also	O
28	increases	O
29	slightly	O
30	in	O
31	rat	O
32	PC12	O
33	cells	O
34	upon	O
35	exposure	O
36	to	O
37	nerve	O
38	growth	O
39	factor	O
40	.	O
1	Furthermore	O
2	,	O
3	beta	B
4	2	O
5	-	O
6	adrenoceptor	O
7	sensitivity	O
8	appears	O
9	to	O
10	be	O
11	unaltered	O
12	in	O
13	BHT	O
14	.	O
1	The	O
2	4	O
3	-	O
4	AP	B
5	(	O
6	4	O
7	-	O
8	20	O
9	mM	O
10	)	O
11	effect	O
12	resulted	O
13	in	O
14	a	O
15	decrease	O
16	of	O
17	the	O
18	sensory	O
19	activity	O
20	,	O
21	which	O
22	was	O
23	fully	O
24	restored	O
25	by	O
26	TEA	O
27	or	O
28	Ba2	O
29	+.	O
1	Hybridization	O
2	of	O
3	a	O
4	probe	O
5	from	O
6	this	O
7	region	O
8	to	O
9	electrophoretic	O
10	blots	O
11	of	O
12	RNAs	O
13	from	O
14	different	O
15	human	O
16	tissues	O
17	showed	O
18	a	O
19	predominant	O
20	2	O
21	.	O
22	8	O
23	-	O
24	kilobase	O
25	(	O
26	kb	O
27	)	O
28	message	O
29	accompanied	O
30	by	O
31	weaker	O
32	bands	O
33	4	O
34	.	O
35	1	O
36	and	O
37	2	O
38	.	O
39	1	O
40	kb	O
41	in	O
42	size	O
43	.	O
1	Prognosis	O
2	of	O
3	asymptomatic	O
4	multiple	O
5	myeloma	O
6	.	O
1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	for	O
7	the	O
8	first	O
9	time	O
10	the	O
11	complete	O
12	primary	O
13	structure	O
14	of	O
15	type	O
16	X	O
17	collagen	O
18	,	O
19	based	O
20	on	O
21	cloning	O
22	and	O
23	sequencing	O
24	of	O
25	cDNA	O
26	and	O
27	genomic	O
28	DNA	O
29	.	O
1	Viable	O
2	flap	O
3	areas	O
4	were	O
5	established	O
6	following	O
7	vascular	O
8	pedicle	O
9	ligation	O
10	(	O
11	both	O
12	vessels	O
13	or	O
14	only	O
15	artery	O
16	or	O
17	vein	O
18	),	O
19	on	O
20	the	O
21	third	O
22	day	O
23	after	O
24	flap	O
25	replantation	O
26	in	O
27	both	O
28	island	O
29	and	O
30	free	O
31	flaps	O
32	.	O
1	The	O
2	effects	O
3	of	O
4	L655	O
5	,	O
6	240	O
7	,	O
8	a	O
9	selective	O
10	thromboxane	O
11	and	O
12	prostaglandin	O
13	endoperoxide	O
14	antagonist	O
15	,	O
16	on	O
17	ischemia	O
18	-	O
19	and	O
20	reperfusion	O
21	-	O
22	induced	O
23	cardiac	O
24	arrhythmias	O
25	.	O
1	In	O
2	10	O
3	pentobarbitalized	O
4	dogs	O
5	,	O
6	plasma	O
7	viscosity	O
8	(	O
9	Ep	O
10	)	O
11	was	O
12	raised	O
13	fourfold	O
14	while	O
15	apparent	O
16	blood	O
17	viscosity	O
18	(	O
19	Ea	O
20	)	O
21	increased	O
22	about	O
23	twofold	O
24	by	O
25	two	O
26	steps	O
27	of	O
28	exchange	O
29	transfusion	O
30	of	O
31	200	O
32	ml	O
33	of	O
34	plasma	O
35	with	O
36	plasma	O
37	containing	O
38	high	O
39	molecular	O
40	weight	O
41	dextran	O
42	(	O
43	mol	O
44	wt	O
45	500	O
46	,	O
47	000	O
48	,	O
49	20	O
50	%	O
51	wt	O
52	/	O
53	vol	O
54	).	O
1	The	O
2	84	O
3	.	O
4	1C	O
5	mAb	O
6	recognizes	O
7	a	O
8	site	O
9	on	O
10	IgE	O
11	which	O
12	is	O
13	identical	O
14	or	O
15	very	O
16	close	O
17	to	O
18	the	O
19	Fc	O
20	epsilon	O
21	R	O
22	binding	O
23	site	O
24	,	O
25	and	O
26	95	O
27	.	O
28	3	O
29	recognizes	O
30	a	O
31	site	O
32	on	O
33	IgE	O
34	which	O
35	is	O
36	related	O
37	,	O
38	but	O
39	not	O
40	identical	O
41	to	O
42	the	O
43	Fc	O
44	epsilon	O
45	R	O
46	binding	O
47	site	O
48	.	O
1	The	O
2	mRNA	O
3	was	O
4	converted	O
5	to	O
6	cDNA	O
7	and	O
8	amplified	O
9	by	O
10	the	O
11	polymerase	B
12	chain	O
13	reaction	O
14	technique	O
15	.	O
1	A	O
2	potential	O
3	TATA	O
4	box	O
5	is	O
6	located	O
7	29	O
8	base	O
9	pairs	O
10	upstream	O
11	of	O
12	the	O
13	first	O
14	transcription	O
15	initiation	O
16	site	O
17	.	O
1	Once	O
2	P	O
3	-	O
4	450scc	O
5	mRNA	O
6	is	O
7	induced	O
8	as	O
9	a	O
10	consequence	O
11	of	O
12	the	O
13	LH	O
14	/	O
15	hCG	O
16	surge	O
17	it	O
18	is	O
19	constitutively	O
20	maintained	O
21	by	O
22	luteinized	O
23	cells	O
24	in	O
25	vivo	O
26	(	O
27	0	O
28	-	O
29	4	O
30	days	O
31	)	O
32	and	O
33	in	O
34	vitro	O
35	(	O
36	0	O
37	-	O
38	9	O
39	days	O
40	)	O
41	in	O
42	the	O
43	absence	O
44	of	O
45	gonadotropins	O
46	,	O
47	is	O
48	susceptible	O
49	to	O
50	modulation	O
51	by	O
52	prolactin	O
53	and	O
54	is	O
55	no	O
56	longer	O
57	regulated	O
58	by	O
59	cAMP	O
60	.	O
1	A	O
2	rapid	O
3	staining	O
4	technique	O
5	for	O
6	Leishmania	O
7	parasites	O
8	in	O
9	splenic	O
10	aspirate	O
11	smears	O
12	.	O
1	NIK	O
2	-	O
3	244	O
4	suppressed	O
5	coronary	O
6	ligation	O
7	-	O
8	and	O
9	digitalis	O
10	-	O
11	induced	O
12	arrhythmias	O
13	,	O
14	and	O
15	the	O
16	minimum	O
17	effective	O
18	plasma	O
19	concentrations	O
20	for	O
21	arrhythmias	O
22	induced	O
23	by	O
24	24	O
25	-	O
26	h	O
27	and	O
28	48	O
29	-	O
30	h	O
31	coronary	O
32	ligation	O
33	and	O
34	digitalis	O
35	were	O
36	0	O
37	.	O
38	41	O
39	+/-	O
40	0	O
41	.	O
42	10	O
43	(	O
44	by	O
45	1	O
46	mg	O
47	/	O
48	kg	O
49	i	O
50	.	O
51	v	O
52	.),	O
53	0	O
54	.	O
55	70	O
56	+/-	O
57	0	O
58	.	O
59	13	O
60	(	O
61	by	O
62	1	O
63	mg	O
64	/	O
65	kg	O
66	i	O
67	.	O
68	v	O
69	.),	O
70	and	O
71	0	O
72	.	O
73	21	O
74	+/-	O
75	0	O
76	.	O
77	08	O
78	(	O
79	by	O
80	0	O
81	.	O
82	5	O
83	mg	O
84	/	O
85	kg	O
86	i	O
87	.	O
88	v	O
89	.)	O
90	microgram	O
91	/	O
92	ml	O
93	,	O
94	respectively	O
95	(	O
96	mean	O
97	+/-	O
98	SD	O
99	of	O
100	the	O
101	mean	O
102	,	O
103	n	O
104	=	O
105	6	O
106	).	O
1	Intravenous	O
2	gamma	B
3	globulins	O
1	Myocardial	O
2	perfusion	O
3	was	O
4	evaluated	O
5	using	O
6	the	O
7	enhanced	O
8	gray	O
9	level	O
10	after	O
11	contrast	O
12	injection	O
13	,	O
14	and	O
15	the	O
16	level	O
17	was	O
18	compared	O
19	with	O
20	the	O
21	morphology	O
22	and	O
23	degree	O
24	of	O
25	collateral	O
26	development	O
27	.	O
1	In	O
2	76	O
3	%	O
4	of	O
5	59	O
6	lead	O
7	-	O
8	toxic	O
9	children	O
10	,	O
11	bone	O
12	lead	O
13	values	O
14	measured	O
15	by	O
16	LXRF	O
17	were	O
18	equal	O
19	to	O
20	or	O
21	greater	O
22	than	O
23	those	O
24	measured	O
25	in	O
26	normal	O
27	and	O
28	industrially	O
29	exposed	O
30	adults	O
31	.	O
1	Functional	O
2	rearranged	O
3	antibody	O
4	genes	O
5	were	O
6	detected	O
7	with	O
8	JH	O
9	and	O
10	VH	O
11	heavy	O
12	chain	O
13	probes	O
14	and	O
15	with	O
16	Jk	O
17	and	O
18	Vk	O
19	light	O
20	chain	O
21	probes	O
22	.	O
1	In	O
2	all	O
3	sessions	O
4	under	O
5	IFN	O
6	,	O
7	the	O
8	latency	O
9	of	O
10	the	O
11	P100	O
12	component	O
13	of	O
14	the	O
15	VEP	O
16	was	O
17	shortened	O
18	as	O
19	compared	O
20	to	O
21	baseline	O
22	conditions	O
23	.	O
1	Gastric	O
2	CO2	O
3	/	O
4	HCO3	O
5	was	O
6	determined	O
7	in	O
8	absence	O
9	of	O
10	simultaneous	O
11	inhibition	O
12	of	O
13	acid	O
14	secretion	O
15	by	O
16	intra	O
17	-	O
18	and	O
19	extragastric	O
20	pCO2	O
21	/	O
22	pH	O
23	measurements	O
24	in	O
25	23	O
26	persons	O
27	and	O
28	calculated	O
29	using	O
30	the	O
31	equation	O
32	of	O
33	Henderson	O
34	-	O
35	Hasselbalch	O
36	.	O
37	pCO2	O
38	was	O
39	measured	O
40	with	O
41	use	O
42	of	O
43	a	O
44	new	O
45	electrode	O
46	.	O
1	None	O
2	were	O
3	restricted	O
4	from	O
5	clinical	O
6	duties	O
7	,	O
8	were	O
9	given	O
10	varicella	O
11	-	O
12	zoster	O
13	immune	O
14	globulin	O
15	,	O
16	or	O
17	developed	O
18	disease	O
19	.	O
1	Radiation	O
2	therapy	O
3	was	O
4	effective	O
5	in	O
6	controlling	O
7	symptomatic	O
8	metastasis	O
9	in	O
10	all	O
11	three	O
12	patients	O
13	.	O
1	The	O
2	methylation	O
3	of	O
4	nuclear	O
5	and	O
6	chloroplast	O
7	DNAs	O
8	has	O
9	been	O
10	examined	O
11	in	O
12	relation	O
13	to	O
14	the	O
15	known	O
16	differential	O
17	expression	O
18	of	O
19	C4	O
20	photosynthesis	O
21	genes	O
22	in	O
23	the	O
24	bundle	O
25	sheath	O
26	and	O
27	mesophyll	O
28	cells	O
29	of	O
30	etiolated	O
31	,	O
32	greening	O
33	,	O
34	and	O
35	fully	O
36	green	O
37	maize	O
38	leaves	O
39	.	O
1	Effects	O
2	of	O
3	nitrogen	O
4	(	O
5	PN2	O
6	:	O
7	5	O
8	and	O
9	14	O
10	MPa	O
11	)	O
12	and	O
13	helium	O
14	(	O
15	PHe	O
16	:	O
17	13	O
18	and	O
19	14	O
20	MPa	O
21	)	O
22	were	O
23	also	O
24	tested	O
25	.	O
1	However	O
2	,	O
3	bilateral	O
4	diffuse	O
5	pulmonary	O
6	infiltrations	O
7	developed	O
8	21	O
9	days	O
10	later	O
11	.	O
1	The	O
2	DNA	O
3	helix	O
4	at	O
5	the	O
6	tandemly	O
7	repeated	O
8	,	O
9	13mer	O
10	sequence	O
11	is	O
12	thermodynamically	O
13	unstable	O
14	,	O
15	as	O
16	evidenced	O
17	by	O
18	hypersensitivity	O
19	to	O
20	single	O
21	-	O
22	strand	O
23	-	O
24	specific	O
25	nuclease	O
26	in	O
27	a	O
28	negatively	O
29	supercoiled	O
30	plasmid	O
31	,	O
32	and	O
33	demonstrated	O
34	by	O
35	stable	O
36	DNA	O
37	unwinding	O
38	seen	O
39	after	O
40	two	O
41	-	O
42	dimensional	O
43	gel	O
44	electrophoresis	O
45	of	O
46	topoisomers	O
47	.	O
1	Other	O
2	hemostatic	O
3	values	O
4	evaluated	O
5	were	O
6	activated	O
7	partial	O
8	thromboplastin	O
9	times	O
10	,	O
11	prothrombin	O
12	times	O
13	,	O
14	thrombin	O
15	times	O
16	,	O
17	fibrinogen	O
18	,	O
19	platelet	O
20	counts	O
21	,	O
22	and	O
23	fibrin	O
24	/	O
25	fibrinogen	O
26	degradation	O
27	products	O
28	.	O
1	Responsiveness	O
2	to	O
3	beta	B
4	-	O
5	2	O
6	agonist	O
7	therapy	O
8	was	O
9	retained	O
10	with	O
11	both	O
12	agents	O
13	(	O
14	p	O
15	less	O
16	than	O
17	0	O
18	.	O
19	05	O
20	).	O
1	Haploid	O
2	cells	O
3	of	O
4	mating	O
5	type	O
6	A	O
7	of	O
8	the	O
9	basidiomycetous	O
10	yeast	O
11	Rhodosporidium	O
12	toruloides	O
13	secrete	O
14	a	O
15	mating	O
16	pheromone	O
17	,	O
18	rhodotorucine	O
19	A	O
20	,	O
21	which	O
22	is	O
23	an	O
24	undecapeptide	O
25	containing	O
26	S	O
27	-	O
28	farnesyl	O
29	cysteine	O
30	at	O
31	its	O
32	carboxy	O
33	terminus	O
34	.	O
1	An	O
2	experiment	O
3	on	O
4	the	O
5	return	O
6	-	O
7	of	O
8	-	O
9	fear	O
10	(	O
11	ROF	O
12	)	O
13	was	O
14	carried	O
15	out	O
16	on	O
17	40	O
18	snake	O
19	-	O
20	or	O
21	spider	O
22	-	O
23	phobic	O
24	subjects	O
25	in	O
26	order	O
27	to	O
28	determine	O
29	whether	O
30	an	O
31	arousing	O
32	event	O
33	that	O
34	occurs	O
35	shortly	O
36	before	O
37	retest	O
38	influences	O
39	the	O
40	magnitude	O
41	of	O
42	the	O
43	ROF	O
44	.	O
1	Selection	O
2	of	O
3	the	O
4	22	O
5	items	O
6	of	O
7	the	O
8	Clinical	O
9	Institute	O
10	Withdrawal	O
11	Assessment	O
12	-	O
13	Benzodiazepines	O
14	(	O
15	CIWA	O
16	-	O
17	B	O
18	)	O
19	was	O
20	based	O
21	on	O
22	statistically	O
23	significant	O
24	differences	O
25	between	O
26	baseline	O
27	and	O
28	critical	O
29	withdrawal	O
30	periods	O
31	in	O
32	high	O
33	-	O
34	dose	O
35	subjects	O
36	and	O
37	between	O
38	symptoms	O
39	associated	O
40	with	O
41	placebo	O
42	and	O
43	diazepam	O
44	in	O
45	low	O
46	-	O
47	dose	O
48	subjects	O
49	,	O
50	using	O
51	contingency	O
52	tables	O
53	and	O
54	logistic	O
55	regression	O
56	analysis	O
57	.	O
1	GN101	O
2	,	O
3	YC819	O
4	-	O
5	9	O
6	,	O
7	and	O
8	SB3	O
9	.	O
1	Analysis	O
2	of	O
3	the	O
4	inferred	O
5	1	O
6	,	O
7	859	O
8	-	O
9	residue	O
10	ama	O
11	-	O
12	1	O
13	product	O
14	showed	O
15	considerable	O
16	identity	O
17	with	O
18	the	O
19	largest	O
20	subunit	O
21	of	O
22	RNAP	O
23	II	O
24	from	O
25	other	O
26	organisms	O
27	,	O
28	including	O
29	the	O
30	presence	O
31	of	O
32	a	O
33	zinc	O
34	finger	O
35	motif	O
36	near	O
37	the	O
38	amino	O
39	terminus	O
40	,	O
41	and	O
42	a	O
43	carboxyl	O
44	-	O
45	terminal	O
46	domain	O
47	of	O
48	42	O
49	tandemly	O
50	reiterated	O
51	heptamers	O
52	with	O
53	the	O
54	consensus	O
55	Tyr	O
56	Ser	O
57	Pro	O
58	Thr	O
59	Ser	O
60	Pro	O
61	Ser	O
62	.	O
1	Nodular	O
2	involvement	O
3	of	O
4	the	O
5	left	O
6	lung	O
7	and	O
8	infiltration	O
9	of	O
10	the	O
11	mucosa	O
12	of	O
13	the	O
14	left	O
15	lower	O
16	lobe	O
17	bronchus	O
18	followed	O
19	very	O
20	gradually	O
21	and	O
22	a	O
23	monoclonal	O
24	gammopathy	O
25	(	O
26	IgA	O
27	--	O
28	Type	O
29	Kappa	O
30	)	O
31	was	O
32	demonstrated	O
33	.	O
1	5	O
2	.	O
1	The	O
2	elements	O
3	responsible	O
4	for	O
5	glucocorticoid	O
6	stimulation	O
7	of	O
8	ADH	O
9	gene	O
10	transcription	O
11	appear	O
12	to	O
13	reside	O
14	outside	O
15	of	O
16	this	O
17	region	O
18	.	O
1	1	O
2	.	O
1	Intracellular	O
2	activity	O
3	studies	O
4	indicated	O
5	that	O
6	,	O
7	at	O
8	ten	O
9	times	O
10	MBC	O
11	,	O
12	only	O
13	penicillin	O
14	had	O
15	any	O
16	significant	O
17	activity	O
18	against	O
19	intracellular	O
20	staphylococci	O
21	,	O
22	reducing	O
23	survival	O
24	by	O
25	28	O
26	%.	O
1	Four	O
2	full	O
3	-	O
4	thickness	O
5	skin	O
6	incisions	O
7	were	O
8	made	O
9	in	O
10	the	O
11	back	O
12	of	O
13	10	O
14	female	O
15	pigs	O
16	that	O
17	treated	O
18	twice	O
19	a	O
20	day	O
21	for	O
22	14	O
23	days	O
24	with	O
25	2	O
26	ml	O
27	of	O
28	epidermal	O
29	growth	O
30	factor	O
31	(	O
32	300	O
33	ng	O
34	/	O
35	ml	O
36	)	O
37	or	O
38	2	O
39	ml	O
40	of	O
41	Ringer	O
42	'	O
43	s	O
44	lactate	O
45	solution	O
46	in	O
47	a	O
48	single	O
49	-	O
50	blind	O
51	,	O
52	randomized	O
53	fashion	O
54	.	O
1	Reagent	O
2	strips	O
3	are	O
4	frequently	O
5	used	O
6	in	O
7	the	O
8	practice	O
9	of	O
10	laboratory	O
11	medicine	O
12	as	O
13	well	O
14	as	O
15	outside	O
16	the	O
17	professional	O
18	laboratories	O
19	.	O
1	The	O
2	lowest	O
3	detectable	O
4	concentration	O
5	was	O
6	1	O
7	.	O
8	0	O
9	ng	O
10	/	O
11	ml	O
12	in	O
13	the	O
14	serum	O
15	.	O
1	Precipitating	O
2	antibodies	O
3	for	O
4	Thermophilic	O
5	actinomycetes	O
6	and	O
7	M	O
8	.	O
9	f	O
10	.	O
11	were	O
12	negative	O
13	.	O
1	We	O
2	investigated	O
3	the	O
4	incidence	O
5	of	O
6	congenital	O
7	color	O
8	deficiency	O
9	among	O
10	Koreans	O
11	by	O
12	the	O
13	use	O
14	of	O
15	H	O
16	-	O
17	R	O
18	-	O
19	R	O
20	pseudoisochromatic	O
21	plates	O
22	.	O
1	The	O
2	relation	O
3	between	O
4	VE	O
5	/	O
6	VO2	O
7	and	O
8	Q	O
9	/	O
10	VO2	O
11	showed	O
12	a	O
13	significant	O
14	negative	O
15	correlation	O
16	(	O
17	r	O
18	=	O
19	-	O
20	0	O
21	.	O
22	93	O
23	,	O
24	p	O
25	less	O
26	than	O
27	0	O
28	.	O
29	01	O
30	).	O
1	Collaborative	O
2	study	O
3	of	O
4	Japanese	O
5	Pharmacopoeia	O
6	Heparin	O
7	Sodium	O
8	Reference	O
9	Standard	O
1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	47	O
6	-	O
7	kilodalton	O
8	major	O
9	integral	O
10	membrane	O
11	immunogen	O
12	of	O
13	Treponema	O
14	pallidum	O
15	.	O
1	Construction	O
2	of	O
3	a	O
4	RIP1	O
5	deletion	O
6	strain	O
7	and	O
8	isolation	O
9	of	O
10	temperature	O
11	-	O
12	sensitive	O
13	mutants	O
14	.	O
1	Doppler	O
2	echo	O
3	in	O
4	evaluating	O
5	arteriovenous	O
6	fistulae	O
7	for	O
8	dialysis	O
1	The	O
2	galactose	O
3	transporter	O
4	shows	O
5	both	O
6	sequence	O
7	and	O
8	structural	O
9	homology	O
10	with	O
11	a	O
12	superfamily	O
13	of	O
14	sugar	O
15	transporters	O
16	which	O
17	includes	O
18	the	O
19	human	O
20	HepG2	O
21	-	O
22	erythrocyte	O
23	and	O
24	fetal	O
25	muscle	O
26	glucose	O
27	transporters	O
28	,	O
29	the	O
30	rat	O
31	brain	O
32	and	O
33	liver	O
34	glucose	O
35	transporters	O
36	,	O
37	the	O
38	Escherichia	O
39	coli	O
40	xylose	O
41	and	O
42	arabinose	O
43	permeases	O
44	,	O
45	and	O
46	the	O
47	S	O
48	.	O
49	cerevisiae	O
50	glucose	O
51	,	O
52	maltose	O
53	,	O
54	and	O
55	galactose	O
56	transporters	O
57	.	O
1	Of	O
2	110	O
3	previously	O
4	untreated	O
5	patients	O
6	who	O
7	had	O
8	entered	O
9	the	O
10	study	O
11	of	O
12	protocol	O
13	TCL821	O
14	,	O
15	96	O
16	were	O
17	evaluable	O
18	.	O
1	Tumor	O
2	necrosis	O
3	factor	O
4	(	O
5	TNF	O
6	)	O
7	is	O
8	reported	O
9	to	O
10	cause	O
11	a	O
12	shock	O
13	syndrome	O
14	similar	O
15	to	O
16	that	O
17	produced	O
18	by	O
19	endotoxin	O
20	(	O
21	LPS	O
22	).	O
1	Of	O
2	the	O
3	single	O
4	-	O
5	stranded	O
6	DNA	O
7	transformants	O
8	,	O
9	65	O
10	%	O
11	resulted	O
12	from	O
13	replacement	O
14	of	O
15	the	O
16	resident	O
17	met2	O
18	mutation	O
19	by	O
20	the	O
21	exogenous	O
22	wild	O
23	-	O
24	type	O
25	allele	O
26	.	O
1	Recently	O
2	,	O
3	an	O
4	alternatively	O
5	spliced	O
6	form	O
7	of	O
8	c	B
9	-	O
10	myb	O
11	-	O
12	encoded	O
13	mRNA	O
14	has	O
15	been	O
16	identified	O
17	in	O
18	murine	O
19	cells	O
20	containing	O
21	either	O
22	normal	O
23	or	O
24	rearranged	O
25	c	B
26	-	O
27	myb	O
28	genes	O
29	.	O
1	Furthermore	O
2	,	O
3	the	O
4	3	O
5	'-	O
6	untranslated	O
7	regions	O
8	of	O
9	pmGT10	O
10	display	O
11	a	O
12	marked	O
13	degree	O
14	of	O
15	homology	O
16	to	O
17	the	O
18	3	O
19	'	O
20	region	O
21	of	O
22	the	O
23	rat	O
24	Yb1	O
25	gene	O
26	,	O
27	while	O
28	this	O
29	region	O
30	of	O
31	pmGT2	O
32	displays	O
33	marked	O
34	homology	O
35	to	O
36	the	O
37	corresponding	O
38	region	O
39	of	O
40	the	O
41	rat	O
42	Yb2	O
43	gene	O
44	.	O
1	During	O
2	the	O
3	first	O
4	3	O
5	min	O
6	of	O
7	recovery	O
8	,	O
9	plasma	O
10	potassium	O
11	fell	O
12	rapidly	O
13	in	O
14	spite	O
15	of	O
16	nearly	O
17	unchanged	O
18	blood	O
19	acidosis	O
20	and	O
21	significantly	O
22	decreasing	O
23	bicarbonate	O
24	concentration	O
25	.	O
1	In	O
2	comparison	O
3	with	O
4	normal	O
5	pregnant	O
6	women	O
7	and	O
8	normal	O
9	non	O
10	-	O
11	pregnant	O
12	women	O
13	,	O
14	women	O
15	with	O
16	PIH	O
17	showed	O
18	an	O
19	increase	O
20	in	O
21	heart	O
22	rate	O
23	,	O
24	suggesting	O
25	an	O
26	increased	O
27	peripheral	O
28	sympathetic	O
29	tone	O
30	,	O
31	and	O
32	an	O
33	initial	O
34	derangement	O
35	in	O
36	renal	O
37	function	O
38	as	O
39	shown	O
40	by	O
41	the	O
42	increase	O
43	in	O
44	serum	O
45	uric	O
46	acid	O
47	and	O
48	reduction	O
49	in	O
50	sodium	O
51	excretion	O
52	and	O
53	total	O
54	and	O
55	fractional	O
56	calcium	O
57	excretion	O
58	at	O
59	any	O
60	given	O
61	level	O
62	of	O
63	sodium	O
64	excretion	O
65	.	O
1	We	O
2	have	O
3	examined	O
4	the	O
5	role	O
6	of	O
7	two	O
8	recombination	O
9	-	O
10	and	O
11	repair	O
12	-	O
13	defective	O
14	mutations	O
15	,	O
16	rad1	O
17	and	O
18	rad52	O
19	,	O
20	on	O
21	direct	O
22	repeat	O
23	recombination	O
24	in	O
25	transcriptionally	O
26	active	O
27	and	O
28	inactive	O
29	sequences	O
30	.	O
1	Thus	O
2	RV	O
3	O2	O
4	demand	O
5	fell	O
6	when	O
7	RC	O
8	O2	O
9	supply	O
10	was	O
11	reduced	O
12	,	O
13	although	O
14	a	O
15	flow	O
16	reserve	O
17	was	O
18	available	O
19	.	O
1	Normocapnic	O
2	(	O
3	PACO2	O
4	=	O
5	40	O
6	mm	O
7	Hg	O
8	)	O
9	ventilatory	O
10	drive	O
11	increased	O
12	significantly	O
13	(	O
14	p	O
15	less	O
16	than	O
17	0	O
18	.	O
19	05	O
20	)	O
21	in	O
22	six	O
23	subjects	O
24	(	O
25	Type	O
26	1	O
27	response	O
28	)	O
29	and	O
30	decreased	O
31	substantially	O
32	in	O
33	the	O
34	others	O
35	(	O
36	Type	O
37	2	O
38	response	O
39	);	O
40	with	O
41	hypercapnia	O
42	,	O
43	the	O
44	changes	O
45	in	O
46	drive	O
47	were	O
48	attenuated	O
49	in	O
50	both	O
51	groups	O
52	.	O
1	Allelic	O
2	variation	O
3	in	O
4	HLA	O
5	-	O
6	B	O
7	and	O
8	HLA	O
9	-	O
10	C	O
11	sequences	O
12	and	O
13	the	O
14	evolution	O
15	of	O
16	the	O
17	HLA	O
18	-	O
19	B	O
20	alleles	O
21	.	O
1	NERVTRACK	O
2	contains	O
3	4000	O
4	anatomical	O
5	data	O
6	items	O
7	arranged	O
8	in	O
9	a	O
10	tree	O
11	-	O
12	like	O
13	manner	O
14	reflecting	O
15	structural	O
16	and	O
17	functional	O
18	relationships	O
19	.	O
1	From	O
2	the	O
3	National	O
4	Institutes	O
5	of	O
6	Health	O
7	.	O
1	Molecular	O
2	cloning	O
3	and	O
4	characterisation	O
5	of	O
6	the	O
7	two	O
8	homologous	O
9	genes	O
10	coding	O
11	for	O
12	nitrate	O
13	reductase	O
14	in	O
15	tobacco	O
16	.	O
1	COUP	O
2	transcription	O
3	factor	O
4	is	O
5	a	O
6	member	O
7	of	O
8	the	O
9	steroid	O
10	receptor	B
11	superfamily	O
12	.	O
1	In	O
2	Experiment	O
3	2	O
4	,	O
5	we	O
6	again	O
7	used	O
8	classification	O
9	,	O
10	but	O
11	the	O
12	fixed	O
13	standard	O
14	75	O
15	was	O
16	not	O
17	at	O
18	the	O
19	center	O
20	of	O
21	the	O
22	range	O
23	of	O
24	target	O
25	numbers	O
26	(	O
27	20	O
28	,	O
29	21	O
30	,	O
31	...	O
1	Cosmid	O
2	clones	O
3	containing	O
4	both	O
5	VNTR	O
6	sequences	O
7	were	O
8	identified	O
9	,	O
10	and	O
11	restriction	O
12	mapping	O
13	showed	O
14	them	O
15	to	O
16	be	O
17	less	O
18	than	O
19	15	O
20	kb	O
21	apart	O
22	.	O
1	Qualitatively	O
2	,	O
3	the	O
4	results	O
5	are	O
6	similar	O
7	for	O
8	the	O
9	two	O
10	species	O
11	:	O
12	Both	O
13	rhesus	O
14	monkey	O
15	and	O
16	man	O
17	have	O
18	photopic	O
19	and	O
20	scotopic	O
21	branches	O
22	,	O
23	which	O
24	cross	O
25	at	O
26	approximately	O
27	the	O
28	same	O
29	time	O
30	in	O
31	the	O
32	dark	O
33	and	O
34	at	O
35	approximately	O
36	the	O
37	same	O
38	background	O
39	luminance	O
40	.	O
1	At	O
2	each	O
3	level	O
4	of	O
5	PaO2	O
6	we	O
7	obtained	O
8	simultaneous	O
9	measures	O
10	of	O
11	arterial	O
12	and	O
13	venous	O
14	blood	O
15	gases	O
16	,	O
17	venous	O
18	lactate	O
19	concentration	O
20	,	O
21	and	O
22	changes	O
23	in	O
24	the	O
25	relative	O
26	concentrations	O
27	of	O
28	inorganic	O
29	phosphate	O
30	,	O
31	phosphocreatine	O
32	,	O
33	and	O
34	ATP	O
35	measured	O
36	with	O
37	31P	O
38	magnetic	O
39	resonance	O
40	spectroscopy	O
41	.	O
1	This	O
2	suggested	O
3	that	O
4	baboon	O
5	liver	O
6	class	O
7	I	O
8	ADH	O
9	is	O
10	of	O
11	the	O
12	same	O
13	ancestral	O
14	lineage	O
15	as	O
16	the	O
17	human	O
18	ADH	O
19	-	O
20	beta	B
21	.	O
1	Each	O
2	individual	O
3	shot	O
4	25	O
5	bullets	O
6	in	O
7	about	O
8	5	O
9	minutes	O
10	,	O
11	at	O
12	an	O
13	intensity	O
14	level	O
15	calculated	O
16	at	O
17	163	O
18	dB	O
19	.	O
1	Dynamic	O
2	and	O
3	static	O
4	scintigrams	O
5	,	O
6	using	O
7	99mtechnetium	O
8	methylene	O
9	diphosphonate	O
10	,	O
11	were	O
12	obtained	O
13	at	O
14	zero	O
15	,	O
16	six	O
17	,	O
18	and	O
19	12	O
20	weeks	O
21	after	O
22	fracture	O
23	.	O
1	This	O
2	would	O
3	have	O
4	had	O
5	the	O
6	effect	O
7	of	O
8	positioning	O
9	the	O
10	genes	O
11	currently	O
12	on	O
13	the	O
14	long	O
15	arm	O
16	adjacent	O
17	to	O
18	the	O
19	centromeric	O
20	heterochromatin	O
21	,	O
22	perhaps	O
23	resulting	O
24	in	O
25	a	O
26	""""	O
27	position	O
28	effect	O
29	""""	O
30	on	O
31	transcription	O
32	of	O
33	these	O
34	genes	O
35	.	O
1	Initial	O
2	experience	O
3	with	O
4	a	O
5	microprocessor	O
6	controlled	O
7	current	O
8	based	O
9	defibrillator	O
10	.	O
1	Heterogeneous	O
2	nuclear	O
3	ribonucleoprotein	O
4	(	O
5	hnRNP	O
6	)	O
7	core	O
8	protein	O
9	A1	O
10	is	O
11	a	O
12	major	O
13	component	O
14	of	O
15	mammalian	O
16	hnRNP	O
17	40	O
18	S	O
19	particles	O
20	.	O
1	Brain	O
2	cholinesterase	O
3	activity	O
4	of	O
5	nestling	O
6	great	O
7	egrets	O
8	,	O
9	snowy	O
10	egrets	O
11	and	O
12	black	O
13	-	O
14	crowned	O
15	night	O
16	-	O
17	herons	O
18	.	O
19	inhibition	O
20	of	O
21	brain	O
22	cholinesterase	O
23	(	O
24	ChE	O
25	)	O
26	activity	O
27	in	O
28	birds	O
29	is	O
30	often	O
31	used	O
32	to	O
33	diagnose	O
34	exposure	O
35	or	O
36	death	O
37	from	O
38	organophosphorus	O
39	or	O
40	carbamate	O
41	pesticides	O
42	.	O
1	The	O
2	effect	O
3	of	O
4	zinc	O
5	deficiency	O
6	on	O
7	trace	O
8	metals	O
9	in	O
10	the	O
11	liver	O
12	,	O
13	spleen	O
14	,	O
15	kidney	O
16	,	O
17	pancreas	O
18	and	O
19	duodenum	O
20	was	O
21	investigated	O
22	in	O
23	the	O
24	control	O
25	and	O
26	zinc	O
27	-	O
28	deficient	O
29	rats	O
30	at	O
31	17	O
32	days	O
33	and	O
34	20	O
35	days	O
36	of	O
37	pregnancy	O
38	.	O
1	Our	O
2	findings	O
3	support	O
4	the	O
5	view	O
6	of	O
7	a	O
8	multifactorial	O
9	genesis	O
10	of	O
11	the	O
12	cardiac	O
13	involvement	O
14	in	O
15	uremic	O
16	patients	O
17	.	O
1	When	O
2	two	O
3	-	O
4	dimensional	O
5	polyacrylamide	O
6	gel	O
7	electrophoretic	O
8	patterns	O
9	of	O
10	[	O
11	35S	O
12	]	O
13	methionine	O
14	-	O
15	labeled	O
16	proteins	O
17	secreted	O
18	from	O
19	cells	O
20	infected	O
21	with	O
22	parental	O
23	and	O
24	recombinant	O
25	viruses	O
26	were	O
27	compared	O
28	,	O
29	a	O
30	spot	O
31	missing	O
32	from	O
33	the	O
34	latter	O
35	corresponded	O
36	in	O
37	molecular	O
38	weigh	O
39	and	O
40	isoelectric	O
41	point	O
42	with	O
43	that	O
44	predicted	O
45	from	O
46	the	O
47	N1L	O
48	ORF	O
49	.	O
1	The	O
2	author	O
3	gives	O
4	an	O
5	account	O
6	of	O
7	antipsychotic	O
8	,	O
9	analgetic	O
10	,	O
11	myorelaxing	O
12	and	O
13	vasodilatating	O
14	effects	O
15	of	O
16	some	O
17	calcium	O
18	antagonists	O
19	,	O
20	and	O
21	their	O
22	clinical	O
23	application	O
24	is	O
25	discussed	O
26	.	O
1	A	O
2	hospital	O
3	-	O
4	based	O
5	study	O
6	of	O
7	the	O
8	relationship	O
9	between	O
10	retained	O
11	placenta	O
12	and	O
13	mastitis	O
14	in	O
15	dairy	O
16	cows	O
17	.	O
1	A	O
2	value	O
3	of	O
4	1	O
5	.	O
6	1	O
7	l	O
8	/	O
9	kg	O
10	was	O
11	used	O
12	for	O
13	V	O
14	in	O
15	calculating	O
16	all	O
17	single	O
18	sample	O
19	estimates	O
20	of	O
21	clearance	O
22	(	O
23	CL	O
24	),	O
25	and	O
26	a	O
27	value	O
28	of	O
29	4	O
30	.	O
31	3	O
32	l	O
33	/	O
34	kg	O
35	was	O
36	used	O
37	to	O
38	calculate	O
39	single	O
40	sample	O
41	estimates	O
42	of	O
43	clearance	O
44	of	O
45	plasma	O
46	unbound	O
47	drug	O
48	(	O
49	CLunb	O
50	).	O
1	Buflomedil	O
2	(	O
3	i	O
4	.	O
5	v	O
6	.)	O
7	induced	O
8	a	O
9	dose	O
10	-	O
11	dependent	O
12	increase	O
13	of	O
14	cardiac	O
15	output	O
16	at	O
17	0	O
18	.	O
19	16	O
20	-	O
21	0	O
22	.	O
23	64	O
24	mg	O
25	/	O
26	kg	O
27	,	O
28	biphasic	O
29	changes	O
30	at	O
31	1	O
32	.	O
33	28	O
34	and	O
35	2	O
36	.	O
37	56	O
38	mg	O
39	/	O
40	kg	O
41	and	O
42	a	O
43	marked	O
44	decrease	O
45	and	O
46	subsequent	O
47	slight	O
48	increase	O
49	at	O
50	a	O
51	large	O
52	dose	O
53	of	O
54	5	O
55	.	O
56	12	O
57	mg	O
58	/	O
59	kg	O
60	.	O
1	Heart	O
2	rate	O
3	(	O
4	HR	O
5	),	O
6	rectal	O
7	temperature	O
8	(	O
9	Tre	O
10	),	O
11	blood	O
12	pressure	O
13	,	O
14	temperature	O
15	and	O
16	relative	O
17	humidity	O
18	changes	O
19	inside	O
20	clothing	O
21	were	O
22	measured	O
23	on	O
24	18	O
25	professional	O
26	firemen	O
27	(	O
28	mean	O
29	age	O
30	29	O
31	.	O
32	4	O
33	+/-	O
34	7	O
35	.	O
36	4	O
37	yr	O
38	,	O
39	VO2	O
40	max	O
41	41	O
42	.	O
43	4	O
44	+	O
45	8	O
46	.	O
47	8	O
48	ml	O
49	kg	O
50	-	O
51	1	O
52	min	O
53	-	O
54	1	O
55	)	O
56	wearing	O
57	fire	O
58	fighter	O
59	'	O
60	s	O
61	uniforms	O
62	(	O
63	SU	O
64	)	O
65	or	O
66	aluminized	O
67	,	O
68	fire	O
69	resistant	O
70	,	O
71	impermeable	O
72	clothing	O
73	with	O
74	self	O
75	contained	O
76	breathing	O
77	apparatus	O
78	(	O
79	FE	O
80	).	O
1	1	O
2	-(	O
3	m	O
4	-	O
5	Chlorophenyl	O
6	)	O
7	piperazine	O
8	(	O
9	mCPP	O
10	,	O
11	0	O
12	.	O
13	1	O
14	-	O
15	3	O
16	.	O
17	0	O
18	mg	O
19	/	O
20	kg	O
21	)	O
22	and	O
23	1	O
24	-(	O
25	m	O
26	-	O
27	trifluoromethylphenyl	O
28	)	O
29	piperazine	O
30	(	O
31	TFMPP	O
32	,	O
33	0	O
34	.	O
35	1	O
36	-	O
37	3	O
38	.	O
39	0	O
40	mg	O
41	/	O
42	kg	O
43	),	O
44	both	O
45	thought	O
46	to	O
47	act	O
48	primarily	O
49	at	O
50	5	O
51	-	O
52	HT1	O
53	sites	O
54	,	O
55	also	O
56	decreased	O
57	responding	O
58	and	O
59	this	O
60	effect	O
61	was	O
62	blocked	O
63	by	O
64	methysergide	O
65	and	O
66	by	O
67	1	O
68	-	O
69	NP	O
70	,	O
71	but	O
72	not	O
73	by	O
74	ketanserin	O
75	.	O
1	The	O
2	characteristic	O
3	feature	O
4	of	O
5	liver	O
6	and	O
7	spleen	O
8	MP	O
9	function	O
10	in	O
11	patients	O
12	with	O
13	VHA	O
14	associated	O
15	with	O
16	HBsAg	O
17	carriership	O
18	consisted	O
19	in	O
20	the	O
21	lack	O
22	of	O
23	the	O
24	compensatory	O
25	reaction	O
26	on	O
27	the	O
28	part	O
29	of	O
30	spleen	O
31	MP	O
32	,	O
33	which	O
34	was	O
35	likely	O
36	to	O
37	be	O
38	connected	O
39	with	O
40	overstrain	O
41	of	O
42	long	O
43	standing	O
44	and	O
45	depletion	O
46	of	O
47	the	O
48	MP	O
49	system	O
50	due	O
51	to	O
52	permanent	O
53	antigenic	O
54	stimulation	O
55	of	O
56	HBsAg	O
57	.	O
1	The	O
2	mature	O
3	protein	O
4	also	O
5	contains	O
6	a	O
7	cysteine	O
8	-	O
9	rich	O
10	,	O
11	highly	O
12	hydrophilic	O
13	region	O
14	homologous	O
15	to	O
16	the	O
17	ovomucoid	O
18	serine	O
19	protease	O
20	inhibitors	O
21	(	O
22	residues	O
23	76	O
24	-	O
25	132	O
26	).	O
1	Third	O
2	-	O
3	and	O
4	later	O
5	-	O
6	parity	O
7	cows	O
8	were	O
9	randomly	O
10	assigned	O
11	after	O
12	each	O
13	parturition	O
14	to	O
15	Charolais	O
16	and	O
17	Red	O
18	Poll	O
19	bulls	O
20	in	O
21	multiple	O
22	-	O
23	sire	O
24	pastures	O
25	.	O
1	The	O
2	system	O
3	consisted	O
4	of	O
5	the	O
6	intact	O
7	canine	O
8	heart	O
9	connected	O
10	to	O
11	a	O
12	microcomputer	O
13	that	O
14	operated	O
15	as	O
16	the	O
17	modulated	O
18	parasystolic	O
19	pacemaker	O
20	.	O
1	Instead	O
2	,	O
3	some	O
4	small	O
5	negative	O
6	effects	O
7	are	O
8	observed	O
9	,	O
10	particularly	O
11	involving	O
12	effects	O
13	of	O
14	husbands	O
15	'	O
16	retirement	O
17	on	O
18	the	O
19	marital	O
20	satisfaction	O
21	of	O
22	employed	O
23	wives	O
24	.	O
1	This	O
2	in	O
3	turn	O
4	will	O
5	further	O
6	enhance	O
7	the	O
8	role	O
9	of	O
10	meta	O
11	-	O
12	analysis	O
13	in	O
14	helping	O
15	clinicians	O
16	and	O
17	policy	O
18	makers	O
19	answer	O
20	clinical	O
21	questions	O
22	.	O
1	Immunohistochemical	O
2	studies	O
3	revealed	O
4	positive	O
5	staining	O
6	for	O
7	S100	O
8	protein	O
9	in	O
10	all	O
11	the	O
12	granular	O
13	cell	O
14	tumors	O
15	of	O
16	the	O
17	adult	O
18	but	O
19	in	O
20	none	O
21	of	O
22	the	O
23	congenital	O
24	granular	O
25	cell	O
26	epulides	O
27	.	O
1	In	O
2	rats	O
3	bearing	O
4	Walker	O
5	-	O
6	256	O
7	-	O
8	carcinosarcoma	O
9	4	O
10	-	O
11	EPI	O
12	was	O
13	effective	O
14	.(	O
15	ABSTRACT	O
16	TRUNCATED	O
17	AT	O
18	250	O
19	WORDS	O
20	)	O
1	In	O
2	terms	O
3	of	O
4	sequence	O
5	repetitions	O
6	,	O
7	seven	O
8	tandemly	O
9	repeated	O
10	copies	O
11	of	O
12	the	O
13	hexanucleotide	O
14	ATTGTT	O
15	and	O
16	three	O
17	flanking	O
18	regions	O
19	of	O
20	dyad	O
21	symmetry	O
22	were	O
23	detected	O
24	,	O
25	all	O
26	in	O
27	ORF	O
28	T3C	O
29	.	O
1	The	O
2	significance	O
3	of	O
4	these	O
5	palindromic	O
6	domains	O
7	in	O
8	this	O
9	ORF	O
10	is	O
11	unclear	O
12	but	O
13	the	O
14	coincidence	O
15	of	O
16	the	O
17	end	O
18	of	O
19	one	O
20	larger	O
21	palindrome	O
22	with	O
23	the	O
24	end	O
25	of	O
26	the	O
27	translated	O
28	protein	O
29	sequence	O
30	that	O
31	has	O
32	homology	O
33	with	O
34	the	O
35	B	O
36	chain	O
37	of	O
38	insulin	B
39	suggests	O
40	that	O
41	the	O
42	palindromes	O
43	may	O
44	divide	O
45	the	O
46	T2	O
47	protein	O
48	into	O
49	several	O
50	functional	O
51	units	O
52	.	O
1	Anoxia	O
2	was	O
3	introduced	O
4	by	O
5	perfusing	O
6	the	O
7	gill	O
8	with	O
9	water	O
10	deprived	O
11	of	O
12	oxygen	O
13	or	O
14	by	O
15	halting	O
16	the	O
17	water	O
18	flow	O
19	to	O
20	the	O
21	gill	O
22	.	O
1	The	O
2	effect	O
3	of	O
4	acetazolamide	O
5	(	O
6	ACZ	O
7	)	O
8	on	O
9	HCO3	O
10	-	O
11	and	O
12	Cl	O
13	-	O
14	activities	O
15	in	O
16	inner	O
17	ear	O
18	fluid	O
19	was	O
20	investigated	O
21	by	O
22	ion	O
23	-	O
24	selective	O
25	microelectrode	O
26	methods	O
27	.	O
1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	organization	O
7	of	O
8	functional	O
9	units	O
10	of	O
11	the	O
12	72	O
13	-	O
14	bp	O
15	repeat	O
16	required	O
17	for	O
18	transcriptional	O
19	enhancement	O
20	of	O
21	the	O
22	early	O
23	promoter	O
24	is	O
25	different	O
26	from	O
27	that	O
28	required	O
29	for	O
30	late	O
31	promoter	O
32	function	O
33	.	O
1	Aplastic	O
2	crisis	O
3	in	O
4	sickle	O
5	cell	O
6	disorders	O
7	:	O
8	bone	O
9	marrow	O
10	necrosis	O
11	and	O
12	human	O
13	parvovirus	O
14	infection	O
15	.	O
1	Amino	O
2	acid	O
3	sequence	O
4	of	O
5	one	O
6	human	O
7	liver	O
8	clone	O
9	(	O
10	HL	O
11	-	O
12	14	O
13	)	O
14	was	O
15	identical	O
16	to	O
17	the	O
18	rabbit	O
19	skeletal	O
20	muscle	O
21	phosphatase	B
22	2A	O
23	cDNA	O
24	(	O
25	with	O
26	97	O
27	%	O
28	nucleotide	O
29	identity	O
30	).	O
1	RVEF	O
2	and	O
3	LVEF	O
4	both	O
5	increased	O
6	by	O
7	about	O
8	14	O
9	%	O
10	(	O
11	p	O
12	less	O
13	than	O
14	0	O
15	.	O
16	05	O
17	and	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	01	O
24	).	O
1	The	O
2	mechanism	O
3	by	O
4	which	O
5	E2	O
6	-	O
7	C	O
8	represses	O
9	E2	O
10	-	O
11	dependent	O
12	enhancer	O
13	activity	O
14	most	O
15	likely	O
16	involves	O
17	competition	O
18	with	O
19	E2	O
20	for	O
21	binding	O
22	to	O
23	a	O
24	common	O
25	transcriptional	O
26	regulatory	O
27	site	O
28	.(	O
29	ABSTRACT	O
30	TRUNCATED	O
31	AT	O
32	400	O
33	WORDS	O
34	)	O
1	A	O
2	family	O
3	of	O
4	RNA	O
5	molecules	O
6	in	O
7	the	O
8	2	O
9	.	O
10	0	O
11	-	O
12	2	O
13	.	O
14	2	O
15	-	O
16	kilobase	O
17	range	O
18	identified	O
19	with	O
20	a	O
21	probe	O
22	from	O
23	this	O
24	gene	O
25	was	O
26	overexpressed	O
27	in	O
28	the	O
29	resistant	O
30	cells	O
31	.	O
1	The	O
2	SV40	O
3	enhancer	O
4	augmented	O
5	replication	O
6	1	O
7	.	O
8	5	O
9	-	O
10	10	O
11	fold	O
12	.	O
1	Fentanyl	O
2	,	O
3	a	O
4	prototypic	O
5	mu	O
6	-	O
7	opiate	O
8	receptor	B
9	agonist	O
10	,	O
11	has	O
12	been	O
13	previously	O
14	shown	O
15	to	O
16	produce	O
17	a	O
18	syndrome	O
19	characterized	O
20	by	O
21	marked	O
22	analgesia	O
23	and	O
24	locomotor	O
25	stimulation	O
26	as	O
27	well	O
28	as	O
29	tachycardia	O
30	,	O
31	tachypnoea	O
32	and	O
33	behavioural	O
34	arousal	O
35	.	O
1	Moreover	O
2	,	O
3	in	O
4	rats	O
5	allowed	O
6	to	O
7	choose	O
8	in	O
9	a	O
10	T	O
11	-	O
12	maze	O
13	between	O
14	immediate	O
15	-	O
16	but	O
17	-	O
18	small	O
19	vs	O
20	.	O
21	delayed	O
22	-	O
23	but	O
24	-	O
25	large	O
26	reward	O
27	,	O
28	BZP	O
29	significantly	O
30	decreased	O
31	the	O
32	frequency	O
33	with	O
34	which	O
35	the	O
36	delayed	O
37	reward	O
38	was	O
39	chosen	O
40	,	O
41	with	O
42	5	O
43	-	O
44	HT	O
45	uptake	O
46	blockers	O
47	producing	O
48	opposite	O
49	effects	O
50	.	O
1	An	O
2	endometrial	O
3	luteal	O
4	phase	O
5	deficiency	O
6	was	O
7	detected	O
8	in	O
9	15	O
10	(	O
11	30	O
12	%)	O
13	of	O
14	aborting	O
15	patients	O
16	.	O
1	A	O
2	drug	O
3	with	O
4	ISA	O
5	""""	O
6	down	O
7	regulates	O
8	""""	O
9	beta	B
10	receptors	O
11	;	O
12	thus	O
13	,	O
14	when	O
15	the	O
16	drug	O
17	is	O
18	withdrawn	O
19	there	O
20	is	O
21	no	O
22	post	O
23	-	O
24	beta	B
25	-	O
26	blocking	O
27	drug	O
28	hypersensitivity	O
29	in	O
30	contrast	O
31	to	O
32	agents	O
33	without	O
34	ISA	O
35	.	O
1	Testing	O
2	blood	O
3	donors	O
4	for	O
5	non	O
6	-	O
7	A	O
8	,	O
9	non	O
10	-	O
11	B	O
12	hepatitis	O
13	:	O
14	irrational	O
15	,	O
16	perhaps	O
17	,	O
18	but	O
19	inescapable	O
20	.	O
1	The	O
2	biosynthesis	O
3	and	O
4	stability	O
5	of	O
6	the	O
7	three	O
8	mutant	O
9	proteins	O
10	were	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	the	O
16	wild	O
17	-	O
18	type	O
19	erbB	O
20	protein	O
21	,	O
22	and	O
23	all	O
24	three	O
25	retained	O
26	the	O
27	ability	O
28	to	O
29	transform	O
30	chicken	O
31	embryo	O
32	fibroblasts	O
33	.	O
1	To	O
2	explore	O
3	the	O
4	functional	O
5	properties	O
6	of	O
7	the	O
8	protein	O
9	encoded	O
10	by	O
11	neu	O
12	,	O
13	we	O
14	created	O
15	a	O
16	fusion	O
17	gene	O
18	that	O
19	joins	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	of	O
24	neu	O
25	to	O
26	the	O
27	extracellular	O
28	portion	O
29	of	O
30	an	O
31	immunoglobulin	O
32	heavy	O
33	chain	O
34	.	O
1	2	O
2	cases	O
3	of	O
4	type	O
5	II	O
6	tyrosinosis	O
7	(	O
8	Richner	O
9	-	O
10	Hanhart	O
11	syndrome	O
12	)	O
1	A	O
2	second	O
3	promoter	O
4	activity	O
5	was	O
6	identified	O
7	in	O
8	the	O
9	region	O
10	between	O
11	the	O
12	two	O
13	major	O
14	transcriptional	O
15	start	O
16	sites	O
17	.	O
1	Effects	O
2	of	O
3	aging	O
4	and	O
5	beta	B
6	-	O
7	adrenergic	O
8	-	O
9	blockade	O
10	on	O
11	standing	O
12	-	O
13	induced	O
14	QT	O
15	/	O
16	QS2	O
17	changes	O
18	.	O
1	A	O
2	patient	O
3	with	O
4	an	O
5	infected	O
6	wound	O
7	or	O
8	one	O
9	on	O
10	a	O
11	primary	O
12	area	O
13	(	O
14	hands	O
15	,	O
16	feet	O
17	,	O
18	face	O
19	,	O
20	or	O
21	perineum	O
22	)	O
23	may	O
24	have	O
25	to	O
26	be	O
27	hospitalized	O
28	to	O
29	ensure	O
30	proper	O
31	care	O
32	.	O
1	The	O
2	risk	O
3	factors	O
4	studied	O
5	were	O
6	male	O
7	sex	O
8	,	O
9	hypertension	O
10	,	O
11	diabetes	O
12	mellitus	O
13	,	O
14	hypercholesterolemia	O
15	,	O
16	cigarette	O
17	smoking	O
18	,	O
19	sedentary	O
20	life	O
21	-	O
22	style	O
23	,	O
24	and	O
25	family	O
26	history	O
27	.	O
1	Controlled	O
2	versus	O
3	uncontrolled	O
4	reperfusion	O
5	of	O
6	ischemic	O
7	myocardium	O
8	after	O
9	experimental	O
10	coronary	O
11	artery	O
12	occlusion	O
13	was	O
14	studied	O
15	to	O
16	determine	O
17	the	O
18	effect	O
19	on	O
20	regional	O
21	ventricular	O
22	wall	O
23	motion	O
24	and	O
25	associated	O
26	biochemical	O
27	alterations	O
28	.	O
1	All	O
2	of	O
3	the	O
4	newly	O
5	acquired	O
6	proviruses	O
7	identified	O
8	in	O
9	mosaic	O
10	founder	O
11	SWR	O
12	/	O
13	J	O
14	-	O
15	RF	O
16	/	O
17	J	O
18	mice	O
19	that	O
20	could	O
21	be	O
22	transmitted	O
23	through	O
24	the	O
25	germ	O
26	line	O
27	were	O
28	also	O
29	present	O
30	in	O
31	somatic	O
32	tissues	O
33	,	O
34	demonstrating	O
35	that	O
36	viral	O
37	integration	O
38	occurred	O
39	before	O
40	the	O
41	germ	O
42	line	O
43	was	O
44	set	O
45	aside	O
46	from	O
47	the	O
48	somatic	O
49	lineages	O
50	.	O
1	Successful	O
2	use	O
3	of	O
4	transureteroureterostomy	O
5	to	O
6	salvage	O
7	ureterosigmoidostomy	O
8	after	O
9	anastomotic	O
10	failure	O
11	.	O
1	Transformed	O
2	cell	O
3	lines	O
4	expressing	O
5	solely	O
6	E1a	O
7	or	O
8	E1a	O
9	and	O
10	E1b	O
11	gene	O
12	products	O
13	derived	O
14	from	O
15	these	O
16	viruses	O
17	display	O
18	enhanced	O
19	anchorage	O
20	-	O
21	independent	O
22	growth	O
23	at	O
24	37	O
25	degrees	O
26	C	O
27	versus	O
28	32	O
29	degrees	O
30	C	O
31	and	O
32	display	O
33	a	O
34	cytoskeletal	O
35	architecture	O
36	resembling	O
37	untransformed	O
38	fibroblastic	O
39	CREF	O
40	cells	O
41	.	O
1	In	O
2	the	O
3	former	O
4	instance	O
5	,	O
6	in	O
7	addition	O
8	to	O
9	serum	O
10	calcium	O
11	and	O
12	phosphorous	O
13	ion	O
14	concentrations	O
15	,	O
16	tissue	O
17	pH	O
18	,	O
19	blood	O
20	supply	O
21	,	O
22	hormones	O
23	,	O
24	i	O
25	.	O
26	e	O
27	.,	O
28	vitamin	O
29	D	O
30	,	O
31	vitamin	O
32	A	O
33	,	O
34	and	O
35	various	O
36	enzymes	O
37	(	O
38	e	O
39	.	O
40	g	O
41	.,	O
42	alkaline	O
43	phosphatase	B
44	and	O
45	pyrophosphatase	O
46	)	O
47	may	O
48	all	O
49	play	O
50	significant	O
51	,	O
52	ancillary	O
53	,	O
54	time	O
55	-	O
56	dependent	O
57	,	O
58	but	O
59	as	O
60	yet	O
61	undetermined	O
62	roles	O
63	.	O
1	Thus	O
2	,	O
3	quantitative	O
4	analysis	O
5	of	O
6	thallium	O
7	-	O
8	201	O
9	uptake	O
10	and	O
11	washout	O
12	provided	O
13	objective	O
14	evidence	O
15	for	O
16	improved	O
17	myocardial	O
18	perfusion	O
19	after	O
20	coronary	O
21	angioplasty	O
22	.	O
1	To	O
2	investigate	O
3	the	O
4	effects	O
5	of	O
6	isotretinoin	O
7	on	O
8	HDL	O
9	,	O
10	we	O
11	measured	O
12	HDL	O
13	-	O
14	C	O
15	,	O
16	HDL	O
17	phospholipids	O
18	(	O
19	HDL	O
20	-	O
21	PL	O
22	),	O
23	apoprotein	O
24	A1	O
25	(	O
26	apo	O
27	A	O
28	-	O
29	1	O
30	),	O
31	and	O
32	HDL	O
33	-	O
34	C	O
35	subfractions	O
36	(	O
37	HDL2	O
38	-	O
39	C	O
40	and	O
41	HDL3	O
42	-	O
43	C	O
44	)	O
45	in	O
46	24	O
47	healthy	O
48	,	O
49	male	O
50	patients	O
51	receiving	O
52	a	O
53	16	O
54	-	O
55	week	O
56	course	O
57	of	O
58	isotretinoin	O
59	(	O
60	1	O
61	.	O
62	0	O
63	mg	O
64	/	O
65	kg	O
66	/	O
67	day	O
68	)	O
69	for	O
70	treatment	O
71	of	O
72	severe	O
73	acne	O
74	vulgaris	O
75	.	O
1	The	O
2	clinical	O
3	picture	O
4	and	O
5	laboratory	O
6	parameters	O
7	were	O
8	consistent	O
9	with	O
10	a	O
11	serum	O
12	sickness	O
13	reaction	O
14	.	O
1	The	O
2	experimental	O
3	end	O
4	points	O
5	were	O
6	the	O
7	time	O
8	required	O
9	for	O
10	treated	O
11	tumors	O
12	to	O
13	reach	O
14	3	O
15	times	O
16	their	O
17	treatment	O
18	size	O
19	,	O
20	the	O
21	survival	O
22	of	O
23	stem	O
24	cells	O
25	in	O
26	the	O
27	duodenal	O
28	crypts	O
29	,	O
30	and	O
31	the	O
32	breathing	O
33	rate	O
34	measured	O
35	early	O
36	(	O
37	19	O
38	-	O
39	23	O
40	weeks	O
41	)	O
42	and	O
43	late	O
44	(	O
45	41	O
46	-	O
47	46	O
48	weeks	O
49	)	O
50	after	O
51	treatment	O
52	.	O
1	The	O
2	seco	O
3	-	O
4	steroid	O
5	hormone	O
6	1	O
7	,	O
8	25	O
9	-	O
10	dihydroxyvitamin	O
11	D3	O
12	is	O
13	known	O
14	to	O
15	induce	O
16	the	O
17	expression	O
18	of	O
19	a	O
20	calcium	O
21	binding	O
22	protein	O
23	termed	O
24	calbindin	O
25	-	O
26	D28K	O
27	in	O
28	a	O
29	variety	O
30	of	O
31	target	O
32	tissues	O
33	.	O
1	The	O
2	absorbable	O
3	perisplenic	O
4	mesh	O
5	is	O
6	an	O
7	important	O
8	improvement	O
9	,	O
10	and	O
11	in	O
12	some	O
13	cases	O
14	it	O
15	may	O
16	replace	O
17	other	O
18	techniques	O
19	for	O
20	arresting	O
21	splenic	O
22	bleeding	O
23	.	O
1	Effects	O
2	of	O
3	single	O
4	and	O
5	combined	O
6	maltose	O
7	tetrapalmitate	O
8	immunotherapy	O
9	,	O
10	cyclophosphamide	O
11	chemotherapy	O
12	and	O
13	radiotherapy	O
14	on	O
15	ethyl	O
16	carbamate	O
17	accelerated	O
18	primary	O
19	lung	O
20	cancer	O
21	in	O
22	A	O
23	/	O
24	J	O
25	mice	O
26	.	O
1	Phase	O
2	II	O
3	study	O
4	of	O
5	VP	O
6	-	O
7	16	O
8	(	O
9	capsule	O
10	)	O
11	in	O
12	solid	O
13	tumors	O
14	.	O
1	Different	O
2	sequence	O
3	elements	O
4	of	O
5	both	O
6	the	O
7	retroviral	O
8	vectors	O
9	and	O
10	the	O
11	c	B
12	-	O
13	myc	O
14	gene	O
15	recombined	O
16	during	O
17	genesis	O
18	of	O
19	highly	O
20	oncogenic	O
21	retroviruses	O
22	CMII	O
23	,	O
24	MC29	O
25	,	O
26	or	O
27	MH2	O
28	.	O
1	Subcloning	O
2	of	O
3	DNA	O
4	fragments	O
5	from	O
6	the	O
7	8	O
8	.	O
9	5	O
10	-	O
11	kilobase	O
12	(	O
13	kb	O
14	)	O
15	insert	O
16	of	O
17	pAVO4	O
18	defined	O
19	a	O
20	4	O
21	-	O
22	kb	O
23	DNA	O
24	fragment	O
25	which	O
26	contained	O
27	the	O
28	functional	O
29	FBP	O
30	+	O
31	gene	O
32	and	O
33	its	O
34	regulatory	O
35	region	O
36	.	O
1	The	O
2	data	O
3	obtained	O
4	up	O
5	to	O
6	now	O
7	only	O
8	suggest	O
9	the	O
10	future	O
11	potentiality	O
12	of	O
13	Bestatin	O
14	treatment	O
15	for	O
16	these	O
17	types	O
18	of	O
19	malignancy	O
20	.	O
1	The	O
2	homology	O
3	to	O
4	v	O
5	-	O
6	mil	O
7	starts	O
8	within	O
9	the	O
10	coding	O
11	sequence	O
12	of	O
13	exon	O
14	1	O
15	and	O
16	ends	O
17	within	O
18	the	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	of	O
24	exon	O
25	11	O
26	,	O
27	12	O
28	nucleotides	O
29	downstream	O
30	from	O
31	the	O
32	nonsense	O
33	codon	O
34	terminating	O
35	the	O
36	large	O
37	open	O
38	reading	O
39	frame	O
40	shared	O
41	between	O
42	c	B
43	-	O
44	mil	O
45	and	O
46	v	O
47	-	O
48	mil	O
49	.	O
1	The	O
2	pet56	O
3	and	O
4	his3	O
5	genes	O
6	are	O
7	transcribed	O
8	divergently	O
9	from	O
10	initiation	O
11	sites	O
12	that	O
13	are	O
14	separated	O
15	by	O
16	only	O
17	192	O
18	bp	O
19	.	O
1	Comparison	O
2	with	O
3	a	O
4	recently	O
5	described	O
6	c	B
7	-	O
8	sis	O
9	cDNA	O
10	clone	O
11	(	O
12	Collins	O
13	et	O
14	al	O
15	.,	O
16	Nature	O
17	316	O
18	,	O
19	748	O
20	-	O
21	750	O
22	(	O
23	1985	O
24	))	O
25	revealed	O
26	that	O
27	the	O
28	1	O
29	.	O
30	9	O
31	kbp	O
32	DNA	O
33	region	O
34	contained	O
35	a	O
36	large	O
37	5	O
38	'	O
39	c	B
40	-	O
41	sis	O
42	exon	O
43	of	O
44	at	O
45	least	O
46	1050	O
47	bp	O
48	.	O
1	The	O
2	5	O
3	'	O
4	and	O
5	3	O
6	'	O
7	untranslated	O
8	sequences	O
9	contain	O
10	characteristic	O
11	sequences	O
12	that	O
13	are	O
14	involved	O
15	in	O
16	the	O
17	initiation	O
18	and	O
19	termination	O
20	of	O
21	transcription	O
22	,	O
23	including	O
24	two	O
25	possible	O
26	promoters	O
27	,	O
28	one	O
29	of	O
30	which	O
31	may	O
32	contain	O
33	two	O
34	overlapping	O
35	-	O
36	10	O
37	sequences	O
38	.	O
1	Thirty	O
2	of	O
3	the	O
4	clones	O
5	contained	O
6	a	O
7	complete	O
8	340	O
9	base	O
10	-	O
11	pair	O
12	dimer	O
13	unit	O
14	of	O
15	the	O
16	repeat	O
17	.	O
1	Human	O
2	alpha	B
3	-	O
4	galactosidase	O
5	A	O
6	:	O
7	nucleotide	O
8	sequence	O
9	of	O
10	a	O
11	cDNA	O
12	clone	O
13	encoding	O
14	the	O
15	mature	O
16	enzyme	O
17	.	O
1	During	O
2	the	O
3	biosynthesis	O
4	of	O
5	all	O
6	three	O
7	mutant	O
8	polypeptides	O
9	,	O
10	the	O
11	signal	O
12	peptide	O
13	is	O
14	efficiently	O
15	and	O
16	accurately	O
17	cleaved	O
18	from	O
19	the	O
20	nascent	O
21	protein	O
22	,	O
23	even	O
24	though	O
25	in	O
26	mutants	O
27	X2	O
28	and	O
29	X3	O
30	the	O
31	cleavage	O
32	site	O
33	itself	O
34	has	O
35	been	O
36	altered	O
37	.	O
1	There	O
2	were	O
3	no	O
4	interfering	O
5	peaks	O
6	in	O
7	the	O
8	quantitation	O
9	of	O
10	sulbactam	O
11	.	O
1	The	O
2	latent	O
3	periods	O
4	from	O
5	the	O
6	antral	O
7	exclusion	O
8	to	O
9	the	O
10	occurrence	O
11	of	O
12	anastomotic	O
13	ulcers	O
14	after	O
15	a	O
16	subtotal	O
17	gastrectomy	O
18	with	O
19	Billroth	O
20	'	O
21	s	O
22	type	O
23	II	O
24	reconstruction	O
25	varied	O
26	from	O
27	a	O
28	few	O
29	days	O
30	to	O
31	19	O
32	years	O
33	,	O
34	with	O
35	an	O
36	average	O
37	of	O
38	2	O
39	.	O
40	8	O
41	years	O
42	.	O
1	The	O
2	molecular	O
3	weight	O
4	of	O
5	in	O
6	vivo	O
7	-	O
8	labeled	O
9	proteins	O
10	was	O
11	increased	O
12	relative	O
13	to	O
14	that	O
15	of	O
16	in	O
17	vitro	O
18	-	O
19	translated	O
20	proteins	O
21	,	O
22	indicating	O
23	that	O
24	a	O
25	posttranslational	O
26	modification	O
27	had	O
28	occurred	O
29	.	O
1	In	O
2	the	O
3	DNAs	O
4	of	O
5	all	O
6	Ph1	O
7	-	O
8	positive	O
9	chronic	O
10	myelocytic	O
11	leukemia	O
12	patients	O
13	studied	O
14	to	O
15	date	O
16	,	O
17	a	O
18	breakpoint	O
19	on	O
20	chromosome	O
21	22	O
22	(	O
23	the	O
24	Ph1	O
25	chromosome	O
26	)	O
27	can	O
28	be	O
29	demonstrated	O
30	with	O
31	a	O
32	probe	O
33	from	O
34	the	O
35	bcr	O
36	(	O
37	breakpoint	O
38	cluster	O
39	region	O
40	).	O
1	The	O
2	96	O
3	-	O
4	bp	O
5	insert	O
6	contained	O
7	a	O
8	termination	O
9	signal	O
10	which	O
11	caused	O
12	the	O
13	premature	O
14	termination	O
15	of	O
16	the	O
17	protein	O
18	,	O
19	leading	O
20	to	O
21	the	O
22	generation	O
23	of	O
24	a	O
25	p53	B
26	product	O
27	9	O
28	amino	O
29	acids	O
30	shorter	O
31	than	O
32	usual	O
33	.	O
1	All	O
2	tumors	O
3	proved	O
4	histologically	O
5	to	O
6	be	O
7	neuroendocrine	O
8	in	O
9	origin	O
10	.	O
1	The	O
2	coding	O
3	region	O
4	of	O
5	2385	O
6	nucleotides	O
7	corresponds	O
8	to	O
9	a	O
10	polypeptide	O
11	chain	O
12	of	O
13	795	O
14	amino	O
15	acids	O
16	,	O
17	giving	O
18	a	O
19	molecular	O
20	weight	O
21	of	O
22	91	O
23	,	O
24	555	O
25	for	O
26	the	O
27	hsp108	O
28	protein	O
29	.	O
1	Gluzman	O
2	,	O
3	EMBO	O
4	J	O
5	.	O
1	The	O
2	second	O
3	group	O
4	of	O
5	homologous	O
6	elements	O
7	is	O
8	present	O
9	in	O
10	the	O
11	upstream	O
12	region	O
13	of	O
14	both	O
15	genes	O
16	.	O
1	A	O
2	centromere	O
3	in	O
4	S	O
5	.	O
6	cerevisiae	O
7	consists	O
8	of	O
9	a	O
10	region	O
11	of	O
12	DNA	O
13	,	O
14	approximately	O
15	150	O
16	bp	O
17	in	O
18	length	O
19	,	O
20	containing	O
21	three	O
22	important	O
23	sequence	O
24	elements	O
25	,	O
26	which	O
27	are	O
28	folded	O
29	with	O
30	proteins	O
31	into	O
32	a	O
33	specific	O
34	conformation	O
35	in	O
36	the	O
37	chromatin	O
38	(	O
39	the	O
40	yeast	O
41	kinetochore	O
42	).	O
1	Constitutive	O
2	function	O
3	of	O
4	a	O
5	positively	O
6	regulated	O
7	promoter	O
8	reveals	O
9	new	O
10	sequences	O
11	essential	O
12	for	O
13	activity	O
14	.	O
1	One	O
2	group	O
3	of	O
4	six	O
5	cDNA	O
6	clones	O
7	was	O
8	derived	O
9	from	O
10	a	O
11	2	O
12	.	O
13	9	O
14	-	O
15	kilobase	O
16	early	O
17	transcript	O
18	encoded	O
19	by	O
20	the	O
21	IR2	O
22	repeat	O
23	element	O
24	and	O
25	showed	O
26	restriction	O
27	site	O
28	polymorphism	O
29	for	O
30	the	O
31	enzyme	O
32	SmaI	O
33	.	O
1	The	O
2	PSS	O
3	gene	O
4	was	O
5	subcloned	O
6	into	O
7	a	O
8	1	O
9	.	O
10	1	O
11	-	O
12	kb	O
13	fragment	O
14	of	O
15	the	O
16	yeast	O
17	DNA	O
18	on	O
19	the	O
20	YEp13	O
21	vector	O
22	.	O
1	4	O
2	.	O
1	In	O
2	general	O
3	,	O
4	the	O
5	values	O
6	obtained	O
7	by	O
8	the	O
9	two	O
10	methods	O
11	were	O
12	in	O
13	agreement	O
14	for	O
15	each	O
16	species	O
17	of	O
18	epidermal	O
19	growth	O
20	factor	O
21	and	O
22	followed	O
23	the	O
24	order	O
25	:	O
26	wild	O
27	type	O
28	greater	O
29	than	O
30	Glu24	O
31	----	O
32	Gly	O
33	greater	O
34	than	O
35	Asp27	O
36	----	O
37	Gly	O
38	much	O
39	greater	O
40	than	O
41	Pro7	O
42	----	O
43	Thr	O
44	greater	O
45	than	O
46	Tyr29	O
47	----	O
48	Gly	O
49	greater	O
50	than	O
51	Leu47	O
52	----	O
53	His	O
54	.	O
1	Bacteriologic	O
2	culture	O
3	of	O
4	pancreatic	O
5	tissue	O
6	was	O
7	positive	O
8	in	O
9	6	O
10	/	O
11	8	O
12	IB	O
13	and	O
14	3	O
15	/	O
16	17	O
17	NIB	O
18	rats	O
19	(	O
20	p	O
21	less	O
22	than	O
23	0	O
24	.	O
25	01	O
26	).	O
1	The	O
2	relationship	O
3	between	O
4	primary	O
5	malignant	O
6	lymphoma	O
7	of	O
8	the	O
9	thyroid	O
10	and	O
11	chronic	O
12	thyroiditis	O
13	is	O
14	discussed	O
15	.	O
1	Although	O
2	large	O
3	epidemiologic	O
4	studies	O
5	are	O
6	best	O
7	able	O
8	to	O
9	identify	O
10	the	O
11	relative	O
12	contributions	O
13	of	O
14	specific	O
15	risk	O
16	factors	O
17	while	O
18	controlling	O
19	for	O
20	other	O
21	risk	O
22	factors	O
23	,	O
24	new	O
25	studies	O
26	need	O
27	to	O
28	focus	O
29	on	O
30	important	O
31	unresolved	O
32	questions	O
33	.	O
1	Thus	O
2	,	O
3	prostacyclin	O
4	enhanced	O
5	the	O
6	autoregulative	O
7	property	O
8	of	O
9	the	O
10	inner	O
11	ear	O
12	vessels	O
13	.	O
1	Factors	O
2	influencing	O
3	the	O
4	bond	O
5	strength	O
6	between	O
7	glass	O
8	polyalkenoate	O
9	(	O
10	ionomer	O
11	)	O
12	cements	O
13	and	O
14	dentine	O
15	.	O
1	During	O
2	insulin	B
3	infusion	O
4	,	O
5	a	O
6	20	O
7	%	O
8	dextrose	O
9	solution	O
10	was	O
11	infused	O
12	by	O
13	a	O
14	Biostator	O
15	in	O
16	order	O
17	to	O
18	maintain	O
19	the	O
20	patient	O
21	'	O
22	s	O
23	glycemia	O
24	at	O
25	90	O
26	mg	O
27	/	O
28	dl	O
29	.	O
1	Finally	O
2	,	O
3	the	O
4	pathophysiological	O
5	aspects	O
6	of	O
7	urinary	O
8	acidification	O
9	are	O
10	discussed	O
11	,	O
12	focusing	O
13	on	O
14	renal	O
15	tubular	O
16	acidosis	O
17	models	O
18	(	O
19	induced	O
20	by	O
21	maleate	O
22	and	O
23	amphotericin	O
24	B	O
25	treatment	O
26	)	O
27	and	O
28	their	O
29	cellular	O
30	mechanisms	O
31	,	O
32	as	O
33	well	O
34	as	O
35	the	O
36	role	O
37	of	O
38	adrenal	O
39	steroids	O
40	in	O
41	urinary	O
42	acidification	O
43	.	O
1	Research	O
2	on	O
3	ethylene	O
4	glycol	O
5	and	O
6	diethylene	O
7	glycol	O
8	for	O
9	carcinogenic	O
10	effects	O
1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	greater	O
7	estrogenic	O
8	influence	O
9	associated	O
10	with	O
11	the	O
12	ethinyl	O
13	estradiol	O
14	-	O
15	containing	O
16	OC	O
17	resulted	O
18	in	O
19	inhibition	O
20	of	O
21	coronary	O
22	artery	O
23	atherosclerosis	O
24	despite	O
25	a	O
26	pronounced	O
27	progestin	O
28	-	O
29	induced	O
30	lowering	O
31	of	O
32	plasma	O
33	HDL	O
34	cholesterol	O
35	concentration	O
36	and	O
37	,	O
38	further	O
39	,	O
40	that	O
41	hormonal	O
42	balance	O
43	may	O
44	have	O
45	a	O
46	marked	O
47	influence	O
48	on	O
49	the	O
50	relationship	O
51	between	O
52	plasma	O
53	lipids	O
54	and	O
55	atherogenesis	O
56	.	O
1	40	O
2	.	O
3	3	O
4	+/-	O
5	10	O
6	.	O
7	1	O
8	mg	O
9	/	O
10	l	O
11	(	O
12	SD	O
13	)	O
14	vs	O
15	31	O
16	.	O
17	2	O
18	+/-	O
19	8	O
20	.	O
21	0	O
22	,	O
23	P	O
24	less	O
25	than	O
26	0	O
27	.	O
28	01	O
29	).	O
30	beta	B
31	2m	O
32	was	O
33	not	O
34	significantly	O
35	higher	O
36	in	O
37	patients	O
38	with	O
39	bone	O
40	cysts	O
41	(	O
42	37	O
43	.	O
44	7	O
45	+/-	O
46	11	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	l	O
52	vs	O
53	37	O
54	.	O
55	0	O
56	+/-	O
57	10	O
58	.	O
59	0	O
60	),	O
61	but	O
62	median	O
63	duration	O
64	of	O
65	dialysis	O
66	was	O
67	significantly	O
68	(	O
69	P	O
70	less	O
71	than	O
72	0	O
73	.	O
74	01	O
75	)	O
76	longer	O
77	in	O
78	patients	O
79	with	O
80	bone	O
81	cysts	O
82	(	O
83	90	O
84	vs	O
85	57	O
86	months	O
87	).	O
88	beta	B
89	2m	O
90	was	O
91	lower	O
92	in	O
93	patients	O
94	maintained	O
95	on	O
96	dialysis	O
97	for	O
98	less	O
99	than	O
100	1	O
101	year	O
102	and	O
103	whose	O
104	residual	O
105	urine	O
106	volume	O
107	was	O
108	greater	O
109	than	O
110	0	O
111	.	O
112	1	O
113	litre	O
114	per	O
115	day	O
116	.	O
1	No	O
2	differences	O
3	in	O
4	fixation	O
5	quality	O
6	were	O
7	observed	O
8	between	O
9	cochleas	O
10	fixed	O
11	by	O
12	intravascular	O
13	perfusion	O
14	and	O
15	cochleas	O
16	fixed	O
17	by	O
18	intralabyrinthine	O
19	perfusion	O
20	.	O
1	The	O
2	requirement	O
3	of	O
4	different	O
5	essential	O
6	fatty	O
7	acids	O
8	in	O
9	patients	O
10	with	O
11	total	O
12	parenteral	O
13	nutrition	O
14	after	O
15	heavy	O
16	injury	O
17	is	O
18	of	O
19	special	O
20	interest	O
21	with	O
22	respect	O
23	to	O
24	the	O
25	development	O
26	and	O
27	prognosis	O
28	of	O
29	shock	O
30	,	O
31	sepsis	O
32	or	O
33	adult	O
34	respiratory	O
35	distress	O
36	syndrome	O
37	.	O
1	The	O
2	results	O
3	of	O
4	these	O
5	experiments	O
6	indicate	O
7	that	O
8	at	O
9	least	O
10	two	O
11	upstream	O
12	activator	O
13	sequences	O
14	(	O
15	UAS	O
16	)	O
17	mediate	O
18	maximum	O
19	induction	O
20	by	O
21	galactose	O
22	.	O
1	This	O
2	suggested	O
3	that	O
4	delta	B
5	6	O
6	and	O
7	delta	B
8	5	O
9	desaturation	O
10	activities	O
11	are	O
12	normal	O
13	in	O
14	these	O
15	conditions	O
16	with	O
17	this	O
18	C18	O
19	:	O
20	2w6	O
21	supply	O
22	.	O
1	It	O
2	is	O
3	suggested	O
4	that	O
5	the	O
6	use	O
7	of	O
8	endogenous	O
9	creatinine	O
10	clearance	O
11	to	O
12	estimate	O
13	the	O
14	glomerular	O
15	filtration	O
16	rate	O
17	(	O
18	GFR	O
19	)	O
20	requires	O
21	caution	O
22	and	O
23	the	O
24	recognition	O
25	of	O
26	the	O
27	limitations	O
28	of	O
29	the	O
30	method	O
31	,	O
32	and	O
33	that	O
34	simpler	O
35	techniques	O
36	(	O
37	serum	O
38	creatinine	O
39	or	O
40	estimated	O
41	endogenous	O
42	creatinine	O
43	clearance	O
44	)	O
45	are	O
46	preferable	O
47	in	O
48	routine	O
49	practice	O
50	.	O
1	The	O
2	5	O
3	'	O
4	end	O
5	of	O
6	the	O
7	coding	O
8	region	O
9	was	O
10	located	O
11	precisely	O
12	by	O
13	comparing	O
14	the	O
15	deduced	O
16	amino	O
17	acid	O
18	sequence	O
19	to	O
20	the	O
21	actual	O
22	N	O
23	-	O
24	terminal	O
25	amino	O
26	acid	O
27	sequence	O
28	of	O
29	IHF	O
30	.	O
1	The	O
2	central	O
3	visual	O
4	fields	O
5	of	O
6	2165	O
7	normal	O
8	and	O
9	106	O
10	glaucoma	O
11	eyes	O
12	were	O
13	measured	O
14	using	O
15	a	O
16	threshold	O
17	related	O
18	suprathreshold	O
19	strategy	O
20	.	O
1	Aviators	O
2	from	O
3	the	O
4	Light	O
5	Attack	O
6	Wing	O
7	,	O
8	Pacific	O
9	were	O
10	surveyed	O
11	and	O
12	the	O
13	results	O
14	were	O
15	categorized	O
16	by	O
17	aircraft	O
18	type	O
19	.	O
1	Evaluation	O
2	of	O
3	human	O
4	and	O
5	bovine	O
6	modified	O
7	-	O
8	hemoglobin	O
9	solution	O
10	as	O
11	oxygen	O
12	-	O
13	carrying	O
14	fluid	O
15	for	O
16	blood	O
17	volume	O
18	replacement	O
19	.	O
1	Chem	O
2	.	O
1	A	O
2	poor	O
3	correlation	O
4	was	O
5	found	O
6	between	O
7	a	O
8	mildly	O
9	-	O
10	atypical	O
11	(	O
12	inflammatory	O
13	)	O
14	cytological	O
15	result	O
16	(	O
17	class	O
18	2	O
19	)	O
20	and	O
21	a	O
22	benign	O
23	histological	O
24	diagnosis	O
25	:	O
26	48	O
27	%	O
28	of	O
29	class	O
30	-	O
31	2	O
32	smears	O
33	were	O
34	diagnosed	O
35	histologically	O
36	as	O
37	dysplasia	O
38	or	O
39	worse	O
40	.	O
1	Interpersonal	O
2	style	O
3	differences	O
4	among	O
5	drug	O
6	abusers	O
7	were	O
8	explored	O
9	using	O
10	Ryan	O
11	'	O
12	s	O
13	(	O
14	1977	O
15	)	O
16	typological	O
17	system	O
18	of	O
19	FIRO	O
20	-	O
21	B	O
22	interpretation	O
23	.	O
1	There	O
2	were	O
3	gene	O
4	clusters	O
5	encoding	O
6	photosynthesis	O
7	components	O
8	such	O
9	as	O
10	the	O
11	psbB	O
12	-	O
13	psbH	O
14	-	O
15	petB	O
16	-	O
17	petD	O
18	and	O
19	the	O
20	psbE	O
21	-	O
22	psbF	O
23	clusters	O
24	.	O
1	An	O
2	11	O
3	-	O
4	month	O
5	-	O
6	old	O
7	girl	O
8	suffering	O
9	from	O
10	Dandy	O
11	-	O
12	Walker	O
13	malformation	O
14	(	O
15	DWM	O
16	)	O
17	associated	O
18	with	O
19	tetralogy	O
20	of	O
21	Fallot	O
22	(	O
23	TOF	O
24	)	O
25	is	O
26	presented	O
27	.	O
1	None	O
2	had	O
3	a	O
4	past	O
5	history	O
6	of	O
7	opportunistic	O
8	infections	O
9	;	O
10	neither	O
11	did	O
12	any	O
13	have	O
14	lymphopenia	O
15	.	O
1	Possible	O
2	factors	O
3	for	O
4	the	O
5	development	O
6	of	O
7	psychotic	O
8	symptomatology	O
9	during	O
10	group	O
11	activities	O
12	and	O
13	the	O
14	role	O
15	of	O
16	group	O
17	dynamics	O
18	acting	O
19	as	O
20	stress	O
21	factors	O
22	precipitating	O
23	functional	O
24	psychoses	O
25	,	O
26	especially	O
27	bipolar	O
28	manifestations	O
29	,	O
30	are	O
31	discussed	O
32	.	O
1	Records	O
2	of	O
3	31	O
4	children	O
5	with	O
6	AIDS	O
7	or	O
8	AIDS	O
9	-	O
10	related	O
11	complex	O
12	admitted	O
13	to	O
14	the	O
15	pediatric	O
16	intensive	O
17	care	O
18	unit	O
19	for	O
20	acute	O
21	respiratory	O
22	failure	O
23	throughout	O
24	a	O
25	46	O
26	-	O
27	month	O
28	period	O
29	were	O
30	reviewed	O
31	.	O
1	The	O
2	murine	O
3	MHC	O
4	class	O
5	I	O
6	genes	O
7	,	O
8	H	O
9	-	O
10	2Dq	O
11	and	O
12	H	O
13	-	O
14	2Lq	O
15	,	O
16	are	O
17	strikingly	O
18	homologous	O
19	to	O
20	each	O
21	other	O
22	,	O
23	H	O
24	-	O
25	2Ld	O
26	,	O
27	and	O
28	two	O
29	genes	O
30	reported	O
31	to	O
32	encode	O
33	tumor	O
34	-	O
35	specific	O
36	antigens	O
37	.	O
1	The	O
2	behavior	O
3	of	O
4	suf12	O
5	-	O
6	null	O
7	/	O
8	SUF12	O
9	+	O
10	heterozygotes	O
11	indicates	O
12	that	O
13	suf12	O
14	is	O
15	co	O
16	-	O
17	dominantly	O
18	expressed	O
19	and	O
20	suggests	O
21	that	O
22	suf12	O
23	allele	O
24	-	O
25	specific	O
26	suppression	O
27	may	O
28	result	O
29	from	O
30	functionally	O
31	distinct	O
32	mutant	O
33	proteins	O
34	rather	O
35	than	O
36	variation	O
37	in	O
38	residual	O
39	wild	O
40	-	O
41	type	O
42	SUF12	O
43	+	O
44	activity	O
45	.	O
1	Hyperprolactinaemia	O
2	,	O
3	moderate	O
4	hypogonadism	O
5	,	O
6	infraclinical	O
7	neuropathies	O
8	,	O
9	arterial	O
10	stenoses	O
11	and	O
12	moderate	O
13	venous	O
14	leakages	O
15	seem	O
16	to	O
17	play	O
18	a	O
19	partial	O
20	role	O
21	of	O
22	organic	O
23	starter	O
24	or	O
25	cofactor	O
26	,	O
27	the	O
28	sexual	O
29	consequences	O
30	of	O
31	which	O
32	are	O
33	amplified	O
34	by	O
35	psychological	O
36	factors	O
37	,	O
38	partly	O
39	secondary	O
40	to	O
41	the	O
42	initial	O
43	sexual	O
44	failures	O
45	.	O
1	Chronic	O
2	endotoxemia	O
3	appears	O
4	to	O
5	be	O
6	associated	O
7	with	O
8	an	O
9	elevated	O
10	pulmonary	O
11	microvascular	O
12	permeability	O
13	and	O
14	a	O
15	tendency	O
16	toward	O
17	a	O
18	hyperdynamic	O
19	circulation	O
20	but	O
21	with	O
22	an	O
23	appreciable	O
24	degree	O
25	of	O
26	refractoriness	O
27	associated	O
28	with	O
29	regional	O
30	hemodynamics	O
31	and	O
32	eicosanoid	O
33	biosynthesis	O
34	.	O
1	In	O
2	contrast	O
3	,	O
4	we	O
5	observed	O
6	high	O
7	concentrations	O
8	in	O
9	29	O
10	of	O
11	75	O
12	patients	O
13	with	O
14	tumors	O
15	of	O
16	the	O
17	central	O
18	nervous	O
19	system	O
20	,	O
21	especially	O
22	in	O
23	meningioma	O
24	(	O
25	6	O
26	/	O
27	9	O
28	),	O
29	glioblastoma	O
30	(	O
31	9	O
32	/	O
33	23	O
34	),	O
35	and	O
36	neurinoma	O
37	(	O
38	5	O
39	/	O
40	5	O
41	).	O
1	Diet	O
2	and	O
3	atopic	O
4	eczema	O
5	.	O
1	Revascularization	O
2	after	O
3	anterior	O
4	maxillary	O
5	and	O
6	mandibular	O
7	osteotomy	O
1	The	O
2	intrapancreatic	O
3	spread	O
4	of	O
5	the	O
6	carcinoma	O
7	correlated	O
8	with	O
9	portal	O
10	invasion	O
11	of	O
12	carcinoma	O
13	,	O
14	hardness	O
15	of	O
16	the	O
17	body	O
18	and	O
19	tail	O
20	,	O
21	obstruction	O
22	of	O
23	main	O
24	pancreatic	O
25	duct	O
26	and	O
27	irregular	O
28	pancreaticogram	O
29	.	O
1	Proctoscopy	O
2	and	O
3	roentgenographic	O
4	studies	O
5	may	O
6	be	O
7	an	O
8	important	O
9	part	O
10	of	O
11	evaluation	O
12	,	O
13	especially	O
14	in	O
15	patients	O
16	who	O
17	present	O
18	with	O
19	perianal	O
20	suppuration	O
21	,	O
22	masses	O
23	,	O
24	or	O
25	anal	O
26	fissures	O
27	.	O
1	In	O
2	vitro	O
3	antimalarial	O
4	activity	O
5	of	O
6	neem	O
7	(	O
8	Azadirachta	O
9	indica	O
10	A	O
11	.	O
1	The	O
2	German	O
3	Society	O
4	of	O
5	Pediatric	O
6	Oncology	O
7	in	O
8	1981	O
9	initiated	O
10	the	O
11	Cooperative	O
12	Ewing	O
13	'	O
14	s	O
15	Sarcoma	O
16	Study	O
17	(	O
18	CESS	O
19	81	O
20	)	O
21	using	O
22	a	O
23	four	O
24	-	O
25	drug	O
26	combination	O
27	of	O
28	chemotherapy	O
29	prior	O
30	to	O
31	definitive	O
32	local	O
33	control	O
34	with	O
35	surgery	O
36	and	O
37	/	O
38	or	O
39	radiation	O
40	.	O
1	The	O
2	program	O
3	has	O
4	been	O
5	written	O
6	in	O
7	a	O
8	generic	O
9	BASIC	O
10	in	O
11	order	O
12	to	O
13	make	O
14	the	O
15	procedure	O
16	user	O
17	-	O
18	friendly	O
19	.	O
1	Since	O
2	high	O
3	levels	O
4	of	O
5	immunoglobulin	O
6	G	O
7	were	O
8	demonstrated	O
9	against	O
10	the	O
11	surface	O
12	of	O
13	the	O
14	NVS	O
15	after	O
16	immunization	O
17	,	O
18	passive	O
19	transfer	O
20	experiments	O
21	were	O
22	initiated	O
23	.	O
1	The	O
2	relations	O
3	among	O
4	various	O
5	negative	O
6	emotional	O
7	and	O
8	behavioral	O
9	characteristics	O
10	(	O
11	e	O
12	.	O
13	g	O
14	.,	O
15	aggression	O
16	,	O
17	anxiety	O
18	,	O
19	undercompliance	O
20	,	O
21	depressive	O
22	mood	O
23	)	O
24	and	O
25	adjustment	O
26	were	O
27	examined	O
28	through	O
29	use	O
30	of	O
31	data	O
32	from	O
33	the	O
34	31	O
35	-	O
36	year	O
37	-	O
38	old	O
39	New	O
40	York	O
41	Longitudinal	O
42	Study	O
43	.	O
1	To	O
2	evaluate	O
3	the	O
4	effect	O
5	of	O
6	altitude	O
7	on	O
8	adolescent	O
9	growth	O
10	and	O
11	development	O
12	,	O
13	three	O
14	groups	O
15	of	O
16	healthy	O
17	,	O
18	well	O
19	-	O
20	nourished	O
21	youth	O
22	of	O
23	similar	O
24	socioeconomic	O
25	status	O
26	and	O
27	ethnic	O
28	grouping	O
29	who	O
30	resided	O
31	at	O
32	sea	O
33	level	O
34	(	O
35	n	O
36	=	O
37	1262	O
38	subjects	O
39	),	O
40	mid	O
41	-	O
42	altitude	O
43	(	O
44	n	O
45	=	O
46	1743	O
47	subjects	O
48	),	O
49	and	O
50	high	O
51	altitude	O
52	(	O
53	n	O
54	=	O
55	1137	O
56	subjects	O
57	)	O
58	were	O
59	studied	O
60	.	O
1	Recent	O
2	developments	O
3	in	O
4	drugs	O
5	antagonistic	O
6	to	O
7	factors	O
8	causing	O
9	peptic	O
10	ulcer	O
11	--	O
12	clinical	O
13	efficacy	O
14	and	O
15	problems	O
16	;	O
17	gastrin	O
18	receptor	B
19	blockaders	O
1	The	O
2	spermicide	O
3	nonoxynol	O
4	-	O
5	9	O
6	is	O
7	a	O
8	member	O
9	of	O
10	a	O
11	homologous	O
12	series	O
13	of	O
14	alkylphenol	O
15	-	O
16	ethoxylates	O
17	(	O
18	polyethoxyethanols	O
19	)	O
20	of	O
21	general	O
22	formula	O
23	C9H19	O
24	-	O
25	C6H6	O
26	-	O
27	O	O
28	-(	O
29	CH2CH2O	O
30	)	O
31	n	O
32	-	O
33	1	O
34	CH2CH2OH	O
35	.	O
1	Static	O
2	magnetic	O
3	fields	O
4	affect	O
5	the	O
6	diffusion	O
7	of	O
8	biological	O
9	particles	O
10	in	O
11	solutions	O
12	through	O
13	the	O
14	Lorentz	O
15	force	O
16	and	O
17	Maxwell	O
18	stress	O
19	.	O
1	Chronic	O
2	administration	O
3	of	O
4	sodium	O
5	cyanate	O
6	decreases	O
7	O2	O
8	extraction	O
9	ratio	O
10	in	O
11	dogs	O
12	.	O
1	The	O
2	pharmacological	O
3	effects	O
4	of	O
5	the	O
6	novel	O
7	compound	O
8	WEB	O
9	1881	O
10	FU	O
11	(	O
12	4	O
13	-	O
14	amino	O
15	-	O
16	methyl	O
17	-	O
18	1	O
19	-	O
20	benzyl	O
21	-	O
22	pyrrolidine	O
23	-	O
24	2	O
25	-	O
26	one	O
27	-	O
28	fumarate	O
29	)	O
30	were	O
31	investigated	O
32	.	O
1	Histopathological	O
2	examination	O
3	revealed	O
4	dose	O
5	-	O
6	related	O
7	proliferation	O
8	of	O
9	type	O
10	II	O
11	pneumocytes	O
12	in	O
13	dams	O
14	and	O
15	proliferation	O
16	of	O
17	interstitial	O
18	cells	O
19	and	O
20	delayed	O
21	septal	O
22	/	O
23	capillary	O
24	development	O
25	in	O
26	neonates	O
27	.(	O
28	ABSTRACT	O
29	TRUNCATED	O
30	AT	O
31	250	O
32	WORDS	O
33	)	O
1	Ischemic	O
2	heart	O
3	disease	O
4	,	O
5	age	O
6	of	O
7	more	O
8	than	O
9	75	O
10	years	O
11	,	O
12	and	O
13	the	O
14	fact	O
15	that	O
16	the	O
17	patient	O
18	was	O
19	a	O
20	woman	O
21	were	O
22	independent	O
23	predictors	O
24	of	O
25	poor	O
26	cardiac	O
27	function	O
28	.	O
1	Liquid	O
2	chromatographic	O
3	method	O
4	for	O
5	determination	O
6	of	O
7	citreoviridin	O
8	in	O
9	corn	O
10	and	O
11	rice	O
12	.	O
1	Pregnant	O
2	rats	O
3	were	O
4	exposed	O
5	to	O
6	one	O
7	of	O
8	the	O
9	following	O
10	:	O
11	(	O
12	1	O
13	)	O
14	10	O
15	%	O
16	O2	O
17	in	O
18	N2	O
19	or	O
20	100	O
21	%	O
22	O2	O
23	for	O
24	2	O
25	days	O
26	beginning	O
27	at	O
28	day	O
29	7	O
30	,	O
31	11	O
32	,	O
33	14	O
34	,	O
35	or	O
36	18	O
37	of	O
38	pregnancy	O
39	;	O
40	(	O
41	2	O
42	)	O
43	10	O
44	%	O
45	O2	O
46	in	O
47	N2	O
48	or	O
49	100	O
50	%	O
51	O2	O
52	for	O
53	10	O
54	h	O
55	/	O
56	day	O
57	beginning	O
58	at	O
59	day	O
60	7	O
61	;	O
62	or	O
63	(	O
64	3	O
65	)	O
66	14	O
67	-	O
68	11	O
69	%	O
70	O2	O
71	in	O
72	N2	O
73	continuously	O
74	beginning	O
75	at	O
76	day	O
77	14	O
78	till	O
79	day	O
80	21	O
81	when	O
82	they	O
83	were	O
84	sacrificed	O
85	.	O
1	The	O
2	incidence	O
3	of	O
4	cryptosporidiosis	O
5	in	O
6	young	O
7	children	O
8	was	O
9	determined	O
10	by	O
11	staining	O
12	of	O
13	faecal	O
14	specimens	O
15	with	O
16	a	O
17	modified	O
18	Kinyoun	O
19	stain	O
20	.	O
1	Overall	O
2	least	O
3	-	O
4	squares	O
5	means	O
6	for	O
7	uncooked	O
8	and	O
9	cooked	O
10	longissimus	O
11	muscle	O
12	and	O
13	subcutaneous	O
14	fat	O
15	were	O
16	63	O
17	.	O
18	32	O
19	,	O
20	80	O
21	.	O
22	27	O
23	and	O
24	98	O
25	.	O
26	90	O
27	mg	O
28	of	O
29	cholesterol	O
30	/	O
31	100	O
32	g	O
33	of	O
34	tissue	O
35	,	O
36	respectively	O
37	.	O
1	Nitrofurazone	O
2	significantly	O
3	reduced	O
4	the	O
5	rise	O
6	in	O
7	LH	O
8	induced	O
9	by	O
10	LHRH	O
11	.	O
1	Ovarian	O
2	tumors	O
3	in	O
4	pregnancy	O
5	.	O
1	X2	O
2	test	O
3	,	O
4	with	O
5	Yates	O
6	correction	O
7	if	O
8	need	O
9	,	O
10	was	O
11	used	O
12	as	O
13	statistical	O
14	.	O
15	method	O
16	.	O
1	All	O
2	patients	O
3	had	O
4	the	O
5	CA	O
6	125	O
7	assay	O
8	performed	O
9	within	O
10	one	O
11	week	O
12	before	O
13	their	O
14	second	O
15	-	O
16	look	O
17	operation	O
18	.	O
1	Mean	O
2	fluorosis	O
3	scores	O
4	,	O
5	however	O
6	,	O
7	were	O
8	similar	O
9	.	O
1	An	O
2	industry	O
3	-	O
4	wide	O
5	retrospective	O
6	cohort	O
7	mortality	O
8	study	O
9	was	O
10	conducted	O
11	on	O
12	6	O
13	,	O
14	152	O
15	chemical	O
16	workers	O
17	(	O
18	2	O
19	,	O
20	460	O
21	exposed	O
22	and	O
23	3	O
24	,	O
25	692	O
26	nonexposed	O
27	)	O
28	engaged	O
29	in	O
30	chloromethyl	O
31	ether	O
32	manufacture	O
33	at	O
34	7	O
35	major	O
36	U	O
37	.	O
38	S	O
39	.	O
40	companies	O
41	between	O
42	1948	O
43	and	O
44	1980	O
45	.	O
1	This	O
2	brief	O
3	hypercapnic	O
4	challenge	O
5	induced	O
6	a	O
7	rapid	O
8	increase	O
9	in	O
10	CBF	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	any	O
16	change	O
17	in	O
18	MABP	O
19	.	O
1	Five	O
2	out	O
3	of	O
4	eight	O
5	consecutive	O
6	cases	O
7	with	O
8	initial	O
9	symptoms	O
10	of	O
11	a	O
12	'	O
13	midline	O
14	granuloma	O
15	'	O
16	were	O
17	identified	O
18	as	O
19	malignant	O
20	histiocytosis	O
21	(	O
22	histiocytic	O
23	sarcoma	O
24	)	O
25	which	O
26	within	O
27	5	O
28	months	O
29	to	O
30	4	O
31	years	O
32	led	O
33	to	O
34	generalization	O
35	and	O
36	death	O
37	.	O
1	All	O
2	patients	O
3	then	O
4	received	O
5	suxamethonium	O
6	1	O
7	.	O
8	5	O
9	mg	O
10	kg	O
11	-	O
12	1	O
13	i	O
14	.	O
15	v	O
16	.	O
1	Ovulation	O
2	was	O
3	induced	O
4	in	O
5	8	O
6	(	O
7	56	O
8	.	O
9	7	O
10	%)	O
11	patients	O
12	who	O
13	conceived	O
14	.	O
1	The	O
2	small	O
3	size	O
4	and	O
5	placement	O
6	of	O
7	the	O
8	mutagenesis	O
9	marker	O
10	(	O
11	the	O
12	supF	O
13	suppressor	O
14	tRNA	O
15	gene	O
16	from	O
17	Escherichia	O
18	coli	O
19	)	O
20	within	O
21	the	O
22	vector	O
23	substantially	O
24	reduced	O
25	the	O
26	frequency	O
27	of	O
28	spontaneous	O
29	mutations	O
30	normally	O
31	observed	O
32	after	O
33	transfection	O
34	of	O
35	mammalian	O
36	cells	O
37	with	O
38	plasmid	O
39	DNA	O
40	;	O
41	hence	O
42	,	O
43	UV	O
44	-	O
45	induced	O
46	mutations	O
47	were	O
48	easily	O
49	identified	O
50	above	O
51	the	O
52	spontaneous	O
53	background	O
54	.	O
1	Based	O
2	on	O
3	our	O
4	observations	O
5	,	O
6	we	O
7	propose	O
8	a	O
9	model	O
10	whereby	O
11	inactive	O
12	precursor	O
13	molecules	O
14	produced	O
15	from	O
16	the	O
17	PEP4	O
18	gene	O
19	self	O
20	-	O
21	activate	O
22	within	O
23	the	O
24	yeast	O
25	vacuole	O
26	and	O
27	subsequently	O
28	activate	O
29	other	O
30	vacuolar	O
31	hydrolases	O
32	.	O
1	Development	O
2	of	O
3	a	O
4	yeast	O
5	system	O
6	to	O
7	assay	O
8	mutational	O
9	specificity	O
10	.	O
1	We	O
2	used	O
3	oligonucleotide	O
4	-	O
5	directed	O
6	mutagenesis	O
7	to	O
8	alter	O
9	a	O
10	site	O
11	in	O
12	MucA	O
13	homologous	O
14	to	O
15	the	O
16	Ala	O
17	-	O
18	Gly	O
19	cleavage	O
20	site	O
21	of	O
22	LexA	O
23	.	O
1	Thus	O
2	,	O
3	a	O
4	negative	O
5	test	O
6	is	O
7	compatible	O
8	with	O
9	low	O
10	disease	O
11	activity	O
12	and	O
13	/	O
14	or	O
15	efficacy	O
16	of	O
17	calcium	O
18	antagonist	O
19	treatment	O
20	.	O
1	The	O
2	effects	O
3	of	O
4	several	O
5	opioid	O
6	agonists	O
7	and	O
8	the	O
9	opioid	O
10	antagonist	O
11	naloxone	O
12	were	O
13	examined	O
14	in	O
15	rats	O
16	responding	O
17	under	O
18	a	O
19	fixed	O
20	-	O
21	consecutive	O
22	-	O
23	number	O
24	(	O
25	FCN	O
26	)	O
27	schedule	O
28	.	O
1	The	O
2	presence	O
3	in	O
4	such	O
5	patients	O
6	of	O
7	antibodies	O
8	to	O
9	adrenaline	O
10	and	O
11	noradrenaline	O
12	is	O
13	indicative	O
14	of	O
15	considerable	O
16	disruption	O
17	of	O
18	catecholamine	O
19	biotransformation	O
20	.	O
1	Radionuclide	O
2	study	O
3	and	O
4	endomyocardial	O
5	biopsy	O
6	revealed	O
7	remarkable	O
8	degeneration	O
9	of	O
10	myocardium	O
11	.	O
1	Comparison	O
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequence	O
7	of	O
8	the	O
9	M	O
10	RNA	O
11	product	O
12	of	O
13	Uukuniemi	O
14	virus	O
15	with	O
16	that	O
17	of	O
18	Punta	O
19	Toro	O
20	and	O
21	Rift	O
22	Valley	O
23	fever	O
24	viruses	O
25	showed	O
26	in	O
27	both	O
28	cases	O
29	a	O
30	weak	O
31	homology	O
32	that	O
33	was	O
34	more	O
35	pronounced	O
36	for	O
37	the	O
38	proteins	O
39	located	O
40	at	O
41	the	O
42	COOH	O
43	-	O
44	terminal	O
45	end	O
46	of	O
47	the	O
48	precursor	O
49	.	O
1	Cyclosporine	O
2	treatment	O
3	for	O
4	intractable	O
5	polymyositis	O
6	.	O
1	To	O
2	evaluate	O
3	the	O
4	relative	O
5	accuracy	O
6	of	O
7	continuous	O
8	wave	O
9	(	O
10	CW	O
11	)	O
12	and	O
13	high	O
14	pulse	O
15	repetition	O
16	frequency	O
17	(	O
18	HPRF	O
19	)	O
20	Doppler	O
21	for	O
22	estimating	O
23	aortic	O
24	transvalvular	O
25	pressure	O
26	gradients	O
27	,	O
28	Doppler	O
29	examinations	O
30	with	O
31	both	O
32	devices	O
33	were	O
34	obtained	O
35	in	O
36	87	O
37	consecutive	O
38	patients	O
39	with	O
40	aortic	O
41	valve	O
42	disease	O
43	.	O
1	Epithelial	O
2	nerve	O
3	fiber	O
4	defects	O
5	included	O
6	absence	O
7	or	O
8	distorted	O
9	architecture	O
10	of	O
11	the	O
12	basal	O
13	epithelial	O
14	plexus	O
15	and	O
16	intra	O
17	-	O
18	epithelial	O
19	terminals	O
20	.	O
1	For	O
2	colostral	O
3	milk	O
4	there	O
5	was	O
6	a	O
7	significant	O
8	correlation	O
9	of	O
10	vitamin	O
11	K1	O
12	to	O
13	cholesterol	O
14	(	O
15	r	O
16	=	O
17	0	O
18	.	O
19	62	O
20	)	O
21	but	O
22	not	O
23	to	O
24	total	O
25	lipid	O
26	or	O
27	phospholipid	O
28	suggesting	O
29	a	O
30	role	O
31	for	O
32	cholesterol	O
33	in	O
34	the	O
35	secretion	O
36	of	O
37	vitamin	O
38	K1	O
39	into	O
40	colostral	O
41	milk	O
42	.	O
1	A	O
2	rate	O
3	-	O
4	decreasing	O
5	dose	O
6	of	O
7	physostigmine	O
8	,	O
9	an	O
10	acetylcholinesterase	O
11	inhibitor	O
12	,	O
13	was	O
14	studied	O
15	in	O
16	combination	O
17	with	O
18	the	O
19	range	O
20	of	O
21	atropine	O
22	doses	O
23	.	O
1	Salzburg	O
2	,	O
3	9	O
4	-	O
5	12	O
6	September	O
7	1987	O
8	.	O
1	Infants	O
2	of	O
3	this	O
4	sample	O
5	had	O
6	monocular	O
7	PL	O
8	visual	O
9	acuities	O
10	similar	O
11	to	O
12	those	O
13	established	O
14	by	O
15	McDonald	O
16	et	O
17	al	O
18	.	O
19	in	O
20	a	O
21	laboratory	O
22	setting	O
23	.	O
1	This	O
2	may	O
3	explain	O
4	in	O
5	part	O
6	a	O
7	secular	O
8	trend	O
9	towards	O
10	reduced	O
11	birthweight	O
12	for	O
13	gestation	O
14	in	O
15	preterm	O
16	infants	O
17	.	O
1	Liver	O
2	TG	O
3	and	O
4	serum	O
5	NEFA	O
6	concentrations	O
7	were	O
8	positively	O
9	correlated	O
10	.	O
1	When	O
2	the	O
3	coronary	O
4	sinus	O
5	pressure	O
6	reached	O
7	15	O
8	torr	O
9	,	O
10	there	O
11	was	O
12	a	O
13	significant	O
14	decrease	O
15	in	O
16	cardiac	O
17	index	O
18	(	O
19	3	O
20	.	O
21	60	O
22	+/-	O
23	0	O
24	.	O
25	5	O
26	to	O
27	2	O
28	.	O
29	70	O
30	+/-	O
31	0	O
32	.	O
33	6	O
34	L	O
35	/	O
36	min	O
37	/	O
38	m2	O
39	,	O
40	p	O
41	less	O
42	than	O
43	0	O
44	.	O
45	001	O
46	),	O
47	coronary	O
48	blood	O
49	flow	O
50	(	O
51	13	O
52	.	O
53	7	O
54	+/-	O
55	3	O
56	.	O
57	1	O
58	to	O
59	7	O
60	.	O
61	0	O
62	+/-	O
63	2	O
64	.	O
65	1	O
66	ml	O
67	/	O
68	min	O
69	,	O
70	p	O
71	less	O
72	than	O
73	0	O
74	.	O
75	001	O
76	),	O
77	rate	O
78	of	O
79	rise	O
80	of	O
81	left	O
82	ventricular	O
83	pressure	O
84	(	O
85	1	O
86	,	O
87	567	O
88	+/-	O
89	275	O
90	to	O
91	1	O
92	,	O
93	331	O
94	+/-	O
95	314	O
96	,	O
97	p	O
98	less	O
99	than	O
100	0	O
101	.	O
102	05	O
103	),	O
104	and	O
105	an	O
106	increase	O
107	in	O
108	coronary	O
109	arteriovenous	O
110	difference	O
111	(	O
112	62	O
113	.	O
114	8	O
115	%	O
116	+/-	O
117	9	O
118	.	O
119	3	O
120	%	O
121	to	O
122	70	O
123	.	O
124	5	O
125	%	O
126	+/-	O
127	5	O
128	.	O
129	4	O
130	%	O
131	saturation	O
132	,	O
133	p	O
134	less	O
135	than	O
136	0	O
137	.	O
138	03	O
139	).	O
1	Calcifications	O
2	in	O
3	the	O
4	thoracic	O
5	aorta	O
6	at	O
7	the	O
8	level	O
9	of	O
10	the	O
11	11th	O
12	and	O
13	the	O
14	12th	O
15	thoracic	O
16	vertebrae	O
17	in	O
18	592	O
19	men	O
20	and	O
21	333	O
22	women	O
23	were	O
24	studied	O
25	using	O
26	computed	O
27	tomography	O
28	.	O
1	Approximately	O
2	60	O
3	%	O
4	of	O
5	cell	O
6	bodies	O
7	of	O
8	primary	O
9	neurons	O
10	innervating	O
11	the	O
12	intra	O
13	and	O
14	perioral	O
15	structures	O
16	through	O
17	the	O
18	inferior	O
19	alveolar	O
20	,	O
21	lingual	O
22	,	O
23	mental	O
24	,	O
25	and	O
26	buccal	O
27	nerves	O
28	were	O
29	in	O
30	the	O
31	range	O
32	between	O
33	300	O
34	and	O
35	600	O
36	micron	O
37	2	O
38	in	O
39	cross	O
40	-	O
41	sectional	O
42	area	O
43	:	O
44	mean	O
45	+/-	O
46	SD	O
47	509	O
48	+/-	O
49	243	O
50	micron	O
51	2	O
52	,	O
53	420	O
54	+/-	O
55	181	O
56	micron	O
57	2	O
58	,	O
59	469	O
60	+/-	O
61	200	O
62	micron	O
63	2	O
64	,	O
65	and	O
66	444	O
67	+/-	O
68	186	O
69	micron	O
70	2	O
71	,	O
72	respectively	O
73	.	O
1	Findings	O
2	of	O
3	positive	O
4	potentials	O
5	showed	O
6	that	O
7	N1	O
8	originated	O
9	in	O
10	the	O
11	area	O
12	of	O
13	ventral	O
14	gray	O
15	matter	O
16	through	O
17	the	O
18	ventro	O
19	-	O
20	lateral	O
21	column	O
22	and	O
23	N2	O
24	through	O
25	the	O
26	dorsal	O
27	column	O
28	.	O
1	One	O
2	hundred	O
3	and	O
4	four	O
5	(	O
6	14	O
7	per	O
8	cent	O
9	)	O
10	second	O
11	primary	O
12	tumours	O
13	were	O
14	reported	O
15	.	O
1	It	O
2	is	O
3	suggested	O
4	that	O
5	these	O
6	results	O
7	may	O
8	raise	O
9	the	O
10	interesting	O
11	possibility	O
12	of	O
13	providing	O
14	a	O
15	means	O
16	of	O
17	identifying	O
18	greater	O
19	or	O
20	lesser	O
21	susceptibility	O
22	to	O
23	the	O
24	coronary	O
25	effects	O
26	of	O
27	Type	O
28	A	O
29	behavior	O
30	.	O
1	The	O
2	relations	O
3	between	O
4	type	O
5	A	O
6	behavior	O
7	,	O
8	clinically	O
9	relevant	O
10	behavior	O
11	,	O
12	academic	O
13	achievement	O
14	,	O
15	and	O
16	IQ	O
17	in	O
18	children	O
19	.	O
1	The	O
2	possibility	O
3	of	O
4	a	O
5	hereditary	O
6	disorder	O
7	leading	O
8	to	O
9	a	O
10	minor	O
11	defect	O
12	in	O
13	elastic	O
14	fibre	O
15	structure	O
16	which	O
17	could	O
18	be	O
19	responsible	O
20	for	O
21	the	O
22	spontaneous	O
23	lesions	O
24	is	O
25	discussed	O
26	.	O
1	Examples	O
2	of	O
3	its	O
4	use	O
5	in	O
6	the	O
7	intensive	O
8	therapy	O
9	unit	O
10	are	O
11	described	O
12	.	O
1	An	O
2	exaggerated	O
3	tissue	O
4	response	O
5	adjacent	O
6	to	O
7	the	O
8	cyanoacrylate	O
9	site	O
10	suggested	O
11	a	O
12	potential	O
13	toxic	O
14	chemical	O
15	or	O
16	thermal	O
17	reaction	O
18	,	O
19	or	O
20	both	O
21	,	O
22	to	O
23	the	O
24	tissue	O
25	adhesive	O
26	,	O
27	but	O
28	there	O
29	was	O
30	no	O
31	evidence	O
32	of	O
33	any	O
34	distant	O
35	ocular	O
36	effects	O
37	.	O
1	While	O
2	the	O
3	examiner	O
4	observed	O
5	the	O
6	interior	O
7	of	O
8	the	O
9	eye	O
10	with	O
11	indirect	O
12	ophthalmoscopy	O
13	,	O
14	the	O
15	point	O
16	source	O
17	of	O
18	light	O
19	from	O
20	the	O
21	fiberoptic	O
22	light	O
23	pipe	O
24	was	O
25	moved	O
26	along	O
27	the	O
28	margins	O
29	of	O
30	the	O
31	episcleral	O
32	plaque	O
33	.	O
1	Since	O
2	the	O
3	integrated	O
4	13h00	O
5	-	O
6	16h00	O
7	plasma	O
8	cortisol	O
9	estimation	O
10	is	O
11	cheaper	O
12	and	O
13	simpler	O
14	than	O
15	the	O
16	mean	O
17	13h00	O
18	-	O
19	16h00	O
20	plasma	O
21	cortisol	O
22	estimation	O
23	,	O
24	we	O
25	recommend	O
26	it	O
27	as	O
28	an	O
29	adjunct	O
30	in	O
31	the	O
32	diagnosis	O
33	of	O
34	Cushing	O
35	'	O
36	s	O
37	syndrome	O
38	.	O
1	The	O
2	risk	O
3	for	O
4	these	O
5	complications	O
6	is	O
7	increased	O
8	by	O
9	the	O
10	following	O
11	factors	O
12	:	O
13	multiple	O
14	gestation	O
15	,	O
16	the	O
17	combination	O
18	of	O
19	magnesium	O
20	sulfate	O
21	and	O
22	beta	B
23	-	O
24	adrenergic	O
25	agonist	O
26	,	O
27	and	O
28	the	O
29	use	O
30	of	O
31	adrenocortico	O
32	-	O
33	steroids	O
34	to	O
35	hasten	O
36	fetal	O
37	pulmonary	O
38	maturity	O
39	.	O
1	Selenium	O
2	(.	O
3	1	O
4	ppm	O
5	)	O
6	and	O
7	E	O
8	(	O
9	50	O
10	IU	O
11	/	O
12	kg	O
13	)	O
14	supplementation	O
15	of	O
16	the	O
17	diet	O
18	of	O
19	the	O
20	sow	O
21	increased	O
22	plasma	O
23	tocopherol	O
24	and	O
25	Se	O
26	concentrations	O
27	,	O
28	but	O
29	did	O
30	not	O
31	increase	O
32	plasma	O
33	glutathione	O
34	peroxidase	O
35	(	O
36	GSH	O
37	-	O
38	Px	O
39	)	O
40	activity	O
41	.	O
1	The	O
2	relationships	O
3	among	O
4	four	O
5	descriptors	O
6	of	O
7	lactate	O
8	increase	O
9	:	O
10	lactate	O
11	threshold	O
12	(	O
13	LT	O
14	)	O
15	(	O
16	the	O
17	VO2	O
18	at	O
19	which	O
20	blood	O
21	lactate	O
22	concentration	O
23	begins	O
24	to	O
25	increase	O
26	above	O
27	the	O
28	resting	O
29	level	O
30	during	O
31	an	O
32	incremental	O
33	exercise	O
34	test	O
35	),	O
36	LT1	O
37	(	O
38	the	O
39	VO2	O
40	at	O
41	which	O
42	blood	O
43	lactate	O
44	increases	O
45	1	O
46	mM	O
47	above	O
48	the	O
49	resting	O
50	level	O
51	),	O
52	LT2	O
53	(	O
54	the	O
55	VO2	O
56	at	O
57	which	O
58	blood	O
59	lactate	O
60	concentration	O
61	reaches	O
62	a	O
63	fixed	O
64	value	O
65	of	O
66	2	O
67	mM	O
68	),	O
69	onset	O
70	of	O
71	blood	O
72	lactate	O
73	accumulation	O
74	(	O
75	OBLA	O
76	;	O
77	the	O
78	VO2	O
79	at	O
80	which	O
81	blood	O
82	lactate	O
83	reaches	O
84	a	O
85	concentration	O
86	of	O
87	4	O
88	mM	O
89	),	O
90	were	O
91	compared	O
92	with	O
93	aerobic	O
94	capacity	O
95	(	O
96	VO2max	O
97	)	O
98	and	O
99	12	O
100	min	O
101	running	O
102	performance	O
103	in	O
104	19	O
105	untrained	O
106	female	O
107	students	O
108	.	O
1	The	O
2	1	O
3	,	O
4	2	O
5	,	O
6	3	O
7	and	O
8	4	O
9	year	O
10	survival	O
11	rates	O
12	were	O
13	94	O
14	%,	O
15	84	O
16	%,	O
17	76	O
18	%	O
19	and	O
20	63	O
21	%,	O
22	respectively	O
23	.	O
1	Inhibition	O
2	of	O
3	histalog	O
4	-	O
5	stimulated	O
6	gastric	O
7	secretion	O
8	by	O
9	40	O
10	749	O
11	RP	O
12	,	O
13	a	O
14	new	O
15	long	O
16	-	O
17	acting	O
18	gastric	O
19	antisecretory	O
20	agent	O
21	.	O
1	Deletion	O
2	mapping	O
3	studies	O
4	revealed	O
5	that	O
6	the	O
7	upstream	O
8	DNA	O
9	sequences	O
10	up	O
11	to	O
12	-	O
13	86	O
14	were	O
15	sufficient	O
16	for	O
17	the	O
18	optimal	O
19	basal	O
20	level	O
21	transcription	O
22	in	O
23	HeLa	O
24	cells	O
25	and	O
26	also	O
27	for	O
28	the	O
29	EIA	O
30	-	O
31	induced	O
32	transcription	O
33	.	O
1	Incorporation	O
2	of	O
3	the	O
4	polyene	O
5	antibiotic	O
6	amphotericin	O
7	B	O
8	(	O
9	AMB	O
10	)	O
11	in	O
12	liposomes	O
13	results	O
14	in	O
15	a	O
16	marked	O
17	reduction	O
18	in	O
19	drug	O
20	toxicity	O
21	with	O
22	no	O
23	loss	O
24	of	O
25	antifungal	O
26	potency	O
27	.	O
1	Serum	O
2	IgM	O
3	and	O
4	IgE	O
5	concentrations	O
6	,	O
7	allergen	O
8	-	O
9	specific	O
10	IgE	O
11	scores	O
12	,	O
13	and	O
14	the	O
15	tumor	O
16	E2R	O
17	status	O
18	were	O
19	combined	O
20	to	O
21	construct	O
22	a	O
23	three	O
24	-	O
25	level	O
26	risk	O
27	classification	O
28	that	O
29	was	O
30	more	O
31	prognostic	O
32	than	O
33	any	O
34	of	O
35	the	O
36	individual	O
37	components	O
38	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	T	O
6	.	O
7	C	O
8	.,	O
9	LDL	O
10	-	O
11	C	O
12	.,	O
13	HDL	O
14	-	O
15	C	O
16	.,	O
17	HDL2	O
18	-	O
19	C	O
20	.,	O
21	apo	O
22	B	O
23	,	O
24	apo	O
25	A	O
26	-	O
27	I	O
28	/	O
29	B	O
30	ratio	O
31	and	O
32	apo	O
33	A	O
34	-	O
35	II	O
36	/	O
37	B	O
38	ratio	O
39	are	O
40	predictive	O
41	risk	O
42	factors	O
43	of	O
44	the	O
45	coronary	O
46	heart	O
47	disease	O
48	.	O
1	In	O
2	19	O
3	patients	O
4	vagotomy	O
5	not	O
6	only	O
7	curbed	O
8	the	O
9	bleeding	O
10	but	O
11	provided	O
12	definitive	O
13	therapy	O
14	(	O
15	Visick	O
16	I	O
17	-	O
18	II	O
19	);	O
20	4	O
21	patients	O
22	died	O
23	(	O
24	mortality	O
25	rate	O
26	16	O
27	%).	O
1	Diagnosis	O
2	of	O
3	unilateral	O
4	renal	O
5	artery	O
6	lesions	O
7	after	O
8	captopril	O
9	administration	O
10	.	O
1	A	O
2	retrospective	O
3	study	O
4	of	O
5	banked	O
6	sera	O
7	from	O
8	19	O
9	cats	O
10	with	O
11	the	O
12	eosinophilic	O
13	granuloma	O
14	complex	O
15	revealed	O
16	that	O
17	68	O
18	%	O
19	of	O
20	affected	O
21	cats	O
22	had	O
23	circulating	O
24	antibodies	O
25	to	O
26	components	O
27	of	O
28	normal	O
29	cat	O
30	epithelium	O
31	.	O
1	New	O
2	techniques	O
3	for	O
4	the	O
5	mass	O
6	spectrometry	O
7	of	O
8	natural	O
9	products	O
10	.	O
1	Although	O
2	no	O
3	statistical	O
4	significance	O
5	was	O
6	achieved	O
7	,	O
8	it	O
9	is	O
10	remarkable	O
11	that	O
12	there	O
13	was	O
14	a	O
15	clear	O
16	trend	O
17	for	O
18	the	O
19	superiority	O
20	of	O
21	Galphimia	O
22	D6	O
23	while	O
24	the	O
25	Galphimia	O
26	dilution	O
27	10	O
28	(-	O
29	6	O
30	)	O
31	was	O
32	about	O
33	equally	O
34	effective	O
35	compared	O
36	with	O
37	placebo	O
38	.	O
1	This	O
2	suggests	O
3	that	O
4	alaproclate	O
5	acutely	O
6	increases	O
7	the	O
8	responsiveness	O
9	of	O
10	postsynaptic	O
11	muscarinic	O
12	and	O
13	alpha	B
14	1	O
15	adrenoceptors	O
16	.	O
1	Biopsies	O
2	of	O
3	the	O
4	jejunal	O
5	mucosa	O
6	have	O
7	shown	O
8	abnormal	O
9	enzyme	O
10	activity	O
11	or	O
12	deficiencies	O
13	in	O
14	transport	O
15	mechanisms	O
16	.	O
1	Three	O
2	chromosomal	O
3	crsA	O
4	mutations	O
5	,	O
6	crsA1	O
7	,	O
8	crsA4	O
9	,	O
10	and	O
11	crsA47	O
12	,	O
13	were	O
14	transferred	O
15	by	O
16	the	O
17	""""	O
18	gene	O
19	conversion	O
20	""""	O
21	process	O
22	to	O
23	B	O
24	.	O
25	subtilis	O
26	plasmid	O
27	pRPD11	O
28	,	O
29	which	O
30	consists	O
31	of	O
32	the	O
33	entire	O
34	wild	O
35	-	O
36	type	O
37	rpoD	O
38	coding	O
39	sequence	O
40	,	O
41	encoding	O
42	the	O
43	major	O
44	sigma	O
45	43	O
46	factor	O
47	of	O
48	B	O
49	.	O
50	subtilis	O
51	RNA	O
52	polymerase	B
53	,	O
54	and	O
55	pUB110	O
56	.	O
1	Selective	O
2	effect	O
3	of	O
4	pulmonary	O
5	oedema	O
6	on	O
7	prostaglandin	O
8	E2	O
9	pharmacokinetics	O
10	in	O
11	rat	O
12	lung	O
13	.	O
1	In	O
2	each	O
3	compartment	O
4	O2	O
5	is	O
6	removed	O
7	by	O
8	the	O
9	tissues	O
10	as	O
11	a	O
12	chemical	O
13	reaction	O
14	takes	O
15	place	O
16	between	O
17	O2	O
18	and	O
19	oxyhemoglobin	O
20	(	O
21	HbO2	O
22	).	O
1	To	O
2	evaluate	O
3	the	O
4	effects	O
5	of	O
6	propranolol	O
7	on	O
8	myocardial	O
9	metabolism	O
10	after	O
11	coronary	O
12	reperfusion	O
13	,	O
14	serial	O
15	measurements	O
16	of	O
17	myocardial	O
18	creatine	O
19	kinase	B
20	(	O
21	CK	O
22	)	O
23	and	O
24	calcium	O
25	(	O
26	Ca	O
27	)	O
28	contents	O
29	and	O
30	CK	O
31	and	O
32	lactic	O
33	acid	O
34	(	O
35	LA	O
36	)	O
37	concentrations	O
38	in	O
39	coronary	O
40	sinus	O
41	blood	O
42	were	O
43	carried	O
44	out	O
45	in	O
46	33	O
47	open	O
48	-	O
49	chest	O
50	dogs	O
51	.	O
1	No	O
2	consistent	O
3	correlation	O
4	between	O
5	blood	O
6	pressure	O
7	change	O
8	and	O
9	SCR	O
10	-	O
11	change	O
12	was	O
13	seen	O
14	.	O
1	A	O
2	flow	O
3	rate	O
4	of	O
5	at	O
6	least	O
7	5	O
8	mL	O
9	/	O
10	h	O
11	is	O
12	required	O
13	through	O
14	the	O
15	receptor	B
16	(	O
17	volume	O
18	,	O
19	0	O
20	.	O
21	4	O
22	mL	O
23	)	O
24	for	O
25	accurate	O
26	results	O
27	.	O
1	The	O
2	frequency	O
3	of	O
4	lactase	O
5	phenotypes	O
6	in	O
7	Aymara	O
8	children	O
9	.	O
1	Electrochemical	O
2	detection	O
3	of	O
4	depressed	O
5	circulating	O
6	levels	O
7	of	O
8	vitamin	O
9	K1	O
10	in	O
11	osteoporosis	O
12	.	O
1	In	O
2	metastasis	O
3	-	O
4	free	O
5	patients	O
6	,	O
7	the	O
8	best	O
9	results	O
10	were	O
11	obtained	O
12	with	O
13	tumor	O
14	diameters	O
15	under	O
16	2	O
17	cm	O
18	regardless	O
19	of	O
20	their	O
21	localization	O
22	in	O
23	lung	O
24	tissue	O
25	and	O
26	with	O
27	2	O
28	--	O
29	4	O
30	.	O
31	9	O
32	cm	O
33	tumors	O
34	embedded	O
35	in	O
36	lung	O
37	parenchyma	O
38	.	O
1	Two	O
2	siblings	O
3	with	O
4	hemolytic	O
5	anemia	O
6	caused	O
7	by	O
8	triosephosphate	O
9	isomerase	O
10	deficiency	O
11	developed	O
12	a	O
13	progressive	O
14	neurological	O
15	syndrome	O
16	featuring	O
17	dystonic	O
18	movements	O
19	,	O
20	tremor	O
21	,	O
22	pyramidal	O
23	tract	O
24	signs	O
25	,	O
26	and	O
27	evidence	O
28	of	O
29	spinal	O
30	motor	O
31	neuron	O
32	involvement	O
33	.	O
1	The	O
2	present	O
3	investigation	O
4	has	O
5	revealed	O
6	that	O
7	the	O
8	distribution	O
9	of	O
10	the	O
11	main	O
12	fatty	O
13	acids	O
14	in	O
15	Leptospira	O
16	phospholipids	O
17	is	O
18	similar	O
19	to	O
20	their	O
21	distribution	O
22	in	O
23	Leptospira	O
24	neutral	O
25	lipids	O
26	with	O
27	the	O
28	exception	O
29	of	O
30	unsaturated	O
31	fatty	O
32	acid	O
33	with	O
34	14	O
35	carbon	O
36	atoms	O
37	,	O
38	occurring	O
39	mainly	O
40	in	O
41	phospholipids	O
42	.	O
1	Sensory	O
2	evoked	O
3	field	O
4	potentials	O
5	were	O
6	recorded	O
7	from	O
8	the	O
9	mesencephalic	O
10	reticular	O
11	formation	O
12	(	O
13	MRF	O
14	),	O
15	central	O
16	gray	O
17	(	O
18	CG	O
19	)	O
20	and	O
21	somatosensory	O
22	cortex	O
23	(	O
24	SCX	O
25	),	O
26	following	O
27	incremental	O
28	doses	O
29	of	O
30	halothane	O
31	in	O
32	freely	O
33	-	O
34	moving	O
35	rats	O
36	.	O
1	Viral	O
2	infections	O
3	have	O
4	long	O
5	been	O
6	suspected	O
7	to	O
8	be	O
9	causative	O
10	agents	O
11	in	O
12	a	O
13	number	O
14	of	O
15	inner	O
16	ear	O
17	dysfunctions	O
18	.	O
1	Because	O
2	of	O
3	its	O
4	wide	O
5	spectrum	O
6	of	O
7	activity	O
8	particularly	O
9	against	O
10	ampicillin	O
11	resistant	O
12	strains	O
13	of	O
14	H	O
15	.	O
16	influenzae	O
17	and	O
18	because	O
19	of	O
20	its	O
21	good	O
22	tolerance	O
23	Cefaclor	O
24	is	O
25	very	O
26	useful	O
27	in	O
28	treatment	O
29	of	O
30	respiratory	O
31	tract	O
32	infections	O
33	in	O
34	children	O
35	.	O
1	Lower	O
2	extremity	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O
1	Treatment	O
2	with	O
3	oxyphenylbutazone	O
4	and	O
5	hydrocortisone	O
6	failed	O
7	to	O
8	inhibit	O
9	the	O
10	raised	O
11	serum	O
12	CPN	O
13	levels	O
14	.	O
1	Histamine	O
2	reactivity	O
3	was	O
4	significantly	O
5	reduced	O
6	after	O
7	the	O
8	nifedipine	O
9	aerosol	O
10	,	O
11	the	O
12	geometric	O
13	mean	O
14	provocative	O
15	concentration	O
16	causing	O
17	a	O
18	35	O
19	%	O
20	fall	O
21	in	O
22	specific	O
23	airway	O
24	conductance	O
25	,	O
26	rising	O
27	from	O
28	5	O
29	.	O
30	0	O
31	to	O
32	10	O
33	.	O
34	9	O
35	mg	O
36	/	O
37	ml	O
38	of	O
39	histamine	O
40	(	O
41	p	O
42	less	O
43	than	O
44	0	O
45	.	O
46	05	O
47	).	O
1	The	O
2	weak	O
3	relationships	O
4	between	O
5	F	O
6	and	O
7	Zn	O
8	to	O
9	Mg	O
10	clearly	O
11	have	O
12	no	O
13	significant	O
14	effect	O
15	on	O
16	the	O
17	contents	O
18	of	O
19	these	O
20	elements	O
21	in	O
22	bone	O
23	.	O
1	Blood	O
2	eosinophils	O
3	in	O
4	patients	O
5	with	O
6	Taenia	O
7	saginata	O
8	taeniasis	O
9	.	O
1	Gains	O
2	increased	O
3	3	O
4	.	O
5	5	O
6	%	O
7	(	O
8	P	O
9	less	O
10	than	O
11	.	O
12	10	O
13	)	O
14	and	O
15	feed	O
16	conversion	O
17	improved	O
18	5	O
19	.	O
20	9	O
21	%	O
22	(	O
23	P	O
24	less	O
25	than	O
26	.	O
27	07	O
28	)	O
29	in	O
30	steers	O
31	fed	O
32	.	O
33	28	O
34	%	O
35	AS	O
36	-	O
37	VFA	O
38	compared	O
39	with	O
40	gain	O
41	and	O
42	feed	O
43	conversion	O
44	of	O
45	the	O
46	control	O
47	steers	O
48	.	O
1	Comparative	O
2	studies	O
3	of	O
4	the	O
5	antithrombin	O
6	III	O
7	level	O
8	and	O
9	plasminogen	O
10	activator	O
11	activity	O
12	in	O
13	patients	O
14	with	O
15	thrombophlebitis	O
1	Renal	O
2	excretion	O
3	of	O
4	sulphadimidine	O
5	in	O
6	normal	O
7	and	O
8	uraemic	O
9	subjects	O
10	.	O
1	The	O
2	effect	O
3	of	O
4	a	O
5	tissue	O
6	emulsion	O
7	,	O
8	vitamin	O
9	A	O
10	and	O
11	nonspecific	O
12	gamma	B
13	-	O
14	globulin	O
15	on	O
16	the	O
17	blood	O
18	clearance	O
19	in	O
20	rabbits	O
1	Inverse	O
2	relation	O
3	between	O
4	serum	O
5	IgG	O
6	concentration	O
7	and	O
8	glucose	O
9	and	O
10	xylose	O
11	absorption	O
12	in	O
13	Zambian	O
14	African	O
15	adults	O
16	.	O
1	Sensitization	O
2	to	O
3	hyperlactatemia	O
4	induced	O
5	by	O
6	phenformin	O
7	after	O
8	subtotal	O
9	ablation	O
10	of	O
11	the	O
12	pancreas	O
13	.	O
1	Vitamin	O
2	D3	O
3	and	O
4	calcium	O
5	absorption	O
6	in	O
7	the	O
8	chick	O
9	.	O
1	Effect	O
2	of	O
3	variations	O
4	in	O
5	time	O
6	interval	O
7	between	O
8	treatment	O
9	with	O
10	BCG	O
11	and	O
12	quartz	O
13	dust	O
14	on	O
15	translocation	O
16	of	O
17	quartz	O
18	dust	O
19	from	O
20	the	O
21	lungs	O
22	to	O
23	their	O
24	regional	O
25	lymph	O
26	nodes	O
27	.	O
1	Clinico	O
2	-	O
3	physiological	O
4	experiment	O
1	Pre	O
2	-	O
3	beta	B
4	-	O
5	1	O
6	lipoprotein	O
7	and	O
8	early	O
9	detection	O
10	of	O
11	risk	O
12	factors	O
13	for	O
14	coronary	O
15	heart	O
16	disease	O
17	.	O
1	Conditions	O
2	influencing	O
3	inhibitors	O
4	of	O
5	the	O
6	colony	O
7	-	O
8	stimulating	O
9	factor	O
10	(	O
11	CSF	B
12	).	O
1	I	O
2	.	O
1	Particles	O
2	resembling	O
3	microbodies	O
4	in	O
5	normal	O
6	and	O
7	neoplastic	O
8	perianal	O
9	glands	O
10	of	O
11	dogs	O
12	.	O
1	Natural	O
2	and	O
3	induced	O
4	malarias	O
5	in	O
6	western	O
7	hemisphere	O
8	monkeys	O
9	.	O
1	Kinetics	O
2	of	O
3	calcium	O
4	metabolism	O
5	.	O
1	On	O
2	the	O
3	transport	O
4	of	O
5	mucus	O
6	and	O
7	its	O
8	rheologic	O
9	simulants	O
10	in	O
11	ciliated	O
12	systems	O
13	.	O
1	Problems	O
2	common	O
3	to	O
4	pediatrics	O
5	and	O
6	anesthesiology	O
1	Effects	O
2	of	O
3	alcoholism	O
4	on	O
5	the	O
6	family	O
1	Junctions	O
2	between	O
3	cells	O
4	of	O
5	the	O
6	human	O
7	enamel	O
8	organ	O
9	.	O
1	Composites	O
2	as	O
3	restoration	O
4	materials	O
1	Proceedings	O
2	:	O
3	Reversible	O
4	complete	O
5	heart	O
6	block	O
7	following	O
8	surgery	O
9	of	O
10	congenital	O
11	heart	O
12	defects	O
1	Cell	O
2	viability	O
3	and	O
4	lysosomal	O
5	enzymes	O
1	State	O
2	-	O
3	approved	O
4	schools	O
5	of	O
6	nursing	O
7	--	O
8	R	O
9	.	O
10	N	O
11	.,	O
12	1972	O
13	.	O
1	Pneumothorax	O
2	following	O
3	lung	O
4	abscess	O
5	in	O
6	the	O
7	renal	O
8	transplant	O
9	patient	O
10	.	O
1	Letter	O
2	:	O
3	Salmonella	O
4	detection	O
1	Role	O
2	of	O
3	biocenosis	O
4	in	O
5	the	O
6	manifestation	O
7	of	O
8	Shigella	O
9	virulence	O
1	Morphology	O
2	of	O
3	bacteriophages	O
4	of	O
5	Klebsiella	O
6	bacilli	O
7	.	O
1	Effect	O
2	of	O
3	triftazin	O
4	and	O
5	aminazin	O
6	on	O
7	hippocampal	O
8	bioelectric	O
9	activity	O
1	Pathological	O
2	processes	O
3	in	O
4	the	O
5	cervix	O
6	uteri	O
1	Benign	O
2	intramural	O
3	tumors	O
4	of	O
5	the	O
6	esophagus	O
1	Measurement	O
2	of	O
3	open	O
4	-	O
5	loop	O
6	responses	O
7	to	O
8	electrical	O
9	stimulation	O
10	in	O
11	olfactory	O
12	bulb	O
13	of	O
14	cat	O
15	.	O
1	Antibiotic	O
2	effect	O
3	of	O
4	the	O
5	mud	O
6	from	O
7	heviz	O
1	Range	O
2	behavior	O
3	of	O
4	Hereford	O
5	,	O
6	Hereford	O
7	x	O
8	Holstein	O
9	and	O
10	Holstein	O
11	non	O
12	-	O
13	lactating	O
14	heifers	O
15	.	O
1	Effects	O
2	of	O
3	cortisone	O
4	,	O
5	starvation	O
6	,	O
7	and	O
8	rickets	O
9	on	O
10	oxidative	O
11	enzyme	O
12	activities	O
13	of	O
14	epiphyseal	O
15	cartilage	O
16	from	O
17	rats	O
18	.	O
1	Familial	O
2	juvenile	O
3	nephronophthisis	O
1	Early	O
2	heparin	O
3	therapy	O
4	in	O
5	60	O
6	children	O
7	with	O
8	acute	O
9	meningococcemia	O
10	.	O
1	Possibilities	O
2	of	O
3	needleless	O
4	administration	O
5	of	O
6	various	O
7	substances	O
8	to	O
9	animals	O
1	Change	O
2	in	O
3	the	O
4	makeup	O
5	of	O
6	the	O
7	blood	O
8	following	O
9	a	O
10	short	O
11	-	O
12	term	O
13	local	O
14	action	O
15	of	O
16	a	O
17	permanent	O
18	magnetic	O
19	field	O
20	on	O
21	the	O
22	human	O
23	body	O
1	Analysis	O
2	of	O
3	clearance	O
4	curve	O
5	of	O
6	rose	O
7	bengal	O
8	-	O
9	I	O
10	-	O
11	131	O
1	Proceedings	O
2	:	O
3	Barrels	O
4	and	O
5	somatotopy	O
6	in	O
7	S	O
8	I	O
9	neocortex	O
10	of	O
11	the	O
12	brush	O
13	-	O
14	tailed	O
15	possum	O
16	.	O
1	Effects	O
2	of	O
3	ionizing	O
4	radiation	O
5	in	O
6	the	O
7	human	O
8	oral	O
9	cavity	O
10	and	O
11	oropharynx	O
12	:	O
13	results	O
14	of	O
15	a	O
16	survey	O
17	.	O
1	Immunelectrophoretic	O
2	pattern	O
3	of	O
4	Wassermann	O
5	reagin	O
6	and	O
7	comparison	O
8	of	O
9	the	O
10	appearance	O
11	time	O
12	between	O
13	RPCF	O
14	and	O
15	FTA	O
16	antibodies	O
1	The	O
2	metabolism	O
3	and	O
4	pharmacology	O
5	of	O
6	5	O
7	-	O
8	fluorouracil	O
9	.	O
1	LA	O
2	-	O
3	3848	O
4	-	O
5	MS	O
6	.	O
1	Morphological	O
2	and	O
3	functional	O
4	alterations	O
5	noted	O
6	after	O
7	baboon	O
8	renal	O
9	allotransplantation	O
10	.	O
1	Reactivities	O
2	to	O
3	horse	O
4	anti	B
5	-	O
6	lymphocyte	O
7	globulin	O
8	.	O
1	Angiography	O
2	of	O
3	aneurysmal	O
4	bone	O
5	cyst	O
6	.	O
1	Successful	O
2	treatment	O
3	of	O
4	candidiasis	O
5	with	O
6	transfer	O
7	factor	O
8	.	O
1	1st	O
2	data	O
3	on	O
4	the	O
5	immunosuppressive	O
6	therapy	O
7	of	O
8	scleroderma	O
1	Slowed	O
2	lysosomal	O
3	enzyme	O
4	release	O
5	and	O
6	its	O
7	normalization	O
8	by	O
9	drugs	O
10	in	O
11	adjuvant	O
12	-	O
13	induced	O
14	polyarthritis	O
15	.	O
1	Treatment	O
2	of	O
3	ovarian	O
4	neoplasms	O
1	I	O
2	.	O
1	Effect	O
2	of	O
3	phenformin	O
4	on	O
5	gluconeogenesis	O
6	in	O
7	perfused	O
8	rat	O
9	liver	O
10	.	O
1	New	O
2	alkaloids	O
3	from	O
4	bark	O
5	of	O
6	Erythrophleum	O
7	ivorense	O
8	.	O
1	Proposals	O
2	on	O
3	authorization	O
4	;	O
5	by	O
6	a	O
7	group	O
8	of	O
9	nurses	O
10	from	O
11	psychiatric	O
12	hospitals	O
1	Successive	O
2	abdominal	O
3	scintillation	O
4	with	O
5	131	O
6	-	O
7	I	O
8	-	O
9	tagged	O
10	BSP	O
11	--	O
12	description	O
13	of	O
14	the	O
15	thyroid	O
16	gland	O
17	,	O
18	kidney	O
19	and	O
20	spleen	O
21	(	O
22	comparison	O
23	with	O
24	131	O
25	-	O
26	I	O
27	-	O
28	RB	O
29	)	O
1	Pneumonia	O
2	in	O
3	children	O
1	Auto	O
2	-	O
3	and	O
4	isotopy	O
5	of	O
6	the	O
7	conjunctiva	O
1	Histopathology	O
2	and	O
3	pathogenesis	O
4	of	O
5	exanthematous	O
6	viroses	O
1	The	O
2	role	O
3	of	O
4	ascorbic	O
5	acid	O
6	in	O
7	the	O
8	prevention	O
9	of	O
10	bladder	O
11	tumor	O
12	formation	O
13	.	O
1	The	O
2	""""	O
3	28	O
4	percent	O
5	""""	O
6	Venturi	O
7	mask	O
8	in	O
9	obstructive	O
10	airway	O
11	disease	O
12	.	O
1	Studies	O
2	on	O
3	the	O
4	pathogenicity	O
5	of	O
6	ECHO	O
7	9	O
8	(	O
9	HILL	O
10	)	O
11	virus	O
12	and	O
13	its	O
14	mutants	O
15	for	O
16	suckling	O
17	mice	O
1	The	O
2	plasma	O
3	growth	O
4	hormone	O
5	concentration	O
6	of	O
7	the	O
8	foetal	O
9	lamb	O
10	.	O
1	The	O
2	association	O
3	of	O
4	clopamide	O
5	and	O
6	hydergine	O
7	(	O
8	Brinedine	O
9	)	O
10	in	O
11	the	O
12	treatment	O
13	of	O
14	the	O
15	vasculo	O
16	-	O
17	renal	O
18	syndromes	O
19	of	O
20	pregnancy	O
1	Quantitation	O
2	of	O
3	exocrine	O
4	IgA	O
5	in	O
6	human	O
7	serum	O
8	in	O
9	health	O
10	and	O
11	disease	O
12	.	O
1	Iodine	O
2	metabolism	O
3	in	O
4	chronic	O
5	thyroiditis	O
6	.	O
1	V	O
2	.	O
1	3	O
2	.	O
1	Open	O
2	head	O
3	-	O
4	brain	O
5	injuries	O
1	Students	O
2	,	O
3	parents	O
4	,	O
5	teachers	O
6	and	O
7	hearing	O
8	disorders	O
1	Changing	O
2	and	O
3	predicting	O
4	doses	O
5	of	O
6	Cs137	O
7	irradiation	O
1	Measurements	O
2	of	O
3	activity	O
4	with	O
5	the	O
6	radioprotective	O
7	chamber	O
8	VA	O
9	-	O
10	K	O
11	-	O
12	254	O
13	of	O
14	the	O
15	osimeter	O
16	VA	O
17	-	O
18	J18	O
1	Identification	O
2	and	O
3	estimation	O
4	of	O
5	monosaccharides	O
6	and	O
7	disaccharides	O
8	in	O
9	urine	O
10	by	O
11	gas	O
12	-	O
13	liquid	O
14	chromatography	O
15	.	O
1	Studies	O
2	carried	O
3	out	O
4	with	O
5	the	O
6	Glossina	O
7	morsitans	O
8	colony	O
9	of	O
10	Lisbon	O
11	.	O
1	I	O
2	.	O
1	Automatic	O
2	view	O
3	box	O
4	.	O
1	Effects	O
2	of	O
3	beta	B
4	-	O
5	adrenergic	O
6	receptor	B
7	blockade	O
8	on	O
9	airway	O
10	conductance	O
11	and	O
12	lung	O
13	volume	O
14	in	O
15	normal	O
16	and	O
17	asthmatic	O
18	subjects	O
19	.	O
1	The	O
2	possibility	O
3	of	O
4	selective	O
5	chemotherapy	O
6	of	O
7	progressive	O
8	recurring	O
9	ovarian	O
10	carcinoma	O
11	with	O
12	the	O
13	aid	O
14	of	O
15	cytodiagnosis	O
16	and	O
17	incorporation	O
18	of	O
19	tagged	O
20	idoxuridine	O
1	Experience	O
2	with	O
3	the	O
4	restoration	O
5	of	O
6	agglutination	O
7	properties	O
8	of	O
9	non	O
10	-	O
11	agglutinating	O
12	dysenterial	O
13	cultures	O
14	with	O
15	the	O
16	use	O
17	of	O
18	Rzhaninov	O
19	'	O
20	s	O
21	method	O
1	Studies	O
2	on	O
3	the	O
4	intracutaneous	O
5	infection	O
6	of	O
7	rabbits	O
8	by	O
9	Staphylococcus	O
10	aureus	O
11	.	O
1	Studies	O
2	on	O
3	powdered	O
4	preparations	O
5	.	O
1	The	O
2	3	O
3	-	O
4	hour	O
5	test	O
6	iodine	O
7	(	O
8	I	O
9	-	O
10	132	O
11	)	O
12	uptake	O
13	by	O
14	the	O
15	thyroid	O
16	in	O
17	children	O
18	with	O
19	growth	O
20	deficiency	O
1	Concussion	O
2	of	O
3	the	O
4	spinal	O
5	cord	O
1	Study	O
2	on	O
3	the	O
4	evagination	O
5	of	O
6	Cysticercus	O
7	pisiformis	O
8	.	O
1	On	O
2	the	O
3	amount	O
4	and	O
5	significance	O
6	of	O
7	the	O
8	effective	O
9	glucose	O
10	level	O
11	in	O
12	tumors	O
13	.	O
1	Iron	O
2	and	O
3	folate	O
4	deficiency	O
5	in	O
6	pregnancy	O
1	Effect	O
2	of	O
3	acute	O
4	and	O
5	chronic	O
6	psychogenic	O
7	stress	O
8	on	O
9	corticoadrenal	O
10	and	O
11	pituitary	O
12	-	O
13	thyroid	O
14	hormones	O
15	in	O
16	male	O
17	rats	O
18	.	O
1	Trial	O
2	treatment	O
3	of	O
4	schizophrenia	O
5	with	O
6	des	O
7	-	O
8	Tyr	O
9	-	O
10	gamma	B
11	-	O
12	endorphin	O
1	Isolation	O
2	of	O
3	Aeromonas	O
4	from	O
5	faeces	O
6	.	O
1	At	O
2	both	O
3	water	O
4	temperatures	O
5	,	O
6	VO2	O
7	increased	O
8	linearly	O
9	with	O
10	increasing	O
11	swimming	O
12	velocity	O
13	.	O
1	All	O
2	radiologists	O
3	using	O
4	the	O
5	machine	O
6	found	O
7	that	O
8	the	O
9	reporting	O
10	terminal	O
11	was	O
12	simple	O
13	to	O
14	operate	O
15	,	O
16	but	O
17	found	O
18	that	O
19	reporting	O
20	abnormalities	O
21	caused	O
22	an	O
23	increased	O
24	effort	O
25	and	O
26	took	O
27	a	O
28	longer	O
29	time	O
30	.	O
1	In	O
2	the	O
3	latter	O
4	category	O
5	particular	O
6	emphasis	O
7	is	O
8	being	O
9	placed	O
10	on	O
11	new	O
12	anthracycline	O
13	analogues	O
14	of	O
15	doxorubicin	O
16	and	O
17	analogues	O
18	of	O
19	cisplatinum	O
20	diammine	O
21	dichloride	O
22	.	O
1	The	O
2	P165	O
3	component	O
4	,	O
5	however	O
6	,	O
7	could	O
8	be	O
9	differentiated	O
10	from	O
11	the	O
12	two	O
13	later	O
14	components	O
15	since	O
16	it	O
17	increased	O
18	in	O
19	amplitude	O
20	with	O
21	increased	O
22	task	O
23	demands	O
24	while	O
25	the	O
26	N2	O
27	and	O
28	P3	O
29	amplitudes	O
30	remained	O
31	constant	O
32	.	O
1	Differential	O
2	drawing	O
3	size	O
4	associated	O
5	with	O
6	unilateral	O
7	brain	O
8	damage	O
9	.	O
1	Subdural	O
2	electrodes	O
3	may	O
4	yield	O
5	larger	O
6	VEP	O
7	amplitudes	O
8	than	O
9	skull	O
10	or	O
11	scalp	O
12	electrodes	O
13	.	O
1	It	O
2	has	O
3	been	O
4	established	O
5	that	O
6	preoperative	O
7	irradiation	O
8	in	O
9	the	O
10	form	O
11	of	O
12	the	O
13	fractionation	O
14	of	O
15	a	O
16	single	O
17	focal	O
18	dose	O
19	of	O
20	6	O
21	Gy	O
22	every	O
23	other	O
24	day	O
25	,	O
26	the	O
27	summary	O
28	dose	O
29	of	O
30	24	O
31	Gy	O
32	within	O
33	8	O
34	-	O
35	10	O
36	days	O
37	followed	O
38	by	O
39	surgery	O
40	1	O
41	-	O
42	3	O
43	days	O
44	after	O
45	irradiation	O
46	does	O
47	not	O
48	either	O
49	complicate	O
50	its	O
51	performance	O
52	or	O
53	the	O
54	course	O
55	of	O
56	the	O
57	postoperative	O
58	period	O
59	,	O
60	and	O
61	by	O
62	the	O
63	short	O
64	-	O
65	and	O
66	long	O
67	-	O
68	term	O
69	results	O
70	it	O
71	is	O
72	no	O
73	worse	O
74	than	O
75	the	O
76	routine	O
77	dose	O
78	fractionation	O
79	.	O
1	Ventricular	O
2	volume	O
3	stiffness	O
4	vs	O
5	.	O
6	the	O
7	mean	O
8	wall	O
9	stress	O
10	relationship	O
11	of	O
12	LVH	O
13	shifted	O
14	upward	O
15	,	O
16	whereas	O
17	the	O
18	normalized	O
19	wall	O
20	muscle	O
21	stiffness	O
22	vs	O
23	.	O
24	the	O
25	mean	O
26	wall	O
27	stress	O
28	relationship	O
29	of	O
30	LVH	O
31	showed	O
32	a	O
33	smaller	O
34	slope	O
35	.	O
1	Synthesis	O
2	of	O
3	(+)-	O
4	lysergic	O
5	acid	O
6	diethylamide	O
7	tartrate	O
1	Catecholamines	O
2	and	O
3	aversive	O
4	learning	O
5	:	O
6	a	O
7	review	O
8	.	O
1	The	O
2	antibody	O
3	titer	O
4	of	O
5	202	O
6	chickens	O
7	to	O
8	SA	O
9	-	O
10	11	O
11	rotavirus	O
12	was	O
13	determined	O
14	by	O
15	enzyme	O
16	-	O
17	linked	O
18	immunosorbent	O
19	blocking	O
20	assay	O
21	.	O
1	Five	O
2	experiments	O
3	examined	O
4	the	O
5	influence	O
6	of	O
7	opiate	O
8	antagonists	O
9	on	O
10	both	O
11	the	O
12	short	O
13	-	O
14	term	O
15	analgesic	O
16	reaction	O
17	resulting	O
18	30	O
19	min	O
20	after	O
21	exposure	O
22	to	O
23	inescapable	O
24	shock	O
25	and	O
26	the	O
27	long	O
28	-	O
29	term	O
30	analgesic	O
31	reaction	O
32	resulting	O
33	after	O
34	reexposure	O
35	to	O
36	shock	O
37	24	O
38	hr	O
39	after	O
40	inescapable	O
41	shock	O
42	exposure	O
43	.	O
1	Because	O
2	RNase	B
3	III	O
4	host	O
5	mutants	O
6	are	O
7	defective	O
8	in	O
9	sib	O
10	regulation	O
11	,	O
12	processing	O
13	of	O
14	the	O
15	PL	O
16	mRNA	O
17	at	O
18	sib	O
19	by	O
20	this	O
21	endoribonuclease	O
22	may	O
23	cause	O
24	int	O
25	mRNA	O
26	decay	O
27	and	O
28	decrease	O
29	int	O
30	synthesis	O
31	.	O
1	In	O
2	fact	O
3	,	O
4	families	O
5	of	O
6	polypeptides	O
7	were	O
8	produced	O
9	by	O
10	initiation	O
11	of	O
12	translation	O
13	at	O
14	AUG	O
15	codons	O
16	within	O
17	sequences	O
18	coding	O
19	for	O
20	VP1	O
21	and	O
22	T	O
23	,	O
24	presumably	O
25	as	O
26	a	O
27	result	O
28	of	O
29	transcription	O
30	initiation	O
31	events	O
32	that	O
33	generated	O
34	5	O
35	'	O
36	ends	O
37	immediately	O
38	upstream	O
39	from	O
40	these	O
41	AUGs	O
42	.	O
1	The	O
2	combination	O
3	of	O
4	MISO	O
5	and	O
6	WR	O
7	-	O
8	2721	O
9	gave	O
10	an	O
11	intermediate	O
12	response	O
13	compared	O
14	with	O
15	either	O
16	drug	O
17	used	O
18	alone	O
19	,	O
20	resulting	O
21	in	O
22	some	O
23	sensitization	O
24	with	O
25	single	O
26	doses	O
27	and	O
28	an	O
29	overall	O
30	protection	O
31	with	O
32	repeated	O
33	small	O
34	doses	O
35	.	O
1	Two	O
2	mutations	O
3	that	O
4	affect	O
5	larval	O
6	cuticle	O
7	protein	O
8	gene	O
9	expression	O
10	in	O
11	the	O
12	2	O
13	/	O
14	3	O
15	variant	O
16	Drosophila	O
17	melanogaster	O
18	strain	O
19	were	O
20	investigated	O
21	.	O
1	The	O
2	ensembles	O
3	are	O
4	considered	O
5	to	O
6	be	O
7	one	O
8	of	O
9	the	O
10	forms	O
11	of	O
12	activity	O
13	of	O
14	the	O
15	structured	O
16	morphofunctional	O
17	cortical	O
18	units	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	the	O
25	columns	O
26	.	O
1	Hybridization	O
2	of	O
3	plasmid	O
4	-	O
5	transformed	O
6	Escherichia	O
7	coli	O
8	RR1	O
9	colonies	O
10	with	O
11	32P	O
12	-	O
13	labeled	O
14	viral	O
15	genome	O
16	RNAs	O
17	demonstrated	O
18	the	O
19	presence	O
20	of	O
21	DNA	O
22	clones	O
23	representative	O
24	of	O
25	each	O
26	of	O
27	the	O
28	10	O
29	reovirus	O
30	RNAs	O
31	and	O
32	10	O
33	of	O
34	the	O
35	11	O
36	constituent	O
37	segments	O
38	of	O
39	the	O
40	rotavirus	O
41	genome	O
42	.	O
1	The	O
2	mutants	O
3	were	O
4	obtained	O
5	by	O
6	substitution	O
7	into	O
8	a	O
9	molecular	O
10	clone	O
11	of	O
12	M	O
13	-	O
14	MuLV	O
15	DNA	O
16	by	O
17	DNA	O
18	from	O
19	two	O
20	acutely	O
21	transforming	O
22	viruses	O
23	,	O
24	Ableson	O
25	MuLV	O
26	(	O
27	Ab	O
28	-	O
29	MuLV	O
30	)	O
31	and	O
32	Moloney	O
33	murine	O
34	sarcoma	O
35	virus	O
36	(	O
37	M	O
38	-	O
39	MSV	O
40	).	O
1	The	O
2	dnaQ	O
3	-	O
4	lacZ	O
5	and	O
6	the	O
7	rnh	O
8	-	O
9	lacZ	O
10	fused	O
11	genes	O
12	were	O
13	constructed	O
14	and	O
15	hybrid	O
16	proteins	O
17	with	O
18	beta	B
19	-	O
20	galactosidase	O
21	activity	O
22	were	O
23	produced	O
24	.	O
1	NPT	O
2	II	O
3	synthesis	O
4	,	O
5	measured	O
6	by	O
7	agar	O
8	plate	O
9	assays	O
10	of	O
11	kanamycin	O
12	resistance	O
13	and	O
14	by	O
15	immunoprecipitation	O
16	of	O
17	the	O
18	NPT	O
19	II	O
20	protein	O
21	,	O
22	was	O
23	repressed	O
24	in	O
25	the	O
26	presence	O
27	of	O
28	cysteine	O
29	and	O
30	derepressed	O
31	in	O
32	its	O
33	absence	O
34	.	O
1	No	O
2	significant	O
3	correlation	O
4	was	O
5	found	O
6	between	O
7	LVM	O
8	or	O
9	wall	O
10	thickness	O
11	and	O
12	body	O
13	surface	O
14	area	O
15	,	O
16	age	O
17	,	O
18	blood	O
19	pressure	O
20	,	O
21	heart	O
22	rate	O
23	,	O
24	cardiac	O
25	output	O
26	,	O
27	total	O
28	peripheral	O
29	resistance	O
30	and	O
31	left	O
32	ventricular	O
33	systolic	O
34	wall	O
35	stress	O
36	,	O
37	whereas	O
38	CD25	O
39	was	O
40	correlated	O
41	with	O
42	urinary	O
43	catecholamines	O
44	only	O
45	in	O
46	hypertensive	O
47	patients	O
48	(	O
49	r	O
50	=	O
51	0	O
52	.	O
53	606	O
54	,	O
55	p	O
56	less	O
57	than	O
58	0	O
59	.	O
60	001	O
61	).	O
1	Furthermore	O
2	,	O
3	no	O
4	Shine	O
5	-	O
6	Dalgarno	O
7	sequences	O
8	are	O
9	present	O
10	upstream	O
11	of	O
12	the	O
13	presumed	O
14	translational	O
15	start	O
16	codons	O
17	.	O
1	The	O
2	myeloproliferative	O
3	sarcoma	O
4	virus	O
5	(	O
6	MPSV	O
7	)	O
8	was	O
9	derived	O
10	by	O
11	passage	O
12	of	O
13	Moloney	O
14	sarcoma	O
15	virus	O
16	(	O
17	Mo	O
18	-	O
19	MuSV	O
20	)	O
21	in	O
22	adult	O
23	mice	O
24	.	O
1	The	O
2	same	O
3	-	O
4	sized	O
5	EBNA	O
6	protein	O
7	(	O
8	approximately	O
9	78	O
10	,	O
11	000	O
12	)	O
13	was	O
14	made	O
15	after	O
16	transfection	O
17	with	O
18	BamHI	O
19	-	O
20	K	O
21	(	O
22	5	O
23	.	O
24	2	O
25	kilobase	O
26	pairs	O
27	[	O
28	kbp	O
29	])	O
30	or	O
31	the	O
32	I1f	O
33	subfragment	O
34	(	O
35	2	O
36	.	O
37	9	O
38	kbp	O
39	).	O
1	Frog	O
2	type	O
3	I	O
4	(	O
5	Ft	O
6	I	O
7	)	O
8	and	O
9	frog	O
10	type	O
11	II	O
12	(	O
13	Ft	O
14	II	O
15	)	O
16	slowly	O
17	adapting	O
18	(	O
19	SA	O
20	)	O
21	units	O
22	produced	O
23	spikes	O
24	only	O
25	at	O
26	the	O
27	indentation	O
28	phase	O
29	,	O
30	and	O
31	the	O
32	threshold	O
33	response	O
34	phase	O
35	(	O
36	TRP	O
37	),	O
38	i	O
39	.	O
40	e	O
41	..	O
42	the	O
43	phase	O
44	of	O
45	the	O
46	first	O
47	spike	O
48	was	O
49	for	O
50	ca	O
51	.	O
1	Grimelius	O
2	stain	O
3	was	O
4	positive	O
5	,	O
6	Masson	O
7	Fontana	O
8	stain	O
9	negative	O
10	.	O
1	Ten	O
2	patients	O
3	with	O
4	advanced	O
5	,	O
6	diffuse	O
7	Hodgkin	O
8	'	O
9	s	O
10	and	O
11	non	O
12	-	O
13	Hodgkin	O
14	'	O
15	s	O
16	lymphomas	O
17	responding	O
18	poorly	O
19	to	O
20	the	O
21	most	O
22	widely	O
23	employed	O
24	primary	O
25	chemotherapy	O
26	regimens	O
27	were	O
28	treated	O
29	with	O
30	a	O
31	high	O
32	-	O
33	dose	O
34	chemotherapy	O
35	(	O
36	HDC	O
37	)	O
38	followed	O
39	by	O
40	rescue	O
41	with	O
42	non	O
43	-	O
44	frozen	O
45	autologous	O
46	bone	O
47	marrow	O
48	infusion	O
49	(	O
50	ABMT	O
51	).	O
1	Freezing	O
2	of	O
3	plasma	O
4	to	O
5	obtain	O
6	better	O
7	yield	O
8	of	O
9	factor	O
10	VIII	O
11	:	O
12	C	O
13	.	O
1	Finding	O
2	of	O
3	Rhodnius	O
4	prolixus	O
5	Stal	O
6	,	O
7	1859	O
8	,	O
9	in	O
10	babassu	O
11	palm	O
12	trees	O
1	Cardiovascular	O
2	and	O
3	adrenal	O
4	medullo	O
5	-	O
6	sympathetic	O
7	reactions	O
8	to	O
9	acute	O
10	tobacco	O
11	poisoning	O
1	The	O
2	response	O
3	properties	O
4	of	O
5	cat	O
6	horizontal	O
7	canal	O
8	afferents	O
9	(	O
10	N	O
11	=	O
12	81	O
13	)	O
14	were	O
15	characterized	O
16	by	O
17	three	O
18	parameters	O
19	:	O
20	their	O
21	long	O
22	time	O
23	constants	O
24	(	O
25	tau	O
26	),	O
27	low	O
28	frequency	O
29	gain	O
30	constants	O
31	(	O
32	G1	O
33	),	O
34	and	O
35	middle	O
36	frequency	O
37	gain	O
38	constants	O
39	(	O
40	Gm	O
41	).	O
1	Hydrocortisone	O
2	seems	O
3	to	O
4	be	O
5	unable	O
6	to	O
7	hinder	O
8	the	O
9	postdenervation	O
10	changes	O
11	in	O
12	the	O
13	muscle	O
14	membrane	O
15	whereas	O
16	high	O
17	doses	O
18	of	O
19	the	O
20	hormone	O
21	are	O
22	able	O
23	to	O
24	induce	O
25	changes	O
26	in	O
27	the	O
28	muscle	O
29	membrane	O
30	.	O
1	Significant	O
2	clinical	O
3	differences	O
4	between	O
5	the	O
6	patients	O
7	treated	O
8	with	O
9	and	O
10	without	O
11	AMB	O
12	were	O
13	longer	O
14	survival	O
15	time	O
16	following	O
17	diagnosis	O
18	of	O
19	illness	O
20	(	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	05	O
27	)	O
28	and	O
29	more	O
30	frequent	O
31	cranial	O
32	nerve	O
33	signs	O
34	in	O
35	the	O
36	treated	O
37	patients	O
38	(	O
39	P	O
40	=	O
41	0	O
42	.	O
43	089	O
44	).	O
1	Thrombocyte	O
2	function	O
3	was	O
4	impaired	O
5	in	O
6	all	O
7	patients	O
8	,	O
9	characterized	O
10	by	O
11	a	O
12	diminished	O
13	platelet	O
14	shape	O
15	change	O
16	.	O
1	In	O
2	two	O
3	experiments	O
4	,	O
5	neonatal	O
6	female	O
7	BALB	O
8	/	O
9	cCrgl	O
10	or	O
11	BALB	O
12	/	O
13	cfC3HCrgl	O
14	mice	O
15	were	O
16	given	O
17	subcutaneous	O
18	injections	O
19	of	O
20	5	O
21	micrograms	O
22	17	O
23	beta	B
24	-	O
25	estradiol	O
26	or	O
27	sesame	O
28	oil	O
29	for	O
30	the	O
31	first	O
32	3	O
33	days	O
34	of	O
35	life	O
36	and	O
37	were	O
38	ovariectomized	O
39	at	O
40	60	O
41	days	O
42	of	O
43	age	O
44	,	O
45	at	O
46	which	O
47	time	O
48	vaginal	O
49	concretions	O
50	(	O
51	Experiments	O
52	I	O
53	and	O
54	II	O
55	)	O
56	or	O
57	silica	O
58	(	O
59	Experiment	O
60	II	O
61	)	O
62	were	O
63	implanted	O
64	intravaginally	O
65	.	O
1	Variable	O
2	FHR	O
3	decelerations	O
4	or	O
5	bradycardias	O
6	were	O
7	encountered	O
8	on	O
9	95	O
10	nonstress	O
11	tests	O
12	(	O
13	18	O
14	.	O
15	8	O
16	%)	O
17	in	O
18	80	O
19	(	O
20	33	O
21	.	O
22	5	O
23	%)	O
24	postdate	O
25	patients	O
26	.	O
1	According	O
2	to	O
3	the	O
4	biochemical	O
5	tests	O
6	,	O
7	high	O
8	activity	O
9	(	O
10	over	O
11	200	O
12	U	O
13	/	O
14	l	O
15	)	O
16	of	O
17	alkaline	O
18	phosphatase	B
19	was	O
20	recorded	O
21	exclusively	O
22	in	O
23	patients	O
24	with	O
25	the	O
26	lymphogranulomatosis	O
27	-	O
28	induced	O
29	liver	O
30	damage	O
31	.	O
1	Other	O
2	uncertainties	O
3	in	O
4	the	O
5	dosimetry	O
6	at	O
7	Y	O
8	-	O
9	12	O
10	and	O
11	Vinca	O
12	are	O
13	unaltered	O
14	.	O
1	Adenyl	O
2	cyclase	O
3	activity	O
4	of	O
5	gastric	O
6	mucosa	O
7	in	O
8	patients	O
9	with	O
10	duodenal	O
11	ulcer	O
12	before	O
13	and	O
14	after	O
15	treatment	O
1	Scientific	O
2	cooperation	O
3	of	O
4	CMEA	O
5	member	O
6	countries	O
7	has	O
8	been	O
9	carried	O
10	out	O
11	since	O
12	1974	O
13	under	O
14	the	O
15	sponsorship	O
16	of	O
17	the	O
18	Cancer	O
19	Research	O
20	Institute	O
21	,	O
22	Slovak	O
23	Academy	O
24	of	O
25	Sciences	O
26	(	O
27	Czechoslovakia	O
28	)	O
29	within	O
30	the	O
31	framework	O
32	of	O
33	CMEA	O
34	.	O
1	However	O
2	,	O
3	there	O
4	was	O
5	a	O
6	difference	O
7	in	O
8	the	O
9	quality	O
10	of	O
11	immunity	O
12	:	O
13	fever	O
14	and	O
15	body	O
16	weight	O
17	loss	O
18	were	O
19	seen	O
20	in	O
21	hamsters	O
22	vaccinated	O
23	with	O
24	the	O
25	killed	O
26	-	O
27	toxoplasma	O
28	vaccine	O
29	after	O
30	they	O
31	were	O
32	challenge	O
33	exposed	O
34	with	O
35	T	O
36	-	O
37	1	O
38	strain	O
39	,	O
40	whereas	O
41	these	O
42	changes	O
43	were	O
44	rarely	O
45	seen	O
46	in	O
47	hamsters	O
48	given	O
49	the	O
50	live	O
51	-	O
52	toxoplasma	O
53	vaccine	O
54	and	O
55	then	O
56	challenge	O
57	exposed	O
58	with	O
59	RH	O
60	strain	O
61	.	O
1	The	O
2	present	O
3	paper	O
4	elucidates	O
5	the	O
6	existing	O
7	discrepancies	O
8	,	O
9	and	O
10	offers	O
11	a	O
12	consistent	O
13	terminology	O
14	incorporating	O
15	also	O
16	such	O
17	terms	O
18	as	O
19	""""	O
20	additivity	O
21	""","	O
22	""""	O
23	potentiation	O
24	""","	O
25	and	O
26	""""	O
27	simple	O
28	similarity	O
29	"""."	O
1	Brainstem	O
2	auditory	O
3	evoked	O
4	responses	O
5	(	O
6	BAERs	O
7	)	O
8	and	O
9	quantitative	O
10	saccadic	O
11	eye	O
12	movement	O
13	studies	O
14	provide	O
15	information	O
16	on	O
17	the	O
18	integrity	O
19	of	O
20	pathways	O
21	traversing	O
22	the	O
23	brainstem	O
24	.	O
1	No	O
2	anisotropism	O
3	was	O
4	recorded	O
5	in	O
6	a	O
7	tetrahydrofuran	O
8	solution	O
9	.	O
1	Hepatitis	O
2	B	O
3	vaccine	O
1	Three	O
2	experiments	O
3	contrasted	O
4	the	O
5	effects	O
6	of	O
7	6	O
8	-	O
9	hydroxydopamine	O
10	-	O
11	induced	O
12	lesions	O
13	of	O
14	the	O
15	ventral	O
16	noradrenergic	O
17	and	O
18	dorsal	O
19	noradrenergic	O
20	projections	O
21	,	O
22	predominantly	O
23	to	O
24	hypothalamus	O
25	and	O
26	cortex	O
27	,	O
28	respectively	O
29	,	O
30	upon	O
31	body	O
32	weight	O
33	changes	O
34	and	O
35	food	O
36	-	O
37	related	O
38	behaviour	O
39	in	O
40	the	O
41	rat	O
42	.	O
1	The	O
2	carcinogen	O
3	bioassay	O
4	therefore	O
5	is	O
6	a	O
7	very	O
8	important	O
9	component	O
10	of	O
11	the	O
12	battery	O
13	of	O
14	toxicological	O
15	tests	O
16	used	O
17	in	O
18	hazard	O
19	evaluation	O
20	.	O
1	Angionephroscintigraphy	O
2	in	O
3	the	O
4	diagnosis	O
5	of	O
6	diseases	O
7	of	O
8	the	O
9	kidney	O
1	[	O
2	82Br	O
3	]	O
4	MISO	O
5	was	O
6	prepared	O
7	by	O
8	irradiating	O
9	samples	O
10	of	O
11	Br	O
12	-	O
13	MISO	O
14	in	O
15	a	O
16	SLOWPOKE	O
17	reactor	O
18	for	O
19	2	O
20	h	O
21	at	O
22	a	O
23	thermal	O
24	neutron	O
25	flux	O
26	of	O
27	10	O
28	(	O
29	12	O
30	)	O
31	n	O
32	cm	O
33	-	O
34	2	O
35	s	O
36	-	O
37	1	O
38	.	O
1	Serum	O
2	lipids	O
3	and	O
4	lipoproteins	O
5	of	O
6	29	O
7	insulin	B
8	dependent	O
9	diabetic	O
10	children	O
11	have	O
12	been	O
13	determined	O
14	and	O
15	related	O
16	to	O
17	the	O
18	metabolic	O
19	status	O
20	of	O
21	the	O
22	patients	O
23	.	O
1	Urinary	O
2	N	O
3	-	O
4	acetylglucosaminidase	O
5	activity	O
6	per	O
7	mg	O
8	creatinine	O
9	did	O
10	not	O
11	differ	O
12	significantly	O
13	between	O
14	groups	O
15	.	O
1	Dipetalonema	O
2	(	O
3	Alafilaria	O
4	)	O
5	hydrochoerus	O
6	subgen	O
7	.	O
8	et	O
9	sp	O
10	.	O
11	n	O
12	.	O
1	The	O
2	mucosal	O
3	defence	O
4	capacity	O
5	against	O
6	proteolytic	O
7	leukocyte	O
8	enzymes	O
9	.	O
1	The	O
2	apparatus	O
3	consists	O
4	of	O
5	an	O
6	Am	O
7	-	O
8	241	O
9	exciting	O
10	source	O
11	(	O
12	300	O
13	mCi	O
14	)	O
15	and	O
16	pure	O
17	Ge	O
18	detector	O
19	(	O
20	50	O
21	mm2	O
22	X	O
23	5	O
24	mm	O
25	)	O
26	for	O
27	measuring	O
28	K	O
29	alpha	B
30	fluorescent	O
31	x	O
32	-	O
33	rays	O
34	(	O
35	28	O
36	.	O
37	3	O
38	and	O
39	28	O
40	.	O
41	6	O
42	KeV	O
43	)	O
44	emitted	O
45	from	O
46	exited	O
47	iodine	O
48	.	O
1	10	O
2	long	O
3	-	O
4	term	O
5	hemodialysis	O
6	patients	O
7	had	O
8	immediate	O
9	and	O
10	redistribution	O
11	thallium	O
12	-	O
13	201	O
14	myocardial	O
15	imaging	O
16	performed	O
17	after	O
18	a	O
19	course	O
20	of	O
21	hemodialysis	O
22	.	O
1	Despite	O
2	total	O
3	tumor	O
4	resection	O
5	,	O
6	multiple	O
7	intraperitoneal	O
8	tumor	O
9	nodules	O
10	of	O
11	varying	O
12	sizes	O
13	were	O
14	found	O
15	and	O
16	resected	O
17	six	O
18	months	O
19	and	O
20	one	O
21	year	O
22	later	O
23	.	O
1	Absorption	O
2	was	O
3	rapid	O
4	,	O
5	with	O
6	a	O
7	mean	O
8	time	O
9	to	O
10	peak	O
11	of	O
12	39	O
13	min	O
14	.	O
1	A	O
2	total	O
3	number	O
4	of	O
5	1628	O
6	cases	O
7	were	O
8	collected	O
9	from	O
10	135	O
11	medical	O
12	institutions	O
13	.	O
1	Is	O
2	nisoldipine	O
3	capable	O
4	of	O
5	reducing	O
6	left	O
7	ventricular	O
8	preload	O
9	?	O
10	In	O
11	ten	O
12	anesthetized	O
13	pigs	O
14	,	O
15	nisoldipine	O
16	(	O
17	2	O
18	-	O
19	4	O
20	micrograms	O
21	X	O
22	kg	O
23	-	O
24	1	O
25	X	O
26	min	O
27	-	O
28	1	O
29	),	O
30	a	O
31	calcium	O
32	channel	O
33	blocker	O
34	structurally	O
35	related	O
36	to	O
37	nifedipine	O
38	,	O
39	reduced	O
40	left	O
41	ventricular	O
42	systolic	O
43	pressure	O
44	(	O
45	40	O
46	%)	O
47	and	O
48	systemic	O
49	vascular	O
50	resistance	O
51	(	O
52	35	O
53	%),	O
54	whereas	O
55	maxLVdP	O
56	/	O
57	dt	O
58	decreased	O
59	by	O
60	20	O
61	%	O
62	and	O
63	cardiac	O
64	output	O
65	was	O
66	unchanged	O
67	.	O
1	HBB	O
2	concentration	O
3	in	O
4	the	O
5	fetuses	O
6	indicated	O
7	little	O
8	,	O
9	if	O
10	any	O
11	accumulation	O
12	.	O
1	Pilot	O
2	study	O
3	of	O
4	blood	O
5	coagulation	O
6	in	O
7	gout	O
8	patients	O
9	.	O
1	The	O
2	pyramidal	O
3	tract	O
4	and	O
5	Mesencephalic	O
6	Reticular	O
7	Formation	O
8	(	O
9	MRF	O
10	)	O
11	were	O
12	stimulated	O
13	before	O
14	and	O
15	after	O
16	the	O
17	transection	O
18	.	O
1	Effects	O
2	of	O
3	methiothepin	O
4	and	O
5	lysergic	O
6	acid	O
7	diethylamide	O
8	on	O
9	serotonin	O
10	release	O
11	in	O
12	vitro	O
13	and	O
14	serotonin	O
15	synthesis	O
16	in	O
17	vivo	O
18	:	O
19	possible	O
20	relation	O
21	to	O
22	serotonin	O
23	autoreceptor	O
24	function	O
25	.	O
1	Postprandial	O
2	plasma	O
3	enteroglucagon	O
4	concentration	O
5	after	O
6	90	O
7	minutes	O
8	in	O
9	untreated	O
10	patients	O
11	correlated	O
12	positively	O
13	to	O
14	the	O
15	faecal	O
16	fat	O
17	excretion	O
18	(	O
19	r	O
20	=	O
21	0	O
22	.	O
23	58	O
24	,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	02	O
31	).	O
1	Adult	O
2	Amblyomma	O
3	lepidum	O
4	ticks	O
5	fed	O
6	as	O
7	nymphs	O
8	on	O
9	this	O
10	goat	O
11	transmitted	O
12	heartwater	O
13	to	O
14	a	O
15	Friesian	O
16	(	O
17	Bos	O
18	taurus	O
19	)	O
20	calf	O
21	.	O
1	Single	O
2	tooth	O
3	replacement	O
4	with	O
5	the	O
6	aid	O
7	of	O
8	the	O
9	ITI	O
10	(	O
11	International	O
12	Team	O
13	fur	O
14	Implantologie	O
15	)	O
16	type	O
17	F	O
18	hollow	O
19	-	O
20	cylinder	O
21	implant	O
1	The	O
2	13	O
3	,	O
4	14	O
5	-	O
6	dihydro	O
7	-	O
8	15	O
9	-	O
10	keto	O
11	-	O
12	metabolites	O
13	of	O
14	PGE2	O
15	and	O
16	PGF2	O
17	alpha	B
18	had	O
19	no	O
20	statistically	O
21	significant	O
22	antiarrhythmic	O
23	effect	O
24	.	O
1	This	O
2	study	O
3	represents	O
4	the	O
5	first	O
6	published	O
7	long	O
8	-	O
9	term	O
10	follow	O
11	-	O
12	up	O
13	regarding	O
14	this	O
15	mode	O
16	of	O
17	treatment	O
18	in	O
19	patients	O
20	with	O
21	alveolar	O
22	hypoventilation	O
23	.	O
1	Nitrogen	O
2	balance	O
3	was	O
4	compared	O
5	,	O
6	and	O
7	metabolic	O
8	complications	O
9	were	O
10	monitored	O
11	by	O
12	evaluating	O
13	BUN	O
14	,	O
15	serum	O
16	creatinine	O
17	,	O
18	creatinine	O
19	clearance	O
20	,	O
21	serum	O
22	CO2	O
23	,	O
24	SGOT	O
25	,	O
26	SGPT	O
27	,	O
28	serum	O
29	LDH	O
30	,	O
31	and	O
32	serum	O
33	alkaline	O
34	phosphatase	B
35	.	O
1	The	O
2	1	O
3	.	O
4	9	O
5	-	O
6	kb	O
7	C	O
8	mu	O
9	RNA	O
10	contains	O
11	the	O
12	3	O
13	'	O
14	sequence	O
15	characteristic	O
16	of	O
17	secreted	O
18	mu	O
19	chain	O
20	,	O
21	whereas	O
22	the	O
23	longer	O
24	species	O
25	bear	O
26	that	O
27	of	O
28	membrane	O
29	-	O
30	bound	O
31	mu	O
32	chin	O
33	.	O
1	The	O
2	role	O
3	of	O
4	DNA	O
5	rearrangement	O
6	and	O
7	alternative	O
8	RNA	O
9	processing	O
10	in	O
11	the	O
12	expression	O
13	of	O
14	immunoglobulin	O
15	delta	B
16	genes	O
17	.	O
1	In	O
2	the	O
3	course	O
4	of	O
5	Hepatitis	O
6	A	O
7	HBs	O
8	-	O
9	and	O
10	HBe	O
11	-	O
12	antigen	B
13	as	O
14	well	O
15	as	O
16	HBc	O
17	(	O
18	IgM	O
19	and	O
20	IgG	O
21	)-,	O
22	HBs	O
23	-	O
24	and	O
25	HBe	O
26	-	O
27	antibodies	O
28	can	O
29	be	O
30	detected	O
31	.	O
1	The	O
2	effect	O
3	of	O
4	the	O
5	fatty	O
6	acid	O
7	cyclo	O
8	-	O
9	oxygenase	O
10	inhibitor	O
11	indomethacin	O
12	on	O
13	cerebral	O
14	blood	O
15	flow	O
16	(	O
17	CBF	O
18	)	O
19	and	O
20	the	O
21	metabolic	O
22	rate	O
23	for	O
24	oxygen	O
25	(	O
26	CMRO2	O
27	)	O
28	was	O
29	studied	O
30	in	O
31	paralyzed	O
32	and	O
33	artificially	O
34	ventilated	O
35	rats	O
36	.	O
1	The	O
2	rat	O
3	incisor	O
4	is	O
5	an	O
6	excellent	O
7	model	O
8	system	O
9	in	O
10	which	O
11	to	O
12	study	O
13	amelgenesis	O
14	.	O
1	This	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	assess	O
7	and	O
8	compare	O
9	the	O
10	ability	O
11	of	O
12	three	O
13	different	O
14	forms	O
15	of	O
16	DSG	O
17	to	O
18	block	O
19	EIB	O
20	.	O
1	LCBF	O
2	in	O
3	normal	O
4	and	O
5	hypoxic	O
6	puppies	O
7	was	O
8	correlated	O
9	with	O
10	local	O
11	cerebral	O
12	glucose	O
13	utilization	O
14	(	O
15	LCGU	O
16	)	O
17	obtained	O
18	under	O
19	the	O
20	same	O
21	experimental	O
22	conditions	O
23	(	O
24	Duffy	O
25	et	O
26	al	O
27	,	O
28	1982	O
29	).	O
1	Other	O
2	properties	O
3	of	O
4	Hg	O
5	-	O
6	and	O
7	Cd	O
8	-	O
9	spores	O
10	were	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	control	O
16	spores	O
17	.	O
1	Apo	O
2	A	O
3	-	O
4	I	O
5	level	O
6	was	O
7	unrelated	O
8	to	O
9	age	O
10	,	O
11	but	O
12	increased	O
13	with	O
14	ethanol	O
15	consumption	O
16	and	O
17	decreased	O
18	with	O
19	adiposity	O
20	.	O
1	Selenium	O
2	,	O
3	as	O
4	a	O
5	constituent	O
6	of	O
7	glutathione	O
8	peroxidase	O
9	,	O
10	plays	O
11	a	O
12	role	O
13	in	O
14	the	O
15	antioxidant	O
16	defense	O
17	systems	O
18	of	O
19	the	O
20	body	O
21	,	O
22	but	O
23	other	O
24	metabolic	O
25	roles	O
26	for	O
27	selenium	O
28	may	O
29	yet	O
30	be	O
31	discovered	O
32	.	O
1	At	O
2	43	O
3	%	O
4	blood	O
5	pressure	O
6	reduction	O
7	,	O
8	PCO2	O
9	fell	O
10	by	O
11	0	O
12	.	O
13	53	O
14	kPa	O
15	,	O
16	a	O
17	decrease	O
18	which	O
19	could	O
20	not	O
21	explain	O
22	the	O
23	observed	O
24	CBF	O
25	fall	O
26	of	O
27	27	O
28	%.	O
1	Asthmatic	O
2	patients	O
3	showed	O
4	greater	O
5	responses	O
6	of	O
7	both	O
8	parameters	O
9	to	O
10	adrenaline	O
11	than	O
12	controls	O
13	indicating	O
14	that	O
15	long	O
16	-	O
17	term	O
18	corticosteroid	O
19	treatment	O
20	enhances	O
21	the	O
22	acute	O
23	responses	O
24	of	O
25	plasminogen	O
26	activator	O
27	and	O
28	clotting	O
29	factor	O
30	VIII	O
31	to	O
32	adrenaline	O
33	infusion	O
34	.	O
1	The	O
2	level	O
3	of	O
4	contamination	O
5	in	O
6	the	O
7	wound	O
8	can	O
9	be	O
10	determined	O
11	with	O
12	the	O
13	rapid	O
14	biopsy	O
15	fixation	O
16	technique	O
17	.	O
1	Fibromuscular	O
2	intimal	O
3	thickening	O
4	was	O
5	seen	O
6	in	O
7	the	O
8	ascending	O
9	and	O
10	thoracic	O
11	aorta	O
12	of	O
13	the	O
14	swine	O
15	fed	O
16	62	O
17	,	O
18	500	O
19	IU	O
20	of	O
21	vitamin	O
22	D3	O
23	/	O
24	kg	O
25	of	O
26	diet	O
27	for	O
28	three	O
29	months	O
30	duration	O
31	;	O
32	and	O
33	after	O
34	3	O
35	months	O
36	of	O
37	vitamin	O
38	D3	O
39	withdrawal	O
40	,	O
41	atherosclerotic	O
42	lesions	O
43	were	O
44	found	O
45	.	O
1	Histological	O
2	signs	O
3	of	O
4	the	O
5	flare	O
6	-	O
7	up	O
8	reaction	O
9	were	O
10	already	O
11	present	O
12	at	O
13	6	O
14	hr	O
15	after	O
16	i	O
17	.	O
18	v	O
19	.	O
20	challenge	O
21	and	O
22	lasted	O
23	for	O
24	at	O
25	least	O
26	4	O
27	days	O
28	.	O
1	Significant	O
2	GMBF	O
3	reductions	O
4	occurred	O
5	in	O
6	early	O
7	shock	O
8	in	O
9	both	O
10	treatment	O
11	groups	O
12	.	O
1	Distal	O
2	tubular	O
3	acidification	O
4	and	O
5	the	O
6	threshold	O
7	for	O
8	proximal	O
9	tubular	O
10	bicarbonate	O
11	reabsorption	O
12	were	O
13	normal	O
14	,	O
15	as	O
16	was	O
17	urine	O
18	concentrating	O
19	capacity	O
20	.	O
1	In	O
2	patients	O
3	with	O
4	complete	O
5	or	O
6	partial	O
7	remission	O
8	of	O
9	the	O
10	tumor	O
11	,	O
12	the	O
13	neopterine	O
14	excretion	O
15	dropped	O
16	to	O
17	normal	O
18	values	O
19	.	O
1	Normal	O
2	rates	O
3	of	O
4	weight	O
5	gain	O
6	were	O
7	seen	O
8	once	O
9	absorbed	O
10	energy	O
11	intakes	O
12	reached	O
13	100	O
14	-	O
15	110	O
16	%	O
17	of	O
18	requirements	O
19	.	O
1	The	O
2	hyperacute	O
3	phase	O
4	of	O
5	posterolateral	O
6	myocardial	O
7	infarction	O
8	.	O
1	The	O
2	infection	O
3	rate	O
4	was	O
5	five	O
6	times	O
7	greater	O
8	in	O
9	patients	O
10	with	O
11	Hickman	O
12	catheters	O
13	than	O
14	in	O
15	those	O
16	with	O
17	Broviac	O
18	catheters	O
19	(	O
20	p	O
21	=	O
22	0	O
23	.	O
24	01	O
25	).	O
1	The	O
2	electrocardiogram	O
3	.	O
1	The	O
2	Authors	O
3	have	O
4	proposed	O
5	to	O
6	develop	O
7	this	O
8	research	O
9	employing	O
10	a	O
11	preparation	O
12	containing	O
13	exclusively	O
14	a	O
15	cortisonic	O
16	,	O
17	the	O
18	desametazone	O
19	,	O
20	in	O
21	order	O
22	to	O
23	evaluate	O
24	the	O
25	alterations	O
26	of	O
27	the	O
28	dentinogenesis	O
29	to	O
30	be	O
31	attributed	O
32	to	O
33	such	O
34	component	O
35	.	O
1	Secretory	O
2	IgA	O
3	and	O
4	serum	O
5	immunoglobulins	O
6	as	O
7	indices	O
8	of	O
9	the	O
10	local	O
11	immunity	O
12	of	O
13	the	O
14	intestinal	O
15	mucosa	O
16	in	O
17	acute	O
18	leukemias	O
1	Thus	O
2	it	O
3	appears	O
4	that	O
5	the	O
6	management	O
7	of	O
8	blood	O
9	,	O
10	including	O
11	washing	O
12	is	O
13	of	O
14	great	O
15	importance	O
16	.	O
1	Range	O
2	,	O
3	variations	O
4	and	O
5	neoplastic	O
6	potential	O
7	.	O
1	Study	O
2	on	O
3	distribution	O
4	of	O
5	metal	O
6	in	O
7	the	O
8	teeth	O
9	treated	O
10	by	O
11	iontophoresis	O
12	with	O
13	transparent	O
14	specimens	O
1	The	O
2	arginyl	O
3	peptide	O
4	bonds	O
5	that	O
6	are	O
7	cleaved	O
8	in	O
9	the	O
10	conversion	O
11	of	O
12	human	O
13	factor	O
14	IX	O
15	to	O
16	factor	O
17	IXa	O
18	by	O
19	factor	O
20	XIa	O
21	were	O
22	identified	O
23	as	O
24	Arg145	O
25	-	O
26	Ala146	O
27	and	O
28	Arg180	O
29	-	O
30	Val181	O
31	.	O
1	Specific	O
2	IgE	O
3	levels	O
4	decreased	O
5	slightly	O
6	,	O
7	but	O
8	always	O
9	remained	O
10	within	O
11	the	O
12	pathological	O
13	range	O
14	.	O
1	The	O
2	daily	O
3	administration	O
4	of	O
5	betamethasone	O
6	for	O
7	three	O
8	weeks	O
9	markedly	O
10	reduced	O
11	the	O
12	absorption	O
13	of	O
14	calcium	O
15	and	O
16	phosphate	O
17	as	O
18	well	O
19	as	O
20	the	O
21	growth	O
22	rate	O
23	.	O
1	The	O
2	extraction	O
3	measurements	O
4	were	O
5	used	O
6	to	O
7	test	O
8	for	O
9	extracerebral	O
10	contamination	O
11	of	O
12	venous	O
13	outflow	O
14	.	O
1	Glomerular	O
2	lesions	O
3	in	O
4	renal	O
5	allografts	O
6	.	O
1	Commonly	O
2	observed	O
3	systemic	O
4	toxic	O
5	effects	O
6	(	O
7	bone	O
8	marrow	O
9	,	O
10	gastrointestinal	O
11	tract	O
12	,	O
13	and	O
14	heart	O
15	)	O
16	were	O
17	not	O
18	seen	O
19	in	O
20	this	O
21	study	O
22	.	O
1	When	O
2	vascular	O
3	pressure	O
4	(	O
5	Pvas	O
6	)	O
7	was	O
8	raised	O
9	abruptly	O
10	from	O
11	-	O
12	5	O
13	to	O
14	+	O
15	25	O
16	cmH2O	O
17	by	O
18	air	O
19	inflation	O
20	for	O
21	60	O
22	min	O
23	,	O
24	Px	O
25	(	O
26	f	O
27	)	O
28	became	O
29	abruptly	O
30	less	O
31	negative	O
32	,	O
33	then	O
34	remained	O
35	stable	O
36	.	O
1	When	O
2	the	O
3	l	O
4	-	O
5	methadone	O
6	-	O
7	sensitive	O
8	,	O
9	opioid	O
10	receptor	B
11	is	O
12	blocked	O
13	by	O
14	naloxone	O
15	or	O
16	tolerance	O
17	has	O
18	developed	O
19	,	O
20	than	O
21	l	O
22	-	O
23	methadone	O
24	can	O
25	produce	O
26	behavioral	O
27	effects	O
28	by	O
29	a	O
30	nonopioid	O
31	mechanism	O
32	.	O
1	Large	O
2	and	O
3	small	O
4	medullary	O
5	lesions	O
6	inhibited	O
7	the	O
8	occurrence	O
9	of	O
10	target	O
11	fibres	O
12	in	O
13	the	O
14	tenotomized	O
15	muscles	O
16	,	O
17	the	O
18	smallest	O
19	one	O
20	being	O
21	neurolysis	O
22	of	O
23	the	O
24	dorsal	O
25	roots	O
26	.	O
1	Use	O
2	of	O
3	subcutaneous	O
4	deferoxamine	O
5	in	O
6	a	O
7	child	O
8	with	O
9	hemochromatosis	O
10	associated	O
11	with	O
12	congenital	O
13	dyserythropoietic	O
14	anemia	O
15	,	O
16	type	O
17	I	O
18	.	O
1	Although	O
2	noninhibitory	O
3	fluid	O
4	had	O
5	higher	O
6	mean	O
7	concentrations	O
8	of	O
9	phosphorus	O
10	and	O
11	zinc	O
12	,	O
13	these	O
14	differences	O
15	did	O
16	not	O
17	hold	O
18	after	O
19	meconium	O
20	-	O
21	stained	O
22	samples	O
23	were	O
24	excluded	O
25	.	O
1	Selenium	O
2	status	O
3	of	O
4	thoroughbreds	O
5	in	O
6	the	O
7	United	O
8	Kingdom	O
9	.	O
1	Before	O
2	turnout	O
3	,	O
4	a	O
5	morantel	O
6	sustained	O
7	release	O
8	bolus	O
9	(	O
10	MSRB	O
11	)	O
12	was	O
13	administered	O
14	to	O
15	each	O
16	animal	O
17	in	O
18	the	O
19	""""	O
20	treated	O
21	""""	O
22	category	O
23	.	O
1	Further	O
2	,	O
3	intracerebroventricular	O
4	injections	O
5	of	O
6	KA	O
7	resulted	O
8	in	O
9	the	O
10	substantial	O
11	loss	O
12	of	O
13	pyramidal	O
14	cells	O
15	in	O
16	the	O
17	whole	O
18	CA3	O
19	field	O
20	of	O
21	the	O
22	hippocampus	O
23	.	O
1	Samples	O
2	obtained	O
3	from	O
4	normal	O
5	volunteers	O
6	and	O
7	from	O
8	the	O
9	great	O
10	majority	O
11	of	O
12	the	O
13	patients	O
14	,	O
15	excluding	O
16	those	O
17	with	O
18	asthma	O
19	,	O
20	had	O
21	no	O
22	effect	O
23	on	O
24	ciliary	O
25	beating	O
26	.	O
1	CSF	B
2	adenosine	O
3	deaminase	O
4	activity	O
5	(	O
6	ADA	O
7	)	O
8	was	O
9	measured	O
10	at	O
11	the	O
12	same	O
13	time	O
14	.	O
1	Ficat	O
2	and	O
3	Bizou	O
4	'	O
5	s	O
6	condylar	O
7	depth	O
8	index	O
9	and	O
10	the	O
11	condylar	O
12	-	O
13	joint	O
14	surface	O
15	angle	O
16	of	O
17	Brattstrom	O
18	are	O
19	recommended	O
20	as	O
21	especially	O
22	suitable	O
23	methods	O
24	of	O
25	measurement	O
26	.	O
1	After	O
2	MOPP	O
3	therapy	O
4	,	O
5	complete	O
6	remission	O
7	of	O
8	Hodgkin	O
9	'	O
10	s	O
11	disease	O
12	was	O
13	accompanied	O
14	by	O
15	normalization	O
16	of	O
17	the	O
18	glucocerebrosidase	O
19	level	O
20	and	O
21	disappearance	O
22	of	O
23	Gaucher	O
24	'	O
25	s	O
26	cells	O
27	.	O
1	Re	O
2	:	O
3	A	O
4	modified	O
5	method	O
6	for	O
7	the	O
8	in	O
9	vivo	O
10	labeling	O
11	of	O
12	red	O
13	blood	O
14	cells	O
15	with	O
16	Tc	O
17	-	O
18	99m	O
19	.	O
1	A	O
2	limited	O
3	study	O
4	in	O
5	a	O
6	glassware	O
7	factory	O
8	(	O
9	As2O3	O
10	exposure	O
11	)	O
12	involving	O
13	the	O
14	measurement	O
15	of	O
16	total	O
17	airborne	O
18	arsenic	O
19	,	O
20	the	O
21	determination	O
22	of	O
23	urinary	O
24	arsenic	O
25	,	O
26	and	O
27	the	O
28	evaluation	O
29	of	O
30	hand	O
31	and	O
32	mouth	O
33	contamination	O
34	by	O
35	arsenic	O
36	before	O
37	and	O
38	after	O
39	the	O
40	workshift	O
41	suggests	O
42	that	O
43	the	O
44	high	O
45	urinary	O
46	arsenic	O
47	levels	O
48	(	O
49	300	O
50	microgram	O
51	/	O
52	g	O
53	creatinine	O
54	)	O
55	are	O
56	likely	O
57	to	O
58	be	O
59	more	O
60	related	O
61	to	O
62	an	O
63	increased	O
64	oral	O
65	intake	O
66	from	O
67	contaminated	O
68	hands	O
69	than	O
70	to	O
71	an	O
72	increased	O
73	absorption	O
74	from	O
75	the	O
76	lungs	O
77	.	O
1	Restarting	O
2	time	O
3	was	O
4	not	O
5	affected	O
6	by	O
7	magnesium	O
8	cardioplegia	O
9	.	O
1	The	O
2	most	O
3	common	O
4	types	O
5	of	O
6	malformations	O
7	were	O
8	eye	O
9	defects	O
10	and	O
11	open	O
12	coeloms	O
13	.	O
1	Histological	O
2	evaluation	O
3	revealed	O
4	a	O
5	more	O
6	than	O
7	twofold	O
8	increase	O
9	in	O
10	the	O
11	number	O
12	of	O
13	interepithelial	O
14	mononuclear	O
15	cells	O
16	(	O
17	p	O
18	less	O
19	than	O
20	0	O
21	.	O
22	005	O
23	),	O
24	while	O
25	the	O
26	number	O
27	of	O
28	epithelial	O
29	cells	O
30	/	O
31	100	O
32	microns	O
33	of	O
34	villous	O
35	mucosa	O
36	and	O
37	the	O
38	mean	O
39	height	O
40	of	O
41	the	O
42	epithelial	O
43	cells	O
44	were	O
45	comparable	O
46	in	O
47	both	O
48	groups	O
49	.	O
1	Asymptomatic	O
2	bacteriospermia	O
3	and	O
4	fertility	O
1	The	O
2	favourable	O
3	effect	O
4	of	O
5	thymic	O
6	shielding	O
7	was	O
8	also	O
9	reflected	O
10	in	O
11	a	O
12	significant	O
13	increase	O
14	of	O
15	LD50	O
16	/	O
17	30	O
18	,	O
19	and	O
20	the	O
21	dose	O
22	reduction	O
23	factor	O
24	was	O
25	equal	O
26	to	O
27	2	O
28	.	O
1	Mastocytosis	O
2	.	O
1	It	O
2	was	O
3	suggested	O
4	that	O
5	the	O
6	absence	O
7	of	O
8	pronounced	O
9	differences	O
10	between	O
11	conditions	O
12	may	O
13	have	O
14	been	O
15	due	O
16	to	O
17	the	O
18	complexity	O
19	of	O
20	the	O
21	task	O
22	or	O
23	the	O
24	type	O
25	of	O
26	prompts	O
27	employed	O
28	.	O
1	Re	O
2	-	O
3	examination	O
4	of	O
5	the	O
6	ED01	O
7	study	O
8	.	O
1	Based	O
2	on	O
3	213	O
4	determinations	O
5	,	O
6	the	O
7	control	O
8	mean	O
9	serum	O
10	CPK	O
11	activity	O
12	was	O
13	262	O
14	+/-	O
15	113	O
16	I	O
17	.	O
18	U	O
19	./	O
20	liter	O
21	.	O
1	A	O
2	method	O
3	for	O
4	determining	O
5	cumulative	O
6	behavioral	O
7	toxicity	O
8	after	O
9	chronic	O
10	oral	O
11	administration	O
12	of	O
13	l	O
14	-	O
15	alpha	B
16	-	O
17	acetylmethadol	O
18	to	O
19	female	O
20	rats	O
21	.	O
1	The	O
2	preferences	O
3	were	O
4	for	O
5	intact	O
6	vis	O
7	-	O
8	a	O
9	-	O
10	vis	O
11	castrated	O
12	males	O
13	,	O
14	though	O
15	injections	O
16	of	O
17	TP	O
18	restored	O
19	the	O
20	castrates	O
21	'	O
22	attractiveness	O
23	to	O
24	the	O
25	females	O
26	.	O
1	Ulcer	O
2	appeared	O
3	on	O
4	the	O
5	angulus	O
6	of	O
7	the	O
8	stomach	O
9	at	O
10	the	O
11	28th	O
12	week	O
13	and	O
14	resulted	O
15	in	O
16	ulcer	O
17	scar	O
18	at	O
19	the	O
20	42nd	O
21	week	O
22	.	O
1	Family	O
2	visits	O
3	and	O
4	involvement	O
5	in	O
6	treatment	O
7	of	O
8	patients	O
9	at	O
10	a	O
11	state	O
12	hospital	O
13	.	O
1	Inhibition	O
2	of	O
3	Fusarium	O
4	moniliforme	O
5	var	O
6	.	O
7	subglutinans	O
8	,	O
9	the	O
10	causal	O
11	agent	O
12	of	O
13	pine	O
14	pitch	O
15	canker	O
16	,	O
17	by	O
18	the	O
19	soil	O
20	bacterium	O
21	Arthrobacter	O
22	sp	O
23	.	O
1	Clinical	O
2	and	O
3	anatomical	O
4	considerations	O
1	Morphological	O
2	features	O
3	of	O
4	Jat	O
5	dentition	O
6	.	O
1	While	O
2	all	O
3	deletions	O
4	within	O
5	the	O
6	sequence	O
7	coding	O
8	for	O
9	the	O
10	mature	O
11	tRNA	O
12	led	O
13	to	O
14	inactivity	O
15	of	O
16	the	O
17	mutated	O
18	genes	O
19	,	O
20	substitution	O
21	of	O
22	the	O
23	central	O
24	portion	O
25	by	O
26	concatenated	O
27	Hind	O
28	III	O
29	linkers	O
30	produced	O
31	gene	O
32	units	O
33	active	O
34	in	O
35	transcription	O
36	.	O
1	Recording	O
2	of	O
3	the	O
4	digital	O
5	sphygmic	O
6	activity	O
7	in	O
8	the	O
9	lower	O
10	extremities	O
11	with	O
12	the	O
13	photoplethysmographic	O
14	and	O
15	strain	O
16	-	O
17	gauge	O
18	methods	O
19	.	O
1	The	O
2	oral	O
3	temperature	O
4	rose	O
5	and	O
6	the	O
7	serum	O
8	creatine	O
9	kinase	B
10	levels	O
11	fell	O
12	only	O
13	in	O
14	those	O
15	patients	O
16	who	O
17	were	O
18	actively	O
19	warmed	O
20	.	O
1	We	O
2	studied	O
3	the	O
4	role	O
5	of	O
6	prostaglandins	O
7	in	O
8	acid	O
9	-	O
10	induced	O
11	esophagitis	O
12	and	O
13	the	O
14	associated	O
15	LES	O
16	hypotension	O
17	by	O
18	simultaneous	O
19	treatment	O
20	of	O
21	some	O
22	animals	O
23	with	O
24	indomethacin	O
25	(	O
26	150	O
27	micrograms	O
28	/	O
29	kg	O
30	intravenous	O
31	),	O
32	a	O
33	specific	O
34	inhibitor	O
35	of	O
36	prostaglandin	O
37	synthesis	O
38	,	O
39	either	O
40	during	O
41	production	O
42	of	O
43	esophagitis	O
44	or	O
45	during	O
46	recovery	O
47	.	O
1	Since	O
2	only	O
3	58	O
4	%	O
5	of	O
6	our	O
7	sample	O
8	could	O
9	be	O
10	adequately	O
11	classified	O
12	with	O
13	one	O
14	diagnosis	O
15	,	O
16	we	O
17	expect	O
18	that	O
19	the	O
20	ASDC	O
21	nosology	O
22	will	O
23	need	O
24	to	O
25	evolve	O
26	further	O
27	.	O
1	A	O
2	surgical	O
3	technique	O
4	for	O
5	correcting	O
6	this	O
7	problem	O
8	is	O
9	described	O
10	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	general	O
7	clinical	O
8	criteria	O
9	for	O
10	inhalation	O
11	injury	O
12	--	O
13	presence	O
14	of	O
15	facial	O
16	or	O
17	oropharyngeal	O
18	burns	O
19	,	O
20	carboxyhemoglobin	O
21	levels	O
22	,	O
23	carbonaceous	O
24	sputum	O
25	,	O
26	or	O
27	closed	O
28	space	O
29	injury	O
30	--	O
31	did	O
32	not	O
33	differentiate	O
34	patients	O
35	with	O
36	airway	O
37	injury	O
38	only	O
39	from	O
40	those	O
41	with	O
42	parenchymal	O
43	injury	O
44	.	O
1	Static	O
2	lung	O
3	function	O
4	in	O
5	puppies	O
6	after	O
7	pneumonectomy	O
8	.	O
1	Bilateral	O
2	Charnley	O
3	arthroplasty	O
4	as	O
5	a	O
6	single	O
7	procedure	O
8	.	O
1	Of	O
2	the	O
3	117	O
4	patients	O
5	(	O
6	out	O
7	of	O
8	the	O
9	136	O
10	)	O
11	with	O
12	serologic	O
13	evidence	O
14	of	O
15	chronic	O
16	thyroiditis	O
17	who	O
18	could	O
19	be	O
20	studied	O
21	,	O
22	eight	O
23	(	O
24	7	O
25	%)	O
26	had	O
27	hyperthyroidism	O
28	and	O
29	45	O
30	(	O
31	38	O
32	%)	O
33	were	O
34	hypothyroid	O
35	.	O
1	The	O
2	new	O
3	semi	O
4	-	O
5	synthetic	O
6	oral	O
7	cephalosporin	O
8	,	O
9	CGP	O
10	9	O
11	,	O
12	000	O
13	,	O
14	has	O
15	been	O
16	evaluated	O
17	in	O
18	a	O
19	large	O
20	number	O
21	of	O
22	hospitalized	O
23	patients	O
24	with	O
25	urinary	O
26	infections	O
27	.	O
1	DMI	O
2	and	O
3	2	O
4	-	O
5	OH	O
6	-	O
7	DMI	O
8	concentrations	O
9	were	O
10	determined	O
11	in	O
12	a	O
13	similar	O
14	group	O
15	of	O
16	61	O
17	DMI	O
18	-	O
19	treated	O
20	patients	O
21	.	O
1	In	O
2	controls	O
3	,	O
4	only	O
5	modest	O
6	differences	O
7	were	O
8	observed	O
9	.	O
1	Progressive	O
2	100	O
3	-	O
4	mmHg	O
5	stepwise	O
6	decreases	O
7	in	O
8	superfusate	O
9	oxygen	O
10	partial	O
11	pressure	O
12	(	O
13	PO2	O
14	)	O
15	from	O
16	control	O
17	(	O
18	95	O
19	%	O
20	O2	O
21	aeration	O
22	,	O
23	PO2	O
24	,	O
25	620	O
26	-	O
27	650	O
28	mmHg	O
29	)	O
30	were	O
31	produced	O
32	,	O
33	and	O
34	subsequent	O
35	changes	O
36	in	O
37	isometric	O
38	active	O
39	and	O
40	resting	O
41	tension	O
42	were	O
43	measured	O
44	.	O
1	Based	O
2	on	O
3	AUC	O
4	infinity	O
5	analyses	O
6	,	O
7	the	O
8	pharmacokinetics	O
9	of	O
10	buflomedil	O
11	were	O
12	found	O
13	to	O
14	be	O
15	linear	O
16	within	O
17	the	O
18	dose	O
19	ranges	O
20	studied	O
21	(	O
22	50	O
23	to	O
24	200	O
25	mg	O
26	for	O
27	i	O
28	.	O
29	v	O
30	.	O
31	injection	O
32	and	O
33	150	O
34	to	O
35	450	O
36	mg	O
37	for	O
38	oral	O
39	administration	O
40	).	O
1	Over	O
2	a	O
3	period	O
4	of	O
5	15	O
6	days	O
7	16	O
8	%	O
9	of	O
10	the	O
11	dose	O
12	administered	O
13	was	O
14	excreted	O
15	with	O
16	faeces	O
17	and	O
18	0	O
19	.	O
20	9	O
21	%	O
22	in	O
23	the	O
24	urine	O
25	.	O
1	Generally	O
2	the	O
3	differences	O
4	between	O
5	short	O
6	gut	O
7	and	O
8	sham	O
9	operation	O
10	animals	O
11	disappeared	O
12	when	O
13	the	O
14	data	O
15	were	O
16	normalised	O
17	for	O
18	mucosal	O
19	weight	O
20	.	O
1	The	O
2	architecture	O
3	of	O
4	microvasculature	O
5	in	O
6	these	O
7	two	O
8	regions	O
9	was	O
10	also	O
11	examined	O
12	by	O
13	scanning	O
14	electron	O
15	microscopy	O
16	,	O
17	using	O
18	the	O
19	resin	O
20	casting	O
21	method	O
22	.	O
1	Micro	O
2	high	O
3	-	O
4	performance	O
5	liquid	O
6	chromatographic	O
7	system	O
8	with	O
9	micro	O
10	precolumn	O
11	and	O
12	dual	O
13	electrochemical	O
14	detector	O
15	for	O
16	direct	O
17	injection	O
18	analysis	O
19	of	O
20	catecholamines	O
21	in	O
22	body	O
23	fluids	O
24	.	O
1	Prevention	O
2	of	O
3	transfusion	O
4	reactions	O
5	by	O
6	the	O
7	use	O
8	of	O
9	saline	O
10	washed	O
11	red	O
12	blood	O
13	cells	O
14	.	O
1	Therefore	O
2	the	O
3	procedure	O
4	of	O
5	Lich	O
6	-	O
7	Gregoir	O
8	is	O
9	not	O
10	to	O
11	be	O
12	recommended	O
13	in	O
14	adults	O
15	.	O
1	Mucoepidermoid	O
2	and	O
3	acinous	O
4	cell	O
5	carcinomas	O
6	of	O
7	salivary	O
8	tissues	O
9	.	O
1	Longitudinal	O
2	force	O
3	-	O
4	length	O
5	relationships	O
6	of	O
7	guinea	O
8	pig	O
9	ureter	O
10	were	O
11	studied	O
12	in	O
13	vitro	O
14	in	O
15	animals	O
16	3	O
17	weeks	O
18	,	O
19	3	O
20	months	O
21	,	O
22	and	O
23	3	O
24	years	O
25	of	O
26	age	O
27	.	O
1	Importance	O
2	of	O
3	determining	O
4	the	O
5	blood	O
6	sulfhydryl	O
7	groups	O
8	in	O
9	fractures	O
10	of	O
11	the	O
12	long	O
13	tubular	O
14	bones	O
15	complicated	O
16	by	O
17	infection	O
1	The	O
2	results	O
3	revealed	O
4	increased	O
5	blood	O
6	lead	O
7	level	O
8	associated	O
9	with	O
10	decreased	O
11	blood	O
12	haemoglobin	O
13	and	O
14	increased	O
15	urinary	O
16	excretion	O
17	of	O
18	delta	B
19	amino	O
20	levulinic	O
21	acid	O
22	.	O
1	A	O
2	16	O
3	-	O
4	year	O
5	follow	O
6	-	O
7	up	O
8	study	O
9	of	O
10	69	O
11	paraplegics	O
12	with	O
13	complete	O
14	lesions	O
15	from	O
16	T1	O
17	-	O
18	L3	O
19	is	O
20	presented	O
21	.	O
1	Cataract	O
2	extraction	O
3	in	O
4	primary	O
5	glaucoma	O
1	Number	O
2	and	O
3	size	O
4	of	O
5	the	O
6	myelin	O
7	structures	O
8	in	O
9	the	O
10	pneumocytes	O
11	typ	O
12	II	O
13	increased	O
14	simultaneously	O
15	.	O
1	For	O
2	the	O
3	study	O
4	of	O
5	the	O
6	transition	O
7	of	O
8	long	O
9	to	O
10	short	O
11	waves	O
12	(	O
13	deep	O
14	-	O
15	water	O
16	waves	O
17	)	O
18	a	O
19	closed	O
20	-	O
21	form	O
22	solution	O
23	is	O
24	advantageous	O
25	;	O
26	this	O
27	can	O
28	,	O
29	however	O
30	,	O
31	only	O
32	be	O
33	obtained	O
34	at	O
35	the	O
36	cost	O
37	of	O
38	further	O
39	simplification	O
40	.	O
1	Fasting	O
2	plasma	O
3	and	O
4	lipoprotein	O
5	lipid	O
6	concentrations	O
7	,	O
8	adipose	O
9	tissue	O
10	lipoprotein	O
11	lipase	O
12	activity	O
13	,	O
14	anthropometric	O
15	data	O
16	,	O
17	alcohol	O
18	consumption	O
19	,	O
20	smoking	O
21	habits	O
22	,	O
23	weekly	O
24	mileage	O
25	run	O
26	and	O
27	performance	O
28	on	O
29	a	O
30	bicycle	O
31	ergometer	O
32	were	O
33	recorded	O
34	before	O
35	and	O
36	after	O
37	the	O
38	training	O
39	period	O
40	.	O
1	At	O
2	pH	O
3	6	O
4	.	O
5	9	O
6	,	O
7	the	O
8	same	O
9	lidocaine	O
10	concentrations	O
11	significantly	O
12	reduced	O
13	resting	O
14	potential	O
15	(	O
16	3	O
17	-	O
18	10	O
19	%),	O
20	action	O
21	potential	O
22	amplitude	O
23	(	O
24	3	O
25	-	O
26	8	O
27	%)	O
28	and	O
29	Vmax	O
30	(	O
31	14	O
32	-	O
33	22	O
34	%).	O
1	Arm	O
2	function	O
3	tests	O
4	.	O
1	Marked	O
2	sedative	O
3	activity	O
4	was	O
5	observed	O
6	with	O
7	9	O
8	-	O
9	methoxy	O
10	-	O
11	5	O
12	-	O
13	phenylpyrrolo	O
14	[	O
15	2	O
16	,	O
17	1	O
18	-	O
19	d	O
20	][	O
21	1	O
22	,	O
23	5	O
24	]	O
25	benzothiazepin	O
26	-	O
27	6	O
28	,	O
29	6	O
30	-	O
31	dioxide	O
32	(	O
33	NF19	O
34	)	O
35	and	O
36	9	O
37	-	O
38	chloro	O
39	-	O
40	5	O
41	-	O
42	p	O
43	-	O
44	nitrophenylpyrrolo	O
45	[	O
46	2	O
47	,	O
48	1	O
49	-	O
50	d	O
51	][	O
52	1	O
53	,	O
54	5	O
55	]	O
56	benzothiazepin	O
57	-	O
58	6	O
59	,	O
60	6	O
61	-	O
62	dioxide	O
63	(	O
64	NF20	O
65	).	O
1	In	O
2	patients	O
3	,	O
4	the	O
5	effect	O
6	of	O
7	CCK	O
8	-	O
9	PZ	O
10	on	O
11	the	O
12	movement	O
13	of	O
14	the	O
15	terminal	O
16	part	O
17	of	O
18	the	O
19	bile	O
20	duct	O
21	was	O
22	measured	O
23	with	O
24	a	O
25	pressure	O
26	sensor	O
27	using	O
28	a	O
29	duodenofiberscope	O
30	.	O
1	Pentachlorophenol	O
2	accelerates	O
3	the	O
4	onset	O
5	of	O
6	HCB	O
7	porphyria	O
8	,	O
9	in	O
10	other	O
11	words	O
12	it	O
13	increases	O
14	the	O
15	total	O
16	urinary	O
17	porphyrin	O
18	excretion	O
19	and	O
20	causes	O
21	an	O
22	earlier	O
23	disturbance	O
24	of	O
25	the	O
26	porphyrin	O
27	pattern	O
28	.	O
1	The	O
2	identification	O
3	of	O
4	viable	O
5	myocardium	O
6	with	O
7	both	O
8	99mTc	O
9	-	O
10	tetrofosmin	O
11	and	O
12	201Tl	O
13	can	O
14	be	O
15	greatly	O
16	enhanced	O
17	to	O
18	a	O
19	similar	O
20	degree	O
21	if	O
22	the	O
23	severity	O
24	of	O
25	reduction	O
26	in	O
27	activity	O
28	within	O
29	nonreversible	O
30	defects	O
31	is	O
32	considered	O
33	.	O
1	However	O
2	,	O
3	in	O
4	contrast	O
5	with	O
6	previous	O
7	in	O
8	vitro	O
9	cell	O
10	-	O
11	free	O
12	integration	O
13	studies	O
14	,	O
15	alteration	O
16	of	O
17	the	O
18	highly	O
19	conserved	O
20	CA	O
21	dinucleotide	O
22	resulted	O
23	in	O
24	a	O
25	mutant	O
26	which	O
27	still	O
28	retained	O
29	40	O
30	%	O
31	of	O
32	wild	O
33	-	O
34	type	O
35	integration	O
36	activity	O
37	.	O
1	BSE	O
2	and	O
3	farmworkers	O
4	.	O
1	This	O
2	is	O
3	particularly	O
4	intriguing	O
5	because	O
6	SKUT	O
7	-	O
8	1B	O
9	-	O
10	20	O
11	cells	O
12	lack	O
13	the	O
14	transcription	O
15	factor	O
16	Pit	O
17	-	O
18	1	O
19	.	O
1	Some	O
2	strains	O
3	of	O
4	A	O
5	.	O
6	parasiticus	O
7	produced	O
8	all	O
9	four	O
10	aflatoxins	O
11	B1	O
12	B2	O
13	G1	O
14	G2	O
15	,	O
16	while	O
17	the	O
18	other	O
19	ones	O
20	produced	O
21	AF	O
22	B1	O
23	+	O
24	G1	O
25	only	O
26	,	O
27	with	O
28	concentrations	O
29	of	O
30	aflatoxins	O
31	from	O
32	0	O
33	.	O
34	1	O
35	to	O
36	450	O
37	mg	O
38	/	O
39	kg	O
40	.	O
1	In	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	the	O
8	PERE	O
9	formed	O
10	three	O
11	major	O
12	complexes	O
13	(	O
14	P1	O
15	,	O
16	P2	O
17	and	O
18	P3	O
19	)	O
20	with	O
21	proteins	O
22	in	O
23	nuclear	O
24	extracts	O
25	from	O
26	HeLa	O
27	or	O
28	293	O
29	cells	O
30	.	O
1	She	O
2	had	O
3	been	O
4	receiving	O
5	MTX	O
6	7	O
7	.	O
8	5	O
9	mg	O
10	/	O
11	week	O
12	for	O
13	2	O
14	.	O
15	5	O
16	months	O
17	because	O
18	of	O
19	her	O
20	vasculitis	O
21	symptoms	O
22	.	O
1	Analysis	O
2	of	O
3	the	O
4	sequence	O
5	identified	O
6	four	O
7	open	O
8	reading	O
9	frames	O
10	(	O
11	ORFs	O
12	)	O
13	which	O
14	are	O
15	designated	O
16	UL1	O
17	,	O
18	UL2	O
19	,	O
20	UL3	O
21	,	O
22	and	O
23	UL3	O
24	.	O
25	5	O
26	based	O
27	on	O
28	their	O
29	homology	O
30	with	O
31	proteins	O
32	of	O
33	herpes	O
34	simplex	O
35	virus	O
36	-	O
37	1	O
38	(	O
39	HSV	O
40	-	O
41	1	O
42	),	O
43	pseudorabies	O
44	virus	O
45	(	O
46	PRV	O
47	),	O
48	equine	O
49	herpesvirus	O
50	-	O
51	1	O
52	,	O
53	and	O
54	varicella	O
55	-	O
56	zoster	O
57	virus	O
58	.	O
1	The	O
2	translation	O
3	products	O
4	of	O
5	both	O
6	clones	O
7	are	O
8	highly	O
9	homologous	O
10	to	O
11	APS1	O
12	(	O
13	66	O
14	and	O
15	86	O
16	%	O
17	identity	O
18	,	O
19	respectively	O
20	)	O
21	over	O
22	their	O
23	entire	O
24	lengths	O
25	,	O
26	including	O
27	amino	O
28	terminal	O
29	sequences	O
30	resembling	O
31	transit	O
32	peptides	O
33	for	O
34	plastid	O
35	localization	O
36	.	O
1	Two	O
2	experiments	O
3	investigating	O
4	the	O
5	effects	O
6	of	O
7	short	O
8	-	O
9	term	O
10	spaceflight	O
11	on	O
12	cancellous	O
13	bone	O
14	turnover	O
15	were	O
16	carried	O
17	out	O
18	:	O
19	Physiological	O
20	Systems	O
21	Experiment	O
22	-	O
23	1	O
24	(	O
25	PSE	O
26	-	O
27	1	O
28	)	O
29	(	O
30	a	O
31	4	O
32	-	O
33	d	O
34	orbital	O
35	spaceflight	O
36	)	O
37	and	O
38	PSE	O
39	-	O
40	2	O
41	(	O
42	a	O
43	10	O
44	-	O
45	d	O
46	flight	O
47	).	O
1	The	O
2	influenza	O
3	virus	O
4	NS1	O
5	protein	O
6	is	O
7	a	O
8	unique	O
9	posttranscriptional	O
10	regulator	O
11	that	O
12	has	O
13	two	O
14	activities	O
15	:	O
16	inhibition	O
17	of	O
18	the	O
19	nuclear	O
20	export	O
21	of	O
22	poly	O
23	A	O
24	-	O
25	containing	O
26	mRNAs	O
27	and	O
28	inhibition	O
29	of	O
30	pre	O
31	-	O
32	mRNA	O
33	splicing	O
34	.	O
1	In	O
2	the	O
3	absence	O
4	of	O
5	E1A243	O
6	,	O
7	YY1	O
8	represses	O
9	CRE	O
10	-	O
11	dependent	O
12	transcription	O
13	of	O
14	c	B
15	-	O
16	fos	O
17	by	O
18	physically	O
19	interacting	O
20	with	O
21	ATF	O
22	/	O
23	CREB	O
24	proteins	O
25	bound	O
26	to	O
27	the	O
28	-	O
29	67	O
30	CRE	O
31	.	O
1	Results	O
2	of	O
3	the	O
4	ECAT	O
5	Angina	O
6	Pectoris	O
7	Study	O
8	Group	O
9	.	O
1	In	O
2	contrast	O
3	with	O
4	the	O
5	previously	O
6	reported	O
7	HMGR1	O
8	mRNA	O
9	(	O
10	HMGR1S	O
11	mRNA	O
12	),	O
13	which	O
14	is	O
15	detected	O
16	at	O
17	high	O
18	levels	O
19	in	O
20	all	O
21	tissues	O
22	of	O
23	the	O
24	plant	O
25	,	O
26	HMGR1L	O
27	mRNA	O
28	is	O
29	present	O
30	at	O
31	relatively	O
32	low	O
33	levels	O
34	and	O
35	its	O
36	expression	O
37	is	O
38	restricted	O
39	mostly	O
40	to	O
41	seedlings	O
42	,	O
43	roots	O
44	and	O
45	inflorescences	O
46	.	O
1	High	O
2	ADR1	O
3	gene	O
4	dosage	O
5	increased	O
6	the	O
7	transcription	O
8	of	O
9	genes	O
10	encoding	O
11	peroxisomal	O
12	proteins	O
13	as	O
14	compared	O
15	to	O
16	one	O
17	copy	O
18	of	O
19	the	O
20	ADR1	O
21	gene	O
22	.	O
1	A	O
2	platelet	O
3	-	O
4	derived	O
5	growth	O
6	factor	O
7	receptor	B
8	(	O
9	PDGF	O
10	-	O
11	R	O
12	)	O
13	phosphopeptide	O
14	containing	O
15	Tyr	O
16	-	O
17	857	O
18	does	O
19	not	O
20	bind	O
21	appreciably	O
22	to	O
23	the	O
24	Src	O
25	SH2	O
26	domain	O
27	,	O
28	suggesting	O
29	it	O
30	is	O
31	not	O
32	the	O
33	PDGF	O
34	-	O
35	R	O
36	binding	O
37	site	O
38	for	O
39	Src	O
40	as	O
41	previously	O
42	reported	O
43	.	O
1	The	O
2	early	O
3	lethality	O
4	of	O
5	the	O
6	left	O
7	-	O
8	sided	O
9	resectio	O
10	was	O
11	0	O
12	%	O
13	and	O
14	the	O
15	postoperative	O
16	survival	O
17	--	O
18	5	O
19	-	O
20	10	O
21	months	O
22	.	O
1	There	O
2	are	O
3	two	O
4	immunogenic	O
5	sites	O
6	on	O
7	the	O
8	type	O
9	A	O
10	influenza	O
11	A	O
12	/	O
13	Japan	O
14	/	O
15	57	O
16	(	O
17	H2N2	O
18	)	O
19	hemagglutinin	O
20	(	O
21	HA	O
22	)	O
23	that	O
24	can	O
25	be	O
26	recognized	O
27	by	O
28	class	O
29	I	O
30	major	O
31	histocompatibility	O
32	complex	O
33	(	O
34	MHC	O
35	),	O
36	H	O
37	-	O
38	2Kd	O
39	-	O
40	restricted	O
41	cytolytic	O
42	T	O
43	lymphocytes	O
44	(	O
45	CTLs	O
46	).	O
1	The	O
2	avidin	O
3	-	O
4	biotin	O
5	complex	O
6	peroxidase	O
7	(	O
8	ABC	O
9	-	O
10	P	O
11	)	O
12	method	O
13	was	O
14	used	O
15	to	O
16	detect	O
17	Mycobacterium	O
18	bovis	O
19	,	O
20	and	O
21	the	O
22	results	O
23	were	O
24	compared	O
25	with	O
26	those	O
27	obtained	O
28	by	O
29	the	O
30	Ziehl	O
31	-	O
32	Neelsen	O
33	(	O
34	ZN	O
35	)	O
36	technique	O
37	.	O
1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O
1	One	O
2	antibody	O
3	,	O
4	mAb1C2	O
5	,	O
6	and	O
7	a	O
8	synthetic	O
9	peptide	O
10	comprising	O
11	its	O
12	epitope	O
13	selectively	O
14	inhibited	O
15	in	O
16	vitro	O
17	transcription	O
18	from	O
19	TATA	O
20	-	O
21	containing	O
22	,	O
23	but	O
24	not	O
25	from	O
26	TATA	O
27	-	O
28	less	O
29	promoters	O
30	,	O
31	irrespective	O
32	of	O
33	whether	O
34	they	O
35	were	O
36	transcribed	O
37	by	O
38	Pol	O
39	II	O
40	or	O
41	Pol	O
42	III	O
43	.	O
1	Anti	O
2	-	O
3	NPROSP	O
4	-	O
5	C	O
6	also	O
7	exclusively	O
8	detected	O
9	time	O
10	-	O
11	dependent	O
12	appearances	O
13	of	O
14	5	O
15	-	O
16	10	O
17	-	O
18	kDa	O
19	proSP	O
20	-	O
21	C	O
22	forms	O
23	in	O
24	lamellar	O
25	bodies	O
26	and	O
27	homogenates	O
28	.	O
1	In	O
2	the	O
3	B6	O
4	-	O
5	derived	O
6	Db	O
7	mutant	O
8	B6	O
9	.	O
10	CH	O
11	-	O
12	2bm13	O
13	(	O
14	bm13	O
15	)	O
16	strain	O
17	,	O
18	part	O
19	of	O
20	the	O
21	class	O
22	I	O
23	Db	O
24	antigen	B
25	-	O
26	presenting	O
27	groove	O
28	is	O
29	shaped	O
30	by	O
31	a	O
32	class	O
33	I	O
34	Kb	O
35	-	O
36	encoded	O
37	sequence	O
38	.	O
1	Three	O
2	mutants	O
3	(	O
4	pms1	O
5	,	O
6	pms2	O
7	and	O
8	pms3	O
9	)	O
10	isolated	O
11	earlier	O
12	from	O
13	MW104	O
14	-	O
15	1B	O
16	were	O
17	shown	O
18	to	O
19	correct	O
20	in	O
21	vitro	O
22	constructed	O
23	plasmids	O
24	with	O
25	defined	O
26	DNA	O
27	mismatches	O
28	(	O
29	G	O
30	/	O
31	T	O
32	,	O
33	A	O
34	/	O
35	C	O
36	,	O
37	G	O
38	/	O
39	G	O
40	,	O
41	etc	O
42	.)	O
43	poorly	O
44	(	O
45	Kramer	O
46	et	O
47	al	O
48	.,	O
49	1989a	O
50	).	O
1	However	O
2	,	O
3	expression	O
4	of	O
5	sigma	O
6	3	O
7	from	O
8	S4	O
9	(	O
10	3	O
11	'	O
12	UTR	O
13	/	O
14	S1	O
15	),	O
16	which	O
17	included	O
18	the	O
19	PKR	O
20	activator	O
21	sequence	O
22	from	O
23	S1	O
24	within	O
25	the	O
26	3	O
27	'-	O
28	UTR	O
29	of	O
30	S4	O
31	,	O
32	was	O
33	comparable	O
34	to	O
35	that	O
36	from	O
37	wild	O
38	-	O
39	type	O
40	S4	O
41	.	O
1	Phosphoamino	O
2	acid	O
3	analysis	O
4	of	O
5	radiolabeled	O
6	ASGPR	O
7	subunits	O
8	identified	O
9	Ser	O
10	(	O
11	P	O
12	)	O
13	as	O
14	the	O
15	predominant	O
16	(	O
17	approximately	O
18	95	O
19	%)	O
20	and	O
21	Thr	O
22	(	O
23	P	O
24	)	O
25	as	O
26	a	O
27	minor	O
28	(	O
29	approximately	O
30	5	O
31	%)	O
32	phosphoamino	O
33	acid	O
34	in	O
35	each	O
36	polypeptide	O
37	and	O
38	confirmed	O
39	the	O
40	presence	O
41	of	O
42	Tyr	O
43	(	O
44	P	O
45	)	O
46	(	O
47	approximately	O
48	1	O
49	%)	O
50	in	O
51	RHL1	O
52	.	O
1	The	O
2	three	O
3	-	O
4	dimensional	O
5	structure	O
6	of	O
7	RT	O
8	shows	O
9	that	O
10	it	O
11	is	O
12	a	O
13	strikingly	O
14	asymmetric	O
15	heterodimer	O
16	consisting	O
17	of	O
18	two	O
19	differently	O
20	folded	O
21	subunits	O
22	(	O
23	molecular	O
24	weights	O
25	66	O
26	kDa	O
27	and	O
28	51	O
29	kDa	O
30	)	O
31	with	O
32	identical	O
33	amino	O
34	-	O
35	terminal	O
36	amino	O
37	acid	O
38	sequences	O
39	(	O
40	residues	O
41	1	O
42	-	O
43	428	O
44	).	O
1	Horvath	O
2	,	O
3	I	O
4	.	O
1	We	O
2	linked	O
3	a	O
4	4	O
5	.	O
6	1	O
7	-	O
8	kilobase	O
9	pair	O
10	HindIII	O
11	DNA	O
12	fragment	O
13	from	O
14	the	O
15	region	O
16	upstream	O
17	of	O
18	the	O
19	human	O
20	AP	B
21	endonuclease	O
22	gene	O
23	(	O
24	APE	O
25	)	O
26	to	O
27	the	O
28	chloramphenicol	O
29	acetyltransferase	O
30	(	O
31	CAT	O
32	)	O
33	gene	O
34	.	O
1	The	O
2	overexpressed	O
3	His6	O
4	-	O
5	tagged	O
6	GrsA	O
7	derivatives	O
8	were	O
9	affinity	O
10	-	O
11	purified	O
12	,	O
13	and	O
14	the	O
15	catalytic	O
16	properties	O
17	of	O
18	the	O
19	deletion	O
20	mutants	O
21	were	O
22	examined	O
23	by	O
24	biochemical	O
25	studies	O
26	including	O
27	ATP	O
28	-	O
29	dependent	O
30	amino	O
31	acid	O
32	activation	O
33	,	O
34	carboxyl	O
35	thioester	O
36	formation	O
37	,	O
38	and	O
39	the	O
40	ability	O
41	to	O
42	racemize	O
43	the	O
44	covalently	O
45	bound	O
46	phenylalanine	O
47	from	O
48	L	O
49	-	O
50	to	O
51	the	O
52	D	O
53	-	O
54	isomer	O
55	.	O
1	MBP	O
2	-	O
3	Rep68	O
4	delta	B
5	-	O
6	mediated	O
7	DNA	O
8	-	O
9	RNA	O
10	helicase	O
11	activity	O
12	required	O
13	ATP	O
14	hydrolysis	O
15	and	O
16	the	O
17	presence	O
18	of	O
19	Mg2	O
20	+	O
21	ions	O
22	and	O
23	was	O
24	inhibited	O
25	by	O
26	high	O
27	ionic	O
28	strength	O
29	.	O
1	When	O
2	combined	O
3	with	O
4	independent	O
5	activating	O
6	mutations	O
7	in	O
8	the	O
9	c	B
10	-	O
11	abl	O
12	kinase	B
13	domain	O
14	or	O
15	NH2	O
16	-	O
17	terminus	O
18	,	O
19	the	O
20	G128R	O
21	mutation	O
22	blocked	O
23	transformation	O
24	by	O
25	the	O
26	double	O
27	mutant	O
28	,	O
29	suggesting	O
30	that	O
31	the	O
32	G128R	O
33	mutant	O
34	was	O
35	unable	O
36	to	O
37	transform	O
38	cells	O
39	for	O
40	trivial	O
41	reasons	O
42	.	O
1	Sequence	O
2	analysis	O
3	of	O
4	these	O
5	regions	O
6	showed	O
7	a	O
8	CAAT	O
9	box	O
10	upstream	O
11	of	O
12	exon	O
13	1a	O
14	and	O
15	high	O
16	G	O
17	-	O
18	C	O
19	content	O
20	regions	O
21	within	O
22	both	O
23	P1	O
24	and	O
25	P2	O
26	.	O
1	In	O
2	on	O
3	-	O
4	going	O
5	screening	O
6	programmes	O
7	,	O
8	the	O
9	Haemoccult	O
10	test	O
11	consists	O
12	of	O
13	six	O
14	slides	O
15	and	O
16	a	O
17	test	O
18	is	O
19	considered	O
20	positive	O
21	if	O
22	at	O
23	least	O
24	one	O
25	slide	O
26	is	O
27	coloured	O
28	.	O
1	METHODS	O
2	:	O
3	rHb1	O
4	.	O
5	1	O
6	or	O
7	human	O
8	serum	O
9	albumin	O
10	was	O
11	administered	O
12	intravenously	O
13	to	O
14	fasting	O
15	male	O
16	volunteers	O
17	.	O
1	Alanine	O
2	aminotransferase	O
3	(	O
4	ALT	O
5	)	O
6	levels	O
7	had	O
8	been	O
9	elevated	O
10	for	O
11	six	O
12	months	O
13	in	O
14	all	O
15	patients	O
16	and	O
17	hepatitis	O
18	B	O
19	viral	O
20	infection	O
21	was	O
22	replicative	O
23	.	O
1	In	O
2	this	O
3	study	O
4	we	O
5	have	O
6	investigated	O
7	the	O
8	role	O
9	of	O
10	C	O
11	/	O
12	EBP	O
13	beta	B
14	in	O
15	initiating	O
16	the	O
17	adipogenic	O
18	program	O
19	by	O
20	overexpressing	O
21	C	O
22	/	O
23	EBP	O
24	beta	B
25	in	O
26	multipotential	O
27	NIH	O
28	-	O
29	3T3	O
30	fibroblasts	O
31	.	O
1	However	O
2	,	O
3	division	O
4	of	O
5	the	O
6	chest	O
7	wall	O
8	muscles	O
9	,	O
10	usually	O
11	with	O
12	diathermy	O
13	,	O
14	contributes	O
15	to	O
16	prolonged	O
17	pain	O
18	and	O
19	morbidity	O
20	.	O
1	Closure	O
2	of	O
3	an	O
4	open	O
5	high	O
6	below	O
7	-	O
8	knee	O
9	guillotine	O
10	amputation	O
11	wound	O
12	using	O
13	a	O
14	skin	O
15	-	O
16	stretching	O
17	device	O
18	.	O
1	Citrate	O
2	synthase	O
3	activity	O
4	was	O
5	increased	O
6	in	O
7	the	O
8	medial	O
9	head	O
10	(	O
11	81	O
12	%,	O
13	P	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	and	O
20	the	O
21	red	O
22	long	O
23	head	O
24	(	O
25	88	O
26	%,	O
27	P	O
28	<	O
29	0	O
30	.	O
31	001	O
32	)	O
33	of	O
34	the	O
35	triceps	O
36	brachii	O
37	muscle	O
38	in	O
39	R	O
40	rats	O
41	but	O
42	not	O
43	in	O
44	the	O
45	white	O
46	long	O
47	head	O
48	(	O
49	25	O
50	%,	O
51	P	O
52	=	O
53	0	O
54	.	O
55	06	O
56	).	O
1	Control	O
2	experiments	O
3	showed	O
4	that	O
5	each	O
6	fusion	O
7	protein	O
8	had	O
9	a	O
10	high	O
11	affinity	O
12	binding	O
13	site	O
14	for	O
15	estradiol	O
16	-	O
17	17	O
18	beta	B
19	and	O
20	could	O
21	transactivate	O
22	an	O
23	ERE	O
24	-	O
25	LacZ	O
26	reporter	O
27	gene	O
28	in	O
29	yeast	O
30	similar	O
31	to	O
32	the	O
33	wild	O
34	type	O
35	ER	O
36	.	O
1	Although	O
2	Micrococcus	O
3	luteus	O
4	UV	O
5	endonuclease	O
6	has	O
7	been	O
8	reported	O
9	to	O
10	be	O
11	an	O
12	18	O
13	-	O
14	kDa	O
15	enzyme	O
16	with	O
17	possible	O
18	homology	O
19	to	O
20	the	O
21	16	O
22	-	O
23	kDa	O
24	endonuclease	O
25	V	O
26	from	O
27	bacteriophage	O
28	T4	O
29	(	O
30	Gordon	O
31	,	O
32	L	O
33	.	O
1	Indeed	O
2	,	O
3	ERM	O
4	and	O
5	c	B
6	-	O
7	Jun	O
8	synergistically	O
9	activated	O
10	the	O
11	EBS	O
12	-	O
13	CRE	O
14	without	O
15	making	O
16	an	O
17	apparent	O
18	ternary	O
19	complex	O
20	.	O
1	A	O
2	mutant	O
3	(	O
4	residues	O
5	1	O
6	-	O
7	332	O
8	)	O
9	showed	O
10	complete	O
11	Ca2	O
12	+/	O
13	CaM	O
14	-	O
15	dependent	O
16	activity	O
17	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	PCNA	O
7	gene	O
8	is	O
9	a	O
10	likely	O
11	target	O
12	gene	O
13	of	O
14	E2F	O
15	.	O
1	The	O
2	range	O
3	of	O
4	eosinophils	O
5	was	O
6	22	O
7	-	O
8	56	O
9	%	O
10	of	O
11	the	O
12	number	O
13	of	O
14	peripheral	O
15	white	O
16	blood	O
17	cells	O
18	(	O
19	mean	O
20	nadir	O
21	33	O
22	%).	O
1	The	O
2	patients	O
3	undergoing	O
4	VTLB	O
5	had	O
6	significantly	O
7	shorter	O
8	operative	O
9	times	O
10	(	O
11	VTLB	O
12	,	O
13	100	O
14	.	O
15	2	O
16	+/-	O
17	27	O
18	.	O
19	2	O
20	min	O
21	.	O
22	vs	O
23	OLB	O
24	,	O
25	119	O
26	.	O
27	8	O
28	+/-	O
29	42	O
30	.	O
31	6	O
32	min	O
33	;	O
34	p	O
35	<	O
36	0	O
37	.	O
38	01	O
39	)	O
40	and	O
41	less	O
42	blood	O
43	loss	O
44	(	O
45	VTLB	O
46	,	O
47	4	O
48	.	O
49	7	O
50	+/-	O
51	14	O
52	.	O
53	6	O
54	ml	O
55	vs	O
56	OLB	O
57	,	O
58	65	O
59	.	O
60	7	O
61	+/-	O
62	77	O
63	.	O
64	0	O
65	ml	O
66	;	O
67	p	O
68	<	O
69	0	O
70	.	O
71	001	O
72	).	O
1	Twenty	O
2	food	O
3	products	O
4	were	O
5	contaminated	O
6	with	O
7	V	O
8	.	O
9	cholerae	O
10	O1	O
11	,	O
12	Ogawa	O
13	,	O
14	toxigenic	O
15	and	O
16	not	O
17	toxigenic	O
18	strains	O
19	:	O
20	yoghurt	O
21	,	O
22	cream	O
23	cheese	O
24	,	O
25	apricot	O
26	marmelade	O
27	,	O
28	hip	O
29	rose	O
30	marmelade	O
31	,	O
32	mayonnaise	O
33	,	O
34	italian	O
35	pasta	O
36	for	O
37	""""	O
38	empanadas	O
39	""","	O
40	""""	O
41	dulce	O
42	de	O
43	leche	O
44	""","	O
45	meat	O
46	sausage	O
47	,	O
48	meat	O
49	and	O
50	spinach	O
51	ravioli	O
52	,	O
53	margarine	O
54	,	O
55	milk	O
56	dessert	O
57	(	O
58	made	O
59	with	O
60	cocoa	O
61	,	O
62	milk	O
63	confiture	O
64	,	O
65	starch	O
66	and	O
67	additives	O
68	),	O
69	lettuce	O
70	,	O
71	tuna	O
72	fish	O
73	,	O
74	ricotta	O
75	and	O
76	sterilized	O
77	milk	O
78	.	O
1	The	O
2	chloramphenicol	O
3	-	O
4	resistance	O
5	transposon	O
6	Tn4451	O
7	undergoes	O
8	precise	O
9	conjugative	O
10	deletion	O
11	from	O
12	its	O
13	parent	O
14	plasmid	O
15	plP401	O
16	in	O
17	Clostridium	O
18	perfringens	O
19	and	O
20	precise	O
21	spontaneous	O
22	excision	O
23	from	O
24	multicopy	O
25	plasmids	O
26	in	O
27	Escherichia	O
28	coli	O
29	.	O
1	Deletions	O
2	were	O
3	examined	O
4	in	O
5	the	O
6	LYS2	O
7	gene	O
8	,	O
9	using	O
10	a	O
11	set	O
12	of	O
13	31	O
14	-	O
15	to	O
16	156	O
17	-	O
18	bp	O
19	inserts	O
20	that	O
21	included	O
22	inserts	O
23	with	O
24	no	O
25	apparent	O
26	potential	O
27	for	O
28	secondary	O
29	structure	O
30	as	O
31	well	O
32	as	O
33	two	O
34	quasipalindromes	O
35	.	O
1	Finally	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	C	O
7	/	O
8	EBP	O
9	alpha	B
10	can	O
11	also	O
12	active	O
13	the	O
14	GM	O
15	-	O
16	CSF	B
17	receptor	I
18	alpha	I
19	promoter	O
20	in	O
21	nonmyeloid	O
22	cells	O
23	.	O
1	The	O
2	Stat5b	O
3	mRNA	O
4	has	O
5	a	O
6	size	O
7	of	O
8	5	O
9	.	O
10	6	O
11	kb	O
12	and	O
13	encodes	O
14	a	O
15	protein	O
16	of	O
17	786	O
18	amino	O
19	acids	O
20	.	O
1	Negative	O
2	-	O
3	staining	O
4	,	O
5	refractile	O
6	mycobacteria	O
7	in	O
8	Romanowsky	O
9	-	O
10	stained	O
11	smears	O
12	.	O
1	Here	O
2	we	O
3	focused	O
4	on	O
5	the	O
6	role	O
7	of	O
8	the	O
9	5	O
10	'	O
11	proximal	O
12	regulatory	O
13	cassette	O
14	(-	O
15	190	O
16	;	O
17	+	O
18	53	O
19	bp	O
20	)	O
21	of	O
22	the	O
23	rat	O
24	enkephalin	O
25	(	O
26	rENK	O
27	)	O
28	gene	O
29	in	O
30	the	O
31	developmental	O
32	regulation	O
33	of	O
34	the	O
35	enkephalin	O
36	phenotype	O
37	.	O
1	Estimated	O
2	daily	O
3	intakes	O
4	(	O
5	EDIs	O
6	)	O
7	per	O
8	person	O
9	were	O
10	0	O
11	.	O
12	56	O
13	microgram	O
14	for	O
15	total	O
16	HCH	O
17	,	O
18	0	O
19	.	O
20	20	O
21	microgram	O
22	for	O
23	gamma	B
24	-	O
25	HCH	O
26	,	O
27	0	O
28	.	O
29	09	O
30	microgram	O
31	for	O
32	dieldrin	O
33	,	O
34	1	O
35	.	O
36	42	O
37	micrograms	O
38	for	O
39	total	O
40	DDT	O
41	,	O
42	and	O
43	0	O
44	.	O
45	15	O
46	microgram	O
47	for	O
48	HCB	O
49	.	O
1	HRES	O
2	has	O
3	been	O
4	found	O
5	to	O
6	be	O
7	clinically	O
8	useful	O
9	in	O
10	assessing	O
11	histologic	O
12	damage	O
13	following	O
14	pneumatic	O
15	dilatation	O
16	and	O
17	in	O
18	localizing	O
19	the	O
20	LES	O
21	during	O
22	the	O
23	administration	O
24	of	O
25	intrasphincter	O
26	botulinum	O
27	toxin	O
28	injection	O
29	in	O
30	the	O
31	treatment	O
32	of	O
33	achalasia	O
34	.	O
1	In	O
2	men	O
3	with	O
4	BMI	O
5	<	O
6	30	O
7	,	O
8	the	O
9	OR	O
10	was	O
11	1	O
12	.	O
13	83	O
14	for	O
15	postprandial	O
16	TG	O
17	(	O
18	P	O
19	=	O
20	.	O
21	041	O
22	)	O
23	and	O
24	2	O
25	.	O
26	77	O
27	for	O
28	postprandial	O
29	RP	O
30	(	O
31	P	O
32	=	O
33	.	O
34	032	O
35	)	O
36	in	O
37	models	O
38	that	O
39	included	O
40	fasting	O
41	TG	O
42	,	O
43	LDL	O
44	-	O
45	C	O
46	,	O
47	and	O
48	hypertension	O
49	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	these	O
6	relations	O
7	,	O
8	a	O
9	risk	O
10	factor	O
11	-	O
12	selection	O
13	scale	O
14	(	O
15	RFSS	O
16	)	O
17	(	O
18	range	O
19	,	O
20	0	O
21	to	O
22	10	O
23	)	O
24	was	O
25	developed	O
26	by	O
27	computing	O
28	appropriate	O
29	weights	O
30	for	O
31	each	O
32	risk	O
33	factor	O
34	.	O
1	The	O
2	Caenorhabditis	O
3	elegans	O
4	death	O
5	susceptibility	O
6	gene	O
7	,	O
8	ced	O
9	-	O
10	3	O
11	,	O
12	has	O
13	a	O
14	number	O
15	of	O
16	homologs	O
17	in	O
18	vertebrate	O
19	species	O
20	,	O
21	including	O
22	interleukin	O
23	-	O
24	1	O
25	beta	B
26	(	O
27	IL	B
28	-	O
29	1	O
30	beta	B
31	)-	O
32	converting	O
33	enzyme	O
34	(	O
35	ICE	O
36	),	O
37	Ich	O
38	-	O
39	1long	O
40	,	O
41	and	O
42	CPP32	O
43	.	O
1	Repression	O
2	of	O
3	glucocorticoid	O
4	receptor	B
5	-	O
6	mediated	O
7	transcriptional	O
8	activation	O
9	by	O
10	unliganded	O
11	thyroid	O
12	hormone	O
13	receptor	B
14	(	O
15	TR	O
16	)	O
17	is	O
18	TR	O
19	isoform	O
20	-	O
21	specific	O
22	.	O
1	The	O
2	finding	O
3	that	O
4	the	O
5	chimeric	O
6	TdT	O
7	::	O
8	Pol	O
9	beta	B
10	protein	O
11	possessed	O
12	significant	O
13	template	O
14	-	O
15	dependent	O
16	polymerase	B
17	activity	O
18	suggests	O
19	that	O
20	aa	O
21	1	O
22	-	O
23	60	O
24	of	O
25	Pol	O
26	beta	B
27	are	O
28	involved	O
29	in	O
30	template	O
31	utilization	O
32	during	O
33	the	O
34	polymerization	O
35	reaction	O
36	,	O
37	as	O
38	suggested	O
39	by	O
40	the	O
41	previous	O
42	finding	O
43	that	O
44	the	O
45	8	O
46	-	O
47	kDa	O
48	N	O
49	-	O
50	terminal	O
51	domain	O
52	of	O
53	Pol	O
54	beta	B
55	possesses	O
56	ssDNA	O
57	-	O
58	binding	O
59	activity	O
60	[	O
61	Kumar	O
62	et	O
63	al	O
64	.,	O
65	J	O
66	.	O
1	A511	O
2	is	O
3	a	O
4	broad	O
5	-	O
6	host	O
7	-	O
8	range	O
9	,	O
10	virulent	O
11	myovirus	O
12	for	O
13	Listeria	O
14	monocytogenes	O
15	.	O
1	The	O
2	single	O
3	-	O
4	stranded	O
5	DNA	O
6	Pur	O
7	alpha	B
8	recognition	O
9	element	O
10	disrupts	O
11	these	O
12	complexes	O
13	.	O
1	The	O
2	interferon	O
3	-	O
4	inducible	O
5	protein	O
6	kinase	B
7	PKR	O
8	modulates	O
9	the	O
10	transcriptional	O
11	activation	O
12	of	O
13	immunoglobulin	O
14	kappa	B
15	gene	O
16	.	O
1	Two	O
2	domains	O
3	of	O
4	EBNA2	O
5	defined	O
6	by	O
7	deletion	O
8	of	O
9	amino	O
10	acids	O
11	247	O
12	-	O
13	337	O
14	and	O
15	437	O
16	-	O
17	476	O
18	were	O
19	found	O
20	to	O
21	be	O
22	important	O
23	for	O
24	the	O
25	activation	O
26	of	O
27	both	O
28	promoters	O
29	,	O
30	while	O
31	two	O
32	different	O
33	domains	O
34	corresponding	O
35	to	O
36	residues	O
37	4	O
38	-	O
39	18	O
40	and	O
41	118	O
42	-	O
43	198	O
44	were	O
45	required	O
46	solely	O
47	for	O
48	the	O
49	LMP1	O
50	promoter	O
51	.	O
1	By	O
2	in	O
3	vitro	O
4	immunoprecipitations	O
5	and	O
6	gel	O
7	shift	O
8	assays	O
9	,	O
10	we	O
11	identified	O
12	two	O
13	classes	O
14	of	O
15	high	O
16	affinity	O
17	Engrailed	O
18	-	O
19	binding	O
20	sites	O
21	upstream	O
22	of	O
23	each	O
24	of	O
25	the	O
26	two	O
27	polyhomeotic	O
28	transcription	O
29	units	O
30	.	O
1	Benefits	O
2	of	O
3	obtaining	O
4	board	O
5	certification	O
6	in	O
7	pharmacotherapy	O
8	.	O
1	The	O
2	structural	O
3	gene	O
4	encoding	O
5	the	O
6	novel	O
7	lantibiotic	O
8	epilancin	O
9	K7	O
10	from	O
11	Staphylococcus	O
12	epidermidis	O
13	K7	O
14	was	O
15	cloned	O
16	and	O
17	its	O
18	nucleotide	O
19	sequence	O
20	was	O
21	determined	O
22	.	O
1	Analysis	O
2	of	O
3	several	O
4	Tat	O
5	mutants	O
6	indicated	O
7	that	O
8	both	O
9	the	O
10	cysteine	O
11	-	O
12	rich	O
13	and	O
14	the	O
15	core	O
16	domains	O
17	of	O
18	this	O
19	transactivator	O
20	are	O
21	necessary	O
22	and	O
23	sufficient	O
24	to	O
25	activate	O
26	transcription	O
27	when	O
28	TBP	O
29	is	O
30	overexpressed	O
31	.	O
1	The	O
2	cryptococcal	O
3	antigen	B
4	test	O
5	was	O
6	positive	O
7	at	O
8	1	O
9	:	O
10	125	O
11	by	O
12	latex	O
13	agglutination	O
14	.	O
1	These	O
2	transcripts	O
3	have	O
4	a	O
5	unique	O
6	5	O
7	'	O
8	untranslated	O
9	region	O
10	and	O
11	NH2	O
12	-	O
13	terminal	O
14	sequence	O
15	and	O
16	encode	O
17	a	O
18	predicted	O
19	protein	O
20	of	O
21	121	O
22	kD	O
23	.	O
1	They	O
2	include	O
3	genes	O
4	encoding	O
5	three	O
6	subunits	O
7	of	O
8	the	O
9	cytochrome	O
10	oxidase	O
11	(	O
12	cox1	O
13	to	O
14	3	O
15	),	O
16	apocytochrome	O
17	b	O
18	(	O
19	cob	O
20	),	O
21	seven	O
22	subunits	O
23	of	O
24	the	O
25	NADH	O
26	dehydrogenase	O
27	complex	O
28	(	O
29	nad1	O
30	to	O
31	6	O
32	,	O
33	nad4L	O
34	),	O
35	two	O
36	ATPase	B
37	subunits	O
38	(	O
39	atp6	O
40	and	O
41	atp9	O
42	),	O
43	three	O
44	ribosomal	O
45	RNAs	O
46	(	O
47	rrn5	O
48	,	O
49	srn	O
50	and	O
51	lrn	O
52	),	O
53	23	O
54	tRNAs	O
55	and	O
56	four	O
57	ribosomal	O
58	proteins	O
59	(	O
60	rps3	O
61	,	O
62	rps11	O
63	,	O
64	rps12	O
65	and	O
66	rpl16	O
67	).	O
1	The	O
2	PEBP2	O
3	alpha	B
4	proteins	O
5	contain	O
6	a	O
7	128	O
8	-	O
9	amino	O
10	-	O
11	acid	O
12	(	O
13	aa	O
14	)	O
15	region	O
16	highly	O
17	homologous	O
18	to	O
19	the	O
20	Drosophila	O
21	melanogaster	O
22	segmentation	O
23	gene	O
24	runt	O
25	.	O
1	All	O
2	subjects	O
3	were	O
4	submitted	O
5	to	O
6	ECG	O
7	and	O
8	arterial	O
9	blood	O
10	pressure	O
11	determination	O
12	and	O
13	were	O
14	assayed	O
15	for	O
16	TSH	O
17	,	O
18	thyroid	O
19	hormone	O
20	,	O
21	PRL	O
22	,	O
23	glucose	O
24	,	O
25	creatinine	O
26	,	O
27	nitrogen	O
28	,	O
29	glutamine	O
30	transaminase	O
31	,	O
32	cholesterol	O
33	and	O
34	triglycerides	O
35	plasma	O
36	levels	O
37	before	O
38	therapy	O
39	(	O
40	T0	O
41	),	O
42	after	O
43	30	O
44	treatment	O
45	days	O
46	(	O
47	T30	O
48	)	O
49	and	O
50	after	O
51	a	O
52	15	O
53	days	O
54	washout	O
55	(	O
56	T45	O
57	).	O
1	For	O
2	Al	O
3	,	O
4	the	O
5	exposure	O
6	to	O
7	1	O
8	.	O
9	36	O
10	mg	O
11	/	O
12	m3	O
13	during	O
14	the	O
15	shift	O
16	corresponded	O
17	to	O
18	a	O
19	urinary	O
20	concentration	O
21	at	O
22	the	O
23	end	O
24	of	O
25	the	O
26	shift	O
27	of	O
28	200	O
29	microgram	O
30	/	O
31	g	O
32	creatinine	O
33	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	RA	O
6	and	O
7	E1A	O
8	induce	O
9	phosphorylation	O
10	of	O
11	the	O
12	E1A	O
13	-	O
14	associated	O
15	300	O
16	kDa	O
17	protein	O
18	(	O
19	p300	O
20	)	O
21	during	O
22	the	O
23	differentiation	O
24	of	O
25	F9	O
26	cells	O
27	.	O
1	CCAAT	O
2	/	O
3	enhancer	O
4	-	O
5	binding	O
6	protein	O
7	isoforms	O
8	beta	B
9	and	O
10	delta	B
11	are	O
12	expressed	O
13	in	O
14	mammary	O
15	epithelial	O
16	cells	O
17	and	O
18	bind	O
19	to	O
20	multiple	O
21	sites	O
22	in	O
23	the	O
24	beta	B
25	-	O
26	casein	O
27	gene	O
28	promoter	O
29	.	O
1	We	O
2	have	O
3	found	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	GTPase	B
9	-	O
10	deficient	O
11	mutants	O
12	of	O
13	alpha	B
14	12	O
15	(	O
16	alpha	B
17	12Q229L	O
18	)	O
19	or	O
20	alpha	B
21	13	O
22	(	O
23	alpha	B
24	13Q226L	O
25	)	O
26	leads	O
27	to	O
28	robust	O
29	activation	O
30	of	O
31	the	O
32	Jun	O
33	kinase	B
34	/	O
35	stress	O
36	-	O
37	activated	O
38	protein	O
39	kinase	B
40	(	O
41	JNK	O
42	/	O
43	SAPK	O
44	)	O
45	pathway	O
46	.	O
1	The	O
2	ARX2	O
3	procedure	O
4	models	O
5	the	O
6	recorded	O
7	signal	O
8	as	O
9	the	O
10	sum	O
11	of	O
12	three	O
13	signals	O
14	:	O
15	(	O
16	a	O
17	)	O
18	the	O
19	background	O
20	EEG	O
21	activity	O
22	,	O
23	modelled	O
24	as	O
25	an	O
26	autoregressive	O
27	process	O
28	driven	O
29	by	O
30	a	O
31	white	O
32	noise	O
33	;	O
34	(	O
35	b	O
36	)	O
37	a	O
38	filtered	O
39	version	O
40	of	O
41	a	O
42	reference	O
43	signal	O
44	carrying	O
45	the	O
46	average	O
47	information	O
48	contained	O
49	in	O
50	each	O
51	sweep	O
52	;	O
53	(	O
54	c	B
55	)	O
56	a	O
57	signal	O
58	due	O
59	to	O
60	the	O
61	ocular	O
62	artefact	O
63	propagation	O
64	.	O
1	The	O
2	expression	O
3	of	O
4	the	O
5	gene	O
6	encoding	O
7	the	O
8	enzyme	O
9	(	O
10	CYP19	O
11	)	O
12	is	O
13	regulated	O
14	,	O
15	in	O
16	part	O
17	,	O
18	by	O
19	tissue	O
20	-	O
21	specific	O
22	promoters	O
23	through	O
24	the	O
25	use	O
26	of	O
27	alternative	O
28	-	O
29	splicing	O
30	mechanisms	O
31	.	O
1	Consistent	O
2	with	O
3	the	O
4	protein	O
5	expression	O
6	data	O
7	,	O
8	V	O
9	beta	B
10	8	O
11	.	O
12	3	O
13	gene	O
14	transcripts	O
15	were	O
16	found	O
17	only	O
18	in	O
19	the	O
20	transgenic	O
21	lines	O
22	with	O
23	the	O
24	wild	O
25	-	O
26	type	O
27	promoter	O
28	.	O
1	We	O
2	also	O
3	show	O
4	that	O
5	in	O
6	fusions	O
7	with	O
8	the	O
9	DNA	O
10	binding	O
11	domain	O
12	of	O
13	GAL4	O
14	,	O
15	full	O
16	activity	O
17	requires	O
18	the	O
19	entire	O
20	BHV	O
21	-	O
22	alpha	B
23	TIF	O
24	,	O
25	although	O
26	both	O
27	amino	O
28	and	O
29	carboxyl	O
30	termini	O
31	display	O
32	some	O
33	activity	O
34	on	O
35	their	O
36	own	O
37	.	O
1	We	O
2	purified	O
3	both	O
4	proteins	O
5	from	O
6	human	O
7	platelet	O
8	membranes	O
9	using	O
10	DEAE	O
11	-	O
12	Sepharose	O
13	chromatography	O
14	followed	O
15	by	O
16	mAb	O
17	F11	O
18	affinity	O
19	chromatography	O
20	.	O
1	This	O
2	inhibition	O
3	can	O
4	be	O
5	overcome	O
6	by	O
7	mutating	O
8	either	O
9	the	O
10	exon	O
11	'	O
12	s	O
13	5	O
14	'	O
15	or	O
16	3	O
17	'	O
18	splice	O
19	site	O
20	to	O
21	make	O
22	it	O
23	correspond	O
24	more	O
25	closely	O
26	to	O
27	the	O
28	relevant	O
29	consensus	O
30	sequence	O
31	.	O
1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	the	O
6	expression	O
7	of	O
8	LIMK	O
9	-	O
10	1	O
11	mRNA	O
12	predominantly	O
13	in	O
14	the	O
15	brain	O
16	and	O
17	the	O
18	expression	O
19	of	O
20	LIMK	O
21	-	O
22	2	O
23	mRNA	O
24	in	O
25	various	O
26	tissues	O
27	in	O
28	the	O
29	rat	O
30	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	this	O
6	anatomic	O
7	concept	O
8	,	O
9	the	O
10	brachioplasty	O
11	procedure	O
12	was	O
13	modified	O
14	to	O
15	provide	O
16	secure	O
17	anchoring	O
18	of	O
19	the	O
20	arm	O
21	flap	O
22	to	O
23	the	O
24	axillary	O
25	fascia	O
26	along	O
27	with	O
28	strong	O
29	superficial	O
30	fascial	O
31	system	O
32	repair	O
33	of	O
34	incisions	O
35	,	O
36	reducing	O
37	the	O
38	risk	O
39	of	O
40	widening	O
41	or	O
42	migration	O
43	of	O
44	scars	O
45	and	O
46	unnatural	O
47	contours	O
48	.	O
1	The	O
2	transport	O
3	of	O
4	a	O
5	genetically	O
6	engineered	O
7	chimeric	O
8	transmembrane	O
9	protein	O
10	connected	O
11	to	O
12	this	O
13	ER	O
14	leader	O
15	sequence	O
16	was	O
17	as	O
18	efficient	O
19	as	O
20	that	O
21	of	O
22	the	O
23	original	O
24	protein	O
25	from	O
26	which	O
27	the	O
28	ER	O
29	sequence	O
30	has	O
31	been	O
32	derived	O
33	.	O
1	The	O
2	plant	O
3	hormone	O
4	auxin	O
5	transcriptionally	O
6	activates	O
7	early	O
8	genes	O
9	.	O
1	The	O
2	test	O
3	was	O
4	not	O
5	performed	O
6	in	O
7	3923	O
8	patients	O
9	because	O
10	of	O
11	contraindications	O
12	.	O
1	We	O
2	used	O
3	deletion	O
4	analysis	O
5	and	O
6	transfection	O
7	assays	O
8	with	O
9	reporter	O
10	gene	O
11	constructs	O
12	to	O
13	examine	O
14	the	O
15	transcription	O
16	control	O
17	elements	O
18	in	O
19	the	O
20	5	O
21	'	O
22	flanking	O
23	region	O
24	of	O
25	the	O
26	human	O
27	EpoR	O
28	gene	O
29	.	O
1	All	O
2	clinical	O
3	isolates	O
4	were	O
5	concomitantly	O
6	tested	O
7	by	O
8	disk	O
9	diffusion	O
10	and	O
11	agar	O
12	dilution	O
13	procedures	O
14	as	O
15	outlined	O
16	by	O
17	the	O
18	National	O
19	Committee	O
20	for	O
21	Clinical	O
22	Laboratory	O
23	Standards	O
24	.	O
1	The	O
2	properties	O
3	of	O
4	the	O
5	phi	O
6	29	O
7	SSB	O
8	-	O
9	ssDNA	O
10	complex	O
11	are	O
12	described	O
13	.	O
1	Genomic	O
2	structure	O
3	and	O
4	chromosomal	O
5	location	O
6	of	O
7	the	O
8	mouse	O
9	pre	O
10	-	O
11	T	O
12	-	O
13	cell	O
14	receptor	B
15	alpha	I
16	gene	O
17	.	O
1	These	O
2	clones	O
3	were	O
4	found	O
5	to	O
6	share	O
7	a	O
8	common	O
9	domain	O
10	encoded	O
11	by	O
12	p	O
13	(	O
14	CA	O
15	)	O
16	n	O
17	repeats	O
18	;	O
19	a	O
20	simple	O
21	sequence	O
22	length	O
23	polymorphism	O
24	(	O
25	SSLP	O
26	).	O
1	The	O
2	TAF	O
3	factor	O
4	appears	O
5	to	O
6	be	O
7	particularly	O
8	significant	O
9	in	O
10	OCD	O
11	.	O
1	Little	O
2	or	O
3	no	O
4	protection	O
5	was	O
6	detected	O
7	using	O
8	adrenal	O
9	cortex	O
10	,	O
11	adrenal	O
12	medulla	O
13	,	O
14	liver	O
15	,	O
16	kidney	O
17	cortex	O
18	,	O
19	spleen	O
20	,	O
21	or	O
22	T	O
23	-	O
24	lymphocyte	O
25	total	O
26	RNA	O
27	.	O
1	The	O
2	ectopic	O
3	expression	O
4	of	O
5	Oct	O
6	-	O
7	3	O
8	/	O
9	4	O
10	in	O
11	hybrid	O
12	cells	O
13	under	O
14	a	O
15	constitutive	O
16	promoter	O
17	is	O
18	sufficient	O
19	for	O
20	transcriptional	O
21	activation	O
22	of	O
23	an	O
24	octamer	O
25	-	O
26	dependent	O
27	promoter	O
28	.	O
1	RT	O
2	-	O
3	PCR	O
4	using	O
5	1	O
6	.	O
7	D	O
8	-	O
9	specific	O
10	primers	O
11	showed	O
12	that	O
13	kidney	O
14	,	O
15	brain	O
16	and	O
17	prostate	O
18	do	O
19	not	O
20	express	O
21	1	O
22	.	O
23	D	O
24	mRNA	O
25	even	O
26	though	O
27	kidney	O
28	and	O
29	brain	O
30	are	O
31	the	O
32	most	O
33	abundant	O
34	source	O
35	for	O
36	aFGF	O
37	protein	O
38	.	O
1	Cytogenetic	O
2	studies	O
3	were	O
4	performed	O
5	in	O
6	lymphocytes	O
7	from	O
8	hospital	O
9	workers	O
10	exposed	O
11	to	O
12	low	O
13	doses	O
14	of	O
15	radiation	O
16	(	O
17	1	O
18	.	O
19	6	O
20	-	O
21	42	O
22	.	O
23	71	O
24	mSv	O
25	).	O
1	The	O
2	genomic	O
3	structure	O
4	of	O
5	four	O
6	members	O
7	of	O
8	the	O
9	SRC	O
10	-	O
11	family	O
12	revealed	O
13	nearly	O
14	identical	O
15	exon	O
16	/	O
17	intron	O
18	boundaries	O
19	within	O
20	the	O
21	catalytic	O
22	domain	O
23	of	O
24	this	O
25	family	O
26	.	O
1	Recombinant	O
2	plasmid	O
3	pFV100	O
4	was	O
5	subsequently	O
6	isolated	O
7	by	O
8	its	O
9	ability	O
10	to	O
11	complement	O
12	B	O
13	-	O
14	band	O
15	expression	O
16	in	O
17	ge6	O
18	.	O
1	We	O
2	here	O
3	demonstrate	O
4	that	O
5	a	O
6	temperature	O
7	-	O
8	sensitive	O
9	fission	O
10	yeast	O
11	mutant	O
12	which	O
13	has	O
14	a	O
15	mutation	O
16	in	O
17	a	O
18	homologous	O
19	gene	O
20	,	O
21	and	O
22	two	O
23	of	O
24	three	O
25	additional	O
26	(	O
27	mtr1	O
28	/	O
29	prp20	O
30	/	O
31	srm1	O
32	)	O
33	mutants	O
34	accumulate	O
35	nuclear	O
36	poly	O
37	(	O
38	A	O
39	)+	O
40	RNA	O
41	at	O
42	37	O
43	degrees	O
44	C	O
45	.	O
1	Prostate	O
2	specific	O
3	antigen	B
4	shows	O
5	the	O
6	metastatic	O
7	cases	O
8	better	O
9	[	O
10	correction	O
11	of	O
12	worse	O
13	]	O
14	than	O
15	prostatic	O
16	acid	O
17	phosphatase	B
18	.	O
1	Protein	O
2	phosphorylation	O
3	appears	O
4	to	O
5	play	O
6	a	O
7	critical	O
8	role	O
9	in	O
10	uPA	O
11	gene	O
12	expression	O
13	in	O
14	these	O
15	cells	O
16	;	O
17	protein	O
18	kinase	B
19	C	O
20	-	O
21	activating	O
22	phorbol	O
23	esters	O
24	cooperate	O
25	with	O
26	pp60v	O
27	-	O
28	src	O
29	to	O
30	synergistically	O
31	increase	O
32	uPA	O
33	mRNA	O
34	,	O
35	whereas	O
36	cyclic	O
37	AMP	O
38	(	O
39	cAMP	O
40	)-	O
41	dependent	O
42	protein	O
43	kinase	B
44	-	O
45	activating	O
46	agents	O
47	(	O
48	e	O
49	.	O
50	g	O
51	.,	O
52	8	O
53	-	O
54	bromo	O
55	cAMP	O
56	)	O
57	repress	O
58	uPA	O
59	mRNA	O
60	levels	O
61	.	O
1	DNase	O
2	I	O
3	footprinting	O
4	of	O
5	the	O
6	proximal	O
7	promoter	O
8	revealed	O
9	four	O
10	regions	O
11	of	O
12	protection	O
13	.	O
1	Finally	O
2	,	O
3	the	O
4	stability	O
5	of	O
6	the	O
7	nucleotide	O
8	binding	O
9	function	O
10	of	O
11	the	O
12	two	O
13	proteins	O
14	is	O
15	similar	O
16	as	O
17	assessed	O
18	by	O
19	sensitivity	O
20	to	O
21	urea	O
22	.	O
1	The	O
2	presence	O
3	of	O
4	the	O
5	RV	O
6	5	O
7	'(+)	O
8	SL	O
9	sequence	O
10	had	O
11	the	O
12	primary	O
13	enhancing	O
14	effect	O
15	on	O
16	translation	O
17	.	O
1	By	O
2	contrast	O
3	,	O
4	all	O
5	proteins	O
6	initiated	O
7	with	O
8	a	O
9	methionine	O
10	placed	O
11	one	O
12	residue	O
13	upstream	O
14	of	O
15	the	O
16	natural	O
17	N	O
18	terminus	O
19	of	O
20	PR	O
21	failed	O
22	to	O
23	show	O
24	specific	O
25	proteolysis	O
26	.	O
1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	We	O
6	report	O
7	our	O
8	experience	O
9	with	O
10	seven	O
11	children	O
12	with	O
13	active	O
14	small	O
15	bowel	O
16	Crohn	O
17	'	O
18	s	O
19	disease	O
20	given	O
21	a	O
22	casein	O
23	-	O
24	based	O
25	,	O
26	polymeric	O
27	feed	O
28	rich	O
29	in	O
30	TGF	O
31	-	O
32	beta	B
33	2	O
34	(	O
35	Specific	O
36	Polymeric	O
37	Diet	O
38	;	O
39	Nestle	O
40	-	O
41	Clintec	O
42	;	O
43	Vevey	O
44	,	O
45	Switzerland	O
46	)	O
47	as	O
48	complete	O
49	nutrition	O
50	for	O
51	8	O
52	weeks	O
53	.	O
1	Cell	O
2	adhesion	O
3	and	O
4	migration	O
5	assays	O
6	demonstrate	O
7	that	O
8	alpha	B
9	6	O
10	beta	B
11	1	O
12	is	O
13	the	O
14	major	O
15	laminin	O
16	receptor	B
17	in	O
18	undifferentiated	O
19	F9	O
20	cells	O
21	as	O
22	well	O
23	as	O
24	F9	O
25	-	O
26	derived	O
27	PE	O
28	cells	O
29	.	O
1	No	O
2	local	O
3	destruction	O
4	by	O
5	tumor	O
6	or	O
7	infection	O
8	could	O
9	be	O
10	demonstrated	O
11	apart	O
12	from	O
13	HIV	O
14	infection	O
15	.	O
1	To	O
2	determine	O
3	which	O
4	sequences	O
5	in	O
6	the	O
7	rat	O
8	P450c17	O
9	promoter	O
10	may	O
11	be	O
12	responsible	O
13	for	O
14	basal	O
15	and	O
16	cAMP	O
17	-	O
18	stimulated	O
19	gene	O
20	transcription	O
21	,	O
22	deletion	O
23	constructs	O
24	containing	O
25	between	O
26	-	O
27	1	O
28	,	O
29	560	O
30	and	O
31	-	O
32	53	O
33	base	O
34	pairs	O
35	of	O
36	5	O
37	'-	O
38	flanking	O
39	DNA	O
40	from	O
41	the	O
42	rat	O
43	P450c17	O
44	gene	O
45	were	O
46	ligated	O
47	to	O
48	plasmids	O
49	expressing	O
50	the	O
51	reporter	O
52	gene	O
53	luciferase	O
54	and	O
55	transfected	O
56	into	O
57	two	O
58	mouse	O
59	cell	O
60	lines	O
61	,	O
62	adrenal	O
63	Y	O
64	-	O
65	1	O
66	cells	O
67	,	O
68	and	O
69	testicular	O
70	Leydig	O
71	MA	O
72	-	O
73	10	O
74	cells	O
75	.	O
1	Such	O
2	a	O
3	mechanism	O
4	may	O
5	allow	O
6	acceleration	O
7	of	O
8	degenerative	O
9	joint	O
10	conditions	O
11	,	O
12	and	O
13	may	O
14	account	O
15	for	O
16	the	O
17	increased	O
18	prevalence	O
19	of	O
20	such	O
21	conditions	O
22	seen	O
23	with	O
24	HMS	O
25	subjects	O
26	.	O
1	Solitary	O
2	thyroid	O
3	nodule	O
4	.	O
1	However	O
2	,	O
3	the	O
4	inability	O
5	to	O
6	export	O
7	RNA	O
8	from	O
9	the	O
10	nucleus	O
11	to	O
12	the	O
13	cytoplasm	O
14	was	O
15	not	O
16	limited	O
17	to	O
18	a	O
19	particular	O
20	phase	O
21	of	O
22	the	O
23	cell	O
24	division	O
25	cycle	O
26	.	O
1	Using	O
2	Ki	O
3	-	O
4	ras	O
5	-	O
6	transformed	O
7	3T3	O
8	cells	O
9	as	O
10	a	O
11	model	O
12	system	O
13	,	O
14	we	O
15	show	O
16	that	O
17	both	O
18	RA	O
19	and	O
20	the	O
21	'	O
22	dissociating	O
23	'	O
24	retinoids	O
25	inhibit	O
26	anchorage	O
27	-	O
28	independent	O
29	cell	O
30	proliferation	O
31	,	O
32	suggesting	O
33	that	O
34	retinoid	O
35	-	O
36	induced	O
37	growth	O
38	inhibition	O
39	may	O
40	be	O
41	related	O
42	to	O
43	AP1	O
44	transrepression	O
45	.	O
1	Atopic	O
2	dermatitis	O
3	is	O
4	an	O
5	""""	O
6	itch	O
7	which	O
8	rashes	O
9	and	O
10	not	O
11	a	O
12	rash	O
13	which	O
14	itches	O
15	""""	O
16	and	O
17	therefore	O
18	,	O
19	any	O
20	patient	O
21	treatment	O
22	program	O
23	should	O
24	address	O
25	the	O
26	multiplicity	O
27	of	O
28	potential	O
29	trigger	O
30	factors	O
31	that	O
32	provoke	O
33	this	O
34	itching	O
35	.	O
1	Primer	O
2	extension	O
3	experiments	O
4	showed	O
5	that	O
6	there	O
7	are	O
8	two	O
9	transcription	O
10	initiation	O
11	sites	O
12	16	O
13	bp	O
14	apart	O
15	in	O
16	the	O
17	mouse	O
18	type	O
19	2	O
20	receptor	B
21	gene	O
22	.	O
1	1972	O
2	.	O
1	Vascular	O
2	endothelial	O
3	cells	O
4	undergo	O
5	profound	O
6	changes	O
7	upon	O
8	cellular	O
9	activation	O
10	including	O
11	expression	O
12	of	O
13	a	O
14	spectrum	O
15	of	O
16	cell	O
17	activation	O
18	-	O
19	associated	O
20	genes	O
21	.	O
1	CONCLUSIONS	O
2	:	O
3	A	O
4	comparison	O
5	of	O
6	the	O
7	LysU	O
8	crystal	O
9	structure	O
10	with	O
11	the	O
12	structures	O
13	of	O
14	seryl	O
15	-	O
16	and	O
17	aspartyl	O
18	-	O
19	tRNA	O
20	synthetases	O
21	enables	O
22	a	O
23	conserved	O
24	core	O
25	to	O
26	be	O
27	identified	O
28	.	O
1	To	O
2	establish	O
3	a	O
4	possible	O
5	association	O
6	between	O
7	familial	O
8	dysfibrinogenemia	O
9	and	O
10	thrombophilia	O
11	,	O
12	data	O
13	on	O
14	cases	O
15	with	O
16	both	O
17	affections	O
18	were	O
19	collected	O
20	in	O
21	a	O
22	study	O
23	within	O
24	the	O
25	framework	O
26	of	O
27	the	O
28	SSC	O
29	Subcommittee	O
30	on	O
31	Fibrinogen	O
32	of	O
33	the	O
34	International	O
35	Society	O
36	on	O
37	Thrombosis	O
38	and	O
39	Haemostasis	O
40	.	O
1	Conjugated	O
2	estrogens	O
3	shorten	O
4	bleeding	O
5	time	O
6	in	O
7	uraemia	O
8	:	O
9	a	O
10	possible	O
11	role	O
12	of	O
13	serotonin	O
14	?	O
1	Female	O
2	patients	O
3	with	O
4	breast	O
5	cancer	O
6	diagnosed	O
7	between	O
8	1982	O
9	and	O
10	1991	O
11	at	O
12	Roswell	O
13	Park	O
14	Cancer	O
15	Institute	O
16	(	O
17	RPCI	O
18	)	O
19	in	O
20	Buffalo	O
21	,	O
22	New	O
23	York	O
24	,	O
25	who	O
26	provided	O
27	information	O
28	on	O
29	their	O
30	cigarette	O
31	smoking	O
32	history	O
33	at	O
34	the	O
35	time	O
36	of	O
37	their	O
38	diagnosis	O
39	were	O
40	included	O
41	.	O
1	Upon	O
2	analysis	O
3	of	O
4	the	O
5	tissue	O
6	distribution	O
7	of	O
8	AAMP	O
9	,	O
10	it	O
11	was	O
12	found	O
13	to	O
14	be	O
15	expressed	O
16	strongly	O
17	in	O
18	endothelial	O
19	cells	O
20	,	O
21	cytotrophoblasts	O
22	,	O
23	and	O
24	poorly	O
25	differentiated	O
26	colon	O
27	adenocarcinoma	O
28	cells	O
29	found	O
30	in	O
31	lymphatics	O
32	.	O
1	Binding	O
2	activity	O
3	in	O
4	rat	O
5	liver	O
6	nuclear	O
7	extracts	O
8	includes	O
9	these	O
10	orphan	O
11	receptors	O
12	as	O
13	judged	O
14	from	O
15	electromobility	O
16	supershift	O
17	experiments	O
18	and	O
19	from	O
20	results	O
21	obtained	O
22	with	O
23	expressed	O
24	receptors	O
25	,	O
26	although	O
27	the	O
28	element	O
29	in	O
30	CYP2C11	O
31	did	O
32	not	O
33	bind	O
34	HNF	O
35	-	O
36	4	O
37	.	O
1	Diagnosis	O
2	of	O
3	FHCS	O
4	has	O
5	been	O
6	weighed	O
7	upon	O
8	laparoscopic	O
9	findings	O
10	.	O
1	His	O
2	carnitine	O
3	palmitoyltransferase	O
4	(	O
5	CPT	O
6	)	O
7	I	O
8	and	O
9	II	O
10	activities	O
11	were	O
12	0	O
13	.	O
14	06	O
15	and	O
16	0	O
17	.	O
18	12	O
19	nmol	O
20	/	O
21	min	O
22	/	O
23	mg	O
24	protein	O
25	,	O
26	as	O
27	compared	O
28	with	O
29	a	O
30	mean	O
31	value	O
32	of	O
33	0	O
34	.	O
35	22	O
36	+/-	O
37	0	O
38	.	O
39	14	O
40	and	O
41	0	O
42	.	O
43	27	O
44	+/-	O
45	0	O
46	.	O
47	07	O
48	nmol	O
49	/	O
50	min	O
51	/	O
52	mg	O
53	protein	O
54	,	O
55	respectively	O
56	,	O
57	in	O
58	control	O
59	subjects	O
60	.	O
1	The	O
2	Myc	O
3	LZ	O
4	was	O
5	found	O
6	to	O
7	prevent	O
8	homodimeric	O
9	interactions	O
10	,	O
11	thus	O
12	explaining	O
13	Myc	O
14	inability	O
15	to	O
16	homodimerize	O
17	efficiently	O
18	.	O
1	Thus	O
2	,	O
3	VF	O
4	resistant	O
5	to	O
6	defibrillation	O
7	is	O
8	not	O
9	necessarily	O
10	associated	O
11	with	O
12	both	O
13	toxic	O
14	plasma	O
15	drug	O
16	level	O
17	and	O
18	remarkably	O
19	decreased	O
20	conduction	O
21	.	O
1	A	O
2	polymorphic	O
3	dinucleotide	O
4	(	O
5	GT	O
6	/	O
7	CA	O
8	)	O
9	n	O
10	repeat	O
11	contained	O
12	in	O
13	the	O
14	NHE5	O
15	cosmid	O
16	was	O
17	identified	O
18	and	O
19	developed	O
20	into	O
21	a	O
22	microsatellite	O
23	PCR	O
24	marker	O
25	.	O
1	Induction	O
2	in	O
3	AP	B
4	-	O
5	1	O
6	DNA	O
7	binding	O
8	correlates	O
9	with	O
10	a	O
11	concomitant	O
12	GH	O
13	trans	O
14	-	O
15	activation	O
16	of	O
17	c	B
18	-	O
19	jun	O
20	and	O
21	c	B
22	-	O
23	fos	O
24	genes	O
25	described	O
26	previously	O
27	.	O
1	The	O
2	maximum	O
3	induction	O
4	of	O
5	ACC	O
6	-	O
7	oxidase	O
8	transcripts	O
9	occurred	O
10	at	O
11	about	O
12	6	O
13	h	O
14	after	O
15	excision	O
16	,	O
17	while	O
18	the	O
19	maximum	O
20	enzyme	O
21	activity	O
22	was	O
23	observed	O
24	at	O
25	24	O
26	h	O
27	.	O
1	The	O
2	present	O
3	study	O
4	describes	O
5	the	O
6	cell	O
7	volume	O
8	dynamics	O
9	in	O
10	intact	O
11	rat	O
12	hearts	O
13	,	O
14	during	O
15	ischemia	O
16	and	O
17	after	O
18	reperfusion	O
19	.	O
1	Mutation	O
2	of	O
3	the	O
4	Sp1	B
5	element	O
6	,	O
7	which	O
8	abolishes	O
9	Sp1	B
10	binding	O
11	,	O
12	results	O
13	in	O
14	a	O
15	6	O
16	-	O
17	10	O
18	-	O
19	fold	O
20	reduction	O
21	in	O
22	reporter	O
23	activity	O
24	.	O
1	Transfection	O
2	of	O
3	non	O
4	-	O
5	deleted	O
6	expression	O
7	vector	O
8	into	O
9	NIH3T3	O
10	cells	O
11	results	O
12	in	O
13	acquisition	O
14	of	O
15	focus	O
16	-	O
17	forming	O
18	activity	O
19	while	O
20	a	O
21	deleted	O
22	form	O
23	of	O
24	expression	O
25	vector	O
26	fails	O
27	to	O
28	show	O
29	this	O
30	activity	O
31	even	O
32	in	O
33	the	O
34	presence	O
35	of	O
36	basic	O
37	FGF	O
38	.	O
1	There	O
2	is	O
3	a	O
4	national	O
5	effort	O
6	to	O
7	begin	O
8	to	O
9	ask	O
10	all	O
11	female	O
12	patients	O
13	about	O
14	family	O
15	violence	O
16	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	in	O
6	cultured	O
7	Jurkat	O
8	T	O
9	cells	O
10	,	O
11	Cbl	O
12	is	O
13	coprecipitated	O
14	with	O
15	antibody	O
16	against	O
17	the	O
18	adapter	O
19	protein	O
20	Grb2	O
21	.	O
1	The	O
2	effect	O
3	of	O
4	these	O
5	cell	O
6	cycle	O
7	regulators	O
8	is	O
9	not	O
10	specific	O
11	to	O
12	the	O
13	rap1s	O
14	or	O
15	hmr	O
16	delta	B
17	A	O
18	mutation	O
19	,	O
20	since	O
21	swi6	O
22	,	O
23	swi4	O
24	,	O
25	and	O
26	clb5	O
27	mutations	O
28	also	O
29	suppress	O
30	mutations	O
31	in	O
32	SIR1	O
33	,	O
34	another	O
35	gene	O
36	implicated	O
37	in	O
38	the	O
39	establishment	O
40	of	O
41	silencing	O
42	.	O
1	The	O
2	RAP74	O
3	subunit	O
4	of	O
5	TFIIF	O
6	alone	O
7	contained	O
8	the	O
9	stimulatory	O
10	activity	O
11	and	O
12	the	O
13	minimal	O
14	region	O
15	sufficient	O
16	for	O
17	stimulation	O
18	corresponds	O
19	to	O
20	COOH	O
21	-	O
22	terminal	O
23	residues	O
24	358	O
25	-	O
26	517	O
27	.	O
1	We	O
2	have	O
3	generated	O
4	various	O
5	base	O
6	substitutions	O
7	and	O
8	internal	O
9	deletions	O
10	in	O
11	and	O
12	around	O
13	DRE	O
14	(	O
15	nucleotide	O
16	positions	O
17	-	O
18	93	O
19	to	O
20	-	O
21	100	O
22	with	O
23	respect	O
24	to	O
25	the	O
26	transcription	O
27	initiation	O
28	site	O
29	)	O
30	of	O
31	the	O
32	PCNA	O
33	gene	O
34	in	O
35	vitro	O
36	and	O
37	subsequently	O
38	examined	O
39	their	O
40	effects	O
41	on	O
42	the	O
43	binding	O
44	to	O
45	DREF	O
46	(	O
47	DRE	O
48	-	O
49	binding	O
50	factor	O
51	)	O
52	and	O
53	PCNA	O
54	gene	O
55	promote	O
56	activity	O
57	in	O
58	cultured	O
59	Drosophila	O
60	Kc	O
61	cells	O
62	as	O
63	well	O
64	as	O
65	in	O
66	living	O
67	flies	O
68	.	O
1	Other	O
2	assays	O
3	also	O
4	distinguished	O
5	the	O
6	processive	O
7	replication	O
8	of	O
9	pNeo	O
10	.	O
11	Myc	O
12	-	O
13	2	O
14	.	O
15	4	O
16	from	O
17	the	O
18	dispersive	O
19	labeling	O
20	of	O
21	control	O
22	plasmids	O
23	.	O
1	Reconstitution	O
2	of	O
3	complexes	O
4	containing	O
5	p62	O
6	and	O
7	the	O
8	src	O
9	family	O
10	kinase	B
11	p59fyn	O
12	in	O
13	HeLa	O
14	cells	O
15	demonstrated	O
16	that	O
17	complex	O
18	formation	O
19	resulted	O
20	in	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	p62	O
25	and	O
26	was	O
27	mediated	O
28	by	O
29	both	O
30	the	O
31	SH3	O
32	and	O
33	SH2	O
34	domains	O
35	of	O
36	p59fyn	O
37	.	O
1	Characterization	O
2	of	O
3	the	O
4	promoter	O
5	for	O
6	the	O
7	human	O
8	85	O
9	kDa	O
10	cytosolic	O
11	phospholipase	O
12	A2	O
13	gene	O
14	.	O
1	Molecular	O
2	dissection	O
3	of	O
4	the	O
5	multimeric	O
6	CD3	O
7	-	O
8	TCR	O
9	complex	O
10	revealed	O
11	that	O
12	at	O
13	least	O
14	two	O
15	associated	O
16	polypeptides	O
17	,	O
18	CD3	O
19	zeta	O
20	and	O
21	CD3	O
22	epsilon	O
23	,	O
24	autonomously	O
25	couple	O
26	antigenic	O
27	recognition	O
28	event	O
29	to	O
30	early	O
31	and	O
32	late	O
33	events	O
34	of	O
35	the	O
36	intracytoplasmic	O
37	activation	O
38	cascade	O
39	.	O
1	Virol	O
2	.	O
1	Coronary	O
2	vasoconstriction	O
3	caused	O
4	by	O
5	endothelin	O
6	-	O
7	1	O
8	is	O
9	enhanced	O
10	by	O
11	ischemia	O
12	-	O
13	reperfusion	O
14	and	O
15	by	O
16	norepinephrine	O
17	present	O
18	in	O
19	concentrations	O
20	typically	O
21	observed	O
22	after	O
23	neonatal	O
24	cardiopulmonary	O
25	bypass	O
26	.	O
1	Atcys1	O
2	,	O
3	Athyp1	O
4	,	O
5	AKin10	O
6	and	O
7	the	O
8	ORF	O
9	are	O
10	very	O
11	close	O
12	to	O
13	each	O
14	other	O
15	and	O
16	organized	O
17	in	O
18	the	O
19	same	O
20	polarity	O
21	;	O
22	hence	O
23	,	O
24	the	O
25	intergenic	O
26	regions	O
27	probably	O
28	contain	O
29	,	O
30	within	O
31	less	O
32	than	O
33	0	O
34	.	O
35	5	O
36	kb	O
37	,	O
38	all	O
39	the	O
40	regulatory	O
41	elements	O
42	necessary	O
43	to	O
44	govern	O
45	initiation	O
46	and	O
47	termination	O
48	of	O
49	transcription	O
50	.	O
1	Furthermore	O
2	,	O
3	the	O
4	identification	O
5	of	O
6	a	O
7	Dr1	O
8	-	O
9	like	O
10	protein	O
11	in	O
12	A	O
13	.	O
14	thaliana	O
15	strongly	O
16	argues	O
17	for	O
18	the	O
19	ubiquity	O
20	of	O
21	this	O
22	protein	O
23	among	O
24	eukaryotic	O
25	genera	O
26	and	O
27	for	O
28	a	O
29	conserved	O
30	mechanism	O
31	to	O
32	regulate	O
33	transcription	O
34	initiation	O
35	that	O
36	involves	O
37	Dr1	O
38	.	O
1	Similarly	O
2	approximately	O
3	300	O
4	bp	O
5	of	O
6	sequence	O
7	downstream	O
8	of	O
9	the	O
10	translation	O
11	terminator	O
12	TGA	O
13	of	O
14	the	O
15	beta	B
16	-	O
17	tubulin	O
18	2	O
19	(	O
20	BTU2	O
21	)	O
22	gene	O
23	could	O
24	substitute	O
25	for	O
26	the	O
27	3	O
28	'	O
29	region	O
30	of	O
31	the	O
32	H4	O
33	-	O
34	I	O
35	gene	O
36	.	O
1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	the	O
6	STR	O
7	family	O
8	of	O
9	genes	O
10	is	O
11	represented	O
12	in	O
13	a	O
14	nematode	O
15	whose	O
16	ancestor	O
17	appeared	O
18	well	O
19	before	O
20	the	O
21	branching	O
22	that	O
23	gave	O
24	rise	O
25	to	O
26	the	O
27	Arthropoda	O
28	and	O
29	Chordata	O
30	.	O
1	The	O
2	enhanced	O
3	cysteine	O
4	formation	O
5	in	O
6	a	O
7	pCSK4F	O
8	plant	O
9	responding	O
10	to	O
11	sulfite	O
12	was	O
13	also	O
14	observed	O
15	in	O
16	leaf	O
17	discs	O
18	.	O
1	Each	O
2	type	O
3	was	O
4	divided	O
5	into	O
6	two	O
7	subgroups	O
8	on	O
9	the	O
10	basis	O
11	of	O
12	whether	O
13	the	O
14	body	O
15	and	O
16	tail	O
17	of	O
18	the	O
19	pancreas	O
20	showed	O
21	intense	O
22	fatty	O
23	replacement	O
24	(	O
25	type	O
26	a	O
27	=	O
28	negative	O
29	for	O
30	intense	O
31	fatty	O
32	replacement	O
33	,	O
34	type	O
35	b	O
36	=	O
37	positive	O
38	for	O
39	intense	O
40	fatty	O
41	replacement	O
42	).	O
1	Basal	O
2	components	O
3	of	O
4	the	O
5	transcription	O
6	apparatus	O
7	(	O
8	RNA	O
9	polymerase	B
10	II	O
11	,	O
12	TATA	O
13	-	O
14	binding	O
15	protein	O
16	)	O
17	contain	O
18	activation	O
19	domains	O
20	:	O
21	is	O
22	the	O
23	repetitive	O
24	C	O
25	-	O
26	terminal	O
27	domain	O
28	(	O
29	CTD	O
30	)	O
31	of	O
32	RNA	O
33	polymerase	B
34	II	O
35	a	O
36	""""	O
37	portable	O
38	enhancer	O
39	domain	O
40	"""?"	O
41	Regions	O
42	rich	O
43	in	O
44	serine	O
45	,	O
46	threonine	O
47	,	O
48	and	O
49	proline	O
50	residues	O
51	can	O
52	be	O
53	found	O
54	in	O
55	transcriptional	O
56	activation	O
57	domains	O
58	,	O
59	as	O
60	well	O
61	as	O
62	in	O
63	the	O
64	N	O
65	-	O
66	terminal	O
67	parts	O
68	of	O
69	mammalian	O
70	TATA	O
71	-	O
72	binding	O
73	proteins	O
74	,	O
75	where	O
76	they	O
77	are	O
78	interrupted	O
79	by	O
80	polyglutamine	O
81	stretches	O
82	.	O
1	The	O
2	drug	O
3	sensitivity	O
4	was	O
5	100	O
6	%	O
7	for	O
8	vancomycin	O
9	(	O
10	VCM	O
11	),	O
12	30	O
13	%	O
14	for	O
15	imipenam	O
16	(	O
17	IMP	O
18	),	O
19	31	O
20	%	O
21	for	O
22	minomycin	O
23	(	O
24	MINO	O
25	),	O
26	31	O
27	%	O
28	for	O
29	amikacin	O
30	(	O
31	AMK	O
32	),	O
33	and	O
34	7	O
35	%	O
36	for	O
37	fosfomycin	O
38	(	O
39	FOM	O
40	).	O
1	To	O
2	understand	O
3	the	O
4	function	O
5	of	O
6	receptor	B
7	-	O
8	linked	O
9	tyrosine	O
10	phosphatases	O
11	in	O
12	neural	O
13	development	O
14	,	O
15	we	O
16	sought	O
17	to	O
18	identify	O
19	LAR	O
20	isoforms	O
21	preferentially	O
22	expressed	O
23	in	O
24	the	O
25	nervous	O
26	system	O
27	and	O
28	cellular	O
29	processes	O
30	regulating	O
31	LAR	O
32	alternative	O
33	splicing	O
34	.	O
1	135	O
2	students	O
3	had	O
4	a	O
5	count	O
6	of	O
7	less	O
8	than	O
9	50	O
10	eggs	O
11	/	O
12	10	O
13	ml	O
14	.	O
15	urine	O
16	and	O
17	56	O
18	had	O
19	more	O
20	than	O
21	50	O
22	eggs	O
23	/	O
24	10ml	O
25	.	O
1	Chrispeels	O
2	[	O
3	1993	O
4	]	O
5	EMBO	O
6	J	O
7	12	O
8	:	O
9	2241	O
10	-	O
11	2247	O
12	).	O
1	Atrial	O
2	fibrillation	O
3	and	O
4	the	O
5	autonomic	O
6	nervous	O
7	system	O
1	Removal	O
2	of	O
3	PDMP	O
4	from	O
5	the	O
6	cell	O
7	medium	O
8	resulted	O
9	in	O
10	reversal	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	changes	O
16	,	O
17	with	O
18	cells	O
19	re	O
20	-	O
21	entering	O
22	the	O
23	S	O
24	phase	O
25	.	O
1	Encapsidation	O
2	of	O
3	poliovirus	O
4	replicons	O
5	encoding	O
6	the	O
7	complete	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	type	O
12	1	O
13	gag	O
14	gene	O
15	by	O
16	using	O
17	a	O
18	complementation	O
19	system	O
20	which	O
21	provides	O
22	the	O
23	P1	O
24	capsid	O
25	protein	O
26	in	O
27	trans	O
28	.	O
1	Removal	O
2	of	O
3	the	O
4	GST	O
5	domain	O
6	from	O
7	GST	O
8	-	O
9	Tax	O
10	by	O
11	thrombin	O
12	restores	O
13	Tax	O
14	'	O
15	s	O
16	ability	O
17	to	O
18	assemble	O
19	a	O
20	ternary	O
21	Tax	O
22	-	O
23	CREB	O
24	-	O
25	21	O
26	-	O
27	bp	O
28	-	O
29	repeat	O
30	complex	O
31	.(	O
32	ABSTRACT	O
33	TRUNCATED	O
34	AT	O
35	400	O
36	WORDS	O
37	)	O
1	These	O
2	data	O
3	indicate	O
4	that	O
5	phosphorylation	O
6	of	O
7	M	O
8	protein	O
9	at	O
10	the	O
11	major	O
12	in	O
13	vivo	O
14	sites	O
15	is	O
16	not	O
17	essential	O
18	for	O
19	virus	O
20	assembly	O
21	.	O
1	The	O
2	MAP	O
3	kinase	B
4	cascade	O
5	is	O
6	highly	O
7	conserved	O
8	in	O
9	all	O
10	eukaryotes	O
11	and	O
12	involved	O
13	in	O
14	numerous	O
15	cellular	O
16	responses	O
17	.	O
1	No	O
2	serious	O
3	side	O
4	effects	O
5	were	O
6	observed	O
7	.	O
1	Lack	O
2	of	O
3	cyclin	B
4	D	O
5	-	O
6	Cdk	O
7	complexes	O
8	in	O
9	Rb	O
10	-	O
11	negative	O
12	cells	O
13	correlates	O
14	with	O
15	high	O
16	levels	O
17	of	O
18	p16INK4	O
19	/	O
20	MTS1	O
21	tumour	O
22	suppressor	O
23	gene	O
24	product	O
25	.	O
1	We	O
2	have	O
3	measured	O
4	the	O
5	release	O
6	of	O
7	interleukin	O
8	-	O
9	1	O
10	beta	B
11	(	O
12	IL	B
13	-	O
14	1	O
15	)	O
16	and	O
17	tumour	O
18	necrosis	O
19	factor	O
20	-	O
21	alpha	B
22	(	O
23	TNF	O
24	)	O
25	by	O
26	unstimulated	O
27	monocytes	O
28	and	O
29	monocytes	O
30	stimulated	O
31	with	O
32	lipopolysaccharide	O
33	(	O
34	LPS	O
35	)	O
36	isolated	O
37	from	O
38	the	O
39	peripheral	O
40	blood	O
41	of	O
42	two	O
43	patients	O
44	with	O
45	acute	O
46	poststreptococcal	O
47	glomerulonephritis	O
48	(	O
49	AGN	O
50	)	O
51	and	O
52	16	O
53	healthy	O
54	controls	O
55	.	O
1	One	O
2	member	O
3	of	O
4	this	O
5	family	O
6	,	O
7	RFX1	O
8	,	O
9	is	O
10	a	O
11	transcription	O
12	factor	O
13	for	O
14	a	O
15	variety	O
16	of	O
17	viral	O
18	and	O
19	cellular	O
20	genes	O
21	.	O
1	Thus	O
2	,	O
3	we	O
4	have	O
5	produced	O
6	lipoyl	O
7	domain	O
8	constructs	O
9	that	O
10	can	O
11	be	O
12	employed	O
13	in	O
14	sorting	O
15	the	O
16	specific	O
17	roles	O
18	of	O
19	E2L1	O
20	and	O
21	E2L2	O
22	in	O
23	facilitating	O
24	catalytic	O
25	and	O
26	regulatory	O
27	processes	O
28	.	O
1	Gene	O
2	expression	O
3	occurs	O
4	in	O
5	a	O
6	circadian	O
7	rhythm	O
8	and	O
9	induced	O
10	by	O
11	light	O
12	in	O
13	leaves	O
14	of	O
15	dark	O
16	-	O
17	adapted	O
18	plants	O
19	.	O
1	In	O
2	a	O
3	second	O
4	experiment	O
5	involving	O
6	an	O
7	18	O
8	-	O
9	h	O
10	lung	O
11	clearance	O
12	assay	O
13	,	O
14	we	O
15	used	O
16	the	O
17	mAb	O
18	3	O
19	.	O
20	2	O
21	.	O
22	3	O
23	to	O
24	deplete	O
25	rats	O
26	of	O
27	LGL	O
28	/	O
29	NK	O
30	cells	O
31	with	O
32	the	O
33	following	O
34	rationale	O
35	:	O
36	if	O
37	LGL	O
38	/	O
39	NK	O
40	cells	O
41	are	O
42	necessary	O
43	to	O
44	mediate	O
45	an	O
46	event	O
47	,	O
48	then	O
49	in	O
50	their	O
51	absence	O
52	,	O
53	that	O
54	event	O
55	should	O
56	not	O
57	occur	O
58	.	O
1	Treatment	O
2	of	O
3	recurrent	O
4	FSGS	O
5	has	O
6	included	O
7	high	O
8	-	O
9	dose	O
10	steroids	O
11	,	O
12	high	O
13	-	O
14	dose	O
15	cyclosporine	O
16	(	O
17	CSA	O
18	),	O
19	plasmapheresis	O
20	,	O
21	and	O
22	ACE	O
23	inhibitors	O
24	with	O
25	mixed	O
26	results	O
27	.	O
1	Promoter	O
2	region	O
3	of	O
4	the	O
5	transcriptional	O
6	unit	O
7	for	O
8	human	O
9	alpha	B
10	1	O
11	-	O
12	chimaerin	O
13	,	O
14	a	O
15	neuron	O
16	-	O
17	specific	O
18	GTPase	B
19	-	O
20	activating	O
21	protein	O
22	for	O
23	p21rac	O
24	.	O
25	alpha	B
26	1	O
27	-	O
28	chimaerin	O
29	is	O
30	a	O
31	neuron	O
32	-	O
33	specific	O
34	GTPase	B
35	-	O
36	activating	O
37	protein	O
38	for	O
39	p21rac	O
40	,	O
41	a	O
42	protein	O
43	involved	O
44	in	O
45	morphological	O
46	events	O
47	.	O
1	Using	O
2	this	O
3	method	O
4	,	O
5	VLPs	O
6	were	O
7	obtained	O
8	in	O
9	quantities	O
10	sufficient	O
11	for	O
12	further	O
13	characterization	O
14	.	O
1	Analysis	O
2	of	O
3	the	O
4	sequence	O
5	upstream	O
6	of	O
7	this	O
8	initiation	O
9	codon	O
10	reveals	O
11	the	O
12	presence	O
13	of	O
14	a	O
15	promotor	O
16	sequence	O
17	.	O
1	Secondary	O
2	pancreatic	O
3	involvement	O
4	of	O
5	mycosis	O
6	fungoides	O
7	detected	O
8	by	O
9	a	O
10	clinically	O
11	palpable	O
12	mass	O
13	.	O
1	The	O
2	NR2	O
3	hybrid	O
4	is	O
5	a	O
6	powerful	O
7	tool	O
8	for	O
9	the	O
10	mapping	O
11	of	O
12	new	O
13	probes	O
14	of	O
15	this	O
16	region	O
17	,	O
18	as	O
19	well	O
20	as	O
21	for	O
22	obtaining	O
23	new	O
24	informative	O
25	probes	O
26	specific	O
27	for	O
28	the	O
29	deletion	O
30	by	O
31	subtractive	O
32	cloning	O
33	of	O
34	the	O
35	region	O
36	.	O
1	A	O
2	potential	O
3	outcome	O
4	of	O
5	these	O
6	biochemical	O
7	effects	O
8	may	O
9	include	O
10	the	O
11	limited	O
12	responsiveness	O
13	of	O
14	infected	O
15	T	O
16	cells	O
17	to	O
18	antigenic	O
19	stimulation	O
20	observed	O
21	during	O
22	HIV	O
23	-	O
24	1	O
25	infection	O
26	.	O
1	Using	O
2	gel	O
3	retardation	O
4	assays	O
5	with	O
6	HepG2	O
7	nuclear	O
8	extract	O
9	,	O
10	we	O
11	demonstrated	O
12	the	O
13	presence	O
14	of	O
15	a	O
16	specific	O
17	protein	O
18	which	O
19	bound	O
20	to	O
21	the	O
22	NRE	O
23	fragment	O
24	.	O
1	Expression	O
2	of	O
3	h6	O
4	.	O
5	1	O
6	in	O
7	COS	O
8	-	O
9	1	O
10	cells	O
11	led	O
12	to	O
13	the	O
14	production	O
15	of	O
16	a	O
17	typical	O
18	type	O
19	IV	O
20	PDE	O
21	activity	O
22	in	O
23	that	O
24	cAMP	O
25	,	O
26	but	O
27	not	O
28	cGMP	O
29	,	O
30	served	O
31	as	O
32	substrate	O
33	and	O
34	its	O
35	activity	O
36	was	O
37	insensitive	O
38	to	O
39	either	O
40	Ca2	O
41	+/	O
42	CaM	O
43	or	O
44	cGMP	O
45	but	O
46	was	O
47	inhibited	O
48	by	O
49	low	O
50	concentrations	O
51	of	O
52	rolipram	O
53	.(	O
54	ABSTRACT	O
55	TRUNCATED	O
56	AT	O
57	400	O
58	WORDS	O
59	)	O
1	Translation	O
2	of	O
3	the	O
4	coding	O
5	segment	O
6	,	O
7	which	O
8	was	O
9	designated	O
10	MsPRP2	O
11	,	O
12	suggested	O
13	it	O
14	encodes	O
15	a	O
16	chimeric	O
17	40	O
18	,	O
19	569	O
20	Da	O
21	cell	O
22	wall	O
23	protein	O
24	with	O
25	an	O
26	amino	O
27	-	O
28	terminal	O
29	signal	O
30	sequence	O
31	,	O
32	a	O
33	repetitive	O
34	proline	O
35	-	O
36	rich	O
37	sequence	O
38	,	O
39	and	O
40	a	O
41	cysteine	O
42	-	O
43	rich	O
44	carboxyl	O
45	-	O
46	terminal	O
47	sequence	O
48	homologous	O
49	to	O
50	nonspecific	O
51	lipid	O
52	transfer	O
53	proteins	O
54	.	O
1	We	O
2	have	O
3	screened	O
4	the	O
5	mouse	O
6	cDNA	O
7	library	O
8	of	O
9	an	O
10	MIN6	O
11	cell	O
12	line	O
13	,	O
14	derived	O
15	from	O
16	pancreatic	O
17	beta	B
18	cells	O
19	,	O
20	for	O
21	its	O
22	novel	O
23	isoform	O
24	and	O
25	have	O
26	identified	O
27	a	O
28	cDNA	O
29	encoding	O
30	a	O
31	593	O
32	-	O
33	amino	O
34	acid	O
35	protein	O
36	having	O
37	63	O
38	,	O
39	53	O
40	,	O
41	and	O
42	30	O
43	%	O
44	identity	O
45	with	O
46	munc	O
47	-	O
48	18	O
49	/	O
50	n	O
51	-	O
52	Sec1	O
53	/	O
54	rbSec1	O
55	,	O
56	Caenorhabditis	O
57	elegans	O
58	unc18	O
59	,	O
60	and	O
61	Saccharomyces	O
62	cerevisiae	O
63	Sec1p	O
64	,	O
65	respectively	O
66	.	O
1	Like	O
2	Epo	O
3	,	O
4	HNF	O
5	-	O
6	4	O
7	is	O
8	expressed	O
9	in	O
10	kidney	O
11	,	O
12	liver	O
13	,	O
14	and	O
15	Hep3B	O
16	cells	O
17	but	O
18	not	O
19	in	O
20	HeLa	O
21	cells	O
22	.	O
1	Moreover	O
2	,	O
3	the	O
4	hypoxia	O
5	-	O
6	induced	O
7	expression	O
8	of	O
9	the	O
10	endogenous	O
11	Epo	O
12	gene	O
13	was	O
14	significantly	O
15	inhibited	O
16	in	O
17	Hep3B	O
18	cells	O
19	stably	O
20	transfected	O
21	with	O
22	HNF	O
23	-	O
24	4	O
25	delta	B
26	C	O
27	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	function	O
7	of	O
8	the	O
9	DS2	O
10	may	O
11	be	O
12	the	O
13	protection	O
14	of	O
15	the	O
16	nuclear	O
17	DNA	O
18	from	O
19	desiccation	O
20	.	O
1	Erythrocyte	O
2	delta	B
3	-	O
4	aminolevulinic	O
5	acid	O
6	dehydratase	O
7	(	O
8	ALAD	O
9	)	O
10	activity	O
11	,	O
12	erythrocyte	O
13	zinc	O
14	protoporphyrin	O
15	(	O
16	ZPP	O
17	)/	O
18	heme	O
19	ratio	O
20	,	O
21	and	O
22	urinary	O
23	coproporphyrin	O
24	(	O
25	UC	O
26	)	O
27	concentration	O
28	have	O
29	been	O
30	employed	O
31	as	O
32	biological	O
33	indicators	O
34	of	O
35	moderate	O
36	-	O
37	to	O
38	high	O
39	-	O
40	level	O
41	lead	O
42	exposure	O
43	,	O
44	corresponding	O
45	to	O
46	blood	O
47	levels	O
48	in	O
49	excess	O
50	of	O
51	50	O
52	micrograms	O
53	/	O
54	dl	O
55	,	O
56	in	O
57	human	O
58	subjects	O
59	.	O
1	Three	O
2	classes	O
3	of	O
4	test	O
5	objects	O
6	were	O
7	considered	O
8	:	O
9	(	O
10	1	O
11	)	O
12	a	O
13	multicompartment	O
14	test	O
15	object	O
16	for	O
17	31P	O
18	MRS	O
19	measurements	O
20	performed	O
21	with	O
22	slice	O
23	-	O
24	selective	O
25	sequences	O
26	;	O
27	(	O
28	2	O
29	)	O
30	a	O
31	two	O
32	-	O
33	compartment	O
34	test	O
35	object	O
36	for	O
37	volume	O
38	-	O
39	selection	O
40	1H	O
41	MRS	O
42	;	O
43	and	O
44	(	O
45	3	O
46	)	O
47	two	O
48	-	O
49	compartment	O
50	test	O
51	objects	O
52	for	O
53	assessing	O
54	the	O
55	performance	O
56	of	O
57	experimental	O
58	systems	O
59	using	O
60	ISIS	O
61	as	O
62	volume	O
63	localization	O
64	sequence	O
65	in	O
66	31P	O
67	MRS	O
68	.	O
1	We	O
2	took	O
3	advantage	O
4	of	O
5	the	O
6	high	O
7	degree	O
8	of	O
9	aa	O
10	sequence	O
11	homology	O
12	between	O
13	DAHPSs	O
14	from	O
15	several	O
16	species	O
17	to	O
18	isolate	O
19	ARO3	O
20	homologues	O
21	from	O
22	the	O
23	pathogenic	O
24	yeast	O
25	Candida	O
26	albicans	O
27	.	O
1	Deletion	O
2	analyses	O
3	of	O
4	the	O
5	construct	O
6	revealed	O
7	that	O
8	the	O
9	transcription	O
10	of	O
11	BOXF1	O
12	gene	O
13	is	O
14	regulated	O
15	by	O
16	BOX	O
17	DNA	O
18	,	O
19	preferentially	O
20	in	O
21	undifferentiated	O
22	EC	O
23	cells	O
24	versus	O
25	differentiated	O
26	cells	O
27	.	O
1	Analysis	O
2	of	O
3	disassociation	O
4	rates	O
5	indicates	O
6	that	O
7	the	O
8	Grf10	O
9	-	O
10	Swi5	O
11	-	O
12	DNA	O
13	complex	O
14	has	O
15	a	O
16	longer	O
17	half	O
18	-	O
19	life	O
20	than	O
21	protein	O
22	-	O
23	DNA	O
24	complexes	O
25	that	O
26	contain	O
27	only	O
28	Swi5	O
29	or	O
30	Grf10	O
31	.	O
1	The	O
2	use	O
3	of	O
4	specific	O
5	antibodies	O
6	allowed	O
7	the	O
8	identification	O
9	of	O
10	at	O
11	least	O
12	RAR	O
13	beta	B
14	in	O
15	some	O
16	of	O
17	the	O
18	DNA	O
19	-	O
20	protein	O
21	complexes	O
22	,	O
23	although	O
24	the	O
25	four	O
26	sequences	O
27	bind	O
28	single	O
29	RARs	O
30	transfected	O
31	in	O
32	COS	O
33	cells	O
34	much	O
35	less	O
36	efficiently	O
37	,	O
38	or	O
39	not	O
40	at	O
41	all	O
42	,	O
43	when	O
44	compared	O
45	to	O
46	a	O
47	canonical	O
48	RAR	O
49	responsive	O
50	element	O
51	.	O
1	HER2	O
2	overexpressing	O
3	cells	O
4	showed	O
5	a	O
6	single	O
7	prominent	O
8	DNase	B
9	I	O
10	hypersensitive	O
11	site	O
12	near	O
13	a	O
14	conserved	O
15	and	O
16	hitherto	O
17	unrecognized	O
18	ets	O
19	response	O
20	element	O
21	(	O
22	GAGGAA	O
23	),	O
24	located	O
25	38	O
26	bases	O
27	down	O
28	-	O
29	stream	O
30	from	O
31	the	O
32	CAAT	O
33	box	O
34	and	O
35	directly	O
36	5	O
37	'	O
38	of	O
39	the	O
40	TATA	O
41	box	O
42	in	O
43	the	O
44	human	O
45	HER2	O
46	promoter	O
47	.	O
1	Similar	O
2	to	O
3	the	O
4	mouse	O
5	gene	O
6	,	O
7	the	O
8	5	O
9	'	O
10	flanking	O
11	region	O
12	of	O
13	human	O
14	CD79	O
15	alpha	B
16	lacks	O
17	a	O
18	TATA	O
19	box	O
20	;	O
21	however	O
22	,	O
23	unlike	O
24	mouse	O
25	CD79	O
26	alpha	B
27	,	O
28	a	O
29	classical	O
30	octamer	O
31	motif	O
32	could	O
33	not	O
34	be	O
35	identified	O
36	in	O
37	the	O
38	human	O
39	gene	O
40	.	O
1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	human	O
9	goosecoid	O
10	gene	O
11	(	O
12	GSC	O
13	)	O
14	from	O
15	a	O
16	genomic	O
17	library	O
18	and	O
19	the	O
20	sequence	O
21	of	O
22	its	O
23	encoded	O
24	protein	O
25	.	O
1	In	O
2	order	O
3	to	O
4	define	O
5	potential	O
6	candidate	O
7	genes	O
8	for	O
9	inherited	O
10	disorders	O
11	characterized	O
12	by	O
13	aberrant	O
14	gene	O
15	expression	O
16	,	O
17	we	O
18	utilized	O
19	Kruppel	O
20	-	O
21	related	O
22	sequences	O
23	to	O
24	isolate	O
25	zinc	O
26	finger	O
27	-	O
28	containing	O
29	cDNAs	O
30	.	O
1	The	O
2	Y	O
3	.	O
4	lipolytica	O
5	genomic	O
6	POT1	O
7	gene	O
8	was	O
9	disrupted	O
10	by	O
11	replacing	O
12	120	O
13	bp	O
14	of	O
15	its	O
16	coding	O
17	sequence	O
18	with	O
19	2	O
20	.	O
21	7	O
22	kbp	O
23	of	O
24	DNA	O
25	including	O
26	the	O
27	Y	O
28	.	O
29	lipolytica	O
30	LEU2	O
31	gene	O
32	.	O
1	It	O
2	is	O
3	concluded	O
4	that	O
5	CT	O
6	should	O
7	be	O
8	routinely	O
9	employed	O
10	in	O
11	patients	O
12	with	O
13	N1	O
14	-	O
15	N3	O
16	neck	O
17	disease	O
18	to	O
19	determine	O
20	the	O
21	proper	O
22	electron	O
23	-	O
24	energy	O
25	prescription	O
26	.	O
1	In	O
2	the	O
3	presence	O
4	of	O
5	the	O
6	in	O
7	vivo	O
8	reducing	O
9	system	O
10	(	O
11	thioredoxin	O
12	,	O
13	thioredoxin	O
14	reductase	O
15	,	O
16	and	O
17	NADPH	O
18	),	O
19	however	O
20	,	O
21	each	O
22	of	O
23	these	O
24	mutants	O
25	catalyzed	O
26	the	O
27	formation	O
28	of	O
29	only	O
30	0	O
31	.	O
32	6	O
33	-	O
34	0	O
35	.	O
36	8	O
37	dCTPs	O
38	per	O
39	mole	O
40	of	O
41	enzyme	O
42	.	O
1	These	O
2	genetic	O
3	alterations	O
4	do	O
5	not	O
6	affect	O
7	synthesis	O
8	of	O
9	the	O
10	major	O
11	c	B
12	-	O
13	myc	O
14	protein	O
15	,	O
16	p64	O
17	,	O
18	which	O
19	is	O
20	initiated	O
21	from	O
22	the	O
23	first	O
24	AUG	O
25	codon	O
26	in	O
27	exon	O
28	2	O
29	.	O
1	In	O
2	addition	O
3	,	O
4	both	O
5	the	O
6	exon	O
7	1	O
8	-	O
9	and	O
10	exon	O
11	2	O
12	-	O
13	initiated	O
14	forms	O
15	of	O
16	the	O
17	c	B
18	-	O
19	Myc	O
20	protein	O
21	stimulated	O
22	transcription	O
23	of	O
24	a	O
25	Myc	O
26	/	O
27	Max	O
28	-	O
29	responsive	O
30	reporter	O
31	construct	O
32	to	O
33	a	O
34	similar	O
35	level	O
36	.	O
1	Genetic	O
2	alterations	O
3	in	O
4	elements	O
5	of	O
6	normal	O
7	signal	O
8	transduction	O
9	mechanisms	O
10	are	O
11	known	O
12	to	O
13	be	O
14	oncogenic	O
15	events	O
16	often	O
17	resulting	O
18	in	O
19	aberrant	O
20	activation	O
21	of	O
22	programs	O
23	of	O
24	gene	O
25	transcription	O
26	.	O
1	The	O
2	p73pct1	O
3	/	O
4	p85cdc10	O
5	complex	O
6	binds	O
7	both	O
8	in	O
9	vitro	O
10	and	O
11	in	O
12	vivo	O
13	to	O
14	MCB	O
15	but	O
16	not	O
17	SCB	O
18	or	O
19	E2F	O
20	sites	O
21	.	O
1	ORF	O
2	2	O
3	potentially	O
4	encoded	O
5	a	O
6	hydrophobic	O
7	protein	O
8	of	O
9	29	O
10	,	O
11	705	O
12	Da	O
13	with	O
14	six	O
15	potential	O
16	membrane	O
17	-	O
18	spanning	O
19	regions	O
20	.	O
1	In	O
2	eight	O
3	groups	O
4	of	O
5	subjects	O
6	operating	O
7	various	O
8	hand	O
9	-	O
10	held	O
11	vibrating	O
12	tools	O
13	and	O
14	aged	O
15	from	O
16	30	O
17	to	O
18	59	O
19	years	O
20	,	O
21	the	O
22	prevalence	O
23	rates	O
24	of	O
25	vibration	O
26	-	O
27	induced	O
28	white	O
29	finger	O
30	(	O
31	VWF	O
32	)	O
33	and	O
34	numbness	O
35	,	O
36	pain	O
37	,	O
38	or	O
39	stiffness	O
40	in	O
41	the	O
42	upper	O
43	and	O
44	lower	O
45	extremities	O
46	were	O
47	investigated	O
48	.	O
1	Plasmids	O
2	were	O
3	constructed	O
4	with	O
5	the	O
6	mouse	O
7	promoter	O
8	region	O
9	linked	O
10	to	O
11	the	O
12	reporter	O
13	gene	O
14	chloramphenicol	O
15	acetyltransferase	O
16	(	O
17	CAT	O
18	),	O
19	and	O
20	transiently	O
21	and	O
22	stably	O
23	transfected	O
24	in	O
25	the	O
26	INS	O
27	-	O
28	1	O
29	cells	O
30	.	O
1	Cytoplasmic	O
2	dynein	O
3	is	O
4	a	O
5	multisubunit	O
6	,	O
7	microtubule	O
8	-	O
9	dependent	O
10	mechanochemical	O
11	enzyme	O
12	that	O
13	has	O
14	been	O
15	proposed	O
16	to	O
17	function	O
18	in	O
19	a	O
20	variety	O
21	of	O
22	intracellular	O
23	movements	O
24	,	O
25	including	O
26	minus	O
27	-	O
28	end	O
29	-	O
30	directed	O
31	transport	O
32	of	O
33	organelles	O
34	.	O
1	Mutually	O
2	exclusive	O
3	interaction	O
4	of	O
5	the	O
6	adenovirus	O
7	E4	O
8	-	O
9	6	O
10	/	O
11	7	O
12	protein	O
13	and	O
14	the	O
15	retinoblastoma	O
16	gene	O
17	product	O
18	with	O
19	internal	O
20	domains	O
21	of	O
22	E2F	O
23	-	O
24	1	O
25	and	O
26	DP	O
27	-	O
28	1	O
29	.	O
1	Human	O
2	T	O
3	-	O
4	cell	O
5	leukemia	O
6	virus	O
7	type	O
8	I	O
9	Tax	O
10	activation	O
11	of	O
12	NF	B
13	-	O
14	kappa	B
15	B	O
16	/	O
17	Rel	O
18	involves	O
19	phosphorylation	O
20	and	O
21	degradation	O
22	of	O
23	I	O
24	kappa	B
25	B	O
26	alpha	B
27	and	O
28	RelA	O
29	(	O
30	p65	O
31	)-	O
32	mediated	O
33	induction	O
34	of	O
35	the	O
36	c	B
37	-	O
38	rel	O
39	gene	O
40	.	O
1	Because	O
2	endogenous	O
3	HSF	O
4	DNA	O
5	-	O
6	binding	O
7	activity	O
8	is	O
9	low	O
10	and	O
11	anti	B
12	-	O
13	hHSF1	O
14	antibody	O
15	does	O
16	not	O
17	recognize	O
18	Xenopus	O
19	HSF	O
20	,	O
21	we	O
22	employed	O
23	this	O
24	system	O
25	for	O
26	mapping	O
27	regions	O
28	in	O
29	hHSF1	O
30	that	O
31	are	O
32	required	O
33	for	O
34	the	O
35	maintenance	O
36	of	O
37	the	O
38	monomeric	O
39	state	O
40	.	O
1	These	O
2	RZR	O
3	subtypes	O
4	represent	O
5	members	O
6	of	O
7	a	O
8	new	O
9	family	O
10	of	O
11	orphan	O
12	nuclear	O
13	receptors	O
14	that	O
15	most	O
16	likely	O
17	regulate	O
18	specific	O
19	gene	O
20	expression	O
21	.	O
1	Mutation	O
2	of	O
3	KRKR	O
4	to	O
5	NGER	O
6	retains	O
7	MO15	O
8	in	O
9	the	O
10	cytoplasmic	O
11	compartment	O
12	,	O
13	whilst	O
14	the	O
15	wild	O
16	-	O
17	type	O
18	protein	O
19	is	O
20	detected	O
21	exclusively	O
22	in	O
23	the	O
24	nucleus	O
25	.	O
1	Univariate	O
2	statistical	O
3	analysis	O
4	based	O
5	on	O
6	Kaplan	O
7	-	O
8	Meier	O
9	-	O
10	estimates	O
11	and	O
12	Log	O
13	-	O
14	Rank	O
15	-	O
16	Test	O
17	showed	O
18	the	O
19	following	O
20	prognostically	O
21	beneficial	O
22	factors	O
23	:	O
24	Limited	O
25	disease	O
26	stage	O
27	(	O
28	p	O
29	=	O
30	0	O
31	.	O
32	009	O
33	),	O
34	NSE	O
35	serum	O
36	level	O
37	less	O
38	than	O
39	25	O
40	micrograms	O
41	/	O
42	l	O
43	(	O
44	p	O
45	=	O
46	0	O
47	.	O
48	016	O
49	),	O
50	serum	O
51	alkaline	O
52	phosphatase	B
53	less	O
54	than	O
55	200	O
56	U	O
57	/	O
58	l	O
59	(	O
60	p	O
61	=	O
62	0	O
63	.	O
64	035	O
65	),	O
66	normal	O
67	serum	O
68	albumin	O
69	(	O
70	p	O
71	=	O
72	0	O
73	.	O
74	003	O
75	)	O
76	and	O
77	activity	O
78	index	O
79	of	O
80	minimum	O
81	of	O
82	70	O
83	(	O
84	p	O
85	<	O
86	0	O
87	.	O
88	001	O
89	).	O
1	HBx	O
2	strongly	O
3	elevates	O
4	levels	O
5	of	O
6	GTP	O
7	-	O
8	bound	O
9	Ras	B
10	,	O
11	activated	O
12	and	O
13	phosphorylated	O
14	Raf	O
15	,	O
16	and	O
17	tyrosine	O
18	-	O
19	phosphorylated	O
20	and	O
21	activated	O
22	MAP	O
23	kinase	B
24	.	O
1	Ten	O
2	volunteers	O
3	were	O
4	tested	O
5	at	O
6	18	O
7	,	O
8	000	O
9	ft	O
10	(	O
11	5	O
12	,	O
13	486	O
14	m	O
15	),	O
16	and	O
17	through	O
18	12	O
19	,	O
20	000	O
21	,	O
22	8	O
23	,	O
24	000	O
25	,	O
26	and	O
27	5	O
28	,	O
29	000	O
30	ft	O
31	(	O
32	3	O
33	,	O
34	657	O
35	,	O
36	2	O
37	,	O
38	438	O
39	,	O
40	and	O
41	1	O
42	,	O
43	524	O
44	m	O
45	)	O
46	with	O
47	directional	O
48	sounds	O
49	recorded	O
50	via	O
51	a	O
52	dummy	O
53	head	O
54	microphone	O
55	and	O
56	presented	O
57	binaurally	O
58	.	O
1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	zebrafish	O
6	egr1	O
7	coding	O
8	region	O
9	revealed	O
10	a	O
11	high	O
12	level	O
13	of	O
14	homology	O
15	to	O
16	the	O
17	mouse	O
18	,	O
19	rat	O
20	,	O
21	and	O
22	human	O
23	Egr1	O
24	genes	O
25	with	O
26	the	O
27	notable	O
28	exception	O
29	of	O
30	a	O
31	polymorphic	O
32	,	O
33	triplet	O
34	nucleotide	O
35	repeat	O
36	sequence	O
37	in	O
38	the	O
39	region	O
40	coding	O
41	for	O
42	the	O
43	amino	O
44	terminus	O
45	of	O
46	the	O
47	Egr1	O
48	protein	O
49	.	O
1	Optima	O
2	)	O
3	genomic	O
4	library	O
5	by	O
6	hybridizing	O
7	with	O
8	elicitor	O
9	-	O
10	induced	O
11	stilbene	O
12	synthase	O
13	cDNA	O
14	as	O
15	a	O
16	probe	O
17	.	O
1	Enhanced	O
2	hepatic	O
3	portal	O
4	blood	O
5	flow	O
6	induced	O
7	by	O
8	prostaglandin	O
9	E1	O
10	following	O
11	liver	O
12	transplantation	O
13	in	O
14	pigs	O
15	.	O
1	One	O
2	gene	O
3	appears	O
4	ubiquitously	O
5	expressed	O
6	while	O
7	the	O
8	other	O
9	is	O
10	prominently	O
11	expressed	O
12	in	O
13	muscle	O
14	.	O
1	E1A	O
2	autoactivation	O
3	mediated	O
4	by	O
5	these	O
6	sites	O
7	was	O
8	about	O
9	twofold	O
10	compared	O
11	with	O
12	a	O
13	ninefold	O
14	activation	O
15	described	O
16	for	O
17	the	O
18	complete	O
19	E1A	O
20	promoter	O
21	.	O
1	Lesion	O
2	diameters	O
3	of	O
4	greater	O
5	than	O
6	20	O
7	mm	O
8	and	O
9	the	O
10	large	O
11	sessile	O
12	-	O
13	type	O
14	configurations	O
15	were	O
16	factors	O
17	that	O
18	were	O
19	associated	O
20	with	O
21	incomplete	O
22	removal	O
23	.	O
1	These	O
2	mutations	O
3	are	O
4	localized	O
5	in	O
6	the	O
7	same	O
8	region	O
9	where	O
10	the	O
11	HSV	O
12	transactivator	O
13	VP16	O
14	binds	O
15	,	O
16	but	O
17	did	O
18	not	O
19	coincide	O
20	with	O
21	the	O
22	VP16	O
23	contacts	O
24	.	O
1	The	O
2	hepatocyte	O
3	nuclear	O
4	factor	O
5	-	O
6	3	O
7	(	O
8	HNF	O
9	-	O
10	3	O
11	)/	O
12	forkhead	O
13	(	O
14	fkh	O
15	)	O
16	proteins	O
17	consist	O
18	of	O
19	an	O
20	extensive	O
21	family	O
22	of	O
23	tissue	O
24	-	O
25	specific	O
26	and	O
27	developmental	O
28	gene	O
29	regulators	O
30	which	O
31	share	O
32	homology	O
33	within	O
34	the	O
35	winged	O
36	helix	O
37	DNA	O
38	binding	O
39	motif	O
40	.	O
1	Homozygous	O
2	null	O
3	embryos	O
4	also	O
5	displayed	O
6	abnormalities	O
7	in	O
8	heart	O
9	development	O
10	,	O
11	consistent	O
12	with	O
13	the	O
14	conclusion	O
15	that	O
16	Tek	O
17	is	O
18	necessary	O
19	for	O
20	endocardial	O
21	/	O
22	myocardial	O
23	interactions	O
24	during	O
25	development	O
26	.	O
1	Interestingly	O
2	,	O
3	dTFIIA	O
4	-	O
5	L	O
6	/	O
7	S	O
8	is	O
9	also	O
10	able	O
11	to	O
12	significantly	O
13	enhance	O
14	transcriptional	O
15	activation	O
16	by	O
17	upstream	O
18	transcription	O
19	factors	O
20	including	O
21	Sp1	B
22	,	O
23	VP16	O
24	,	O
25	and	O
26	NTF	O
27	-	O
28	1	O
29	.	O
1	In	O
2	particular	O
3	,	O
4	changes	O
5	in	O
6	intracellular	O
7	Ca2	O
8	+	O
9	have	O
10	the	O
11	potential	O
12	to	O
13	either	O
14	inhibit	O
15	or	O
16	augment	O
17	the	O
18	ability	O
19	of	O
20	cAMP	O
21	to	O
22	stimulate	O
23	transcription	O
24	,	O
25	depending	O
26	on	O
27	the	O
28	presence	O
29	of	O
30	specific	O
31	forms	O
32	of	O
33	Ca2	O
34	+/	O
35	calmodulin	O
36	-	O
37	dependent	O
38	protein	O
39	kinases	B
40	.	O
1	C	O
2	/	O
3	EBP	O
4	alpha	B
5	also	O
6	activates	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	rat	O
12	class	O
13	-	O
14	I	O
15	ADH	O
16	gene	O
17	in	O
18	a	O
19	sequence	O
20	-	O
21	specific	O
22	manner	O
23	[	O
24	Potter	O
25	et	O
26	al	O
27	.,	O
28	Arch	O
29	.	O
1	IFI16	O
2	consists	O
3	of	O
4	ten	O
5	exons	O
6	and	O
7	nine	O
8	intervening	O
9	introns	O
10	spanning	O
11	at	O
12	least	O
13	28	O
14	kilobases	O
15	(	O
16	kb	O
17	)	O
18	of	O
19	DNA	O
20	.	O
1	Homology	O
2	was	O
3	also	O
4	detected	O
5	between	O
6	the	O
7	putative	O
8	transit	O
9	peptide	O
10	sequence	O
11	of	O
12	cysteine	O
13	synthase	O
14	C	O
15	and	O
16	other	O
17	mitochondrion	O
18	-	O
19	targeting	O
20	leader	O
21	sequences	O
22	.	O
1	The	O
2	P131	O
3	ORF	O
4	is	O
5	followed	O
6	in	O
7	-	O
8	frame	O
9	by	O
10	a	O
11	second	O
12	ORF	O
13	which	O
14	is	O
15	probably	O
16	expressed	O
17	by	O
18	partial	O
19	readthrough	O
20	of	O
21	the	O
22	UGA	O
23	termination	O
24	codon	O
25	of	O
26	the	O
27	P131	O
28	ORF	O
29	to	O
30	produce	O
31	a	O
32	polypeptide	O
33	of	O
34	M	O
35	(	O
36	r	O
37	)	O
38	191044	O
39	(	O
40	P191	O
41	).	O
1	Elementary	O
2	visual	O
3	hallucinations	O
4	in	O
5	migraine	O
6	and	O
7	epilepsy	O
8	.	O
1	Transient	O
2	transfections	O
3	of	O
4	a	O
5	construct	O
6	expressing	O
7	the	O
8	RNA	O
9	transcript	O
10	defined	O
11	by	O
12	clone	O
13	B1	O
14	.	O
15	1	O
16	into	O
17	D17	O
18	cells	O
19	led	O
20	to	O
21	the	O
22	expression	O
23	of	O
24	an	O
25	Env	O
26	/	O
27	Mlvi	O
28	-	O
29	4	O
30	fusion	O
31	protein	O
32	with	O
33	an	O
34	apparent	O
35	molecular	O
36	mass	O
37	of	O
38	33	O
39	kDa	O
40	.	O
1	The	O
2	sample	O
3	includes	O
4	all	O
5	the	O
6	HIV	O
7	-	O
8	infected	O
9	-	O
10	patients	O
11	continuously	O
12	referred	O
13	to	O
14	the	O
15	Outpatient	O
16	Service	O
17	of	O
18	the	O
19	Infectious	O
20	Diseases	B
21	dept	O
22	.	O
23	of	O
24	Bologna	O
25	'	O
26	s	O
27	""""	O
28	Ospedale	O
29	Maggiore	O
30	""""	O
31	General	O
32	Hospital	O
33	during	O
34	some	O
35	five	O
36	days	O
37	(	O
38	19	O
39	-	O
40	23rd	O
41	,	O
42	July	O
43	1993	O
44	).	O
1	Using	O
2	in	O
3	organello	O
4	footprint	O
5	analysis	O
6	,	O
7	we	O
8	demonstrate	O
9	that	O
10	within	O
11	human	O
12	placental	O
13	mitochondria	O
14	there	O
15	is	O
16	a	O
17	high	O
18	level	O
19	of	O
20	protein	O
21	-	O
22	DNA	O
23	binding	O
24	at	O
25	regularly	O
26	phased	O
27	intervals	O
28	throughout	O
29	a	O
30	500	O
31	-	O
32	bp	O
33	region	O
34	encompassing	O
35	the	O
36	D	O
37	-	O
38	loop	O
39	DNA	O
40	origins	O
41	and	O
42	two	O
43	promoter	O
44	regions	O
45	.	O
1	The	O
2	Nur77	O
3	protein	O
4	can	O
5	act	O
6	as	O
7	a	O
8	potent	O
9	transcription	O
10	activator	O
11	and	O
12	may	O
13	function	O
14	to	O
15	regulate	O
16	the	O
17	expression	O
18	of	O
19	downstream	O
20	genes	O
21	in	O
22	response	O
23	to	O
24	extracellular	O
25	stimuli	O
26	.	O
1	The	O
2	recovery	O
3	value	O
4	of	O
5	systolic	O
6	pressure	O
7	was	O
8	higher	O
9	than	O
10	diastolic	O
11	pressure	O
12	and	O
13	pulse	O
14	pressure	O
15	increased	O
16	.	O
1	Basal	O
2	plasma	O
3	AVP	O
4	levels	O
5	and	O
6	AVP	O
7	release	O
8	after	O
9	postural	O
10	change	O
11	were	O
12	assessed	O
13	,	O
14	and	O
15	plasma	O
16	NPY	O
17	levels	O
18	were	O
19	measured	O
20	in	O
21	the	O
22	same	O
23	samples	O
24	.	O
1	Our	O
2	previous	O
3	study	O
4	suggested	O
5	that	O
6	pertussis	O
7	toxin	O
8	(	O
9	IAP	O
10	)-	O
11	sensitive	O
12	GTP	O
13	-	O
14	binding	O
15	protein	O
16	(	O
17	s	O
18	)	O
19	(	O
20	G	O
21	-	O
22	protein	O
23	)	O
24	is	O
25	involved	O
26	in	O
27	the	O
28	process	O
29	of	O
30	differentiation	O
31	by	O
32	hormones	O
33	/	O
34	IBMX	O
35	,	O
36	accompanied	O
37	by	O
38	c	B
39	-	O
40	fos	O
41	induction	O
42	.	O
1	Point	O
2	mutations	O
3	that	O
4	suppressed	O
5	the	O
6	in	O
7	vitro	O
8	binding	O
9	of	O
10	NF	B
11	-	O
12	Y	O
13	to	O
14	the	O
15	internal	O
16	palindromic	O
17	arm	O
18	reduced	O
19	the	O
20	activity	O
21	of	O
22	the	O
23	resident	O
24	P4	O
25	promoter	O
26	,	O
27	while	O
28	those	O
29	preventing	O
30	complex	O
31	formation	O
32	with	O
33	USF	O
34	did	O
35	not	O
36	,	O
37	as	O
38	determined	O
39	by	O
40	transient	O
41	expression	O
42	assays	O
43	using	O
44	the	O
45	luciferase	O
46	reporter	O
47	gene	O
48	.	O
1	Surprisingly	O
2	,	O
3	Northern	O
4	(	O
5	RNA	O
6	)	O
7	blot	O
8	analysis	O
9	and	O
10	reverse	O
11	transcriptase	O
12	-	O
13	PCRs	O
14	performed	O
15	after	O
16	transfection	O
17	of	O
18	COS	O
19	-	O
20	7	O
21	or	O
22	HeLa	O
23	cells	O
24	with	O
25	these	O
26	viral	O
27	RNAs	O
28	revealed	O
29	that	O
30	Y88S	O
31	and	O
32	Y88L	O
33	RNAs	O
34	replicated	O
35	at	O
36	only	O
37	very	O
38	low	O
39	levels	O
40	.	O
1	Surprisingly	O
2	,	O
3	nuclear	O
4	forms	O
5	of	O
6	IE110	O
7	were	O
8	found	O
9	to	O
10	move	O
11	a	O
12	cytoplasmic	O
13	form	O
14	of	O
15	IE175	O
16	into	O
17	nuclear	O
18	punctate	O
19	structures	O
20	,	O
21	and	O
22	a	O
23	cytoplasmic	O
24	form	O
25	of	O
26	IE110	O
27	was	O
28	able	O
29	to	O
30	retain	O
31	nuclear	O
32	forms	O
33	of	O
34	IE175	O
35	in	O
36	cytoplasmic	O
37	punctate	O
38	structures	O
39	.	O
1	The	O
2	inflation	O
3	hub	O
4	of	O
5	the	O
6	probe	O
7	is	O
8	recreated	O
9	by	O
10	modifying	O
11	a	O
12	standard	O
13	USCI	O
14	Tuohy	O
15	-	O
16	Borst	O
17	Y	O
18	adaptor	O
19	and	O
20	attaching	O
21	this	O
22	to	O
23	the	O
24	transected	O
25	probe	O
26	hypotube	O
27	.	O
1	The	O
2	other	O
3	element	O
4	bound	O
5	RBP	O
6	-	O
7	J	O
8	kappa	B
9	with	O
10	low	O
11	affinity	O
12	.	O
1	2	O
2	patients	O
3	(	O
4	11	O
5	%)	O
6	had	O
7	significant	O
8	morbidity	O
9	502	O
10	and	O
11	529	O
12	days	O
13	respectively	O
14	after	O
15	transplantation	O
16	.	O
1	A	O
2	recent	O
3	index	O
4	(	O
5	Fluorosis	O
6	Risk	O
7	Index	O
8	)	O
9	developed	O
10	by	O
11	Pendrys	O
12	(	O
13	1990	O
14	)	O
15	is	O
16	also	O
17	included	O
18	in	O
19	this	O
20	review	O
21	.	O
1	Alternative	O
2	splicing	O
3	of	O
4	the	O
5	cytoplasmic	O
6	tail	O
7	appears	O
8	to	O
9	generate	O
10	multiple	O
11	PECAM	O
12	-	O
13	1	O
14	isoforms	O
15	that	O
16	may	O
17	regulate	O
18	phosphorylation	O
19	,	O
20	cytoskeletal	O
21	association	O
22	,	O
23	and	O
24	affinity	O
25	modulation	O
26	of	O
27	the	O
28	mature	O
29	protein	O
30	.	O
1	Transfer	O
2	also	O
3	correlated	O
4	inversely	O
5	with	O
6	gastric	O
7	juice	O
8	pH	O
9	(	O
10	r	O
11	=	O
12	-	O
13	0	O
14	.	O
15	619	O
16	,	O
17	P	O
18	<	O
19	0	O
20	.	O
21	02	O
22	).	O
1	This	O
2	technique	O
3	has	O
4	a	O
5	sensitivity	O
6	and	O
7	a	O
8	specificity	O
9	of	O
10	almost	O
11	100	O
12	%,	O
13	and	O
14	is	O
15	currently	O
16	the	O
17	best	O
18	way	O
19	to	O
20	diagnose	O
21	nodal	O
22	involvement	O
23	,	O
24	apart	O
25	from	O
26	laparotomy	O
27	.	O
1	Cumulated	O
2	maximum	O
3	lod	O
4	scores	O
5	between	O
6	FRDA	O
7	and	O
8	D9S5	O
9	and	O
10	between	O
11	FRDA	O
12	and	O
13	D9S15	O
14	are	O
15	above	O
16	36	O
17	and	O
18	61	O
19	,	O
20	respectively	O
21	,	O
22	at	O
23	a	O
24	recombination	O
25	fraction	O
26	of	O
27	0	O
28	,	O
29	indicating	O
30	that	O
31	recombination	O
32	events	O
33	needed	O
34	to	O
35	orient	O
36	the	O
37	search	O
38	of	O
39	the	O
40	gene	O
41	are	O
42	very	O
43	difficult	O
44	to	O
45	identify	O
46	and	O
47	ascertain	O
48	.	O
1	A	O
2	cDNA	O
3	clone	O
4	pCZ1	O
5	,	O
6	with	O
7	a	O
8	1	O
9	.	O
10	1	O
11	kb	O
12	insert	O
13	,	O
14	was	O
15	isolated	O
16	from	O
17	a	O
18	NaCl	O
19	-	O
20	adapted	O
21	tobacco	O
22	cell	O
23	cDNA	O
24	library	O
25	that	O
26	encodes	O
27	an	O
28	apparently	O
29	full	O
30	-	O
31	length	O
32	29	O
33	kDa	O
34	protein	O
35	(	O
36	251	O
37	amino	O
38	acids	O
39	)	O
40	with	O
41	a	O
42	calculated	O
43	pI	O
44	of	O
45	5	O
46	.	O
47	7	O
48	.	O
1	I	O
2	hypothesize	O
3	that	O
4	white	O
5	gene	O
6	expression	O
7	from	O
8	P	O
9	[	O
10	en	O
11	]	O
12	is	O
13	repressed	O
14	by	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	protein	O
20	complex	O
21	which	O
22	is	O
23	initiated	O
24	at	O
25	the	O
26	engrailed	O
27	PS	O
28	sites	O
29	and	O
30	also	O
31	requires	O
32	interactions	O
33	with	O
34	flanking	O
35	genomic	O
36	DNA	O
37	.	O
1	Deletion	O
2	studies	O
3	identified	O
4	a	O
5	distal	O
6	response	O
7	element	O
8	that	O
9	is	O
10	responsible	O
11	for	O
12	the	O
13	cytokine	O
14	response	O
15	and	O
16	has	O
17	properties	O
18	of	O
19	an	O
20	inducible	O
21	transcriptional	O
22	enhancer	O
23	.	O
1	2	O
2	.	O
1	The	O
2	complete	O
3	gene	O
4	organization	O
5	was	O
6	obtained	O
7	by	O
8	combining	O
9	the	O
10	results	O
11	of	O
12	the	O
13	sequence	O
14	of	O
15	these	O
16	clones	O
17	and	O
18	those	O
19	of	O
20	the	O
21	characterization	O
22	of	O
23	polymerase	B
24	chain	O
25	reaction	O
26	-	O
27	amplified	O
28	genomic	O
29	segments	O
30	.	O
1	Sample	O
2	treatment	O
3	was	O
4	optimized	O
5	in	O
6	order	O
7	to	O
8	achieve	O
9	a	O
10	complete	O
11	extraction	O
12	of	O
13	labetalol	O
14	diastereoisomers	O
15	and	O
16	to	O
17	avoid	O
18	racemization	O
19	during	O
20	extraction	O
21	.	O
1	In	O
2	control	O
3	patients	O
4	,	O
5	baseline	O
6	images	O
7	presented	O
8	Type	O
9	I	O
10	in	O
11	25	O
12	,	O
13	Type	O
14	II	O
15	in	O
16	7	O
17	,	O
18	and	O
19	the	O
20	Type	O
21	III	O
22	&	O
23	IV	O
24	in	O
25	0	O
26	,	O
27	and	O
28	the	O
29	Type	O
30	after	O
31	loading	O
32	was	O
33	the	O
34	same	O
35	as	O
36	the	O
37	Type	O
38	at	O
39	baseline	O
40	.	O
1	A	O
2	randomised	O
3	,	O
4	controlled	O
5	trial	O
6	was	O
7	undertaken	O
8	in	O
9	40	O
10	patients	O
11	with	O
12	active	O
13	Crohn	O
14	'	O
15	s	O
16	disease	O
17	to	O
18	evaluate	O
19	clinical	O
20	and	O
21	nutritional	O
22	outcomes	O
23	after	O
24	an	O
25	amino	O
26	acid	O
27	based	O
28	diet	O
29	containing	O
30	3	O
31	%	O
32	fat	O
33	was	O
34	given	O
35	by	O
36	a	O
37	feeding	O
38	tube	O
39	compared	O
40	with	O
41	a	O
42	peptide	O
43	based	O
44	diet	O
45	containing	O
46	33	O
47	%	O
48	fat	O
49	.	O
1	The	O
2	fepA	O
3	-	O
4	entD	O
5	and	O
6	fes	O
7	-	O
8	entF	O
9	operons	O
10	in	O
11	the	O
12	enterobactin	O
13	synthesis	O
14	and	O
15	transport	O
16	system	O
17	are	O
18	divergently	O
19	transcribed	O
20	from	O
21	overlapping	O
22	promoters	O
23	,	O
24	and	O
25	both	O
26	are	O
27	inhibited	O
28	by	O
29	the	O
30	Fur	O
31	repressor	O
32	protein	O
33	under	O
34	iron	O
35	-	O
36	replete	O
37	conditions	O
38	.	O
1	In	O
2	an	O
3	in	O
4	vitro	O
5	study	O
6	,	O
7	10	O
8	/	O
9	0	O
10	nylon	O
11	was	O
12	found	O
13	to	O
14	require	O
15	a	O
16	significantly	O
17	lower	O
18	laser	O
19	energy	O
20	density	O
21	to	O
22	produce	O
23	suture	O
24	lysis	O
25	following	O
26	a	O
27	single	O
28	shot	O
29	than	O
30	either	O
31	10	O
32	/	O
33	0	O
34	Dacron	O
35	or	O
36	10	O
37	/	O
38	0	O
39	prolene	O
40	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	microinjection	O
6	of	O
7	an	O
8	anti	B
9	-	O
10	CBP	O
11	antiserum	O
12	into	O
13	fibroblasts	O
14	can	O
15	inhibit	O
16	transcription	O
17	from	O
18	a	O
19	cAMP	O
20	responsive	O
21	promoter	O
22	.	O
1	However	O
2	,	O
3	by	O
4	an	O
5	NS35	O
6	-	O
7	specific	O
8	RNA	O
9	capture	O
10	assay	O
11	,	O
12	the	O
13	multimers	O
14	were	O
15	shown	O
16	to	O
17	possess	O
18	the	O
19	RNA	O
20	-	O
21	binding	O
22	activity	O
23	previously	O
24	demonstrated	O
25	for	O
26	NS35	O
27	.	O
1	Ketamine	O
2	in	O
3	the	O
4	treatment	O
5	of	O
6	bronchospasm	O
7	during	O
8	mechanical	O
9	ventilation	O
10	.	O
1	Number	O
2	and	O
3	size	O
4	of	O
5	silver	O
6	-	O
7	stained	O
8	nucleoli	O
9	(	O
10	Ag	O
11	-	O
12	NOR	O
13	clusters	O
14	)	O
15	in	O
16	canine	O
17	seminomas	O
18	:	O
19	correlation	O
20	with	O
21	histological	O
22	features	O
23	and	O
24	tumour	O
25	behaviour	O
26	.	O
1	The	O
2	tumor	O
3	suppressor	O
4	and	O
5	transcriptional	O
6	factor	O
7	p53	B
8	is	O
9	a	O
10	phosphorylated	O
11	protein	O
12	.	O
1	However	O
2	,	O
3	regional	O
4	MVO2	O
5	increased	O
6	to	O
7	about	O
8	the	O
9	same	O
10	extent	O
11	in	O
12	the	O
13	CFX	O
14	(	O
15	from	O
16	6	O
17	.	O
18	0	O
19	+/-	O
20	0	O
21	.	O
22	7	O
23	to	O
24	12	O
25	.	O
26	4	O
27	+/-	O
28	0	O
29	.	O
30	9	O
31	ml	O
32	O2	O
33	.	O
34	min	O
35	-	O
36	1	O
37	times	O
38	100	O
39	g	O
40	-	O
41	1	O
42	)	O
43	and	O
44	the	O
45	LAD	O
46	region	O
47	(	O
48	from	O
49	7	O
50	.	O
51	0	O
52	+/-	O
53	0	O
54	.	O
55	6	O
56	to	O
57	14	O
58	.	O
59	5	O
60	+/-	O
61	1	O
62	.	O
63	3	O
64	ml	O
65	O2	O
66	.	O
67	min	O
68	-	O
69	1	O
70	times	O
71	100	O
72	g	O
73	-	O
74	1	O
75	).	O
1	IGF	O
2	I	O
3	and	O
4	insulin	B
5	receptors	O
6	are	O
7	homologous	O
8	proteins	O
9	that	O
10	function	O
11	in	O
12	distinct	O
13	physiological	O
14	pathways	O
15	.	O
1	Acute	O
2	pancreatitis	O
3	:	O
4	a	O
5	multisystem	O
6	disease	O
7	.	O
1	Alginate	O
2	biosynthesis	O
3	is	O
4	controlled	O
5	by	O
6	a	O
7	complex	O
8	regulatory	O
9	mechanism	O
10	.	O
1	The	O
2	sequence	O
3	upstream	O
4	of	O
5	the	O
6	rhlA	O
7	promoter	O
8	contains	O
9	two	O
10	inverted	O
11	repeats	O
12	which	O
13	define	O
14	putative	O
15	binding	O
16	sites	O
17	for	O
18	the	O
19	RhlR	O
20	regulator	O
21	.	O
1	We	O
2	have	O
3	examined	O
4	by	O
5	in	O
6	vitro	O
7	footprinting	O
8	a	O
9	region	O
10	located	O
11	downstream	O
12	of	O
13	the	O
14	human	O
15	immunodeficiency	O
16	virus	O
17	,	O
18	type	O
19	1	O
20	(	O
21	HIV	O
22	-	O
23	1	O
24	)	O
25	promoter	O
26	found	O
27	to	O
28	be	O
29	hypersensitive	O
30	to	O
31	DNase	B
32	I	O
33	digestion	O
34	in	O
35	vivo	O
36	.	O
1	Heparin	O
2	had	O
3	no	O
4	effect	O
5	on	O
6	rAC	O
7	-	O
8	st	O
9	myosin	O
10	light	O
11	chain	O
12	phosphatase	B
13	activity	O
14	,	O
15	while	O
16	the	O
17	B	O
18	subunit	O
19	-	O
20	containing	O
21	forms	O
22	were	O
23	stimulated	O
24	2	O
25	-	O
26	3	O
27	-	O
28	fold	O
29	.	O
1	The	O
2	first	O
3	85	O
4	nt	O
5	upstream	O
6	of	O
7	the	O
8	transcription	O
9	initiation	O
10	site	O
11	of	O
12	the	O
13	mouse	O
14	desmin	O
15	gene	O
16	,	O
17	which	O
18	contain	O
19	an	O
20	E	O
21	box	O
22	(	O
23	E1	O
24	),	O
25	the	O
26	binding	O
27	site	O
28	of	O
29	the	O
30	helix	O
31	-	O
32	loop	O
33	-	O
34	helix	O
35	myogenic	O
36	regulators	O
37	,	O
38	are	O
39	sufficient	O
40	to	O
41	confer	O
42	low	O
43	level	O
44	muscle	O
45	-	O
46	specific	O
47	expression	O
48	.	O
1	Long	O
2	-	O
3	latency	O
4	:	O
5	locked	O
6	units	O
7	responded	O
8	to	O
9	shocks	O
10	with	O
11	little	O
12	jitter	O
13	and	O
14	long	O
15	latency	O
16	(	O
17	4	O
18	-	O
19	11	O
20	ms	O
21	).	O
1	An	O
2	in	O
3	vitro	O
4	binding	O
5	site	O
6	selection	O
7	procedure	O
8	was	O
9	used	O
10	to	O
11	determine	O
12	DNA	O
13	sequences	O
14	preferentially	O
15	bound	O
16	by	O
17	wild	O
18	-	O
19	type	O
20	HLF	O
21	and	O
22	chimeric	O
23	E2A	O
24	-	O
25	HLF	O
26	proteins	O
27	isolated	O
28	from	O
29	various	O
30	t	O
31	(	O
32	17	O
33	;	O
34	19	O
35	)-	O
36	bearing	O
37	leukemias	O
38	.	O
1	The	O
2	Oct	O
3	-	O
4	2	O
5	glutamine	O
6	-	O
7	rich	O
8	and	O
9	proline	O
10	-	O
11	rich	O
12	activation	O
13	domains	O
14	can	O
15	synergize	O
16	with	O
17	each	O
18	other	O
19	or	O
20	duplicates	O
21	of	O
22	themselves	O
23	to	O
24	activate	O
25	transcription	O
26	.	O
1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	Dbf8p	O
9	plays	O
10	an	O
11	essential	O
12	role	O
13	in	O
14	chromosome	O
15	segregation	O
16	.	O
1	Marine	O
2	oils	O
3	and	O
4	cardiovascular	O
5	reactivity	O
6	.	O
1	These	O
2	alternative	O
3	splice	O
4	variants	O
5	were	O
6	detected	O
7	in	O
8	RNA	O
9	isolated	O
10	from	O
11	several	O
12	sources	O
13	,	O
14	including	O
15	primary	O
16	leptomeningeal	O
17	tissue	O
18	and	O
19	an	O
20	established	O
21	line	O
22	of	O
23	leptomeningeal	O
24	cells	O
25	(	O
26	LMC	O
27	).	O
1	Roux	O
2	-	O
3	en	O
4	-	O
5	Y	O
6	gastroenterostomy	O
7	severely	O
8	disturbs	O
9	emptying	O
10	of	O
11	the	O
12	gallbladder	O
13	.	O
1	Large	O
2	interpatient	O
3	variation	O
4	in	O
5	peak	O
6	PCZ	O
7	plasma	O
8	levels	O
9	(	O
10	91	O
11	-	O
12	3215	O
13	ng	O
14	/	O
15	ml	O
16	)	O
17	was	O
18	seen	O
19	,	O
20	with	O
21	the	O
22	plasma	O
23	half	O
24	-	O
25	life	O
26	(	O
27	t1	O
28	/	O
29	2	O
30	alpha	B
31	)	O
32	being	O
33	approximately	O
34	57	O
35	min	O
36	in	O
37	patients	O
38	given	O
39	135	O
40	-	O
41	180	O
42	mg	O
43	/	O
44	m2	O
45	PCZ	O
46	.	O
1	The	O
2	newly	O
3	recognised	O
4	skeletogenital	O
5	syndrome	O
6	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	leader	O
6	-	O
7	mRNA	O
8	fusion	O
9	in	O
10	coronavirus	O
11	transcription	O
12	does	O
13	not	O
14	require	O
15	direct	O
16	RNA	O
17	-	O
18	RNA	O
19	interaction	O
20	between	O
21	complementary	O
22	sequences	O
23	.	O
1	This	O
2	alternatively	O
3	spliced	O
4	transcript	O
5	contained	O
6	an	O
7	open	O
8	reading	O
9	frame	O
10	extending	O
11	from	O
12	the	O
13	upstream	O
14	J	O
15	alpha	B
16	11	O
17	-	O
18	2	O
19	region	O
20	to	O
21	82	O
22	nucleotides	O
23	downstream	O
24	of	O
25	the	O
26	beginning	O
27	of	O
28	the	O
29	TCR	O
30	C	O
31	alpha	B
32	region	O
33	,	O
34	and	O
35	potentially	O
36	encoded	O
37	a	O
38	36	O
39	amino	O
40	acid	O
41	polypeptide	O
42	.	O
1	These	O
2	mutants	O
3	had	O
4	deletions	O
5	of	O
6	the	O
7	extreme	O
8	amino	O
9	-	O
10	terminal	O
11	residues	O
12	as	O
13	far	O
14	as	O
15	amino	O
16	acid	O
17	residue	O
18	30	O
19	.	O
1	Double	O
2	-	O
3	staining	O
4	confirmed	O
5	that	O
6	there	O
7	were	O
8	separate	O
9	populations	O
10	of	O
11	CD68	O
12	-	O
13	positive	O
14	macrophages	O
15	and	O
16	XIIIa	O
17	-	O
18	positive	O
19	dendrocytes	O
20	.	O
1	Vasopressin	O
2	(	O
3	AVP	O
4	),	O
5	the	O
6	antidiuretic	O
7	hormone	O
8	,	O
9	is	O
10	a	O
11	cyclic	O
12	nonapeptide	O
13	that	O
14	acts	O
15	through	O
16	binding	O
17	to	O
18	G	O
19	protein	O
20	-	O
21	coupled	O
22	specific	O
23	membrane	O
24	receptors	O
25	pharmacologically	O
26	divided	O
27	into	O
28	three	O
29	subtypes	O
30	(	O
31	V1a	O
32	,	O
33	V1b	O
34	,	O
35	and	O
36	V2	O
37	)	O
38	linked	O
39	to	O
40	distinct	O
41	second	O
42	messengers	O
43	.	O
1	When	O
2	the	O
3	promoter	O
4	region	O
5	was	O
6	linked	O
7	with	O
8	a	O
9	heterologous	O
10	reporter	O
11	gene	O
12	,	O
13	we	O
14	found	O
15	that	O
16	the	O
17	promoter	O
18	region	O
19	is	O
20	inducible	O
21	by	O
22	both	O
23	interferons	O
24	(	O
25	interferon	O
26	-	O
27	alpha	B
28	and	O
29	-	O
30	gamma	B
31	)	O
32	and	O
33	interferon	O
34	regulatory	O
35	factor	O
36	1	O
37	.	O
1	All	O
2	other	O
3	normal	O
4	and	O
5	transformed	O
6	lymphoid	O
7	and	O
8	nonlymphoid	O
9	cell	O
10	lines	O
11	and	O
12	normal	O
13	tissues	O
14	were	O
15	negative	O
16	for	O
17	PANG	O
18	expression	O
19	except	O
20	for	O
21	the	O
22	brain	O
23	,	O
24	wherein	O
25	unique	O
26	4	O
27	.	O
28	0	O
29	-	O
30	and	O
31	6	O
32	.	O
33	1	O
34	-	O
35	kb	O
36	transcripts	O
37	were	O
38	detected	O
39	.	O
1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	LBP	O
7	-	O
8	1	O
9	represses	O
10	HIV	O
11	-	O
12	1	O
13	transcription	O
14	by	O
15	inhibiting	O
16	the	O
17	binding	O
18	of	O
19	TFIID	O
20	to	O
21	the	O
22	TATA	O
23	box	O
24	.	O
1	However	O
2	,	O
3	three	O
4	Hm1	O
5	mutants	O
6	that	O
7	were	O
8	moderately	O
9	deficient	O
10	in	O
11	stimulating	O
12	PI	O
13	turnover	O
14	displayed	O
15	normal	O
16	sequestration	O
17	,	O
18	suggesting	O
19	distinct	O
20	mechanisms	O
21	.	O
1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	In	O
6	25	O
7	open	O
8	-	O
9	chest	O
10	,	O
11	anesthetized	O
12	dogs	O
13	,	O
14	progressive	O
15	circumflex	O
16	artery	O
17	stenosis	O
18	led	O
19	to	O
20	a	O
21	concordant	O
22	decrease	O
23	of	O
24	circumflex	O
25	artery	O
26	resting	O
27	and	O
28	hyperemic	O
29	flow	O
30	,	O
31	coronary	O
32	flow	O
33	reserve	O
34	,	O
35	and	O
36	inverse	O
37	angiographic	O
38	mean	O
39	transit	O
40	time	O
41	Tmicro	O
42	-	O
43	1	O
44	(	O
45	P	O
46	<	O
47	.	O
48	01	O
49	).	O
1	The	O
2	ipiO	O
3	genes	O
4	code	O
5	for	O
6	two	O
7	almost	O
8	identical	O
9	152	O
10	-	O
11	aa	O
12	proteins	O
13	which	O
14	do	O
15	not	O
16	have	O
17	any	O
18	homology	O
19	with	O
20	sequences	O
21	present	O
22	in	O
23	data	O
24	libraries	O
25	.	O
1	The	O
2	alpha	B
3	7A	O
4	form	O
5	RNA	O
6	contains	O
7	an	O
8	additional	O
9	113	O
10	nucleotides	O
11	compared	O
12	to	O
13	the	O
14	B	O
15	form	O
16	,	O
17	and	O
18	a	O
19	common	O
20	coding	O
21	region	O
22	in	O
23	the	O
24	A	O
25	and	O
26	B	O
27	form	O
28	RNAs	O
29	is	O
30	used	O
31	in	O
32	alternate	O
33	reading	O
34	frames	O
35	.	O
1	CRS	O
2	function	O
3	in	O
4	a	O
5	5	O
6	'	O
7	LTR	O
8	-	O
9	linked	O
10	gene	O
11	expression	O
12	assay	O
13	correlates	O
14	with	O
15	the	O
16	ability	O
17	of	O
18	both	O
19	p60CRS	O
20	and	O
21	p40CRS	O
22	to	O
23	interact	O
24	with	O
25	5	O
26	'	O
27	LTR	O
28	RNA	O
29	in	O
30	vitro	O
31	.	O
1	Serial	O
2	levels	O
3	of	O
4	troponin	O
5	T	O
6	and	O
7	the	O
8	activity	O
9	of	O
10	CK	O
11	-	O
12	MB	O
13	were	O
14	measured	O
15	6	O
16	,	O
17	12	O
18	,	O
19	24	O
20	and	O
21	48	O
22	h	O
23	after	O
24	aortic	O
25	unclamping	O
26	.	O
1	Regionalization	O
2	of	O
3	drug	O
4	delivery	O
5	is	O
6	a	O
7	potential	O
8	method	O
9	to	O
10	avoid	O
11	this	O
12	problem	O
13	.	O
1	Members	O
2	of	O
3	SVA	O
4	are	O
5	also	O
6	present	O
7	in	O
8	the	O
9	complement	O
10	C2	O
11	gene	O
12	located	O
13	about	O
14	20	O
15	kilobases	O
16	upstream	O
17	of	O
18	RP1	O
19	in	O
20	the	O
21	HLA	O
22	and	O
23	in	O
24	the	O
25	cytochrome	O
26	CYP1A1	O
27	gene	O
28	.	O
1	The	O
2	mutations	O
3	did	O
4	not	O
5	affect	O
6	the	O
7	repression	O
8	of	O
9	CPA1	O
10	by	O
11	arginine	O
12	.	O
1	A	O
2	segment	O
3	of	O
4	mRNA	O
5	encoding	O
6	the	O
7	leader	O
8	peptide	O
9	of	O
10	the	O
11	CPA1	O
12	gene	O
13	confers	O
14	repression	O
15	by	O
16	arginine	O
17	on	O
18	a	O
19	heterologous	O
20	yeast	O
21	gene	O
22	transcript	O
23	.	O
1	The	O
2	cysteine	O
3	-	O
4	rich	O
5	region	O
6	of	O
7	raf	O
8	-	O
9	1	O
10	kinase	B
11	contains	O
12	zinc	O
13	,	O
14	translocates	O
15	to	O
16	liposomes	O
17	,	O
18	and	O
19	is	O
20	adjacent	O
21	to	O
22	a	O
23	segment	O
24	that	O
25	binds	O
26	GTP	O
27	-	O
28	ras	O
29	.	O
1	Rather	O
2	,	O
3	complete	O
4	skipping	O
5	of	O
6	exon	O
7	V	O
8	and	O
9	subsequent	O
10	joining	O
11	of	O
12	exon	O
13	IV	O
14	to	O
15	exon	O
16	VI	O
17	caused	O
18	a	O
19	shift	O
20	in	O
21	the	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	which	O
27	remodeled	O
28	GPHe	O
29	(	O
30	P2	O
31	)	O
32	with	O
33	an	O
34	elongated	O
35	new	O
36	hydrophobic	O
37	sequence	O
38	for	O
39	membrane	O
40	anchoring	O
41	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	PKC	B
7	alpha	I
8	(	O
9	calcium	O
10	dependent	O
11	)	O
12	and	O
13	PKC	B
14	delta	I
15	(	O
16	calcium	O
17	independent	O
18	)	O
19	may	O
20	mediate	O
21	the	O
22	transcription	O
23	of	O
24	TPA	O
25	-	O
26	inducible	O
27	genes	O
28	through	O
29	both	O
30	AP	B
31	-	O
32	1	O
33	and	O
34	non	O
35	-	O
36	AP	B
37	-	O
38	1	O
39	sequences	O
40	.	O
1	Sequence	O
2	comparisons	O
3	have	O
4	shown	O
5	that	O
6	Aps1p	O
7	is	O
8	more	O
9	similar	O
10	to	O
11	the	O
12	sigma	O
13	subunit	O
14	of	O
15	the	O
16	Golgi	O
17	-	O
18	localized	O
19	mammalian	O
20	AP	B
21	-	O
22	1	O
23	complex	O
24	than	O
25	Aps2p	O
26	,	O
27	which	O
28	is	O
29	more	O
30	related	O
31	to	O
32	the	O
33	plasma	O
34	membrane	O
35	AP	B
36	-	O
37	2	O
38	sigma	O
39	subunit	O
40	.	O
1	These	O
2	results	O
3	are	O
4	the	O
5	first	O
6	to	O
7	demonstrate	O
8	the	O
9	structural	O
10	organization	O
11	of	O
12	a	O
13	vertebrate	O
14	gene	O
15	encoding	O
16	an	O
17	integral	O
18	membrane	O
19	protein	O
20	of	O
21	the	O
22	nuclear	O
23	envelope	O
24	that	O
25	may	O
26	be	O
27	a	O
28	member	O
29	of	O
30	a	O
31	family	O
32	of	O
33	polypeptides	O
34	conserved	O
35	in	O
36	evolution	O
37	.	O
1	The	O
2	presence	O
3	of	O
4	the	O
5	foreign	O
6	gene	O
7	was	O
8	confirmed	O
9	by	O
10	Southern	O
11	analysis	O
12	.	O
1	All	O
2	patients	O
3	with	O
4	deterioriation	O
5	in	O
6	mental	O
7	status	O
8	showed	O
9	a	O
10	marked	O
11	increase	O
12	in	O
13	liver	O
14	enzymes	O
15	(	O
16	aspartate	O
17	and	O
18	alanine	O
19	aminotransaminases	O
20	)	O
21	and	O
22	severe	O
23	coagulopathy	O
24	.	O
1	Eleven	O
2	patients	O
3	tested	O
4	positive	O
5	for	O
6	the	O
7	hepatitis	O
8	B	O
9	surface	O
10	antigen	B
11	(	O
12	HBsAg	O
13	).	O
1	Surprisingly	O
2	,	O
3	TFIIIC	O
4	alpha	B
5	has	O
6	no	O
7	homology	O
8	to	O
9	any	O
10	of	O
11	the	O
12	yeast	O
13	TFIIIC	O
14	subunits	O
15	already	O
16	cloned	O
17	,	O
18	suggesting	O
19	a	O
20	significant	O
21	degree	O
22	of	O
23	evolutionary	O
24	divergence	O
25	for	O
26	RNA	O
27	polymerase	B
28	III	O
29	factors	O
30	.	O
1	Location	O
2	and	O
3	orientation	O
4	of	O
5	an	O
6	activating	O
7	region	O
8	in	O
9	the	O
10	Escherichia	O
11	coli	O
12	transcription	O
13	factor	O
14	,	O
15	FNR	O
16	.	O
1	The	O
2	class	O
3	II	O
4	Escherichia	O
5	coli	O
6	alanine	O
7	tRNA	O
8	synthetase	O
9	aminoacylates	O
10	RNA	O
11	miniduplexes	O
12	,	O
13	which	O
14	reconstruct	O
15	the	O
16	acceptor	O
17	end	O
18	of	O
19	alanine	O
20	tRNA	O
21	with	O
22	the	O
23	critical	O
24	G3	O
25	:	O
26	U70	O
27	base	O
28	pair	O
29	.	O
1	A	O
2	concentration	O
3	of	O
4	12	O
5	.	O
6	5	O
7	ppm	O
8	SO2	O
9	induced	O
10	a	O
11	decrease	O
12	from	O
13	baseline	O
14	values	O
15	of	O
16	approximately	O
17	80	O
18	%	O
19	in	O
20	mean	O
21	MCA	O
22	and	O
23	of	O
24	roughly	O
25	70	O
26	%	O
27	in	O
28	mean	O
29	CBF	O
30	.	O
1	The	O
2	data	O
3	suggest	O
4	that	O
5	ICP10	O
6	constitutively	O
7	increases	O
8	ras	O
9	activity	O
10	,	O
11	and	O
12	its	O
13	TM	O
14	segment	O
15	plays	O
16	a	O
17	critical	O
18	role	O
19	in	O
20	transformation	O
21	-	O
22	related	O
23	signaling	O
24	pathways	O
25	.	O
1	Northern	O
2	analysis	O
3	,	O
4	to	O
5	search	O
6	for	O
7	a	O
8	pcbAB	O
9	transcript	O
10	,	O
11	showed	O
12	no	O
13	distinct	O
14	transcript	O
15	and	O
16	indicated	O
17	severely	O
18	degraded	O
19	mRNA	O
20	.	O
1	The	O
2	efficacy	O
3	of	O
4	a	O
5	Propionibacterium	O
6	acnes	O
7	product	O
8	for	O
9	treatment	O
10	of	O
11	coliform	O
12	mastitis	O
13	was	O
14	evaluated	O
15	following	O
16	intramammary	O
17	infusion	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O
1	The	O
2	human	O
3	eps15	O
4	gene	O
5	,	O
6	encoding	O
7	a	O
8	tyrosine	O
9	kinase	B
10	substrate	O
11	,	O
12	is	O
13	conserved	O
14	in	O
15	evolution	O
16	and	O
17	maps	O
18	to	O
19	1p31	O
20	-	O
21	p32	O
22	.	O
1	Frequent	O
2	loss	O
3	of	O
4	heterozygosity	O
5	(	O
6	LOH	O
7	)	O
8	of	O
9	>	O
10	30	O
11	%	O
12	of	O
13	the	O
14	informative	O
15	cases	O
16	was	O
17	observed	O
18	on	O
19	chromosomes	O
20	3p	O
21	(	O
22	41	O
23	.	O
24	1	O
25	%),	O
26	5q	O
27	(	O
28	52	O
29	.	O
30	6	O
31	%),	O
32	6p	O
33	(	O
34	30	O
35	.	O
36	4	O
37	%),	O
38	8p	O
39	(	O
40	33	O
41	.	O
42	3	O
43	%),	O
44	9p	O
45	(	O
46	35	O
47	.	O
48	7	O
49	%),	O
50	9q	O
51	(	O
52	30	O
53	.	O
54	8	O
55	%),	O
56	11p	O
57	(	O
58	32	O
59	.	O
60	4	O
61	%),	O
62	13q	O
63	(	O
64	52	O
65	.	O
66	7	O
67	%),	O
68	17p	O
69	(	O
70	55	O
71	.	O
72	2	O
73	%),	O
74	17q	O
75	(	O
76	33	O
77	.	O
78	3	O
79	%),	O
80	18q	O
81	(	O
82	45	O
83	.	O
84	7	O
85	%),	O
86	and	O
87	19q	O
88	(	O
89	30	O
90	.	O
91	4	O
92	%).	O
1	Glutamyl	O
2	-	O
3	tRNA	O
4	synthetase	O
5	and	O
6	prolyl	O
7	-	O
8	tRNA	O
9	synthetase	O
10	belong	O
11	to	O
12	different	O
13	classes	O
14	of	O
15	aminoacyl	O
16	-	O
17	tRNA	O
18	synthetases	O
19	that	O
20	are	O
21	thought	O
22	to	O
23	have	O
24	evolved	O
25	along	O
26	independent	O
27	evolutionary	O
28	pathways	O
29	.	O
1	Restriction	O
2	analysis	O
3	and	O
4	Southern	O
5	hybridization	O
6	revealed	O
7	the	O
8	presence	O
9	of	O
10	Tn5422	O
11	in	O
12	all	O
13	the	O
14	plasmid	O
15	-	O
16	mediated	O
17	cadmium	O
18	-	O
19	resistant	O
20	L	O
21	.	O
22	monocytogenes	O
23	strains	O
24	tested	O
25	but	O
26	not	O
27	in	O
28	strains	O
29	encoding	O
30	cadmium	O
31	resistance	O
32	on	O
33	the	O
34	chromosome	O
35	.	O
1	Identification	O
2	of	O
3	an	O
4	immediate	O
5	-	O
6	early	O
7	gene	O
8	in	O
9	the	O
10	Marek	O
11	'	O
12	s	O
13	disease	O
14	virus	O
15	long	O
16	internal	O
17	repeat	O
18	region	O
19	which	O
20	encodes	O
21	a	O
22	unique	O
23	14	O
24	-	O
25	kilodalton	O
26	polypeptide	O
27	.	O
1	We	O
2	have	O
3	used	O
4	a	O
5	full	O
6	-	O
7	length	O
8	cDNA	O
9	clone	O
10	of	O
11	a	O
12	mouse	O
13	hepatitis	O
14	virus	O
15	strain	O
16	A59	O
17	defective	O
18	interfering	O
19	(	O
20	DI	O
21	)	O
22	RNA	O
23	,	O
24	pMIDI	O
25	-	O
26	C	O
27	,	O
28	and	O
29	cassette	O
30	mutagenesis	O
31	to	O
32	study	O
33	the	O
34	mechanism	O
35	of	O
36	coronavirus	O
37	subgenomic	O
38	mRNA	O
39	synthesis	O
40	.	O
1	To	O
2	study	O
3	the	O
4	structure	O
5	-	O
6	function	O
7	of	O
8	the	O
9	gene	O
10	5	O
11	product	O
12	,	O
13	wild	O
14	-	O
15	type	O
16	and	O
17	mutant	O
18	forms	O
19	of	O
20	NS53	O
21	were	O
22	produced	O
23	by	O
24	using	O
25	a	O
26	recombinant	O
27	baculovirus	O
28	expression	O
29	system	O
30	and	O
31	a	O
32	recombinant	O
33	vaccinia	O
34	virus	O
35	/	O
36	T7	O
37	(	O
38	vTF7	O
39	-	O
40	3	O
41	)	O
42	expression	O
43	system	O
44	.	O
1	Women	O
2	'	O
3	s	O
4	opportunities	O
5	for	O
6	paid	O
7	work	O
8	outside	O
9	the	O
10	home	O
11	are	O
12	constrained	O
13	by	O
14	their	O
15	role	O
16	as	O
17	primary	O
18	carer	O
19	within	O
20	the	O
21	family	O
22	,	O
23	writes	O
24	Trudy	O
25	Wynne	O
26	.	O
1	In	O
2	the	O
3	case	O
4	of	O
5	congenital	O
6	protein	O
7	C	O
8	deficiency	O
9	,	O
10	vitamin	O
11	K	O
12	antagonists	O
13	must	O
14	be	O
15	started	O
16	cautiously	O
17	due	O
18	to	O
19	the	O
20	risk	O
21	of	O
22	skin	O
23	necrosis	O
24	.	O
1	On	O
2	physical	O
3	examination	O
4	a	O
5	mild	O
6	symmetrical	O
7	polyarthritis	O
8	of	O
9	small	O
10	and	O
11	large	O
12	joints	O
13	was	O
14	seen	O
15	.	O
1	VP	O
2	-	O
3	16	O
4	,	O
5	ifosfamide	O
6	and	O
7	cisplatin	O
8	(	O
9	VIP	O
10	)	O
11	for	O
12	extensive	O
13	small	O
14	cell	O
15	lung	O
16	cancer	O
17	.	O
1	A	O
2	genomic	O
3	clone	O
4	for	O
5	the	O
6	cyc07	O
7	gene	O
8	,	O
9	which	O
10	is	O
11	expressed	O
12	specifically	O
13	at	O
14	the	O
15	S	O
16	phase	O
17	during	O
18	the	O
19	cell	O
20	cycle	O
21	in	O
22	synchronous	O
23	cultures	O
24	of	O
25	periwinkle	O
26	(	O
27	Catharanthus	O
28	roseus	O
29	)	O
30	cells	O
31	,	O
32	was	O
33	isolated	O
34	.	O
1	Southern	O
2	blotting	O
3	analysis	O
4	implied	O
5	the	O
6	occurrence	O
7	of	O
8	multiple	O
9	COXVb	O
10	genes	O
11	in	O
12	the	O
13	rat	O
14	genome	O
15	.	O
1	Electrophoretic	O
2	mobility	O
3	shift	O
4	analysis	O
5	indicates	O
6	that	O
7	NF	B
8	-	O
9	IL	B
10	-	O
11	6	O
12	,	O
13	as	O
14	well	O
15	as	O
16	other	O
17	related	O
18	members	O
19	of	O
20	this	O
21	family	O
22	,	O
23	bind	O
24	specifically	O
25	to	O
26	the	O
27	NF	B
28	-	O
29	IL	B
30	-	O
31	6	O
32	site	O
33	in	O
34	the	O
35	IL	B
36	-	O
37	8	O
38	promoter	O
39	.	O
1	The	O
2	p53	B
3	tumor	O
4	suppressor	O
5	gene	O
6	product	O
7	,	O
8	a	O
9	sequence	O
10	-	O
11	specific	O
12	DNA	O
13	-	O
14	binding	O
15	protein	O
16	,	O
17	has	O
18	been	O
19	shown	O
20	to	O
21	act	O
22	as	O
23	a	O
24	transcriptional	O
25	activator	O
26	and	O
27	repressor	O
28	both	O
29	in	O
30	vitro	O
31	and	O
32	in	O
33	vivo	O
34	.	O
1	Mutational	O
2	analysis	O
3	of	O
4	chromosomal	O
5	segment	O
6	64AB	O
7	,	O
8	a	O
9	region	O
10	containing	O
11	the	O
12	glutamic	O
13	acid	O
14	decarboxylase	O
15	gene	O
16	.	O
1	Cloning	O
2	and	O
3	sequencing	O
4	of	O
5	the	O
6	corresponding	O
7	cDNAs	O
8	indicates	O
9	that	O
10	,	O
11	via	O
12	alternative	O
13	splicing	O
14	,	O
15	the	O
16	rearranged	O
17	gene	O
18	codes	O
19	for	O
20	two	O
21	proteins	O
22	of	O
23	84	O
24	and	O
25	85	O
26	kD	O
27	(	O
28	p84	O
29	/	O
30	85	O
31	)	O
32	which	O
33	retain	O
34	the	O
35	DNA	O
36	-	O
37	binding	O
38	rel	O
39	domain	O
40	and	O
41	the	O
42	first	O
43	five	O
44	ankyrin	O
45	repeats	O
46	,	O
47	but	O
48	have	O
49	lost	O
50	their	O
51	carboxy	O
52	-	O
53	terminus	O
54	including	O
55	the	O
56	seventh	O
57	ankyrin	O
58	repeat	O
59	.	O
1	Open	O
2	reading	O
3	frames	O
4	in	O
5	a	O
6	4556	O
7	nucleotide	O
8	sequence	O
9	within	O
10	MDV	O
11	-	O
12	1	O
13	BamHI	O
14	-	O
15	D	O
16	DNA	O
17	fragment	O
18	:	O
19	evidence	O
20	for	O
21	splicing	O
22	of	O
23	mRNA	O
24	from	O
25	a	O
26	new	O
27	viral	O
28	glycoprotein	O
29	gene	O
30	.	O
1	The	O
2	PRB	O
3	-	O
4	1b	O
5	gene	O
6	encodes	O
7	for	O
8	a	O
9	basic	O
10	-	O
11	type	O
12	component	O
13	of	O
14	the	O
15	pathogenesis	O
16	-	O
17	related	O
18	PR	O
19	-	O
20	1	O
21	protein	O
22	family	O
23	.	O
1	Reviewing	O
2	manuscripts	O
3	:	O
4	developing	O
5	an	O
6	efficient	O
7	system	O
8	.	O
1	We	O
2	also	O
3	compared	O
4	the	O
5	sequence	O
6	with	O
7	the	O
8	partly	O
9	homologous	O
10	products	O
11	of	O
12	the	O
13	S	O
14	.	O
15	cerevisiae	O
16	genes	O
17	TPS2	O
18	and	O
19	TSL1	O
20	which	O
21	code	O
22	for	O
23	the	O
24	larger	O
25	subunits	O
26	of	O
27	the	O
28	trehalose	O
29	synthase	O
30	complex	O
31	and	O
32	with	O
33	a	O
34	TSL1	O
35	homologue	O
36	,	O
37	TPS3	O
38	,	O
39	of	O
40	unknown	O
41	function	O
42	.	O
1	Stimulation	O
2	of	O
3	[	O
4	3H	O
5	]	O
6	PA	O
7	production	O
8	upon	O
9	CD3	O
10	cross	O
11	-	O
12	linking	O
13	was	O
14	77	O
15	%	O
16	lower	O
17	in	O
18	permeabilized	O
19	CD45	O
20	-	O
21	cells	O
22	than	O
23	in	O
24	CD45	O
25	+	O
26	cells	O
27	,	O
28	consistent	O
29	with	O
30	the	O
31	reduced	O
32	activity	O
33	of	O
34	p59fyn	O
35	in	O
36	CD45	O
37	-	O
38	cells	O
39	.	O
1	CONCLUSION	O
2	:	O
3	The	O
4	study	O
5	demonstrates	O
6	that	O
7	transvaginal	O
8	ultrasonography	O
9	has	O
10	an	O
11	efficiency	O
12	of	O
13	88	O
14	%	O
15	in	O
16	differentiating	O
17	endometriomas	O
18	from	O
19	other	O
20	ovarian	O
21	masses	O
22	with	O
23	a	O
24	specificity	O
25	of	O
26	90	O
27	%.	O
1	Unfolding	O
2	can	O
3	be	O
4	described	O
5	by	O
6	a	O
7	two	O
8	-	O
9	state	O
10	process	O
11	since	O
12	a	O
13	ratio	O
14	of	O
15	delta	B
16	Hcalorimetric	O
17	to	O
18	delta	B
19	Hvan	O
20	'	O
21	t	O
22	Hoff	O
23	equals	O
24	0	O
25	.	O
26	96	O
27	.	O
1	By	O
2	using	O
3	total	O
4	-	O
5	protein	O
6	extracts	O
7	from	O
8	mycelia	O
9	grown	O
10	under	O
11	penicillin	O
12	producing	O
13	conditions	O
14	we	O
15	have	O
16	detected	O
17	a	O
18	DNA	O
19	-	O
20	binding	O
21	activity	O
22	that	O
23	specifically	O
24	shifts	O
25	a	O
26	promoter	O
27	fragment	O
28	located	O
29	between	O
30	-	O
31	654	O
32	and	O
33	-	O
34	455	O
35	(	O
36	relative	O
37	to	O
38	IPNS	O
39	tsp	O
40	).	O
1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	the	O
7	36K	O
8	protein	O
9	and	O
10	known	O
11	structures	O
12	of	O
13	proteins	O
14	.	O
1	As	O
2	regards	O
3	lipid	O
4	metabolism	O
5	,	O
6	the	O
7	mean	O
8	values	O
9	for	O
10	total	O
11	triglycerides	O
12	,	O
13	cholesterol	O
14	,	O
15	LDL	O
16	-	O
17	cholesterol	O
18	and	O
19	HDL	O
20	-	O
21	cholesterol	O
22	seen	O
23	at	O
24	the	O
25	end	O
26	of	O
27	five	O
28	years	O
29	of	O
30	Norplant	O
31	-	O
32	2	O
33	rod	O
34	use	O
35	and	O
36	six	O
37	months	O
38	postremoval	O
39	were	O
40	similar	O
41	to	O
42	the	O
43	preinsertion	O
44	mean	O
45	.	O
1	At	O
2	a	O
3	PaCO2	O
4	of	O
5	40	O
6	mmHg	O
7	,	O
8	baseline	O
9	brain	O
10	pHi	O
11	measured	O
12	7	O
13	.	O
14	03	O
15	+/-	O
16	0	O
17	.	O
18	04	O
19	,	O
20	while	O
21	regional	O
22	cortical	O
23	blood	O
24	flow	O
25	was	O
26	47	O
27	.	O
28	0	O
29	+/-	O
30	4	O
31	.	O
32	3	O
33	ml	O
34	.	O
35	100	O
36	g	O
37	-	O
38	1	O
39	.	O
40	min	O
41	-	O
42	1	O
43	.	O
1	Effects	O
2	of	O
3	diltiazem	O
4	on	O
5	netilmicin	O
6	-	O
7	induced	O
8	nephrotoxicity	O
9	in	O
10	rabbits	O
11	.	O
1	To	O
2	our	O
3	knowledge	O
4	this	O
5	is	O
6	the	O
7	first	O
8	case	O
9	in	O
10	which	O
11	a	O
12	probable	O
13	association	O
14	between	O
15	cholelithiasis	O
16	and	O
17	Wildervanck	O
18	'	O
19	s	O
20	syndrome	O
21	has	O
22	been	O
23	recorded	O
24	.	O
1	Both	O
2	4	O
3	,	O
4	8	O
5	-	O
6	DiMeIQx	O
7	and	O
8	A	O
9	alpha	B
10	C	O
11	were	O
12	found	O
13	at	O
14	<	O
15	1	O
16	p	O
17	.	O
18	p	O
19	.	O
20	b	O
21	.	O
1	Three	O
2	cysteine	O
3	and	O
4	four	O
5	tryptophan	O
6	residues	O
7	,	O
8	previously	O
9	identified	O
10	as	O
11	conserved	O
12	amongst	O
13	nitrous	O
14	-	O
15	oxide	O
16	reductases	O
17	,	O
18	are	O
19	found	O
20	in	O
21	the	O
22	Paracoccus	O
23	enzyme	O
24	.	O
1	These	O
2	combined	O
3	observations	O
4	define	O
5	a	O
6	promoter	O
7	and	O
8	an	O
9	enhancer	O
10	for	O
11	the	O
12	chicken	O
13	L	O
14	-	O
15	CAM	O
16	gene	O
17	.	O
1	The	O
2	rate	O
3	of	O
4	enzymic	O
5	stimulation	O
6	induced	O
7	by	O
8	a	O
9	given	O
10	nitrate	O
11	correlates	O
12	closely	O
13	with	O
14	the	O
15	rate	O
16	of	O
17	measured	O
18	NO	O
19	production	O
20	from	O
21	the	O
22	nitrate	O
23	molecule	O
24	.	O
1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O
1	The	O
2	promoter	O
3	and	O
4	upstream	O
5	region	O
6	of	O
7	the	O
8	Brassica	O
9	napus	O
10	2S	O
11	storage	O
12	protein	O
13	napA	O
14	gene	O
15	were	O
16	studied	O
17	to	O
18	identify	O
19	cis	O
20	-	O
21	acting	O
22	sequences	O
23	involved	O
24	in	O
25	developmental	O
26	seed	O
27	-	O
28	specific	O
29	expression	O
30	.	O
1	We	O
2	have	O
3	explored	O
4	the	O
5	mechanism	O
6	of	O
7	action	O
8	of	O
9	the	O
10	fibronectin	O
11	splicing	O
12	enhancer	O
13	and	O
14	found	O
15	that	O
16	the	O
17	SE	O
18	element	O
19	is	O
20	required	O
21	for	O
22	efficient	O
23	assembly	O
24	of	O
25	early	O
26	splicing	O
27	complexes	O
28	,	O
29	allowing	O
30	a	O
31	more	O
32	efficient	O
33	interaction	O
34	of	O
35	the	O
36	U2	O
37	snRNP	O
38	with	O
39	branch	O
40	site	O
41	sequences	O
42	.	O
1	We	O
2	conclude	O
3	that	O
4	sequences	O
5	outside	O
6	of	O
7	the	O
8	hLEF	O
9	HMG	O
10	box	O
11	mediate	O
12	cell	O
13	-	O
14	and	O
15	context	O
16	-	O
17	specific	O
18	activation	O
19	of	O
20	the	O
21	TCR	O
22	alpha	B
23	enhancer	O
24	and	O
25	may	O
26	facilitate	O
27	interactions	O
28	between	O
29	hLEF	O
30	and	O
31	other	O
32	T	O
33	-	O
34	cell	O
35	-	O
36	specific	O
37	factors	O
38	recruited	O
39	to	O
40	the	O
41	enhancer	O
42	.	O
1	Using	O
2	a	O
3	series	O
4	of	O
5	mutant	O
6	T	O
7	antigens	O
8	expressed	O
9	by	O
10	recombinant	O
11	baculoviruses	O
12	in	O
13	Sf9	O
14	cells	O
15	,	O
16	we	O
17	find	O
18	that	O
19	the	O
20	origin	O
21	unwinding	O
22	activities	O
23	of	O
24	both	O
25	TS677	O
26	-->	O
27	A	O
28	and	O
29	TS677	O
30	,	O
31	679	O
32	-->	O
33	A	O
34	are	O
35	inhibited	O
36	by	O
37	the	O
38	T	O
39	-	O
40	antigen	B
41	kinase	I
42	,	O
43	as	O
44	is	O
45	wild	O
46	-	O
47	type	O
48	T	O
49	antigen	B
50	.	O
1	Using	O
2	a	O
3	3	O
4	'-	O
5	rapid	O
6	amplification	O
7	of	O
8	cDNA	O
9	ends	O
10	strategy	O
11	,	O
12	we	O
13	have	O
14	cloned	O
15	cDNAs	O
16	representing	O
17	the	O
18	3	O
19	'-	O
20	termini	O
21	of	O
22	both	O
23	the	O
24	native	O
25	and	O
26	mutant	O
27	transcripts	O
28	from	O
29	both	O
30	P388	O
31	/	O
32	ADR	O
33	/	O
34	3	O
35	and	O
36	P388	O
37	/	O
38	ADR	O
39	/	O
40	7	O
41	cells	O
42	.	O
1	TGF	O
2	beta	B
3	1	O
4	expression	O
5	is	O
6	largely	O
7	governed	O
8	by	O
9	three	O
10	AP	B
11	-	O
12	1	O
13	binding	O
14	sites	O
15	located	O
16	in	O
17	two	O
18	different	O
19	promoters	O
20	of	O
21	this	O
22	gene	O
23	.	O
1	Strategic	O
2	change	O
3	in	O
4	the	O
5	NHS	O
6	.	O
1	Response	O
2	durations	O
3	were	O
4	short	O
5	.	O
1	In	O
2	addition	O
3	,	O
4	REP21	O
5	plants	O
6	were	O
7	resistant	O
8	to	O
9	an	O
10	unusually	O
11	broad	O
12	range	O
13	of	O
14	tobamoviruses	O
15	including	O
16	tomato	O
17	mosaic	O
18	virus	O
19	,	O
20	tobacco	O
21	mild	O
22	green	O
23	mosaic	O
24	virus	O
25	,	O
26	TMV	O
27	-	O
28	U5	O
29	,	O
30	green	O
31	tomato	O
32	atypical	O
33	mosaic	O
34	virus	O
35	,	O
36	and	O
37	ribgrass	O
38	mosaic	O
39	virus	O
40	.	O
1	The	O
2	kinase	B
3	inhibitor	O
4	staurosporine	O
5	(	O
6	1	O
7	microM	O
8	)	O
9	blocks	O
10	LPA	O
11	-	O
12	induced	O
13	,	O
14	but	O
15	not	O
16	epidermal	O
17	growth	O
18	factor	O
19	-	O
20	induced	O
21	,	O
22	activation	O
23	of	O
24	p21ras	O
25	and	O
26	MAP	O
27	kinase	B
28	,	O
29	consistent	O
30	with	O
31	an	O
32	intermediate	O
33	protein	O
34	kinase	B
35	linking	O
36	the	O
37	LPA	O
38	receptor	B
39	to	O
40	p21ras	O
41	activation	O
42	.	O
1	The	O
2	psaD	O
3	,	O
4	psaF	O
5	,	O
6	psaH	O
7	,	O
8	and	O
9	psaL	O
10	products	O
11	have	O
12	two	O
13	isoforms	O
14	each	O
15	that	O
16	are	O
17	distinguished	O
18	by	O
19	different	O
20	mobilities	O
21	in	O
22	polyacrylamide	O
23	gel	O
24	electrophoresis	O
25	,	O
26	and	O
27	the	O
28	psaE	O
29	product	O
30	has	O
31	four	O
32	isoforms	O
33	.	O
1	The	O
2	secondary	O
3	,	O
4	but	O
5	not	O
6	the	O
7	primary	O
8	,	O
9	antibody	O
10	responses	O
11	of	O
12	male	O
13	C57Bl	O
14	/	O
15	6	O
16	mice	O
17	were	O
18	higher	O
19	among	O
20	mice	O
21	housed	O
22	alone	O
23	compared	O
24	to	O
25	mice	O
26	housed	O
27	in	O
28	groups	O
29	;	O
30	differences	O
31	were	O
32	observed	O
33	for	O
34	both	O
35	IgM	O
36	and	O
37	IgG	O
38	anti	B
39	-	O
40	KLH	O
41	antibodies	O
42	.	O
1	However	O
2	,	O
3	a	O
4	surprisingly	O
5	high	O
6	degree	O
7	of	O
8	conservation	O
9	of	O
10	intron	O
11	sequences	O
12	was	O
13	observed	O
14	between	O
15	both	O
16	species	O
17	.	O
1	Other	O
2	parameters	O
3	of	O
4	iron	O
5	metabolism	O
6	,	O
7	including	O
8	ferritin	O
9	,	O
10	were	O
11	not	O
12	found	O
13	to	O
14	contribute	O
15	to	O
16	the	O
17	risk	O
18	.	O
1	Because	O
2	of	O
3	the	O
4	small	O
5	number	O
6	of	O
7	visceral	O
8	angiography	O
9	procedures	O
10	performed	O
11	(	O
12	38	O
13	),	O
14	no	O
15	definitive	O
16	conclusions	O
17	could	O
18	be	O
19	drawn	O
20	as	O
21	to	O
22	the	O
23	differences	O
24	between	O
25	ionic	O
26	and	O
27	nonionic	O
28	agents	O
29	regarding	O
30	grade	O
31	-	O
32	2	O
33	and	O
34	grade	O
35	-	O
36	3	O
37	adverse	O
38	events	O
39	.	O
1	The	O
2	structural	O
3	analysis	O
4	also	O
5	demonstrated	O
6	that	O
7	the	O
8	heterogeneity	O
9	of	O
10	the	O
11	HDC	O
12	mRNA	O
13	is	O
14	caused	O
15	by	O
16	an	O
17	insertion	O
18	of	O
19	the	O
20	seventh	O
21	intron	O
22	sequence	O
23	and	O
24	alternative	O
25	use	O
26	of	O
27	the	O
28	splicing	O
29	acceptor	O
30	site	O
31	at	O
32	the	O
33	12th	O
34	exon	O
35	.	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	rep	O
6	strongly	O
7	enhances	O
8	the	O
9	function	O
10	of	O
11	negative	O
12	regulatory	O
13	elements	O
14	of	O
15	the	O
16	LTR	O
17	.	O
1	However	O
2	,	O
3	artificially	O
4	ventilated	O
5	rats	O
6	,	O
7	pretreated	O
8	with	O
9	MK	O
10	-	O
11	801	O
12	,	O
13	were	O
14	more	O
15	sensitive	O
16	(	O
17	lethal	O
18	cocaine	O
19	dose	O
20	,	O
21	76	O
22	.	O
23	6	O
24	+/-	O
25	8	O
26	.	O
27	0	O
28	mg	O
29	/	O
30	kg	O
31	,	O
32	n	O
33	=	O
34	5	O
35	)	O
36	than	O
37	vehicle	O
38	pretreated	O
39	rats	O
40	(	O
41	129	O
42	.	O
43	4	O
44	+/-	O
45	15	O
46	.	O
47	8	O
48	mg	O
49	/	O
50	kg	O
51	,	O
52	n	O
53	=	O
54	6	O
55	),	O
56	indicating	O
57	that	O
58	MK	O
59	-	O
60	801	O
61	may	O
62	increase	O
63	both	O
64	the	O
65	respiratory	O
66	and	O
67	the	O
68	cardiac	O
69	toxicity	O
70	of	O
71	cocaine	O
72	in	O
73	urethane	O
74	anesthetized	O
75	rats	O
76	.	O
1	Each	O
2	repeat	O
3	consists	O
4	of	O
5	12	O
6	nt	O
7	,	O
8	coding	O
9	for	O
10	the	O
11	reiterated	O
12	sequence	O
13	,	O
14	K	O
15	/	O
16	NPAG	O
17	.	O
1	This	O
2	distribution	O
3	parallels	O
4	that	O
5	of	O
6	the	O
7	neurotransmitters	O
8	glutamate	O
9	and	O
10	aspartate	O
11	;	O
12	however	O
13	,	O
14	neither	O
15	of	O
16	these	O
17	excitatory	O
18	amino	O
19	acids	O
20	is	O
21	a	O
22	substrate	O
23	for	O
24	transport	O
25	.	O
1	Transcriptional	O
2	analysis	O
3	of	O
4	a	O
5	series	O
6	of	O
7	deletion	O
8	mutants	O
9	of	O
10	the	O
11	gene	O
12	in	O
13	the	O
14	nuclear	O
15	extracts	O
16	prepared	O
17	from	O
18	the	O
19	middle	O
20	silk	O
21	gland	O
22	of	O
23	2	O
24	-	O
25	day	O
26	-	O
27	old	O
28	fifth	O
29	instar	O
30	larvae	O
31	revealed	O
32	the	O
33	presence	O
34	of	O
35	multiple	O
36	cis	O
37	-	O
38	regulatory	O
39	elements	O
40	located	O
41	both	O
42	upstream	O
43	and	O
44	downstream	O
45	of	O
46	the	O
47	initiation	O
48	site	O
49	.	O
1	Monospecific	O
2	antibodies	O
3	raised	O
4	against	O
5	rat	O
6	cytochrome	O
7	P	O
8	-	O
9	450	O
10	1A1	O
11	recognized	O
12	a	O
13	protein	O
14	in	O
15	the	O
16	hepatic	O
17	microsomes	O
18	of	O
19	the	O
20	double	O
21	-	O
22	crested	O
23	cormorant	O
24	,	O
25	and	O
26	also	O
27	in	O
28	those	O
29	of	O
30	the	O
31	great	O
32	blue	O
33	heron	O
34	(	O
35	Ardea	O
36	herodias	O
37	),	O
38	using	O
39	immunoblotting	O
40	.	O
1	Depletion	O
2	of	O
3	dopamine	O
4	in	O
5	the	O
6	nucleus	O
7	accumbens	O
8	led	O
9	to	O
10	a	O
11	dramatic	O
12	shift	O
13	in	O
14	behavior	O
15	in	O
16	which	O
17	there	O
18	was	O
19	a	O
20	significant	O
21	decrease	O
22	in	O
23	lever	O
24	pressing	O
25	but	O
26	a	O
27	significant	O
28	increase	O
29	in	O
30	consumption	O
31	of	O
32	lab	O
33	chow	O
34	.	O
1	Thus	O
2	,	O
3	the	O
4	system	O
5	can	O
6	be	O
7	used	O
8	to	O
9	detect	O
10	and	O
11	study	O
12	dynamic	O
13	perfusion	O
14	changes	O
15	from	O
16	the	O
17	brain	O
18	surface	O
19	with	O
20	minimal	O
21	tissue	O
22	damage	O
23	.	O
1	The	O
2	positive	O
3	-	O
4	acting	O
5	global	O
6	sulfur	O
7	regulatory	O
8	protein	O
9	,	O
10	CYS3	O
11	,	O
12	of	O
13	Neurospora	O
14	crassa	O
15	turns	O
16	on	O
17	the	O
18	expression	O
19	of	O
20	a	O
21	family	O
22	of	O
23	unlinked	O
24	structural	O
25	genes	O
26	that	O
27	encode	O
28	enzymes	O
29	of	O
30	sulfur	O
31	catabolism	O
32	.	O
1	The	O
2	5	O
3	'	O
4	ends	O
5	of	O
6	F3R	O
7	late	O
8	transcripts	O
9	were	O
10	located	O
11	to	O
12	an	O
13	A	O
14	within	O
15	the	O
16	sequence	O
17	5	O
18	'-	O
19	TAAAG	O
20	,	O
21	41	O
22	nt	O
23	downstream	O
24	from	O
25	the	O
26	early	O
27	promoter	O
28	and	O
29	17	O
30	nt	O
31	upstream	O
32	from	O
33	the	O
34	initiation	O
35	codon	O
36	.	O
1	There	O
2	was	O
3	no	O
4	clear	O
5	correlation	O
6	between	O
7	the	O
8	MFA	O
9	and	O
10	the	O
11	severity	O
12	of	O
13	the	O
14	UTS	O
15	phenotype	O
16	.	O
1	The	O
2	sequence	O
3	of	O
4	the	O
5	putative	O
6	RBP1	O
7	protein	O
8	contains	O
9	two	O
10	copies	O
11	of	O
12	an	O
13	RNA	O
14	recognition	O
15	motif	O
16	,	O
17	two	O
18	glutamine	O
19	stretches	O
20	,	O
21	an	O
22	asparagine	O
23	-	O
24	rich	O
25	region	O
26	,	O
27	a	O
28	methionine	O
29	-	O
30	rich	O
31	region	O
32	,	O
33	and	O
34	two	O
35	long	O
36	potential	O
37	alpha	B
38	-	O
39	helixes	O
40	.	O
1	One	O
2	defective	O
3	RNA	O
4	with	O
5	a	O
6	large	O
7	deletion	O
8	in	O
9	the	O
10	p70	O
11	coding	O
12	region	O
13	was	O
14	able	O
15	to	O
16	replicate	O
17	efficiently	O
18	,	O
19	both	O
20	when	O
21	inoculated	O
22	with	O
23	the	O
24	helper	O
25	genome	O
26	and	O
27	when	O
28	inoculated	O
29	with	O
30	a	O
31	second	O
32	complementing	O
33	defective	O
34	RNA	O
35	that	O
36	supplied	O
37	a	O
38	wild	O
39	-	O
40	type	O
41	p70	O
42	.	O
1	Release	O
2	of	O
3	this	O
4	selective	O
5	pressure	O
6	,	O
7	however	O
8	,	O
9	gave	O
10	way	O
11	to	O
12	homologous	O
13	resolution	O
14	of	O
15	the	O
16	cointegrate	O
17	structures	O
18	.	O
1	Complete	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	bacteriophage	O
7	K1F	O
8	tail	O
9	gene	O
10	encoding	O
11	endo	O
12	-	O
13	N	O
14	-	O
15	acylneuraminidase	O
16	(	O
17	endo	O
18	-	O
19	N	O
20	)	O
21	and	O
22	comparison	O
23	to	O
24	an	O
25	endo	O
26	-	O
27	N	O
28	homolog	O
29	in	O
30	bacteriophage	O
31	PK1E	O
32	.	O
1	Morphometrical	O
2	quantification	O
3	of	O
4	brain	O
5	edema	O
6	related	O
7	to	O
8	experimental	O
9	multiple	O
10	micro	O
11	-	O
12	infarcts	O
13	in	O
14	mice	O
15	:	O
16	assessment	O
17	of	O
18	neurotropin	O
19	effect	O
20	.	O
1	Indeed	O
2	,	O
3	significant	O
4	level	O
5	of	O
6	CAT	O
7	activity	O
8	was	O
9	observed	O
10	in	O
11	human	O
12	lung	O
13	adenocarcinoma	O
14	(	O
15	A549	O
16	-	O
17	1	O
18	)	O
19	cells	O
20	which	O
21	had	O
22	been	O
23	incubated	O
24	with	O
25	a	O
26	complex	O
27	of	O
28	T7	O
29	RNA	O
30	polymerase	B
31	,	O
32	pT7	O
33	-	O
34	EMC	O
35	-	O
36	CAT	O
37	DNA	O
38	and	O
39	DC	O
40	-	O
41	chol	O
42	cationic	O
43	liposomes	O
44	.	O
1	In	O
2	infected	O
3	mammalian	O
4	cells	O
5	,	O
6	the	O
7	ARV	O
8	G	O
9	and	O
10	GNS	O
11	genes	O
12	are	O
13	transcribed	O
14	primarily	O
15	as	O
16	a	O
17	polycistronic	O
18	mRNA	O
19	which	O
20	appears	O
21	to	O
22	extend	O
23	from	O
24	the	O
25	consensus	O
26	sequence	O
27	(	O
28	AACAG	O
29	)	O
30	at	O
31	the	O
32	start	O
33	of	O
34	the	O
35	G	O
36	gene	O
37	to	O
38	the	O
39	next	O
40	recognized	O
41	polyadenylation	O
42	signal	O
43	(	O
44	CATG	O
45	[	O
46	A	O
47	]	O
48	7	O
49	)	O
50	located	O
51	697	O
52	nucleotides	O
53	downstream	O
54	of	O
55	the	O
56	GNS	O
57	protein	O
58	termination	O
59	codon	O
60	.	O
1	The	O
2	phosphorylation	O
3	efficiency	O
4	is	O
5	improved	O
6	by	O
7	increasing	O
8	the	O
9	number	O
10	of	O
11	N	O
12	-	O
13	terminal	O
14	arginine	O
15	residues	O
16	and	O
17	by	O
18	moving	O
19	the	O
20	arginyl	O
21	cluster	O
22	one	O
23	residue	O
24	further	O
25	away	O
26	from	O
27	the	O
28	serine	O
29	,	O
30	the	O
31	nonapeptide	O
32	(	O
33	Arg	O
34	)	O
35	4	O
36	-	O
37	Ala	O
38	-	O
39	Ala	O
40	-	O
41	Ser	O
42	-	O
43	Val	O
44	-	O
45	Ala	O
46	being	O
47	the	O
48	best	O
49	substrate	O
50	among	O
51	all	O
52	the	O
53	short	O
54	peptides	O
55	tested	O
56	(	O
57	Km	O
58	=	O
59	15	O
60	microM	O
61	).	O
1	Botulinum	O
2	toxin	O
3	:	O
4	preferred	O
5	treatment	O
6	for	O
7	hemifacial	O
8	spasm	O
9	.	O
1	The	O
2	Saccharomyces	O
3	cerevisiae	O
4	GAL1	O
5	and	O
6	GAL10	O
7	genes	O
8	are	O
9	controlled	O
10	in	O
11	response	O
12	to	O
13	the	O
14	availability	O
15	of	O
16	galactose	O
17	and	O
18	glucose	O
19	by	O
20	multiple	O
21	activating	O
22	and	O
23	repressing	O
24	proteins	O
25	bound	O
26	at	O
27	adjacent	O
28	or	O
29	overlapping	O
30	sites	O
31	in	O
32	UASG	O
33	.	O
1	We	O
2	suggest	O
3	that	O
4	the	O
5	ER	O
6	lumenal	O
7	variable	O
8	domain	O
9	of	O
10	gp19K	O
11	has	O
12	a	O
13	specific	O
14	tertiary	O
15	structure	O
16	that	O
17	is	O
18	important	O
19	for	O
20	binding	O
21	to	O
22	the	O
23	polymorphic	O
24	alpha	B
25	1	O
26	and	O
27	alpha	B
28	2	O
29	domains	O
30	of	O
31	class	O
32	I	O
33	heavy	O
34	(	O
35	alpha	B
36	)	O
37	chains	O
38	.	O
1	We	O
2	recently	O
3	found	O
4	that	O
5	17	O
6	beta	B
7	-	O
8	estradiol	O
9	(	O
10	E2	O
11	)	O
12	not	O
13	only	O
14	suppresses	O
15	bone	O
16	resorption	O
17	but	O
18	also	O
19	stimulates	O
20	bone	O
21	formation	O
22	in	O
23	the	O
24	cancellous	O
25	bone	O
26	of	O
27	female	O
28	rats	O
29	.	O
1	Protein	O
2	tyrosine	O
3	phosphatases	O
4	(	O
5	PTPs	O
6	),	O
7	together	O
8	with	O
9	protein	O
10	tyrosine	O
11	kinases	B
12	(	O
13	PTKs	O
14	),	O
15	are	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	cell	O
22	activation	O
23	,	O
24	growth	O
25	,	O
26	and	O
27	differentiation	O
28	.	O
1	ST	O
2	elevation	O
3	occurs	O
4	in	O
5	5	O
6	patients	O
7	(	O
8	55	O
9	.	O
10	5	O
11	%)	O
12	of	O
13	subgroup	O
14	A	O
15	and	O
16	in	O
17	no	O
18	patient	O
19	of	O
20	the	O
21	subgroup	O
22	B	O
23	.	O
1	HTLV	O
2	-	O
3	1	O
4	gene	O
5	expression	O
6	by	O
7	defective	O
8	proviruses	O
9	in	O
10	an	O
11	infected	O
12	T	O
13	-	O
14	cell	O
15	line	O
16	.	O
1	XII	O
2	.	O
1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	the	O
7	structures	O
8	of	O
9	the	O
10	b	O
11	-	O
12	Zip	O
13	domain	O
14	are	O
15	well	O
16	conserved	O
17	among	O
18	these	O
19	Maf	O
20	-	O
21	related	O
22	proteins	O
23	.	O
1	Dissipation	O
2	of	O
3	claudication	O
4	pain	O
5	after	O
6	walking	O
7	:	O
8	implications	O
9	for	O
10	endurance	O
11	training	O
12	.	O
1	The	O
2	binding	O
3	specificity	O
4	of	O
5	this	O
6	protein	O
7	was	O
8	compared	O
9	to	O
10	that	O
11	of	O
12	human	O
13	E2F	O
14	using	O
15	a	O
16	number	O
17	of	O
18	mutant	O
19	E2F	O
20	sites	O
21	as	O
22	competitors	O
23	.	O
1	To	O
2	analyze	O
3	the	O
4	VH	O
5	regions	O
6	of	O
7	polyreactive	O
8	antibodies	O
9	,	O
10	with	O
11	particular	O
12	attention	O
13	at	O
14	their	O
15	somatically	O
16	mutated	O
17	status	O
18	,	O
19	we	O
20	generated	O
21	five	O
22	IgG	O
23	(	O
24	three	O
25	IgG1	O
26	and	O
27	two	O
28	IgG3	O
29	)	O
30	mAb	O
31	(	O
32	using	O
33	B	O
34	cells	O
35	from	O
36	a	O
37	healthy	O
38	subject	O
39	,	O
40	a	O
41	patient	O
42	with	O
43	insulin	B
44	-	O
45	dependent	O
46	diabetes	O
47	mellitus	O
48	and	O
49	a	O
50	patient	O
51	with	O
52	SLE	O
53	),	O
54	which	O
55	bound	O
56	with	O
57	various	O
58	efficiencies	O
59	a	O
60	number	O
61	of	O
62	different	O
63	self	O
64	and	O
65	foreign	O
66	Ag	O
67	.	O
1	These	O
2	cell	O
3	lines	O
4	,	O
5	selected	O
6	for	O
7	the	O
8	ability	O
9	to	O
10	support	O
11	the	O
12	replication	O
13	of	O
14	a	O
15	temperature	O
16	-	O
17	sensitive	O
18	VP5	O
19	mutant	O
20	,	O
21	were	O
22	used	O
23	to	O
24	isolate	O
25	VP5	O
26	and	O
27	VP23	O
28	null	O
29	mutants	O
30	.	O
1	The	O
2	E1	O
3	nuclear	O
4	transport	O
5	motif	O
6	is	O
7	highly	O
8	conserved	O
9	in	O
10	the	O
11	animal	O
12	and	O
13	human	O
14	papillomaviruses	O
15	and	O
16	is	O
17	encoded	O
18	in	O
19	a	O
20	similar	O
21	region	O
22	in	O
23	the	O
24	related	O
25	E1	O
26	genes	O
27	.	O
1	Optimal	O
2	activation	O
3	of	O
4	T	O
5	cells	O
6	requires	O
7	at	O
8	least	O
9	two	O
10	signals	O
11	.	O
1	A	O
2	sequence	O
3	comparison	O
4	reveals	O
5	two	O
6	CCAAT	O
7	/	O
8	enhancer	O
9	binding	O
10	protein	O
11	(	O
12	C	O
13	/	O
14	EBP	O
15	)	O
16	consensus	O
17	sequences	O
18	,	O
19	basic	O
20	DNA	O
21	binding	O
22	region	O
23	and	O
24	leucine	O
25	zippers	O
26	1	O
27	and	O
28	2	O
29	(	O
30	bZIP1	O
31	and	O
32	bZIP2	O
33	),	O
34	within	O
35	this	O
36	region	O
37	.	O
1	One	O
2	of	O
3	these	O
4	genes	O
5	,	O
6	REC114	O
7	,	O
8	is	O
9	described	O
10	here	O
11	,	O
12	and	O
13	the	O
14	data	O
15	confirm	O
16	that	O
17	REC114	O
18	is	O
19	a	O
20	meiosis	O
21	-	O
22	specific	O
23	recombination	O
24	gene	O
25	with	O
26	no	O
27	detectable	O
28	function	O
29	in	O
30	mitosis	O
31	.	O
1	Nuclear	O
2	protein	O
3	phosphatase	B
4	2A	O
5	dephosphorylates	O
6	protein	O
7	kinase	B
8	A	O
9	-	O
10	phosphorylated	O
11	CREB	O
12	and	O
13	regulates	O
14	CREB	O
15	transcriptional	O
16	stimulation	O
17	.	O
1	This	O
2	stimulatory	O
3	effect	O
4	could	O
5	also	O
6	be	O
7	elicited	O
8	by	O
9	c	B
10	-	O
11	Jun	O
12	,	O
13	which	O
14	interacts	O
15	with	O
16	topo	O
17	II	O
18	,	O
19	but	O
20	not	O
21	by	O
22	c	B
23	-	O
24	Fos	O
25	,	O
26	which	O
27	does	O
28	not	O
29	bind	O
30	topo	O
31	II	O
32	in	O
33	our	O
34	in	O
35	vitro	O
36	assay	O
37	.	O
1	The	O
2	regulation	O
3	of	O
4	Myf	O
5	-	O
6	5	O
7	and	O
8	MyoD	O
9	function	O
10	by	O
11	a	O
12	cAMP	O
13	-	O
14	dependent	O
15	pathway	O
16	may	O
17	partly	O
18	explain	O
19	how	O
20	external	O
21	signals	O
22	generated	O
23	by	O
24	serum	O
25	and	O
26	certain	O
27	peptide	O
28	growth	O
29	factors	O
30	can	O
31	be	O
32	transduced	O
33	to	O
34	the	O
35	nucleus	O
36	and	O
37	inhibit	O
38	dominant	O
39	-	O
40	acting	O
41	factors	O
42	that	O
43	are	O
44	responsible	O
45	for	O
46	myoblast	O
47	differentiation	O
48	.	O
1	Replacement	O
2	of	O
3	the	O
4	wild	O
5	-	O
6	type	O
7	5	O
8	'-	O
9	regulatory	O
10	region	O
11	with	O
12	either	O
13	of	O
14	the	O
15	mutants	O
16	'	O
17	cis	O
18	-	O
19	acting	O
20	regulatory	O
21	element	O
22	resulted	O
23	in	O
24	the	O
25	anaerobic	O
26	expression	O
27	of	O
28	active	O
29	Mn	O
30	-	O
31	superoxide	O
32	dismutase	O
33	.	O
1	IE2	O
2	-	O
3	IE2	O
4	interactions	O
5	were	O
6	mapped	O
7	to	O
8	a	O
9	domain	O
10	containing	O
11	a	O
12	putative	O
13	helix	O
14	-	O
15	turn	O
16	-	O
17	helix	O
18	motif	O
19	located	O
20	near	O
21	the	O
22	C	O
23	terminus	O
24	of	O
25	IE2	O
26	,	O
27	between	O
28	amino	O
29	acids	O
30	456	O
31	and	O
32	539	O
33	.	O
1	The	O
2	Sp1	B
3	region	O
4	,	O
5	however	O
6	,	O
7	is	O
8	converted	O
9	to	O
10	a	O
11	functionally	O
12	strong	O
13	TRE	O
14	by	O
15	the	O
16	viral	O
17	tat	O
18	factor	O
19	.	O
1	Precipitation	O
2	using	O
3	GST	O
4	fusion	O
5	proteins	O
6	containing	O
7	Fyn	O
8	SH2	O
9	,	O
10	SH3	O
11	,	O
12	and	O
13	SH2	O
14	/	O
15	SH3	O
16	domains	O
17	revealed	O
18	that	O
19	PI	O
20	3	O
21	-	O
22	kinase	B
23	bound	O
24	principally	O
25	to	O
26	the	O
27	SH3	O
28	domain	O
29	of	O
30	Fyn	O
31	.	O
1	Nuclear	O
2	localization	O
3	and	O
4	protein	O
5	sequence	O
6	similarities	O
7	suggested	O
8	that	O
9	the	O
10	SPT2	O
11	/	O
12	SIN1	O
13	protein	O
14	may	O
15	be	O
16	related	O
17	to	O
18	the	O
19	nonhistone	O
20	chromosomal	O
21	protein	O
22	HMG1	O
23	.	O
1	The	O
2	conserved	O
3	ninth	O
4	C	O
5	-	O
6	terminal	O
7	heptad	O
8	in	O
9	thyroid	O
10	hormone	O
11	and	O
12	retinoic	O
13	acid	O
14	receptors	O
15	mediates	O
16	diverse	O
17	responses	O
18	by	O
19	affecting	O
20	heterodimer	O
21	but	O
22	not	O
23	homodimer	O
24	formation	O
25	.	O
1	These	O
2	experiments	O
3	confirm	O
4	that	O
5	the	O
6	6	O
7	-	O
8	S	O
9	liganded	O
10	form	O
11	of	O
12	the	O
13	receptor	B
14	identified	O
15	in	O
16	nuclear	O
17	extracts	O
18	of	O
19	cells	O
20	treated	O
21	with	O
22	2	O
23	,	O
24	3	O
25	,	O
26	7	O
27	,	O
28	8	O
29	-	O
30	tetrachlorodibenzo	O
31	-	O
32	p	O
33	-	O
34	dioxin	O
35	(	O
36	TCDD	O
37	)	O
38	contains	O
39	the	O
40	Ah	O
41	receptor	B
42	protein	O
43	and	O
44	ARNT	O
45	but	O
46	not	O
47	the	O
48	90	O
49	-	O
50	kDa	O
51	heat	O
52	shock	O
53	protein	O
54	.	O
1	Regulated	O
2	activity	O
3	of	O
4	the	O
5	distal	O
6	promoter	O
7	-	O
8	like	O
9	element	O
10	of	O
11	the	O
12	human	O
13	corticotropin	O
14	-	O
15	releasing	O
16	hormone	O
17	gene	O
18	and	O
19	secondary	O
20	structural	O
21	features	O
22	of	O
23	its	O
24	corresponding	O
25	transcripts	O
26	.	O
1	INTERVENTIONS	O
2	--	O
3	Patients	O
4	allocated	O
5	to	O
6	treatment	O
7	with	O
8	levodopa	O
9	/	O
10	dopa	O
11	decarboxylase	O
12	inhibitor	O
13	alone	O
14	(	O
15	arm	O
16	1	O
17	),	O
18	levodopa	O
19	/	O
20	decarboxylase	O
21	inhibitor	O
22	/	O
23	selegiline	O
24	in	O
25	combination	O
26	(	O
27	arm	O
28	2	O
29	),	O
30	or	O
31	bromocriptine	O
32	(	O
33	arm	O
34	3	O
35	).	O
1	French	O
2	bean	O
3	contains	O
4	a	O
5	small	O
6	family	O
7	of	O
8	genes	O
9	encoding	O
10	PAL	O
11	and	O
12	two	O
13	of	O
14	these	O
15	genes	O
16	,	O
17	PAL2	O
18	and	O
19	PAL3	O
20	,	O
21	have	O
22	been	O
23	shown	O
24	to	O
25	be	O
26	differentially	O
27	expressed	O
28	at	O
29	the	O
30	mRNA	O
31	level	O
32	in	O
33	bean	O
34	tissues	O
35	.	O
1	Moreover	O
2	,	O
3	in	O
4	transient	O
5	transfection	O
6	assays	O
7	,	O
8	PU	O
9	.	O
10	1	O
11	alone	O
12	activated	O
13	reporter	O
14	constructs	O
15	containing	O
16	the	O
17	JB	O
18	cis	O
19	-	O
20	element	O
21	,	O
22	and	O
23	the	O
24	activation	O
25	was	O
26	shown	O
27	to	O
28	be	O
29	dependent	O
30	on	O
31	a	O
32	glutamine	O
33	-	O
34	rich	O
35	sequence	O
36	in	O
37	the	O
38	amino	O
39	-	O
40	terminal	O
41	portion	O
42	of	O
43	PU	O
44	.	O
45	1	O
46	.	O
1	Hops	O
2	,	O
3	and	O
4	L	O
5	.	O
1	Continued	O
2	absorption	O
3	of	O
4	amino	O
5	acids	O
6	by	O
7	the	O
8	NBB	O
9	carrier	O
10	(	O
11	for	O
12	neutral	O
13	amino	O
14	acids	O
15	),	O
16	the	O
17	Y	O
18	+	O
19	system	O
20	(	O
21	for	O
22	dibasic	O
23	amino	O
24	acids	O
25	),	O
26	and	O
27	the	O
28	PHE	O
29	carrier	O
30	were	O
31	operative	O
32	even	O
33	during	O
34	the	O
35	actively	O
36	purging	O
37	stage	O
38	of	O
39	watery	O
40	diarrhoea	O
41	due	O
42	to	O
43	cholera	O
44	.	O
1	Skin	O
2	and	O
3	bowel	O
4	TPO2	O
5	varied	O
6	with	O
7	DO2	O
8	and	O
9	each	O
10	other	O
11	(	O
12	P	O
13	<	O
14	0	O
15	.	O
16	05	O
17	).	O
1	We	O
2	have	O
3	isolated	O
4	a	O
5	cosmid	O
6	containing	O
7	DNA	O
8	that	O
9	corresponds	O
10	to	O
11	the	O
12	site	O
13	of	O
14	transposon	O
15	insertion	O
16	in	O
17	257DH4	O
18	and	O
19	have	O
20	localized	O
21	Tn5	O
22	on	O
23	an	O
24	8	O
25	.	O
26	0	O
27	kb	O
28	EcoRI	O
29	fragment	O
30	.	O
1	The	O
2	scr	O
3	regulon	O
4	of	O
5	pUR400	O
6	and	O
7	the	O
8	chromosomally	O
9	encoded	O
10	scr	O
11	regulon	O
12	of	O
13	Klebsiella	O
14	pneumoniae	O
15	KAY2026	O
16	are	O
17	both	O
18	negatively	O
19	controlled	O
20	by	O
21	a	O
22	specific	O
23	repressor	O
24	(	O
25	ScrR	O
26	).	O
1	The	O
2	Ntl1	O
3	gene	O
4	is	O
5	present	O
6	as	O
7	a	O
8	unique	O
9	copy	O
10	in	O
11	the	O
12	diploid	O
13	N	O
14	.	O
15	plumbaginifolia	O
16	species	O
17	.	O
1	Consistent	O
2	with	O
3	the	O
4	hypothesis	O
5	that	O
6	it	O
7	acts	O
8	as	O
9	transcriptional	O
10	regulator	O
11	,	O
12	wild	O
13	-	O
14	type	O
15	p53	B
16	protein	O
17	binds	O
18	DNA	O
19	and	O
20	activates	O
21	transcription	O
22	of	O
23	several	O
24	promoters	O
25	.	O
1	These	O
2	CTD	O
3	kinases	B
4	,	O
5	designated	O
6	CTDK1	O
7	and	O
8	CTDK2	O
9	,	O
10	are	O
11	fractionated	O
12	by	O
13	chromatography	O
14	on	O
15	Mono	O
16	Q	O
17	.	O
1	They	O
2	were	O
3	called	O
4	PACE4	O
5	and	O
6	PC4	O
7	.	O
1	Both	O
2	fusion	O
3	proteins	O
4	form	O
5	stable	O
6	specific	O
7	complexes	O
8	with	O
9	a	O
10	short	O
11	DNA	O
12	duplex	O
13	harboring	O
14	the	O
15	CTGT	O
16	(	O
17	at	O
18	)	O
19	4ACAG	O
20	consensus	O
21	sequence	O
22	of	O
23	the	O
24	LexA	O
25	repressor	O
26	.	O
1	CONCLUSIONS	O
2	:	O
3	Free	O
4	protein	O
5	S	O
6	deficiency	O
7	is	O
8	common	O
9	among	O
10	hospitalized	O
11	patients	O
12	,	O
13	even	O
14	in	O
15	the	O
16	absence	O
17	of	O
18	a	O
19	recognized	O
20	predisposing	O
21	condition	O
22	.	O
1	During	O
2	the	O
3	past	O
4	decade	O
5	,	O
6	different	O
7	types	O
8	of	O
9	endogenous	O
10	retroviral	O
11	sequences	O
12	have	O
13	been	O
14	defined	O
15	in	O
16	the	O
17	human	O
18	genome	O
19	usually	O
20	by	O
21	low	O
22	stringency	O
23	hybridization	O
24	employing	O
25	DNA	O
26	probes	O
27	of	O
28	evolutionary	O
29	conserved	O
30	animal	O
31	retrovirus	O
32	genes	O
33	.	O
1	The	O
2	use	O
3	of	O
4	this	O
5	model	O
6	for	O
7	investigating	O
8	pathophysiologically	O
9	significant	O
10	issues	O
11	in	O
12	denervating	O
13	diseases	O
14	is	O
15	illustrated	O
16	with	O
17	five	O
18	different	O
19	sets	O
20	of	O
21	parameters	O
22	.	O
1	The	O
2	half	O
3	-	O
4	life	O
5	of	O
6	the	O
7	serum	O
8	-	O
9	induced	O
10	CBP	O
11	/	O
12	tk	O
13	binding	O
14	activity	O
15	was	O
16	estimated	O
17	to	O
18	be	O
19	less	O
20	than	O
21	1	O
22	h	O
23	.(	O
24	ABSTRACT	O
25	TRUNCATED	O
26	AT	O
27	400	O
28	WORDS	O
29	)	O
1	These	O
2	data	O
3	establish	O
4	Smd1p	O
5	as	O
6	a	O
7	required	O
8	component	O
9	of	O
10	the	O
11	cellular	O
12	splicing	O
13	apparatus	O
14	and	O
15	a	O
16	factor	O
17	in	O
18	snRNA	O
19	maturation	O
20	and	O
21	stability	O
22	.	O
1	Deletion	O
2	of	O
3	the	O
4	apeA	O
5	gene	O
6	,	O
7	either	O
8	with	O
9	or	O
10	without	O
11	deletion	O
12	of	O
13	other	O
14	proteinases	O
15	(	O
16	protease	O
17	IV	O
18	and	O
19	aminopeptidase	O
20	N	O
21	),	O
22	did	O
23	not	O
24	have	O
25	any	O
26	effect	O
27	on	O
28	cell	O
29	growth	O
30	in	O
31	the	O
32	various	O
33	media	O
34	tested	O
35	.	O
1	In	O
2	Experiment	O
3	2	O
4	scopolamine	O
5	hydrobromide	O
6	,	O
7	0	O
8	.	O
9	5	O
10	and	O
11	1	O
12	.	O
13	0	O
14	mg	O
15	/	O
16	kg	O
17	i	O
18	.	O
19	p	O
20	.,	O
21	was	O
22	administered	O
23	1	O
24	h	O
25	before	O
26	each	O
27	electrical	O
28	stimulation	O
29	until	O
30	each	O
31	rat	O
32	showed	O
33	the	O
34	stage	O
35	-	O
36	3	O
37	seizure	O
38	.	O
1	PNT	O
2	,	O
3	ADD	O
4	and	O
5	BSS	O
6	in	O
7	the	O
8	initial	O
9	stage	O
10	of	O
11	kindling	O
12	,	O
13	kindling	O
14	rate	O
15	for	O
16	the	O
17	stage	O
18	-	O
19	3	O
20	and	O
21	-	O
22	5	O
23	seizures	O
24	,	O
25	seizure	O
26	parameters	O
27	at	O
28	the	O
29	first	O
30	stage	O
31	-	O
32	3	O
33	and	O
34	-	O
35	5	O
36	were	O
37	recorded	O
38	and	O
39	compared	O
40	to	O
41	the	O
42	values	O
43	of	O
44	saline	O
45	-	O
46	treated	O
47	,	O
48	control	O
49	group	O
50	.	O
1	CONCLUSIONS	O
2	.	O
1	There	O
2	was	O
3	a	O
4	positive	O
5	correlation	O
6	between	O
7	pyridinium	O
8	cross	O
9	-	O
10	link	O
11	excretion	O
12	and	O
13	thyroid	O
14	hormone	O
15	concentrations	O
16	.	O
1	The	O
2	activity	O
3	of	O
4	the	O
5	coat	O
6	protein	O
7	promoter	O
8	of	O
9	chloris	O
10	striate	O
11	mosaic	O
12	virus	O
13	is	O
14	enhanced	O
15	by	O
16	its	O
17	own	O
18	and	O
19	C1	O
20	-	O
21	C2	O
22	gene	O
23	products	O
24	.	O
1	These	O
2	studies	O
3	demonstrate	O
4	that	O
5	both	O
6	G	O
7	alpha	B
8	i	O
9	genes	O
10	are	O
11	dynamically	O
12	regulated	O
13	in	O
14	LLC	O
15	-	O
16	PK1	O
17	cells	O
18	by	O
19	both	O
20	growth	O
21	,	O
22	differentiation	O
23	,	O
24	and	O
25	hormone	O
26	signals	O
27	.	O
1	Histochemical	O
2	localization	O
3	of	O
4	GUS	O
5	revealed	O
6	promoter	O
7	function	O
8	in	O
9	leaf	O
10	epidermis	O
11	,	O
12	mesophyll	O
13	and	O
14	vascular	O
15	bundles	O
16	,	O
17	in	O
18	the	O
19	cortex	O
20	and	O
21	vascular	O
22	cylinder	O
23	of	O
24	the	O
25	root	O
26	.	O
1	Pathways	O
2	linking	O
3	the	O
4	olfactory	O
5	bulbs	O
6	with	O
7	the	O
8	medial	O
9	preoptic	O
10	anterior	O
11	hypothalamus	O
12	are	O
13	important	O
14	for	O
15	intermale	O
16	aggression	O
17	in	O
18	mice	O
19	.	O
1	Following	O
2	seizure	O
3	induction	O
4	,	O
5	MABP	O
6	increased	O
7	to	O
8	105	O
9	mm	O
10	Hg	O
11	and	O
12	brain	O
13	pHi	O
14	fell	O
15	to	O
16	6	O
17	.	O
18	79	O
19	+/-	O
20	0	O
21	.	O
22	03	O
23	within	O
24	15	O
25	min	O
26	and	O
27	remained	O
28	at	O
29	this	O
30	level	O
31	for	O
32	1	O
33	h	O
34	(	O
35	P	O
36	<	O
37	0	O
38	.	O
39	001	O
40	).	O
1	In	O
2	contrast	O
3	,	O
4	rats	O
5	receiving	O
6	U74500A	O
7	(	O
8	2	O
9	mg	O
10	/	O
11	kg	O
12	i	O
13	.	O
14	v	O
15	.	O
16	infusion	O
17	commencing	O
18	30	O
19	min	O
20	prior	O
21	to	O
22	revascularisation	O
23	)	O
24	exhibited	O
25	enhanced	O
26	GMBF	O
27	throughout	O
28	reperfusion	O
29	[	O
30	PI	O
31	10	O
32	min	O
33	:	O
34	3	O
35	.	O
36	26	O
37	(	O
38	2	O
39	.	O
40	56	O
41	-	O
42	3	O
43	.	O
44	63	O
45	);	O
46	120	O
47	min	O
48	:	O
49	2	O
50	.	O
51	03	O
52	(	O
53	1	O
54	.	O
55	73	O
56	-	O
57	2	O
58	.	O
59	25	O
60	);	O
61	240	O
62	min	O
63	:	O
64	2	O
65	.	O
66	13	O
67	(	O
68	1	O
69	.	O
70	75	O
71	-	O
72	2	O
73	.	O
74	44	O
75	),	O
76	p	O
77	<	O
78	0	O
79	.	O
80	01	O
81	vs	O
82	.	O
83	controls	O
84	and	O
85	normals	O
86	]	O
87	with	O
88	complete	O
89	muscle	O
90	salvage	O
91	[	O
92	GMV	O
93	100	O
94	%	O
95	in	O
96	all	O
97	reperfused	O
98	muscles	O
99	,	O
100	p	O
101	<	O
102	0	O
103	.	O
104	01	O
105	vs	O
106	.	O
107	controls	O
108	,	O
109	not	O
110	significant	O
111	(	O
112	NS	O
113	)	O
114	vs	O
115	.	O
116	normals	O
117	and	O
118	6	O
119	h	O
120	ischaemia	O
121	].(	O
122	ABSTRACT	O
123	TRUNCATED	O
124	AT	O
125	250	O
126	WORDS	O
127	)	O
1	Sequencing	O
2	of	O
3	a	O
4	1	O
5	.	O
6	3	O
7	-	O
8	kilobase	O
9	fragment	O
10	of	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	TSG6	O
19	gene	O
20	identified	O
21	TATA	O
22	-	O
23	like	O
24	and	O
25	CAAT	O
26	sequences	O
27	near	O
28	the	O
29	transcription	O
30	start	O
31	site	O
32	.	O
1	Nuclear	O
2	beta	B
3	II	O
4	PKC	B
5	,	O
6	like	O
7	p34cdc2	O
8	kinase	B
9	,	O
10	may	O
11	function	O
12	to	O
13	regulate	O
14	nuclear	O
15	lamina	O
16	structural	O
17	stability	O
18	during	O
19	cell	O
20	cycle	O
21	.	O
1	Finger	O
2	associated	O
3	box	O
4	-	O
5	zinc	O
6	finger	O
7	proteins	O
8	(	O
9	FAX	O
10	-	O
11	ZFPs	O
12	)	O
13	constitute	O
14	a	O
15	subfamily	O
16	of	O
17	the	O
18	many	O
19	C2H2	O
20	type	O
21	ZFPs	O
22	in	O
23	Xenopus	O
24	laevis	O
25	.	O
1	Examination	O
2	of	O
3	the	O
4	immediate	O
5	sequence	O
6	5	O
7	'	O
8	to	O
9	the	O
10	mRNA	O
11	start	O
12	site	O
13	reveals	O
14	no	O
15	TATA	O
16	box	O
17	and	O
18	multiple	O
19	known	O
20	enhancer	O
21	sequences	O
22	.	O
1	B	O
2	cell	O
3	-	O
4	specific	O
5	mb	O
6	-	O
7	1	O
8	and	O
9	B29	O
10	genes	O
11	encode	O
12	the	O
13	alpha	B
14	/	O
15	beta	B
16	components	O
17	of	O
18	the	O
19	BCR	O
20	-	O
21	associated	O
22	complex	O
23	in	O
24	mature	O
25	sIgM	O
26	+	O
27	B	O
28	cells	O
29	.	O
1	These	O
2	protective	O
3	influences	O
4	were	O
5	observed	O
6	throughout	O
7	the	O
8	range	O
9	of	O
10	filling	O
11	pressures	O
12	measured	O
13	,	O
14	from	O
15	0	O
16	to	O
17	30	O
18	mmHg	O
19	.	O
1	The	O
2	nifJ	O
3	and	O
4	nifH	O
5	promoters	O
6	of	O
7	Klebsiella	O
8	pneumoniae	O
9	are	O
10	divergently	O
11	transcribed	O
12	sigma	O
13	54	O
14	-	O
15	dependent	O
16	promoters	O
17	that	O
18	are	O
19	positively	O
20	activated	O
21	by	O
22	the	O
23	NifA	O
24	protein	O
25	.	O
1	These	O
2	data	O
3	show	O
4	that	O
5	PTH	O
6	and	O
7	cAMP	O
8	can	O
9	repress	O
10	collagen	O
11	promoter	O
12	activity	O
13	in	O
14	calvariae	O
15	from	O
16	transgenic	O
17	mice	O
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	alpha	B
23	1	O
24	(	O
25	I	O
26	)	O
27	collagen	O
28	promoter	O
29	may	O
30	contain	O
31	cis	O
32	elements	O
33	down	O
34	-	O
35	stream	O
36	of	O
37	-	O
38	2	O
39	.	O
40	3	O
41	kilobases	O
42	that	O
43	mediate	O
44	PTH	O
45	and	O
46	cAMP	O
47	repression	O
48	of	O
49	collagen	O
50	gene	O
51	expression	O
52	in	O
53	bone	O
54	.	O
1	We	O
2	conclude	O
3	that	O
4	the	O
5	alpha	B
6	-	O
7	subunit	O
8	of	O
9	the	O
10	telomere	O
11	-	O
12	binding	O
13	protein	O
14	,	O
15	like	O
16	many	O
17	transcription	O
18	factors	O
19	,	O
20	has	O
21	separable	O
22	DNA	O
23	-	O
24	binding	O
25	and	O
26	protein	O
27	-	O
28	protein	O
29	interaction	O
30	domains	O
31	.	O
1	This	O
2	sequence	O
3	similarity	O
4	raises	O
5	the	O
6	possibility	O
7	that	O
8	GCN1	O
9	interacts	O
10	with	O
11	ribosomes	O
12	or	O
13	tRNA	O
14	molecules	O
15	and	O
16	functions	O
17	in	O
18	conjunction	O
19	with	O
20	GCN2	O
21	in	O
22	monitoring	O
23	uncharged	O
24	tRNA	O
25	levels	O
26	during	O
27	the	O
28	process	O
29	of	O
30	translation	O
31	elongation	O
32	.	O
1	In	O
2	conclusion	O
3	,	O
4	changes	O
5	in	O
6	carotid	O
7	sinus	O
8	stimulation	O
9	alters	O
10	blood	O
11	flow	O
12	to	O
13	the	O
14	hindlimb	O
15	through	O
16	changes	O
17	in	O
18	both	O
19	Pcrit	O
20	and	O
21	Ra	O
22	.	O
1	Multizone	O
2	PRK	O
3	has	O
4	been	O
5	suggested	O
6	to	O
7	increase	O
8	the	O
9	predictability	O
10	of	O
11	higher	O
12	myopic	O
13	corrections	O
14	.	O
1	In	O
2	17	O
3	patients	O
4	with	O
5	deletions	O
6	,	O
7	the	O
8	parental	O
9	origin	O
10	of	O
11	deletion	O
12	was	O
13	determined	O
14	.	O
1	The	O
2	HMG	O
3	CoA	O
4	reductase	O
5	inhibitors	O
6	are	O
7	the	O
8	most	O
9	effective	O
10	cholesterol	O
11	-	O
12	lowering	O
13	agents	O
14	currently	O
15	available	O
16	.	O
1	Members	O
2	of	O
3	the	O
4	C	O
5	/	O
6	EBP	O
7	family	O
8	of	O
9	basic	O
10	-	O
11	leucine	O
12	zipper	O
13	(	O
14	bZip	O
15	)	O
16	transcription	O
17	factors	O
18	form	O
19	heterodimers	O
20	and	O
21	bind	O
22	to	O
23	the	O
24	CAAT	O
25	box	O
26	and	O
27	other	O
28	sequence	O
29	-	O
30	related	O
31	enhancer	O
32	motifs	O
33	.	O
1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	ischaemia	O
7	and	O
8	non	O
9	-	O
10	ischaemia	O
11	groups	O
12	on	O
13	the	O
14	basis	O
15	of	O
16	the	O
17	change	O
18	in	O
19	lactate	O
20	extraction	O
21	ratio	O
22	during	O
23	balloon	O
24	inflation	O
25	.	O
1	A	O
2	36	O
3	-	O
4	kDa	O
5	protein	O
6	that	O
7	was	O
8	localized	O
9	to	O
10	the	O
11	membrane	O
12	fraction	O
13	was	O
14	detected	O
15	in	O
16	minicells	O
17	containing	O
18	plasmids	O
19	with	O
20	the	O
21	ftsN	O
22	gene	O
23	,	O
24	confirming	O
25	that	O
26	FtsN	O
27	was	O
28	a	O
29	membrane	O
30	protein	O
31	.	O
1	Against	O
2	200	O
3	strains	O
4	of	O
5	methicillin	O
6	-	O
7	resistant	O
8	Staphylococcus	O
9	aureus	O
10	(	O
11	MRSA	O
12	)	O
13	isolated	O
14	from	O
15	1990	O
16	to	O
17	1991	O
18	,	O
19	minimum	O
20	inhibitory	O
21	concentrations	O
22	(	O
23	MICs	O
24	)	O
25	of	O
26	a	O
27	total	O
28	of	O
29	15	O
30	antibacterial	O
31	agents	O
32	including	O
33	arbekacin	O
34	(	O
35	ABK	O
36	)	O
37	were	O
38	determined	O
39	.	O
1	RESULTS	O
2	:	O
3	Statistically	O
4	significant	O
5	differences	O
6	were	O
7	obtained	O
8	between	O
9	group	O
10	I	O
11	and	O
12	II	O
13	concerning	O
14	the	O
15	number	O
16	of	O
17	patients	O
18	in	O
19	whom	O
20	induced	O
21	atrial	O
22	fibrillation	O
23	with	O
24	conduction	O
25	by	O
26	the	O
27	accessory	O
28	pathway	O
29	and	O
30	RR	O
31	<	O
32	or	O
33	=	O
34	250	O
35	msec	O
36	was	O
37	found	O
38	(	O
39	0	O
40	vs	O
41	6	O
42	,	O
43	p	O
44	=	O
45	0	O
46	.	O
47	0045	O
48	).	O
1	A	O
2	second	O
3	hydrophobic	O
4	domain	O
5	,	O
6	bordered	O
7	by	O
8	two	O
9	hydrophilic	O
10	regions	O
11	strongly	O
12	suggests	O
13	a	O
14	transmembrane	O
15	region	O
16	.	O
1	This	O
2	gene	O
3	spans	O
4	23	O
5	kb	O
6	and	O
7	is	O
8	composed	O
9	of	O
10	five	O
11	exons	O
12	and	O
13	four	O
14	introns	O
15	.	O
1	This	O
2	conclusion	O
3	is	O
4	based	O
5	on	O
6	the	O
7	observations	O
8	of	O
9	the	O
10	immunologic	O
11	changes	O
12	that	O
13	characterize	O
14	the	O
15	acute	O
16	stages	O
17	of	O
18	illness	O
19	as	O
20	well	O
21	as	O
22	on	O
23	the	O
24	demonstrated	O
25	association	O
26	with	O
27	toxin	O
28	-	O
29	producing	O
30	bacteria	O
31	in	O
32	the	O
33	pharynx	O
34	and	O
35	gastrointestinal	O
36	tract	O
37	.	O
1	Refugees	O
2	living	O
3	in	O
4	Lund	O
5	and	O
6	repatriated	O
7	to	O
8	Chile	O
9	considered	O
10	their	O
11	health	O
12	as	O
13	bad	O
14	in	O
15	a	O
16	higher	O
17	proportion	O
18	than	O
19	their	O
20	Swedish	O
21	counterparts	O
22	,	O
23	with	O
24	an	O
25	odds	O
26	ratio	O
27	of	O
28	3	O
29	.	O
30	48	O
31	(	O
32	2	O
33	.	O
34	03	O
35	-	O
36	5	O
37	.	O
38	66	O
39	)	O
40	and	O
41	4	O
42	.	O
43	78	O
44	(	O
45	2	O
46	.	O
47	1	O
48	-	O
49	10	O
50	.	O
51	25	O
52	)	O
53	respectively	O
54	.	O
1	Unlike	O
2	ARF	O
3	,	O
4	the	O
5	ARP	O
6	immunoreactivity	O
7	was	O
8	detected	O
9	in	O
10	plasma	O
11	membranes	O
12	but	O
13	not	O
14	in	O
15	cytosol	O
16	of	O
17	fractionated	O
18	3T3	O
19	-	O
20	L1	O
21	cells	O
22	.	O
1	All	O
2	three	O
3	NR	O
4	isoforms	O
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O
1	The	O
2	Arabidopsis	O
3	FAD7	O
4	gene	O
5	encodes	O
6	a	O
7	chloroplast	O
8	omega	O
9	-	O
10	3	O
11	fatty	O
12	acid	O
13	desaturase	O
14	that	O
15	catalyzes	O
16	the	O
17	desaturation	O
18	of	O
19	lipid	O
20	-	O
21	linked	O
22	dienoic	O
23	fatty	O
24	acids	O
25	(	O
26	18	O
27	:	O
28	2	O
29	and	O
30	16	O
31	:	O
32	2	O
33	).	O
1	Protein	O
2	kinases	B
3	play	O
4	pivotal	O
5	roles	O
6	in	O
7	the	O
8	control	O
9	of	O
10	many	O
11	cellular	O
12	processes	O
13	.	O
1	A	O
2	human	O
3	recombinant	O
4	cDNA	O
5	clone	O
6	that	O
7	encoded	O
8	253	O
9	amino	O
10	acids	O
11	residues	O
12	of	O
13	a	O
14	zinc	O
15	-	O
16	finger	O
17	protein	O
18	(	O
19	THZif	O
20	-	O
21	1	O
22	)	O
23	was	O
24	cloned	O
25	by	O
26	screening	O
27	a	O
28	cDNA	O
29	library	O
30	prepared	O
31	from	O
32	human	O
33	promyelocytic	O
34	leukemia	O
35	HL60	O
36	cells	O
37	with	O
38	synthetic	O
39	oligodeoxynucleotide	O
40	probes	O
41	that	O
42	corresponded	O
43	to	O
44	the	O
45	amino	O
46	acid	O
47	sequences	O
48	of	O
49	tryptic	O
50	peptides	O
51	derived	O
52	from	O
53	the	O
54	DNA	O
55	-	O
56	binding	O
57	protein	O
58	specific	O
59	for	O
60	the	O
61	nuclease	O
62	-	O
63	hypersensitive	O
64	element	O
65	(	O
66	NHE	O
67	)	O
68	of	O
69	the	O
70	human	O
71	c	B
72	-	O
73	myc	O
74	gene	O
75	.	O
1	The	O
2	XS2	O
3	gene	O
4	down	O
5	-	O
6	regulates	O
7	but	O
8	does	O
9	not	O
10	abolish	O
11	expression	O
12	of	O
13	LU	O
14	genes	O
15	and	O
16	does	O
17	not	O
18	affect	O
19	expression	O
20	of	O
21	CD44	O
22	.	O
1	According	O
2	to	O
3	the	O
4	investigation	O
5	,	O
6	the	O
7	recent	O
8	burst	O
9	of	O
10	pseudoterranovosis	O
11	in	O
12	this	O
13	area	O
14	can	O
15	be	O
16	attributed	O
17	to	O
18	the	O
19	increased	O
20	presence	O
21	of	O
22	sea	O
23	lions	O
24	,	O
25	which	O
26	proliferate	O
27	in	O
28	the	O
29	Arctic	O
30	region	O
31	,	O
32	then	O
33	migrate	O
34	to	O
35	the	O
36	northern	O
37	Japan	O
38	Sea	O
39	and	O
40	eat	O
41	the	O
42	intermediate	O
43	host	O
44	fish	O
45	.	O
1	To	O
2	identify	O
3	some	O
4	of	O
5	the	O
6	genes	O
7	expressed	O
8	in	O
9	LPS	O
10	-	O
11	activated	O
12	coelomocytes	O
13	,	O
14	we	O
15	sequenced	O
16	randomly	O
17	chosen	O
18	clones	O
19	from	O
20	a	O
21	directionally	O
22	constructed	O
23	cDNA	O
24	library	O
25	to	O
26	produce	O
27	a	O
28	set	O
29	of	O
30	expressed	O
31	sequence	O
32	tags	O
33	(	O
34	ESTs	O
35	).	O
1	Thus	O
2	,	O
3	SPECT	O
4	was	O
5	not	O
6	as	O
7	sensitive	O
8	as	O
9	PET	O
10	in	O
11	this	O
12	activation	O
13	task	O
14	.	O
1	Three	O
2	of	O
3	these	O
4	subunits	O
5	are	O
6	also	O
7	homologous	O
8	to	O
9	the	O
10	dimeric	O
11	POR	O
12	from	O
13	a	O
14	mesophilic	O
15	archaeon	O
16	,	O
17	Halobacterium	O
18	halobium	O
19	(	O
20	21	O
21	%	O
22	identity	O
23	).	O
1	CXC	O
2	chemokines	O
3	bind	O
4	to	O
5	unique	O
6	sets	O
7	of	O
8	selectivity	O
9	determinants	O
10	that	O
11	can	O
12	function	O
13	independently	O
14	and	O
15	are	O
16	broadly	O
17	distributed	O
18	on	O
19	multiple	O
20	domains	O
21	of	O
22	human	O
23	interleukin	O
24	-	O
25	8	O
26	receptor	B
27	B	O
28	.	O
1	We	O
2	have	O
3	identified	O
4	and	O
5	characterized	O
6	a	O
7	vitamin	O
8	D	O
9	response	O
10	element	O
11	(	O
12	VDRE	O
13	)	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	c	B
19	-	O
20	fos	O
21	.	O
1	A	O
2	short	O
3	open	O
4	reading	O
5	frame	O
6	(	O
7	ORF2	O
8	),	O
9	of	O
10	unknown	O
11	function	O
12	,	O
13	is	O
14	present	O
15	in	O
16	all	O
17	FIV	O
18	isolates	O
19	.	O
1	Mg2	O
2	+	O
3	and	O
4	Mn2	O
5	+	O
6	compete	O
7	for	O
8	binding	O
9	sites	O
10	,	O
11	with	O
12	the	O
13	former	O
14	having	O
15	lower	O
16	affinity	O
17	.	O
1	Neither	O
2	class	O
3	II	O
4	nor	O
5	IV	O
6	infections	O
7	precluded	O
8	transplantation	O
9	.	O
1	However	O
2	,	O
3	it	O
4	remains	O
5	an	O
6	open	O
7	question	O
8	whether	O
9	vertebrate	O
10	Hox	O
11	genes	O
12	expressed	O
13	under	O
14	the	O
15	control	O
16	of	O
17	Drosophila	O
18	regulatory	O
19	sequences	O
20	can	O
21	substitute	O
22	the	O
23	function	O
24	of	O
25	Drosophila	O
26	Hox	O
27	genes	O
28	.	O
1	Although	O
2	the	O
3	consumption	O
4	of	O
5	myoglobin	O
6	-	O
7	bound	O
8	O2	O
9	(	O
10	MbO2	O
11	)	O
12	stores	O
13	in	O
14	seal	O
15	muscles	O
16	has	O
17	been	O
18	demonstrated	O
19	in	O
20	seal	O
21	muscles	O
22	during	O
23	laboratory	O
24	simulations	O
25	of	O
26	diving	O
27	,	O
28	this	O
29	may	O
30	not	O
31	be	O
32	a	O
33	feature	O
34	of	O
35	normal	O
36	field	O
37	diving	O
38	in	O
39	which	O
40	measurements	O
41	of	O
42	heart	O
43	rate	O
44	and	O
45	lactate	O
46	production	O
47	show	O
48	marked	O
49	differences	O
50	from	O
51	the	O
52	profound	O
53	diving	O
54	response	O
55	induced	O
56	by	O
57	forced	O
58	immersion	O
59	.	O
1	In	O
2	our	O
3	opinion	O
4	,	O
5	the	O
6	SM	O
7	-	O
8	CMA	O
9	system	O
10	is	O
11	,	O
12	despite	O
13	some	O
14	shortcomings	O
15	in	O
16	its	O
17	user	O
18	-	O
19	interface	O
20	,	O
21	a	O
22	useful	O
23	and	O
24	versatile	O
25	instrument	O
26	for	O
27	examination	O
28	of	O
29	human	O
30	semen	O
31	samples	O
32	,	O
33	with	O
34	desirable	O
35	features	O
36	.	O
1	Disruption	O
2	of	O
3	RB	O
4	/	O
5	E2F	O
6	-	O
7	1	O
8	interaction	O
9	by	O
10	single	O
11	point	O
12	mutations	O
13	in	O
14	E2F	O
15	-	O
16	1	O
17	enhances	O
18	S	O
19	-	O
20	phase	O
21	entry	O
22	and	O
23	apoptosis	O
24	.	O
1	The	O
2	Clb5	O
3	kinase	B
4	,	O
5	which	O
6	promotes	O
7	S	O
8	phase	O
9	,	O
10	remains	O
11	active	O
12	during	O
13	the	O
14	G2	O
15	-	O
16	phase	O
17	arrest	O
18	of	O
19	cells	O
20	of	O
21	the	O
22	parental	O
23	strain	O
24	,	O
25	but	O
26	its	O
27	activity	O
28	declines	O
29	rapidly	O
30	in	O
31	sim	O
32	mutants	O
33	.	O
1	Rad6	O
2	mutants	O
3	display	O
4	a	O
5	remarkably	O
6	pleiotropic	O
7	phenotype	O
8	,	O
9	implicating	O
10	the	O
11	protein	O
12	in	O
13	DNA	O
14	damage	O
15	-	O
16	induced	O
17	mutagenesis	O
18	,	O
19	postreplication	O
20	repair	O
21	,	O
22	repression	O
23	of	O
24	retrotransposition	O
25	,	O
26	and	O
27	sporulation	O
28	.	O
1	Molecular	O
2	cloning	O
3	,	O
4	expression	O
5	pattern	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	human	O
12	CDKN2D	O
13	/	O
14	INK4d	O
15	,	O
16	an	O
17	inhibitor	O
18	of	O
19	cyclin	B
20	D	O
21	-	O
22	dependent	O
23	kinases	B
24	.	O
1	Overproduction	O
2	of	O
3	HrcA	O
4	protein	O
5	from	O
6	a	O
7	second	O
8	copy	O
9	of	O
10	hrcA	O
11	derived	O
12	from	O
13	a	O
14	plasmid	O
15	(	O
16	phrcA	O
17	+)	O
18	in	O
19	B	O
20	.	O
21	subtilis	O
22	wild	O
23	-	O
24	type	O
25	and	O
26	delta	B
27	hrcA	O
28	strains	O
29	prevented	O
30	heat	O
31	shock	O
32	induction	O
33	of	O
34	the	O
35	dnaK	O
36	and	O
37	groE	O
38	operons	O
39	at	O
40	the	O
41	level	O
42	of	O
43	transcription	O
44	almost	O
45	completely	O
46	and	O
47	strongly	O
48	reduced	O
49	the	O
50	amounts	O
51	of	O
52	mRNA	O
53	at	O
54	a	O
55	low	O
56	temperature	O
57	as	O
58	well	O
59	.	O
1	A	O
2	genetic	O
3	and	O
4	molecular	O
5	analysis	O
6	of	O
7	non	O
8	-	O
9	inducible	O
10	qutA	O
11	mutants	O
12	showed	O
13	that	O
14	all	O
15	23	O
16	mutations	O
17	analysed	O
18	map	O
19	within	O
20	the	O
21	N	O
22	-	O
23	terminal	O
24	half	O
25	of	O
26	the	O
27	encoded	O
28	QUTA	O
29	protein	O
30	.	O
1	Suppressors	O
2	of	O
3	defective	O
4	silencing	O
5	in	O
6	yeast	O
7	:	O
8	effects	O
9	on	O
10	transcriptional	O
11	repression	O
12	at	O
13	the	O
14	HMR	O
15	locus	O
16	,	O
17	cell	O
18	growth	O
19	and	O
20	telomere	O
21	structure	O
22	.	O
1	Hybrid	O
2	female	O
3	mice	O
4	(	O
5	C57BL	O
6	x	O
7	CBA	O
8	)	O
9	were	O
10	paired	O
11	with	O
12	breeder	O
13	males	O
14	(	O
15	CD	O
16	-	O
17	1	O
18	)	O
19	and	O
20	LNG	O
21	pellets	O
22	were	O
23	implanted	O
24	on	O
25	day	O
26	0	O
27	,	O
28	the	O
29	day	O
30	on	O
31	which	O
32	copulation	O
33	plugs	O
34	were	O
35	found	O
36	,	O
37	or	O
38	on	O
39	day	O
40	2	O
41	or	O
42	day	O
43	3	O
44	in	O
45	the	O
46	postcoital	O
47	period	O
48	.	O
1	Regressing	O
2	microaneurysms	O
3	in	O
4	5	O
5	cases	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	related	O
11	polyarteritis	O
12	nodosa	O
13	.	O
1	In	O
2	these	O
3	constructs	O
4	,	O
5	GUS	O
6	expression	O
7	was	O
8	driven	O
9	by	O
10	promoter	O
11	regions	O
12	derived	O
13	from	O
14	the	O
15	Arabidopsis	O
16	alcohol	O
17	dehydrogenase	O
18	(	O
19	Adh1	O
20	),	O
21	maize	O
22	ubiquitin	O
23	(	O
24	Ubi1	O
25	),	O
26	rice	O
27	actin	O
28	(	O
29	Act1	O
30	)	O
31	and	O
32	CaMV	O
33	35S	O
34	genes	O
35	.	O
1	The	O
2	DNA	O
3	sequences	O
4	upstream	O
5	of	O
6	these	O
7	termini	O
8	exhibit	O
9	homology	O
10	to	O
11	plant	O
12	mitochondrial	O
13	-	O
14	processing	O
15	sites	O
16	,	O
17	therefore	O
18	the	O
19	proximal	O
20	5	O
21	'	O
22	ends	O
23	are	O
24	most	O
25	probably	O
26	generated	O
27	by	O
28	RNA	O
29	processing	O
30	.	O
1	QBMDs	O
2	for	O
3	a	O
4	5	O
5	%	O
6	change	O
7	in	O
8	response	O
9	(	O
10	QBMD05	O
11	)	O
12	were	O
13	6	O
14	-	O
15	fold	O
16	lower	O
17	,	O
18	on	O
19	average	O
20	,	O
21	than	O
22	the	O
23	corresponding	O
24	NOAEL	O
25	.	O
1	The	O
2	gene	O
3	encodes	O
4	an	O
5	ATP	O
6	-	O
7	binding	O
8	cassette	O
9	,	O
10	ABC	O
11	transporter	O
12	.	O
1	The	O
2	T	O
3	-	O
4	box	O
5	motif	O
6	is	O
7	present	O
8	in	O
9	a	O
10	family	O
11	of	O
12	genes	O
13	whose	O
14	structural	O
15	features	O
16	and	O
17	expression	O
18	patterns	O
19	support	O
20	their	O
21	involvement	O
22	in	O
23	developmental	O
24	gene	O
25	regulation	O
26	.	O
1	In	O
2	contrast	O
3	to	O
4	the	O
5	signaling	O
6	triggered	O
7	by	O
8	surface	O
9	Ig	O
10	engagement	O
11	in	O
12	B	O
13	lymphocytes	O
14	,	O
15	CD38	O
16	ligation	O
17	did	O
18	not	O
19	appear	O
20	to	O
21	induce	O
22	tyrosine	O
23	phosphorylation	O
24	of	O
25	the	O
26	src	O
27	-	O
28	like	O
29	protein	O
30	tyrosine	O
31	kinases	B
32	lyn	O
33	,	O
34	fyn	O
35	,	O
36	and	O
37	btk	O
38	,	O
39	or	O
40	of	O
41	vav	O
42	-	O
43	and	O
44	ras	O
45	-	O
46	GTPase	B
47	-	O
48	activating	O
49	protein	O
50	,	O
51	nor	O
52	did	O
53	it	O
54	induce	O
55	detectable	O
56	changes	O
57	in	O
58	cytosolic	O
59	CA2	O
60	+	O
61	concentrations	O
62	.	O
1	The	O
2	evidence	O
3	presented	O
4	here	O
5	suggests	O
6	that	O
7	the	O
8	p40	O
9	complex	O
10	is	O
11	a	O
12	ribonucleoprotein	O
13	complex	O
14	containing	O
15	L1Hs	O
16	RNA	O
17	(	O
18	s	O
19	)	O
20	and	O
21	that	O
22	protein	O
23	-	O
24	protein	O
25	interactions	O
26	in	O
27	which	O
28	alpha	B
29	-	O
30	helix	O
31	structures	O
32	participate	O
33	,	O
34	for	O
35	example	O
36	coiled	O
37	-	O
38	coils	O
39	,	O
40	may	O
41	occur	O
42	in	O
43	the	O
44	complex	O
45	.	O
1	Pseudomembranous	O
2	conjunctivitis	O
3	following	O
4	bone	O
5	marrow	O
6	transplantation	O
7	:	O
8	immunopathological	O
9	and	O
10	ultrastructural	O
11	study	O
12	of	O
13	one	O
14	case	O
15	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	RPF	O
6	-	O
7	1	O
8	is	O
9	likely	O
10	to	O
11	be	O
12	involved	O
13	in	O
14	early	O
15	steps	O
16	in	O
17	the	O
18	differentiation	O
19	of	O
20	amacrine	O
21	and	O
22	ganglion	O
23	cells	O
24	.	O
1	However	O
2	,	O
3	for	O
4	the	O
5	evaluable	O
6	cases	O
7	,	O
8	the	O
9	performances	O
10	of	O
11	the	O
12	CD3500	O
13	and	O
14	the	O
15	STKS	O
16	were	O
17	broadly	O
18	similar	O
19	and	O
20	generally	O
21	correlated	O
22	well	O
23	with	O
24	the	O
25	manual	O
26	reference	O
27	procedure	O
28	.	O
1	Carboxy	O
2	-	O
3	terminal	O
4	Spc110p	O
5	truncations	O
6	lacking	O
7	the	O
8	calmodulin	O
9	binding	O
10	site	O
11	can	O
12	support	O
13	growth	O
14	and	O
15	are	O
16	also	O
17	phosphorylated	O
18	in	O
19	a	O
20	cell	O
21	cycle	O
22	-	O
23	specific	O
24	manner	O
25	.	O
1	In	O
2	electromobility	O
3	shift	O
4	assays	O
5	,	O
6	EWS	O
7	-	O
8	FLI	O
9	-	O
10	1	O
11	binding	O
12	to	O
13	the	O
14	SRE	O
15	is	O
16	detectable	O
17	in	O
18	the	O
19	absence	O
20	of	O
21	SRF	O
22	whereas	O
23	the	O
24	binding	O
25	of	O
26	FLI	O
27	-	O
28	1	O
29	is	O
30	not	O
31	,	O
32	suggesting	O
33	that	O
34	the	O
35	interaction	O
36	with	O
37	DNA	O
38	is	O
39	the	O
40	step	O
41	which	O
42	limits	O
43	ternary	O
44	complex	O
45	formation	O
46	by	O
47	FLI	O
48	-	O
49	1	O
50	.	O
1	Variables	O
2	evaluated	O
3	were	O
4	number	O
5	of	O
6	weekly	O
7	anginal	O
8	events	O
9	,	O
10	data	O
11	from	O
12	ergometric	O
13	exercise	O
14	testing	O
15	with	O
16	simultaneous	O
17	electrocardiographic	O
18	registration	O
19	,	O
20	semiquantitative	O
21	evaluation	O
22	of	O
23	Tc	O
24	-	O
25	99m	O
26	2	O
27	-	O
28	methoxy	O
29	isobutyl	O
30	isonitrile	O
31	(	O
32	MIBI	O
33	)	O
34	scans	O
35	and	O
36	rheologic	O
37	variables	O
38	.	O
1	The	O
2	alpha	B
3	T3	O
4	-	O
5	1	O
6	cell	O
7	line	O
8	,	O
9	a	O
10	GnRH	O
11	-	O
12	responsive	O
13	gonadotroph	O
14	cell	O
15	line	O
16	developed	O
17	by	O
18	targeted	O
19	oncogenesis	O
20	in	O
21	transgenic	O
22	mice	O
23	,	O
24	was	O
25	used	O
26	to	O
27	study	O
28	regulation	O
29	of	O
30	the	O
31	glycoprotein	O
32	hormone	O
33	alpha	B
34	-	O
35	subunit	O
36	by	O
37	activin	O
38	.	O
1	As	O
2	expected	O
3	,	O
4	glycosylation	O
5	of	O
6	Env	O
7	produced	O
8	from	O
9	mutants	O
10	was	O
11	affected	O
12	but	O
13	,	O
14	irrespective	O
15	of	O
16	the	O
17	glycosylation	O
18	phenotype	O
19	,	O
20	(	O
21	i	O
22	)	O
23	similar	O
24	quantities	O
25	of	O
26	Env	O
27	were	O
28	synthesized	O
29	,	O
30	(	O
31	ii	O
32	)	O
33	the	O
34	immunoreactivity	O
35	of	O
36	V3	O
37	was	O
38	similar	O
39	,	O
40	(	O
41	iii	O
42	)	O
43	gp160	O
44	was	O
45	efficiently	O
46	cleaved	O
47	into	O
48	gp120	O
49	and	O
50	gp41	O
51	,	O
52	(	O
53	vi	O
54	)	O
55	Env	O
56	was	O
57	exposed	O
58	at	O
59	the	O
60	cell	O
61	membrane	O
62	,	O
63	(	O
64	v	O
65	)	O
66	secreted	O
67	gp120	O
68	bound	O
69	CD4	O
70	,	O
71	and	O
72	(	O
73	vi	O
74	)	O
75	membrane	O
76	gp41	O
77	was	O
78	able	O
79	to	O
80	induce	O
81	membrane	O
82	fusion	O
83	with	O
84	CD4	O
85	+	O
86	cells	O
87	.	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	sequences	O
6	in	O
7	the	O
8	SH2	O
9	/	O
10	SH3	O
11	/	O
12	SH2	O
13	region	O
14	of	O
15	p120	O
16	GAP	O
17	are	O
18	required	O
19	for	O
20	full	O
21	catalytic	O
22	activity	O
23	toward	O
24	Ras	B
25	.	O
1	Analysis	O
2	of	O
3	RAR	O
4	alpha	B
5	mutants	O
6	in	O
7	transfection	O
8	studies	O
9	reveals	O
10	that	O
11	the	O
12	DNA	O
13	binding	O
14	domain	O
15	is	O
16	sufficient	O
17	for	O
18	inhibition	O
19	of	O
20	BZLF1	O
21	activity	O
22	.	O
1	In	O
2	agreement	O
3	with	O
4	these	O
5	data	O
6	,	O
7	western	O
8	blot	O
9	experiments	O
10	using	O
11	an	O
12	antibody	O
13	directed	O
14	against	O
15	the	O
16	carboxy	O
17	-	O
18	terminal	O
19	portion	O
20	of	O
21	the	O
22	mouse	O
23	c	B
24	-	O
25	kit	O
26	protein	O
27	showed	O
28	that	O
29	a	O
30	polypeptide	O
31	,	O
32	of	O
33	the	O
34	size	O
35	predicted	O
36	by	O
37	the	O
38	open	O
39	reading	O
40	frame	O
41	of	O
42	the	O
43	spermatid	O
44	-	O
45	specific	O
46	c	B
47	-	O
48	kit	O
49	cDNA	O
50	,	O
51	accumulates	O
52	in	O
53	the	O
54	latest	O
55	stages	O
56	of	O
57	spermatogenesis	O
58	and	O
59	in	O
60	epididymal	O
61	spermatozoa	O
62	.	O
1	LY290181	O
2	appears	O
3	to	O
4	inhibit	O
5	uPA	O
6	promoter	O
7	activation	O
8	by	O
9	blocking	O
10	phorbol	O
11	ester	O
12	-	O
13	stimulated	O
14	binding	O
15	of	O
16	nuclear	O
17	proteins	O
18	to	O
19	the	O
20	uPA	O
21	PEA3	O
22	/	O
23	12	O
24	-	O
25	0	O
26	-	O
27	tetradecanoylphorbol	O
28	13	O
29	-	O
30	acetate	O
31	responsive	O
32	element	O
33	(	O
34	TRE	O
35	).	O
1	Biol	O
2	.	O
1	Gas6	O
2	contains	O
3	an	O
4	NH2	O
5	-	O
6	terminal	O
7	Gla	O
8	domain	O
9	followed	O
10	by	O
11	four	O
12	epidermal	O
13	growth	O
14	factor	O
15	-	O
16	like	O
17	repeats	O
18	and	O
19	tandem	O
20	globular	O
21	(	O
22	G	O
23	)	O
24	domains	O
25	.	O
1	The	O
2	protein	O
3	folds	O
4	correctly	O
5	with	O
6	two	O
7	disulfide	O
8	bonds	O
9	and	O
10	a	O
11	free	O
12	thiol	O
13	group	O
14	at	O
15	Cys25	O
16	.	O
1	The	O
2	men	O
3	self	O
4	-	O
5	selected	O
6	a	O
7	prescribed	O
8	diet	O
9	at	O
10	home	O
11	emphasizing	O
12	saturated	O
13	fat	O
14	as	O
15	the	O
16	visible	O
17	fat	O
18	for	O
19	1	O
20	week	O
21	.	O
1	These	O
2	results	O
3	illuminate	O
4	a	O
5	hitherto	O
6	unanticipated	O
7	function	O
8	of	O
9	U6	O
10	RNA	O
11	:	O
12	the	O
13	modulation	O
14	of	O
15	a	O
16	phosphorylation	O
17	-	O
18	dephosphorylation	O
19	cycle	O
20	of	O
21	C1	O
22	hnRNP	O
23	protein	O
24	that	O
25	influences	O
26	the	O
27	binding	O
28	affinity	O
29	of	O
30	this	O
31	protein	O
32	for	O
33	pre	O
34	-	O
35	mRNA	O
36	.	O
1	Truncated	O
2	mammalian	O
3	Notch1	O
4	activates	O
5	CBF1	O
6	/	O
7	RBPJk	O
8	-	O
9	repressed	O
10	genes	O
11	by	O
12	a	O
13	mechanism	O
14	resembling	O
15	that	O
16	of	O
17	Epstein	O
18	-	O
19	Barr	O
20	virus	O
21	EBNA2	O
22	.	O
1	The	O
2	large	O
3	subfamily	O
4	of	O
5	receptor	B
6	tyrosine	O
7	kinases	B
8	(	O
9	RTKs	O
10	)	O
11	for	O
12	which	O
13	EPH	O
14	is	O
15	the	O
16	prototype	O
17	have	O
18	likely	O
19	roles	O
20	in	O
21	intercellular	O
22	communication	O
23	during	O
24	normal	O
25	mammalian	O
26	development	O
27	,	O
28	but	O
29	the	O
30	biochemical	O
31	signalling	O
32	pathways	O
33	utilised	O
34	by	O
35	this	O
36	family	O
37	are	O
38	poorly	O
39	characterised	O
40	.	O
1	The	O
2	17	O
3	-	O
4	kDa	O
5	protein	O
6	is	O
7	required	O
8	for	O
9	the	O
10	systemic	O
11	infection	O
12	of	O
13	plants	O
14	.	O
1	We	O
2	present	O
3	here	O
4	a	O
5	detailed	O
6	genomic	O
7	sequencing	O
8	analysis	O
9	of	O
10	the	O
11	cytosine	O
12	methylation	O
13	patterns	O
14	of	O
15	the	O
16	transposase	O
17	binding	O
18	sites	O
19	within	O
20	both	O
21	Ac	O
22	ends	O
23	in	O
24	the	O
25	wx	O
26	-	O
27	m9	O
28	::	O
29	Ac	O
30	allele	O
31	,	O
32	where	O
33	Ac	O
34	is	O
35	inserted	O
36	into	O
37	the	O
38	tenth	O
39	exon	O
40	of	O
41	the	O
42	Waxy	O
43	gene	O
44	.	O
1	Clones	O
2	33F	O
3	and	O
4	34B	O
5	encoded	O
6	identical	O
7	aromatase	O
8	proteins	O
9	of	O
10	503	O
11	amino	O
12	acids	O
13	,	O
14	but	O
15	differed	O
16	in	O
17	size	O
18	due	O
19	to	O
20	alternative	O
21	polyadenylation	O
22	signal	O
23	usage	O
24	for	O
25	the	O
26	corresponding	O
27	mRNAs	O
28	.	O
1	In	O
2	sorted	O
3	bone	O
4	marrow	O
5	cells	O
6	expression	O
7	of	O
8	both	O
9	VpreB	O
10	genes	O
11	was	O
12	detected	O
13	in	O
14	pro	O
15	-	O
16	B	O
17	/	O
18	pre	O
19	-	O
20	BI	O
21	and	O
22	large	O
23	pre	O
24	-	O
25	BII	O
26	cells	O
27	,	O
28	while	O
29	the	O
30	RNA	O
31	steady	O
32	state	O
33	levels	O
34	were	O
35	at	O
36	least	O
37	100	O
38	-	O
39	fold	O
40	lower	O
41	in	O
42	small	O
43	pre	O
44	-	O
45	BII	O
46	and	O
47	immature	O
48	/	O
49	mature	O
50	B	O
51	cells	O
52	.	O
1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	3574	O
8	-	O
9	bp	O
10	Bacillus	O
11	subtilis	O
12	(	O
13	Bs	O
14	)	O
15	DNA	O
16	fragment	O
17	located	O
18	between	O
19	the	O
20	nrdA	O
21	and	O
22	citB	O
23	genes	O
24	at	O
25	about	O
26	169	O
27	degrees	O
28	on	O
29	the	O
30	chromosome	O
31	.	O
1	Apart	O
2	from	O
3	two	O
4	proline	O
5	-	O
6	rich	O
7	regions	O
8	(	O
9	amino	O
10	acids	O
11	1	O
12	-	O
13	117	O
14	and	O
15	239	O
16	-	O
17	270	O
18	),	O
19	p230	O
20	contains	O
21	a	O
22	very	O
23	high	O
24	frequency	O
25	of	O
26	heptad	O
27	repeats	O
28	,	O
29	characteristic	O
30	of	O
31	alpha	B
32	-	O
33	helices	O
34	that	O
35	form	O
36	dimeric	O
37	coiled	O
38	-	O
39	coil	O
40	structures	O
41	.	O
42	p230	O
43	also	O
44	includes	O
45	the	O
46	sequence	O
47	ESLALEELEL	O
48	(	O
49	amino	O
50	acids	O
51	538	O
52	-	O
53	546	O
54	),	O
55	a	O
56	motif	O
57	found	O
58	in	O
59	the	O
60	granin	O
61	family	O
62	of	O
63	acidic	O
64	proteins	O
65	present	O
66	in	O
67	secretory	O
68	granules	O
69	of	O
70	neuroendocrine	O
71	cells	O
72	.	O
1	Binding	O
2	specificity	O
3	and	O
4	modulation	O
5	of	O
6	the	O
7	ApoA	O
8	-	O
9	I	O
10	promoter	O
11	activity	O
12	by	O
13	homo	O
14	-	O
15	and	O
16	heterodimers	O
17	of	O
18	nuclear	O
19	receptors	O
20	.	O
1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	demonstrated	O
7	that	O
8	HSV	O
9	infection	O
10	caused	O
11	enhanced	O
12	binding	O
13	of	O
14	protein	O
15	factors	O
16	,	O
17	including	O
18	the	O
19	64	O
20	-	O
21	kDa	O
22	component	O
23	of	O
24	cleavage	O
25	stimulation	O
26	factor	O
27	(	O
28	CstF	O
29	),	O
30	to	O
31	poly	O
32	(	O
33	A	O
34	)	O
35	site	O
36	RNAs	O
37	from	O
38	virus	O
39	genes	O
40	of	O
41	all	O
42	temporal	O
43	classes	O
44	and	O
45	that	O
46	this	O
47	enhanced	O
48	binding	O
49	required	O
50	expression	O
51	of	O
52	IE63	O
53	.	O
1	A	O
2	developmentally	O
3	regulated	O
4	4	O
5	.	O
6	6	O
7	kb	O
8	mRNA	O
9	is	O
10	recognized	O
11	on	O
12	Northern	O
13	blots	O
14	of	O
15	oocyte	O
16	RNA	O
17	using	O
18	the	O
19	X	O
20	.	O
21	laevis	O
22	cDNA	O
23	.	O
1	Several	O
2	cytokines	O
3	exhibit	O
4	a	O
5	high	O
6	degree	O
7	of	O
8	temporal	O
9	regulation	O
10	as	O
11	well	O
12	as	O
13	somnogenic	O
14	potency	O
15	(	O
16	e	O
17	.	O
18	g	O
19	.,	O
20	interleukin	O
21	-	O
22	1	O
23	[	O
24	IL	B
25	-	O
26	1	O
27	],	O
28	tumor	O
29	necrosis	O
30	factor	O
31	-	O
32	alpha	B
33	[	O
34	TNF	O
35	-	O
36	alpha	B
37	]).	O
1	This	O
2	interaction	O
3	is	O
4	mediated	O
5	by	O
6	the	O
7	SH2	O
8	domain	O
9	of	O
10	Crk	O
11	and	O
12	can	O
13	be	O
14	inhibited	O
15	with	O
16	a	O
17	phosphopeptide	O
18	containing	O
19	the	O
20	Crk	O
21	-	O
22	SH2	O
23	binding	O
24	motif	O
25	.	O
1	A	O
2	DNA	O
3	fragment	O
4	carrying	O
5	1	O
6	,	O
7	100	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	UGT1A1	O
19	gene	O
20	was	O
21	enough	O
22	for	O
23	MC	O
24	induction	O
25	.	O
1	The	O
2	frequency	O
3	of	O
4	integrations	O
5	that	O
6	led	O
7	to	O
8	transcription	O
9	of	O
10	the	O
11	lacZ	O
12	gene	O
13	was	O
14	estimated	O
15	to	O
16	be	O
17	0	O
18	.	O
19	5	O
20	%	O
21	of	O
22	all	O
23	integrations	O
24	,	O
25	of	O
26	which	O
27	14	O
28	%	O
29	were	O
30	downregulated	O
31	on	O
32	differentiation	O
33	of	O
34	32D	O
35	cells	O
36	towards	O
37	neutrophils	O
38	.	O
1	This	O
2	protein	O
3	encoded	O
4	by	O
5	this	O
6	cDNA	O
7	,	O
8	which	O
9	we	O
10	have	O
11	termed	O
12	p150TSP	O
13	(	O
14	for	O
15	TPR	O
16	-	O
17	containing	O
18	,	O
19	SH2	O
20	-	O
21	binding	O
22	phosphoprotein	O
23	),	O
24	is	O
25	located	O
26	predominantly	O
27	in	O
28	the	O
29	nucleus	O
30	and	O
31	is	O
32	highly	O
33	conserved	O
34	in	O
35	evolution	O
36	.	O
1	Adduction	O
2	of	O
3	the	O
4	human	O
5	N	O
6	-	O
7	ras	O
8	codon	O
9	61	O
10	sequence	O
11	with	O
12	(-)-(	O
13	7S	O
14	,	O
15	8R	O
16	,	O
17	9R	O
18	,	O
19	10S	O
20	)-	O
21	7	O
22	,	O
23	8	O
24	-	O
25	dihydroxy	O
26	-	O
27	9	O
28	,	O
29	10	O
30	-	O
31	epoxy	O
32	-	O
33	7	O
34	,	O
35	8	O
36	,	O
37	9	O
38	,	O
39	10	O
40	-	O
41	tetrahydrobenzo	O
42	[	O
43	a	O
44	]	O
45	pyrene	O
46	:	O
47	structural	O
48	refinement	O
49	of	O
50	the	O
51	intercalated	O
52	SRSR	O
53	(	O
54	61	O
55	,	O
56	2	O
57	)	O
58	(-)-(	O
59	7S	O
60	,	O
61	8R	O
62	,	O
63	9S	O
64	,	O
65	10R	O
66	)-	O
67	N6	O
68	-[	O
69	10	O
70	-(	O
71	7	O
72	,	O
73	8	O
74	,	O
75	9	O
76	,	O
77	10	O
78	-	O
79	tetrahydrobenzo	O
80	[	O
81	a	O
82	]	O
83	pyrenyl	O
84	)]-	O
85	2	O
86	'-	O
87	deoxyadenosyl	O
88	adduct	O
89	from	O
90	1H	O
91	NMR	O
92	.	O
1	Exposure	O
2	of	O
3	peripheral	O
4	blood	O
5	T	O
6	cells	O
7	from	O
8	young	O
9	subjects	O
10	to	O
11	PHA	O
12	or	O
13	cross	O
14	-	O
15	linked	O
16	anti	B
17	-	O
18	CD3	O
19	monoclonal	O
20	antibodies	O
21	stimulated	O
22	rapid	O
23	increases	O
24	in	O
25	MAPK	O
26	and	O
27	MEK	O
28	enzymatic	O
29	activity	O
30	.	O
1	This	O
2	region	O
3	includes	O
4	verA	O
5	,	O
6	a	O
7	structural	O
8	gene	O
9	previously	O
10	shown	O
11	to	O
12	be	O
13	required	O
14	for	O
15	ST	O
16	biosynthesis	O
17	,	O
18	and	O
19	24	O
20	additional	O
21	closely	O
22	spaced	O
23	transcripts	O
24	ranging	O
25	in	O
26	size	O
27	from	O
28	0	O
29	.	O
30	6	O
31	to	O
32	7	O
33	.	O
34	2	O
35	kb	O
36	that	O
37	are	O
38	coordinately	O
39	induced	O
40	only	O
41	under	O
42	ST	O
43	-	O
44	producing	O
45	conditions	O
46	.	O
1	A	O
2	human	O
3	cytoplasmic	O
4	signaling	O
5	protein	O
6	has	O
7	been	O
8	cloned	O
9	that	O
10	possesses	O
11	the	O
12	same	O
13	structural	O
14	arrangement	O
15	of	O
16	SH3	O
17	-	O
18	SH2	O
19	-	O
20	SH3	O
21	domains	O
22	as	O
23	Grb2	O
24	.	O
1	Cloning	O
2	of	O
3	individual	O
4	ZI	O
5	domains	O
6	upstream	O
7	of	O
8	a	O
9	minimal	O
10	promoter	O
11	demonstrated	O
12	that	O
13	the	O
14	ZIA	O
15	,	O
16	ZIC	O
17	,	O
18	and	O
19	ZID	O
20	domains	O
21	,	O
22	but	O
23	not	O
24	the	O
25	ZIB	O
26	domain	O
27	,	O
28	are	O
29	TPA	O
30	responsive	O
31	.	O
1	We	O
2	have	O
3	isolated	O
4	and	O
5	analyzed	O
6	human	O
7	CTCF	O
8	cDNA	O
9	clones	O
10	and	O
11	show	O
12	here	O
13	that	O
14	the	O
15	ubiquitously	O
16	expressed	O
17	11	O
18	-	O
19	zinc	O
20	-	O
21	finger	O
22	factor	O
23	CTCF	O
24	is	O
25	an	O
26	exceptionally	O
27	highly	O
28	conserved	O
29	protein	O
30	displaying	O
31	93	O
32	%	O
33	identity	O
34	between	O
35	avian	O
36	and	O
37	human	O
38	amino	O
39	acid	O
40	sequences	O
41	.	O
1	The	O
2	growth	O
3	defect	O
4	of	O
5	a	O
6	reg1	O
7	reg2	O
8	double	O
9	mutant	O
10	is	O
11	alleviated	O
12	by	O
13	a	O
14	loss	O
15	-	O
16	of	O
17	-	O
18	function	O
19	mutation	O
20	in	O
21	the	O
22	SNF1	O
23	-	O
24	encoded	O
25	protein	O
26	kinase	B
27	.	O
1	Sp1	B
2	binds	O
3	two	O
4	sites	O
5	in	O
6	the	O
7	CD11c	O
8	promoter	O
9	in	O
10	vivo	O
11	specifically	O
12	in	O
13	myeloid	O
14	cells	O
15	and	O
16	cooperates	O
17	with	O
18	AP1	O
19	to	O
20	activate	O
21	transcription	O
22	.	O
1	The	O
2	DNA	O
3	sequence	O
4	immediately	O
5	upstream	O
6	from	O
7	the	O
8	-	O
9	10	O
10	hexamer	O
11	contained	O
12	the	O
13	TGn	O
14	motif	O
15	described	O
16	as	O
17	an	O
18	extended	O
19	-	O
20	10	O
21	region	O
22	in	O
23	prokaryotic	O
24	promoters	O
25	.	O
1	We	O
2	conclude	O
3	from	O
4	these	O
5	studies	O
6	that	O
7	CKII	O
8	may	O
9	act	O
10	as	O
11	a	O
12	positive	O
13	regulator	O
14	of	O
15	myogenesis	O
16	by	O
17	preventing	O
18	E	O
19	protein	O
20	homodimers	O
21	from	O
22	binding	O
23	to	O
24	muscle	O
25	gene	O
26	regulatory	O
27	elements	O
28	.	O
1	The	O
2	mMIWC1	O
3	promoter	O
4	was	O
5	identified	O
6	and	O
7	contained	O
8	TATA	O
9	,	O
10	CAAT	O
11	,	O
12	GATA	O
13	,	O
14	and	O
15	AP	B
16	-	O
17	2	O
18	elements	O
19	;	O
20	primer	O
21	extension	O
22	revealed	O
23	mMIWC	O
24	transcription	O
25	initiation	O
26	at	O
27	621	O
28	bp	O
29	upstream	O
30	from	O
31	the	O
32	mMIWC1	O
33	translational	O
34	initiation	O
35	site	O
36	.	O
1	The	O
2	exon	O
3	-	O
4	intron	O
5	distribution	O
6	of	O
7	Cdebp	O
8	appears	O
9	strikingly	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	the	O
15	App	O
16	gene	O
17	in	O
18	the	O
19	regions	O
20	encoding	O
21	the	O
22	conserved	O
23	domains	O
24	,	O
25	with	O
26	a	O
27	divergent	O
28	structure	O
29	in	O
30	the	O
31	other	O
32	parts	O
33	.	O
1	Some	O
2	users	O
3	will	O
4	willingly	O
5	comply	O
6	with	O
7	management	O
8	measures	O
9	,	O
10	other	O
11	users	O
12	will	O
13	comply	O
14	in	O
15	response	O
16	to	O
17	education	O
18	,	O
19	but	O
20	there	O
21	will	O
22	be	O
23	another	O
24	group	O
25	who	O
26	will	O
27	only	O
28	respond	O
29	to	O
30	enforcement	O
31	activities	O
32	.	O
1	The	O
2	front	O
3	(	O
4	F	O
5	)	O
6	interaction	O
7	occurs	O
8	ahead	O
9	of	O
10	the	O
11	growing	O
12	end	O
13	of	O
14	RNA	O
15	.	O
1	None	O
2	of	O
3	the	O
4	five	O
5	proprotein	O
6	processing	O
7	proteases	O
8	tested	O
9	were	O
10	capable	O
11	of	O
12	cleaving	O
13	human	O
14	pro	O
15	-	O
16	LPH	O
17	,	O
18	strongly	O
19	suggesting	O
20	that	O
21	they	O
22	are	O
23	not	O
24	involved	O
25	in	O
26	the	O
27	maturation	O
28	of	O
29	this	O
30	enzyme	O
31	.	O
1	SETTING	O
2	--	O
3	Delhi	O
4	,	O
5	urban	O
6	India	O
7	,	O
8	1985	O
9	-	O
10	6	O
11	.	O
1	These	O
2	findings	O
3	suggest	O
4	that	O
5	direct	O
6	cDNA	O
7	mapping	O
8	using	O
9	fluorescence	O
10	in	O
11	situ	O
12	hybridization	O
13	provides	O
14	an	O
15	accurate	O
16	and	O
17	rapid	O
18	approach	O
19	to	O
20	the	O
21	definition	O
22	of	O
23	a	O
24	transcribed	O
25	map	O
26	of	O
27	the	O
28	human	O
29	genome	O
30	.	O
1	Vacuolar	O
2	membrane	O
3	vesicles	O
4	from	O
5	hum1	O
6	mutants	O
7	lack	O
8	all	O
9	Ca2	O
10	+/	O
11	H	O
12	+	O
13	antiport	O
14	activity	O
15	,	O
16	demonstrating	O
17	that	O
18	Hum1p	O
19	catalyzes	O
20	the	O
21	exchange	O
22	of	O
23	Ca2	O
24	+	O
25	for	O
26	H	O
27	+	O
28	across	O
29	the	O
30	yeast	O
31	vacuolar	O
32	membrane	O
33	.	O
1	Outcome	O
2	of	O
3	severe	O
4	congenital	O
5	hypothyroidism	O
6	.	O
1	Only	O
2	fully	O
3	processed	O
4	Pra	O
5	(	O
6	N0	O
7	and	O
8	Nb	O
9	)	O
10	and	O
11	ICP35	O
12	(	O
13	ICP35	O
14	e	O
15	,	O
16	f	O
17	)	O
18	are	O
19	present	O
20	in	O
21	B	O
22	capsids	O
23	,	O
24	which	O
25	are	O
26	believed	O
27	to	O
28	be	O
29	precursors	O
30	of	O
31	mature	O
32	virions	O
33	.	O
1	A	O
2	phylogenetic	O
3	tree	O
4	of	O
5	members	O
6	of	O
7	the	O
8	T2	O
9	/	O
10	S	O
11	-	O
12	RNase	B
13	superfamily	O
14	in	O
15	plants	O
16	was	O
17	obtained	O
18	.	O
1	In	O
2	a	O
3	Hoosier	O
4	Oncology	O
5	Group	O
6	randomized	O
7	study	O
8	involving	O
9	extensive	O
10	-	O
11	disease	O
12	SCLC	O
13	patients	O
14	,	O
15	VIP	O
16	was	O
17	superior	O
18	to	O
19	etoposide	O
20	/	O
21	cisplatin	O
22	with	O
23	regard	O
24	to	O
25	median	O
26	time	O
27	to	O
28	progression	O
29	(	O
30	6	O
31	.	O
32	6	O
33	v	O
34	5	O
35	.	O
36	8	O
37	months	O
38	),	O
39	median	O
40	survival	O
41	times	O
42	(	O
43	9	O
44	.	O
45	1	O
46	v	O
47	7	O
48	.	O
49	3	O
50	months	O
51	),	O
52	and	O
53	2	O
54	-	O
55	and	O
56	3	O
57	-	O
58	year	O
59	survival	O
60	rates	O
61	(	O
62	13	O
63	%	O
64	v	O
65	5	O
66	%	O
67	and	O
68	5	O
69	%	O
70	v	O
71	0	O
72	%,	O
73	respectively	O
74	).	O
1	It	O
2	was	O
3	shown	O
4	that	O
5	administration	O
6	of	O
7	immunomodulator	O
8	neurotropin	O
9	(	O
10	NSP	O
11	)	O
12	results	O
13	in	O
14	more	O
15	steady	O
16	consolidation	O
17	and	O
18	retention	O
19	of	O
20	feeding	O
21	and	O
22	avoidance	O
23	behavior	O
24	,	O
25	and	O
26	some	O
27	neurophysiological	O
28	mechanisms	O
29	of	O
30	that	O
31	phenomena	O
32	were	O
33	revealed	O
34	.	O
1	HS	O
2	inducibility	O
3	required	O
4	the	O
5	HSE	O
6	which	O
7	was	O
8	bound	O
9	by	O
10	HS	O
11	transcription	O
12	factor	O
13	-	O
14	1	O
15	(	O
16	HSF	O
17	-	O
18	1	O
19	)	O
20	present	O
21	in	O
22	extracts	O
23	prepared	O
24	from	O
25	cells	O
26	exposed	O
27	to	O
28	HS	O
29	.	O
1	Limited	O
2	role	O
3	for	O
4	PCR	O
5	-	O
6	based	O
7	diagnosis	O
8	of	O
9	Whipple	O
10	'	O
11	s	O
12	disease	O
13	from	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	.	O
1	The	O
2	ability	O
3	of	O
4	A20	O
5	to	O
6	block	O
7	NF	B
8	-	O
9	kappaB	O
10	activation	O
11	was	O
12	mapped	O
13	to	O
14	its	O
15	C	O
16	-	O
17	terminal	O
18	zinc	O
19	finger	O
20	domain	O
21	.	O
1	By	O
2	using	O
3	a	O
4	DNA	O
5	sequence	O
6	selected	O
7	for	O
8	its	O
9	ability	O
10	to	O
11	bind	O
12	recombinant	O
13	BCL	O
14	-	O
15	6	O
16	in	O
17	vitro	O
18	,	O
19	we	O
20	show	O
21	here	O
22	that	O
23	BCL	O
24	-	O
25	6	O
26	is	O
27	present	O
28	in	O
29	DNA	O
30	-	O
31	binding	O
32	complexes	O
33	in	O
34	nuclear	O
35	extracts	O
36	from	O
37	various	O
38	B	O
39	-	O
40	cell	O
41	lines	O
42	.	O
1	RESULTS	O
2	:	O
3	The	O
4	LV	O
5	maximum	O
6	brightness	O
7	and	O
8	area	O
9	under	O
10	the	O
11	curve	O
12	showed	O
13	significant	O
14	negative	O
15	correlations	O
16	(	O
17	p	O
18	=	O
19	<	O
20	0	O
21	.	O
22	004	O
23	)	O
24	with	O
25	the	O
26	FIO2	O
27	,	O
28	while	O
29	the	O
30	minimum	O
31	brightness	O
32	showed	O
33	a	O
34	significant	O
35	positive	O
36	correlation	O
37	(	O
38	p	O
39	=	O
40	<	O
41	0	O
42	.	O
43	002	O
44	).	O
1	The	O
2	results	O
3	also	O
4	imply	O
5	that	O
6	the	O
7	absence	O
8	of	O
9	perforin	O
10	expression	O
11	in	O
12	non	O
13	-	O
14	cytotoxic	O
15	cells	O
16	may	O
17	be	O
18	due	O
19	to	O
20	the	O
21	suppression	O
22	of	O
23	the	O
24	induction	O
25	of	O
26	the	O
27	killer	O
28	-	O
29	cell	O
30	-	O
31	specific	O
32	trans	O
33	-	O
34	acting	O
35	factor	O
36	NF	B
37	-	O
38	P2	O
39	.	O
1	The	O
2	expression	O
3	of	O
4	ERV3	O
5	env	O
6	mRNA	O
7	was	O
8	found	O
9	to	O
10	be	O
11	differentiation	O
12	-	O
13	associated	O
14	,	O
15	with	O
16	high	O
17	expression	O
18	detected	O
19	in	O
20	the	O
21	late	O
22	stages	O
23	of	O
24	monocytic	O
25	development	O
26	.	O
1	Aggravating	O
2	process	O
3	induced	O
4	by	O
5	indomethacin	O
6	on	O
7	chronic	O
8	gastric	O
9	lesion	O
10	in	O
11	rat	O
12	.	O
1	Epstein	O
2	-	O
3	Barr	O
4	virus	O
5	nuclear	O
6	protein	O
7	2	O
8	(	O
9	EBNA2	O
10	)	O
11	binds	O
12	to	O
13	a	O
14	component	O
15	of	O
16	the	O
17	human	O
18	SNF	O
19	-	O
20	SWI	O
21	complex	O
22	,	O
23	hSNF5	O
24	/	O
25	Ini1	O
26	.	O
1	5	O
2	)	O
3	We	O
4	'	O
5	ve	O
6	noticed	O
7	that	O
8	the	O
9	mean	O
10	value	O
11	of	O
12	the	O
13	cost	O
14	for	O
15	episode	O
16	of	O
17	pnx	O
18	s	O
19	.	O
20	in	O
21	class	O
22	A	O
23	was	O
24	more	O
25	than	O
26	15	O
27	%	O
28	compared	O
29	to	O
30	class	O
31	B	O
32	and	O
33	the	O
34	cost	O
35	for	O
36	patient	O
37	in	O
38	class	O
39	A	O
40	was	O
41	nearly	O
42	double	O
43	than	O
44	in	O
45	class	O
46	B	O
47	.	O
1	Cbl	O
2	constitutively	O
3	interacts	O
4	with	O
5	the	O
6	SH3	O
7	domains	O
8	of	O
9	Grb2	O
10	,	O
11	with	O
12	a	O
13	preference	O
14	for	O
15	the	O
16	amino	O
17	-	O
18	terminal	O
19	domain	O
20	,	O
21	and	O
22	is	O
23	in	O
24	this	O
25	way	O
26	recruited	O
27	to	O
28	Shc	O
29	upon	O
30	BCR	O
31	stimulation	O
32	.	O
1	METHODS	O
2	:	O
3	DSF	O
4	was	O
5	instilled	O
6	in	O
7	one	O
8	eye	O
9	chosen	O
10	at	O
11	random	O
12	and	O
13	CF	O
14	in	O
15	the	O
16	fellow	O
17	eye	O
18	of	O
19	13	O
20	normal	O
21	subjects	O
22	and	O
23	in	O
24	13	O
25	patients	O
26	with	O
27	KCS	O
28	.	O
1	Possible	O
2	relationship	O
3	between	O
4	hyperinsulinemia	O
5	and	O
6	glomerular	O
7	hypertrophy	O
8	in	O
9	nephrosclerosis	O
10	.	O
1	However	O
2	,	O
3	as	O
4	determined	O
5	by	O
6	PCR	O
7	with	O
8	primers	O
9	specific	O
10	for	O
11	the	O
12	26	O
13	-	O
14	kDa	O
15	product	O
16	,	O
17	the	O
18	majority	O
19	of	O
20	cats	O
21	at	O
22	2	O
23	and	O
24	4	O
25	weeks	O
26	p	O
27	.	O
28	t	O
29	.	O
30	had	O
31	gastric	O
32	fluid	O
33	samples	O
34	which	O
35	were	O
36	positive	O
37	for	O
38	H	O
39	.	O
40	pylori	O
41	and	O
42	three	O
43	of	O
44	three	O
45	cats	O
46	at	O
47	2	O
48	weeks	O
49	p	O
50	.	O
51	t	O
52	.	O
53	had	O
54	dental	O
55	plaque	O
56	which	O
57	was	O
58	positive	O
59	for	O
60	H	O
61	.	O
62	pylori	O
63	.	O
1	Amplification	O
2	and	O
3	overexpression	O
4	of	O
5	the	O
6	c	B
7	-	O
8	erbB	O
9	-	O
10	2	O
11	gene	O
12	in	O
13	21MT	O
14	-	O
15	2	O
16	and	O
17	21MT	O
18	-	O
19	1	O
20	human	O
21	breast	O
22	carcinoma	O
23	cells	O
24	results	O
25	in	O
26	progressively	O
27	elevated	O
28	levels	O
29	of	O
30	constitutively	O
31	tyrosine	O
32	-	O
33	phosphorylated	O
34	p185erbB	O
35	-	O
36	2	O
37	and	O
38	is	O
39	associated	O
40	with	O
41	progressive	O
42	insulin	B
43	-	O
44	like	O
45	growth	O
46	factor	O
47	(	O
48	IGF	O
49	)	O
50	and	O
51	combined	O
52	IGF	O
53	/	O
54	epidermal	O
55	growth	O
56	factor	O
57	(	O
58	EGF	O
59	)	O
60	independence	O
61	in	O
62	culture	O
63	.	O
1	Facioscapulohumeral	O
2	muscular	O
3	dystrophy	O
4	(	O
5	FSHD	O
6	)	O
7	is	O
8	an	O
9	autosomal	O
10	dominant	O
11	,	O
12	neuromuscular	O
13	disorder	O
14	characterized	O
15	by	O
16	progressive	O
17	weakness	O
18	of	O
19	muscles	O
20	in	O
21	the	O
22	face	O
23	,	O
24	shoulder	O
25	and	O
26	upper	O
27	arm	O
28	.	O
1	Nonetheless	O
2	,	O
3	that	O
4	ventricular	O
5	afferents	O
6	,	O
7	in	O
8	certain	O
9	special	O
10	settings	O
11	,	O
12	are	O
13	able	O
14	to	O
15	induce	O
16	e	O
17	.	O
18	g	O
19	.	O
20	generalised	O
21	vasodilation	O
22	and	O
23	hypotension	O
24	cannot	O
25	be	O
26	excluded	O
27	.	O
1	Large	O
2	ones	O
3	were	O
4	similar	O
5	in	O
6	size	O
7	to	O
8	the	O
9	main	O
10	lobe	O
11	and	O
12	small	O
13	ones	O
14	were	O
15	approximately	O
16	1	O
17	/	O
18	4	O
19	of	O
20	the	O
21	length	O
22	of	O
23	the	O
24	main	O
25	lobe	O
26	.	O
1	Furthermore	O
2	,	O
3	cpxA	O
4	*	O
5	mutations	O
6	suppress	O
7	the	O
8	toxicity	O
9	conferred	O
10	by	O
11	the	O
12	LamB	O
13	-	O
14	LacZ	O
15	hybrid	O
16	protein	O
17	,	O
18	which	O
19	exerts	O
20	its	O
21	effects	O
22	in	O
23	the	O
24	cytoplasm	O
25	,	O
26	sequestered	O
27	from	O
28	DegP	O
29	.	O
1	Hoeben	O
2	,	O
3	F	O
4	.	O
5	J	O
6	.	O
1	Twelve	O
2	genomic	O
3	fragments	O
4	containing	O
5	novel	O
6	response	O
7	elements	O
8	are	O
9	described	O
10	,	O
11	and	O
12	the	O
13	transcription	O
14	unit	O
15	associated	O
16	with	O
17	one	O
18	of	O
19	them	O
20	,	O
21	NN	O
22	-	O
23	84AG	O
24	,	O
25	was	O
26	characterized	O
27	in	O
28	detail	O
29	.	O
1	Moreover	O
2	,	O
3	glucan	O
4	synthase	O
5	activity	O
6	,	O
7	which	O
8	is	O
9	activated	O
10	by	O
11	Rho1p	O
12	,	O
13	was	O
14	significantly	O
15	reduced	O
16	in	O
17	the	O
18	deltabem4	O
19	mutant	O
20	.	O
1	Two	O
2	classes	O
3	of	O
4	Xanthomonas	O
5	pathogens	O
6	evading	O
7	Bs2	O
8	host	O
9	resistance	O
10	and	O
11	displaying	O
12	reduced	O
13	fitness	O
14	were	O
15	found	O
16	to	O
17	be	O
18	specifically	O
19	mutated	O
20	in	O
21	avrBs2	O
22	.	O
1	Previous	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	the	O
7	616	O
8	amino	O
9	acid	O
10	,	O
11	70	O
12	-	O
13	kDa	O
14	subunit	O
15	of	O
16	RPA	O
17	(	O
18	RPA	O
19	70	O
20	)	O
21	is	O
22	composed	O
23	of	O
24	multiple	O
25	structural	O
26	/	O
27	functional	O
28	domains	O
29	.	O
1	Our	O
2	results	O
3	support	O
4	a	O
5	model	O
6	where	O
7	both	O
8	E2F	O
9	-	O
10	and	O
11	CDE	O
12	-	O
13	mediated	O
14	repression	O
15	,	O
16	acting	O
17	at	O
18	different	O
19	stages	O
20	in	O
21	the	O
22	cell	O
23	cycle	O
24	,	O
25	are	O
26	dependent	O
27	on	O
28	promoter	O
29	-	O
30	specific	O
31	CHR	O
32	elements	O
33	.	O
1	Potentially	O
2	load	O
3	-	O
4	insensitive	O
5	measures	O
6	of	O
7	ventricular	O
8	performance	O
9	were	O
10	therefore	O
11	evaluated	O
12	in	O
13	10	O
14	open	O
15	-	O
16	and	O
17	closed	O
18	-	O
19	chested	O
20	,	O
21	anesthetized	O
22	rabbits	O
23	.	O
1	In	O
2	an	O
3	effort	O
4	to	O
5	isolate	O
6	genes	O
7	with	O
8	down	O
9	-	O
10	regulated	O
11	expression	O
12	at	O
13	the	O
14	mRNA	O
15	level	O
16	during	O
17	oncogenic	O
18	transformation	O
19	of	O
20	human	O
21	mammary	O
22	epithelial	O
23	cells	O
24	(	O
25	MECs	O
26	),	O
27	we	O
28	performed	O
29	subtractive	O
30	hybridization	O
31	between	O
32	normal	O
33	MEC	O
34	strain	O
35	76N	O
36	and	O
37	its	O
38	radiation	O
39	-	O
40	transformed	O
41	tumorigenic	O
42	derivative	O
43	76R	O
44	-	O
45	30	O
46	.	O
1	CASE	O
2	REPORT	O
3	:	O
4	Referred	O
5	because	O
6	of	O
7	a	O
8	right	O
9	corneal	O
10	perforation	O
11	with	O
12	cellular	O
13	reaction	O
14	in	O
15	anterior	O
16	chamber	O
17	,	O
18	a	O
19	patient	O
20	was	O
21	sutured	O
22	and	O
23	treated	O
24	with	O
25	a	O
26	single	O
27	intravitreal	O
28	injection	O
29	of	O
30	0	O
31	.	O
32	2	O
33	ml	O
34	(	O
35	1	O
36	mg	O
37	)	O
38	Amikacin	O
39	and	O
40	0	O
41	.	O
42	2	O
43	ml	O
44	(	O
45	1	O
46	mg	O
47	)	O
48	Vancomycin	O
49	.	O
1	We	O
2	have	O
3	recently	O
4	shown	O
5	that	O
6	the	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	of	O
12	the	O
13	RAR	O
14	beta	B
15	2	O
16	gene	O
17	in	O
18	mouse	O
19	embryos	O
20	is	O
21	regulated	O
22	at	O
23	the	O
24	translational	O
25	level	O
26	by	O
27	short	O
28	upstream	O
29	open	O
30	reading	O
31	frames	O
32	(	O
33	uORFs	O
34	)	O
35	In	O
36	the	O
37	5	O
38	'-	O
39	untranslated	O
40	region	O
41	(	O
42	Zimmer	O
43	,	O
44	A	O
45	.,	O
46	A	O
47	.	O
48	M	O
49	.	O
1	We	O
2	have	O
3	previously	O
4	isolated	O
5	a	O
6	cDNA	O
7	for	O
8	a	O
9	transcription	O
10	factor	O
11	referred	O
12	to	O
13	as	O
14	Zfhep	O
15	(	O
16	zinc	O
17	finger	O
18	homeodomain	O
19	enhancer	O
20	-	O
21	binding	O
22	protein	O
23	)	O
24	containing	O
25	two	O
26	separate	O
27	zinc	O
28	finger	O
29	domains	O
30	,	O
31	ZD1	O
32	and	O
33	ZD2	O
34	,	O
35	each	O
36	of	O
37	which	O
38	binds	O
39	DNA	O
40	,	O
41	and	O
42	a	O
43	homeodomain	O
44	.	O
1	The	O
2	patients	O
3	are	O
4	two	O
5	healthy	O
6	adult	O
7	males	O
8	.	O
1	A	O
2	neuropsychological	O
3	test	O
4	battery	O
5	was	O
6	used	O
7	that	O
8	contained	O
9	the	O
10	Wisconsin	O
11	card	O
12	sorting	O
13	test	O
14	,	O
15	Street	O
16	completion	O
17	test	O
18	,	O
19	Stroop	O
20	test	O
21	,	O
22	a	O
23	dichotic	O
24	memory	O
25	listening	O
26	test	O
27	,	O
28	and	O
29	a	O
30	facial	O
31	recognition	O
32	test	O
33	.	O
1	We	O
2	conclude	O
3	that	O
4	CPET	O
5	is	O
6	a	O
7	useful	O
8	investigation	O
9	in	O
10	the	O
11	management	O
12	of	O
13	patients	O
14	with	O
15	cardiopulmonary	O
16	disease	O
17	and	O
18	complements	O
19	the	O
20	various	O
21	other	O
22	investigations	O
23	offered	O
24	by	O
25	a	O
26	pulmonary	O
27	function	O
28	laboratory	O
29	.	O
1	This	O
2	is	O
3	concluded	O
4	from	O
5	the	O
6	isolation	O
7	of	O
8	cDNAs	O
9	from	O
10	spinach	O
11	(	O
12	Spinacia	O
13	oleracea	O
14	)	O
15	and	O
16	barley	O
17	(	O
18	Hordeum	O
19	vulgare	O
20	cv	O
21	.	O
1	In	O
2	the	O
3	rat	O
4	rnu	O
5	allele	O
6	described	O
7	here	O
8	,	O
9	a	O
10	nonsense	O
11	mutation	O
12	in	O
13	exon	O
14	8	O
15	of	O
16	the	O
17	whn	O
18	gene	O
19	was	O
20	identified	O
21	.	O
1	On	O
2	the	O
3	basis	O
4	of	O
5	its	O
6	bZIP	O
7	structural	O
8	homology	O
9	,	O
10	meq	O
11	is	O
12	perhaps	O
13	the	O
14	only	O
15	member	O
16	of	O
17	the	O
18	jun	O
19	-	O
20	fos	O
21	gene	O
22	family	O
23	completely	O
24	viral	O
25	in	O
26	origin	O
27	.	O
1	The	O
2	triple	O
3	combination	O
4	of	O
5	nizatidine	O
6	,	O
7	clarithromycin	O
8	,	O
9	and	O
10	bismuth	O
11	subcitrate	O
12	resulted	O
13	in	O
14	an	O
15	ulcer	O
16	healing	O
17	rate	O
18	of	O
19	98	O
20	%	O
21	and	O
22	an	O
23	H	O
24	.	O
25	pylori	O
26	eradication	O
27	rate	O
28	of	O
29	90	O
30	%.	O
1	The	O
2	DNA	O
3	binding	O
4	and	O
5	multimerization	O
6	activities	O
7	of	O
8	c	B
9	-	O
10	Myb	O
11	appear	O
12	to	O
13	be	O
14	unaffected	O
15	by	O
16	the	O
17	S528A	O
18	substitution	O
19	,	O
20	suggesting	O
21	that	O
22	phosphorylation	O
23	of	O
24	serine	O
25	528	O
26	may	O
27	mediate	O
28	its	O
29	effect	O
30	on	O
31	the	O
32	transcription	O
33	transactivating	O
34	activity	O
35	of	O
36	c	B
37	-	O
38	Myb	O
39	by	O
40	regulating	O
41	interactions	O
42	with	O
43	other	O
44	proteins	O
45	.	O
1	The	O
2	amount	O
3	of	O
4	these	O
5	factors	O
6	was	O
7	reduced	O
8	in	O
9	GEO	O
10	cells	O
11	in	O
12	which	O
13	the	O
14	u	O
15	-	O
16	PAR	O
17	gene	O
18	is	O
19	only	O
20	weakly	O
21	transcriptionally	O
22	activated	O
23	.	O
1	Myelomatous	O
2	pleural	O
3	effusion	O
4	as	O
5	presentation	O
6	form	O
7	of	O
8	multiple	O
9	myeloma	O
1	Northern	O
2	blot	O
3	analysis	O
4	,	O
5	using	O
6	the	O
7	Ltp4	O
8	-	O
9	specific	O
10	probe	O
11	,	O
12	indicated	O
13	that	O
14	Xanthomonas	O
15	campestris	O
16	pv	O
17	.	O
18	translucens	O
19	induced	O
20	an	O
21	increase	O
22	over	O
23	basal	O
24	levels	O
25	of	O
26	Ltp4	O
27	mRNA	O
28	,	O
29	while	O
30	Pseudomonas	O
31	syringae	O
32	pv	O
33	.	O
34	japonica	O
35	caused	O
36	a	O
37	decrease	O
38	.	O
1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	isolated	O
6	genomic	O
7	clone	O
8	revealed	O
9	that	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	of	O
15	this	O
16	orphan	O
17	receptor	B
18	is	O
19	most	O
20	homologous	O
21	to	O
22	the	O
23	human	O
24	TR2	O
25	receptor	B
26	.	O
1	Melatonin	O
2	and	O
3	seasonality	O
4	:	O
5	filling	O
6	the	O
7	gap	O
8	.	O
1	A	O
2	subsequent	O
3	screen	O
4	for	O
5	the	O
6	loss	O
7	of	O
8	the	O
9	positively	O
10	selectable	O
11	target	O
12	locus	O
13	marker	O
14	detects	O
15	the	O
16	desired	O
17	replacement	O
18	at	O
19	modest	O
20	frequency	O
21	(>	O
22	2	O
23	%).	O
1	PCNA	O
2	mRNA	O
3	has	O
4	a	O
5	3	O
6	'	O
7	UTR	O
8	antisense	O
9	to	O
10	yellow	O
11	crescent	O
12	RNA	O
13	and	O
14	is	O
15	localized	O
16	in	O
17	ascidian	O
18	eggs	O
19	and	O
20	embryos	O
21	.	O
1	The	O
2	third	O
3	ORF	O
4	generates	O
5	a	O
6	transcript	O
7	of	O
8	1	O
9	.	O
10	6	O
11	kb	O
12	and	O
13	encodes	O
14	a	O
15	protein	O
16	of	O
17	382	O
18	residues	O
19	including	O
20	a	O
21	perfect	O
22	match	O
23	to	O
24	the	O
25	consensus	O
26	sequence	O
27	of	O
28	a	O
29	C2H2	O
30	zinc	O
31	finger	O
32	domain	O
33	;	O
34	it	O
35	shares	O
36	a	O
37	strong	O
38	homology	O
39	with	O
40	yeast	O
41	Mig1p	O
42	and	O
43	Cre	O
44	-	O
45	A	O
46	from	O
47	Aspergillus	O
48	,	O
49	Emericella	O
50	and	O
51	E	O
52	.	O
53	coli	O
54	.	O
1	The	O
2	elevation	O
3	of	O
4	cyclic	O
5	AMP	O
6	(	O
7	cAMP	O
8	)	O
9	levels	O
10	in	O
11	the	O
12	cell	O
13	downregulates	O
14	the	O
15	activity	O
16	of	O
17	the	O
18	Raf	O
19	-	O
20	1	O
21	kinase	B
22	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	inhibition	O
6	of	O
7	Jun	O
8	kinase	B
9	activation	O
10	was	O
11	sufficient	O
12	to	O
13	inhibit	O
14	Ras	B
15	transformation	O
16	even	O
17	in	O
18	the	O
19	presence	O
20	of	O
21	activated	O
22	Erk	O
23	-	O
24	2	O
25	.	O
1	Our	O
2	analysis	O
3	suggests	O
4	that	O
5	Upf1p	O
6	is	O
7	a	O
8	multifunctional	O
9	protein	O
10	with	O
11	separable	O
12	activities	O
13	that	O
14	can	O
15	affect	O
16	mRNA	O
17	turnover	O
18	and	O
19	nonsense	O
20	suppression	O
21	.	O
1	Identification	O
2	of	O
3	Ste4	O
4	as	O
5	a	O
6	potential	O
7	regulator	O
8	of	O
9	Byr2	O
10	in	O
11	the	O
12	sexual	O
13	response	O
14	pathway	O
15	of	O
16	Schizosaccharomyces	O
17	pombe	O
18	.	O
1	Two	O
2	closely	O
3	related	O
4	variants	O
5	of	O
6	Stat5	O
7	,	O
8	Stat5a	O
9	and	O
10	Stat5b	O
11	,	O
12	are	O
13	encoded	O
14	by	O
15	distinct	O
16	genes	O
17	.	O
1	Almost	O
2	complete	O
3	sequence	O
4	identity	O
5	was	O
6	found	O
7	between	O
8	the	O
9	3	O
10	'	O
11	end	O
12	of	O
13	the	O
14	DXS6673E	O
15	gene	O
16	and	O
17	two	O
18	expressed	O
19	sequence	O
20	tags	O
21	(	O
22	ESTs	O
23	)	O
24	and	O
25	between	O
26	the	O
27	5	O
28	'	O
29	end	O
30	of	O
31	the	O
32	DXS6673E	O
33	gene	O
34	and	O
35	a	O
36	third	O
37	EST	O
38	.	O
1	Sequencing	O
2	of	O
3	the	O
4	16p	O
5	11	O
6	.	O
7	1	O
8	/	O
9	Xq28	O
10	duplication	O
11	breakpoints	O
12	has	O
13	revealed	O
14	the	O
15	presence	O
16	of	O
17	repetitive	O
18	immunoglobulin	O
19	-	O
20	like	O
21	CAGGG	O
22	pentamer	O
23	sequences	O
24	at	O
25	or	O
26	near	O
27	the	O
28	paralogy	O
29	boundaries	O
30	.	O
1	Feline	O
2	leukemia	O
3	viruses	O
4	(	O
5	FeLVs	O
6	),	O
7	which	O
8	are	O
9	replication	O
10	-	O
11	competent	O
12	oncoretroviruses	O
13	of	O
14	the	O
15	domestic	O
16	cat	O
17	species	O
18	,	O
19	are	O
20	contagiously	O
21	transmitted	O
22	in	O
23	natural	O
24	environments	O
25	.	O
1	We	O
2	performed	O
3	dipole	O
4	estimation	O
5	of	O
6	spikes	O
7	and	O
8	SEP	O
9	components	O
10	in	O
11	identical	O
12	patients	O
13	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	comparison	O
6	of	O
7	the	O
8	hCHLR	O
9	gene	O
10	sequences	O
11	with	O
12	available	O
13	databases	O
14	indicates	O
15	that	O
16	a	O
17	large	O
18	portion	O
19	of	O
20	these	O
21	genes	O
22	,	O
23	including	O
24	exons	O
25	encoding	O
26	two	O
27	functional	O
28	domains	O
29	of	O
30	the	O
31	carboxyl	O
32	-	O
33	terminal	O
34	region	O
35	of	O
36	these	O
37	proteins	O
38	,	O
39	has	O
40	been	O
41	duplicated	O
42	as	O
43	part	O
44	of	O
45	a	O
46	larger	O
47	human	O
48	telomeric	O
49	repeat	O
50	sequence	O
51	found	O
52	on	O
53	many	O
54	human	O
55	chromosomes	O
56	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	LIM	O
7	domain	O
8	homeobox	O
9	protein	O
10	isl	O
11	-	O
12	1	O
13	activates	O
14	the	O
15	rat	O
16	amylin	O
17	promoter	O
18	in	O
19	both	O
20	fibroblast	O
21	and	O
22	islet	O
23	cell	O
24	lines	O
25	.	O
1	The	O
2	CD4	O
3	count	O
4	at	O
5	which	O
6	remission	O
7	occurs	O
8	may	O
9	reflect	O
10	severe	O
11	immunodeficiency	O
12	such	O
13	that	O
14	risk	O
15	for	O
16	AIDS	O
17	-	O
18	related	O
19	infection	O
20	is	O
21	high	O
22	.	O
1	Although	O
2	diagnostic	O
3	laparoscopy	O
4	is	O
5	still	O
6	considered	O
7	the	O
8	standard	O
9	reference	O
10	in	O
11	the	O
12	diagnosis	O
13	of	O
14	ectopic	O
15	pregnancy	O
16	(	O
17	EP	O
18	),	O
19	use	O
20	of	O
21	high	O
22	-	O
23	resolution	O
24	endovaginal	O
25	sonography	O
26	,	O
27	in	O
28	conjunction	O
29	with	O
30	qualitative	O
31	serum	O
32	assays	O
33	of	O
34	the	O
35	beta	B
36	subunit	O
37	of	O
38	human	O
39	chorionic	O
40	gonadotropin	O
41	(	O
42	beta	B
43	-	O
44	hCG	O
45	),	O
46	allows	O
47	detection	O
48	of	O
49	earlier	O
50	and	O
51	smaller	O
52	EPs	O
53	.	O
1	These	O
2	two	O
3	repeat	O
4	motifs	O
5	are	O
6	organized	O
7	in	O
8	an	O
9	extremely	O
10	well	O
11	-	O
12	ordered	O
13	pattern	O
14	in	O
15	each	O
16	domain	O
17	,	O
18	which	O
19	suggests	O
20	that	O
21	SbHRGP3	O
22	belongs	O
23	to	O
24	a	O
25	new	O
26	group	O
27	of	O
28	proteins	O
29	having	O
30	the	O
31	repeat	O
32	motifs	O
33	of	O
34	two	O
35	distinct	O
36	groups	O
37	of	O
38	dicot	O
39	extensins	O
40	.	O
1	Tilmicosin	O
2	is	O
3	a	O
4	novel	O
5	macrolide	O
6	antibiotic	O
7	developed	O
8	for	O
9	exclusive	O
10	use	O
11	in	O
12	veterinary	O
13	medicine	O
14	.	O
1	Effect	O
2	of	O
3	nitrous	O
4	oxide	O
5	(	O
6	N2O	O
7	)	O
8	on	O
9	the	O
10	somatosympathetic	O
11	A	O
12	-	O
13	and	O
14	C	O
15	-	O
16	reflexes	O
17	was	O
18	investigated	O
19	using	O
20	artificially	O
21	ventilated	O
22	rats	O
23	anesthetized	O
24	with	O
25	alpha	B
26	-	O
27	chloralose	O
28	and	O
29	urethane	O
30	.	O
1	In	O
2	the	O
3	absence	O
4	of	O
5	Swi4	O
6	and	O
7	Swi6	O
8	cell	O
9	viability	O
10	is	O
11	lost	O
12	,	O
13	but	O
14	can	O
15	be	O
16	regained	O
17	by	O
18	ectopic	O
19	expression	O
20	of	O
21	the	O
22	G1	O
23	cyclin	B
24	encoding	O
25	genes	O
26	,	O
27	CLN1	O
28	or	O
29	CLN2	O
30	.	O
1	Demispan	O
2	is	O
3	a	O
4	reliable	O
5	and	O
6	reproducible	O
7	measure	O
8	of	O
9	stature	O
10	in	O
11	the	O
12	elderly	O
13	.	O
1	We	O
2	have	O
3	performed	O
4	toeprinting	O
5	analyses	O
6	on	O
7	repA	O
8	mRNA	O
9	of	O
10	plasmid	O
11	R1	O
12	,	O
13	both	O
14	free	O
15	and	O
16	in	O
17	duplex	O
18	with	O
19	the	O
20	antisense	O
21	RNA	O
22	,	O
23	CopA	O
24	.	O
1	The	O
2	enzyme	O
3	activities	O
4	studied	O
5	are	O
6	important	O
7	elements	O
8	in	O
9	the	O
10	pathophysiology	O
11	of	O
12	dental	O
13	caries	O
14	and	O
15	may	O
16	even	O
17	be	O
18	addressed	O
19	as	O
20	virulence	O
21	factors	O
22	.	O
1	This	O
2	paper	O
3	gives	O
4	an	O
5	overview	O
6	of	O
7	the	O
8	global	O
9	pattern	O
10	of	O
11	casualties	O
12	in	O
13	earthquakes	O
14	which	O
15	occurred	O
16	during	O
17	the	O
18	30	O
19	-	O
20	month	O
21	period	O
22	from	O
23	1	O
24	September	O
25	1993	O
26	to	O
27	29	O
28	February	O
29	1996	O
30	.	O
1	The	O
2	elevations	O
3	achieved	O
4	by	O
5	LDEE	O
6	given	O
7	s	O
8	.	O
9	c	B
10	.	O
11	were	O
12	higher	O
13	than	O
14	those	O
15	achieved	O
16	after	O
17	i	O
18	.	O
19	p	O
20	.	O
21	administration	O
22	and	O
23	lasted	O
24	for	O
25	longer	O
26	periods	O
27	.	O
1	Thus	O
2	,	O
3	although	O
4	p28	O
5	may	O
6	play	O
7	only	O
8	a	O
9	limited	O
10	role	O
11	during	O
12	the	O
13	early	O
14	embryonic	O
15	cleavages	O
16	,	O
17	it	O
18	may	O
19	function	O
20	later	O
21	in	O
22	development	O
23	to	O
24	establish	O
25	a	O
26	somatic	O
27	type	O
28	of	O
29	cell	O
30	cycle	O
31	.	O
1	The	O
2	main	O
3	aim	O
4	of	O
5	the	O
6	contribution	O
7	,	O
8	which	O
9	opens	O
10	an	O
11	arena	O
12	for	O
13	discussion	O
14	on	O
15	the	O
16	Rivista	O
17	dell	O
18	'	O
19	Infermiere	O
20	is	O
21	to	O
22	critically	O
23	appraise	O
24	published	O
25	research	O
26	works	O
27	focusing	O
28	both	O
29	on	O
30	strengths	O
31	and	O
32	novelty	O
33	and	O
34	weaknesses	O
35	in	O
36	the	O
37	hypothesis	O
38	formulation	O
39	,	O
40	methods	O
41	and	O
42	instruments	O
43	used	O
44	,	O
45	discussion	O
46	of	O
47	results	O
48	.	O
1	Previous	O
2	studies	O
3	demonstrated	O
4	that	O
5	the	O
6	flavin	O
7	-	O
8	containing	O
9	monooxygenases	O
10	(	O
11	FMO	O
12	)	O
13	are	O
14	expressed	O
15	in	O
16	a	O
17	tissue	O
18	-	O
19	specific	O
20	manner	O
21	.	O
1	Taken	O
2	together	O
3	,	O
4	these	O
5	observations	O
6	indicate	O
7	that	O
8	the	O
9	C	O
10	-	O
11	terminal	O
12	24	O
13	amino	O
14	acids	O
15	are	O
16	sufficient	O
17	for	O
18	NodO	O
19	secretion	O
20	although	O
21	the	O
22	region	O
23	adjacent	O
24	to	O
25	this	O
26	domain	O
27	appears	O
28	to	O
29	affect	O
30	secretion	O
31	efficiency	O
32	.	O
1	Thus	O
2	,	O
3	despite	O
4	the	O
5	potential	O
6	for	O
7	common	O
8	regulatory	O
9	mechanisms	O
10	,	O
11	the	O
12	available	O
13	evidence	O
14	indicates	O
15	that	O
16	the	O
17	Mtx	O
18	minimal	O
19	promoter	O
20	does	O
21	not	O
22	significantly	O
23	affect	O
24	Thbs3	O
25	gene	O
26	expression	O
27	.	O
1	B	O
2	cell	O
3	antigen	B
4	receptor	I
5	(	O
6	BCR	O
7	)-	O
8	induced	O
9	apoptosis	O
10	in	O
11	the	O
12	WEHI	O
13	-	O
14	231	O
15	B	O
16	lymphoma	O
17	cell	O
18	line	O
19	can	O
20	be	O
21	prevented	O
22	by	O
23	engaging	O
24	CD40	O
25	.	O
1	Thus	O
2	,	O
3	the	O
4	N	O
5	-	O
6	Nus	O
7	complex	O
8	may	O
9	be	O
10	affected	O
11	through	O
12	contacts	O
13	with	O
14	the	O
15	CTD	O
16	of	O
17	the	O
18	alpha	B
19	subunit	O
20	of	O
21	RNA	O
22	polymerase	B
23	,	O
24	as	O
25	is	O
26	a	O
27	group	O
28	of	O
29	regulatory	O
30	proteins	O
31	that	O
32	influences	O
33	initiation	O
34	of	O
35	transcription	O
36	.	O
1	A	O
2	subset	O
3	of	O
4	these	O
5	DMP1	O
6	recognition	O
7	sequences	O
8	containing	O
9	a	O
10	GGA	O
11	trinucleotide	O
12	core	O
13	can	O
14	also	O
15	function	O
16	as	O
17	Ets	O
18	-	O
19	responsive	O
20	elements	O
21	.	O
1	This	O
2	technique	O
3	was	O
4	employed	O
5	in	O
6	12	O
7	patients	O
8	with	O
9	a	O
10	unicameral	O
11	bone	O
12	cyst	O
13	.	O
1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	F	O
7	-	O
8	wave	O
9	may	O
10	be	O
11	elicited	O
12	in	O
13	motoneuron	O
14	of	O
15	different	O
16	depolarization	O
17	threshold	O
18	but	O
19	primarily	O
20	in	O
21	larger	O
22	and	O
23	faster	O
24	nerve	O
25	fibers	O
26	,	O
27	with	O
28	a	O
29	lower	O
30	threshold	O
31	of	O
32	depolarization	O
33	.	O
1	Spliced	O
2	exons	O
3	of	O
4	adenovirus	O
5	late	O
6	RNAs	O
7	colocalize	O
8	with	O
9	snRNP	O
10	in	O
11	a	O
12	specific	O
13	nuclear	O
14	domain	O
15	.	O
1	Using	O
2	Spurr	O
3	'	O
4	s	O
5	resin	O
6	as	O
7	a	O
8	mounting	O
9	medium	O
10	,	O
11	we	O
12	could	O
13	observe	O
14	thick	O
15	specimens	O
16	with	O
17	oil	O
18	immersion	O
19	objective	O
20	lens	O
21	without	O
22	the	O
23	use	O
24	of	O
25	coverslips	O
26	,	O
27	then	O
28	avoid	O
29	air	O
30	bubbles	O
31	near	O
32	the	O
33	specimen	O
34	.	O
1	T	O
2	.,	O
3	Patel	O
4	,	O
5	S	O
6	.	O
1	Vascular	O
2	responses	O
3	to	O
4	reactive	O
5	hyperemia	O
6	(	O
7	with	O
8	flow	O
9	increase	O
10	leading	O
11	to	O
12	endothelium	O
13	-	O
14	dependent	O
15	dilation	O
16	)	O
17	and	O
18	to	O
19	sublingual	O
20	glyceryl	O
21	trinitrate	O
22	(	O
23	GTN	O
24	;	O
25	endothelium	O
26	-	O
27	independent	O
28	dilation	O
29	)	O
30	were	O
31	recorded	O
32	.	O
1	Intraperitoneal	O
2	administration	O
3	of	O
4	L	O
5	-	O
6	5	O
7	-	O
8	hydroxytryptophan	O
9	(	O
10	L	O
11	-	O
12	5	O
13	-	O
14	HTP	O
15	)	O
16	at	O
17	doses	O
18	of	O
19	25	O
20	to	O
21	100	O
22	mg	O
23	/	O
24	kg	O
25	dramatically	O
26	increase	O
27	defecation	O
28	in	O
29	mice	O
30	.	O
1	These	O
2	patients	O
3	appear	O
4	to	O
5	have	O
6	slightly	O
7	better	O
8	pulmonary	O
9	function	O
10	and	O
11	nutritional	O
12	status	O
13	;	O
14	yet	O
15	,	O
16	they	O
17	seem	O
18	to	O
19	have	O
20	a	O
21	higher	O
22	degree	O
23	of	O
24	health	O
25	care	O
26	utilization	O
27	.	O
1	This	O
2	observation	O
3	calls	O
4	for	O
5	careful	O
6	monitoring	O
7	of	O
8	calcium	O
9	and	O
10	alkaline	O
11	phosphatase	B
12	values	O
13	and	O
14	possible	O
15	adjustments	O
16	of	O
17	vitamin	O
18	D	O
19	intake	O
20	when	O
21	fortifiers	O
22	are	O
23	used	O
24	for	O
25	extended	O
26	periods	O
27	.	O
1	Kss1	O
2	binds	O
3	specifically	O
4	to	O
5	a	O
6	GST	O
7	-	O
8	Dig1	O
9	fusion	O
10	in	O
11	the	O
12	absence	O
13	of	O
14	any	O
15	other	O
16	yeast	O
17	protein	O
18	.	O
1	Transient	O
2	expression	O
3	of	O
4	VSF	O
5	-	O
6	1	O
7	in	O
8	protoplasts	O
9	stimulated	O
10	vs	O
11	-	O
12	1	O
13	dependent	O
14	activation	O
15	of	O
16	the	O
17	-	O
18	76	O
19	/	O
20	grp1	O
21	.	O
22	8	O
23	minimal	O
24	promoter	O
25	.	O
1	Analysis	O
2	of	O
3	one	O
4	cDNA	O
5	revealed	O
6	an	O
7	unusual	O
8	splicing	O
9	event	O
10	involving	O
11	EZH1	O
12	and	O
13	a	O
14	tandemly	O
15	linked	O
16	gene	O
17	GPR2	O
18	and	O
19	suggests	O
20	a	O
21	potential	O
22	mechanism	O
23	for	O
24	modifying	O
25	the	O
26	EZH1	O
27	protein	O
28	in	O
29	the	O
30	conserved	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	.	O
1	Immunoblotting	O
2	of	O
3	expressed	O
4	recombinant	O
5	proteins	O
6	with	O
7	the	O
8	monoclonal	O
9	08L	O
10	antibody	O
11	localized	O
12	the	O
13	08L	O
14	epitope	O
15	to	O
16	the	O
17	carboxyl	O
18	end	O
19	of	O
20	the	O
21	protein	O
22	.	O
1	The	O
2	current	O
3	study	O
4	defines	O
5	the	O
6	vinculin	O
7	-	O
8	and	O
9	FAK	O
10	-	O
11	interaction	O
12	domains	O
13	on	O
14	paxillin	O
15	and	O
16	identifies	O
17	the	O
18	principal	O
19	paxillin	O
20	focal	O
21	adhesion	O
22	targeting	O
23	motif	O
24	.	O
1	These	O
2	results	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	well	O
8	established	O
9	polarity	O
10	of	O
11	RXR	O
12	heterodimer	O
13	binding	O
14	to	O
15	bipartite	O
16	hormone	O
17	response	O
18	elements	O
19	,	O
20	with	O
21	the	O
22	VDR	O
23	recognizing	O
24	the	O
25	3	O
26	'-	O
27	half	O
28	-	O
29	element	O
30	.	O
1	PPAR	O
2	gamma	B
3	mRNA	O
4	levels	O
5	were	O
6	reduced	O
7	by	O
8	95	O
9	%	O
10	with	O
11	3	O
12	nM	O
13	TNF	O
14	alpha	B
15	treatment	O
16	for	O
17	24	O
18	h	O
19	.	O
1	Growth	O
2	factor	O
3	allows	O
4	effective	O
5	dose	O
6	-	O
7	intensive	O
8	regimen	O
9	in	O
10	advanced	O
11	breast	O
12	cancer	O
13	patients	O
14	.	O
1	Ki	O
2	-	O
3	ras	O
4	and	O
5	p53	B
6	mutations	O
7	in	O
8	pancreatic	O
9	ductal	O
10	adenocarcinoma	O
11	.	O
1	Epidemiological	O
2	data	O
3	are	O
4	quite	O
5	controversial	O
6	but	O
7	sudden	O
8	death	O
9	occurring	O
10	during	O
11	sporting	O
12	activity	O
13	is	O
14	probably	O
15	not	O
16	a	O
17	rare	O
18	occurrence	O
19	.	O
1	These	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	E2F	O
8	or	O
9	an	O
10	E2F	O
11	-	O
12	related	O
13	transcription	O
14	factor	O
15	is	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	nonmuscle	O
22	myosin	O
23	expression	O
24	.	O
1	Small	O
2	Maf	O
3	proteins	O
4	interact	O
5	with	O
6	the	O
7	human	O
8	transcription	O
9	factor	O
10	TCF11	O
11	/	O
12	Nrf1	O
13	/	O
14	LCR	O
15	-	O
16	F1	O
17	.	O
1	On	O
2	the	O
3	third	O
4	occasion	O
5	water	O
6	(	O
7	W	O
8	)	O
9	was	O
10	ingested	O
11	throughout	O
12	the	O
13	run	O
14	.	O
1	Discordance	O
2	on	O
3	the	O
4	cost	O
5	dimension	O
6	correlated	O
7	negatively	O
8	with	O
9	G	O
10	Hb	O
11	,	O
12	suggesting	O
13	better	O
14	glycemic	O
15	control	O
16	with	O
17	greater	O
18	disagreement	O
19	.	O
1	The	O
2	accumulation	O
3	of	O
4	both	O
5	LHA4	O
6	and	O
7	LHA2	O
8	mRNAs	O
9	is	O
10	induced	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	exogenous	O
16	sugars	O
17	and	O
18	this	O
19	induction	O
20	appears	O
21	to	O
22	be	O
23	dependent	O
24	on	O
25	sugar	O
26	uptake	O
27	and	O
28	metabolism	O
29	,	O
30	because	O
31	mannitol	O
32	and	O
33	3	O
34	-	O
35	O	O
36	-	O
37	methylglucose	O
38	do	O
39	not	O
40	stimulate	O
41	mRNA	O
42	accumulation	O
43	.	O
1	Recurrent	O
2	G	O
3	-	O
4	to	O
5	-	O
6	A	O
7	substitution	O
8	in	O
9	a	O
10	single	O
11	codon	O
12	of	O
13	SREBP	O
14	cleavage	O
15	-	O
16	activating	O
17	protein	O
18	causes	O
19	sterol	O
20	resistance	O
21	in	O
22	three	O
23	mutant	O
24	Chinese	O
25	hamster	O
26	ovary	O
27	cell	O
28	lines	O
29	.	O
1	FK506	O
2	is	O
3	10	O
4	-	O
5	to	O
6	100	O
7	-	O
8	fold	O
9	more	O
10	potent	O
11	than	O
12	cyclosporin	O
13	A	O
14	in	O
15	preventing	O
16	organ	O
17	rejection	O
18	and	O
19	in	O
20	toxicity	O
21	.	O
1	Therefore	O
2	,	O
3	both	O
4	the	O
5	Chilean	O
6	and	O
7	the	O
8	Japanese	O
9	samples	O
10	collected	O
11	in	O
12	high	O
13	-	O
14	risk	O
15	areas	O
16	showed	O
17	higher	O
18	mutagenic	O
19	rates	O
20	than	O
21	the	O
22	Japanese	O
23	ones	O
24	in	O
25	a	O
26	low	O
27	-	O
28	risk	O
29	area	O
30	,	O
31	with	O
32	a	O
33	statistical	O
34	significance	O
35	(	O
36	p	O
37	<	O
38	0	O
39	.	O
40	001	O
41	),	O
42	chi	O
43	-	O
44	square	O
45	test	O
46	).	O
1	Disruption	O
2	of	O
3	re	O
4	-	O
5	replication	O
6	control	O
7	by	O
8	overexpression	O
9	of	O
10	human	O
11	ORC1	O
12	in	O
13	fission	O
14	yeast	O
15	.	O
1	Human	O
2	acid	O
3	ceramidase	O
4	((	O
5	AC	O
6	)	O
7	N	O
8	-	O
9	acylsphingosine	O
10	amidohydrolase	O
11	,	O
12	EC	O
13	3	O
14	.	O
15	5	O
16	.	O
1	Northern	O
2	(	O
3	RNA	O
4	)	O
5	blot	O
6	analyses	O
7	indicated	O
8	that	O
9	the	O
10	cdh	O
11	genes	O
12	encoding	O
13	the	O
14	five	O
15	subunits	O
16	and	O
17	an	O
18	open	O
19	reading	O
20	frame	O
21	(	O
22	ORF1	O
23	)	O
24	with	O
25	unknown	O
26	function	O
27	are	O
28	cotranscribed	O
29	during	O
30	growth	O
31	on	O
32	acetate	O
33	.	O
1	Two	O
2	classes	O
3	of	O
4	mutations	O
5	were	O
6	obtained	O
7	:	O
8	(	O
9	i	O
10	)	O
11	those	O
12	that	O
13	altered	O
14	the	O
15	coding	O
16	region	O
17	of	O
18	HOL1	O
19	,	O
20	conferring	O
21	the	O
22	ability	O
23	to	O
24	take	O
25	up	O
26	histidinol	O
27	;	O
28	and	O
29	(	O
30	ii	O
31	)	O
32	cis	O
33	-	O
34	acting	O
35	mutations	O
36	(	O
37	selected	O
38	in	O
39	a	O
40	mutant	O
41	HOL1	O
42	-	O
43	1	O
44	background	O
45	)	O
46	that	O
47	increased	O
48	expression	O
49	of	O
50	the	O
51	Hol1	O
52	protein	O
53	.	O
1	Lipid	O
2	hydroperoxide	O
3	levels	O
4	in	O
5	plasma	O
6	and	O
7	LDL	O
8	remained	O
9	unchanged	O
10	throughout	O
11	the	O
12	study	O
13	.	O
1	When	O
2	the	O
3	degree	O
4	of	O
5	exercise	O
6	was	O
7	maximal	O
8	,	O
9	mPAP	O
10	was	O
11	maintained	O
12	,	O
13	SVI	O
14	decreased	O
15	,	O
16	HR	O
17	was	O
18	unchanged	O
19	,	O
20	and	O
21	CO	O
22	and	O
23	VO2	O
24	decreased	O
25	.	O
1	There	O
2	were	O
3	no	O
4	significant	O
5	differences	O
6	in	O
7	graft	O
8	survival	O
9	between	O
10	groups	O
11	with	O
12	early	O
13	graft	O
14	function	O
15	(	O
16	EGF	O
17	)	O
18	and	O
19	DGF	O
20	,	O
21	either	O
22	in	O
23	first	O
24	transplantations	O
25	or	O
26	retransplantations	O
27	.	O
1	These	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	GG	O
7	motifs	O
8	contributed	O
9	to	O
10	the	O
11	cell	O
12	-	O
13	specific	O
14	transcription	O
15	of	O
16	the	O
17	human	O
18	insulin	B
19	gene	O
20	in	O
21	association	O
22	with	O
23	the	O
24	binding	O
25	of	O
26	the	O
27	sequence	O
28	-	O
29	specific	O
30	nuclear	O
31	factor	O
32	.	O
1	The	O
2	promoter	O
3	segment	O
4	was	O
5	inactive	O
6	when	O
7	introduced	O
8	into	O
9	the	O
10	rat	O
11	glioma	O
12	cell	O
13	line	O
14	C6B4	O
15	,	O
16	the	O
17	rat	O
18	submandibular	O
19	cell	O
20	line	O
21	RSMT	O
22	-	O
23	A5	O
24	,	O
25	and	O
26	the	O
27	rat	O
28	pancreatic	O
29	beta	B
30	cell	O
31	line	O
32	RIN	O
33	-	O
34	5AH	O
35	,	O
36	all	O
37	of	O
38	which	O
39	do	O
40	not	O
41	express	O
42	the	O
43	endogenous	O
44	alpha2c	O
45	-	O
46	AR	O
47	gene	O
48	.	O
1	The	O
2	SCMV	O
3	SNE	O
4	sites	O
5	contain	O
6	potential	O
7	overlapping	O
8	core	O
9	recognition	O
10	binding	O
11	motifs	O
12	for	O
13	SRF	O
14	,	O
15	Rel	O
16	/	O
17	NFkappaB	O
18	,	O
19	ETS	O
20	,	O
21	and	O
22	YY1	O
23	class	O
24	transcription	O
25	factors	O
26	but	O
27	fail	O
28	to	O
29	respond	O
30	to	O
31	either	O
32	serum	O
33	or	O
34	tumor	O
35	necrosis	O
36	factor	O
37	alpha	B
38	.	O
1	The	O
2	effect	O
3	of	O
4	six	O
5	arginine	O
6	mutations	O
7	of	O
8	oxidative	O
9	phosphorylation	O
10	and	O
11	AAC	O
12	expression	O
13	.	O
1	G	O
2	-	O
3	CSF	B
4	activates	O
5	multiple	O
6	signaling	O
7	molecules	O
8	,	O
9	including	O
10	the	O
11	JAK1	O
12	and	O
13	JAK2	O
14	kinases	B
15	and	O
16	the	O
17	STAT	O
18	transcription	O
19	factors	O
20	.	O
1	In	O
2	addition	O
3	,	O
4	double	O
5	mutants	O
6	with	O
7	either	O
8	dim1	O
9	-	O
10	delta	B
11	or	O
12	dim2	O
13	-	O
14	1	O
15	and	O
16	the	O
17	endocytosis	O
18	mutants	O
19	end4	O
20	-	O
21	1	O
22	or	O
23	act1	O
24	-	O
25	1	O
26	displayed	O
27	synthetic	O
28	growth	O
29	defects	O
30	,	O
31	indicating	O
32	that	O
33	the	O
34	DIM	O
35	gene	O
36	products	O
37	function	O
38	in	O
39	a	O
40	common	O
41	or	O
42	parallel	O
43	endocytic	O
44	pathway	O
45	.	O
1	The	O
2	identification	O
3	of	O
4	the	O
5	hepatitis	O
6	C	O
7	virus	O
8	as	O
9	the	O
10	major	O
11	cause	O
12	of	O
13	liver	O
14	disease	O
15	both	O
16	in	O
17	dialysis	O
18	patients	O
19	and	O
20	in	O
21	transplant	O
22	patients	O
23	has	O
24	focused	O
25	attention	O
26	on	O
27	the	O
28	epidemiology	O
29	and	O
30	the	O
31	impact	O
32	of	O
33	continuing	O
34	infection	O
35	in	O
36	these	O
37	patient	O
38	groups	O
39	.	O
1	Further	O
2	,	O
3	the	O
4	PIP2	O
5	content	O
6	of	O
7	the	O
8	85	O
9	-	O
10	90	O
11	kDa	O
12	protein	O
13	appeared	O
14	to	O
15	decrease	O
16	with	O
17	CSF	B
18	-	O
19	1	O
20	treatment	O
21	.	O
1	The	O
2	STAT	O
3	-	O
4	1	O
5	signaling	O
6	pathway	O
7	provides	O
8	at	O
9	least	O
10	one	O
11	mechanism	O
12	for	O
13	activation	O
14	of	O
15	the	O
16	CAEV	O
17	LTR	O
18	by	O
19	IFN	O
20	-	O
21	gamma	B
22	in	O
23	monocytes	O
24	.	O
1	The	O
2	syndrome	O
3	of	O
4	resistance	O
5	to	O
6	thyroid	O
7	hormone	O
8	is	O
9	characterized	O
10	by	O
11	elevated	O
12	serum	O
13	free	O
14	thyroid	O
15	hormones	O
16	,	O
17	failure	O
18	to	O
19	suppress	O
20	pituitary	O
21	thyrotropin	O
22	secretion	O
23	,	O
24	and	O
25	variable	O
26	peripheral	O
27	refractoriness	O
28	to	O
29	hormone	O
30	action	O
31	.	O
1	BACKGROUND	O
2	:	O
3	Mitosis	O
4	is	O
5	regulated	O
6	by	O
7	MPF	O
8	(	O
9	maturation	O
10	promoting	O
11	factor	O
12	),	O
13	the	O
14	active	O
15	form	O
16	of	O
17	Cdc2	O
18	/	O
19	28	O
20	-	O
21	cyclin	B
22	B	O
23	complexes	O
24	.	O
1	An	O
2	N	O
3	-	O
4	terminal	O
5	arm	O
6	from	O
7	each	O
8	subunit	O
9	wraps	O
10	around	O
11	the	O
12	dinucleotide	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	an	O
18	adjacent	O
19	subunit	O
20	,	O
21	covering	O
22	the	O
23	adenine	O
24	ring	O
25	of	O
26	NADP	O
27	.	O
1	Lack	O
2	of	O
3	sufficient	O
4	data	O
5	on	O
6	vibration	O
7	measurements	O
8	and	O
9	employment	O
10	durations	O
11	add	O
12	to	O
13	the	O
14	uncertainty	O
15	,	O
16	as	O
17	do	O
18	variations	O
19	in	O
20	tool	O
21	conditions	O
22	(	O
23	grinder	O
24	wheels	O
25	,	O
26	etc	O
27	)	O
28	and	O
29	inherent	O
30	difficulties	O
31	in	O
32	measurement	O
33	.	O
1	In	O
2	the	O
3	p51	O
4	subunit	O
5	,	O
6	the	O
7	Cys181	O
8	side	O
9	-	O
10	chain	O
11	is	O
12	oriented	O
13	in	O
14	a	O
15	similar	O
16	direction	O
17	to	O
18	the	O
19	Tyr181	O
20	side	O
21	-	O
22	chain	O
23	in	O
24	the	O
25	wild	O
26	-	O
27	type	O
28	complex	O
29	.	O
1	BCL	O
2	-	O
3	2	O
4	,	O
5	an	O
6	inhibitor	O
7	of	O
8	apoptosis	O
9	in	O
10	a	O
11	wide	O
12	variety	O
13	of	O
14	cell	O
15	types	O
16	,	O
17	has	O
18	been	O
19	reported	O
20	to	O
21	prevent	O
22	oxidative	O
23	stress	O
24	-	O
25	induced	O
26	cell	O
27	death	O
28	.	O
1	The	O
2	human	O
3	p100	O
4	protein	O
5	was	O
6	recently	O
7	identified	O
8	as	O
9	a	O
10	coactivator	O
11	of	O
12	the	O
13	Epstein	O
14	-	O
15	Barr	O
16	virus	O
17	nuclear	O
18	antigen	B
19	2	O
20	.	O
1	This	O
2	report	O
3	presents	O
4	the	O
5	isolation	O
6	and	O
7	characterization	O
8	of	O
9	the	O
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	(	O
15	1	O
16	.	O
17	2	O
18	kb	O
19	)	O
20	and	O
21	exon	O
22	1	O
23	of	O
24	the	O
25	human	O
26	RII	O
27	alpha	B
28	gene	O
29	.	O
1	Serotonin	O
2	concentration	O
3	in	O
4	the	O
5	blood	O
6	of	O
7	patients	O
8	with	O
9	hemorrhagic	O
10	fever	O
11	with	O
12	renal	O
13	syndrome	O
1	JNK	O
2	and	O
3	p38	O
4	are	O
5	constitutively	O
6	present	O
7	in	O
8	the	O
9	nucleus	O
10	,	O
11	and	O
12	DNA	O
13	-	O
14	bound	O
15	c	B
16	-	O
17	JUN	O
18	and	O
19	ATF	O
20	-	O
21	2	O
22	are	O
23	stably	O
24	contacted	O
25	by	O
26	JNK	O
27	and	O
28	p38	O
29	,	O
30	respectively	O
31	.	O
1	Cholesterol	O
2	side	O
3	-	O
4	chain	O
5	cleavage	O
6	cytochrome	O
7	P450	O
8	(	O
9	CYP11A	O
10	;	O
11	P450scc	O
12	)	O
13	gene	O
14	expression	O
15	is	O
16	regulated	O
17	by	O
18	gonadotropins	O
19	via	O
20	cAMP	O
21	in	O
22	the	O
23	ovary	O
24	and	O
25	by	O
26	ACTH	O
27	via	O
28	cAMP	O
29	in	O
30	adrenal	O
31	cortical	O
32	cells	O
33	.	O
1	In	O
2	this	O
3	method	O
4	,	O
5	PLP	O
6	in	O
7	plasma	O
8	can	O
9	be	O
10	determined	O
11	with	O
12	high	O
13	sensitivity	O
14	using	O
15	derivatization	O
16	with	O
17	sodium	O
18	bisulfite	O
19	in	O
20	the	O
21	mobile	O
22	phase	O
23	.	O
1	Both	O
2	HEF1	O
3	and	O
4	Cas	O
5	were	O
6	found	O
7	to	O
8	complex	O
9	with	O
10	the	O
11	related	O
12	adhesion	O
13	focal	O
14	tyrosine	O
15	kinase	B
16	(	O
17	RAFTK	O
18	),	O
19	and	O
20	when	O
21	tyrosine	O
22	phosphorylated	O
23	,	O
24	with	O
25	the	O
26	adapter	O
27	molecule	O
28	CrkL	O
29	.	O
1	SIM1	O
2	and	O
3	SIM2	O
4	do	O
5	not	O
6	form	O
7	homodimers	O
8	,	O
9	and	O
10	they	O
11	do	O
12	not	O
13	interact	O
14	with	O
15	AHR	O
16	.	O
1	cDNA	O
2	cloning	O
3	,	O
4	expression	O
5	analysis	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	a	O
12	gene	O
13	with	O
14	high	O
15	homology	O
16	to	O
17	wheat	O
18	eIF	O
19	-(	O
20	iso	O
21	)	O
22	4F	O
23	and	O
24	mammalian	O
25	eIF	O
26	-	O
27	4G	O
28	.	O
1	Therefore	O
2	,	O
3	it	O
4	is	O
5	important	O
6	to	O
7	control	O
8	hypertension	O
9	and	O
10	keep	O
11	appropriate	O
12	renal	O
13	blood	O
14	flow	O
15	during	O
16	living	O
17	renal	O
18	transplantation	O
19	surgery	O
20	.	O
1	The	O
2	initial	O
3	patients	O
4	treated	O
5	with	O
6	AZQ	O
7	and	O
8	mitroxantrone	O
9	experienced	O
10	prolonged	O
11	bone	O
12	marrow	O
13	suppression	O
14	and	O
15	,	O
16	therefore	O
17	,	O
18	subsequent	O
19	cohorts	O
20	were	O
21	treated	O
22	with	O
23	G	O
24	-	O
25	CSF	B
26	,	O
27	5	O
28	micrograms	O
29	/	O
30	kg	O
31	,	O
32	beginning	O
33	the	O
34	day	O
35	after	O
36	completion	O
37	of	O
38	the	O
39	third	O
40	cycle	O
41	of	O
42	chemotherapy	O
43	.	O
1	In	O
2	order	O
3	to	O
4	provide	O
5	adequate	O
6	local	O
7	control	O
8	without	O
9	compromising	O
10	cosmetic	O
11	outcome	O
12	,	O
13	the	O
14	amount	O
15	of	O
16	breast	O
17	tissue	O
18	that	O
19	must	O
20	be	O
21	excised	O
22	in	O
23	BCT	O
24	needs	O
25	to	O
26	be	O
27	individualized	O
28	.	O
1	The	O
2	14	O
3	.	O
4	1	O
5	(	O
6	IGLL1	O
7	)	O
8	gene	O
9	is	O
10	expressed	O
11	in	O
12	a	O
13	lineage	O
14	-	O
15	and	O
16	stage	O
17	-	O
18	restricted	O
19	manner	O
20	.	O
1	Enhancer	O
2	activity	O
3	requires	O
4	both	O
5	the	O
6	AP	B
7	-	O
8	1	O
9	site	O
10	and	O
11	these	O
12	adjacent	O
13	sequences	O
14	.	O
1	Overexpression	O
2	of	O
3	the	O
4	bZip	O
5	interaction	O
6	domain	O
7	of	O
8	CBP	O
9	specifically	O
10	abolishes	O
11	the	O
12	positive	O
13	cross	O
14	talk	O
15	between	O
16	TR	O
17	and	O
18	p45	O
19	/	O
20	NF	B
21	-	O
22	E2	O
23	.	O
1	We	O
2	report	O
3	herein	O
4	the	O
5	case	O
6	of	O
7	a	O
8	30	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	in	O
15	whom	O
16	ectopic	O
17	mediastinal	O
18	parathyroid	O
19	adenoma	O
20	was	O
21	detected	O
22	by	O
23	99mTc	O
24	-	O
25	methoxyisobutylisonitrile	O
26	scintigraphy	O
27	(	O
28	99mTc	O
29	-	O
30	MIBI	O
31	).	O
1	We	O
2	have	O
3	studied	O
4	the	O
5	biokinetics	O
6	of	O
7	BLM	O
8	labeled	O
9	with	O
10	indium	O
11	-	O
12	111	O
13	(	O
14	In	O
15	-	O
16	111	O
17	).	O
1	Mutations	O
2	in	O
3	the	O
4	alpha	B
5	and	O
6	sigma	O
7	-	O
8	70	O
9	subunits	O
10	of	O
11	RNA	O
12	polymerase	B
13	affect	O
14	expression	O
15	of	O
16	the	O
17	mer	O
18	operon	O
19	.	O
1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	an	O
8	AP	B
9	-	O
10	2	O
11	but	O
12	not	O
13	an	O
14	Egr	O
15	-	O
16	1	O
17	expression	O
18	vector	O
19	activated	O
20	VPF	O
21	/	O
22	VEGF	O
23	transcription	O
24	,	O
25	thus	O
26	indicating	O
27	that	O
28	AP	B
29	-	O
30	2	O
31	protein	O
32	is	O
33	functionally	O
34	important	O
35	in	O
36	TGF	O
37	alpha	B
38	-	O
39	induced	O
40	VPF	O
41	/	O
42	VEGF	O
43	gene	O
44	expression	O
45	.	O
1	RESULTS	O
2	:	O
3	The	O
4	medians	O
5	of	O
6	average	O
7	daily	O
8	CD34	O
9	+	O
10	cell	O
11	yields	O
12	for	O
13	patients	O
14	who	O
15	received	O
16	paclitaxel	O
17	plus	O
18	CY	O
19	,	O
20	CE	O
21	,	O
22	and	O
23	CEP	O
24	with	O
25	G	O
26	-	O
27	CSF	B
28	were	O
29	12	O
30	.	O
31	9	O
32	,	O
33	11	O
34	.	O
35	03	O
36	,	O
37	and	O
38	5	O
39	.	O
40	37	O
41	x	O
42	10	O
43	(	O
44	6	O
45	)/	O
46	kg	O
47	,	O
48	respectively	O
49	,	O
50	compared	O
51	with	O
52	2	O
53	.	O
54	02	O
55	x	O
56	10	O
57	(	O
58	6	O
59	)/	O
60	kg	O
61	in	O
62	the	O
63	reference	O
64	group	O
65	that	O
66	received	O
67	CY	O
68	with	O
69	G	O
70	-	O
71	CSF	B
72	(	O
73	P	O
74	=	O
75	<	O
76	.	O
77	0001	O
78	,	O
79	.	O
80	002	O
81	,	O
82	and	O
83	.	O
84	09	O
85	,	O
86	respectively	O
87	).	O
1	Exploratory	O
2	-	O
3	motor	O
4	task	O
5	to	O
6	evaluate	O
7	right	O
8	frontal	O
9	lobe	O
10	damage	O
11	.	O
1	99mTc	O
2	-	O
3	HMPAO	O
4	was	O
5	distributed	O
6	in	O
7	the	O
8	territories	O
9	of	O
10	the	O
11	ACA	O
12	and	O
13	MCA	O
14	in	O
15	the	O
16	two	O
17	patients	O
18	who	O
19	were	O
20	treated	O
21	with	O
22	intraarterial	O
23	infusion	O
24	of	O
25	papaverine	O
26	from	O
27	the	O
28	C4	O
29	segment	O
30	,	O
31	but	O
32	was	O
33	distributed	O
34	only	O
35	to	O
36	the	O
37	territory	O
38	of	O
39	the	O
40	ACA	O
41	in	O
42	four	O
43	patients	O
44	who	O
45	were	O
46	treated	O
47	with	O
48	intraarterial	O
49	infusion	O
50	of	O
51	papaverine	O
52	from	O
53	the	O
54	C1	O
55	segment	O
56	at	O
57	1	O
58	ml	O
59	/	O
60	min	O
61	.	O
1	This	O
2	brief	O
3	review	O
4	analyses	O
5	these	O
6	interactions	O
7	and	O
8	defines	O
9	clinical	O
10	settings	O
11	where	O
12	antibiotic	O
13	-	O
14	induced	O
15	endotoxin	O
16	release	O
17	may	O
18	prove	O
19	to	O
20	be	O
21	clinically	O
22	relevant	O
23	.	O
1	This	O
2	promoter	O
3	segment	O
4	could	O
5	drive	O
6	expression	O
7	of	O
8	a	O
9	luciferase	O
10	reporter	O
11	gene	O
12	,	O
13	could	O
14	confer	O
15	correct	O
16	transcriptional	O
17	initiation	O
18	to	O
19	the	O
20	reporter	O
21	and	O
22	could	O
23	confer	O
24	the	O
25	EGF	O
26	-	O
27	responsiveness	O
28	previously	O
29	observed	O
30	in	O
31	the	O
32	native	O
33	gene	O
34	.	O
1	The	O
2	second	O
3	class	O
4	of	O
5	cDNA	O
6	hybridized	O
7	to	O
8	a	O
9	13	O
10	kb	O
11	transcript	O
12	,	O
13	which	O
14	was	O
15	approximately	O
16	twice	O
17	as	O
18	large	O
19	as	O
20	the	O
21	mammalian	O
22	lactase	O
23	mRNA	O
24	.	O
1	Circulating	O
2	oxytocin	O
3	in	O
4	male	O
5	guinea	O
6	pigs	O
7	affected	O
8	by	O
9	the	O
10	female	O
11	cohabitation	O
12	and	O
13	reproductive	O
14	condition	O
15	.	O
1	In	O
2	cellular	O
3	supernatant	O
4	fraction	O
5	,	O
6	SHRSP	O
7	showed	O
8	a	O
9	decrease	O
10	of	O
11	magnesium	O
12	in	O
13	many	O
14	tissues	O
15	and	O
16	an	O
17	elevation	O
18	of	O
19	the	O
20	calcium	O
21	to	O
22	magnesium	O
23	ratio	O
24	when	O
25	compared	O
26	to	O
27	age	O
28	-	O
29	matched	O
30	WKY	O
31	and	O
32	SHRSR	O
33	.	O
1	Recognition	O
2	mechanisms	O
3	of	O
4	the	O
5	minus	O
6	-	O
7	strand	O
8	origin	O
9	of	O
10	phage	O
11	f1	O
12	by	O
13	Escherichia	O
14	coli	O
15	RNA	O
16	polymerase	B
17	.	O
1	MOP5	O
2	contained	O
3	the	O
4	characteristic	O
5	PAS	O
6	domain	O
7	and	O
8	a	O
9	variable	O
10	C	O
11	terminus	O
12	;	O
13	it	O
14	is	O
15	possible	O
16	that	O
17	the	O
18	cDNA	O
19	contains	O
20	a	O
21	bHLH	O
22	domain	O
23	,	O
24	but	O
25	the	O
26	entire	O
27	open	O
28	reading	O
29	frame	O
30	has	O
31	yet	O
32	to	O
33	be	O
34	completed	O
35	.	O
1	Molecular	O
2	characterization	O
3	of	O
4	a	O
5	large	O
6	Borrelia	O
7	burgdorferi	O
8	motility	O
9	operon	O
10	which	O
11	is	O
12	initiated	O
13	by	O
14	a	O
15	consensus	O
16	sigma70	O
17	promoter	O
18	.	O
1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	have	O
8	isolated	O
9	and	O
10	sequenced	O
11	several	O
12	p15E	O
13	cDNA	O
14	gene	O
15	fragments	O
16	amplified	O
17	by	O
18	means	O
19	of	O
20	polymerase	B
21	chain	O
22	reaction	O
23	(	O
24	PCR	O
25	)	O
26	from	O
27	parental	O
28	(	O
29	P815	O
30	)	O
31	and	O
32	xenogenized	O
33	(	O
34	P815	O
35	/	O
36	DTIC	O
37	)	O
38	tumour	O
39	cells	O
40	.	O
1	Grade	O
2	3	O
3	-	O
4	4	O
5	mucositis	O
6	was	O
7	present	O
8	in	O
9	13	O
10	%	O
11	of	O
12	the	O
13	cycles	O
14	.	O
1	Therefore	O
2	more	O
3	active	O
4	and	O
5	tolerable	O
6	salvage	O
7	regimens	O
8	are	O
9	needed	O
10	.	O
1	The	O
2	prominent	O
3	lesions	O
4	were	O
5	confined	O
6	to	O
7	the	O
8	cerebral	O
9	surface	O
10	layer	O
11	and	O
12	leptomeningeal	O
13	tissue	O
14	including	O
15	the	O
16	arachnoid	O
17	vessels	O
18	,	O
19	which	O
20	were	O
21	all	O
22	bathed	O
23	in	O
24	the	O
25	cerebrospinal	O
26	fluid	O
27	,	O
28	suggesting	O
29	that	O
30	some	O
31	necrotizing	O
32	toxins	O
33	had	O
34	been	O
35	secreted	O
36	into	O
37	the	O
38	fluid	O
39	by	O
40	the	O
41	B	O
42	.	O
43	cereus	O
44	.	O
1	Movement	O
2	time	O
3	and	O
4	kinematic	O
5	characteristics	O
6	were	O
7	analyzed	O
8	together	O
9	with	O
10	the	O
11	magnitude	O
12	of	O
13	cerebral	O
14	blood	O
15	flow	O
16	to	O
17	identify	O
18	areas	O
19	of	O
20	brain	O
21	activity	O
22	proportionate	O
23	to	O
24	task	O
25	and	O
26	movement	O
27	variables	O
28	.	O
1	Recent	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	U1	O
8	snRNP	O
9	is	O
10	recruited	O
11	to	O
12	the	O
13	5	O
14	'	O
15	splice	O
16	site	O
17	by	O
18	protein	O
19	/	O
20	protein	O
21	interactions	O
22	involving	O
23	the	O
24	SR	O
25	domains	O
26	of	O
27	the	O
28	U1	O
29	-	O
30	70K	O
31	protein	O
32	and	O
33	SF2	O
34	/	O
35	ASF	O
36	.	O
1	However	O
2	,	O
3	the	O
4	same	O
5	U1A	O
6	peptide	O
7	,	O
8	when	O
9	conjugated	O
10	to	O
11	BSA	O
12	,	O
13	inhibits	O
14	vertebrate	O
15	PAP	O
16	.	O
1	Plasma	O
2	levels	O
3	of	O
4	protein	O
5	C	O
6	,	O
7	protein	O
8	S	O
9	,	O
10	and	O
11	antithrombin	O
12	III	O
13	in	O
14	patients	O
15	with	O
16	subarachnoid	O
17	haemorrhage	O
18	.	O
1	Idiopathic	O
2	bilateral	O
3	recurrent	O
4	branch	O
5	retinal	O
6	arterial	O
7	occlusion	O
8	(	O
9	IBRBRAO	O
10	)	O
11	is	O
12	a	O
13	rare	O
14	syndrome	O
15	characterized	O
16	by	O
17	migraine	O
18	headaches	O
19	,	O
20	tinnitus	O
21	,	O
22	vertigo	O
23	,	O
24	hearing	O
25	loss	O
26	,	O
27	and	O
28	recurrent	O
29	branch	O
30	retinal	O
31	artery	O
32	occlusion	O
33	of	O
34	unknown	O
35	etiology	O
36	.	O
1	Autorosette	O
2	-	O
3	forming	O
4	cells	O
5	are	O
6	characterized	O
7	by	O
8	a	O
9	high	O
10	activity	O
11	of	O
12	alkaline	O
13	and	O
14	acid	O
15	phosphatases	O
16	and	O
17	low	O
18	NBT	O
19	-	O
20	test	O
21	values	O
22	.	O
1	Candidate	O
2	tumor	O
3	suppressor	O
4	genes	O
5	,	O
6	Mts1	O
7	(	O
8	p16INK4a	O
9	)	O
10	and	O
11	Mts2	O
12	(	O
13	p15INK4b	O
14	),	O
15	have	O
16	been	O
17	mapped	O
18	to	O
19	this	O
20	region	O
21	,	O
22	but	O
23	by	O
24	Southern	O
25	blot	O
26	analysis	O
27	,	O
28	no	O
29	homozygous	O
30	deletions	O
31	were	O
32	detected	O
33	in	O
34	either	O
35	gene	O
36	.	O
1	An	O
2	aromatic	O
3	stacking	O
4	interaction	O
5	between	O
6	subunits	O
7	helps	O
8	mediate	O
9	DNA	O
10	sequence	O
11	specificity	O
12	:	O
13	operator	O
14	site	O
15	discrimination	O
16	by	O
17	phage	O
18	lambda	O
19	cI	O
20	repressor	O
21	.	O
1	Here	O
2	we	O
3	report	O
4	the	O
5	purification	O
6	of	O
7	this	O
8	larger	O
9	form	O
10	as	O
11	an	O
12	approximately	O
13	320	O
14	-	O
15	kDa	O
16	particle	O
17	that	O
18	contains	O
19	mRNP3	O
20	+	O
21	4	O
22	and	O
23	nine	O
24	additional	O
25	polypeptides	O
26	,	O
27	including	O
28	mRNA	O
29	-	O
30	binding	O
31	polypeptides	O
32	of	O
33	34	O
34	and	O
35	36	O
36	kDa	O
37	and	O
38	a	O
39	doublet	O
40	of	O
41	110	O
42	/	O
43	105	O
44	kDa	O
45	that	O
46	proved	O
47	to	O
48	be	O
49	nucleolin	O
50	.	O
1	Inductively	O
2	coupled	O
3	plasma	O
4	atomic	O
5	emission	O
6	spectroscopy	O
7	was	O
8	employed	O
9	to	O
10	obtain	O
11	the	O
12	tissue	O
13	silicon	O
14	measurements	O
15	.	O
1	Results	O
2	from	O
3	our	O
4	and	O
5	other	O
6	laboratories	O
7	have	O
8	suggested	O
9	that	O
10	UCN	O
11	-	O
12	01	O
13	induces	O
14	preferential	O
15	G1	O
16	-	O
17	phase	O
18	accumulation	O
19	in	O
20	several	O
21	human	O
22	tumor	O
23	cell	O
24	lines	O
25	tested	O
26	.	O
1	To	O
2	identify	O
3	cis	O
4	-	O
5	acting	O
6	elements	O
7	that	O
8	target	O
9	c	B
10	-	O
11	myc	O
12	mRNA	O
13	for	O
14	downregulation	O
15	during	O
16	myogenesis	O
17	,	O
18	we	O
19	stably	O
20	transfected	O
21	C2C12	O
22	cells	O
23	with	O
24	mutant	O
25	myc	O
26	genes	O
27	or	O
28	chimeric	O
29	genes	O
30	in	O
31	which	O
32	various	O
33	myc	O
34	sequences	O
35	were	O
36	fused	O
37	to	O
38	the	O
39	human	O
40	beta	B
41	-	O
42	globin	O
43	gene	O
44	or	O
45	to	O
46	the	O
47	bacterial	O
48	chloramphenicol	O
49	acetyltransferase	O
50	(	O
51	CAT	O
52	)	O
53	gene	O
54	.	O
1	In	O
2	particular	O
3	,	O
4	Western	O
5	,	O
6	supershift	O
7	,	O
8	and	O
9	promoter	O
10	deletion	O
11	analyses	O
12	suggested	O
13	a	O
14	role	O
15	for	O
16	CCAAT	O
17	/	O
18	enhancer	O
19	-	O
20	binding	O
21	protein	O
22	-	O
23	beta	B
24	(	O
25	C	O
26	/	O
27	EBP	O
28	-	O
29	beta	B
30	)	O
31	binding	O
32	site	O
33	between	O
34	-	O
35	2010	O
36	and	O
37	-	O
38	1954	O
39	in	O
40	regulating	O
41	transcription	O
42	of	O
43	collagenase	O
44	-	O
45	1	O
46	in	O
47	monocytic	O
48	cells	O
49	.	O
1	Cdc2	O
2	co	O
3	-	O
4	precipitates	O
5	with	O
6	Pch1	O
7	in	O
8	S	O
9	.	O
10	pombe	O
11	cell	O
12	lysates	O
13	,	O
14	although	O
15	Cdc2	O
16	may	O
17	not	O
18	be	O
19	the	O
20	major	O
21	catalytic	O
22	partner	O
23	of	O
24	a	O
25	Pch1	O
26	kinase	B
27	in	O
28	vivo	O
29	.	O
1	The	O
2	Ras	B
3	guanine	O
4	nucleotide	O
5	-	O
6	binding	O
7	protein	O
8	functions	O
9	as	O
10	a	O
11	molecular	O
12	switch	O
13	in	O
14	signalling	O
15	downstream	O
16	of	O
17	protein	O
18	-	O
19	tyrosine	O
20	kinases	B
21	.	O
1	Time	O
2	-	O
3	activity	O
4	curves	O
5	from	O
6	the	O
7	gastric	O
8	region	O
9	of	O
10	interest	O
11	were	O
12	used	O
13	,	O
14	after	O
15	subjection	O
16	to	O
17	appropriate	O
18	corrective	O
19	procedures	O
20	,	O
21	to	O
22	calculate	O
23	the	O
24	mean	O
25	gastric	O
26	transit	O
27	time	O
28	(	O
29	MTT	O
30	90	O
31	)	O
32	and	O
33	the	O
34	fraction	O
35	of	O
36	the	O
37	test	O
38	meal	O
39	retained	O
40	in	O
41	the	O
42	stomach	O
43	after	O
44	90	O
45	min	O
46	(	O
47	F90	O
48	).	O
1	The	O
2	electromyographically	O
3	recorded	O
4	responses	O
5	consisted	O
6	of	O
7	an	O
8	early	O
9	R1	O
10	response	O
11	in	O
12	the	O
13	orbicularis	O
14	oculi	O
15	muscle	O
16	ipsilateral	O
17	to	O
18	the	O
19	side	O
20	of	O
21	stimulation	O
22	,	O
23	a	O
24	bilateral	O
25	late	O
26	response	O
27	(	O
28	ipsilateral	O
29	R2	O
30	and	O
31	contralateral	O
32	Rc	O
33	)	O
34	and	O
35	a	O
36	third	O
37	,	O
38	R3	O
39	response	O
40	,	O
41	in	O
42	the	O
43	ipsilateral	O
44	orbicularis	O
45	oculi	O
46	muscle	O
47	.	O
1	The	O
2	prognosis	O
3	of	O
4	seven	O
5	patients	O
6	who	O
7	received	O
8	ABSCT	O
9	was	O
10	significantly	O
11	better	O
12	than	O
13	that	O
14	of	O
15	13	O
16	patients	O
17	who	O
18	received	O
19	conventional	O
20	therapy	O
21	alone	O
22	.	O
1	Malonate	O
2	decarboxylation	O
3	in	O
4	Malonomonas	O
5	rubra	O
6	involves	O
7	the	O
8	formation	O
9	of	O
10	malonyl	O
11	-	O
12	S	O
13	-[	O
14	acyl	O
15	-	O
16	carrier	O
17	protein	O
18	]	O
19	from	O
20	acetyl	O
21	-	O
22	S	O
23	-[	O
24	acyl	O
25	-	O
26	carrier	O
27	protein	O
28	]	O
29	and	O
30	malonate	O
31	,	O
32	carboxyltransfer	O
33	to	O
34	a	O
35	biotin	O
36	protein	O
37	and	O
38	its	O
39	decarboxylation	O
40	that	O
41	is	O
42	coupled	O
43	to	O
44	delta	B
45	mu	O
46	Na	O
47	+	O
48	generation	O
49	.	O
1	The	O
2	Jem	O
3	peptide	O
4	sequence	O
5	shows	O
6	a	O
7	'	O
8	leucine	O
9	-	O
10	zipper	O
11	'	O
12	dimerisation	O
13	motif	O
14	with	O
15	limited	O
16	homology	O
17	to	O
18	Fos	O
19	/	O
20	Jun	O
21	and	O
22	ATF	O
23	/	O
24	CREB	O
25	proteins	O
26	and	O
27	several	O
28	putative	O
29	phosphorylation	O
30	sites	O
31	.	O
1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	protein	O
9	that	O
10	binds	O
11	to	O
12	enhancer	O
13	site	O
14	III	O
15	.	O
1	Further	O
2	support	O
3	for	O
4	a	O
5	direct	O
6	interaction	O
7	of	O
8	Tub4p	O
9	,	O
10	Spc98p	O
11	and	O
12	Spc97p	O
13	comes	O
14	from	O
15	the	O
16	toxicity	O
17	of	O
18	strong	O
19	SPC97	O
20	overexpression	O
21	which	O
22	is	O
23	suppressed	O
24	by	O
25	co	O
26	-	O
27	overexpression	O
28	of	O
29	TUB4	O
30	or	O
31	SPC98	O
32	.	O
1	Sequences	O
2	needed	O
3	for	O
4	iron	O
5	-	O
6	regulated	O
7	expression	O
8	of	O
9	sid1	O
10	were	O
11	localized	O
12	to	O
13	a	O
14	306	O
15	bp	O
16	region	O
17	mapping	O
18	2	O
19	.	O
20	3	O
21	and	O
22	2	O
23	.	O
24	6	O
25	kb	O
26	upstream	O
27	of	O
28	the	O
29	ATG	O
30	.	O
1	Cyclin	O
2	G2	O
3	is	O
4	highly	O
5	expressed	O
6	in	O
7	the	O
8	immune	O
9	system	O
10	where	O
11	immunologic	O
12	tolerance	O
13	subjects	O
14	self	O
15	-	O
16	reactive	O
17	lymphocytes	O
18	to	O
19	negative	O
20	selection	O
21	and	O
22	clonal	O
23	deletion	O
24	via	O
25	apoptosis	O
26	.	O
1	Thus	O
2	,	O
3	the	O
4	P	O
5	.	O
6	aeruginosa	O
7	orfX	O
8	and	O
9	vfr	O
10	promoters	O
11	are	O
12	arranged	O
13	in	O
14	a	O
15	back	O
16	-	O
17	to	O
18	-	O
19	back	O
20	orientation	O
21	rather	O
22	than	O
23	the	O
24	face	O
25	-	O
26	to	O
27	-	O
28	face	O
29	orientation	O
30	of	O
31	the	O
32	dorf	O
33	and	O
34	crp	O
35	promoters	O
36	.	O
1	(	O
2	3	O
3	)	O
4	This	O
5	effect	O
6	occurs	O
7	without	O
8	removing	O
9	TRs	O
10	from	O
11	the	O
12	TRE	O
13	.	O
1	This	O
2	finding	O
3	is	O
4	the	O
5	first	O
6	example	O
7	of	O
8	utilization	O
9	of	O
10	noncomplementary	O
11	dinucleotide	O
12	primer	O
13	by	O
14	an	O
15	RNA	O
16	polymerase	B
17	.	O
1	A	O
2	promising	O
3	new	O
4	cement	O
5	,	O
6	4	O
7	-	O
8	META	O
9	/	O
10	MMA	O
11	-	O
12	TBB	O
13	opaque	O
14	resin	O
15	,	O
16	has	O
17	shown	O
18	remarkable	O
19	adhesive	O
20	properties	O
21	as	O
22	a	O
23	bone	O
24	cement	O
25	in	O
26	vivo	O
27	.	O
1	We	O
2	also	O
3	review	O
4	the	O
5	role	O
6	of	O
7	grains	O
8	in	O
9	the	O
10	formation	O
11	of	O
12	complex	O
13	molecules	O
14	in	O
15	interstellar	O
16	molecular	O
17	clouds	O
18	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	dietary	O
6	safflower	O
7	phospholipids	O
8	may	O
9	be	O
10	a	O
11	valuable	O
12	ingredient	O
13	to	O
14	layers	O
15	for	O
16	reducing	O
17	liver	O
18	triglycerides	O
19	and	O
20	serum	O
21	cholesterol	O
22	without	O
23	any	O
24	adverse	O
25	effects	O
26	.	O
1	Using	O
2	various	O
3	techniques	O
4	,	O
5	we	O
6	have	O
7	undertaken	O
8	a	O
9	systematic	O
10	analysis	O
11	of	O
12	the	O
13	natural	O
14	TATA	O
15	-	O
16	less	O
17	human	O
18	DNA	O
19	polymerase	B
20	beta	I
21	(	O
22	beta	B
23	-	O
24	pol	O
25	)	O
26	gene	O
27	promoter	O
28	.	O
1	To	O
2	determine	O
3	if	O
4	signing	O
5	,	O
6	when	O
7	established	O
8	,	O
9	would	O
10	compete	O
11	with	O
12	SIB	O
13	when	O
14	both	O
15	were	O
16	reinforced	O
17	,	O
18	extinction	O
19	was	O
20	then	O
21	withdrawn	O
22	.	O
1	This	O
2	association	O
3	appears	O
4	to	O
5	be	O
6	mediated	O
7	by	O
8	Src	O
9	-	O
10	SH2	O
11	domain	O
12	,	O
13	because	O
14	PECAM	O
15	-	O
16	1	O
17	can	O
18	be	O
19	precipitated	O
20	by	O
21	a	O
22	GST	O
23	-	O
24	Src	O
25	-	O
26	SH2	O
27	affinity	O
28	matrix	O
29	.	O
1	An	O
2	alternatively	O
3	spliced	O
4	MAdCAM	O
5	-	O
6	1	O
7	variant	O
8	was	O
9	identified	O
10	that	O
11	lacks	O
12	exon	O
13	4	O
14	encoding	O
15	the	O
16	mucin	O
17	domain	O
18	,	O
19	and	O
20	may	O
21	mediate	O
22	leukocyte	O
23	adhesion	O
24	to	O
25	LPAM	O
26	-	O
27	1	O
28	without	O
29	adhesion	O
30	to	O
31	the	O
32	alternate	O
33	receptor	B
34	,	O
35	L	O
36	-	O
37	selectin	O
38	.	O
1	More	O
2	recently	O
3	,	O
4	however	O
5	,	O
6	a	O
7	number	O
8	of	O
9	developments	O
10	such	O
11	as	O
12	the	O
13	successful	O
14	use	O
15	of	O
16	the	O
17	inhaled	O
18	steroid	O
19	budesonide	O
20	and	O
21	oral	O
22	dexamethasone	O
23	have	O
24	reinforced	O
25	the	O
26	argument	O
27	for	O
28	using	O
29	steroids	O
30	.	O
1	A	O
2	xylE	O
3	transcriptional	O
4	fusion	O
5	to	O
6	the	O
7	putative	O
8	mxbD	O
9	promoter	O
10	showed	O
11	low	O
12	-	O
13	level	O
14	expression	O
15	in	O
16	wild	O
17	-	O
18	type	O
19	cells	O
20	grown	O
21	on	O
22	one	O
23	-	O
24	carbon	O
25	(	O
26	C1	O
27	)	O
28	compounds	O
29	and	O
30	no	O
31	detectable	O
32	expression	O
33	in	O
34	cells	O
35	grown	O
36	on	O
37	succinate	O
38	.	O
1	Mutation	O
2	of	O
3	nucleotides	O
4	adjacent	O
5	to	O
6	the	O
7	AP	B
8	-	O
9	1	O
10	cis	O
11	-	O
12	response	O
13	elements	O
14	had	O
15	no	O
16	effect	O
17	on	O
18	trans	O
19	-	O
20	activation	O
21	.	O
1	Cloning	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	cDNA	O
7	encoding	O
8	a	O
9	bacteriophage	O
10	-	O
11	type	O
12	RNA	O
13	polymerase	B
14	from	O
15	the	O
16	higher	O
17	plant	O
18	Chenopodium	O
19	album	O
20	.	O
1	These	O
2	six	O
3	amino	O
4	acids	O
5	are	O
6	part	O
7	of	O
8	an	O
9	amphipathic	O
10	helix	O
11	that	O
12	is	O
13	highly	O
14	conserved	O
15	among	O
16	nuclear	O
17	hormone	O
18	receptors	O
19	and	O
20	contains	O
21	the	O
22	core	O
23	domain	O
24	of	O
25	the	O
26	ligand	O
27	-	O
28	dependent	O
29	transactivation	O
30	function	O
31	,	O
32	AF	O
33	-	O
34	2	O
35	.	O
1	In	O
2	ciliates	O
3	,	O
4	both	O
5	mechanisms	O
6	are	O
7	readily	O
8	observed	O
9	.	O
1	It	O
2	is	O
3	concluded	O
4	that	O
5	fludarabine	O
6	is	O
7	a	O
8	highly	O
9	useful	O
10	agent	O
11	in	O
12	CLL	O
13	.	O
1	A	O
2	similar	O
3	chimera	O
4	was	O
5	assembled	O
6	from	O
7	the	O
8	two	O
9	halves	O
10	of	O
11	the	O
12	molecule	O
13	expressed	O
14	separately	O
15	in	O
16	different	O
17	bacteria	O
18	and	O
19	refolded	O
20	together	O
21	.	O
1	We	O
2	analysed	O
3	two	O
4	regions	O
5	involved	O
6	in	O
7	preS2	O
8	/	O
9	S	O
10	gene	O
11	transcription	O
12	of	O
13	the	O
14	HBV	O
15	adw	O
16	subtype	O
17	:	O
18	the	O
19	diverged	O
20	TATA	O
21	box	O
22	and	O
23	a	O
24	putative	O
25	initiator	O
26	element	O
27	.	O
1	Indeed	O
2	the	O
3	predicted	O
4	folding	O
5	of	O
6	the	O
7	5	O
8	'	O
9	and	O
10	3	O
11	'-	O
12	untranslated	O
13	regions	O
14	revealed	O
15	patterns	O
16	of	O
17	stem	O
18	and	O
19	loop	O
20	structures	O
21	conserved	O
22	for	O
23	all	O
24	tick	O
25	-	O
26	borne	O
27	flaviviruses	O
28	suggesting	O
29	a	O
30	purifying	O
31	selection	O
32	for	O
33	preservation	O
34	of	O
35	essential	O
36	RNA	O
37	secondary	O
38	structures	O
39	which	O
40	could	O
41	be	O
42	involved	O
43	in	O
44	translational	O
45	control	O
46	and	O
47	replication	O
48	.	O
1	Recently	O
2	we	O
3	have	O
4	performed	O
5	a	O
6	detailed	O
7	analysis	O
8	of	O
9	specific	O
10	neuronal	O
11	populations	O
12	affected	O
13	by	O
14	the	O
15	mutation	O
16	which	O
17	shed	O
18	new	O
19	light	O
20	on	O
21	the	O
22	role	O
23	of	O
24	Krox	O
25	-	O
26	20	O
27	in	O
28	the	O
29	segmentation	O
30	and	O
31	on	O
32	the	O
33	physiological	O
34	consequences	O
35	of	O
36	its	O
37	inactivation	O
38	.	O
1	The	O
2	most	O
3	important	O
4	one	O
5	among	O
6	them	O
7	is	O
8	Cyclosporin	O
9	A	O
10	,	O
11	which	O
12	is	O
13	a	O
14	selective	O
15	immunosuppressive	O
16	drug	O
17	.	O
1	The	O
2	extended	O
3	rat	O
4	SP	O
5	-	O
6	A	O
7	isoforms	O
8	were	O
9	enriched	O
10	in	O
11	the	O
12	more	O
13	fully	O
14	glycosylated	O
15	and	O
16	multimeric	O
17	SP	O
18	-	O
19	A	O
20	species	O
21	separated	O
22	on	O
23	SDS	O
24	-	O
25	PAGE	O
26	gels	O
27	.	O
1	Induction	O
2	of	O
3	correctly	O
4	spliced	O
5	germline	O
6	transcripts	O
7	is	O
8	necessary	O
9	to	O
10	target	O
11	a	O
12	switch	O
13	region	O
14	for	O
15	recombination	O
16	and	O
17	switching	O
18	.	O
1	Cytological	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	transgenes	O
7	associate	O
8	with	O
9	a	O
10	nucleolus	O
11	.	O
1	The	O
2	immunophilin	O
3	,	O
4	which	O
5	can	O
6	be	O
7	of	O
8	the	O
9	FK506	O
10	-	O
11	or	O
12	cyclosporin	O
13	A	O
14	-	O
15	binding	O
16	class	O
17	,	O
18	binds	O
19	to	O
20	hsp90	O
21	via	O
22	its	O
23	tetratricopeptide	O
24	repeat	O
25	(	O
26	TPR	O
27	)	O
28	domain	O
29	,	O
30	and	O
31	different	O
32	receptor	B
33	heterocomplexes	O
34	exist	O
35	depending	O
36	upon	O
37	which	O
38	immunophilin	O
39	occupies	O
40	the	O
41	TPR	O
42	-	O
43	binding	O
44	region	O
45	of	O
46	hsp90	O
47	.	O
1	Sequencing	O
2	of	O
3	the	O
4	facB	O
5	gene	O
6	revealed	O
7	that	O
8	it	O
9	encodes	O
10	a	O
11	protein	O
12	that	O
13	contains	O
14	an	O
15	N	O
16	-	O
17	terminal	O
18	GAL4	O
19	-	O
20	like	O
21	Zn	O
22	(	O
23	II	O
24	)	O
25	2Cys6	O
26	(	O
27	or	O
28	C6	O
29	zinc	O
30	)	O
31	binuclear	O
32	cluster	O
33	for	O
34	DNA	O
35	binding	O
36	,	O
37	leucine	O
38	zipper	O
39	-	O
40	like	O
41	heptad	O
42	repeat	O
43	motifs	O
44	and	O
45	central	O
46	and	O
47	C	O
48	-	O
49	terminal	O
50	acidic	O
51	alpha	B
52	-	O
53	helical	O
54	regions	O
55	,	O
56	consistent	O
57	with	O
58	a	O
59	function	O
60	as	O
61	a	O
62	DNA	O
63	-	O
64	binding	O
65	transcriptional	O
66	activator	O
67	.	O
1	Overexpression	O
2	of	O
3	Sed5p	O
4	allowed	O
5	growth	O
6	in	O
7	the	O
8	absence	O
9	of	O
10	Vti1p	O
11	.	O
1	Furthermore	O
2	,	O
3	p150	O
4	suppresses	O
5	actin	O
6	gelation	O
7	,	O
8	which	O
9	is	O
10	induced	O
11	by	O
12	smooth	O
13	muscle	O
14	alpha	B
15	-	O
16	actinin	O
17	.	O
1	Based	O
2	on	O
3	these	O
4	results	O
5	and	O
6	because	O
7	Cdc68	O
8	has	O
9	been	O
10	implicated	O
11	as	O
12	a	O
13	regulator	O
14	of	O
15	chromatin	O
16	structure	O
17	,	O
18	we	O
19	postulate	O
20	that	O
21	polymerase	B
22	alpha	I
23	may	O
24	interact	O
25	with	O
26	these	O
27	proteins	O
28	to	O
29	gain	O
30	access	O
31	to	O
32	its	O
33	template	O
34	or	O
35	to	O
36	origins	O
37	of	O
38	replication	O
39	in	O
40	vivo	O
41	.	O
1	In	O
2	1990	O
3	,	O
4	an	O
5	International	O
6	Commission	O
7	for	O
8	the	O
9	Certification	O
10	of	O
11	Eradication	O
12	of	O
13	Poliomyelitis	O
14	Eradication	O
15	(	O
16	ICCPE	O
17	)	O
18	was	O
19	established	O
20	by	O
21	the	O
22	Pan	O
23	American	O
24	Health	O
25	Organization	O
26	to	O
27	eventually	O
28	determine	O
29	if	O
30	transmission	O
31	was	O
32	interrupted	O
33	.	O
1	Identification	O
2	of	O
3	five	O
4	new	O
5	genes	O
6	,	O
7	closely	O
8	related	O
9	to	O
10	the	O
11	interleukin	O
12	-	O
13	1beta	O
14	converting	O
15	enzyme	O
16	gene	O
17	,	O
18	that	O
19	do	O
20	not	O
21	encode	O
22	functional	O
23	proteases	O
24	.	O
1	Surveillance	O
2	for	O
3	preeclampsia	O
4	was	O
5	conducted	O
6	by	O
7	personnel	O
8	unaware	O
9	of	O
10	treatment	O
11	-	O
12	group	O
13	assignments	O
14	,	O
15	using	O
16	standardized	O
17	measurements	O
18	of	O
19	blood	O
20	pressure	O
21	and	O
22	urinary	O
23	protein	O
24	excretion	O
25	at	O
26	uniformly	O
27	scheduled	O
28	prenatal	O
29	visits	O
30	,	O
31	protocols	O
32	for	O
33	monitoring	O
34	these	O
35	measurements	O
36	during	O
37	the	O
38	hospitalization	O
39	for	O
40	delivery	O
41	,	O
42	and	O
43	reviews	O
44	of	O
45	medical	O
46	records	O
47	of	O
48	unscheduled	O
49	outpatient	O
50	visits	O
51	and	O
52	all	O
53	hospitalizations	O
54	.	O
1	We	O
2	isolated	O
3	several	O
4	overlapping	O
5	A	O
6	-	O
7	phage	O
8	and	O
9	cosmid	O
10	clones	O
11	that	O
12	cover	O
13	more	O
14	than	O
15	100	O
16	kb	O
17	of	O
18	human	O
19	DNA	O
20	and	O
21	contained	O
22	the	O
23	entire	O
24	VDR	O
25	gene	O
26	.	O
1	Colorectal	O
2	carcinoma	O
3	:	O
4	therapeutic	O
5	approach	O
6	in	O
7	patients	O
8	already	O
9	treated	O
10	with	O
11	metastasis	O
12	resection	O
1	The	O
2	products	O
3	of	O
4	the	O
5	Saccharomyces	O
6	cerevisiae	O
7	CIN1	O
8	,	O
9	CIN2	O
10	and	O
11	CIN4	O
12	genes	O
13	participate	O
14	in	O
15	a	O
16	nonessential	O
17	pathway	O
18	required	O
19	for	O
20	normal	O
21	microtubule	O
22	function	O
23	.	O
1	Serum	O
2	response	O
3	factor	O
4	(	O
5	SRF	O
6	),	O
7	a	O
8	member	O
9	of	O
10	an	O
11	ancient	O
12	family	O
13	of	O
14	DNA	O
15	-	O
16	binding	O
17	proteins	O
18	,	O
19	is	O
20	generally	O
21	assumed	O
22	to	O
23	be	O
24	a	O
25	ubiquitous	O
26	transcription	O
27	factor	O
28	involved	O
29	in	O
30	regulating	O
31	growth	O
32	factor	O
33	-	O
34	responsive	O
35	genes	O
36	.	O
1	The	O
2	selective	O
3	5	O
4	-	O
5	HT3	O
6	receptor	B
7	antagonists	O
8	ramosetron	O
9	(	O
10	YM060	O
11	),	O
12	YM114	O
13	(	O
14	KAE	O
15	-	O
16	393	O
17	),	O
18	granisetron	O
19	and	O
20	ondansetron	O
21	,	O
22	and	O
23	the	O
24	substituted	O
25	benzamides	O
26	(	O
27	5	O
28	-	O
29	HT4	O
30	receptor	B
31	agonist	O
32	/	O
33	5	O
34	-	O
35	HT3	O
36	receptor	B
37	antagonists	O
38	)	O
39	cisapride	O
40	mosapride	O
41	and	O
42	SC	O
43	-	O
44	53116	O
45	dose	O
46	-	O
47	dependently	O
48	enhanced	O
49	gastric	O
50	emptying	O
51	in	O
52	normal	O
53	rats	O
54	.	O
1	3600	O
2	-	O
3	fold	O
4	to	O
5	apparent	O
6	homogeneity	O
7	with	O
8	a	O
9	41	O
10	%	O
11	yield	O
12	by	O
13	affinity	O
14	chromatography	O
15	utilizing	O
16	DNA	O
17	-	O
18	cellulose	O
19	;	O
20	the	O
21	purity	O
22	of	O
23	the	O
24	final	O
25	preparation	O
26	was	O
27	assessed	O
28	by	O
29	SDS	O
30	/	O
31	PAGE	O
32	,	O
33	lack	O
34	of	O
35	contamination	O
36	by	O
37	other	O
38	nucleases	O
39	and	O
40	production	O
41	of	O
42	a	O
43	monospecific	O
44	antibody	O
45	against	O
46	the	O
47	enzyme	O
48	.	O
1	The	O
2	mean	O
3	times	O
4	to	O
5	detection	O
6	of	O
7	all	O
8	mycobacteria	O
9	with	O
10	BACTEC	O
11	9000	O
12	MB	O
13	and	O
14	BACTEC	O
15	460	O
16	TB	O
17	were	O
18	similar	O
19	(	O
20	10	O
21	.	O
22	3	O
23	and	O
24	10	O
25	.	O
26	0	O
27	days	O
28	,	O
29	respectively	O
30	).	O
1	JNK	O
2	is	O
3	additionally	O
4	regulated	O
5	by	O
6	the	O
7	Ras	B
8	-	O
9	related	O
10	G	O
11	proteins	O
12	Rac	O
13	and	O
14	Cdc42	O
15	.	O
1	Although	O
2	neither	O
3	constitutively	O
4	activated	O
5	MEK	O
6	(	O
7	MEK	O
8	-	O
9	2E	O
10	)	O
11	nor	O
12	v	O
13	-	O
14	Src	O
15	was	O
16	sufficient	O
17	individually	O
18	to	O
19	differentiate	O
20	the	O
21	H19	O
22	-	O
23	7	O
24	cells	O
25	,	O
26	coexpression	O
27	of	O
28	constitutively	O
29	activated	O
30	MEK	O
31	and	O
32	v	O
33	-	O
34	Src	O
35	induced	O
36	neurite	O
37	outgrowth	O
38	.	O
1	This	O
2	mechanism	O
3	is	O
4	in	O
5	contrast	O
6	to	O
7	other	O
8	cases	O
9	of	O
10	splicing	O
11	regulation	O
12	by	O
13	PTB	O
14	,	O
15	in	O
16	which	O
17	the	O
18	protein	O
19	represses	O
20	the	O
21	splice	O
22	site	O
23	to	O
24	which	O
25	it	O
26	binds	O
27	.	O
1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	O
13	not	O
14	directly	O
15	involved	O
16	in	O
17	transrepression	O
18	of	O
19	AP	B
20	-	O
21	1	O
22	activity	O
23	.	O
1	Both	O
2	of	O
3	these	O
4	dogs	O
5	had	O
6	low	O
7	serum	O
8	IgG	O
9	(	O
10	3	O
11	.	O
12	5	O
13	to	O
14	7	O
15	.	O
16	2	O
17	mg	O
18	/	O
19	ml	O
20	)	O
21	and	O
22	the	O
23	second	O
24	littermate	O
25	also	O
26	had	O
27	reduced	O
28	serum	O
29	IgA	O
30	(<	O
31	0	O
32	.	O
33	1	O
34	to	O
35	0	O
36	.	O
37	15	O
38	mg	O
39	/	O
40	ml	O
41	).	O
1	The	O
2	Ogg1	O
3	protein	O
4	efficiently	O
5	cleaves	O
6	a	O
7	DNA	O
8	duplex	O
9	where	O
10	a	O
11	preformed	O
12	AP	B
13	site	O
14	is	O
15	placed	O
16	opposite	O
17	a	O
18	cytosine	O
19	(	O
20	AP	B
21	/	O
22	C	O
23	).	O
1	A	O
2	consensus	O
3	sequence	O
4	indicates	O
5	a	O
6	highly	O
7	conserved	O
8	lysine	O
9	residue	O
10	,	O
11	K120	O
12	of	O
13	endonuclease	O
14	III	O
15	or	O
16	K241	O
17	of	O
18	Ogg1	O
19	,	O
20	respectively	O
21	.	O
1	Volunteers	O
2	were	O
3	irradiated	O
4	on	O
5	their	O
6	backs	O
7	with	O
8	suberythemal	O
9	UV	O
10	daily	O
11	for	O
12	5	O
13	d	O
14	after	O
15	application	O
16	of	O
17	the	O
18	sunscreens	O
19	and	O
20	their	O
21	base	O
22	lotion	O
23	to	O
24	different	O
25	sites	O
26	.	O
1	Proteinuria	O
2	in	O
3	a	O
4	young	O
5	man	O
6	.	O
1	We	O
2	had	O
3	previously	O
4	analyzed	O
5	repair	O
6	rates	O
7	of	O
8	cyclobutane	O
9	pyrimidine	O
10	dimers	O
11	at	O
12	nucleotide	O
13	resolution	O
14	along	O
15	the	O
16	human	O
17	JUN	O
18	gene	O
19	in	O
20	normal	O
21	fibroblasts	O
22	and	O
23	found	O
24	very	O
25	efficient	O
26	repair	O
27	of	O
28	sequences	O
29	near	O
30	the	O
31	transcription	O
32	initiation	O
33	site	O
34	but	O
35	slow	O
36	repair	O
37	along	O
38	the	O
39	promoter	O
40	.	O
1	Then	O
2	we	O
3	correlated	O
4	HRCT	O
5	findings	O
6	with	O
7	the	O
8	clinical	O
9	features	O
10	,	O
11	pulmonary	O
12	functions	O
13	and	O
14	methacholine	O
15	PC20	O
16	(	O
17	PC20M	O
18	)	O
19	and	O
20	studied	O
21	their	O
22	clinical	O
23	significance	O
24	.	O
1	The	O
2	human	O
3	U4	O
4	/	O
5	U6	O
6	snRNP	O
7	contains	O
8	60	O
9	and	O
10	90kD	O
11	proteins	O
12	that	O
13	are	O
14	structurally	O
15	homologous	O
16	to	O
17	the	O
18	yeast	O
19	splicing	O
20	factors	O
21	Prp4p	O
22	and	O
23	Prp3p	O
24	.	O
1	Mutation	O
2	of	O
3	Enh4	O
4	,	O
5	an	O
6	essential	O
7	GT	O
8	-	O
9	IIC	O
10	-	O
11	like	O
12	enhanson	O
13	in	O
14	the	O
15	context	O
16	of	O
17	the	O
18	intact	O
19	enhancer	O
20	,	O
21	abolishes	O
22	silencer	O
23	activity	O
24	,	O
25	and	O
26	multimerized	O
27	GT	O
28	-	O
29	IIC	O
30	enhansons	O
31	mimic	O
32	the	O
33	intact	O
34	CSEn	O
35	enhancer	O
36	/	O
37	silencer	O
38	activities	O
39	in	O
40	BeWo	O
41	and	O
42	GC	O
43	cells	O
44	,	O
45	respectively	O
46	.	O
1	The	O
2	mouse	O
3	extracellular	O
4	signal	O
5	-	O
6	regulated	O
7	kinase	B
8	2	O
9	gene	O
10	.	O
1	MR	O
2	imaging	O
3	of	O
4	traumatic	O
5	head	O
6	injuries	O
7	using	O
8	FLAIR	O
9	technique	O
1	Eight	O
2	induced	O
3	cDNA	O
4	sequences	O
5	were	O
6	identified	O
7	and	O
8	designated	O
9	message	O
10	up	O
11	-	O
12	regulated	O
13	during	O
14	death	O
15	(	O
16	mud	O
17	)-	O
18	1	O
19	-	O
20	8	O
21	.	O
1	Together	O
2	,	O
3	these	O
4	data	O
5	support	O
6	a	O
7	model	O
8	in	O
9	which	O
10	Tax	O
11	anchors	O
12	CBP	O
13	to	O
14	the	O
15	HTLV	O
16	-	O
17	1	O
18	promoter	O
19	,	O
20	with	O
21	strong	O
22	transcriptional	O
23	activation	O
24	resulting	O
25	from	O
26	the	O
27	CBP	O
28	-	O
29	associated	O
30	activities	O
31	of	O
32	nucleosome	O
33	remodeling	O
34	and	O
35	recruitment	O
36	of	O
37	the	O
38	general	O
39	transcription	O
40	machinery	O
41	.	O
1	Consistent	O
2	with	O
3	this	O
4	model	O
5	,	O
6	a	O
7	synthetic	O
8	construct	O
9	containing	O
10	three	O
11	tandem	O
12	copies	O
13	of	O
14	the	O
15	native	O
16	LDL	O
17	receptor	B
18	SREBP	O
19	site	O
20	linked	O
21	to	O
22	a	O
23	single	O
24	Sp1	B
25	site	O
26	was	O
27	also	O
28	significantly	O
29	activated	O
30	in	O
31	a	O
32	buttonhead	O
33	-	O
34	independent	O
35	fashion	O
36	.	O
1	In	O
2	the	O
3	adult	O
4	mouse	O
5	,	O
6	ERR	O
7	alpha	B
8	is	O
9	most	O
10	highly	O
11	expressed	O
12	in	O
13	kidney	O
14	,	O
15	heart	O
16	,	O
17	and	O
18	brown	O
19	adipocytes	O
20	,	O
21	tissues	O
22	which	O
23	preferentially	O
24	metabolize	O
25	fatty	O
26	acids	O
27	.	O
1	Examination	O
2	of	O
3	the	O
4	MMP	O
5	-	O
6	2	O
7	RE1	O
8	sequence	O
9	revealed	O
10	an	O
11	incomplete	O
12	Y	O
13	-	O
14	box	O
15	sequence	O
16	(	O
17	CTGCTGGGCAAG	O
18	),	O
19	which	O
20	specifically	O
21	interacted	O
22	with	O
23	recombinant	O
24	YB	O
25	-	O
26	1	O
27	on	O
28	DMS	O
29	protection	O
30	footprinting	O
31	analysis	O
32	.	O
1	CONCLUSION	O
2	:	O
3	Patients	O
4	wit	O
5	clinically	O
6	palpable	O
7	neck	O
8	disease	O
9	(	O
10	N1	O
11	-	O
12	3	O
13	),	O
14	histological	O
15	evidence	O
16	of	O
17	metastatic	O
18	nodal	O
19	disease	O
20	,	O
21	extracapsular	O
22	spread	O
23	,	O
24	and	O
25	three	O
26	or	O
27	more	O
28	positive	O
29	lymph	O
30	nodes	O
31	are	O
32	at	O
33	greater	O
34	risk	O
35	of	O
36	developing	O
37	failure	O
38	at	O
39	distant	O
40	sites	O
41	.	O
1	The	O
2	combination	O
3	of	O
4	hydralazine	O
5	hydrochloride	O
6	and	O
7	isosorbide	O
8	dinitrate	O
9	also	O
10	improves	O
11	survival	O
12	,	O
13	but	O
14	direct	O
15	comparison	O
16	of	O
17	both	O
18	regimens	O
19	provided	O
20	evidence	O
21	for	O
22	a	O
23	less	O
24	favourable	O
25	effect	O
26	than	O
27	that	O
28	of	O
29	the	O
30	ACE	O
31	inhibitors	O
32	.	O
1	To	O
2	address	O
3	mechanisms	O
4	that	O
5	define	O
6	interactions	O
7	of	O
8	Site	O
9	II	O
10	regulatory	O
11	factors	O
12	with	O
13	this	O
14	cell	O
15	cycle	O
16	control	O
17	element	O
18	,	O
19	we	O
20	have	O
21	investigated	O
22	these	O
23	determinants	O
24	of	O
25	transcriptional	O
26	regulation	O
27	at	O
28	the	O
29	G1	O
30	/	O
31	S	O
32	phase	O
33	transition	O
34	in	O
35	FDC	O
36	-	O
37	P1	O
38	hematopoietic	O
39	progenitor	O
40	cells	O
41	.	O
1	There	O
2	were	O
3	differences	O
4	between	O
5	males	O
6	(	O
7	p	O
8	<	O
9	0	O
10	.	O
11	05	O
12	)	O
13	for	O
14	most	O
15	of	O
16	the	O
17	characteristics	O
18	studied	O
19	.	O
1	Their	O
2	circadian	O
3	responses	O
4	to	O
5	both	O
6	photic	O
7	and	O
8	non	O
9	-	O
10	photic	O
11	cues	O
12	were	O
13	then	O
14	tested	O
15	.	O
1	Neither	O
2	mutant	O
3	exhibited	O
4	derepression	O
5	of	O
6	the	O
7	silent	O
8	mating	O
9	type	O
10	loci	O
11	.	O
1	The	O
2	cycle	O
3	length	O
4	of	O
5	induced	O
6	VT	O
7	(	O
8	n	O
9	=	O
10	10	O
11	VTs	O
12	)	O
13	was	O
14	380	O
15	+/-	O
16	41	O
17	msec	O
18	.	O
1	A	O
2	specific	O
3	distal	O
4	promoter	O
5	controls	O
6	gamma	B
7	-	O
8	glutamyl	O
9	transpeptidase	O
10	gene	O
11	expression	O
12	in	O
13	undifferentiated	O
14	rat	O
15	transformed	O
16	liver	O
17	cells	O
18	.	O
1	These	O
2	repressor	O
3	sites	O
4	are	O
5	pyrimidine	O
6	rich	O
7	and	O
8	bind	O
9	avidly	O
10	to	O
11	the	O
12	polypyrimidine	O
13	tract	O
14	binding	O
15	protein	O
16	(	O
17	PTB	O
18	)	O
19	in	O
20	HeLa	O
21	nuclear	O
22	extracts	O
23	as	O
24	determined	O
25	by	O
26	UV	O
27	crosslinking	O
28	/	O
29	competition	O
30	assays	O
31	.	O
1	Within	O
2	a	O
3	135	O
4	-	O
5	bp	O
6	core	O
7	homology	O
8	region	O
9	,	O
10	the	O
11	human	O
12	HS12	O
13	enhancers	O
14	are	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	the	O
21	murine	O
22	homolog	O
23	and	O
24	include	O
25	several	O
26	motifs	O
27	previously	O
28	demonstrated	O
29	to	O
30	be	O
31	important	O
32	for	O
33	function	O
34	of	O
35	the	O
36	murine	O
37	enhancer	O
38	;	O
39	additional	O
40	segments	O
41	of	O
42	high	O
43	sequence	O
44	conservation	O
45	suggest	O
46	the	O
47	possibility	O
48	of	O
49	previously	O
50	unrecognized	O
51	functional	O
52	motifs	O
53	.	O
1	In	O
2	contrast	O
3	to	O
4	the	O
5	wild	O
6	-	O
7	type	O
8	protein	O
9	,	O
10	expression	O
11	of	O
12	p45	O
13	NF	B
14	-	O
15	E2	O
16	lacking	O
17	this	O
18	activation	O
19	domain	O
20	in	O
21	an	O
22	NF	B
23	-	O
24	E2	O
25	null	O
26	cell	O
27	line	O
28	fails	O
29	to	O
30	support	O
31	enhancer	O
32	-	O
33	dependent	O
34	transcription	O
35	in	O
36	transient	O
37	assays	O
38	.	O
1	These	O
2	findings	O
3	suggest	O
4	one	O
5	potential	O
6	mechanism	O
7	for	O
8	direct	O
9	recruitment	O
10	of	O
11	distal	O
12	regulatory	O
13	regions	O
14	of	O
15	the	O
16	globin	O
17	loci	O
18	to	O
19	the	O
20	individual	O
21	promoters	O
22	.	O
1	When	O
2	the	O
3	downstream	O
4	operator	O
5	was	O
6	altered	O
7	,	O
8	there	O
9	was	O
10	a	O
11	fourfold	O
12	reduction	O
13	in	O
14	reporter	O
15	enzyme	O
16	levels	O
17	.	O
1	In	O
2	support	O
3	of	O
4	this	O
5	interpretation	O
6	we	O
7	demonstrate	O
8	that	O
9	MQ9b	O
10	binds	O
11	strongly	O
12	5	O
13	of	O
14	17	O
15	motif	O
16	-	O
17	positive	O
18	,	O
19	pathogen	O
20	-	O
21	derived	O
22	synthetic	O
23	peptides	O
24	.	O
1	Gaucher	O
2	'	O
3	s	O
4	disease	O
5	is	O
6	a	O
7	rare	O
8	metabolic	O
9	disorder	O
10	characterized	O
11	by	O
12	the	O
13	lack	O
14	of	O
15	beta	B
16	-	O
17	glucocerebrosidase	O
18	enzyme	O
19	.	O
1	Overexpression	O
2	of	O
3	BAG	O
4	-	O
5	1	O
6	also	O
7	protected	O
8	certain	O
9	cell	O
10	lines	O
11	from	O
12	heat	O
13	shock	O
14	-	O
15	induced	O
16	cell	O
17	death	O
18	.	O
1	Evidence	O
2	for	O
3	such	O
4	peak	O
5	shifts	O
6	has	O
7	been	O
8	found	O
9	in	O
10	the	O
11	responses	O
12	of	O
13	auditory	O
14	nerve	O
15	fibers	O
16	,	O
17	cochlear	O
18	microphonics	O
19	,	O
20	and	O
21	the	O
22	responses	O
23	of	O
24	outer	O
25	hair	O
26	cells	O
27	and	O
28	supporting	O
29	cells	O
30	in	O
31	the	O
32	cochlea	O
33	,	O
34	as	O
35	well	O
36	as	O
37	in	O
38	basilar	O
39	membrane	O
40	vibration	O
41	measurements	O
42	,	O
43	and	O
44	indirectly	O
45	,	O
46	in	O
47	psychophysical	O
48	data	O
49	.	O
1	However	O
2	,	O
3	we	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	a	O
9	p4	O
10	molecule	O
11	.	O
1	(	O
2	iv	O
3	)	O
4	The	O
5	accumulation	O
6	of	O
7	cyclin	B
8	D3	O
9	protein	O
10	in	O
11	Vero	O
12	cells	O
13	infected	O
14	with	O
15	an	O
16	alpha0	O
17	deletion	O
18	mutant	O
19	was	O
20	reduced	O
21	relative	O
22	to	O
23	that	O
24	of	O
25	cells	O
26	infected	O
27	with	O
28	wild	O
29	-	O
30	type	O
31	virus	O
32	or	O
33	a	O
34	recombinant	O
35	virus	O
36	in	O
37	which	O
38	the	O
39	deleted	O
40	alpha0	O
41	sequences	O
42	were	O
43	restored	O
44	.	O
1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	Src	O
8	homology	O
9	-	O
10	2	O
11	(	O
12	SH2	O
13	)	O
14	domain	O
15	-	O
16	containing	O
17	protein	O
18	-	O
19	tyrosine	O
20	phosphatase	B
21	,	O
22	SHP	O
23	-	O
24	2	O
25	,	O
26	associates	O
27	with	O
28	the	O
29	cytoplasmic	O
30	domain	O
31	of	O
32	PECAM	O
33	-	O
34	1	O
35	as	O
36	it	O
37	becomes	O
38	tyrosine	O
39	-	O
40	phosphorylated	O
41	during	O
42	platelet	O
43	aggregation	O
44	:	O
45	a	O
46	process	O
47	that	O
48	can	O
49	be	O
50	mimicked	O
51	in	O
52	part	O
53	by	O
54	small	O
55	synthetic	O
56	phosphopeptides	O
57	corresponding	O
58	to	O
59	the	O
60	cytoplasmic	O
61	domain	O
62	of	O
63	PECAM	O
64	-	O
65	1	O
66	encompassing	O
67	tyrosine	O
68	residues	O
69	Tyr	O
70	-	O
71	663	O
72	or	O
73	Tyr	O
74	-	O
75	686	O
76	.	O
1	This	O
2	family	O
3	of	O
4	proteins	O
5	binds	O
6	GC	O
7	-	O
8	rich	O
9	motifs	O
10	widely	O
11	distributed	O
12	in	O
13	gene	O
14	promoters	O
15	,	O
16	resulting	O
17	in	O
18	distinct	O
19	activation	O
20	or	O
21	repression	O
22	of	O
23	transcriptional	O
24	activities	O
25	.	O
1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	gene	O
9	has	O
10	significant	O
11	homology	O
12	to	O
13	the	O
14	interferon	O
15	regulatory	O
16	factors	O
17	(	O
18	IRFs	O
19	).	O
1	However	O
2	,	O
3	Cbf5p	O
4	was	O
5	found	O
6	to	O
7	be	O
8	nucleolar	O
9	and	O
10	is	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	rat	O
16	nucleolar	O
17	protein	O
18	NAP57	O
19	,	O
20	which	O
21	coimmunoprecipitates	O
22	with	O
23	Nopp140	O
24	and	O
25	which	O
26	is	O
27	postulated	O
28	to	O
29	be	O
30	involved	O
31	in	O
32	nucleolar	O
33	-	O
34	cytoplasmic	O
35	shuttling	O
36	(	O
37	U	O
38	.	O
1	The	O
2	histidine	O
3	-	O
4	tagged	O
5	gene	O
6	,	O
7	rpoCHIS	O
8	,	O
9	was	O
10	used	O
11	to	O
12	replace	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	allele	O
18	in	O
19	the	O
20	chromosome	O
21	of	O
22	S	O
23	.	O
24	coelicolor	O
25	and	O
26	S	O
27	.	O
28	lividans	O
29	.	O
1	Lack	O
2	of	O
3	controlled	O
4	prospective	O
5	studies	O
6	of	O
7	sleep	O
8	electroencephalograms	O
9	(	O
10	EEG	O
11	),	O
12	and	O
13	the	O
14	use	O
15	of	O
16	medication	O
17	,	O
18	in	O
19	children	O
20	with	O
21	developmental	O
22	dysphasia	O
23	,	O
24	may	O
25	deny	O
26	appropriate	O
27	treatment	O
28	strategies	O
29	to	O
30	children	O
31	with	O
32	severe	O
33	developmental	O
34	speech	O
35	and	O
36	language	O
37	disorders	O
38	.	O
1	Ovaries	O
2	of	O
3	10	O
4	animals	O
5	per	O
6	group	O
7	from	O
8	16	O
9	studies	O
10	in	O
11	CD	O
12	-	O
13	1	O
14	mice	O
15	and	O
16	1	O
17	study	O
18	each	O
19	in	O
20	C3H	O
21	and	O
22	C57BL	O
23	/	O
24	6	O
25	mice	O
26	were	O
27	sectioned	O
28	serially	O
29	at	O
30	6	O
31	microm	O
32	.	O
1	This	O
2	is	O
3	the	O
4	first	O
5	study	O
6	in	O
7	which	O
8	mutation	O
9	screening	O
10	has	O
11	been	O
12	performed	O
13	for	O
14	both	O
15	the	O
16	EXT1	O
17	and	O
18	EXT2	O
19	genes	O
20	prior	O
21	to	O
22	any	O
23	linkage	O
24	analysis	O
25	.	O
1	The	O
2	regurgitation	O
3	of	O
4	large	O
5	vitreous	O
6	injections	O
7	.	O
1	Positron	O
2	emission	O
3	tomography	O
4	radioligands	O
5	for	O
6	dopamine	O
7	transporters	O
8	and	O
9	studies	O
10	in	O
11	human	O
12	and	O
13	nonhuman	O
14	primates	O
15	.	O
1	Attenuation	O
2	from	O
3	the	O
4	vit	O
5	A2	O
6	consensus	O
7	ERE	O
8	is	O
9	not	O
10	necessarily	O
11	dependent	O
12	on	O
13	DNA	O
14	binding	O
15	as	O
16	the	O
17	TR	O
18	alpha	B
19	DNA	O
20	binding	O
21	mutant	O
22	was	O
23	still	O
24	able	O
25	to	O
26	inhibit	O
27	E	O
28	-	O
29	dependent	O
30	transactivation	O
31	.	O
1	Hprp3p	O
2	is	O
3	a	O
4	77	O
5	kDa	O
6	protein	O
7	,	O
8	which	O
9	is	O
10	homologous	O
11	to	O
12	the	O
13	Saccharomyces	O
14	cerevisiae	O
15	splicing	O
16	factor	O
17	Prp3p	O
18	.	O
1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	expression	O
7	of	O
8	a	O
9	tumour	O
10	derived	O
11	brk	O
12	cDNA	O
13	in	O
14	mouse	O
15	embryonic	O
16	fibroblasts	O
17	and	O
18	human	O
19	mammary	O
20	epithelial	O
21	cells	O
22	supports	O
23	anchorage	O
24	independent	O
25	growth	O
26	,	O
27	and	O
28	in	O
29	the	O
30	latter	O
31	potentiates	O
32	the	O
33	mitogenic	O
34	response	O
35	to	O
36	epidermal	O
37	growth	O
38	factor	O
39	.	O
1	One	O
2	skull	O
3	does	O
4	not	O
5	a	O
6	species	O
7	make	O
8	.	O
1	Null	O
2	mutations	O
3	in	O
4	daf	O
5	-	O
6	3	O
7	suppress	O
8	mutations	O
9	in	O
10	genes	O
11	encoding	O
12	this	O
13	TGF	O
14	-	O
15	beta	B
16	signal	O
17	,	O
18	its	O
19	receptors	O
20	,	O
21	and	O
22	associated	O
23	Smad	O
24	signal	O
25	transduction	O
26	proteins	O
27	.	O
28	daf	O
29	-	O
30	3	O
31	encodes	O
32	a	O
33	Smad	O
34	protein	O
35	that	O
36	is	O
37	most	O
38	closely	O
39	related	O
40	to	O
41	mammalian	O
42	DPC4	O
43	,	O
44	and	O
45	is	O
46	expressed	O
47	throughout	O
48	development	O
49	in	O
50	many	O
51	of	O
52	the	O
53	tissues	O
54	that	O
55	are	O
56	remodeled	O
57	during	O
58	dauer	O
59	development	O
60	.	O
1	Our	O
2	results	O
3	favor	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	Drosophila	O
9	EGF	O
10	receptor	B
11	DER	O
12	/	O
13	Egfr	O
14	expressed	O
15	by	O
16	the	O
17	EMA	O
18	cells	O
19	functions	O
20	as	O
21	a	O
22	receptor	B
23	for	O
24	Vein	O
25	.	O
1	We	O
2	also	O
3	identified	O
4	Sp1	B
5	,	O
6	Sp3	O
7	,	O
8	and	O
9	NGFI	O
10	-	O
11	A	O
12	/	O
13	Egr	O
14	-	O
15	1	O
16	as	O
17	the	O
18	primary	O
19	nuclear	O
20	transcription	O
21	factors	O
22	binding	O
23	to	O
24	TRE1	O
25	which	O
26	mediate	O
27	Tax	O
28	responsiveness	O
29	.	O
1	Interestingly	O
2	,	O
3	segment	O
4	nesting	O
5	differentially	O
6	increases	O
7	the	O
8	copy	O
9	number	O
10	of	O
11	genes	O
12	encoded	O
13	by	O
14	segment	O
15	W	O
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	unusual	O
21	genomic	O
22	organization	O
23	of	O
24	PDVs	O
25	may	O
26	be	O
27	directly	O
28	linked	O
29	to	O
30	the	O
31	unique	O
32	functions	O
33	of	O
34	this	O
35	virus	O
36	in	O
37	its	O
38	obligate	O
39	mutualistic	O
40	association	O
41	with	O
42	parasitic	O
43	wasps	O
44	.	O
1	Furthermore	O
2	,	O
3	deletion	O
4	and	O
5	mutation	O
6	analyses	O
7	of	O
8	the	O
9	VCAM	O
10	-	O
11	1	O
12	promoter	O
13	performed	O
14	with	O
15	chloramphenicol	O
16	acetyltransferase	O
17	constructs	O
18	revealed	O
19	that	O
20	Tax	O
21	was	O
22	trans	O
23	activating	O
24	the	O
25	VCAM	O
26	-	O
27	1	O
28	promoter	O
29	via	O
30	two	O
31	NF	B
32	-	O
33	kappaB	O
34	sites	O
35	present	O
36	at	O
37	bp	O
38	-	O
39	72	O
40	and	O
41	-	O
42	57	O
43	in	O
44	the	O
45	VCAM	O
46	-	O
47	1	O
48	gene	O
49	promoter	O
50	,	O
51	with	O
52	both	O
53	of	O
54	them	O
55	being	O
56	required	O
57	for	O
58	the	O
59	Tax	O
60	-	O
61	induced	O
62	expression	O
63	of	O
64	this	O
65	adhesion	O
66	molecule	O
67	.	O
1	Alanine	O
2	substitution	O
3	mutations	O
4	in	O
5	the	O
6	Zta	O
7	activation	O
8	domain	O
9	which	O
10	eliminate	O
11	the	O
12	ability	O
13	of	O
14	Zta	O
15	to	O
16	stimulate	O
17	the	O
18	D	O
19	-	O
20	A	O
21	complex	O
22	were	O
23	examined	O
24	.	O
1	In	O
2	the	O
3	predicted	O
4	transmembrane	O
5	domain	O
6	,	O
7	Casr	O
8	-	O
9	rs2	O
10	and	O
11	Casr	O
12	-	O
13	rs3	O
14	are	O
15	95	O
16	%	O
17	identical	O
18	to	O
19	Casr	O
20	-	O
21	rs1	O
22	.	O
1	F	O
2	-	O
3	box	O
4	proteins	O
5	are	O
6	receptors	O
7	that	O
8	recruit	O
9	phosphorylated	O
10	substrates	O
11	to	O
12	the	O
13	SCF	O
14	ubiquitin	O
15	-	O
16	ligase	O
17	complex	O
18	.	O
1	In	O
2	the	O
3	context	O
4	of	O
5	liver	O
6	allograft	O
7	shortage	O
8	,	O
9	our	O
10	results	O
11	suggest	O
12	that	O
13	an	O
14	ELT	O
15	should	O
16	not	O
17	be	O
18	performed	O
19	in	O
20	patients	O
21	with	O
22	cardiac	O
23	failure	O
24	,	O
25	more	O
26	than	O
27	two	O
28	OSF	O
29	,	O
30	or	O
31	an	O
32	APACHE	O
33	II	O
34	score	O
35	higher	O
36	than	O
37	30	O
38	.	O
1	By	O
2	far	O
3	-	O
4	Western	O
5	analysis	O
6	and	O
7	coimmunoprecipitation	O
8	studies	O
9	,	O
10	we	O
11	demonstrate	O
12	that	O
13	ZNF74	O
14	interacts	O
15	,	O
16	via	O
17	its	O
18	zinc	O
19	finger	O
20	domain	O
21	,	O
22	with	O
23	the	O
24	hyperphosphorylated	O
25	largest	O
26	subunit	O
27	of	O
28	RNA	O
29	polymerase	B
30	II	O
31	(	O
32	pol	O
33	IIo	O
34	)	O
35	but	O
36	not	O
37	with	O
38	the	O
39	hypophosphorylated	O
40	form	O
41	.	O
1	Induction	O
2	of	O
3	AtP5CS1	O
4	mRNA	O
5	accumulation	O
6	in	O
7	salt	O
8	-	O
9	treated	O
10	seedlings	O
11	involves	O
12	an	O
13	immediate	O
14	early	O
15	transcriptional	O
16	response	O
17	regulated	O
18	by	O
19	ABA	O
20	signalling	O
21	that	O
22	is	O
23	not	O
24	inhibited	O
25	by	O
26	cycloheximide	O
27	,	O
28	but	O
29	abolished	O
30	by	O
31	the	O
32	deficiency	O
33	of	O
34	ABA	O
35	biosynthesis	O
36	in	O
37	the	O
38	aba1	O
39	Arabidopsis	O
40	mutant	O
41	.	O
1	It	O
2	thus	O
3	appears	O
4	that	O
5	MAPK	O
6	functions	O
7	in	O
8	meiotic	O
9	maturation	O
10	by	O
11	preventing	O
12	unfertilized	O
13	eggs	O
14	from	O
15	proceeding	O
16	into	O
17	parthenogenetic	O
18	development	O
19	.	O
1	A	O
2	positive	O
3	correlation	O
4	between	O
5	serum	O
6	myoglobin	O
7	and	O
8	CA	O
9	III	O
10	concentrations	O
11	(	O
12	rs	O
13	=	O
14	0	O
15	.	O
16	933	O
17	,	O
18	P	O
19	<	O
20	0	O
21	.	O
22	001	O
23	)	O
24	was	O
25	observed	O
26	in	O
27	hemodialyzed	O
28	patients	O
29	with	O
30	chronic	O
31	renal	O
32	failure	O
33	.	O
1	The	O
2	full	O
3	length	O
4	cDNA	O
5	sequence	O
6	of	O
7	a	O
8	Type	O
9	I	O
10	transforming	O
11	growth	O
12	factor	O
13	-	O
14	beta	B
15	(	O
16	TGF	O
17	-	O
18	beta	B
19	)	O
20	receptor	B
21	has	O
22	been	O
23	isolated	O
24	from	O
25	the	O
26	filarial	O
27	parasitic	O
28	nematode	O
29	Brugia	O
30	pahangi	O
31	.	O
1	Codon	O
2	optimization	O
3	for	O
4	high	O
5	-	O
6	level	O
7	expression	O
8	of	O
9	human	O
10	erythropoietin	O
11	(	O
12	EPO	O
13	)	O
14	in	O
15	mammalian	O
16	cells	O
17	.	O
1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	Rat7p	O
9	/	O
10	Nup159p	O
11	is	O
12	anchored	O
13	within	O
14	the	O
15	NPC	O
16	through	O
17	its	O
18	coiled	O
19	-	O
20	coil	O
21	region	O
22	and	O
23	adjacent	O
24	sequences	O
25	.	O
1	The	O
2	Fis	O
3	protein	O
4	regulates	O
5	site	O
6	-	O
7	specific	O
8	DNA	O
9	inversion	O
10	catalyzed	O
11	by	O
12	a	O
13	family	O
14	of	O
15	DNA	O
16	invertases	O
17	when	O
18	bound	O
19	to	O
20	a	O
21	cis	O
22	-	O
23	acting	O
24	recombinational	O
25	enhancer	O
26	.	O
1	The	O
2	cell	O
3	cycle	O
4	-	O
5	regulated	O
6	transcription	O
7	factor	O
8	E2F	O
9	is	O
10	also	O
11	known	O
12	to	O
13	bend	O
14	DNA	O
15	upon	O
16	binding	O
17	.	O
1	The	O
2	presence	O
3	of	O
4	an	O
5	additional	O
6	sequence	O
7	of	O
8	nucleotides	O
9	145	O
10	-	O
11	165	O
12	from	O
13	the	O
14	3	O
15	'	O
16	end	O
17	of	O
18	RNA3	O
19	enhanced	O
20	template	O
21	recognition	O
22	by	O
23	RdRp	O
24	in	O
25	vitro	O
26	and	O
27	accumulation	O
28	of	O
29	RNA3	O
30	in	O
31	vivo	O
32	to	O
33	wild	O
34	-	O
35	type	O
36	levels	O
37	.	O
1	Restriction	O
2	enzyme	O
3	mapping	O
4	,	O
5	subcloning	O
6	,	O
7	and	O
8	DNA	O
9	sequencing	O
10	analysis	O
11	of	O
12	recombinant	O
13	phage	O
14	lambda	O
15	and	O
16	P1	O
17	clones	O
18	revealed	O
19	that	O
20	exons	O
21	encoding	O
22	the	O
23	1	O
24	.	O
25	9	O
26	-	O
27	kb	O
28	mouse	O
29	TS	O
30	mRNA	O
31	are	O
32	dispersed	O
33	over	O
34	>	O
35	150	O
36	kb	O
37	genomic	O
38	DNA	O
39	.	O
1	Transfection	O
2	analyses	O
3	indicated	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	Tbxas1	O
9	is	O
10	controlled	O
11	by	O
12	a	O
13	short	O
14	(	O
15	70	O
16	-	O
17	bp	O
18	)	O
19	positive	O
20	regulatory	O
21	sequence	O
22	and	O
23	several	O
24	upstream	O
25	repressive	O
26	elements	O
27	.	O
1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	suggest	O
7	that	O
8	NF	B
9	-	O
10	kappaB	O
11	activity	O
12	may	O
13	be	O
14	regulated	O
15	by	O
16	its	O
17	interaction	O
18	with	O
19	the	O
20	cell	O
21	cycle	O
22	regulatory	O
23	protein	O
24	,	O
25	E2F	O
26	-	O
27	1	O
28	.	O
1	The	O
2	pen	O
3	can	O
4	heal	O
5	.	O
1	Thus	O
2	,	O
3	the	O
4	synergistic	O
5	effects	O
6	of	O
7	HNF	O
8	-	O
9	1beta	O
10	and	O
11	the	O
12	GR	O
13	on	O
14	dexamethasone	O
15	-	O
16	stimulated	O
17	promoter	O
18	activity	O
19	require	O
20	that	O
21	they	O
22	are	O
23	bound	O
24	to	O
25	the	O
26	HNF	O
27	-	O
28	1	O
29	site	O
30	and	O
31	the	O
32	GRE	O
33	,	O
34	respectively	O
35	,	O
36	and	O
37	may	O
38	involve	O
39	protein	O
40	-	O
41	protein	O
42	interactions	O
43	between	O
44	the	O
45	transcription	O
46	factors	O
47	,	O
48	or	O
49	between	O
50	them	O
51	and	O
52	the	O
53	basal	O
54	transcription	O
55	machinery	O
56	or	O
57	a	O
58	steroid	O
59	receptor	B
60	coactivator	O
61	.	O
1	Electromobility	O
2	shift	O
3	and	O
4	cotransfection	O
5	assays	O
6	demonstrated	O
7	that	O
8	HNF1alpha	O
9	,	O
10	but	O
11	not	O
12	HNF4	O
13	,	O
14	bound	O
15	to	O
16	its	O
17	cognate	O
18	site	O
19	and	O
20	transactivated	O
21	G6Pase	B
22	gene	O
23	expression	O
24	.	O
1	Both	O
2	inserts	O
3	are	O
4	larger	O
5	than	O
6	their	O
7	homologues	O
8	in	O
9	eIF	O
10	-	O
11	2alpha	O
12	kinases	B
13	.	O
1	Polysome	O
2	analyses	O
3	in	O
4	a	O
5	temperature	O
6	-	O
7	sensitive	O
8	fal1	O
9	-	O
10	1	O
11	mutant	O
12	and	O
13	a	O
14	Fal1p	O
15	-	O
16	depleted	O
17	strain	O
18	reveal	O
19	a	O
20	decrease	O
21	in	O
22	the	O
23	number	O
24	of	O
25	40S	O
26	ribosomal	O
27	subunits	O
28	.	O
1	Identification	O
2	of	O
3	dynein	O
4	heavy	O
5	chain	O
6	genes	O
7	expressed	O
8	in	O
9	human	O
10	and	O
11	mouse	O
12	testis	O
13	:	O
14	chromosomal	O
15	localization	O
16	of	O
17	an	O
18	axonemal	O
19	dynein	O
20	gene	O
21	.	O
1	Bitter	O
2	cassava	O
3	contains	O
4	cyanogenic	O
5	glycosides	O
6	;	O
7	processing	O
8	breaks	O
9	them	O
10	down	O
11	to	O
12	acetone	O
13	cyanohydrin	O
14	and	O
15	hydrogen	O
16	cyanide	O
17	.	O
1	Two	O
2	sterol	O
3	regulatory	O
4	element	O
5	-	O
6	like	O
7	sequences	O
8	mediate	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	caveolin	O
14	gene	O
15	transcription	O
16	in	O
17	response	O
18	to	O
19	low	O
20	density	O
21	lipoprotein	O
22	free	O
23	cholesterol	O
24	.	O
1	Direct	O
2	proof	O
3	that	O
4	the	O
5	heightened	O
6	renal	O
7	cellular	O
8	apoptosis	O
9	in	O
10	PKD	O
11	is	O
12	not	O
13	occurring	O
14	through	O
15	p53	B
16	was	O
17	obtained	O
18	by	O
19	successive	O
20	matings	O
21	between	O
22	SBM	O
23	and	O
24	p53	B
25	(-/-)	O
26	mice	O
27	.	O
1	Accumulated	O
2	evidence	O
3	indicates	O
4	that	O
5	,	O
6	upon	O
7	stimulation	O
8	with	O
9	interferon	O
10	-	O
11	gamma	B
12	(	O
13	IFN	O
14	-	O
15	gamma	B
16	),	O
17	three	O
18	beta	B
19	-	O
20	type	O
21	subunits	O
22	,	O
23	designated	O
24	LMP2	O
25	,	O
26	LMP7	O
27	,	O
28	and	O
29	PSMB10	O
30	,	O
31	are	O
32	incorporated	O
33	into	O
34	the	O
35	20S	O
36	proteasome	O
37	by	O
38	displacing	O
39	the	O
40	housekeeping	O
41	beta	B
42	-	O
43	type	O
44	subunits	O
45	designated	O
46	PSMB6	O
47	,	O
48	PSMB5	O
49	,	O
50	and	O
51	PSMB7	O
52	,	O
53	respectively	O
54	.	O
1	Inhibition	O
2	appears	O
3	to	O
4	result	O
5	from	O
6	titration	O
7	of	O
8	general	O
9	transcription	O
10	factors	O
11	because	O
12	MDM2	O
13	overexpression	O
14	inhibits	O
15	c	B
16	-	O
17	fos	O
18	as	O
19	well	O
20	as	O
21	other	O
22	promoters	O
23	in	O
24	vivo	O
25	and	O
26	basal	O
27	transcription	O
28	in	O
29	vitro	O
30	.	O
1	In	O
2	a	O
3	similar	O
4	fashion	O
5	to	O
6	adipose	O
7	stromal	O
8	cells	O
9	,	O
10	serum	O
11	potentiated	O
12	the	O
13	response	O
14	to	O
15	dexamethasone	O
16	but	O
17	had	O
18	no	O
19	effect	O
20	on	O
21	phorbol	O
22	ester	O
23	-	O
24	stimulated	O
25	activity	O
26	.	O
1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	find	O
9	out	O
10	whether	O
11	it	O
12	was	O
13	possible	O
14	to	O
15	detect	O
16	normal	O
17	lymph	O
18	nodes	O
19	by	O
20	high	O
21	-	O
22	resolution	O
23	mediastinal	O
24	US	O
25	.	O
1	CKbeta4GT	O
2	-	O
3	II	O
4	is	O
5	predicted	O
6	to	O
7	encode	O
8	a	O
9	type	O
10	II	O
11	transmembrane	O
12	glycoprotein	O
13	of	O
14	43	O
15	kDa	O
16	with	O
17	five	O
18	potential	O
19	N	O
20	-	O
21	linked	O
22	glycosylation	O
23	sites	O
24	.	O
1	We	O
2	now	O
3	demonstrate	O
4	that	O
5	CCAAT	O
6	/	O
7	enhancer	O
8	-	O
9	binding	O
10	protein	O
11	(	O
12	C	O
13	/	O
14	EBP	O
15	)	O
16	delta	B
17	is	O
18	a	O
19	major	O
20	component	O
21	of	O
22	a	O
23	PGE2	O
24	-	O
25	stimulated	O
26	DNA	O
27	-	O
28	protein	O
29	complex	O
30	involving	O
31	HS3D	O
32	and	O
33	find	O
34	that	O
35	C	O
36	/	O
37	EBPdelta	O
38	transactivates	O
39	IGF	O
40	-	O
41	I	O
42	promoter	O
43	1	O
44	through	O
45	this	O
46	site	O
47	.	O
1	Southern	O
2	blot	O
3	analysis	O
4	of	O
5	endonuclease	O
6	-	O
7	digested	O
8	genomic	O
9	DNA	O
10	from	O
11	primary	O
12	chick	O
13	embryo	O
14	fibroblasts	O
15	(	O
16	CEF	O
17	)	O
18	suggested	O
19	that	O
20	MEK2	O
21	is	O
22	a	O
23	single	O
24	-	O
25	copy	O
26	gene	O
27	in	O
28	this	O
29	vertebrate	O
30	species	O
31	.	O
1	Similarities	O
2	between	O
3	the	O
4	hIGFBP	O
5	-	O
6	1	O
7	and	O
8	phosphoenolpyruvate	O
9	kinase	B
10	(	O
11	PEPCK	O
12	)	O
13	promoters	O
14	,	O
15	including	O
16	regions	O
17	conferring	O
18	insulin	B
19	,	O
20	glucocorticoid	O
21	,	O
22	and	O
23	cyclic	O
24	adenosine	O
25	-	O
26	monophosphate	O
27	responses	O
28	,	O
29	are	O
30	consistent	O
31	with	O
32	our	O
33	previous	O
34	hypothesis	O
35	that	O
36	IGFBP	O
37	-	O
38	1	O
39	is	O
40	involved	O
41	in	O
42	regulation	O
43	of	O
44	glucose	O
45	metabolism	O
46	.	O
1	Large	O
2	genomic	O
3	constructs	O
4	integrate	O
5	at	O
6	the	O
7	endogenous	O
8	locus	O
9	by	O
10	homologous	O
11	recombination	O
12	,	O
13	but	O
14	cDNA	O
15	-	O
16	derived	O
17	sequences	O
18	lacking	O
19	long	O
20	stretches	O
21	of	O
22	contiguous	O
23	genomic	O
24	DNA	O
25	(	O
26	due	O
27	to	O
28	intron	O
29	excision	O
30	)	O
31	typically	O
32	integrate	O
33	into	O
34	chromosomal	O
35	DNA	O
36	by	O
37	nonhomologous	O
38	recombination	O
39	.	O
1	Moreover	O
2	,	O
3	moderate	O
4	overexpression	O
5	of	O
6	Chk1	O
7	suppresses	O
8	the	O
9	phenotypes	O
10	of	O
11	cut5	O
12	and	O
13	crb2	O
14	mutants	O
15	.	O
1	Bilateral	O
2	basal	O
3	arteries	O
4	were	O
5	measured	O
6	by	O
7	the	O
8	transtemporal	O
9	approach	O
10	with	O
11	a	O
12	2	O
13	MHz	O
14	pulsed	O
15	Doppler	O
16	instrument	O
17	(	O
18	TC	O
19	-	O
20	2	O
21	64B	O
22	EME	O
23	).	O
1	At	O
2	the	O
3	genomic	O
4	level	O
5	,	O
6	the	O
7	sequences	O
8	of	O
9	two	O
10	members	O
11	of	O
12	this	O
13	family	O
14	are	O
15	known	O
16	in	O
17	the	O
18	rat	O
19	Rattus	O
20	norvegicus	O
21	:	O
22	the	O
23	VCSA1	O
24	gene	O
25	,	O
26	encoding	O
27	the	O
28	prohormone	O
29	-	O
30	like	O
31	polypeptide	O
32	SMR1	O
33	,	O
34	and	O
35	the	O
36	VCSB1	O
37	gene	O
38	,	O
39	encoding	O
40	a	O
41	salivary	O
42	Pro	O
43	-	O
44	rich	O
45	polypeptide	O
46	.	O
1	Resistance	O
2	training	O
3	shifts	O
4	the	O
5	power	O
6	curve	O
7	in	O
8	a	O
9	positive	O
10	direction	O
11	when	O
12	the	O
13	measurements	O
14	are	O
15	determined	O
16	with	O
17	absolute	O
18	loads	O
19	,	O
20	but	O
21	the	O
22	increased	O
23	power	O
24	may	O
25	not	O
26	be	O
27	transferred	O
28	to	O
29	an	O
30	absolute	O
31	performance	O
32	task	O
33	like	O
34	the	O
35	SSP	O
36	.	O
1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	depletion	O
7	of	O
8	protein	O
9	kinase	B
10	C	O
11	by	O
12	long	O
13	-	O
14	term	O
15	treatment	O
16	of	O
17	B16	O
18	mouse	O
19	melanoma	O
20	cells	O
21	with	O
22	phorbol	O
23	dibutyrate	O
24	(	O
25	PDBu	O
26	)	O
27	prevented	O
28	cell	O
29	density	O
30	-	O
31	dependent	O
32	melanogenesis	O
33	.	O
1	To	O
2	facilitate	O
3	the	O
4	investigation	O
5	of	O
6	parameters	O
7	that	O
8	govern	O
9	selective	O
10	export	O
11	in	O
12	adenovirus	O
13	-	O
14	infected	O
15	cells	O
16	,	O
17	we	O
18	constructed	O
19	a	O
20	marked	O
21	human	O
22	beta	B
23	-	O
24	actin	O
25	minigene	O
26	under	O
27	the	O
28	control	O
29	of	O
30	the	O
31	glucocorticoid	O
32	-	O
33	inducible	O
34	enhancer	O
35	-	O
36	promoter	O
37	of	O
38	mouse	O
39	mammary	O
40	tumor	O
41	virus	O
42	and	O
43	introduced	O
44	it	O
45	into	O
46	the	O
47	left	O
48	end	O
49	of	O
50	the	O
51	adenovirus	O
52	type	O
53	5	O
54	(	O
55	Ad5	O
56	)	O
57	genome	O
58	.	O
1	C	O
2	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	affinities	O
6	of	O
7	CBF2	O
8	for	O
9	binding	O
10	to	O
11	the	O
12	LMP	O
13	-	O
14	1	O
15	,	O
16	LMP	O
17	-	O
18	2	O
19	,	O
20	and	O
21	CD23	O
22	promoters	O
23	were	O
24	also	O
25	measured	O
26	.	O
1	A	O
2	cAMP	O
3	-	O
4	responsive	O
5	element	O
6	-	O
7	like	O
8	(	O
9	CRE	O
10	-	O
11	like	O
12	,	O
13	TGACGTGA	O
14	)	O
15	promoter	O
16	sequence	O
17	and	O
18	a	O
19	protein	O
20	kinase	B
21	A	O
22	signaling	O
23	pathway	O
24	are	O
25	involved	O
26	in	O
27	this	O
28	induction	O
29	,	O
30	and	O
31	activation	O
32	of	O
33	both	O
34	CRE	O
35	binding	O
36	protein	O
37	(	O
38	CREB	O
39	)	O
40	and	O
41	activating	O
42	transcription	O
43	factor	O
44	-	O
45	2	O
46	(	O
47	ATF	O
48	-	O
49	2	O
50	)	O
51	is	O
52	required	O
53	in	O
54	the	O
55	above	O
56	process	O
57	.	O
1	Protease	O
2	activities	O
3	in	O
4	cultures	O
5	of	O
6	the	O
7	streptococcal	O
8	strains	O
9	were	O
10	associated	O
11	with	O
12	species	O
13	of	O
14	different	O
15	molecular	O
16	masses	O
17	ranging	O
18	from	O
19	130	O
20	to	O
21	200	O
22	kDa	O
23	,	O
24	suggesting	O
25	posttranslational	O
26	processing	O
27	possibly	O
28	as	O
29	a	O
30	result	O
31	of	O
32	autoproteolysis	O
33	at	O
34	post	O
35	-	O
36	proline	O
37	peptide	O
38	bonds	O
39	in	O
40	the	O
41	N	O
42	-	O
43	terminal	O
44	parts	O
45	of	O
46	the	O
47	molecules	O
48	.	O
1	The	O
2	cglIM	O
3	gene	O
4	is	O
5	organized	O
6	in	O
7	an	O
8	unusual	O
9	operon	O
10	which	O
11	contains	O
12	,	O
13	in	O
14	addition	O
15	,	O
16	two	O
17	genes	O
18	encoding	O
19	stress	O
20	-	O
21	sensitive	O
22	restriction	O
23	enzymes	O
24	.	O
1	A	O
2	cytosolic	O
3	variant	O
4	of	O
5	the	O
6	protein	O
7	underwent	O
8	efficient	O
9	transphosphorylation	O
10	,	O
11	yet	O
12	failed	O
13	to	O
14	activate	O
15	appreciably	O
16	either	O
17	p70	O
18	(	O
19	S6k	O
20	)	O
21	or	O
22	MAP	O
23	kinase	B
24	following	O
25	treatment	O
26	with	O
27	FK1012	O
28	.	O
1	S	O
2	.,	O
3	and	O
4	Walter	O
5	,	O
6	P	O
7	.	O
1	Perhaps	O
2	in	O
3	addition	O
4	to	O
5	,	O
6	or	O
7	as	O
8	part	O
9	of	O
10	,	O
11	its	O
12	essential	O
13	function	O
14	in	O
15	late	O
16	mitosis	O
17	,	O
18	MOB1	O
19	is	O
20	required	O
21	for	O
22	a	O
23	cell	O
24	cycle	O
25	reset	O
26	function	O
27	necessary	O
28	for	O
29	the	O
30	initiation	O
31	of	O
32	the	O
33	spindle	O
34	pole	O
35	body	O
36	duplication	O
37	.	O
1	Reconstitution	O
2	of	O
3	Raf	O
4	-	O
5	1	O
6	activity	O
7	was	O
8	observed	O
9	only	O
10	with	O
11	kinase	B
12	active	O
13	Jak1	O
14	in	O
15	both	O
16	cell	O
17	lines	O
18	.	O
1	Sip1	O
2	was	O
3	initially	O
4	identified	O
5	by	O
6	virtue	O
7	of	O
8	its	O
9	interaction	O
10	with	O
11	SC35	O
12	,	O
13	a	O
14	splicing	O
15	factor	O
16	of	O
17	the	O
18	SR	O
19	family	O
20	.	O
1	Several	O
2	studies	O
3	have	O
4	characterized	O
5	the	O
6	upstream	O
7	regulatory	O
8	region	O
9	of	O
10	c	B
11	-	O
12	fos	O
13	,	O
14	and	O
15	identified	O
16	cis	O
17	-	O
18	acting	O
19	elements	O
20	termed	O
21	the	O
22	cyclic	O
23	AMP	O
24	(	O
25	cAMP	O
26	)	O
27	response	O
28	elements	O
29	(	O
30	CREs	O
31	)	O
32	that	O
33	are	O
34	critical	O
35	for	O
36	c	B
37	-	O
38	fos	O
39	transcription	O
40	in	O
41	response	O
42	to	O
43	a	O
44	variety	O
45	of	O
46	extracellular	O
47	stimuli	O
48	.	O
1	Interleukin	O
2	-	O
3	6	O
4	(	O
5	IL	B
6	-	O
7	6	O
8	)	O
9	is	O
10	a	O
11	pleiotropic	O
12	cytokine	O
13	,	O
14	which	O
15	is	O
16	involved	O
17	in	O
18	inflammatory	O
19	and	O
20	immune	O
21	responses	O
22	,	O
23	acute	O
24	phase	O
25	reactions	O
26	,	O
27	and	O
28	hematopoiesis	O
29	.	O
1	This	O
2	region	O
3	,	O
4	however	O
5	,	O
6	contains	O
7	a	O
8	CCAATC	O
9	box	O
10	in	O
11	the	O
12	reverse	O
13	complement	O
14	and	O
15	several	O
16	GC	O
17	boxes	O
18	that	O
19	are	O
20	recognition	O
21	sites	O
22	for	O
23	SP1	O
24	.	O
1	51	O
2	.	O
3	9	O
4	%	O
5	(	O
6	P	O
7	=	O
8	0	O
9	.	O
10	0006	O
11	)	O
12	in	O
13	the	O
14	MMF	O
15	versus	O
16	the	O
17	AZA	O
18	groups	O
19	,	O
20	respectively	O
21	.	O
1	The	O
2	observation	O
3	that	O
4	beta	B
5	2m	O
6	with	O
7	covalently	O
8	attached	O
9	peptide	O
10	can	O
11	effectively	O
12	create	O
13	CTL	O
14	target	O
15	structures	O
16	in	O
17	vitro	O
18	offers	O
19	new	O
20	possibilities	O
21	for	O
22	the	O
23	in	O
24	vivo	O
25	induction	O
26	of	O
27	epitope	O
28	-	O
29	specific	O
30	CTL	O
31	responses	O
32	by	O
33	either	O
34	DNA	O
35	immunization	O
36	or	O
37	injection	O
38	of	O
39	the	O
40	purified	O
41	epitope	O
42	-	O
43	linked	O
44	beta	B
45	2m	O
46	.	O
1	In	O
2	the	O
3	tissues	O
4	tested	O
5	,	O
6	except	O
7	brain	O
8	,	O
9	the	O
10	message	O
11	for	O
12	CLIP	O
13	-	O
14	170	O
15	was	O
16	more	O
17	abundant	O
18	than	O
19	that	O
20	for	O
21	Restin	O
22	.	O
1	The	O
2	cloned	O
3	alcR	O
4	gene	O
5	provided	O
6	in	O
7	trans	O
8	restored	O
9	these	O
10	siderophore	O
11	system	O
12	activities	O
13	to	O
14	the	O
15	mutants	O
16	.	O
1	The	O
2	frequency	O
3	of	O
4	SPs	O
5	for	O
6	both	O
7	the	O
8	moderate	O
9	and	O
10	severe	O
11	groups	O
12	was	O
13	significantly	O
14	higher	O
15	than	O
16	that	O
17	in	O
18	patients	O
19	with	O
20	a	O
21	normal	O
22	MMFCV	O
23	(	O
24	p	O
25	<	O
26	.	O
27	01	O
28	);	O
29	of	O
30	154	O
31	arms	O
32	with	O
33	a	O
34	normal	O
35	MMFCV	O
36	,	O
37	only	O
38	9	O
39	(	O
40	6	O
41	%)	O
42	had	O
43	an	O
44	SP	O
45	.	O
1	We	O
2	analyzed	O
3	the	O
4	P	O
5	-	O
6	SAECG	O
7	in	O
8	the	O
9	time	O
10	and	O
11	frequency	O
12	domain	O
13	in	O
14	23	O
15	patients	O
16	with	O
17	Paf	O
18	and	O
19	19	O
20	controls	O
21	.	O
1	Competitive	O
2	reverse	O
3	transcription	O
4	-	O
5	polymerase	B
6	chain	O
7	reaction	O
8	and	O
9	HPLC	O
10	analysis	O
11	showed	O
12	that	O
13	RUSH	O
14	-	O
15	1alpha	O
16	is	O
17	the	O
18	progesterone	O
19	-	O
20	dependent	O
21	splice	O
22	variant	O
23	.	O
1	Oncostatin	O
2	M	O
3	stimulates	O
4	c	B
5	-	O
6	Fos	O
7	to	O
8	bind	O
9	a	O
10	transcriptionally	O
11	responsive	O
12	AP	B
13	-	O
14	1	O
15	element	O
16	within	O
17	the	O
18	tissue	O
19	inhibitor	O
20	of	O
21	metalloproteinase	O
22	-	O
23	1	O
24	promoter	O
25	.	O
1	Soluble	O
2	FasR	O
3	ligand	O
4	-	O
5	binding	O
6	domain	O
7	:	O
8	high	O
9	-	O
10	yield	O
11	production	O
12	of	O
13	active	O
14	fusion	O
15	and	O
16	non	O
17	-	O
18	fusion	O
19	recombinant	O
20	proteins	O
21	using	O
22	the	O
23	baculovirus	O
24	/	O
25	insect	O
26	cell	O
27	system	O
28	.	O
1	When	O
2	tested	O
3	with	O
4	wild	O
5	-	O
6	type	O
7	(	O
8	DBA	O
9	/	O
10	2	O
11	)	O
12	p16	O
13	,	O
14	both	O
15	A134C	O
16	and	O
17	G232A	O
18	BALB	O
19	/	O
20	c	B
21	-	O
22	specific	O
23	variants	O
24	of	O
25	p16	O
26	were	O
27	inefficient	O
28	in	O
29	their	O
30	ability	O
31	to	O
32	inhibit	O
33	the	O
34	activity	O
35	of	O
36	cyclin	B
37	D2	O
38	/	O
39	CDK4	O
40	in	O
41	kinase	B
42	assays	O
43	with	O
44	retinoblastoma	O
45	protein	O
46	,	O
47	suggesting	O
48	this	O
49	defective	O
50	,	O
51	inherited	O
52	allele	O
53	plays	O
54	an	O
55	important	O
56	role	O
57	in	O
58	the	O
59	genetic	O
60	susceptibility	O
61	of	O
62	BALB	O
63	/	O
64	c	B
65	mice	O
66	for	O
67	plasmacytoma	O
68	induction	O
69	and	O
70	that	O
71	p16	O
72	(	O
73	INK4a	O
74	)	O
75	is	O
76	a	O
77	strong	O
78	candidate	O
79	for	O
80	the	O
81	Pctr1	O
82	locus	O
83	.	O
1	METHODS	O
2	:	O
3	A	O
4	population	O
5	survey	O
6	was	O
7	undertaken	O
8	in	O
9	10	O
10	,	O
11	148	O
12	individuals	O
13	to	O
14	measure	O
15	the	O
16	prevalence	O
17	and	O
18	identify	O
19	the	O
20	causes	O
21	of	O
22	blindness	O
23	in	O
24	Lebanon	O
25	.	O
1	During	O
2	organogenesis	O
3	,	O
4	HFH	O
5	-	O
6	8	O
7	expression	O
8	is	O
9	found	O
10	in	O
11	the	O
12	splanchnic	O
13	mesoderm	O
14	in	O
15	close	O
16	apposition	O
17	of	O
18	the	O
19	gut	O
20	endoderm	O
21	,	O
22	suggesting	O
23	a	O
24	role	O
25	in	O
26	mesenchymal	O
27	-	O
28	epithelial	O
29	induction	O
30	of	O
31	lung	O
32	and	O
33	gut	O
34	morphogenesis	O
35	.	O
1	To	O
2	determine	O
3	the	O
4	true	O
5	molecular	O
6	identity	O
7	of	O
8	SFD	O
9	,	O
10	both	O
11	the	O
12	50	O
13	-	O
14	and	O
15	57	O
16	-	O
17	kDa	O
18	polypeptides	O
19	were	O
20	directly	O
21	sequenced	O
22	.	O
1	In	O
2	C	O
3	.	O
4	albicans	O
5	,	O
6	HST6	O
7	is	O
8	expressed	O
9	constitutively	O
10	at	O
11	high	O
12	levels	O
13	in	O
14	the	O
15	different	O
16	cell	O
17	types	O
18	analysed	O
19	(	O
20	yeast	O
21	,	O
22	hyphae	O
23	,	O
24	white	O
25	and	O
26	opaque	O
27	),	O
28	demonstrating	O
29	that	O
30	HST6	O
31	transcription	O
32	is	O
33	not	O
34	repressed	O
35	in	O
36	this	O
37	diploid	O
38	yeast	O
39	,	O
40	unlike	O
41	in	O
42	diploid	O
43	S	O
44	.	O
45	cerevisiae	O
46	,	O
47	and	O
48	suggesting	O
49	a	O
50	basic	O
51	biological	O
52	function	O
53	for	O
54	the	O
55	Hst6p	O
56	transporter	O
57	in	O
58	C	O
59	.	O
60	albicans	O
61	.	O
1	Furthermore	O
2	,	O
3	binding	O
4	of	O
5	recombinant	O
6	Myb	O
7	and	O
8	Ets	O
9	-	O
10	2	O
11	protein	O
12	to	O
13	these	O
14	fragments	O
15	could	O
16	be	O
17	competed	O
18	with	O
19	an	O
20	excess	O
21	of	O
22	double	O
23	stranded	O
24	oligodeoxynucleotides	O
25	containing	O
26	canonical	O
27	,	O
28	but	O
29	not	O
30	mutated	O
31	,	O
32	Myb	O
33	-	O
34	or	O
35	Ets	O
36	-	O
37	binding	O
38	sites	O
39	.	O
1	To	O
2	understand	O
3	the	O
4	regulatory	O
5	mechanism	O
6	controlling	O
7	its	O
8	expression	O
9	at	O
10	low	O
11	temperature	O
12	,	O
13	the	O
14	promoter	O
15	region	O
16	has	O
17	been	O
18	characterized	O
19	.	O
1	In	O
2	the	O
3	current	O
4	study	O
5	,	O
6	the	O
7	roles	O
8	of	O
9	two	O
10	putative	O
11	cis	O
12	-	O
13	acting	O
14	elements	O
15	within	O
16	the	O
17	-	O
18	73	O
19	to	O
20	+	O
21	44	O
22	region	O
23	in	O
24	basal	O
25	exon	O
26	2	O
27	promoter	O
28	activity	O
29	were	O
30	evaluated	O
31	using	O
32	mutagenesis	O
33	and	O
34	nuclear	O
35	protein	O
36	-	O
37	DNA	O
38	binding	O
39	assays	O
40	.	O
1	For	O
2	the	O
3	5HT5A	O
4	receptor	B
5	the	O
6	addition	O
7	of	O
8	yohimbine	O
9	resulted	O
10	in	O
11	a	O
12	similar	O
13	but	O
14	smaller	O
15	effect	O
16	.	O
1	We	O
2	have	O
3	examined	O
4	reporter	O
5	gene	O
6	(	O
7	beta	B
8	-	O
9	gal	O
10	)	O
11	expression	O
12	directed	O
13	by	O
14	human	O
15	heat	O
16	shock	O
17	transcription	O
18	factors	O
19	1	O
20	and	O
21	2	O
22	(	O
23	HSF1	O
24	and	O
25	HSF2	O
26	)	O
27	in	O
28	HeLa	O
29	cells	O
30	and	O
31	in	O
32	yeast	O
33	(	O
34	Saccharomyces	O
35	cerevisiae	O
36	).	O
1	RESULTS	O
2	:	O
3	Patients	O
4	in	O
5	Group	O
6	A	O
7	had	O
8	a	O
9	higher	O
10	incidence	O
11	of	O
12	posterolateral	O
13	wall	O
14	motion	O
15	abnormalities	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	on	O
24	radionuclide	O
25	ventriculography	O
26	,	O
27	a	O
28	larger	O
29	infarct	O
30	area	O
31	(	O
32	as	O
33	evidenced	O
34	by	O
35	higher	O
36	peak	O
37	creatine	O
38	kinase	B
39	levels	O
40	)	O
41	(	O
42	p	O
43	<	O
44	0	O
45	.	O
46	02	O
47	)	O
48	and	O
49	a	O
50	lower	O
51	left	O
52	ventricular	O
53	ejection	O
54	fraction	O
55	(	O
56	LVEF	O
57	)	O
58	at	O
59	hospital	O
60	discharge	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	008	O
67	)	O
68	than	O
69	those	O
70	in	O
71	Group	O
72	B	O
73	.	O
1	CyIIa	O
2	transcription	O
3	follows	O
4	,	O
5	and	O
6	is	O
7	therefore	O
8	downstream	O
9	of	O
10	,	O
11	the	O
12	initial	O
13	specification	O
14	of	O
15	these	O
16	embryonic	O
17	domains	O
18	.	O
1	Cis	O
2	-	O
3	regulation	O
4	downstream	O
5	of	O
6	cell	O
7	type	O
8	specification	O
9	:	O
10	a	O
11	single	O
12	compact	O
13	element	O
14	controls	O
15	the	O
16	complex	O
17	expression	O
18	of	O
19	the	O
20	CyIIa	O
21	gene	O
22	in	O
23	sea	O
24	urchin	O
25	embryos	O
26	.	O
1	In	O
2	patients	O
3	with	O
4	myalgia	O
5	,	O
6	Raynaud	O
7	'	O
8	s	O
9	syndrome	O
10	,	O
11	skin	O
12	vasculitis	O
13	and	O
14	vascular	O
15	diseases	O
16	WFAg	O
17	concentrations	O
18	were	O
19	higher	O
20	than	O
21	in	O
22	patients	O
23	without	O
24	them	O
25	.	O
1	Therapeutic	O
2	use	O
3	of	O
4	cannabis	O
5	.	O
1	The	O
2	cAMP	O
3	-	O
4	dependent	O
5	mitogenic	O
6	pathway	O
7	is	O
8	unique	O
9	as	O
10	it	O
11	is	O
12	independent	O
13	of	O
14	mitogen	O
15	-	O
16	activated	O
17	protein	O
18	kinase	B
19	activation	O
20	and	O
21	differs	O
22	from	O
23	growth	O
24	factor	O
25	-	O
26	dependent	O
27	pathways	O
28	at	O
29	the	O
30	level	O
31	of	O
32	the	O
33	expression	O
34	of	O
35	several	O
36	protooncogenes	O
37	/	O
38	transcription	O
39	factors	O
40	.	O
1	CONCLUSIONS	O
2	:	O
3	Use	O
4	of	O
5	the	O
6	first	O
7	method	O
8	was	O
9	associated	O
10	with	O
11	a	O
12	reduction	O
13	in	O
14	the	O
15	time	O
16	patients	O
17	remained	O
18	in	O
19	the	O
20	ICU	O
21	before	O
22	transfer	O
23	to	O
24	another	O
25	unit	O
26	and	O
27	savings	O
28	in	O
29	nursing	O
30	time	O
31	,	O
32	but	O
33	the	O
34	two	O
35	methods	O
36	did	O
37	not	O
38	differ	O
39	according	O
40	to	O
41	clinical	O
42	outcomes	O
43	.	O
1	Two	O
2	hundred	O
3	sixty	O
4	-	O
5	four	O
6	patients	O
7	scheduled	O
8	for	O
9	DCBM	O
10	were	O
11	randomized	O
12	to	O
13	receive	O
14	intravenously	O
15	geG	O
16	0	O
17	.	O
18	25	O
19	mg	O
20	(	O
21	geG	O
22	-	O
23	25	O
24	),	O
25	or	O
26	geG	O
27	0	O
28	.	O
29	5	O
30	mg	O
31	(	O
32	geG	O
33	-	O
34	50	O
35	),	O
36	or	O
37	HBB	O
38	20	O
39	mg	O
40	as	O
41	hypotonic	O
42	agent	O
43	.	O
1	The	O
2	spontaneous	O
3	mutation	O
4	blocking	O
5	pca	O
6	gene	O
7	expression	O
8	was	O
9	located	O
10	in	O
11	the	O
12	promoter	O
13	for	O
14	the	O
15	pca	O
16	operon	O
17	.	O
1	The	O
2	study	O
3	enrolled	O
4	994	O
5	people	O
6	co	O
7	-	O
8	infected	O
9	with	O
10	CMV	O
11	and	O
12	HIV	O
13	,	O
14	with	O
15	at	O
16	least	O
17	one	O
18	CD4	O
19	count	O
20	recorded	O
21	<	O
22	100	O
23	x	O
24	10	O
25	(	O
26	6	O
27	)	O
28	cells	O
29	/	O
30	l	O
31	.	O
1	Both	O
2	TRE	O
3	-	O
4	like	O
5	elements	O
6	were	O
7	capable	O
8	of	O
9	binding	O
10	AP1	O
11	.	O
1	The	O
2	mei4	O
3	+	O
4	gene	O
5	of	O
6	the	O
7	fission	O
8	yeast	O
9	Schizosaccharomyces	O
10	pombe	O
11	was	O
12	cloned	O
13	by	O
14	functional	O
15	complementation	O
16	.	O
1	Cotransfection	O
2	analyses	O
3	of	O
4	the	O
5	T	O
6	/	O
7	EBP	O
8	promoter	O
9	-	O
10	reporter	O
11	constructs	O
12	with	O
13	a	O
14	T	O
15	/	O
16	EBP	O
17	expression	O
18	vector	O
19	into	O
20	human	O
21	HepG2	O
22	cells	O
23	,	O
24	which	O
25	do	O
26	not	O
27	express	O
28	T	O
29	/	O
30	EBP	O
31	,	O
32	suggested	O
33	that	O
34	autoregulation	O
35	may	O
36	be	O
37	involved	O
38	in	O
39	controlling	O
40	both	O
41	rat	O
42	and	O
43	human	O
44	T	O
45	/	O
46	EBP	O
47	gene	O
48	expression	O
49	.	O
1	Jean	O
2	Klig	O
3	reviews	O
4	recent	O
5	literature	O
6	about	O
7	lower	O
8	respiratory	O
9	tract	O
10	infection	O
11	in	O
12	children	O
13	.	O
1	Despite	O
2	its	O
3	requirement	O
4	for	O
5	enhancer	O
6	-	O
7	dependent	O
8	splicing	O
9	activity	O
10	in	O
11	vitro	O
12	,	O
13	the	O
14	dU2AF38	O
15	RS	O
16	domain	O
17	was	O
18	also	O
19	inessential	O
20	in	O
21	vivo	O
22	.	O
1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	m	O
8	-	O
9	Staf	O
10	is	O
11	highly	O
12	homologous	O
13	to	O
14	that	O
15	of	O
16	Staf	O
17	,	O
18	another	O
19	selenocysteine	O
20	tRNA	O
21	gene	O
22	transcription	O
23	activating	O
24	factor	O
25	of	O
26	Xenopus	O
27	laevis	O
28	.	O
1	On	O
2	a	O
3	separate	O
4	occasion	O
5	the	O
6	T1	O
7	weighted	O
8	and	O
9	T2	O
10	weighted	O
11	sagittal	O
12	and	O
13	T2	O
14	weighted	O
15	axial	O
16	sequences	O
17	were	O
18	reported	O
19	blind	O
20	in	O
21	relation	O
22	to	O
23	the	O
24	initial	O
25	assessment	O
26	.	O
1	Furthermore	O
2	,	O
3	a	O
4	minor	O
5	start	O
6	site	O
7	was	O
8	localized	O
9	179	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	major	O
15	site	O
16	using	O
17	reverse	O
18	transcriptase	O
19	-	O
20	polymerase	B
21	chain	O
22	reaction	O
23	with	O
24	various	O
25	P1	O
26	primers	O
27	(	O
28	primer	O
29	walking	O
30	),	O
31	primer	O
32	extension	O
33	,	O
34	and	O
35	cDNA	O
36	cloning	O
37	.	O
1	Furthermore	O
2	,	O
3	the	O
4	deletion	O
5	of	O
6	bcp	O
7	from	O
8	the	O
9	chromosome	O
10	had	O
11	no	O
12	effect	O
13	on	O
14	gcv	O
15	-	O
16	lacZ	O
17	expression	O
18	.	O
1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	investigate	O
7	the	O
8	mechanism	O
9	underlying	O
10	Ras	B
11	activation	O
12	upon	O
13	stimulation	O
14	of	O
15	these	O
16	two	O
17	types	O
18	of	O
19	receptors	O
20	in	O
21	hematopoietic	O
22	cells	O
23	.	O
1	Therefore	O
2	,	O
3	we	O
4	conclude	O
5	that	O
6	DnaA	O
7	may	O
8	contact	O
9	the	O
10	beta	B
11	subunit	O
12	of	O
13	RNA	O
14	polymerase	B
15	during	O
16	activation	O
17	of	O
18	the	O
19	pR	O
20	promoter	O
21	.	O
1	These	O
2	mutants	O
3	were	O
4	tested	O
5	for	O
6	ability	O
7	to	O
8	bind	O
9	each	O
10	of	O
11	the	O
12	Site	O
13	II	O
14	cognate	O
15	proteins	O
16	,	O
17	and	O
18	subsequently	O
19	evaluated	O
20	for	O
21	ability	O
22	to	O
23	confer	O
24	H4	O
25	transcriptional	O
26	activity	O
27	using	O
28	chimeric	O
29	H4	O
30	promoter	O
31	/	O
32	CAT	O
33	fusion	O
34	constructs	O
35	in	O
36	different	O
37	cell	O
38	types	O
39	.	O
1	Furthermore	O
2	,	O
3	in	O
4	the	O
5	ischemia	O
6	/	O
7	angiotension	O
8	II	O
9	-	O
10	induced	O
11	AHF	O
12	model	O
13	,	O
14	NIC	O
15	decreased	O
16	left	O
17	ventricular	O
18	end	O
19	-	O
20	diastolic	O
21	pressure	O
22	(	O
23	LVEDP	O
24	).	O
1	CONCLUSIONS	O
2	:	O
3	These	O
4	routinely	O
5	collected	O
6	data	O
7	provided	O
8	quantitative	O
9	estimates	O
10	of	O
11	changes	O
12	in	O
13	CBZ	O
14	Cl	O
15	/	O
16	F	O
17	due	O
18	to	O
19	comedication	O
20	and	O
21	an	O
22	age	O
23	-	O
24	related	O
25	decrease	O
26	in	O
27	Cl	O
28	/	O
29	F	O
30	The	O
31	derived	O
32	regression	O
33	equations	O
34	reasonably	O
35	predicted	O
36	concentrations	O
37	in	O
38	a	O
39	separate	O
40	validation	O
41	set	O
42	.	O
1	ATP	O
2	-	O
3	dependent	O
4	assembly	O
5	of	O
6	a	O
7	ternary	O
8	complex	O
9	consisting	O
10	of	O
11	a	O
12	DNA	O
13	mismatch	O
14	and	O
15	the	O
16	yeast	O
17	MSH2	O
18	-	O
19	MSH6	O
20	and	O
21	MLH1	O
22	-	O
23	PMS1	O
24	protein	O
25	complexes	O
26	.	O
1	Recombinant	O
2	HRMT1L2	O
3	protein	O
4	encoded	O
5	by	O
6	the	O
7	most	O
8	common	O
9	5	O
10	'-	O
11	variant	O
12	exhibited	O
13	methyltransferase	O
14	activity	O
15	in	O
16	vitro	O
17	.	O
1	The	O
2	possible	O
3	roles	O
4	of	O
5	HRMT1L1	O
6	and	O
7	HRMT1L2	O
8	in	O
9	human	O
10	disease	O
11	are	O
12	currently	O
13	unknown	O
14	.	O
1	The	O
2	ether	O
3	phospholipid	O
4	1	O
5	-	O
6	O	O
7	-	O
8	octadecyl	O
9	-	O
10	2	O
11	-	O
12	O	O
13	-	O
14	methyl	O
15	-	O
16	rac	O
17	-	O
18	glycero	O
19	-	O
20	3	O
21	-	O
22	phosphocholine	O
23	(	O
24	ET	O
25	-	O
26	18	O
27	-	O
28	OCH3	O
29	;	O
30	edelfosine	O
31	)	O
32	is	O
33	a	O
34	potent	O
35	inducer	O
36	of	O
37	apoptosis	O
38	in	O
39	human	O
40	tumor	O
41	cells	O
42	.	O
1	When	O
2	data	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	cumulative	O
8	manner	O
9	,	O
10	the	O
11	response	O
12	to	O
13	intravenous	O
14	adenosine	O
15	3	O
16	mg	O
17	,	O
18	6	O
19	mg	O
20	,	O
21	9	O
22	mg	O
23	and	O
24	12	O
25	mg	O
26	in	O
27	the	O
28	24	O
29	episodes	O
30	of	O
31	PSVT	O
32	were	O
33	5	O
34	episodes	O
35	(	O
36	21	O
37	%),	O
38	16	O
39	episodes	O
40	(	O
41	67	O
42	%),	O
43	20	O
44	episodes	O
45	(	O
46	83	O
47	%)	O
48	and	O
49	20	O
50	episodes	O
51	(	O
52	83	O
53	%)	O
54	respectively	O
55	.	O
1	RNAs	O
2	are	O
3	not	O
4	only	O
5	essential	O
6	components	O
7	of	O
8	both	O
9	ribosomal	O
10	subunits	O
11	but	O
12	also	O
13	transiently	O
14	interacting	O
15	factors	O
16	during	O
17	particle	O
18	formation	O
19	.	O
1	To	O
2	study	O
3	retinoid	O
4	signalling	O
5	in	O
6	zebrafish	O
7	embryos	O
8	,	O
9	we	O
10	developed	O
11	a	O
12	novel	O
13	method	O
14	to	O
15	detect	O
16	endogenous	O
17	retinoids	O
18	in	O
19	situ	O
20	in	O
21	embryos	O
22	,	O
23	using	O
24	a	O
25	fusion	O
26	protein	O
27	of	O
28	the	O
29	ligand	O
30	inducible	O
31	transactivation	O
32	domain	O
33	of	O
34	a	O
35	retinoic	O
36	acid	O
37	receptor	B
38	and	O
39	a	O
40	heterologous	O
41	DNA	O
42	binding	O
43	domain	O
44	.	O
1	The	O
2	N	O
3	-	O
4	syndecan	O
5	-	O
6	dependent	O
7	neurite	O
8	outgrowth	O
9	is	O
10	inhibited	O
11	by	O
12	the	O
13	tyrosine	O
14	kinase	B
15	inhibitors	O
16	herbimycin	O
17	A	O
18	and	O
19	PP1	O
20	.	O
1	The	O
2	pharmacokinetic	O
3	patterns	O
4	of	O
5	estradiol	O
6	(	O
7	CAS	O
8	50	O
9	-	O
10	28	O
11	-	O
12	2	O
13	)	O
14	and	O
15	of	O
16	estrone	O
17	(	O
18	CAS	O
19	53	O
20	-	O
21	16	O
22	-	O
23	7	O
24	)	O
25	were	O
26	investigated	O
27	in	O
28	18	O
29	women	O
30	in	O
31	natural	O
32	or	O
33	surgical	O
34	menopause	O
35	during	O
36	the	O
37	application	O
38	of	O
39	a	O
40	new	O
41	estradiol	O
42	transdermal	O
43	patch	O
44	with	O
45	active	O
46	matrix	O
47	and	O
48	without	O
49	absorption	O
50	enhancers	O
51	designed	O
52	for	O
53	epicutaneous	O
54	applications	O
55	of	O
56	7	O
57	days	O
58	(	O
59	hereinafter	O
60	called	O
61	""""	O
62	patch	O
63	7D	O
64	""")."	O
1	It	O
2	bound	O
3	to	O
4	vitamin	O
5	D	O
6	receptor	B
7	(	O
8	VDR	O
9	)	O
10	but	O
11	not	O
12	retinoic	O
13	acid	O
14	Xalpha	O
15	receptor	B
16	(	O
17	RXRalpha	O
18	)	O
19	in	O
20	the	O
21	human	O
22	T	O
23	cell	O
24	line	O
25	MT2	O
26	cells	O
27	.	O
1	Post	O
2	-	O
3	translational	O
4	modifications	O
5	such	O
6	as	O
7	glycosylation	O
8	and	O
9	phosphorylation	O
10	could	O
11	be	O
12	excluded	O
13	as	O
14	potential	O
15	explanations	O
16	for	O
17	the	O
18	protein	O
19	heterogeneity	O
20	.	O
1	Ime1	O
2	plays	O
3	a	O
4	pivotal	O
5	role	O
6	in	O
7	the	O
8	initiation	O
9	of	O
10	meiosis	O
11	in	O
12	a	O
13	/	O
14	alpha	B
15	diploid	O
16	cells	O
17	of	O
18	Saccharomyces	O
19	cerevisiae	O
20	.	O
1	Deltamethrin	O
2	was	O
3	most	O
4	effective	O
5	on	O
6	the	O
7	thatched	O
8	surface	O
9	and	O
10	produced	O
11	100	O
12	%	O
13	mortality	O
14	of	O
15	An	O
16	.	O
17	culicifacies	O
18	adults	O
19	up	O
20	to	O
21	12	O
22	weeks	O
23	,	O
24	even	O
25	when	O
26	exposed	O
27	at	O
28	the	O
29	lowest	O
30	dose	O
31	/	O
32	12	O
33	.	O
34	5	O
35	mg	O
36	/	O
37	m2	O
38	.	O
1	Trichloroethylene	O
2	,	O
3	in	O
4	turn	O
5	,	O
6	increased	O
7	the	O
8	AUC	O
9	5	O
10	.	O
11	0	O
12	(	O
13	1	O
14	.	O
15	9	O
16	-	O
17	13	O
18	.	O
19	4	O
20	),	O
21	25	O
22	.	O
23	8	O
24	(	O
25	8	O
26	.	O
27	2	O
28	-	O
29	80	O
30	.	O
31	8	O
32	)	O
33	and	O
34	2	O
35	.	O
36	9	O
37	(	O
38	1	O
39	.	O
40	6	O
41	-	O
42	5	O
43	.	O
44	4	O
45	),	O
46	respectively	O
47	,	O
48	whereas	O
49	the	O
50	corresponding	O
51	values	O
52	for	O
53	n	O
54	-	O
55	hexane	O
56	were	O
57	1	O
58	.	O
59	9	O
60	(	O
61	0	O
62	.	O
63	7	O
64	-	O
65	5	O
66	.	O
67	1	O
68	),	O
69	1	O
70	.	O
71	5	O
72	(	O
73	0	O
74	.	O
75	5	O
76	-	O
77	4	O
78	.	O
79	6	O
80	),	O
81	and	O
82	3	O
83	.	O
84	2	O
85	(	O
86	1	O
87	.	O
88	8	O
89	-	O
90	5	O
91	.	O
92	9	O
93	).	O
1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	effect	O
7	of	O
8	acute	O
9	administration	O
10	of	O
11	various	O
12	doses	O
13	of	O
14	malathion	O
15	via	O
16	oral	O
17	and	O
18	dermal	O
19	routes	O
20	to	O
21	mice	O
22	and	O
23	rats	O
24	on	O
25	serum	O
26	levels	O
27	of	O
28	histamine	O
29	was	O
30	evaluated	O
31	.	O
1	In	O
2	addition	O
3	to	O
4	DNA	O
5	-	O
6	protein	O
7	interactions	O
8	,	O
9	protein	O
10	-	O
11	protein	O
12	interactions	O
13	with	O
14	partner	O
15	proteins	O
16	often	O
17	play	O
18	major	O
19	roles	O
20	in	O
21	targeting	O
22	ETS	O
23	-	O
24	domain	O
25	proteins	O
26	to	O
27	specific	O
28	promoters	O
29	.	O
1	The	O
2	complete	O
3	exon	O
4	-	O
5	intron	O
6	organization	O
7	of	O
8	the	O
9	murine	O
10	gene	O
11	encoding	O
12	M	O
13	-	O
14	protein	O
15	,	O
16	a	O
17	structural	O
18	protein	O
19	of	O
20	sarcomeric	O
21	myofibrils	O
22	,	O
23	was	O
24	determined	O
25	.	O
1	PURPOSE	O
2	:	O
3	To	O
4	introduce	O
5	an	O
6	image	O
7	analysis	O
8	of	O
9	the	O
10	cornea	O
11	in	O
12	photorefractive	O
13	keratectomy	O
14	(	O
15	PRK	O
16	)	O
17	for	O
18	preoperative	O
19	and	O
20	early	O
21	postoperative	O
22	determination	O
23	of	O
24	changes	O
25	in	O
26	the	O
27	condition	O
28	of	O
29	the	O
30	cornea	O
31	.	O
1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O
1	Finally	O
2	,	O
3	a	O
4	role	O
5	for	O
6	NF	B
7	-	O
8	kappaB	O
9	in	O
10	preventing	O
11	apoptosis	O
12	induced	O
13	by	O
14	ER	O
15	calcium	O
16	release	O
17	was	O
18	demonstrated	O
19	by	O
20	data	O
21	showing	O
22	that	O
23	sAPPalpha	O
24	prevents	O
25	thapsigargin	O
26	-	O
27	induced	O
28	apoptosis	O
29	,	O
30	an	O
31	effect	O
32	blocked	O
33	by	O
34	kappaB	O
35	decoy	O
36	DNA	O
37	.	O
1	These	O
2	modifications	O
3	may	O
4	improve	O
5	the	O
6	interlaboratory	O
7	reproducibility	O
8	of	O
9	CD34	O
10	determinations	O
11	due	O
12	to	O
13	the	O
14	reduction	O
15	in	O
16	sample	O
17	handling	O
18	and	O
19	calculation	O
20	of	O
21	results	O
22	.	O
1	UDP	O
2	-	O
3	GlcNAc	O
4	:	O
5	alpha	B
6	-	O
7	6	O
8	-	O
9	D	O
10	-	O
11	mannoside	O
12	beta	B
13	-	O
14	1	O
15	,	O
16	2	O
17	-	O
18	N	O
19	-	O
20	acetylglucosaminyltransferase	O
21	II	O
22	(	O
23	GnT	O
24	II	O
25	;	O
26	EC	O
27	2	O
28	.	O
29	4	O
30	.	O
31	1	O
32	.	O
33	143	O
34	)	O
35	is	O
36	essential	O
37	for	O
38	the	O
39	normal	O
40	assembly	O
41	of	O
42	complex	O
43	Asn	O
44	-	O
45	linked	O
46	glycans	O
47	.	O
1	These	O
2	patients	O
3	failed	O
4	to	O
5	respond	O
6	to	O
7	intravenous	O
8	cyclophosphamide	O
9	and	O
10	steroids	O
11	and	O
12	were	O
13	then	O
14	changed	O
15	to	O
16	receive	O
17	oral	O
18	cyclosporine	O
19	A	O
20	,	O
21	at	O
22	a	O
23	dose	O
24	of	O
25	5	O
26	mg	O
27	/	O
28	kg	O
29	/	O
30	day	O
31	.	O
1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	is	O
7	78	O
8	.	O
9	0	O
10	%	O
11	identical	O
12	to	O
13	the	O
14	cytoplasmic	O
15	dynein	O
16	heavy	O
17	chain	O
18	of	O
19	Neurospora	O
20	crassa	O
21	,	O
22	70	O
23	.	O
24	2	O
25	%	O
26	identical	O
27	to	O
28	that	O
29	of	O
30	Aspergillus	O
31	nidulans	O
32	and	O
33	24	O
34	.	O
35	8	O
36	%	O
37	identical	O
38	to	O
39	that	O
40	of	O
41	Saccharomyces	O
42	cerevisiae	O
43	.	O
1	The	O
2	DNA	O
3	binding	O
4	activities	O
5	of	O
6	the	O
7	three	O
8	repressor	O
9	preparations	O
10	were	O
11	studied	O
12	using	O
13	fragments	O
14	containing	O
15	CIRs	O
16	(	O
17	CIR3	O
18	-	O
19	CIR6	O
20	)	O
21	from	O
22	the	O
23	essential	O
24	early	O
25	region	O
26	as	O
27	templates	O
28	for	O
29	DNase	B
30	I	O
31	footprinting	O
32	.	O
1	In	O
2	connective	O
3	tissue	O
4	,	O
5	cell	O
6	structure	O
7	contributes	O
8	to	O
9	type	O
10	I	O
11	collagen	O
12	expression	O
13	.	O
1	In	O
2	patients	O
3	with	O
4	type	O
5	IA	O
6	maple	O
7	syrup	O
8	urine	O
9	disease	O
10	,	O
11	the	O
12	E1alpha	O
13	subunit	O
14	is	O
15	affected	O
16	,	O
17	resulting	O
18	in	O
19	the	O
20	loss	O
21	of	O
22	E1	O
23	and	O
24	branched	O
25	-	O
26	chain	O
27	ketoacid	O
28	dehydrogenase	O
29	catalytic	O
30	activities	O
31	.	O
1	DESIGN	O
2	AND	O
3	METHODS	O
4	:	O
5	Case	B
6	study	O
7	.	O
1	In	O
2	support	O
3	of	O
4	a	O
5	role	O
6	at	O
7	the	O
8	spindle	O
9	,	O
10	two	O
11	-	O
12	hybrid	O
13	library	O
14	screening	O
15	with	O
16	HEF1	O
17	identifies	O
18	the	O
19	human	O
20	homolog	O
21	of	O
22	the	O
23	G2	O
24	/	O
25	M	O
26	spindle	O
27	-	O
28	regulatory	O
29	protein	O
30	Dim1p	O
31	as	O
32	a	O
33	specific	O
34	interactor	O
35	with	O
36	a	O
37	region	O
38	of	O
39	HEF1	O
40	encompassed	O
41	in	O
42	p55	O
43	(	O
44	HEF1	O
45	).	O
1	The	O
2	bZP2	O
3	cDNA	O
4	(	O
5	115	O
6	-	O
7	1914	O
8	nt	O
9	,	O
10	1	O
11	.	O
12	8	O
13	kb	O
14	),	O
15	excluding	O
16	sequences	O
17	coding	O
18	for	O
19	N	O
20	-	O
21	terminal	O
22	signal	O
23	sequence	O
24	and	O
25	C	O
26	-	O
27	terminal	O
28	transmembranelike	O
29	domain	O
30	,	O
31	was	O
32	PCR	O
33	amplified	O
34	and	O
35	Sac1	O
36	-	O
37	Sal1	O
38	restricted	O
39	fragment	O
40	cloned	O
41	in	O
42	frame	O
43	downstream	O
44	of	O
45	the	O
46	T5	O
47	promoter	O
48	under	O
49	the	O
50	lac	O
51	operator	O
52	control	O
53	in	O
54	a	O
55	pQE	O
56	-	O
57	30	O
58	vector	O
59	.	O
1	Class	O
2	I	O
3	alpha1	O
4	,	O
5	2	O
6	-	O
7	mannosidases	O
8	play	O
9	an	O
10	essential	O
11	role	O
12	in	O
13	the	O
14	elaboration	O
15	of	O
16	complex	O
17	and	O
18	hybrid	O
19	N	O
20	-	O
21	glycans	O
22	in	O
23	mammalian	O
24	cells	O
25	.	O
1	Analysis	O
2	of	O
3	a	O
4	Mac1p	O
5	mutant	O
6	,	O
7	refractile	O
8	for	O
9	copper	O
10	-	O
11	dependent	O
12	repression	O
13	of	O
14	the	O
15	Cu	O
16	(	O
17	I	O
18	)	O
19	transport	O
20	genes	O
21	,	O
22	showed	O
23	an	O
24	aberrant	O
25	pattern	O
26	of	O
27	CUP1	O
28	expression	O
29	and	O
30	copper	O
31	sensitivity	O
32	.	O
1	Fregnac	O
2	,	O
3	M	O
4	.	O
1	Two	O
2	protease	O
3	-	O
4	resistant	O
5	fragments	O
6	spanning	O
7	the	O
8	N	O
9	-	O
10	and	O
11	C	O
12	-	O
13	terminal	O
14	halves	O
15	of	O
16	the	O
17	nuclease	O
18	were	O
19	identified	O
20	using	O
21	different	O
22	proteases	O
23	which	O
24	cleave	O
25	the	O
26	protein	O
27	in	O
28	the	O
29	same	O
30	region	O
31	.	O
1	A	O
2	phylogenetic	O
3	analysis	O
4	of	O
5	the	O
6	reverse	O
7	transcriptase	O
8	domain	O
9	confirms	O
10	our	O
11	differential	O
12	genetic	O
13	assessment	O
14	that	O
15	Cyclops	O
16	from	O
17	pea	O
18	is	O
19	a	O
20	novel	O
21	element	O
22	with	O
23	no	O
24	specific	O
25	relationship	O
26	to	O
27	the	O
28	previously	O
29	described	O
30	Gypsy	O
31	-	O
32	like	O
33	elements	O
34	from	O
35	plants	O
36	.	O
1	In	O
2	mammals	O
3	,	O
4	the	O
5	Rb	O
6	protein	O
7	interacts	O
8	specifically	O
9	with	O
10	D	O
11	-	O
12	type	O
13	cyclins	O
14	and	O
15	regulates	O
16	cell	O
17	proliferation	O
18	by	O
19	binding	O
20	and	O
21	inhibiting	O
22	E2F	O
23	transcription	O
24	factors	O
25	.	O
1	Two	O
2	members	O
3	of	O
4	the	O
5	Cbl	O
6	family	O
7	have	O
8	since	O
9	been	O
10	defined	O
11	in	O
12	mammals	O
13	(	O
14	c	B
15	-	O
16	Cbl	O
17	and	O
18	Cbl	O
19	-	O
20	b	O
21	),	O
22	one	O
23	in	O
24	C	O
25	.	O
26	elegans	O
27	(	O
28	Sli	O
29	-	O
30	1	O
31	)	O
32	and	O
33	one	O
34	in	O
35	Drosophila	O
36	(	O
37	D	O
38	-	O
39	Cbl	O
40	).	O
1	As	O
2	predicted	O
3	by	O
4	the	O
5	Wing	O
6	and	O
7	Kristofferson	O
8	model	O
9	,	O
10	the	O
11	durations	O
12	of	O
13	successive	O
14	ISIs	O
15	tended	O
16	to	O
17	be	O
18	negatively	O
19	correlated	O
20	.	O
1	Thus	O
2	,	O
3	included	O
4	in	O
5	the	O
6	KG1a	O
7	EST	O
8	dataset	O
9	are	O
10	candidates	O
11	for	O
12	new	O
13	human	O
14	genes	O
15	that	O
16	may	O
17	play	O
18	roles	O
19	in	O
20	hematopoietic	O
21	differentiative	O
22	progression	O
23	and	O
24	lineage	O
25	commitment	O
26	.	O
1	After	O
2	the	O
3	first	O
4	cycle	O
5	,	O
6	18	O
7	cases	O
8	were	O
9	treated	O
10	at	O
11	dose	O
12	level	O
13	1	O
14	,	O
15	after	O
16	a	O
17	second	O
18	cycle	O
19	,	O
20	13	O
21	cases	O
22	were	O
23	treated	O
24	at	O
25	dose	O
26	level	O
27	2	O
28	.	O
1	In	O
2	this	O
3	study	O
4	we	O
5	examined	O
6	hepatic	O
7	stellate	O
8	cell	O
9	regulation	O
10	of	O
11	M6P	O
12	/	O
13	IGFIIR	O
14	expression	O
15	and	O
16	found	O
17	that	O
18	M6P	O
19	/	O
20	IGFIIR	O
21	mRNA	O
22	transcript	O
23	levels	O
24	increased	O
25	in	O
26	stellate	O
27	cells	O
28	from	O
29	rats	O
30	exposed	O
31	to	O
32	carbon	O
33	tetrachloride	O
34	(	O
35	CCl4	O
36	),	O
37	a	O
38	potent	O
39	fibrogenic	O
40	stimulant	O
41	.	O
1	The	O
2	pre	O
3	-	O
4	mRNA	O
5	splicing	O
6	factor	O
7	U2AF	O
8	(	O
9	U2	O
10	small	O
11	nuclear	O
12	ribonucleoprotein	O
13	particle	O
14	[	O
15	snRNP	O
16	]	O
17	auxiliary	O
18	factor	O
19	)	O
20	plays	O
21	a	O
22	critical	O
23	role	O
24	in	O
25	3	O
26	'	O
27	splice	O
28	site	O
29	selection	O
30	.	O
1	Hematocrit	O
2	and	O
3	PaO2	O
4	did	O
5	not	O
6	change	O
7	.	O
1	Regulation	O
2	of	O
3	myosin	O
4	phosphatase	B
5	activity	O
6	involves	O
7	changes	O
8	in	O
9	subunit	O
10	interactions	O
11	,	O
12	although	O
13	molecular	O
14	mechanisms	O
15	are	O
16	not	O
17	defined	O
18	.	O
1	The	O
2	major	O
3	type	O
4	involves	O
5	activator	O
6	proteins	O
7	that	O
8	bind	O
9	to	O
10	DNA	O
11	adjacent	O
12	to	O
13	where	O
14	the	O
15	RNA	O
16	polymerase	B
17	(	O
18	RNAP	O
19	)	O
20	holoenzyme	O
21	binds	O
22	,	O
23	usually	O
24	assisting	O
25	in	O
26	recruitment	O
27	of	O
28	the	O
29	RNAP	O
30	to	O
31	the	O
32	promoter	O
33	.	O
1	Atmospheric	O
2	benzene	O
3	,	O
4	urinary	O
5	muconic	O
6	acid	O
7	(	O
8	tt	O
9	-	O
10	MA	O
11	)	O
12	and	O
13	leukocyte	O
14	alkaline	O
15	phosphatase	B
16	activity	O
17	(	O
18	LAPA	O
19	)	O
20	were	O
21	evaluated	O
22	among	O
23	66	O
24	car	O
25	mechanics	O
26	,	O
27	34	O
28	road	O
29	tanker	O
30	drivers	O
31	,	O
32	and	O
33	28	O
34	nonexposed	O
35	workers	O
36	.	O
1	After	O
2	profound	O
3	normovolemic	O
4	hemodilution	O
5	(	O
6	Hct	O
7	9	O
8	%)	O
9	superiority	O
10	of	O
11	LV	O
12	MC	O
13	and	O
14	LV	O
15	diastolic	O
16	properties	O
17	was	O
18	found	O
19	,	O
20	when	O
21	myocardial	O
22	oxygenation	O
23	was	O
24	supported	O
25	by	O
26	i	O
27	.	O
28	v	O
29	.	O
30	perflubron	O
31	emulsion	O
32	,	O
33	a	O
34	temporary	O
35	O2	O
36	carrier	O
37	.	O
1	[	O
2	Treatment	O
3	of	O
4	early	O
5	T1	O
6	small	O
7	T2N	O
8	breast	O
9	cancers	O
10	.	O
1	The	O
2	general	O
3	recombination	O
4	at	O
5	a	O
6	polarizing	O
7	voltage	O
8	of	O
9	300	O
10	V	O
11	is	O
12	less	O
13	than	O
14	2	O
15	%	O
16	for	O
17	dose	O
18	-	O
19	rates	O
20	up	O
21	to	O
22	about	O
23	100	O
24	mGy	O
25	min	O
26	-	O
27	1	O
28	.	O
1	Strengthening	O
2	the	O
3	biological	O
4	weapons	O
5	convention	O
6	and	O
7	implications	O
8	on	O
9	the	O
10	pharmaceutical	O
11	and	O
12	biotechnology	O
13	industry	O
14	.	O
1	VirD2	O
2	is	O
3	one	O
4	of	O
5	the	O
6	key	O
7	Agrobacterium	O
8	tumefaciens	O
9	proteins	O
10	involved	O
11	in	O
12	T	O
13	-	O
14	DNA	O
15	processing	O
16	and	O
17	transfer	O
18	.	O
1	The	O
2	DHEAS	O
3	levels	O
4	in	O
5	all	O
6	stages	O
7	of	O
8	decreased	O
9	BMD	O
10	were	O
11	significantly	O
12	lower	O
13	than	O
14	those	O
15	in	O
16	the	O
17	group	O
18	with	O
19	normal	O
20	BMD	O
21	.	O
1	Malaria	O
2	had	O
3	diminished	O
4	significantly	O
5	by	O
6	the	O
7	early	O
8	1940s	O
9	,	O
10	and	O
11	this	O
12	paper	O
13	queries	O
14	whether	O
15	that	O
16	reduction	O
17	was	O
18	due	O
19	to	O
20	the	O
21	control	O
22	projects	O
23	of	O
24	the	O
25	thirties	O
26	,	O
27	and	O
28	,	O
29	if	O
30	so	O
31	,	O
32	whether	O
33	such	O
34	projects	O
35	should	O
36	be	O
37	a	O
38	model	O
39	for	O
40	the	O
41	current	O
42	developing	O
43	world	O
44	,	O
45	where	O
46	malaria	O
47	is	O
48	a	O
49	growing	O
50	problem	O
51	today	O
52	.	O
1	In	O
2	the	O
3	DNA	O
4	recognition	O
5	helix	O
6	of	O
7	finger	O
8	II	O
9	,	O
10	the	O
11	conserved	O
12	Arg	O
13	at	O
14	position	O
15	62	O
16	(	O
17	N	O
18	-	O
19	terminal	O
20	side	O
21	of	O
22	the	O
23	first	O
24	zinc	O
25	-	O
26	coordinating	O
27	histidine	O
28	)	O
29	was	O
30	changed	O
31	to	O
32	a	O
33	Leu	O
34	or	O
35	Gln	O
36	.	O
1	As	O
2	the	O
3	high	O
4	-	O
5	affinity	O
6	Mg2	O
7	+	O
8	binding	O
9	sites	O
10	are	O
11	filled	O
12	,	O
13	the	O
14	primer	O
15	terminus	O
16	migrates	O
17	from	O
18	the	O
19	exonuclease	O
20	site	O
21	to	O
22	a	O
23	highly	O
24	based	O
25	stacked	O
26	polymerase	B
27	active	O
28	site	O
29	.	O
1	One	O
2	missense	O
3	allele	O
4	(	O
5	P236S	O
6	)	O
7	with	O
8	complete	O
9	loss	O
10	of	O
11	function	O
12	at	O
13	30	O
14	degreesC	O
15	and	O
16	four	O
17	missense	O
18	alleles	O
19	(	O
20	L173F	O
21	,	O
22	E225K	O
23	,	O
24	S269L	O
25	and	O
26	E274K	O
27	)	O
28	that	O
29	conferred	O
30	a	O
31	temperature	O
32	sensitive	O
33	phenotype	O
34	were	O
35	identified	O
36	.	O
1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	demonstrated	O
6	specific	O
7	nuclear	O
8	protein	O
9	binding	O
10	to	O
11	-	O
12	85	O
13	/-	O
14	64	O
15	,	O
16	and	O
17	single	O
18	point	O
19	mutations	O
20	suggested	O
21	important	O
22	binding	O
23	nucleotides	O
24	between	O
25	-	O
26	79	O
27	/-	O
28	68	O
29	with	O
30	five	O
31	critical	O
32	bases	O
33	between	O
34	-	O
35	74	O
36	/-	O
37	70	O
38	(	O
39	5	O
40	'-	O
41	CTCCT	O
42	-	O
43	3	O
44	').	O
1	We	O
2	demonstrate	O
3	that	O
4	Ddc1p	O
5	interacts	O
6	physically	O
7	in	O
8	vivo	O
9	with	O
10	Mec3p	O
11	,	O
12	and	O
13	this	O
14	interaction	O
15	requires	O
16	Rad17p	O
17	.	O
1	One	O
2	is	O
3	to	O
4	act	O
5	within	O
6	the	O
7	visceral	O
8	endoderm	O
9	to	O
10	promote	O
11	proper	O
12	streak	O
13	morphogenesis	O
14	.	O
1	We	O
2	then	O
3	studied	O
4	four	O
5	unrelated	O
6	Japanese	O
7	families	O
8	with	O
9	GSD	O
10	-	O
11	Ib	O
12	,	O
13	and	O
14	found	O
15	three	O
16	novel	O
17	mutations	O
18	:	O
19	a	O
20	four	O
21	-	O
22	base	O
23	deletion	O
24	/	O
25	two	O
26	-	O
27	base	O
28	insertion	O
29	,	O
30	a	O
31	point	O
32	mutation	O
33	within	O
34	a	O
35	consensus	O
36	splicing	O
37	donor	O
38	site	O
39	,	O
40	and	O
41	a	O
42	missense	O
43	mutation	O
44	(	O
45	W118R	O
46	).	O
1	To	O
2	gain	O
3	insight	O
4	into	O
5	the	O
6	expression	O
7	of	O
8	the	O
9	AtCP1	O
10	gene	O
11	,	O
12	northern	O
13	blot	O
14	analysis	O
15	was	O
16	carried	O
17	out	O
18	.	O
1	The	O
2	combination	O
3	of	O
4	Pitx2	O
5	and	O
6	another	O
7	homeodomain	O
8	protein	O
9	,	O
10	Pit	O
11	-	O
12	1	O
13	,	O
14	yielded	O
15	a	O
16	synergistic	O
17	55	O
18	-	O
19	fold	O
20	activation	O
21	of	O
22	the	O
23	prolactin	O
24	promoter	O
25	in	O
26	transfection	O
27	assays	O
28	.	O
1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	crucial	O
7	role	O
8	of	O
9	the	O
10	mutations	O
11	activating	O
12	v	O
13	-	O
14	erbA	O
15	as	O
16	an	O
17	oncogene	O
18	is	O
19	to	O
20	'	O
21	freeze	O
22	'	O
23	c	B
24	-	O
25	ErbA	O
26	/	O
27	TRalpha	O
28	in	O
29	its	O
30	non	O
31	-	O
32	liganded	O
33	,	O
34	repressive	O
35	conformation	O
36	and	O
37	to	O
38	facilitate	O
39	its	O
40	overexpression	O
41	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	describe	O
7	a	O
8	mammalian	O
9	cell	O
10	-	O
11	free	O
12	transcription	O
13	system	O
14	reconstituted	O
15	with	O
16	only	O
17	recombinant	O
18	proteins	O
19	and	O
20	epitope	O
21	-	O
22	tagged	O
23	multiprotein	O
24	complexes	O
25	.	O
1	We	O
2	propose	O
3	a	O
4	model	O
5	in	O
6	which	O
7	Sro7	O
8	function	O
9	is	O
10	involved	O
11	in	O
12	the	O
13	targeting	O
14	of	O
15	the	O
16	myosin	O
17	proteins	O
18	to	O
19	their	O
20	intrinsic	O
21	pathways	O
22	.	O
1	We	O
2	found	O
3	sequences	O
4	related	O
5	to	O
6	this	O
7	insertion	O
8	in	O
9	wild	O
10	-	O
11	type	O
12	strains	O
13	of	O
14	N	O
15	.	O
16	crassa	O
17	and	O
18	other	O
19	Neurospora	O
20	species	O
21	.	O
1	When	O
2	cysteine	O
3	is	O
4	scanned	O
5	through	O
6	the	O
7	helices	O
8	,	O
9	characteristic	O
10	repeating	O
11	patterns	O
12	of	O
13	solvent	O
14	exposure	O
15	and	O
16	burial	O
17	are	O
18	observed	O
19	.	O
1	The	O
2	C	O
3	-	O
4	terminal	O
5	region	O
6	contains	O
7	the	O
8	PTP	O
9	-	O
10	like	O
11	domain	O
12	,	O
13	whereas	O
14	the	O
15	N	O
16	-	O
17	terminal	O
18	region	O
19	shows	O
20	no	O
21	homology	O
22	to	O
23	any	O
24	known	O
25	mammalian	O
26	protein	O
27	.	O
1	Our	O
2	laboratory	O
3	has	O
4	recently	O
5	identified	O
6	two	O
7	phosducin	O
8	-	O
9	like	O
10	orphan	O
11	proteins	O
12	(	O
13	PhLOP1	O
14	and	O
15	PhLOP2	O
16	)	O
17	that	O
18	lack	O
19	the	O
20	ability	O
21	to	O
22	interact	O
23	with	O
24	Gbetagamma	O
25	.	O
1	Reverse	O
2	transcriptase	O
3	-	O
4	polymerase	B
5	chain	O
6	reaction	O
7	(	O
8	RT	O
9	-	O
10	PCR	O
11	)	O
12	was	O
13	performed	O
14	using	O
15	eyestalk	O
16	complementary	O
17	DNA	O
18	of	O
19	the	O
20	sand	O
21	shrimp	O
22	Metapenaeus	O
23	ensis	O
24	.	O
1	These	O
2	results	O
3	establish	O
4	that	O
5	hydroquinones	O
6	lead	O
7	to	O
8	mutagenicity	O
9	and	O
10	carcinogenicity	O
11	.	O
1	Acute	O
2	idiopathic	O
3	thrombocytopenic	O
4	purpura	O
5	presenting	O
6	a	O
7	high	O
8	serum	O
9	level	O
10	of	O
11	immunoglobulin	O
12	E	O
13	and	O
14	eosinophilia	O
15	in	O
16	an	O
17	elderly	O
18	patient	O
19	.	O
1	E2F	O
2	-	O
3	6	O
4	shares	O
5	significant	O
6	homology	O
7	with	O
8	E2Fs	O
9	1	O
10	-	O
11	5	O
12	,	O
13	especially	O
14	within	O
15	the	O
16	DNA	O
17	binding	O
18	,	O
19	heterodimerization	O
20	and	O
21	marked	O
22	box	O
23	domains	O
24	.	O
1	MK	O
2	-	O
3	801	O
4	administration	O
5	resulted	O
6	in	O
7	a	O
8	biphasic	O
9	response	O
10	in	O
11	seizure	O
12	latency	O
13	.	O
1	In	O
2	the	O
3	former	O
4	cells	O
5	,	O
6	ets	O
7	-	O
8	2	O
9	was	O
10	a	O
11	CSF	B
12	-	O
13	1	O
14	immediate	O
15	-	O
16	early	O
17	response	O
18	gene	O
19	,	O
20	and	O
21	phosphorylated	O
22	ets	O
23	-	O
24	2	O
25	was	O
26	detected	O
27	after	O
28	2	O
29	to	O
30	4	O
31	h	O
32	,	O
33	coincident	O
34	with	O
35	expression	O
36	of	O
37	ets	O
38	-	O
39	2	O
40	protein	O
41	.	O
1	Vam7p	O
2	,	O
3	a	O
4	SNAP	O
5	-	O
6	25	O
7	-	O
8	like	O
9	molecule	O
10	,	O
11	and	O
12	Vam3p	O
13	,	O
14	a	O
15	syntaxin	O
16	homolog	O
17	,	O
18	function	O
19	together	O
20	in	O
21	yeast	O
22	vacuolar	O
23	protein	O
24	trafficking	O
25	.	O
1	We	O
2	have	O
3	tested	O
4	this	O
5	possibility	O
6	by	O
7	constructing	O
8	a	O
9	consecutive	O
10	series	O
11	of	O
12	cysteine	O
13	substitutions	O
14	in	O
15	the	O
16	Neu	O
17	juxtamembrane	O
18	domain	O
19	in	O
20	order	O
21	to	O
22	force	O
23	dimerization	O
24	along	O
25	a	O
26	series	O
27	of	O
28	interreceptor	O
29	faces	O
30	.	O
1	Tctex	O
2	-	O
3	1	O
4	binding	O
5	required	O
6	the	O
7	first	O
8	19	O
9	amino	O
10	acids	O
11	of	O
12	Fyn	O
13	and	O
14	integrity	O
15	of	O
16	two	O
17	lysine	O
18	residues	O
19	within	O
20	this	O
21	sequence	O
22	that	O
23	were	O
24	previously	O
25	shown	O
26	to	O
27	be	O
28	important	O
29	for	O
30	Fyn	O
31	interactions	O
32	with	O
33	the	O
34	immunoreceptor	O
35	tyrosine	O
36	-	O
37	based	O
38	activation	O
39	motifs	O
40	(	O
41	ITAMs	O
42	)	O
43	of	O
44	lymphocyte	O
45	Ag	O
46	receptors	O
47	.	O
1	The	O
2	prothrombin	O
3	gene	O
4	G20210A	O
5	mutation	O
6	is	O
7	not	O
8	found	O
9	among	O
10	Japanese	O
11	patients	O
12	with	O
13	deep	O
14	vein	O
15	thrombosis	O
16	and	O
17	healthy	O
18	individuals	O
19	.	O
1	These	O
2	sequence	O
3	analyses	O
4	suggest	O
5	that	O
6	xIRS	O
7	-	O
8	u	O
9	is	O
10	a	O
11	novel	O
12	member	O
13	of	O
14	the	O
15	IRS	O
16	family	O
17	rather	O
18	than	O
19	a	O
20	Xenopus	O
21	homolog	O
22	of	O
23	an	O
24	existing	O
25	member	O
26	.	O
1	The	O
2	Abbreviated	O
3	Injury	O
4	Scale	O
5	(	O
6	AIS	O
7	),	O
8	Injury	O
9	Severity	O
10	Scale	O
11	and	O
12	TRISS	O
13	methodology	O
14	comprise	O
15	a	O
16	mathematically	O
17	sound	O
18	system	O
19	for	O
20	the	O
21	analysis	O
22	of	O
23	injuries	O
24	and	O
25	injured	O
26	patients	O
27	.	O
1	Furthermore	O
2	,	O
3	early	O
4	-	O
5	and	O
6	late	O
7	-	O
8	firing	O
9	origins	O
10	differ	O
11	not	O
12	in	O
13	the	O
14	timing	O
15	of	O
16	their	O
17	recruitment	O
18	of	O
19	an	O
20	Mcm	O
21	protein	O
22	,	O
23	but	O
24	in	O
25	the	O
26	timing	O
27	of	O
28	RPA	O
29	'	O
30	s	O
31	recruitment	O
32	.	O
1	CONCLUSION	O
2	:	O
3	Although	O
4	quantitative	O
5	and	O
6	qualitative	O
7	criteria	O
8	for	O
9	diagnosing	O
10	fatty	O
11	liver	O
12	on	O
13	helical	O
14	CT	O
15	can	O
16	be	O
17	determined	O
18	,	O
19	they	O
20	are	O
21	protocol	O
22	-	O
23	specific	O
24	.	O
1	Alternatively	O
2	,	O
3	the	O
4	similarity	O
5	in	O
6	apparent	O
7	regulatory	O
8	action	O
9	of	O
10	the	O
11	genes	O
12	may	O
13	indicate	O
14	allelic	O
15	differences	O
16	wherein	O
17	the	O
18	IS1112C	O
19	Rf3	O
20	allele	O
21	may	O
22	differ	O
23	from	O
24	alleles	O
25	of	O
26	maintainer	O
27	lines	O
28	by	O
29	the	O
30	capability	O
31	to	O
32	regulate	O
33	both	O
34	orf107	O
35	and	O
36	urf209	O
37	processing	O
38	activities	O
39	.	O
1	Transfection	O
2	of	O
3	increasing	O
4	amounts	O
5	of	O
6	delta5ERalpha	O
7	expression	O
8	vector	O
9	into	O
10	[	O
11	ERalpha	O
12	+]	O
13	OS	O
14	cells	O
15	resulted	O
16	in	O
17	potentiation	O
18	of	O
19	E2	O
20	-	O
21	stimulated	O
22	ERELuc	O
23	activity	O
24	in	O
25	a	O
26	synergistic	O
27	,	O
28	dose	O
29	-	O
30	dependent	O
31	manner	O
32	.	O
1	Studies	O
2	using	O
3	the	O
4	yeast	O
5	two	O
6	-	O
7	hybrid	O
8	system	O
9	also	O
10	did	O
11	not	O
12	provide	O
13	evidence	O
14	for	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	VDR	O
20	-	O
21	TR	O
22	protein	O
23	-	O
24	protein	O
25	interaction	O
26	.	O
1	The	O
2	only	O
3	abundant	O
4	viral	O
5	transcript	O
6	expressed	O
7	during	O
8	latency	O
9	is	O
10	the	O
11	latency	O
12	-	O
13	related	O
14	(	O
15	LR	O
16	)	O
17	RNA	O
18	.	O
1	The	O
2	defect	O
3	in	O
4	these	O
5	proteins	O
6	was	O
7	also	O
8	uniformly	O
9	suppressed	O
10	by	O
11	either	O
12	Mn2	O
13	+,	O
14	or	O
15	the	O
16	Mu	O
17	B	O
18	protein	O
19	in	O
20	the	O
21	presence	O
22	of	O
23	ATP	O
24	and	O
25	target	O
26	DNA	O
27	.	O
1	Second	O
2	,	O
3	the	O
4	wild	O
5	-	O
6	type	O
7	m8	O
8	3	O
9	'	O
10	UTR	O
11	strongly	O
12	reduces	O
13	accumulation	O
14	of	O
15	heterologous	O
16	transcripts	O
17	in	O
18	vivo	O
19	,	O
20	an	O
21	activity	O
22	that	O
23	requires	O
24	its	O
25	K	O
26	box	O
27	sequences	O
28	.	O
1	During	O
2	the	O
3	2h	O
4	resuscitation	O
5	period	O
6	,	O
7	extracellular	O
8	aspartate	O
9	and	O
10	glutamate	O
11	concentrations	O
12	in	O
13	the	O
14	cerebral	O
15	striatum	O
16	were	O
17	higher	O
18	during	O
19	hypoxaemic	O
20	resuscitation	O
21	(	O
22	p	O
23	=	O
24	0	O
25	.	O
26	044	O
27	and	O
28	p	O
29	=	O
30	0	O
31	.	O
32	055	O
33	,	O
34	respectively	O
35	)	O
36	than	O
37	during	O
38	resuscitation	O
39	with	O
40	21	O
41	%	O
42	O2	O
43	or	O
44	100	O
45	%	O
46	O2	O
47	,	O
48	suggesting	O
49	an	O
50	unfavourable	O
51	accumulation	O
52	of	O
53	potent	O
54	excitotoxins	O
55	during	O
56	hypoxaemic	O
57	resuscitation	O
58	.	O
1	Anastrozole	O
2	is	O
3	the	O
4	first	O
5	aromatase	O
6	inhibitor	O
7	to	O
8	show	O
9	a	O
10	significant	O
11	survival	O
12	advantage	O
13	over	O
14	megestrol	O
15	acetate	O
16	in	O
17	post	O
18	-	O
19	menopausal	O
20	women	O
21	with	O
22	advanced	O
23	breast	O
24	cancer	O
25	.	O
1	Mutation	O
2	of	O
3	either	O
4	the	O
5	AP	B
6	-	O
7	1	O
8	or	O
9	the	O
10	ets	O
11	component	O
12	of	O
13	this	O
14	site	O
15	also	O
16	prevented	O
17	promoter	O
18	activity	O
19	in	O
20	SMCs	O
21	.	O
1	Surprisingly	O
2	,	O
3	double	O
4	mutants	O
5	of	O
6	the	O
7	shy2	O
8	-	O
9	1D	O
10	mutant	O
11	with	O
12	the	O
13	phytochrome	O
14	-	O
15	deficient	O
16	mutants	O
17	hy2	O
18	,	O
19	hy3	O
20	(	O
21	phyB	O
22	-	O
23	1	O
24	)	O
25	and	O
26	fre1	O
27	-	O
28	1	O
29	(	O
30	phyA	O
31	-	O
32	201	O
33	)	O
34	showed	O
35	reduced	O
36	photomorphogenic	O
37	response	O
38	in	O
39	darkness	O
40	with	O
41	a	O
42	longer	O
43	hypocotyl	O
44	,	O
45	a	O
46	longer	O
47	inflorescence	O
48	stem	O
49	,	O
50	and	O
51	a	O
52	lower	O
53	level	O
54	expression	O
55	of	O
56	the	O
57	CAB	O
58	gene	O
59	than	O
60	the	O
61	shy2	O
62	-	O
63	1D	O
64	single	O
65	mutant	O
66	.	O
1	This	O
2	suggests	O
3	that	O
4	while	O
5	underpredictions	O
6	of	O
7	pain	O
8	do	O
9	not	O
10	hurt	O
11	more	O
12	,	O
13	disruption	O
14	on	O
15	primary	O
16	tasks	O
17	and	O
18	physiological	O
19	impact	O
20	are	O
21	higher	O
22	.	O
1	The	O
2	SH2	O
3	-	O
4	containing	O
5	adapter	O
6	protein	O
7	GRB10	O
8	interacts	O
9	with	O
10	BCR	O
11	-	O
12	ABL	O
13	.	O
1	Badcock	O
2	and	O
3	Westheimer	O
4	(	O
5	Spatial	O
6	Vision	O
7	1	O
8	(	O
9	1	O
10	),	O
11	3	O
12	-	O
13	11	O
14	,	O
15	1985	O
16	)	O
17	showed	O
18	that	O
19	a	O
20	thin	O
21	vertical	O
22	line	O
23	induces	O
24	nearby	O
25	zones	O
26	of	O
27	attraction	O
28	and	O
29	repulsion	O
30	;	O
31	this	O
32	study	O
33	extends	O
34	those	O
35	results	O
36	by	O
37	more	O
38	closely	O
39	examining	O
40	the	O
41	horizontal	O
42	and	O
43	vertical	O
44	extents	O
45	of	O
46	the	O
47	repulsion	O
48	zone	O
49	and	O
50	by	O
51	using	O
52	an	O
53	illusory	O
54	contour	O
55	to	O
56	induce	O
57	repulsion	O
58	.	O
1	desmethyltrimebutine	O
2	was	O
3	inactive	O
4	.	O
1	However	O
2	,	O
3	ICK1	O
4	was	O
5	induced	O
6	by	O
7	ABA	O
8	,	O
9	and	O
10	along	O
11	with	O
12	ICK1	O
13	induction	O
14	there	O
15	was	O
16	a	O
17	decrease	O
18	in	O
19	Cdc2	O
20	-	O
21	like	O
22	histone	O
23	H1	O
24	kinase	B
25	activity	O
26	.	O
1	BACKGROUND	O
2	:	O
3	Fluoroquinolones	O
4	(	O
5	FQ	O
6	)	O
7	are	O
8	contraindicated	O
9	in	O
10	children	O
11	because	O
12	of	O
13	the	O
14	risk	O
15	of	O
16	cartilage	O
17	damage	O
18	.	O
1	The	O
2	interaction	O
3	of	O
4	U1	O
5	-	O
6	70K	O
7	with	O
8	the	O
9	SRZ	O
10	proteins	O
11	is	O
12	confirmed	O
13	further	O
14	in	O
15	vitro	O
16	using	O
17	a	O
18	blot	O
19	overlay	O
20	assay	O
21	.	O
1	The	O
2	major	O
3	phenotypes	O
4	resulting	O
5	from	O
6	Fab1p	O
7	kinase	B
8	inactivation	O
9	include	O
10	temperature	O
11	-	O
12	sensitive	O
13	growth	O
14	,	O
15	vacuolar	O
16	acidification	O
17	defects	O
18	,	O
19	and	O
20	dramatic	O
21	increases	O
22	in	O
23	vacuolar	O
24	size	O
25	.	O
1	The	O
2	murine	O
3	facilitative	O
4	glucose	O
5	transporter	O
6	isoform	O
7	3	O
8	(	O
9	Glut	O
10	3	O
11	)	O
12	is	O
13	developmentally	O
14	regulated	O
15	and	O
16	is	O
17	predominantly	O
18	expressed	O
19	in	O
20	neurons	O
21	and	O
22	trophoblasts	O
23	.	O
1	The	O
2	levels	O
3	of	O
4	transactivation	O
5	are	O
6	correlated	O
7	with	O
8	the	O
9	respective	O
10	binding	O
11	affinities	O
12	of	O
13	the	O
14	response	O
15	elements	O
16	(	O
17	IRper	O
18	-	O
19	1	O
20	>	O
21	DR	O
22	-	O
23	4	O
24	>	O
25	IRhsp	O
26	-	O
27	1	O
28	).	O
1	Inactivation	O
2	of	O
3	p53	B
4	but	O
5	not	O
6	p73	O
7	by	O
8	adenovirus	O
9	type	O
10	5	O
11	E1B	O
12	55	O
13	-	O
14	kilodalton	O
15	and	O
16	E4	O
17	34	O
18	-	O
19	kilodalton	O
20	oncoproteins	O
21	.	O
1	The	O
2	Epstein	O
3	-	O
4	Barr	O
5	virus	O
6	transactivator	O
7	Zta	O
8	triggers	O
9	lytic	O
10	gene	O
11	expression	O
12	and	O
13	is	O
14	essential	O
15	for	O
16	replication	O
17	of	O
18	the	O
19	lytic	O
20	origin	O
21	,	O
22	oriLyt	O
23	.	O
1	Cotransfection	O
2	of	O
3	the	O
4	helicase	O
5	-	O
6	primase	O
7	proteins	O
8	,	O
9	one	O
10	of	O
11	which	O
12	was	O
13	fused	O
14	to	O
15	a	O
16	heterologous	O
17	activation	O
18	domain	O
19	,	O
20	led	O
21	to	O
22	Zta	O
23	-	O
24	dependent	O
25	superactivation	O
26	of	O
27	CAT	O
28	expression	O
29	.	O
1	Previous	O
2	genetic	O
3	studies	O
4	led	O
5	to	O
6	the	O
7	conclusion	O
8	that	O
9	nitrate	O
10	and	O
11	nitrite	O
12	induction	O
13	of	O
14	nasF	O
15	operon	O
16	expression	O
17	is	O
18	determined	O
19	by	O
20	a	O
21	transcriptional	O
22	antitermination	O
23	mechanism	O
24	.	O
1	We	O
2	have	O
3	recently	O
4	identified	O
5	a	O
6	mouse	O
7	enzyme	O
8	termed	O
9	gamma	B
10	-	O
11	glutamyl	O
12	leukotrienase	O
13	(	O
14	GGL	O
15	)	O
16	that	O
17	converts	O
18	leukotriene	O
19	C4	O
20	(	O
21	LTC4	O
22	)	O
23	to	O
24	leukotriene	O
25	D4	O
26	(	O
27	LTD4	O
28	).	O
1	The	O
2	ARF	O
3	promoter	O
4	was	O
5	also	O
6	found	O
7	to	O
8	be	O
9	highly	O
10	responsive	O
11	to	O
12	E2F1	O
13	expression	O
14	,	O
15	in	O
16	keeping	O
17	with	O
18	previous	O
19	results	O
20	at	O
21	the	O
22	RNA	O
23	level	O
24	.	O
1	After	O
2	measuring	O
3	baseline	O
4	Vmca	O
5	at	O
6	a	O
7	partial	O
8	pressure	O
9	of	O
10	carbon	O
11	dioxide	O
12	in	O
13	arterial	O
14	blood	O
15	(	O
16	PaCO2	O
17	)	O
18	of	O
19	37	O
20	.	O
21	7	O
22	+/-	O
23	4	O
24	.	O
25	5	O
26	mmHg	O
27	(	O
28	mean	O
29	+/-	O
30	SD	O
31	),	O
32	measurements	O
33	were	O
34	repeated	O
35	at	O
36	a	O
37	PaCO	O
38	of	O
39	44	O
40	.	O
41	2	O
42	+/-	O
43	3	O
44	.	O
45	8	O
46	mmHg	O
47	,	O
48	and	O
49	the	O
50	carbon	O
51	dioxide	O
52	reactivity	O
53	(	O
54	absolute	O
55	value	O
56	:	O
57	cm	O
58	x	O
59	s	O
60	(-	O
61	1	O
62	)	O
63	x	O
64	mmHg	O
65	(-	O
66	1	O
67	);	O
68	relative	O
69	value	O
70	:	O
71	percentage	O
72	of	O
73	baseline	O
74	Vmca	O
75	/	O
76	mmHg	O
77	)	O
78	was	O
79	calculated	O
80	.	O
1	Multivariate	O
2	Cox	O
3	survival	O
4	analysis	O
5	identified	O
6	baseline	O
7	EF	O
8	<	O
9	or	O
10	=	O
11	30	O
12	%,	O
13	presence	O
14	of	O
15	significant	O
16	mitral	O
17	regurgitation	O
18	(>	O
19	2	O
20	+)	O
21	before	O
22	ablation	O
23	,	O
24	and	O
25	failure	O
26	to	O
27	exhibit	O
28	improved	O
29	cardiac	O
30	performance	O
31	by	O
32	1	O
33	month	O
34	after	O
35	ablation	O
36	as	O
37	the	O
38	only	O
39	independent	O
40	predictors	O
41	of	O
42	death	O
43	.	O
1	Sequencing	O
2	of	O
3	a	O
4	40	O
5	-	O
6	kb	O
7	DNA	O
8	segment	O
9	of	O
10	the	O
11	FK506	O
12	gene	O
13	cluster	O
14	from	O
15	Streptomyces	O
16	sp	O
17	.	O
1	Handling	O
2	on	O
3	PND	O
4	9	O
5	did	O
6	not	O
7	result	O
8	in	O
9	elevated	O
10	CORT	O
11	levels	O
12	in	O
13	any	O
14	of	O
15	the	O
16	groups	O
17	.	O
1	We	O
2	previously	O
3	delineated	O
4	a	O
5	region	O
6	in	O
7	the	O
8	fatty	O
9	-	O
10	acid	O
11	synthase	O
12	promoter	O
13	,	O
14	which	O
15	was	O
16	responsible	O
17	for	O
18	obesity	O
19	-	O
20	related	O
21	overexpression	O
22	of	O
23	the	O
24	fatty	O
25	-	O
26	acid	O
27	synthase	O
28	(	O
29	FAS	O
30	)	O
31	gene	O
32	,	O
33	by	O
34	negatively	O
35	regulating	O
36	the	O
37	activity	O
38	of	O
39	the	O
40	downstream	O
41	promoter	O
42	in	O
43	lean	O
44	but	O
45	not	O
46	obese	O
47	rat	O
48	fat	O
49	cells	O
50	.	O
1	Additionally	O
2	in	O
3	seven	O
4	subjects	O
5	adrenaline	O
6	(	O
7	A	O
8	)	O
9	and	O
10	noradrenaline	O
11	(	O
12	NA	O
13	)	O
14	concentrations	O
15	were	O
16	determined	O
17	.	O
1	We	O
2	also	O
3	mapped	O
4	a	O
5	3	O
6	'-	O
7	polyadenylation	O
8	site	O
9	504bp	O
10	downstream	O
11	of	O
12	the	O
13	TGA	O
14	stop	O
15	codon	O
16	,	O
17	consistent	O
18	with	O
19	the	O
20	2	O
21	.	O
22	5kb	O
23	transcript	O
24	size	O
25	.	O
1	RBP56	O
2	protein	O
3	turned	O
4	out	O
5	to	O
6	be	O
7	hTAFII68	O
8	which	O
9	was	O
10	isolated	O
11	as	O
12	a	O
13	TATA	O
14	-	O
15	binding	O
16	protein	O
17	associated	O
18	factor	O
19	(	O
20	TAF	O
21	)	O
22	from	O
23	a	O
24	sub	O
25	-	O
26	population	O
27	of	O
28	TFIID	O
29	complexes	O
30	(	O
31	Bertolotti	O
32	A	O
33	.,	O
34	Lutz	O
35	,	O
36	Y	O
37	.,	O
38	Heard	O
39	,	O
40	D	O
41	.	O
42	J	O
43	.,	O
44	Chambon	O
45	,	O
46	P	O
47	.,	O
48	Tora	O
49	,	O
50	L	O
51	.,	O
52	1996	O
53	.	O
54	hTAFII68	O
55	,	O
56	a	O
57	novel	O
58	RNA	O
59	/	O
60	ssDNA	O
61	-	O
62	binding	O
63	protein	O
64	with	O
65	homology	O
66	to	O
67	the	O
68	proto	O
69	-	O
70	oncoproteins	O
71	TLS	O
72	/	O
73	FUS	O
74	and	O
75	EWS	O
76	is	O
77	associated	O
78	with	O
79	both	O
80	TFIID	O
81	and	O
82	RNA	O
83	polymerase	B
84	II	O
85	.	O
1	AMY	O
2	-	O
3	1	O
4	was	O
5	localized	O
6	in	O
7	the	O
8	cytoplasm	O
9	in	O
10	cells	O
11	expressing	O
12	c	B
13	-	O
14	myc	O
15	at	O
16	low	O
17	levels	O
18	,	O
19	but	O
20	in	O
21	the	O
22	nucleus	O
23	in	O
24	the	O
25	cells	O
26	of	O
27	a	O
28	high	O
29	c	B
30	-	O
31	myc	O
32	expression	O
33	in	O
34	transiently	O
35	transfected	O
36	cells	O
37	.	O
1	On	O
2	Day	O
3	8	O
4	,	O
5	the	O
6	CIDR	O
7	-	O
8	B	O
9	was	O
10	removed	O
11	and	O
12	500	O
13	micrograms	O
14	cloprostenol	O
15	injected	O
16	,	O
17	IM	O
18	.	O
1	SRF	O
2	-	O
3	deficient	O
4	embryos	O
5	(	O
6	Srf	O
7	-/-)	O
8	have	O
9	a	O
10	severe	O
11	gastrulation	O
12	defect	O
13	and	O
14	do	O
15	not	O
16	develop	O
17	to	O
18	term	O
19	.	O
1	Over	O
2	-	O
3	expression	O
4	of	O
5	Azf1p	O
6	in	O
7	the	O
8	yeast	O
9	cell	O
10	does	O
11	not	O
12	influence	O
13	the	O
14	expression	O
15	level	O
16	of	O
17	the	O
18	mitochondrial	O
19	transcription	O
20	factor	O
21	Mtf1p	O
22	,	O
23	indicating	O
24	that	O
25	the	O
26	influence	O
27	of	O
28	Azf1p	O
29	on	O
30	the	O
31	suppression	O
32	of	O
33	the	O
34	special	O
35	mitochondrial	O
36	RNA	O
37	polymerase	B
38	mutant	O
39	is	O
40	an	O
41	indirect	O
42	one	O
43	.	O
1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	ARNO	O
7	localizes	O
8	to	O
9	the	O
10	plasma	O
11	membrane	O
12	in	O
13	vivo	O
14	and	O
15	efficiently	O
16	catalyzes	O
17	ARF6	O
18	nucleotide	O
19	exchange	O
20	in	O
21	vitro	O
22	.	O
1	Dose	O
2	of	O
3	20	O
4	ig	O
5	were	O
6	administered	O
7	within	O
8	a	O
9	scheme	O
10	from	O
11	0	O
12	.	O
13	1	O
14	to	O
15	6	O
16	months	O
17	in	O
18	order	O
19	to	O
20	study	O
21	its	O
22	immunogenicity	O
23	,	O
24	which	O
25	was	O
26	evaluated	O
27	at	O
28	2	O
29	,	O
30	7	O
31	,	O
32	and	O
33	12	O
34	months	O
35	after	O
36	the	O
37	first	O
38	dose	O
39	.	O
1	Rather	O
2	,	O
3	usp	O
4	is	O
5	required	O
6	in	O
7	late	O
8	third	O
9	instar	O
10	larvae	O
11	for	O
12	appropriate	O
13	developmental	O
14	and	O
15	transcriptional	O
16	responses	O
17	to	O
18	the	O
19	ecdysone	O
20	pulse	O
21	that	O
22	triggers	O
23	puparium	O
24	formation	O
25	.	O
1	An	O
2	intact	O
3	neurovascular	O
4	supply	O
5	is	O
6	essential	O
7	for	O
8	the	O
9	viability	O
10	of	O
11	a	O
12	muscle	O
13	flap	O
14	.	O
1	Fatal	O
2	apneusis	O
3	was	O
4	observed	O
5	under	O
6	following	O
7	conditions	O
8	:	O
9	(	O
10	1	O
11	)	O
12	Persistent	O
13	apnea	O
14	was	O
15	produced	O
16	after	O
17	a	O
18	single	O
19	KA	O
20	microinjection	O
21	in	O
22	one	O
23	side	O
24	of	O
25	the	O
26	VRG	O
27	-	O
28	Apa	O
29	(	O
30	5	O
31	animals	O
32	).	O
1	The	O
2	human	O
3	2	O
4	',	O
5	5	O
6	'-	O
7	oligoadenylate	O
8	(	O
9	2	O
10	-	O
11	5A	O
12	)	O
13	synthetases	O
14	are	O
15	members	O
16	of	O
17	a	O
18	family	O
19	interferon	O
20	(	O
21	IFN	O
22	)-	O
23	inducible	O
24	anti	B
25	-	O
26	viral	O
27	proteins	O
28	.	O
1	The	O
2	pharmacokinetic	O
3	parameters	O
4	which	O
5	helped	O
6	predict	O
7	these	O
8	toxicities	O
9	included	O
10	area	O
11	under	O
12	the	O
13	curve	O
14	and	O
15	peak	O
16	plasma	O
17	level	O
18	.	O
1	However	O
2	,	O
3	the	O
4	use	O
5	of	O
6	cyclosporin	O
7	A	O
8	is	O
9	associated	O
10	with	O
11	an	O
12	increased	O
13	prevalence	O
14	of	O
15	hypertension	O
16	in	O
17	kidney	O
18	transplant	O
19	recipients	O
20	.	O
1	(	O
2	1992	O
3	)	O
4	Biochemistry	O
5	31	O
6	,	O
7	3351	O
8	-	O
9	3358	O
10	].	O
1	The	O
2	zona	O
3	pellucida	O
4	(	O
5	ZP	O
6	),	O
7	the	O
8	extracellular	O
9	glycocalyx	O
10	that	O
11	surrounds	O
12	the	O
13	oocyte	O
14	,	O
15	is	O
16	well	O
17	known	O
18	to	O
19	mediate	O
20	homologous	O
21	gamete	O
22	interaction	O
23	.	O
1	Although	O
2	pathological	O
3	thyroid	O
4	function	O
5	is	O
6	related	O
7	to	O
8	changes	O
9	in	O
10	energy	O
11	expenditure	O
12	and	O
13	body	O
14	composition	O
15	,	O
16	its	O
17	possible	O
18	influence	O
19	on	O
20	leptin	O
21	levels	O
22	remains	O
23	to	O
24	be	O
25	determined	O
26	.	O
1	Quinone	O
2	-	O
3	binding	O
4	domain	O
5	and	O
6	amino	O
7	acid	O
8	residues	O
9	involved	O
10	in	O
11	quinone	O
12	binding	O
13	.	O
1	Effect	O
2	of	O
3	enteral	O
4	nutritional	O
5	products	O
6	differing	O
7	in	O
8	carbohydrate	O
9	and	O
10	fat	O
11	on	O
12	indices	O
13	of	O
14	carbohydrate	O
15	and	O
16	lipid	O
17	metabolism	O
18	in	O
19	patients	O
20	with	O
21	NIDDM	O
22	.	O
1	It	O
2	is	O
3	now	O
4	well	O
5	established	O
6	that	O
7	progression	O
8	through	O
9	the	O
10	eukaryotic	O
11	cell	O
12	cycle	O
13	is	O
14	controlled	O
15	by	O
16	oscillations	O
17	in	O
18	the	O
19	activity	O
20	of	O
21	cyclin	B
22	-	O
23	dependent	O
24	kinases	B
25	(	O
26	CDKs	O
27	).	O
1	The	O
2	repression	O
3	domain	O
4	,	O
5	and	O
6	indeed	O
7	the	O
8	entire	O
9	Cdc68	O
10	protein	O
11	,	O
12	is	O
13	highly	O
14	conserved	O
15	,	O
16	as	O
17	shown	O
18	by	O
19	the	O
20	sequence	O
21	of	O
22	the	O
23	Cdc68	O
24	functional	O
25	homolog	O
26	from	O
27	the	O
28	yeast	O
29	Kluyveromyces	O
30	lactis	O
31	and	O
32	by	O
33	database	O
34	searches	O
35	.	O
1	Pyrrolidine	O
2	dithiocarbamate	O
3	,	O
4	a	O
5	potent	O
6	transcriptional	O
7	inhibitor	O
8	of	O
9	the	O
10	viral	O
11	LTR	O
12	,	O
13	abrogated	O
14	the	O
15	cytokine	O
16	responses	O
17	in	O
18	both	O
19	U1	O
20	and	O
21	ACH	O
22	-	O
23	2	O
24	cells	O
25	,	O
26	suggesting	O
27	a	O
28	common	O
29	TNF	O
30	-	O
31	alpha	B
32	-	O
33	mediated	O
34	transcriptional	O
35	mechanism	O
36	in	O
37	these	O
38	cell	O
39	types	O
40	despite	O
41	their	O
42	different	O
43	modes	O
44	of	O
45	provirus	O
46	latency	O
47	.	O
1	Biochemical	O
2	analysis	O
3	reveals	O
4	that	O
5	KS1	O
6	is	O
7	a	O
8	nuclear	O
9	protein	O
10	containing	O
11	two	O
12	transcriptional	O
13	repressor	O
14	domains	O
15	,	O
16	R1	O
17	and	O
18	R2	O
19	.	O
1	We	O
2	have	O
3	identified	O
4	two	O
5	overlapping	O
6	expressed	O
7	sequence	O
8	tag	O
9	clones	O
10	,	O
11	which	O
12	contain	O
13	the	O
14	missing	O
15	4	O
16	.	O
17	4	O
18	-	O
19	kb	O
20	3	O
21	'-	O
22	UTR	O
23	of	O
24	the	O
25	human	O
26	D2	O
27	(	O
28	hD2	O
29	)	O
30	cDNA	O
31	.	O
1	Neither	O
2	Ha	O
3	-	O
4	Ras	B
5	(	O
6	G12V	O
7	,	O
8	T35S	O
9	)	O
10	(	O
11	Ha	O
12	-	O
13	RasV12S35	O
14	),	O
15	which	O
16	activates	O
17	the	O
18	Rafl	O
19	signaling	O
20	pathway	O
21	,	O
22	nor	O
23	Ha	O
24	-	O
25	Ras	B
26	(	O
27	G12V	O
28	,	O
29	E37G	O
30	)	O
31	(	O
32	Ha	O
33	-	O
34	RasV12G37	O
35	),	O
36	which	O
37	stimulates	O
38	the	O
39	RalGDS	O
40	pathway	O
41	,	O
42	did	O
43	not	O
44	have	O
45	significant	O
46	effects	O
47	on	O
48	factor	O
49	-	O
50	withdrawal	O
51	apoptosis	O
52	of	O
53	myeloid	O
54	cells	O
55	.	O
1	Raf	O
2	is	O
3	a	O
4	key	O
5	serine	O
6	-	O
7	threonine	O
8	protein	O
9	kinase	B
10	which	O
11	participates	O
12	in	O
13	the	O
14	transmission	O
15	of	O
16	growth	O
17	,	O
18	anti	B
19	-	O
20	apoptotic	O
21	and	O
22	differentiation	O
23	messages	O
24	.	O
1	This	O
2	survey	O
3	included	O
4	3000	O
5	randomly	O
6	selected	O
7	Norwegians	O
8	above	O
9	18	O
10	years	O
11	of	O
12	age	O
13	who	O
14	received	O
15	the	O
16	European	O
17	Organization	O
18	for	O
19	Research	O
20	and	O
21	Treatment	O
22	of	O
23	Cancer	O
24	Core	O
25	Quality	O
26	of	O
27	Life	O
28	Questionnaire	O
29	(	O
30	EORTC	O
31	QLQ	O
32	-	O
33	C30	O
34	(+	O
35	3	O
36	)	O
37	by	O
38	mail	O
39	.	O
1	During	O
2	presentation	O
3	of	O
4	happy	O
5	facial	O
6	expressions	O
7	,	O
8	we	O
9	detected	O
10	a	O
11	signal	O
12	increase	O
13	predominantly	O
14	in	O
15	the	O
16	left	O
17	anterior	O
18	cingulate	O
19	gyrus	O
20	,	O
21	bilateral	O
22	posterior	O
23	cingulate	O
24	gyri	O
25	,	O
26	medial	O
27	frontal	O
28	cortex	O
29	and	O
30	right	O
31	supramarginal	O
32	gyrus	O
33	,	O
34	brain	O
35	regions	O
36	previously	O
37	implicated	O
38	in	O
39	visuospatial	O
40	and	O
41	emotion	O
42	processing	O
43	tasks	O
44	.	O
1	Both	O
2	the	O
3	presence	O
4	of	O
5	arginine	O
6	and	O
7	anaerobiosis	O
8	are	O
9	needed	O
10	to	O
11	trigger	O
12	induction	O
13	of	O
14	the	O
15	pathway	O
16	.	O
1	The	O
2	human	O
3	SHBG	O
4	proximal	O
5	promoter	O
6	was	O
7	analyzed	O
8	by	O
9	DNase	B
10	I	O
11	footprinting	O
12	,	O
13	and	O
14	the	O
15	functional	O
16	significance	O
17	of	O
18	6	O
19	footprinted	O
20	regions	O
21	(	O
22	FP1	O
23	-	O
24	FP6	O
25	)	O
26	within	O
27	the	O
28	proximal	O
29	promoter	O
30	was	O
31	studied	O
32	in	O
33	human	O
34	HepG2	O
35	hepatoblastoma	O
36	cells	O
37	.	O
1	In	O
2	vitro	O
3	translation	O
4	and	O
5	in	O
6	vivo	O
7	polysome	O
8	profile	O
9	analysis	O
10	indicated	O
11	that	O
12	transcripts	O
13	C	O
14	and	O
15	E	O
16	were	O
17	translated	O
18	with	O
19	similar	O
20	translational	O
21	efficiencies	O
22	that	O
23	are	O
24	substantially	O
25	greater	O
26	than	O
27	that	O
28	of	O
29	transcript	O
30	D	O
31	,	O
32	suggesting	O
33	that	O
34	5	O
35	'-	O
36	untranslated	O
37	regions	O
38	play	O
39	a	O
40	role	O
41	in	O
42	translational	O
43	control	O
44	.	O
1	Although	O
2	we	O
3	predicted	O
4	that	O
5	overexpression	O
6	of	O
7	the	O
8	COOH	O
9	-	O
10	terminal	O
11	domains	O
12	,	O
13	which	O
14	were	O
15	thought	O
16	to	O
17	be	O
18	involved	O
19	in	O
20	the	O
21	regulation	O
22	of	O
23	SREBP	O
24	processing	O
25	,	O
26	would	O
27	result	O
28	in	O
29	disruption	O
30	of	O
31	the	O
32	SREBP	O
33	-	O
34	dependent	O
35	transcriptional	O
36	regulation	O
37	of	O
38	several	O
39	genes	O
40	,	O
41	the	O
42	mRNA	O
43	levels	O
44	for	O
45	3	O
46	-	O
47	hydroxy	O
48	-	O
49	3	O
50	-	O
51	methylglutaryl	O
52	coenzyme	O
53	A	O
54	(	O
55	HMG	O
56	CoA	O
57	)	O
58	synthase	O
59	in	O
60	these	O
61	two	O
62	cell	O
63	lines	O
64	were	O
65	regulated	O
66	in	O
67	a	O
68	sterol	O
69	-	O
70	dependent	O
71	manner	O
72	.	O
1	Mean	O
2	intake	O
3	of	O
4	vitamin	O
5	A	O
6	amounted	O
7	to	O
8	1	O
9	.	O
10	1	O
11	and	O
12	0	O
13	.	O
14	9	O
15	mg	O
16	RE	O
17	/	O
18	day	O
19	for	O
20	men	O
21	and	O
22	women	O
23	,	O
24	respectively	O
25	;	O
26	the	O
27	contributions	O
28	of	O
29	meat	O
30	,	O
31	fats	O
32	and	O
33	oils	O
34	,	O
35	vegetables	O
36	and	O
37	dairy	O
38	products	O
39	to	O
40	total	O
41	intake	O
42	were	O
43	35	O
44	%,	O
45	24	O
46	%,	O
47	16	O
48	%,	O
49	and	O
50	16	O
51	%,	O
52	respectively	O
53	.	O
1	Expression	O
2	of	O
3	p130	O
4	(	O
5	Cas	O
6	)	O
7	(	O
8	Cas	O
9	),	O
10	a	O
11	major	O
12	binding	O
13	protein	O
14	for	O
15	the	O
16	Crk	O
17	SH2	O
18	-	O
19	domain	O
20	,	O
21	also	O
22	induced	O
23	JNK	O
24	activation	O
25	,	O
26	which	O
27	was	O
28	blocked	O
29	by	O
30	the	O
31	SH2	O
32	-	O
33	mutant	O
34	of	O
35	Crk	O
36	.	O
1	Further	O
2	,	O
3	we	O
4	show	O
5	that	O
6	this	O
7	EIA	O
8	-	O
9	inducible	O
10	CBF	O
11	/	O
12	cdc2	O
13	is	O
14	related	O
15	to	O
16	the	O
17	CBF	O
18	which	O
19	was	O
20	shown	O
21	to	O
22	activate	O
23	the	O
24	heat	O
25	shock	O
26	protein	O
27	70	O
28	promoter	O
29	.	O
1	The	O
2	orbitofrontal	O
3	,	O
4	cingulate	O
5	,	O
6	and	O
7	anteromedial	O
8	part	O
9	of	O
10	the	O
11	dorsal	O
12	premotor	O
13	areas	O
14	were	O
15	preferentially	O
16	activated	O
17	by	O
18	the	O
19	self	O
20	-	O
21	initiated	O
22	hand	O
23	movement	O
24	task	O
25	(	O
26	SELF	O
27	).	O
1	Six	O
2	putative	O
3	MDV	O
4	genome	O
5	products	O
6	,	O
7	including	O
8	one	O
9	Rep	O
10	and	O
11	five	O
12	non	O
13	-	O
14	Rep	O
15	proteins	O
16	,	O
17	show	O
18	high	O
19	(	O
20	70	O
21	.	O
22	4	O
23	-	O
24	90	O
25	.	O
26	9	O
27	%)	O
28	amino	O
29	acid	O
30	identity	O
31	to	O
32	the	O
33	corresponding	O
34	six	O
35	FBNYV	O
36	proteins	O
37	,	O
38	whereas	O
39	two	O
40	other	O
41	Rep	O
42	proteins	O
43	encoded	O
44	by	O
45	MDV	O
46	-	O
47	C2	O
48	and	O
49	C3	O
50	are	O
51	82	O
52	.	O
53	3	O
54	%	O
55	and	O
56	73	O
57	.	O
58	0	O
59	%	O
60	identical	O
61	to	O
62	those	O
63	encoded	O
64	by	O
65	SCSV	O
66	-	O
67	C2	O
68	and	O
69	C6	O
70	,	O
71	respectively	O
72	.	O
1	TRAF2	O
2	is	O
3	known	O
4	to	O
5	associate	O
6	with	O
7	TRADD	O
8	,	O
9	and	O
10	expression	O
11	of	O
12	a	O
13	dominant	O
14	-	O
15	negative	O
16	N	O
17	-	O
18	terminal	O
19	deletion	O
20	TRAF2	O
21	mutant	O
22	was	O
23	found	O
24	to	O
25	partially	O
26	inhibit	O
27	LMP1	O
28	-	O
29	induced	O
30	JNK	O
31	activation	O
32	in	O
33	293	O
34	cells	O
35	.	O
1	These	O
2	genes	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	Saccharomyces	O
8	cerevisiae	O
9	mutant	O
10	in	O
11	which	O
12	the	O
13	endogenous	O
14	ferrochelatase	O
15	gene	O
16	(	O
17	HEM15	O
18	)	O
19	had	O
20	been	O
21	deleted	O
22	,	O
23	and	O
24	the	O
25	phenotypes	O
26	of	O
27	the	O
28	transformants	O
29	were	O
30	characterized	O
31	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	evidence	O
6	is	O
7	presented	O
8	that	O
9	temporally	O
10	and	O
11	spatially	O
12	specific	O
13	mef2	O
14	expression	O
15	is	O
16	controlled	O
17	by	O
18	a	O
19	complex	O
20	array	O
21	of	O
22	cis	O
23	-	O
24	acting	O
25	regulatory	O
26	modules	O
27	that	O
28	are	O
29	responsive	O
30	to	O
31	different	O
32	genetic	O
33	signals	O
34	.	O
1	Furthermore	O
2	,	O
3	using	O
4	transgenic	O
5	mouse	O
6	technology	O
7	we	O
8	localized	O
9	independent	O
10	cis	O
11	-	O
12	regulatory	O
13	elements	O
14	controlling	O
15	the	O
16	tissue	O
17	-	O
18	specific	O
19	expression	O
20	of	O
21	Pax6	O
22	.	O
1	Immunological	O
2	testing	O
3	was	O
4	performed	O
5	on	O
6	all	O
7	brewery	O
8	workers	O
9	and	O
10	some	O
11	control	O
12	volunteers	O
13	using	O
14	skin	O
15	prick	O
16	testing	O
17	with	O
18	hops	O
19	,	O
20	barley	O
21	,	O
22	and	O
23	yeast	O
24	antigens	O
25	as	O
26	well	O
27	as	O
28	other	O
29	nonoccupational	O
30	allergens	O
31	,	O
32	and	O
33	by	O
34	determining	O
35	total	O
36	serum	O
37	IgE	O
38	levels	O
39	.	O
1	BACKGROUND	O
2	:	O
3	Diazepam	O
4	,	O
5	one	O
6	of	O
7	the	O
8	benzodiazepine	O
9	group	O
10	of	O
11	tranquilizers	O
12	,	O
13	is	O
14	used	O
15	as	O
16	an	O
17	adjunctive	O
18	drug	O
19	for	O
20	sedation	O
21	and	O
22	for	O
23	relief	O
24	of	O
25	anxiety	O
26	in	O
27	the	O
28	treatment	O
29	of	O
30	epilepsy	O
31	.	O
1	This	O
2	Tbx6	O
3	-	O
4	subfamily	O
5	gene	O
6	is	O
7	likely	O
8	to	O
9	participate	O
10	in	O
11	paraxial	O
12	mesoderm	O
13	formation	O
14	and	O
15	somitogenesis	O
16	in	O
17	human	O
18	embryo	O
19	.	O
1	Carbohydrates	O
2	and	O
3	glycoconjugates	O
4	biophysical	O
5	methods	O
6	.	O
1	In	O
2	such	O
3	a	O
4	manner	O
5	,	O
6	activated	O
7	PKR	O
8	inhibits	O
9	cell	O
10	growth	O
11	and	O
12	induces	O
13	apoptosis	O
14	,	O
15	whereas	O
16	disruption	O
17	of	O
18	normal	O
19	PKR	O
20	signaling	O
21	results	O
22	in	O
23	unregulated	O
24	cell	O
25	growth	O
26	.	O
1	Nip7p	O
2	-	O
3	depleted	O
4	cells	O
5	exhibited	O
6	the	O
7	same	O
8	defects	O
9	as	O
10	Nop8p	O
11	-	O
12	depleted	O
13	cells	O
14	,	O
15	except	O
16	that	O
17	they	O
18	accumulated	O
19	27S	O
20	precursors	O
21	.	O
1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	the	O
6	ubiquitous	O
7	expression	O
8	of	O
9	2	O
10	.	O
11	9	O
12	kb	O
13	and	O
14	3	O
15	.	O
1	Magnetically	O
2	induced	O
3	optical	O
4	self	O
5	-	O
6	pulsing	O
7	in	O
8	a	O
9	nonlinear	O
10	resonator	O
11	.	O
1	Next	O
2	,	O
3	to	O
4	identify	O
5	regions	O
6	of	O
7	the	O
8	promoter	O
9	involved	O
10	,	O
11	we	O
12	examined	O
13	a	O
14	series	O
15	of	O
16	tenascin	O
17	-	O
18	C	O
19	promoter	O
20	constructs	O
21	with	O
22	5	O
23	'	O
24	deletions	O
25	and	O
26	showed	O
27	that	O
28	denatured	O
29	collagen	O
30	-	O
31	dependent	O
32	promoter	O
33	activity	O
34	was	O
35	retained	O
36	by	O
37	a	O
38	122	O
39	-	O
40	base	O
41	pair	O
42	element	O
43	,	O
44	located	O
45	-	O
46	43	O
47	to	O
48	-	O
49	165	O
50	bp	O
51	upstream	O
52	of	O
53	the	O
54	RNA	O
55	start	O
56	site	O
57	.	O
1	Human	O
2	MGP	O
3	is	O
4	a	O
5	10	O
6	-	O
7	kD	O
8	skeletal	O
9	extracellular	O
10	matrix	O
11	(	O
12	ECM	O
13	)	O
14	protein	O
15	that	O
16	consists	O
17	of	O
18	an	O
19	84	O
20	-	O
21	aa	O
22	mature	O
23	protein	O
24	and	O
25	a	O
26	19	O
27	-	O
28	aa	O
29	transmembrane	O
30	signal	O
31	peptide	O
32	.	O
1	Dual	O
2	roles	O
3	of	O
4	p82	O
5	,	O
6	the	O
7	clam	O
8	CPEB	O
9	homolog	O
10	,	O
11	in	O
12	cytoplasmic	O
13	polyadenylation	O
14	and	O
15	translational	O
16	masking	O
17	.	O
1	The	O
2	pattern	O
3	of	O
4	RNase	B
5	E	O
6	digestion	O
7	of	O
8	finP305	O
9	RNA	O
10	differed	O
11	from	O
12	FinP	O
13	,	O
14	and	O
15	GST	O
16	-	O
17	FinO	O
18	did	O
19	not	O
20	protect	O
21	finP305	O
22	RNA	O
23	from	O
24	cleavage	O
25	in	O
26	vitro	O
27	.	O
1	In	O
2	the	O
3	second	O
4	case	O
5	,	O
6	an	O
7	epidermal	O
8	cyst	O
9	was	O
10	diagnosed	O
11	.	O
1	MotA	O
2	also	O
3	binds	O
4	a	O
5	DNA	O
6	sequence	O
7	(	O
8	a	O
9	MotA	O
10	box	O
11	),	O
12	centered	O
13	at	O
14	position	O
15	-	O
16	30	O
17	.	O
1	Chem	O
2	.	O
1	C3	O
2	toxin	O
3	completely	O
4	inhibited	O
5	RhoA	O
6	function	O
7	,	O
8	partially	O
9	inhibited	O
10	SRE	O
11	:	O
12	Luc	O
13	activity	O
14	,	O
15	but	O
16	had	O
17	no	O
18	effect	O
19	on	O
20	LPA	O
21	-	O
22	stimulated	O
23	c	B
24	-	O
25	Fos	O
26	expression	O
27	.	O
1	The	O
2	aim	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	examine	O
10	the	O
11	antimicrobial	O
12	susceptibility	O
13	to	O
14	10	O
15	currently	O
16	used	O
17	antimicrobial	O
18	agents	O
19	of	O
20	50	O
21	strains	O
22	of	O
23	P	O
24	.	O
25	acnes	O
26	isolated	O
27	from	O
28	acne	O
29	lesions	O
30	and	O
31	identified	O
32	using	O
33	a	O
34	Rap	O
35	ID	O
36	ANA	O
37	II	O
38	panel	O
39	.	O
1	OBJECTIVE	O
2	:	O
3	This	O
4	meta	O
5	-	O
6	analysis	O
7	of	O
8	67	O
9	controlled	O
10	trials	O
11	was	O
12	performed	O
13	to	O
14	quantify	O
15	the	O
16	cholesterol	O
17	-	O
18	lowering	O
19	effect	O
20	of	O
21	major	O
22	dietary	O
23	fibers	O
24	.	O
1	When	O
2	the	O
3	high	O
4	affinity	O
5	hnRNP	O
6	A1	O
7	binding	O
8	site	O
9	was	O
10	inserted	O
11	into	O
12	the	O
13	beta	B
14	-	O
15	globin	O
16	reporter	O
17	,	O
18	Rev	O
19	was	O
20	able	O
21	to	O
22	increase	O
23	the	O
24	cytoplasmic	O
25	levels	O
26	of	O
27	unspliced	O
28	mRNAs	O
29	to	O
30	14	O
31	%.	O
1	Another	O
2	group	O
3	of	O
4	HIPP	O
5	-	O
6	and	O
7	HCX	O
8	-	O
9	lesioned	O
10	animals	O
11	trained	O
12	on	O
13	the	O
14	tasks	O
15	after	O
16	the	O
17	lesion	O
18	showed	O
19	reduced	O
20	impairments	O
21	of	O
22	the	O
23	type	O
24	described	O
25	above	O
26	,	O
27	suggesting	O
28	that	O
29	extrahippocampal	O
30	structures	O
31	trained	O
32	after	O
33	the	O
34	lesion	O
35	can	O
36	assume	O
37	the	O
38	role	O
39	of	O
40	the	O
41	hippocampus	O
42	to	O
43	some	O
44	degree	O
45	.	O
1	Anisotropic	O
2	heat	O
3	transport	O
4	in	O
5	the	O
6	octylcyanobiphenyl	O
7	(	O
8	8CB	O
9	)	O
10	liquid	O
11	crystal	O
12	.	O
1	The	O
2	lytic	O
3	cycle	O
4	of	O
5	KSHV	O
6	,	O
7	probably	O
8	under	O
9	the	O
10	initial	O
11	control	O
12	of	O
13	the	O
14	KSHV	O
15	/	O
16	Rta	O
17	gene	O
18	,	O
19	may	O
20	directly	O
21	contribute	O
22	to	O
23	tumor	O
24	pathogenesis	O
25	.	O
1	Most	O
2	recently	O
3	,	O
4	the	O
5	use	O
6	of	O
7	the	O
8	product	O
9	of	O
10	brain	O
11	weight	O
12	and	O
13	clearance	O
14	has	O
15	been	O
16	proposed	O
17	.	O
1	In	O
2	concert	O
3	with	O
4	the	O
5	coactivator	O
6	CREB	O
7	binding	O
8	protein	O
9	/	O
10	p300	O
11	,	O
12	which	O
13	interacts	O
14	with	O
15	GABPalpha	O
16	,	O
17	the	O
18	binding	O
19	of	O
20	GABPalpha	O
21	and	O
22	-	O
23	beta	B
24	to	O
25	the	O
26	dyad	O
27	symmetry	O
28	element	O
29	controls	O
30	the	O
31	induction	O
32	of	O
33	IL	B
34	-	O
35	16	O
36	promoter	O
37	in	O
38	T	O
39	cells	O
40	.	O
1	TPO	O
2	by	O
3	itself	O
4	did	O
5	not	O
6	activate	O
7	ERK1	O
8	,	O
9	ERK2	O
10	and	O
11	protein	O
12	kinase	B
13	C	O
14	(	O
15	PKC	B
16	),	O
17	whereas	O
18	TPO	O
19	directly	O
20	enhanced	O
21	the	O
22	PKC	B
23	-	O
24	dependent	O
25	activation	O
26	of	O
27	ERKs	O
28	induced	O
29	by	O
30	other	O
31	agonists	O
32	including	O
33	thrombin	O
34	and	O
35	phorbol	O
36	esters	O
37	,	O
38	without	O
39	affecting	O
40	the	O
41	PKC	B
42	activation	O
43	by	O
44	those	O
45	agonists	O
46	.	O
1	BACKGROUND	O
2	:	O
3	In	O
4	the	O
5	ubiquitin	O
6	-	O
7	dependent	O
8	proteolysis	O
9	pathway	O
10	,	O
11	a	O
12	ubiquitin	O
13	ligase	O
14	(	O
15	E3	O
16	)	O
17	is	O
18	responsible	O
19	for	O
20	substrate	O
21	selectivity	O
22	and	O
23	timing	O
24	of	O
25	degradation	O
26	.	O
1	Temperature	O
2	dependence	O
3	of	O
4	the	O
5	sublattice	O
6	spontaneous	O
7	magnetization	O
8	of	O
9	YBa2Cu3O6	O
10	.	O
1	Testing	O
2	gravity	O
3	to	O
4	second	O
5	post	O
6	-	O
7	Newtonian	O
8	order	O
9	:	O
10	A	O
11	field	O
12	-	O
13	theory	O
14	approach	O
15	.	O
1	In	O
2	the	O
3	current	O
4	model	O
5	,	O
6	Wingless	O
7	/	O
8	Wnt	O
9	signal	O
10	stabilizes	O
11	Armadillo	O
12	/	O
13	beta	B
14	-	O
15	catenin	O
16	,	O
17	which	O
18	then	O
19	accumulates	O
20	in	O
21	nuclei	O
22	and	O
23	binds	O
24	TCF	O
25	/	O
26	LEF	O
27	family	O
28	proteins	O
29	,	O
30	forming	O
31	bipartite	O
32	transcription	O
33	factors	O
34	which	O
35	activate	O
36	transcription	O
37	of	O
38	Wingless	O
39	/	O
40	Wnt	O
41	responsive	O
42	genes	O
43	.	O
1	However	O
2	,	O
3	unlike	O
4	the	O
5	SIN3	O
6	gene	O
7	of	O
8	Saccharomyces	O
9	cerevisiae	O
10	,	O
11	pst1	O
12	(+)	O
13	is	O
14	essential	O
15	for	O
16	cell	O
17	viability	O
18	.	O
1	The	O
2	inhibition	O
3	by	O
4	the	O
5	RIalpha	O
6	subunit	O
7	is	O
8	reversed	O
9	by	O
10	addition	O
11	of	O
12	nanomolar	O
13	concentrations	O
14	of	O
15	cAMP	O
16	(	O
17	Ka	O
18	=	O
19	40	O
20	nM	O
21	),	O
22	thus	O
23	demonstrating	O
24	that	O
25	PrKX	O
26	is	O
27	a	O
28	novel	O
29	,	O
30	type	O
31	I	O
32	cAMP	O
33	-	O
34	dependent	O
35	protein	O
36	kinase	B
37	that	O
38	is	O
39	activated	O
40	at	O
41	lower	O
42	cAMP	O
43	concentrations	O
44	than	O
45	the	O
46	holoenzyme	O
47	with	O
48	the	O
49	Calpha	O
50	subunit	O
51	of	O
52	cAMP	O
53	-	O
54	dependent	O
55	protein	O
56	kinase	B
57	.	O
1	Most	O
2	other	O
3	end	O
4	points	O
5	were	O
6	highly	O
7	significant	O
8	,	O
9	and	O
10	death	O
11	,	O
12	which	O
13	was	O
14	monitored	O
15	across	O
16	the	O
17	U	O
18	.	O
19	S	O
20	.	O
21	program	O
22	,	O
23	was	O
24	different	O
25	with	O
26	p	O
27	<	O
28	0	O
29	.	O
30	0001	O
31	.	O
1	Oscillatory	O
2	exchange	O
3	of	O
4	atoms	O
5	between	O
6	traps	O
7	containing	O
8	Bose	O
9	condensates	O
10	.	O
1	Structure	O
2	determination	O
3	of	O
4	an	O
5	adsorbate	O
6	-	O
7	induced	O
8	multilayer	O
9	reconstruction	O
10	:	O
11	(	O
12	1	O
13	x	O
14	2	O
15	)-	O
16	H	O
17	/	O
18	Ni	O
19	(	O
20	110	O
21	).	O
1	Successful	O
2	interaction	O
3	of	O
4	ARF	O
5	and	O
6	PKC	B
7	-	O
8	alpha	B
9	with	O
10	PLD1	O
11	was	O
12	not	O
13	achieved	O
14	,	O
15	but	O
16	a	O
17	C	O
18	-	O
19	terminal	O
20	fragment	O
21	of	O
22	human	O
23	PLD1	O
24	(	O
25	denoted	O
26	""""	O
27	D4	O
28	""")"	O
29	interacted	O
30	with	O
31	the	O
32	active	O
33	mutant	O
34	of	O
35	RhoA	O
36	,	O
37	RhoAVal	O
38	-	O
39	14	O
40	.	O
1	Recombinant	O
2	unr	O
3	acts	O
4	synergistically	O
5	with	O
6	recombinant	O
7	PTB	O
8	to	O
9	stimulate	O
10	translation	O
11	dependent	O
12	on	O
13	the	O
14	rhinovirus	O
15	IRES	O
16	.	O
1	Identification	O
2	of	O
3	RNase	B
4	T	O
5	as	O
6	a	O
7	high	O
8	-	O
9	copy	O
10	suppressor	O
11	of	O
12	the	O
13	UV	O
14	sensitivity	O
15	associated	O
16	with	O
17	single	O
18	-	O
19	strand	O
20	DNA	O
21	exonuclease	O
22	deficiency	O
23	in	O
24	Escherichia	O
25	coli	O
26	.	O
1	Mutations	O
2	of	O
3	the	O
4	AP	B
5	-	O
6	1	O
7	site	O
8	of	O
9	the	O
10	TIMP	O
11	-	O
12	1	O
13	promoter	O
14	that	O
15	prevented	O
16	formation	O
17	of	O
18	HMAP	O
19	-	O
20	1	O
21	caused	O
22	a	O
23	70	O
24	%	O
25	loss	O
26	of	O
27	activity	O
28	in	O
29	transfected	O
30	activated	O
31	HSCs	O
32	.	O
1	Spectroscopy	O
2	of	O
3	negative	O
4	ions	O
5	utilizing	O
6	multiphoton	O
7	detachment	O
8	in	O
9	a	O
10	Raman	O
11	coupling	O
12	regime	O
13	.	O
1	CPDs	O
2	at	O
3	these	O
4	three	O
5	sites	O
6	may	O
7	partially	O
8	displace	O
9	TFIIIA	O
10	,	O
11	thereby	O
12	enabling	O
13	rapid	O
14	repair	O
15	.	O
1	Cyclin	O
2	D1	O
3	-	O
4	associated	O
5	kinase	B
6	activity	O
7	and	O
8	protein	O
9	levels	O
10	were	O
11	increased	O
12	in	O
13	mammary	O
14	tumors	O
15	from	O
16	murine	O
17	mammary	O
18	tumor	O
19	virus	O
20	-	O
21	pp60	O
22	(	O
23	c	B
24	-	O
25	src527F	O
26	)	O
27	transgenic	O
28	mice	O
29	.	O
1	We	O
2	also	O
3	identified	O
4	an	O
5	alternative	O
6	spliced	O
7	form	O
8	of	O
9	Lyp	O
10	RNA	O
11	,	O
12	Lyp2	O
13	.	O
1	Nipponbare	O
2	as	O
3	well	O
4	as	O
5	O	O
6	.	O
7	australiensis	O
8	.	O
1	The	O
2	results	O
3	of	O
4	supershift	O
5	analysis	O
6	using	O
7	specific	O
8	antibodies	O
9	against	O
10	transcription	O
11	factors	O
12	suggested	O
13	that	O
14	both	O
15	binding	O
16	complexes	O
17	contained	O
18	the	O
19	NF	B
20	-	O
21	kappaB	O
22	components	O
23	p50	O
24	and	O
25	p65	O
26	,	O
27	and	O
28	did	O
29	not	O
30	contain	O
31	other	O
32	NF	B
33	-	O
34	kappaB	O
35	proteins	O
36	(	O
37	p52	O
38	,	O
39	c	B
40	-	O
41	Rel	O
42	,	O
43	Rel	O
44	B	O
45	),	O
46	AP	B
47	-	O
48	1	O
49	proteins	O
50	(	O
51	c	B
52	-	O
53	Fos	O
54	,	O
55	C	O
56	-	O
57	Jun	O
58	),	O
59	CREB	O
60	or	O
61	C	O
62	/	O
63	EBPbeta	O
64	(	O
65	NF	B
66	-	O
67	IL6	O
68	).	O
1	Functional	O
2	domains	O
3	of	O
4	c	B
5	-	O
6	myc	O
7	promoter	O
8	binding	O
9	protein	O
10	1	O
11	involved	O
12	in	O
13	transcriptional	O
14	repression	O
15	and	O
16	cell	O
17	growth	O
18	regulation	O
19	.	O
1	Because	O
2	there	O
3	is	O
4	great	O
5	need	O
6	for	O
7	iron	O
8	in	O
9	the	O
10	EPO	O
11	-	O
12	stimulated	O
13	erythroid	O
14	progenitors	O
15	,	O
16	it	O
17	is	O
18	essential	O
19	that	O
20	serum	O
21	ferritin	O
22	and	O
23	transferrin	O
24	saturation	O
25	levels	O
26	should	O
27	be	O
28	maintained	O
29	over	O
30	300	O
31	microg	O
32	/	O
33	liter	O
34	and	O
35	30	O
36	%,	O
37	respectively	O
38	.	O
1	FASEB	O
2	Federal	O
3	Funding	O
4	Consensus	O
5	Conference	O
6	FY	O
7	2000	O
8	.	O
1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	binding	O
7	sites	O
8	for	O
9	the	O
10	repressor	O
11	proteins	O
12	BP1	O
13	and	O
14	BP2	O
15	in	O
16	the	O
17	upstream	O
18	portion	O
19	of	O
20	the	O
21	beta	B
22	globin	O
23	gene	O
24	flanking	O
25	region	O
26	led	O
27	to	O
28	a	O
29	4	O
30	-	O
31	6	O
32	fold	O
33	increase	O
34	in	O
35	promoter	O
36	activity	O
37	.	O
1	31	O
2	,	O
3	1997	O
4	,	O
5	40	O
6	patients	O
7	had	O
8	died	O
9	(	O
10	35	O
11	in	O
12	the	O
13	ERA	O
14	-	O
15	II	O
16	group	O
17	and	O
18	5	O
19	in	O
20	the	O
21	ERA	O
22	-	O
23	III	O
24	group	O
25	),	O
26	for	O
27	a	O
28	crude	O
29	mortality	O
30	rate	O
31	of	O
32	8	O
33	.	O
34	0	O
35	%.	O
1	Because	O
2	of	O
3	concerns	O
4	regarding	O
5	blood	O
6	transfusion	O
7	-	O
8	related	O
9	communicable	O
10	disease	O
11	(	O
12	eg	O
13	,	O
14	acquired	O
15	immune	O
16	deficiency	O
17	syndrome	O
18	and	O
19	non	O
20	-	O
21	A	O
22	,	O
23	non	O
24	-	O
25	B	O
26	hepatitis	O
27	),	O
28	there	O
29	has	O
30	been	O
31	increasing	O
32	research	O
33	effort	O
34	into	O
35	postoperative	O
36	hemorrhage	O
37	related	O
38	to	O
39	cardiopulmonary	O
40	bypass	O
41	with	O
42	extracorporeal	O
43	circulation	O
44	.	O
1	These	O
2	results	O
3	suggest	O
4	KCC3	O
5	is	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	KCC	O
12	family	O
13	that	O
14	is	O
15	under	O
16	distinct	O
17	regulation	O
18	from	O
19	KCC1	O
20	.	O
1	The	O
2	peroxisome	O
3	proliferator	O
4	-	O
5	activated	O
6	receptors	O
7	(	O
8	PPARs	O
9	)	O
10	are	O
11	members	O
12	of	O
13	the	O
14	nuclear	O
15	hormone	O
16	receptor	B
17	superfamily	O
18	.	O
1	However	O
2	,	O
3	F	O
4	-	O
5	SRC	O
6	-	O
7	1	O
8	mutant	O
9	lacking	O
10	CBP	O
11	-	O
12	interacting	O
13	domain	O
14	still	O
15	preserved	O
16	enhancing	O
17	activity	O
18	.	O
1	The	O
2	Asian	O
3	mouse	O
4	Mus	O
5	castaneus	O
6	is	O
7	resistant	O
8	to	O
9	infection	O
10	by	O
11	the	O
12	polytropic	O
13	mink	O
14	cell	O
15	focus	O
16	-	O
17	inducing	O
18	(	O
19	MCF	O
20	)	O
21	subgroup	O
22	of	O
23	murine	O
24	leukemia	O
25	viruses	O
26	(	O
27	MuLVs	O
28	).	O
1	Three	O
2	different	O
3	site	O
4	-	O
5	directed	O
6	mutations	O
7	of	O
8	the	O
9	cyclic	O
10	AMP	O
11	response	O
12	element	O
13	each	O
14	reduced	O
15	the	O
16	nerve	O
17	growth	O
18	factor	O
19	effect	O
20	by	O
21	>	O
22	90	O
23	%.	O
1	Using	O
2	an	O
3	RNase	B
4	H	O
5	protection	O
6	assay	O
7	and	O
8	specific	O
9	blocking	O
10	oligonucleotides	O
11	,	O
12	we	O
13	find	O
14	that	O
15	recognition	O
16	of	O
17	the	O
18	5	O
19	'	O
20	splice	O
21	-	O
22	site	O
23	(	O
24	5	O
25	'	O
26	ss	O
27	)	O
28	and	O
29	branchpoint	O
30	sequence	O
31	(	O
32	BPS	O
33	)	O
34	elements	O
35	by	O
36	U11	O
37	and	O
38	U12	O
39	snRNPs	O
40	,	O
41	respectively	O
42	,	O
43	displays	O
44	strong	O
45	cooperativity	O
46	,	O
47	requiring	O
48	both	O
49	sites	O
50	in	O
51	the	O
52	pre	O
53	-	O
54	mRNA	O
55	substrate	O
56	for	O
57	efficient	O
58	complex	O
59	formation	O
60	.	O
1	Analysis	O
2	of	O
3	lacZ	O
4	transcriptional	O
5	fusions	O
6	shows	O
7	that	O
8	the	O
9	KdgR	O
10	-	O
11	binding	O
12	sites	O
13	negatively	O
14	affect	O
15	the	O
16	expression	O
17	of	O
18	rsmB	O
19	.	O
1	In	O
2	ischemic	O
3	and	O
4	hypoxic	O
5	hypoxia	O
6	,	O
7	a	O
8	strong	O
9	correlation	O
10	was	O
11	found	O
12	between	O
13	cyt	O
14	a	O
15	,	O
16	a3	O
17	oxidation	O
18	level	O
19	and	O
20	VO2	O
21	in	O
22	both	O
23	ischemic	O
24	and	O
25	hypoxic	O
26	hypoxia	O
27	(	O
28	r2	O
29	=.	O
30	90	O
31	and	O
32	.	O
33	87	O
34	,	O
35	respectively	O
36	).	O
1	An	O
2	endogenous	O
3	mammalian	O
4	regulator	O
5	of	O
6	this	O
7	process	O
8	,	O
9	named	O
10	Usurpin	O
11	,	O
12	has	O
13	been	O
14	identified	O
15	(	O
16	aliases	O
17	for	O
18	Usurpin	O
19	include	O
20	CASH	O
21	,	O
22	Casper	O
23	,	O
24	CLARP	O
25	,	O
26	FLAME	O
27	-	O
28	1	O
29	,	O
30	FLIP	O
31	,	O
32	I	O
33	-	O
34	FLICE	O
35	and	O
36	MRIT	O
37	).	O
1	Technetium	O
2	-	O
3	99m	O
4	methylene	O
5	diphosphonate	O
6	scintimammography	O
7	for	O
8	evaluation	O
9	of	O
10	palpable	O
11	breast	O
12	masses	O
13	.	O
1	INTERVENTIONS	O
2	:	O
3	Study	O
4	patients	O
5	were	O
6	randomly	O
7	divided	O
8	into	O
9	four	O
10	parallel	O
11	groups	O
12	to	O
13	receive	O
14	either	O
15	terbinafine	O
16	250	O
17	mg	O
18	a	O
19	day	O
20	for	O
21	12	O
22	or	O
23	16	O
24	weeks	O
25	(	O
26	groups	O
27	T12	O
28	and	O
29	T16	O
30	)	O
31	or	O
32	itraconazole	O
33	400	O
34	mg	O
35	a	O
36	day	O
37	for	O
38	1	O
39	week	O
40	in	O
41	every	O
42	4	O
43	weeks	O
44	for	O
45	12	O
46	or	O
47	16	O
48	weeks	O
49	(	O
50	groups	O
51	I3	O
52	and	O
53	I4	O
54	).	O
1	The	O
2	Fyn	O
3	NH2	O
4	terminus	O
5	was	O
6	necessary	O
7	but	O
8	not	O
9	sufficient	O
10	for	O
11	interaction	O
12	with	O
13	zeta	O
14	and	O
15	both	O
16	Fyn	O
17	kinase	B
18	and	O
19	SH2	O
20	domains	O
21	were	O
22	required	O
23	,	O
24	directing	O
25	phosphorylation	O
26	of	O
27	zeta	O
28	ITAM	O
29	tyrosines	O
30	and	O
31	binding	O
32	to	O
33	zeta	O
34	ITAM	O
35	phosphotyrosines	O
36	.	O
1	Antithrombin	O
2	III	O
3	prevents	O
4	60	O
5	min	O
6	warm	O
7	intestinal	O
8	ischemia	O
9	reperfusion	O
10	injury	O
11	in	O
12	rats	O
13	.	O
1	Significantly	O
2	greater	O
3	improvement	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	05	O
10	)	O
11	in	O
12	the	O
13	sertraline	O
14	group	O
15	first	O
16	became	O
17	apparent	O
18	by	O
19	the	O
20	end	O
21	of	O
22	week	O
23	3	O
24	on	O
25	the	O
26	Y	O
27	-	O
28	BOCS	O
29	and	O
30	the	O
31	CGI	O
32	Improvement	O
33	scale	O
34	,	O
35	and	O
36	by	O
37	the	O
38	end	O
39	of	O
40	weeks	O
41	6	O
42	and	O
43	8	O
44	,	O
45	respectively	O
46	,	O
47	on	O
48	the	O
49	NIMH	O
50	and	O
51	CGI	O
52	Severity	O
53	scale	O
54	.	O
1	Significant	O
2	correlations	O
3	between	O
4	mental	O
5	status	O
6	as	O
7	measured	O
8	by	O
9	the	O
10	Mini	O
11	-	O
12	Mental	O
13	State	O
14	Examination	O
15	and	O
16	NA	O
17	/	O
18	mI	O
19	,	O
20	mI	O
21	/	O
22	Cr	O
23	and	O
24	NA	O
25	were	O
26	found	O
27	.	O
1	Solution	O
2	structure	O
3	and	O
4	mechanism	O
5	of	O
6	the	O
7	MutT	O
8	pyrophosphohydrolase	O
9	.	O
1	Their	O
2	afterglows	O
3	are	O
4	brighter	O
5	than	O
6	supernovae	O
7	and	O
8	therefore	O
9	are	O
10	called	O
11	hypernovae	O
12	.	O
1	Evidence	O
2	for	O
3	the	O
4	involvement	O
5	of	O
6	the	O
7	Glc7	O
8	-	O
9	Reg1	O
10	phosphatase	B
11	and	O
12	the	O
13	Snf1	O
14	-	O
15	Snf4	O
16	kinase	B
17	in	O
18	the	O
19	regulation	O
20	of	O
21	INO1	O
22	transcription	O
23	in	O
24	Saccharomyces	O
25	cerevisiae	O
26	.	O
1	Commonly	O
2	used	O
3	stressors	O
4	are	O
5	mental	O
6	arithmetics	O
7	,	O
8	speech	O
9	tasks	O
10	,	O
11	the	O
12	Stroop	O
13	test	O
14	,	O
15	videogame	O
16	playing	O
17	,	O
18	films	O
19	or	O
20	videotapes	O
21	and	O
22	interviews	O
23	.	O
1	The	O
2	5	O
3	'	O
4	untranslated	O
5	and	O
6	coding	O
7	regions	O
8	are	O
9	contained	O
10	within	O
11	12	O
12	exons	O
13	,	O
14	with	O
15	the	O
16	translation	O
17	start	O
18	site	O
19	located	O
20	within	O
21	the	O
22	first	O
23	exon	O
24	.	O
1	The	O
2	motility	O
3	of	O
4	sperm	O
5	,	O
6	except	O
7	for	O
8	those	O
9	adjacent	O
10	to	O
11	both	O
12	electrodes	O
13	,	O
14	did	O
15	not	O
16	change	O
17	after	O
18	stimulation	O
19	for	O
20	60s	O
21	,	O
22	despite	O
23	a	O
24	high	O
25	electrical	O
26	energy	O
27	.	O
1	A	O
2	Bub2p	O
3	-	O
4	dependent	O
5	spindle	O
6	checkpoint	O
7	pathway	O
8	regulates	O
9	the	O
10	Dbf2p	O
11	kinase	B
12	in	O
13	budding	O
14	yeast	O
15	.	O
1	Two	O
2	-	O
3	dimensional	O
4	gel	O
5	electrophoresis	O
6	of	O
7	anti	B
8	-	O
9	p59fyn	O
10	immunoprecipitates	O
11	obtained	O
12	from	O
13	non	O
14	-	O
15	transformed	O
16	resting	O
17	human	O
18	T	O
19	lymphocytes	O
20	resulted	O
21	in	O
22	the	O
23	identification	O
24	of	O
25	an	O
26	oligomeric	O
27	protein	O
28	complex	O
29	which	O
30	is	O
31	constitutively	O
32	formed	O
33	between	O
34	Fyn	O
35	and	O
36	several	O
37	additional	O
38	phosphoproteins	O
39	(	O
40	pp43	O
41	,	O
42	pp72	O
43	,	O
44	pp85	O
45	,	O
46	the	O
47	protein	O
48	tyrosine	O
49	kinase	B
50	Pyk2	O
51	,	O
52	as	O
53	well	O
54	as	O
55	the	O
56	two	O
57	recently	O
58	cloned	O
59	adaptor	O
60	proteins	O
61	,	O
62	SKAP55	O
63	and	O
64	SLAP	O
65	-	O
66	130	O
67	).	O
1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	showed	O
6	that	O
7	two	O
8	adjacent	O
9	SP1	O
10	sites	O
11	proximal	O
12	to	O
13	exon	O
14	1	O
15	were	O
16	equally	O
17	important	O
18	in	O
19	sustaining	O
20	basal	O
21	promoter	O
22	activity	O
23	.	O
1	Despite	O
2	the	O
3	reported	O
4	detrimental	O
5	effects	O
6	on	O
7	CNS	O
8	development	O
9	,	O
10	a	O
11	number	O
12	of	O
13	animal	O
14	studies	O
15	have	O
16	shown	O
17	that	O
18	pretreatment	O
19	with	O
20	corticosteroids	O
21	nevertheless	O
22	protect	O
23	the	O
24	brain	O
25	from	O
26	hypoxia	O
27	-	O
28	ischemic	O
29	injury	O
30	;	O
31	however	O
32	,	O
33	clinically	O
34	such	O
35	treatment	O
36	is	O
37	no	O
38	longer	O
39	favored	O
40	.	O
1	Predictors	O
2	of	O
3	success	O
4	in	O
5	pharmacy	O
6	school	O
7	:	O
8	PCAT	O
9	vs	O
10	.	O
11	other	O
12	admission	O
13	criteria	O
14	.	O
1	Canadian	O
2	survey	O
3	reveals	O
4	widespread	O
5	dissatisfaction	O
6	among	O
7	physicians	O
8	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	calpeptin	O
6	inhibits	O
7	tyrosine	O
8	phosphatases	O
9	,	O
10	enhancing	O
11	tyrosine	O
12	phosphorylation	O
13	particularly	O
14	of	O
15	paxillin	O
16	.	O
1	Taken	O
2	together	O
3	,	O
4	these	O
5	findings	O
6	show	O
7	that	O
8	16K	O
9	hPRL	O
10	inhibits	O
11	the	O
12	VEGF	O
13	-	O
14	induced	O
15	Ras	B
16	activation	O
17	;	O
18	this	O
19	antagonism	O
20	represents	O
21	a	O
22	novel	O
23	and	O
24	potentially	O
25	important	O
26	mechanism	O
27	for	O
28	the	O
29	control	O
30	of	O
31	angiogenesis	O
32	.	O
1	Rep63A	O
2	(	O
3	513	O
4	amino	O
5	acids	O
6	[	O
7	aa	O
8	]),	O
9	encoded	O
10	by	O
11	the	O
12	largest	O
13	ORF	O
14	,	O
15	displayed	O
16	strong	O
17	similarity	O
18	(	O
19	40	O
20	%	O
21	identity	O
22	)	O
23	to	O
24	the	O
25	replication	O
26	proteins	O
27	from	O
28	plasmids	O
29	pAMbeta1	O
30	,	O
31	pIP501	O
32	,	O
33	and	O
34	pSM19035	O
35	,	O
36	indicating	O
37	that	O
38	the	O
39	pAW63	O
40	replicon	O
41	belongs	O
42	to	O
43	the	O
44	pAMbeta1	O
45	family	O
46	of	O
47	gram	O
48	-	O
49	positive	O
50	theta	O
51	-	O
52	replicating	O
53	plasmids	O
54	.	O
1	According	O
2	to	O
3	pilot	O
4	experiments	O
5	which	O
6	considered	O
7	various	O
8	durations	O
9	of	O
10	global	O
11	no	O
12	-	O
13	flow	O
14	ischemia	O
15	ranging	O
16	from	O
17	10	O
18	to	O
19	20	O
20	minutes	O
21	,	O
22	two	O
23	durations	O
24	were	O
25	chosen	O
26	for	O
27	the	O
28	present	O
29	study	O
30	:	O
31	20	O
32	minutes	O
33	(	O
34	group	O
35	20	O
36	)	O
37	in	O
38	which	O
39	ventricular	O
40	fibrillation	O
41	(	O
42	VF	O
43	)	O
44	was	O
45	the	O
46	predominant	O
47	form	O
48	of	O
49	arrhythmias	O
50	,	O
51	and	O
52	18	O
53	minutes	O
54	(	O
55	group	O
56	18	O
57	)	O
58	in	O
59	which	O
60	the	O
61	prevalence	O
62	of	O
63	VF	O
64	was	O
65	markedly	O
66	lower	O
67	despite	O
68	the	O
69	small	O
70	difference	O
71	in	O
72	the	O
73	duration	O
74	of	O
75	ischemia	O
76	.	O
1	In	O
2	the	O
3	case	O
4	of	O
5	the	O
6	unspliceable	O
7	intron	O
8	,	O
9	repression	O
10	of	O
11	luciferase	O
12	expression	O
13	likely	O
14	involved	O
15	two	O
16	AUF1	O
17	-	O
18	binding	O
19	sequences	O
20	,	O
21	since	O
22	luciferase	O
23	expression	O
24	was	O
25	increased	O
26	by	O
27	deletion	O
28	of	O
29	these	O
30	sites	O
31	.	O
1	This	O
2	dimer	O
3	interface	O
4	is	O
5	likely	O
6	important	O
7	for	O
8	increasing	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	specificity	O
14	and	O
15	affinity	O
16	of	O
17	the	O
18	trimeric	O
19	form	O
20	of	O
21	HSF	O
22	,	O
23	as	O
24	well	O
25	as	O
26	for	O
27	increasing	O
28	cooperativity	O
29	between	O
30	adjacent	O
31	trimers	O
32	.	O
1	While	O
2	determination	O
3	of	O
4	the	O
5	protein	O
6	content	O
7	of	O
8	the	O
9	formulae	O
10	gave	O
11	no	O
12	valid	O
13	information	O
14	,	O
15	RAST	O
16	/	O
17	EAST	O
18	inhibition	O
19	was	O
20	highest	O
21	for	O
22	cow	O
23	'	O
24	s	O
25	milk	O
26	,	O
27	followed	O
28	by	O
29	the	O
30	partially	O
31	hydrolysed	O
32	whey	O
33	formula	O
34	,	O
35	partially	O
36	hydrolysed	O
37	whey	O
38	/	O
39	casein	O
40	formula	O
41	,	O
42	soy	O
43	/	O
44	pork	O
45	collagen	O
46	formula	O
47	,	O
48	and	O
49	the	O
50	amino	O
51	acid	O
52	formula	O
53	.	O
1	The	O
2	influence	O
3	of	O
4	Epstein	O
5	-	O
6	Barr	O
7	virus	O
8	seropositivity	O
9	on	O
10	the	O
11	efficacy	O
12	of	O
13	intravenous	O
14	immune	O
15	globulin	O
16	in	O
17	children	O
18	with	O
19	immune	O
20	thrombocytopenic	O
21	purpura	O
22	.	O
1	Amisulpride	O
2	400	O
3	mg	O
4	had	O
5	several	O
6	adverse	O
7	effects	O
8	on	O
9	psychomotor	O
10	and	O
11	,	O
12	although	O
13	less	O
14	severe	O
15	,	O
16	on	O
17	cognitive	O
18	performance	O
19	on	O
20	the	O
21	fifth	O
22	day	O
23	only	O
24	.	O
1	MutY	O
2	is	O
3	an	O
4	adenine	O
5	-	O
6	DNA	O
7	glycosylase	O
8	with	O
9	specificity	O
10	for	O
11	mismatches	O
12	involving	O
13	8	O
14	-	O
15	oxoguanine	O
16	(	O
17	oG	O
18	.	O
19	A	O
20	)	O
21	or	O
22	guanine	O
23	(	O
24	G	O
25	.	O
26	A	O
27	).	O
1	DAF16	O
2	is	O
3	known	O
4	to	O
5	be	O
6	a	O
7	component	O
8	of	O
9	a	O
10	signaling	O
11	pathway	O
12	that	O
13	has	O
14	been	O
15	partially	O
16	dissected	O
17	genetically	O
18	and	O
19	includes	O
20	homologues	O
21	of	O
22	the	O
23	insulin	B
24	/	O
25	IGF	O
26	-	O
27	1	O
28	receptor	B
29	,	O
30	PtdIns	O
31	3	O
32	-	O
33	kinase	B
34	and	O
35	PKB	O
36	.	O
1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	the	O
8	expression	O
9	of	O
10	c	B
11	-	O
12	Jun	O
13	plus	O
14	c	B
15	-	O
16	Fos	O
17	enhanced	O
18	the	O
19	transactivation	O
20	of	O
21	oIFNtau	O
22	-	O
23	CAT	O
24	but	O
25	the	O
26	expression	O
27	of	O
28	GATA	O
29	-	O
30	1	O
31	,	O
32	GATA	O
33	-	O
34	2	O
35	or	O
36	GATA	O
37	-	O
38	3	O
39	did	O
40	not	O
41	.	O
1	They	O
2	also	O
3	occur	O
4	in	O
5	similar	O
6	locations	O
7	in	O
8	the	O
9	promoters	O
10	of	O
11	several	O
12	other	O
13	ribosomal	O
14	protein	O
15	genes	O
16	.	O
1	RESULTS	O
2	:	O
3	Transpulmonary	O
4	passage	O
5	of	O
6	contrast	O
7	occurred	O
8	in	O
9	sufficient	O
10	amounts	O
11	to	O
12	enhance	O
13	the	O
14	intensity	O
15	of	O
16	the	O
17	Doppler	O
18	signal	O
19	significantly	O
20	,	O
21	but	O
22	the	O
23	duration	O
24	of	O
25	this	O
26	effect	O
27	was	O
28	short	O
29	.	O
1	In	O
2	this	O
3	paper	O
4	,	O
5	such	O
6	lesions	O
7	in	O
8	two	O
9	cases	O
10	were	O
11	evaluated	O
12	by	O
13	ultrasonography	O
14	.	O
1	These	O
2	regions	O
3	contain	O
4	inverted	O
5	E	O
6	-	O
7	box	O
8	palindromic	O
9	or	O
10	direct	O
11	repeat	O
12	motifs	O
13	and	O
14	bind	O
15	SREBP	O
16	-	O
17	1	O
18	with	O
19	different	O
20	affinities	O
21	.	O
1	To	O
2	address	O
3	these	O
4	questions	O
5	,	O
6	a	O
7	recombinant	O
8	FRAP	O
9	/	O
10	mTOR	O
11	protein	O
12	and	O
13	a	O
14	FRAP	O
15	/	O
16	mTOR	O
17	immunoprecipitate	O
18	were	O
19	utilized	O
20	in	O
21	in	O
22	vitro	O
23	kinase	B
24	assays	O
25	to	O
26	phosphorylate	O
27	4E	O
28	-	O
29	BP1	O
30	.	O
1	With	O
2	exon	O
3	trapping	O
4	,	O
5	we	O
6	could	O
7	isolate	O
8	five	O
9	potential	O
10	exons	O
11	from	O
12	the	O
13	YAC	O
14	946E12	O
15	that	O
16	spans	O
17	the	O
18	region	O
19	,	O
20	four	O
21	of	O
22	which	O
23	could	O
24	be	O
25	placed	O
26	in	O
27	the	O
28	contig	O
29	in	O
30	the	O
31	vicinity	O
32	of	O
33	the	O
34	breakpoints	O
35	.	O
1	Binding	O
2	affinities	O
3	of	O
4	these	O
5	recombinant	O
6	phages	O
7	as	O
8	determined	O
9	by	O
10	the	O
11	retention	O
12	of	O
13	these	O
14	phages	O
15	by	O
16	a	O
17	His	O
18	-	O
19	tag	O
20	immobilized	O
21	gp17	O
22	column	O
23	,	O
24	and	O
25	by	O
26	co	O
27	-	O
28	immunoprecipitation	O
29	with	O
30	purified	O
31	terminase	O
32	supported	O
33	the	O
34	specific	O
35	nature	O
36	of	O
37	the	O
38	portal	O
39	protein	O
40	and	O
41	terminase	O
42	interaction	O
43	sites	O
44	.	O
1	The	O
2	FCMS	O
3	conditions	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	2	O
9	kW	O
10	maximum	O
11	electrical	O
12	power	O
13	consumption	O
14	,	O
15	800	O
16	V	O
17	maximum	O
18	capacitor	O
19	voltage	O
20	,	O
21	720	O
22	microseconds	O
23	pulsewidth	O
24	(	O
25	180	O
26	microseconds	O
27	rise	O
28	time	O
29	),	O
30	and	O
31	5	O
32	-	O
33	30	O
34	Hz	O
35	frequency	O
36	.	O
1	The	O
2	major	O
3	transcription	O
4	factors	O
5	controlling	O
6	arginine	O
7	metabolism	O
8	in	O
9	Escherichia	O
10	coli	O
11	and	O
12	Bacillus	O
13	subtilis	O
14	,	O
15	ArgR	O
16	and	O
17	AhrC	O
18	,	O
19	respectively	O
20	,	O
21	are	O
22	homologous	O
23	multimeric	O
24	proteins	O
25	that	O
26	form	O
27	l	O
28	-	O
29	arginine	O
30	-	O
31	dependent	O
32	DNA	O
33	-	O
34	binding	O
35	complexes	O
36	capable	O
37	of	O
38	repressing	O
39	transcription	O
40	of	O
41	the	O
42	biosynthetic	O
43	genes	O
44	(	O
45	both	O
46	),	O
47	activating	O
48	transcription	O
49	of	O
50	catabolic	O
51	genes	O
52	(	O
53	AhrC	O
54	only	O
55	)	O
56	or	O
57	facilitating	O
58	plasmid	O
59	dimer	O
60	resolution	O
61	(	O
62	both	O
63	).	O
1	As	O
2	is	O
3	deduced	O
4	from	O
5	the	O
6	nucleotide	O
7	sequence	O
8	of	O
9	the	O
10	cDNA	O
11	,	O
12	CBS	O
13	-	O
14	1	O
15	contains	O
16	an	O
17	open	O
18	reading	O
19	frame	O
20	consisting	O
21	of	O
22	182	O
23	amino	O
24	acids	O
25	,	O
26	with	O
27	a	O
28	molecular	O
29	weight	O
30	of	O
31	19	O
32	.	O
33	5kDa	O
34	.	O
1	Basic	O
2	fibroblast	O
3	growth	O
4	factor	O
5	(	O
6	bFGF	O
7	)	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	induce	O
13	angiogenesis	O
14	in	O
15	various	O
16	animal	O
17	models	O
18	,	O
19	but	O
20	the	O
21	methods	O
22	of	O
23	administration	O
24	used	O
25	experimentally	O
26	are	O
27	not	O
28	clinically	O
29	feasible	O
30	.	O
1	These	O
2	single	O
3	mutational	O
4	defects	O
5	in	O
6	the	O
7	eRF1	O
8	-	O
9	eRF3	O
10	interaction	O
11	became	O
12	evident	O
13	when	O
14	either	O
15	truncated	O
16	protein	O
17	eRF3C	O
18	or	O
19	C	O
20	-	O
21	terminally	O
22	altered	O
23	eRF1	O
24	proteins	O
25	were	O
26	used	O
27	for	O
28	the	O
29	authentic	O
30	protein	O
31	,	O
32	providing	O
33	further	O
34	support	O
35	for	O
36	the	O
37	presence	O
38	of	O
39	a	O
40	C	O
41	-	O
42	terminal	O
43	interaction	O
44	.	O
1	Consistent	O
2	with	O
3	this	O
4	possibility	O
5	,	O
6	a	O
7	non	O
8	-	O
9	MBD	O
10	region	O
11	of	O
12	Bin1	O
13	was	O
14	sufficient	O
15	to	O
16	recruit	O
17	a	O
18	repression	O
19	function	O
20	to	O
21	DNA	O
22	that	O
23	was	O
24	unrelated	O
25	to	O
26	histone	O
27	deacetylase	O
28	.	O
1	The	O
2	results	O
3	of	O
4	these	O
5	studies	O
6	support	O
7	a	O
8	model	O
9	in	O
10	which	O
11	VirB4	O
12	dimers	O
13	or	O
14	homomultimers	O
15	contribute	O
16	structural	O
17	information	O
18	for	O
19	the	O
20	assembly	O
21	of	O
22	a	O
23	transenvelope	O
24	channel	O
25	competent	O
26	for	O
27	bidirectional	O
28	DNA	O
29	transfer	O
30	,	O
31	whereas	O
32	an	O
33	ATP	O
34	-	O
35	dependent	O
36	activity	O
37	is	O
38	required	O
39	for	O
40	configuring	O
41	this	O
42	channel	O
43	as	O
44	a	O
45	dedicated	O
46	export	O
47	machine	O
48	.	O
1	The	O
2	penicillin	O
3	binding	O
4	proteins	O
5	(	O
6	PBPs	O
7	)	O
8	synthesize	O
9	and	O
10	remodel	O
11	peptidoglycan	O
12	,	O
13	the	O
14	structural	O
15	component	O
16	of	O
17	the	O
18	bacterial	O
19	cell	O
20	wall	O
21	.	O
1	Point	O
2	mutations	O
3	of	O
4	the	O
5	site	O
6	that	O
7	suppressed	O
8	Pit	O
9	-	O
10	1	O
11	binding	O
12	in	O
13	vitro	O
14	restored	O
15	full	O
16	tiGH	O
17	promoter	O
18	activity	O
19	.	O
1	The	O
2	bovine	O
3	papillomavirus	O
4	E2	O
5	protein	O
6	can	O
7	inhibit	O
8	the	O
9	proliferation	O
10	of	O
11	HT	O
12	-	O
13	3	O
14	cells	O
15	,	O
16	a	O
17	p53	B
18	-	O
19	negative	O
20	cervical	O
21	carcinoma	O
22	cell	O
23	line	O
24	containing	O
25	integrated	O
26	human	O
27	papillomavirus	O
28	type	O
29	30	O
30	DNA	O
31	.	O
1	The	O
2	PAC	O
3	clone	O
4	with	O
5	an	O
6	insert	O
7	size	O
8	of	O
9	120kb	O
10	was	O
11	isolated	O
12	and	O
13	mapped	O
14	by	O
15	restriction	O
16	analysis	O
17	.	O
1	About	O
2	20	O
3	kb	O
4	upstream	O
5	of	O
6	LAMB2	O
7	we	O
8	found	O
9	a	O
10	gene	O
11	encoding	O
12	a	O
13	transcribed	O
14	,	O
15	non	O
16	-	O
17	processed	O
18	LAMB2	O
19	-	O
20	like	O
21	pseudogene	O
22	(	O
23	LAMB2L	O
24	).	O
1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	R2	O
8	protein	O
9	was	O
10	used	O
11	to	O
12	provide	O
13	evidence	O
14	that	O
15	this	O
16	motif	O
17	is	O
18	also	O
19	part	O
20	of	O
21	the	O
22	active	O
23	site	O
24	of	O
25	the	O
26	endonuclease	O
27	encoded	O
28	by	O
29	this	O
30	element	O
31	.	O
1	G	O
2	-	O
3	box	O
4	-	O
5	directed	O
6	expression	O
7	in	O
8	leaves	O
9	required	O
10	the	O
11	presence	O
12	of	O
13	an	O
14	enhancer	O
15	region	O
16	from	O
17	the	O
18	cauliflower	O
19	mosaic	O
20	virus	O
21	(	O
22	CaMV	O
23	)	O
24	35S	O
25	promoter	O
26	.	O
1	Our	O
2	data	O
3	therefore	O
4	indicate	O
5	that	O
6	it	O
7	is	O
8	possible	O
9	to	O
10	engineer	O
11	the	O
12	HA	O
13	envelope	O
14	glycoprotein	O
15	by	O
16	fusing	O
17	ligands	O
18	to	O
19	its	O
20	amino	O
21	-	O
22	terminal	O
23	end	O
24	without	O
25	affecting	O
26	its	O
27	fusion	O
28	activity	O
29	.	O
1	Characterisation	O
2	of	O
3	the	O
4	chicken	O
5	apolipoprotein	O
6	A	O
7	-	O
8	I	O
9	gene	O
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	members	O
6	of	O
7	the	O
8	ATF	O
9	family	O
10	are	O
11	involved	O
12	in	O
13	mediating	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	the	O
19	KGF	O
20	gene	O
21	in	O
22	response	O
23	to	O
24	extracellular	O
25	stimuli	O
26	via	O
27	a	O
28	novel	O
29	CRE	O
30	regulatory	O
31	element	O
32	.	O
1	Moreover	O
2	,	O
3	a	O
4	high	O
5	proportion	O
6	of	O
7	blood	O
8	samples	O
9	from	O
10	a	O
11	random	O
12	sample	O
13	of	O
14	the	O
15	rest	O
16	of	O
17	the	O
18	suspects	O
19	tested	O
20	positive	O
21	for	O
22	trypanosome	O
23	-	O
24	specific	O
25	DNA	O
26	by	O
27	PCR	O
28	(	O
29	79	O
30	.	O
31	9	O
32	%	O
33	for	O
34	T	O
35	.	O
36	b	O
37	.	O
38	gambiense	O
39	and	O
40	13	O
41	.	O
42	9	O
43	%	O
44	for	O
45	T	O
46	.	O
47	b	O
48	.	O
49	rhodesiense	O
50	).	O
1	CXCR4	O
2	is	O
3	a	O
4	chemokine	O
5	receptor	B
6	and	O
7	a	O
8	coreceptor	O
9	for	O
10	T	O
11	-	O
12	cell	O
13	-	O
14	line	O
15	-	O
16	tropic	O
17	(	O
18	X4	O
19	)	O
20	and	O
21	dual	O
22	-	O
23	tropic	O
24	(	O
25	R5X4	O
26	)	O
27	human	O
28	immunodeficiency	O
29	virus	O
30	type	O
31	1	O
32	(	O
33	HIV	O
34	-	O
35	1	O
36	)	O
37	isolates	O
38	.	O
1	SM	O
2	is	O
3	also	O
4	shown	O
5	to	O
6	be	O
7	associated	O
8	in	O
9	vivo	O
10	with	O
11	other	O
12	components	O
13	of	O
14	the	O
15	CRM	O
16	1	O
17	export	O
18	pathway	O
19	,	O
20	including	O
21	the	O
22	small	O
23	GTPase	B
24	Ran	O
25	and	O
26	the	O
27	nucleoporin	O
28	CAN	O
29	/	O
30	Nup214	O
31	.	O
1	Auditory	O
2	clicks	O
3	were	O
4	given	O
5	at	O
6	a	O
7	rate	O
8	of	O
9	20	O
10	s	O
11	(-	O
12	1	O
13	).	O
1	The	O
2	transcriptional	O
3	activities	O
4	of	O
5	the	O
6	full	O
7	-	O
8	length	O
9	promoter	O
10	(-	O
11	295	O
12	to	O
13	+	O
14	85	O
15	)	O
16	and	O
17	of	O
18	three	O
19	deletion	O
20	constructs	O
21	(-	O
22	197	O
23	,	O
24	-	O
25	154	O
26	and	O
27	-	O
28	74	O
29	to	O
30	+	O
31	85	O
32	)	O
33	were	O
34	significantly	O
35	down	O
36	-	O
37	regulated	O
38	in	O
39	resistant	O
40	cells	O
41	.	O
1	Chemical	O
2	stability	O
3	tests	O
4	and	O
5	site	O
6	-	O
7	specific	O
8	mutagenesis	O
9	identified	O
10	amino	O
11	acids	O
12	H219	O
13	and	O
14	D63	O
15	of	O
16	RegS	O
17	and	O
18	RegR	O
19	,	O
20	respectively	O
21	,	O
22	as	O
23	the	O
24	phosphorylated	O
25	residues	O
26	.	O
1	An	O
2	overexpression	O
3	of	O
4	the	O
5	betaAPP	O
6	gene	O
7	in	O
8	certain	O
9	areas	O
10	of	O
11	the	O
12	AD	O
13	brain	O
14	has	O
15	been	O
16	suggested	O
17	to	O
18	be	O
19	an	O
20	important	O
21	factor	O
22	in	O
23	the	O
24	neuropathology	O
25	of	O
26	AD	O
27	.	O
1	For	O
2	functional	O
3	studies	O
4	,	O
5	two	O
6	promoter	O
7	regions	O
8	were	O
9	cloned	O
10	upstream	O
11	of	O
12	the	O
13	reporter	O
14	gene	O
15	,	O
16	chloramphenicol	O
17	acetyl	O
18	transferase	O
19	(	O
20	CAT	O
21	):	O
22	(	O
23	i	O
24	)	O
25	phbetaE	O
26	-	O
27	B	O
28	-	O
29	the	O
30	plasmid	O
31	that	O
32	contains	O
33	the	O
34	human	O
35	(	O
36	h	O
37	)	O
38	promoter	O
39	region	O
40	(-	O
41	2832	O
42	to	O
43	+	O
44	101	O
45	)	O
46	including	O
47	URE	O
48	,	O
49	and	O
50	(	O
51	ii	O
52	)	O
53	prhbetaE	O
54	-	O
55	B	O
56	-	O
57	the	O
58	plasmid	O
59	that	O
60	contains	O
61	the	O
62	rhesus	O
63	(	O
64	rh	O
65	)	O
66	promoter	O
67	region	O
68	excluding	O
69	URE	O
70	as	O
71	it	O
72	lacks	O
73	a	O
74	270	O
75	bp	O
76	region	O
77	of	O
78	the	O
79	hbetaAPP	O
80	promoter	O
81	(-	O
82	2435	O
83	to	O
84	-	O
85	2165	O
86	).	O
1	This	O
2	approximately	O
3	125	O
4	-	O
5	nt	O
6	RNA	O
7	proved	O
8	to	O
9	arise	O
10	via	O
11	RNase	B
12	E	O
13	cleavage	O
14	from	O
15	the	O
16	3	O
17	'-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	mRNAs	O
23	bearing	O
24	the	O
25	terminator	O
26	.	O
1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	in	O
7	contrast	O
8	to	O
9	other	O
10	extracellular	O
11	matrix	O
12	molecules	O
13	pepsin	O
14	-	O
15	solubilized	O
16	collagen	O
17	VI	O
18	(	O
19	CVI	O
20	)	O
21	can	O
22	stimulate	O
23	DNA	O
24	synthesis	O
25	of	O
26	various	O
27	mesenchymal	O
28	cell	O
29	types	O
30	,	O
31	apparently	O
32	independent	O
33	of	O
34	integrin	O
35	-	O
36	mediated	O
37	signal	O
38	transduction	O
39	.	O
1	The	O
2	enzyme	O
3	displays	O
4	optimal	O
5	activity	O
6	at	O
7	about	O
8	0	O
9	.	O
10	5	O
11	mM	O
12	pantoate	O
13	(	O
14	k	O
15	(	O
16	cat	O
17	)	O
18	0	O
19	.	O
20	63	O
21	s	O
22	(-	O
23	1	O
24	))	O
25	and	O
26	at	O
27	pH	O
28	7	O
29	.	O
30	8	O
31	.	O
1	Epidemiologic	O
2	evidence	O
3	indicates	O
4	that	O
5	estrogen	O
6	replacement	O
7	therapy	O
8	after	O
9	menopause	O
10	increases	O
11	breast	O
12	cancer	O
13	risk	O
14	.	O
1	Although	O
2	the	O
3	risk	O
4	of	O
5	malformation	O
6	in	O
7	children	O
8	born	O
9	after	O
10	ICSI	O
11	is	O
12	not	O
13	increased	O
14	there	O
15	is	O
16	an	O
17	increased	O
18	risk	O
19	to	O
20	transmit	O
21	genetic	O
22	abnormalities	O
23	in	O
24	case	O
25	of	O
26	NOA	O
27	(	O
28	such	O
29	as	O
30	the	O
31	rate	O
32	of	O
33	sex	O
34	chromosome	O
35	,	O
36	or	O
37	microdeletions	O
38	of	O
39	the	O
40	Y	O
41	chromosome	O
42	)	O
43	and	O
44	in	O
45	case	O
46	of	O
47	congenital	O
48	OA	O
49	(	O
50	mutations	O
51	of	O
52	the	O
53	cystic	O
54	fibrosis	O
55	gene	O
56	).	O
1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	mouse	O
7	growth	O
8	hormone	O
9	receptor	B
10	/	O
11	growth	O
12	hormone	O
13	binding	O
14	protein	O
15	gene	O
16	.	O
1	This	O
2	report	O
3	presents	O
4	state	O
5	-	O
6	specific	O
7	MMRs	O
8	for	O
9	1987	O
10	-	O
11	1996	O
12	,	O
13	focusing	O
14	on	O
15	persistent	O
16	disparities	O
17	in	O
18	maternal	O
19	mortality	O
20	between	O
21	black	O
22	and	O
23	white	O
24	women	O
25	.	O
1	Preheparin	O
2	LPL	O
3	mass	O
4	level	O
5	did	O
6	not	O
7	significantly	O
8	differ	O
9	in	O
10	individuals	O
11	from	O
12	19	O
13	to	O
14	70	O
15	years	O
16	old	O
17	,	O
18	for	O
19	both	O
20	men	O
21	and	O
22	women	O
23	.	O
1	This	O
2	review	O
3	summarizes	O
4	the	O
5	clinical	O
6	evidence	O
7	to	O
8	support	O
9	current	O
10	therapies	O
11	in	O
12	irritable	O
13	bowel	O
14	syndrome	O
15	(	O
16	IBS	O
17	).	O
1	There	O
2	were	O
3	27	O
4	men	O
5	and	O
6	156	O
7	women	O
8	.	O
1	Spfkh1	O
2	is	O
3	transcribed	O
4	in	O
5	one	O
6	open	O
7	reading	O
8	frame	O
9	that	O
10	contains	O
11	the	O
12	DNA	O
13	binding	O
14	domain	O
15	,	O
16	nuclear	O
17	localization	O
18	signal	O
19	and	O
20	transactivation	O
21	domain	O
22	.	O
1	The	O
2	molecular	O
3	mechanism	O
4	of	O
5	Tax	O
6	-	O
7	mediated	O
8	trans	O
9	-	O
10	activation	O
11	has	O
12	been	O
13	well	O
14	investigated	O
15	.	O
1	Identity	O
2	elements	O
3	in	O
4	tRNA	O
5	for	O
6	mono	O
7	-	O
8	and	O
9	dimethylation	O
10	reactions	O
11	by	O
12	the	O
13	recombinant	O
14	pfTrm1p	O
15	were	O
16	identified	O
17	using	O
18	in	O
19	vitro	O
20	T7	O
21	transcripts	O
22	of	O
23	33	O
24	variants	O
25	of	O
26	tRNA	O
27	(	O
28	Asp	O
29	)	O
30	and	O
31	tRNA	O
32	(	O
33	Phe	O
34	)	O
35	from	O
36	yeast	O
37	.	O
1	Fewer	O
2	recombination	O
3	events	O
4	are	O
5	detected	O
6	in	O
7	four	O
8	different	O
9	B	O
10	and	O
11	T	O
12	cell	O
13	lines	O
14	that	O
15	do	O
16	not	O
17	undergo	O
18	switch	O
19	recombination	O
20	of	O
21	their	O
22	endogenous	O
23	genes	O
24	.	O
1	In	O
2	summary	O
3	,	O
4	the	O
5	no	O
6	-	O
7	adverse	O
8	-	O
9	effect	O
10	-	O
11	level	O
12	for	O
13	this	O
14	study	O
15	was	O
16	determined	O
17	to	O
18	be	O
19	1000	O
20	ppm	O
21	,	O
22	based	O
23	on	O
24	decreased	O
25	weight	O
26	gain	O
27	in	O
28	female	O
29	rats	O
30	,	O
31	and	O
32	on	O
33	slight	O
34	organ	O
35	weight	O
36	changes	O
37	in	O
38	both	O
39	sexes	O
40	at	O
41	3000	O
42	ppm	O
43	.	O
1	Some	O
2	of	O
3	them	O
4	produce	O
5	gigantic	O
6	sperm	O
7	several	O
8	times	O
9	the	O
10	total	O
11	male	O
12	body	O
13	length	O
14	.	O
1	In	O
2	contrast	O
3	,	O
4	the	O
5	differentiation	O
6	of	O
7	neoplastically	O
8	transformed	O
9	cells	O
10	does	O
11	not	O
12	repress	O
13	mitogenic	O
14	responsiveness	O
15	or	O
16	junB	O
17	or	O
18	c	B
19	-	O
20	fos	O
21	inducibility	O
22	.	O
1	Transformation	O
2	blocks	O
3	differentiation	O
4	-	O
5	induced	O
6	inhibition	O
7	of	O
8	serum	O
9	response	O
10	factor	O
11	interactions	O
12	with	O
13	serum	O
14	response	O
15	elements	O
16	.	O
1	The	O
2	STAT	O
3	protein	O
4	accumulation	O
5	resulting	O
6	from	O
7	C	O
8	/	O
9	EBP	O
10	expression	O
11	was	O
12	tightly	O
13	coupled	O
14	to	O
15	the	O
16	morphological	O
17	conversion	O
18	of	O
19	fibroblasts	O
20	to	O
21	adipocytes	O
22	and	O
23	represents	O
24	an	O
25	expression	O
26	profile	O
27	identical	O
28	to	O
29	that	O
30	reported	O
31	for	O
32	mature	O
33	adipocytes	O
34	in	O
35	vivo	O
36	.	O
1	Myocardial	O
2	antioxidant	O
3	enzymes	O
4	,	O
5	catalase	O
6	,	O
7	glutathione	O
8	peroxidase	O
9	and	O
10	superoxide	O
11	dismutase	O
12	,	O
13	in	O
14	the	O
15	MCT	O
16	-	O
17	treated	O
18	rats	O
19	were	O
20	not	O
21	different	O
22	compared	O
23	to	O
24	control	O
25	rats	O
26	.	O
1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	whether	O
6	administration	O
7	of	O
8	misoprostol	O
9	prevents	O
10	gastric	O
11	hemorrhage	O
12	in	O
13	healthy	O
14	dogs	O
15	treated	O
16	with	O
17	high	O
18	doses	O
19	of	O
20	methylprednisolone	O
21	sodium	O
22	succinate	O
23	(	O
24	MPSS	O
25	).	O
1	In	O
2	addition	O
3	to	O
4	homologues	O
5	of	O
6	the	O
7	human	O
8	genes	O
9	PSMB5	O
10	through	O
11	PSMB9	O
12	,	O
13	two	O
14	new	O
15	genes	O
16	,	O
17	PSMB11	O
18	and	O
19	PSMB12	O
20	,	O
21	have	O
22	been	O
23	found	O
24	for	O
25	which	O
26	there	O
27	are	O
28	no	O
29	known	O
30	corresponding	O
31	genes	O
32	in	O
33	humans	O
34	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	for	O
7	the	O
8	HML	O
9	ARS	O
10	cluster	O
11	(	O
12	ARS303	O
13	,	O
14	ARS320	O
15	,	O
16	and	O
17	ARS302	O
18	),	O
19	inactivity	O
20	of	O
21	origins	O
22	is	O
23	independent	O
24	of	O
25	local	O
26	transcriptional	O
27	silencing	O
28	,	O
29	even	O
30	though	O
31	origins	O
32	and	O
33	silencers	O
34	share	O
35	key	O
36	cis	O
37	-	O
38	and	O
39	trans	O
40	-	O
41	acting	O
42	components	O
43	.	O
1	Interdomain	O
2	signaling	O
3	in	O
4	a	O
5	two	O
6	-	O
7	domain	O
8	fragment	O
9	of	O
10	the	O
11	human	O
12	glucocorticoid	O
13	receptor	B
14	.	O
1	Collectively	O
2	,	O
3	these	O
4	results	O
5	show	O
6	that	O
7	the	O
8	differential	O
9	utilization	O
10	of	O
11	Staf	O
12	zinc	O
13	finger	O
14	1	O
15	represents	O
16	a	O
17	new	O
18	,	O
19	critical	O
20	determinant	O
21	of	O
22	the	O
23	transcriptional	O
24	activation	O
25	mechanism	O
26	for	O
27	the	O
28	Xenopus	O
29	tRNA	O
30	(	O
31	Sec	O
32	)	O
33	and	O
34	human	O
35	U6	O
36	snRNA	O
37	genes	O
38	.	O
1	Viscosity	O
2	experiments	O
3	on	O
4	the	O
5	catalytic	O
6	fragment	O
7	kinase	B
8	reaction	O
9	demonstrated	O
10	that	O
11	the	O
12	chemical	O
13	(	O
14	phosphoryl	O
15	transfer	O
16	)	O
17	step	O
18	had	O
19	a	O
20	reduced	O
21	rate	O
22	.	O
1	The	O
2	Trk	O
3	/	O
4	Nerve	O
5	Growth	O
6	Factor	O
7	receptor	B
8	mediates	O
9	the	O
10	rapid	O
11	activation	O
12	of	O
13	a	O
14	number	O
15	of	O
16	intracellular	O
17	signaling	O
18	proteins	O
19	,	O
20	including	O
21	phosphatidylinositol	O
22	3	O
23	-	O
24	kinase	B
25	(	O
26	PI	O
27	3	O
28	-	O
29	kinase	B
30	).	O
1	Recent	O
2	molecular	O
3	analysis	O
4	has	O
5	revealed	O
6	that	O
7	the	O
8	S	O
9	locus	O
10	is	O
11	highly	O
12	polymorphic	O
13	and	O
14	contains	O
15	several	O
16	genes	O
17	,	O
18	i	O
19	.	O
20	e	O
21	.,	O
22	SLG	O
23	,	O
24	SRK	O
25	,	O
26	the	O
27	as	O
28	-	O
29	yet	O
30	-	O
31	unidentified	O
32	pollen	O
33	S	O
34	gene	O
35	(	O
36	s	O
37	),	O
38	and	O
39	other	O
40	linked	O
41	genes	O
42	.	O
1	In	O
2	early	O
3	Xenopus	O
4	embryos	O
5	,	O
6	the	O
7	transforming	O
8	growth	O
9	factor	O
10	-	O
11	beta	B
12	member	O
13	activin	O
14	induces	O
15	the	O
16	gene	O
17	Mix	O
18	.	O
19	2	O
20	by	O
21	stimulating	O
22	the	O
23	formation	O
24	of	O
25	a	O
26	multiprotein	O
27	complex	O
28	,	O
29	activin	O
30	-	O
31	responsive	O
32	factor	O
33	(	O
34	ARF	O
35	).	O
1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	O
6	cell	O
7	Ag	O
8	receptor	B
9	(	O
10	BCR	O
11	)	O
12	to	O
13	surface	O
14	Fc	O
15	receptors	O
16	for	O
17	IgG	O
18	(	O
19	Fc	O
20	gamma	B
21	R	O
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O
1	Cotransfection	O
2	of	O
3	the	O
4	coactivator	O
5	CREB	O
6	-	O
7	binding	O
8	protein	O
9	relieved	O
10	the	O
11	transcriptional	O
12	repression	O
13	of	O
14	PPARalphawt	O
15	by	O
16	PPARalphatr	O
17	,	O
18	suggesting	O
19	that	O
20	the	O
21	dominant	O
22	negative	O
23	effect	O
24	of	O
25	PPARalphatr	O
26	might	O
27	occur	O
28	through	O
29	competition	O
30	for	O
31	essential	O
32	coactivators	O
33	.	O
1	A	O
2	novel	O
3	Drosophila	O
4	A	O
5	kinase	B
6	anchor	O
7	protein	O
8	,	O
9	Drosophila	O
10	A	O
11	kinase	B
12	anchor	O
13	protein	O
14	200	O
15	(	O
16	DAKAP200	O
17	),	O
18	is	O
19	predicted	O
20	to	O
21	be	O
22	involved	O
23	in	O
24	routing	O
25	,	O
26	mediating	O
27	,	O
28	and	O
29	integrating	O
30	signals	O
31	carried	O
32	by	O
33	cAMP	O
34	,	O
35	Ca	O
36	(	O
37	2	O
38	+),	O
39	and	O
40	diacylglycerol	O
41	(	O
42	Li	O
43	,	O
44	Z	O
45	.,	O
46	Rossi	O
47	,	O
48	E	O
49	.	O
1	Mutation	O
2	of	O
3	TTF	O
4	-	O
5	1	O
6	-	O
7	binding	O
8	sites	O
9	(	O
10	TBE	O
11	)	O
12	1	O
13	,	O
14	3	O
15	,	O
16	and	O
17	4	O
18	in	O
19	combination	O
20	markedly	O
21	decreased	O
22	transcriptional	O
23	activity	O
24	of	O
25	SP	O
26	-	O
27	A	O
28	promoter	O
29	-	O
30	chloramphenicol	O
31	acetyltransferase	O
32	constructs	O
33	containing	O
34	SP	O
35	-	O
36	A	O
37	gene	O
38	sequences	O
39	from	O
40	-	O
41	256	O
42	to	O
43	+	O
44	45	O
45	.	O
1	Insulin	O
2	-	O
3	like	O
4	growth	O
5	factor	O
6	-	O
7	I	O
8	induces	O
9	bcl	O
10	-	O
11	2	O
12	promoter	O
13	through	O
14	the	O
15	transcription	O
16	factor	O
17	cAMP	O
18	-	O
19	response	O
20	element	O
21	-	O
22	binding	O
23	protein	O
24	.	O
1	NF	B
2	-	O
3	kappaB	O
4	plays	O
5	a	O
6	critical	O
7	role	O
8	in	O
9	activation	O
10	of	O
11	HIV	O
12	-	O
13	1	O
14	gene	O
15	expression	O
16	by	O
17	cytokines	O
18	and	O
19	other	O
20	stimuli	O
21	,	O
22	but	O
23	the	O
24	signal	O
25	transduction	O
26	pathways	O
27	that	O
28	regulate	O
29	the	O
30	switch	O
31	from	O
32	latent	O
33	to	O
34	productive	O
35	infection	O
36	have	O
37	not	O
38	been	O
39	defined	O
40	.	O
1	A	O
2	human	O
3	nuclear	O
4	-	O
5	localized	O
6	chaperone	O
7	that	O
8	regulates	O
9	dimerization	O
10	,	O
11	DNA	O
12	binding	O
13	,	O
14	and	O
15	transcriptional	O
16	activity	O
17	of	O
18	bZIP	O
19	proteins	O
20	.	O
1	These	O
2	results	O
3	show	O
4	that	O
5	targeting	O
6	of	O
7	Ras	B
8	-	O
9	GAP	O
10	could	O
11	represent	O
12	a	O
13	novel	O
14	anticancer	O
15	approach	O
16	.	O
1	Since	O
2	sildenafil	O
3	came	O
4	on	O
5	the	O
6	market	O
7	,	O
8	it	O
9	seems	O
10	that	O
11	the	O
12	place	O
13	of	O
14	MUSE	O
15	is	O
16	reduced	O
17	because	O
18	comparative	O
19	studies	O
20	give	O
21	better	O
22	results	O
23	for	O
24	sildenafil	O
25	than	O
26	MUSE	O
27	(	O
28	70	O
29	%	O
30	vs	O
31	40	O
32	%)	O
33	and	O
34	of	O
35	course	O
36	with	O
37	a	O
38	better	O
39	acceptance	O
40	.	O
1	CONCLUSIONS	O
2	:	O
3	These	O
4	results	O
5	show	O
6	that	O
7	once	O
8	daily	O
9	oral	O
10	valganciclovir	O
11	can	O
12	produce	O
13	exposures	O
14	of	O
15	ganciclovir	O
16	(	O
17	AUC24	O
18	)	O
19	exceeding	O
20	those	O
21	attained	O
22	using	O
23	intravenous	O
24	ganciclovir	O
25	10	O
26	mg	O
27	/	O
28	kg	O
29	.	O
1	All	O
2	were	O
3	experienced	O
4	hearing	O
5	aid	O
6	users	O
7	who	O
8	wore	O
9	linear	O
10	Class	O
11	D	O
12	instruments	O
13	with	O
14	input	O
15	compression	O
16	limiting	O
17	at	O
18	the	O
19	time	O
20	of	O
21	their	O
22	enrollment	O
23	in	O
24	this	O
25	study	O
26	.	O
1	A	O
2	total	O
3	of	O
4	174	O
5	primer	O
6	pairs	O
7	gave	O
8	interpretable	O
9	banding	O
10	patterns	O
11	,	O
12	137	O
13	(	O
14	79	O
15	%)	O
16	of	O
17	which	O
18	revealed	O
19	at	O
20	least	O
21	two	O
22	alleles	O
23	on	O
24	native	O
25	polyacrylamide	O
26	gels	O
27	.	O
1	A	O
2	population	O
3	pharmacokinetic	O
4	study	O
5	of	O
6	cyclosporin	O
7	in	O
8	organ	O
9	transplant	O
10	patients	O
11	,	O
12	including	O
13	elderly	O
14	allograft	O
15	recipients	O
16	up	O
17	to	O
18	75	O
19	years	O
20	of	O
21	age	O
22	,	O
23	did	O
24	not	O
25	identify	O
26	age	O
27	as	O
28	a	O
29	covariable	O
30	influencing	O
31	cyclosporin	O
32	pharmacokinetics	O
33	.	O
1	For	O
2	EPV	O
3	3	O
4	,	O
5	10	O
6	,	O
7	or	O
8	40	O
9	,	O
10	the	O
11	bias	O
12	exceeded	O
13	25	O
14	%	O
15	for	O
16	7	O
17	,	O
18	3	O
19	,	O
20	and	O
21	1	O
22	in	O
23	the	O
24	8	O
25	-	O
26	predictor	O
27	model	O
28	respectively	O
29	,	O
30	when	O
31	a	O
32	conventional	O
33	selection	O
34	criterion	O
35	was	O
36	used	O
37	(	O
38	alpha	B
39	=	O
40	0	O
41	.	O
42	05	O
43	).	O
1	Duch	O
2	,	O
3	and	O
4	F	O
5	.	O
1	Aggregation	O
2	of	O
3	vHnf1	O
4	-	O
5	deficient	O
6	embryonic	O
7	stem	O
8	cells	O
9	with	O
10	wild	O
11	-	O
12	type	O
13	tetraploid	O
14	embryos	O
15	,	O
16	which	O
17	contribute	O
18	exclusively	O
19	to	O
20	extraembryonic	O
21	tissues	O
22	,	O
23	rescues	O
24	periimplantation	O
25	lethality	O
26	and	O
27	allows	O
28	development	O
29	to	O
30	progress	O
31	to	O
32	early	O
33	organogenesis	O
34	.	O
1	This	O
2	effect	O
3	required	O
4	(	O
5	i	O
6	)	O
7	IR	O
8	activation	O
9	since	O
10	it	O
11	was	O
12	abrogated	O
13	by	O
14	IR	O
15	mutation	O
16	at	O
17	tyrosines	O
18	1162	O
19	and	O
20	1163	O
21	and	O
22	(	O
23	ii	O
24	)	O
25	NF	B
26	-	O
27	kappaB	O
28	activation	O
29	since	O
30	it	O
31	was	O
32	abolished	O
33	by	O
34	overexpression	O
35	of	O
36	dominant	O
37	-	O
38	negative	O
39	IkappaB	O
40	-	O
41	alpha	B
42	(	O
43	A32	O
44	/	O
45	36	O
46	)	O
47	and	O
48	mimicked	O
49	by	O
50	overexpression	O
51	of	O
52	the	O
53	NF	B
54	-	O
55	kappaB	O
56	c	B
57	-	O
58	Rel	O
59	subunit	O
60	.	O
1	Cloning	O
2	and	O
3	expression	O
4	of	O
5	a	O
6	specific	O
7	human	O
8	alpha	B
9	1	O
10	,	O
11	2	O
12	-	O
13	mannosidase	O
14	that	O
15	trims	O
16	Man9GlcNAc2	O
17	to	O
18	Man8GlcNAc2	O
19	isomer	O
20	B	O
21	during	O
22	N	O
23	-	O
24	glycan	O
25	biosynthesis	O
26	.	O
1	The	O
2	ORs	O
3	of	O
4	GC	O
5	,	O
6	adjusted	O
7	for	O
8	age	O
9	and	O
10	sex	O
11	,	O
12	varied	O
13	from	O
14	17	O
15	.	O
16	1	O
17	,	O
18	for	O
19	those	O
20	with	O
21	baseline	O
22	diagnoses	O
23	of	O
24	superficial	O
25	intestinal	O
26	metaplasia	O
27	(	O
28	IM	O
29	),	O
30	to	O
31	29	O
32	.	O
33	3	O
34	,	O
35	for	O
36	those	O
37	with	O
38	deep	O
39	IM	O
40	or	O
41	mild	O
42	dysplasia	O
43	(	O
44	DYS	O
45	)	O
46	or	O
47	IM	O
48	with	O
49	glandular	O
50	atrophy	O
51	and	O
52	neck	O
53	hyperplasia	O
54	,	O
55	to	O
56	104	O
57	.	O
58	2	O
59	,	O
60	for	O
61	those	O
62	with	O
63	moderate	O
64	or	O
65	severe	O
66	DYS	O
67	,	O
68	as	O
69	compared	O
70	with	O
71	subjects	O
72	with	O
73	superficial	O
74	gastritis	O
75	(	O
76	SG	O
77	)	O
78	or	O
79	chronic	O
80	atrophic	O
81	gastritis	O
82	(	O
83	CAG	O
84	)	O
85	at	O
86	baseline	O
87	.	O
1	Thus	O
2	,	O
3	CHOP	O
4	not	O
5	only	O
6	is	O
7	a	O
8	negative	O
9	or	O
10	a	O
11	positive	O
12	regulator	O
13	of	O
14	C	O
15	/	O
16	EBP	O
17	target	O
18	genes	O
19	but	O
20	also	O
21	,	O
22	when	O
23	tethered	O
24	to	O
25	AP	B
26	-	O
27	1	O
28	factors	O
29	,	O
30	can	O
31	activate	O
32	AP	B
33	-	O
34	1	O
35	target	O
36	genes	O
37	.	O
1	RNase	O
2	MRP	O
3	is	O
4	a	O
5	ribonucleoprotein	O
6	endoribonuclease	O
7	that	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	have	O
13	roles	O
14	in	O
15	both	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	and	O
20	nuclear	O
21	5	O
22	.	O
23	8S	O
24	rRNA	O
25	processing	O
26	.	O
1	16	O
2	percent	O
3	,	O
4	P	O
5	<	O
6	0	O
7	.	O
8	001	O
9	),	O
10	and	O
11	sustained	O
12	normalization	O
13	of	O
14	serum	O
15	alanine	O
16	aminotransferase	O
17	levels	O
18	(	O
19	41	O
20	percent	O
21	vs	O
22	.	O
1	The	O
2	N	O
3	-	O
4	terminal	O
5	domain	O
6	of	O
7	approximately	O
8	70	O
9	kDa	O
10	exhibits	O
11	11	O
12	imperfect	O
13	amino	O
14	acid	O
15	repeats	O
16	that	O
17	show	O
18	some	O
19	homology	O
20	to	O
21	promastigote	O
22	surface	O
23	glycoproteins	O
24	of	O
25	the	O
26	psa2	O
27	/	O
28	gp46	O
29	complex	O
30	.	O
1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	we	O
8	found	O
9	no	O
10	evidence	O
11	for	O
12	VDR	O
13	-	O
14	TR	O
15	heterodimer	O
16	interaction	O
17	with	O
18	any	O
19	tested	O
20	element	O
21	.	O
1	Using	O
2	immunolocalization	O
3	,	O
4	we	O
5	observe	O
6	that	O
7	ACE3	O
8	,	O
9	a	O
10	440	O
11	-	O
12	bp	O
13	chorion	O
14	element	O
15	that	O
16	contains	O
17	information	O
18	sufficient	O
19	to	O
20	drive	O
21	amplification	O
22	,	O
23	directs	O
24	DmORC	O
25	localization	O
26	in	O
27	follicle	O
28	cells	O
29	.	O
1	The	O
2	requirement	O
3	for	O
4	proteolytic	O
5	activity	O
6	of	O
7	both	O
8	FVIIa	O
9	and	O
10	FXa	O
11	suggests	O
12	that	O
13	protease	O
14	-	O
15	activated	O
16	receptors	O
17	may	O
18	be	O
19	involved	O
20	.	O
1	In	O
2	particular	O
3	,	O
4	the	O
5	S1	O
6	'	O
7	specificity	O
8	site	O
9	is	O
10	a	O
11	deep	O
12	and	O
13	highly	O
14	hydrophobic	O
15	cavity	O
16	.	O
1	EIAV	O
2	LTR	O
3	sequence	O
4	variability	O
5	is	O
6	confined	O
7	mostly	O
8	to	O
9	a	O
10	small	O
11	portion	O
12	of	O
13	the	O
14	enhancer	O
15	within	O
16	the	O
17	U3	O
18	segment	O
19	of	O
20	the	O
21	LTR	O
22	.	O
1	Phosphatidylinositol	O
2	3	O
3	-	O
4	kinase	B
5	requirement	O
6	in	O
7	activation	O
8	of	O
9	the	O
10	ras	O
11	/	O
12	C	O
13	-	O
14	raf	O
15	-	O
16	1	O
17	/	O
18	MEK	O
19	/	O
20	ERK	O
21	and	O
22	p70	O
23	(	O
24	s6k	O
25	)	O
26	signaling	O
27	cascade	O
28	by	O
29	the	O
30	insulinomimetic	O
31	agent	O
32	vanadyl	O
33	sulfate	O
34	.	O
1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	Immediately	O
6	before	O
7	radical	O
8	prostatectomy	O
9	,	O
10	bone	O
11	marrow	O
12	aspirates	O
13	from	O
14	both	O
15	sides	O
16	of	O
17	the	O
18	iliac	O
19	crest	O
20	were	O
21	taken	O
22	from	O
23	287	O
24	patients	O
25	.	O
1	In	O
2	an	O
3	earlier	O
4	study	O
5	(	O
6	Kimura	O
7	,	O
8	Y	O
9	.,	O
10	Kurzydlowski	O
11	,	O
12	K	O
13	.,	O
14	Tada	O
15	,	O
16	M	O
17	.,	O
18	and	O
19	MacLennan	O
20	,	O
21	D	O
22	.	O
1	The	O
2	cop	O
3	region	O
4	also	O
5	harbors	O
6	a	O
7	region	O
8	of	O
9	plasmid	O
10	incompatibility	O
11	,	O
12	inc	O
13	,	O
14	encompassing	O
15	a	O
16	stem	O
17	-	O
18	loop	O
19	structure	O
20	,	O
21	the	O
22	repA	O
23	promoter	O
24	,	O
25	Prep	O
26	,	O
27	as	O
28	well	O
29	as	O
30	two	O
31	distinct	O
32	RepA	O
33	binding	O
34	sites	O
35	,	O
36	BD	O
37	-	O
38	1	O
39	and	O
40	BD	O
41	-	O
42	2	O
43	.	O
1	WA	O
2	constructs	O
3	afforded	O
4	relaxed	O
5	and	O
6	positive	O
7	topoisomers	O
8	,	O
9	and	O
10	cyclization	O
11	kinetics	O
12	indicated	O
13	slow	O
14	interconversion	O
15	of	O
16	precursors	O
17	to	O
18	the	O
19	two	O
20	topoisomers	O
21	.	O
1	Epstein	O
2	-	O
3	Barr	O
4	virus	O
5	(	O
6	EBV	O
7	)	O
8	latent	O
9	membrane	O
10	protein	O
11	1	O
12	(	O
13	LMP1	O
14	)	O
15	is	O
16	essential	O
17	for	O
18	EBV	O
19	-	O
20	mediated	O
21	transformation	O
22	of	O
23	primary	O
24	B	O
25	lymphocytes	O
26	.	O
1	The	O
2	GPI	O
3	anchor	O
4	moiety	O
5	is	O
6	either	O
7	absent	O
8	or	O
9	present	O
10	at	O
11	a	O
12	very	O
13	low	O
14	level	O
15	in	O
16	the	O
17	polypeptide	O
18	expressed	O
19	from	O
20	the	O
21	cDNA	O
22	that	O
23	contained	O
24	both	O
25	the	O
26	signal	O
27	peptide	O
28	and	O
29	GPI	O
30	signal	O
31	sequences	O
32	.	O
1	The	O
2	effect	O
3	of	O
4	smoking	O
5	was	O
6	not	O
7	examined	O
8	in	O
9	this	O
10	study	O
11	,	O
12	as	O
13	such	O
14	data	O
15	were	O
16	not	O
17	available	O
18	.	O
1	Serum	O
2	insulin	B
3	-	O
4	like	O
5	growth	O
6	factor	O
7	I	O
8	(	O
9	IGF	O
10	-	O
11	I	O
12	)	O
13	SD	O
14	score	O
15	increased	O
16	from	O
17	-	O
18	2	O
19	.	O
20	2	O
21	and	O
22	-	O
23	4	O
24	.	O
25	2	O
26	in	O
27	men	O
28	and	O
29	women	O
30	,	O
31	respectively	O
32	,	O
33	to	O
34	1	O
35	.	O
36	8	O
37	and	O
38	-	O
39	0	O
40	.	O
41	9	O
42	at	O
43	6	O
44	months	O
45	and	O
46	0	O
47	.	O
48	8	O
49	and	O
50	-	O
51	0	O
52	.	O
53	7	O
54	at	O
55	12	O
56	months	O
57	.	O
1	The	O
2	elm1	O
3	kinase	B
4	functions	O
5	in	O
6	a	O
7	mitotic	O
8	signaling	O
9	network	O
10	in	O
11	budding	O
12	yeast	O
13	.	O
1	Reverse	O
2	transcription	O
3	(	O
4	RT	O
5	)-	O
6	PCR	O
7	products	O
8	were	O
9	synthesized	O
10	with	O
11	two	O
12	degenerate	O
13	primers	O
14	derived	O
15	from	O
16	the	O
17	conserved	O
18	motifs	O
19	of	O
20	various	O
21	tyrosine	O
22	kinases	B
23	.	O
1	We	O
2	have	O
3	isolated	O
4	a	O
5	binding	O
6	partner	O
7	for	O
8	the	O
9	Fanconi	O
10	anemia	O
11	group	O
12	C	O
13	protein	O
14	(	O
15	FANCC	O
16	)	O
17	by	O
18	yeast	O
19	two	O
20	-	O
21	hybrid	O
22	screening	O
23	.	O
1	Klebsiella	O
2	oxytoca	O
3	can	O
4	assimilate	O
5	nitrate	O
6	and	O
7	nitrite	O
8	by	O
9	using	O
10	enzymes	O
11	encoded	O
12	by	O
13	the	O
14	nasFEDCBA	O
15	operon	O
16	.	O
1	Marked	O
2	hemolysis	O
3	significantly	O
4	increased	O
5	plasma	O
6	values	O
7	of	O
8	potassium	O
9	,	O
10	phosphorus	O
11	,	O
12	total	O
13	protein	O
14	,	O
15	and	O
16	aspartate	O
17	aminotransferase	O
18	.	O
1	Conversely	O
2	,	O
3	E1A	O
4	binding	O
5	to	O
6	only	O
7	p300	O
8	/	O
9	CBP	O
10	results	O
11	in	O
12	an	O
13	increase	O
14	in	O
15	PARP	O
16	enzyme	O
17	activity	O
18	and	O
19	consequently	O
20	in	O
21	cell	O
22	death	O
23	susceptibility	O
24	to	O
25	irradiation	O
26	,	O
27	which	O
28	is	O
29	effectively	O
30	counteracted	O
31	by	O
32	the	O
33	PARP	O
34	chemical	O
35	inhibitor	O
36	3	O
37	-	O
38	aminobenzamide	O
39	.	O
1	This	O
2	distinction	O
3	was	O
4	based	O
5	upon	O
6	whether	O
7	the	O
8	diagnosis	O
9	provided	O
10	a	O
11	straightforward	O
12	range	O
13	of	O
14	prognoses	O
15	or	O
16	an	O
17	ambiguous	O
18	clinical	O
19	implication	O
20	.	O
1	Syndromes	O
2	of	O
3	abnormal	O
4	fat	O
5	redistribution	O
6	and	O
7	metabolic	O
8	complications	O
9	in	O
10	HIV	O
11	-	O
12	infected	O
13	patients	O
14	.	O
1	Cytoprotection	O
2	with	O
3	amifostine	O
4	in	O
5	radiotherapy	O
6	or	O
7	radio	O
8	-	O
9	chemotherapy	O
10	of	O
11	head	O
12	and	O
13	neck	O
14	tumors	O
1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	third	O
7	SH3	O
8	domain	O
9	binds	O
10	to	O
11	Sos	O
12	,	O
13	a	O
14	guanine	O
15	nucleotide	O
16	exchange	O
17	factor	O
18	for	O
19	Ras	B
20	and	O
21	Rac	O
22	,	O
23	both	O
24	in	O
25	vitro	O
26	and	O
27	in	O
28	vivo	O
29	.	O
1	Point	O
2	mutations	O
3	in	O
4	the	O
5	third	O
6	SH3	O
7	domain	O
8	abolished	O
9	the	O
10	vinexin	O
11	-	O
12	Sos	O
13	interaction	O
14	.	O
1	Demyelinating	O
2	diseases	O
3	involving	O
4	the	O
5	grey	O
6	matter	O
7	were	O
8	very	O
9	rare	O
10	,	O
11	but	O
12	we	O
13	must	O
14	consider	O
15	the	O
16	presence	O
17	of	O
18	symmetrical	O
19	thalamic	O
20	involvement	O
21	in	O
22	patients	O
23	with	O
24	ADEM	O
25	.	O
1	Is	O
2	radical	O
3	trachelectomy	O
4	a	O
5	safe	O
6	alternative	O
7	to	O
8	radical	O
9	hysterectomy	O
10	for	O
11	patients	O
12	with	O
13	stage	O
14	IA	O
15	-	O
16	B	O
17	carcinoma	O
18	of	O
19	the	O
20	cervix	O
21	?	O
22	BACKGROUND	O
23	:	O
24	The	O
25	prognosis	O
26	associated	O
27	with	O
28	lymph	O
29	node	O
30	negative	O
31	,	O
32	early	O
33	stage	O
34	carcinoma	O
35	of	O
36	the	O
37	cervix	O
38	is	O
39	excellent	O
40	,	O
41	with	O
42	5	O
43	-	O
44	year	O
45	survival	O
46	rates	O
47	greater	O
48	than	O
49	90	O
50	%.	O
1	In	O
2	summary	O
3	,	O
4	WT1	O
5	is	O
6	enriched	O
7	by	O
8	oligo	O
9	(	O
10	dT	O
11	)	O
12	chromatography	O
13	,	O
14	as	O
15	are	O
16	U2AF65	O
17	,	O
18	the	O
19	U5	O
20	small	O
21	nuclear	O
22	RNP	O
23	-	O
24	associated	O
25	protein	O
26	p116	O
27	and	O
28	hnRNP	O
29	A1	O
30	.	O
1	Twelve	O
2	out	O
3	of	O
4	43	O
5	renal	O
6	failure	O
7	patients	O
8	had	O
9	troponin	O
10	I	O
11	0	O
12	.	O
13	13	O
14	-	O
15	0	O
16	.	O
17	9	O
18	microg	O
19	/	O
20	l	O
21	using	O
22	Axsym	O
23	method	O
24	and	O
25	4	O
26	had	O
27	levels	O
28	of	O
29	0	O
30	.	O
31	07	O
32	-	O
33	0	O
34	.	O
35	13	O
36	microg	O
37	/	O
38	l	O
39	using	O
40	Immuno	O
41	1	O
42	.	O
1	The	O
2	RET	O
3	/	O
4	PTC3	O
5	rearrangement	O
6	is	O
7	formed	O
8	by	O
9	fusion	O
10	of	O
11	the	O
12	ELE1	O
13	and	O
14	RET	O
15	genes	O
16	,	O
17	and	O
18	is	O
19	highly	O
20	prevalent	O
21	in	O
22	radiation	O
23	-	O
24	induced	O
25	post	O
26	-	O
27	Chernobyl	O
28	papillary	O
29	thyroid	O
30	carcinomas	O
31	.	O
1	The	O
2	rhabdomyosarcoma	O
3	R1H	O
4	growing	O
5	on	O
6	the	O
7	right	O
8	flank	O
9	of	O
10	male	O
11	WAG	O
12	/	O
13	Rij	O
14	rats	O
15	was	O
16	clamped	O
17	for	O
18	2	O
19	or	O
20	4	O
21	h	O
22	at	O
23	20	O
24	degrees	O
25	C	O
26	or	O
27	37	O
28	degrees	O
29	C	O
30	.	O
1	In	O
2	addition	O
3	,	O
4	SLK	O
5	displays	O
6	high	O
7	homology	O
8	to	O
9	microtubule	O
10	and	O
11	nuclear	O
12	associated	O
13	protein	O
14	(	O
15	M	O
16	-	O
17	NAP	O
18	)	O
19	and	O
20	AT1	O
21	-	O
22	46	O
23	,	O
24	both	O
25	of	O
26	unknown	O
27	function	O
28	.	O
1	Thrombolysis	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O
1	Based	O
2	on	O
3	a	O
4	type	O
5	I	O
6	error	O
7	of	O
8	0	O
9	.	O
10	05	O
11	,	O
12	our	O
13	study	O
14	had	O
15	a	O
16	power	O
17	greater	O
18	than	O
19	or	O
20	equal	O
21	to	O
22	75	O
23	%	O
24	to	O
25	detect	O
26	group	O
27	differences	O
28	in	O
29	treatment	O
30	effect	O
31	of	O
32	greater	O
33	than	O
34	or	O
35	equal	O
36	to	O
37	15	O
38	%	O
39	to	O
40	20	O
41	%.	O
1	Haycocknema	O
2	perplexum	O
3	n	O
4	.	O
5	g	O
6	.,	O
7	n	O
8	.	O
9	sp	O
10	.	O
1	Rams	O
2	were	O
3	weighed	O
4	and	O
5	testis	O
6	size	O
7	was	O
8	estimated	O
9	by	O
10	orchimetry	O
11	at	O
12	each	O
13	time	O
14	period	O
15	.	O
1	Animal	O
2	studies	O
3	showed	O
4	that	O
5	beam	O
6	equalization	O
7	significantly	O
8	improved	O
9	fluoroscopic	O
10	and	O
11	angiographic	O
12	image	O
13	quality	O
14	.	O
1	Clear	O
2	and	O
3	evidenced	O
4	-	O
5	based	O
6	information	O
7	should	O
8	be	O
9	provided	O
10	to	O
11	patients	O
12	as	O
13	to	O
14	the	O
15	means	O
16	of	O
17	prevention	O
18	with	O
19	special	O
20	attention	O
21	to	O
22	individual	O
23	risk	O
24	groups	O
25	such	O
26	as	O
27	IV	O
28	drug	O
29	abusers	O
30	.	O
1	We	O
2	demonstrate	O
3	that	O
4	both	O
5	R	O
6	and	O
7	Z	O
8	activate	O
9	the	O
10	cellular	O
11	stress	O
12	mitogen	O
13	-	O
14	activated	O
15	protein	O
16	(	O
17	MAP	O
18	)	O
19	kinases	B
20	,	O
21	p38	O
22	and	O
23	JNK	O
24	,	O
25	resulting	O
26	in	O
27	phosphorylation	O
28	(	O
29	and	O
30	activation	O
31	)	O
32	of	O
33	the	O
34	cellular	O
35	transcription	O
36	factor	O
37	ATF2	O
38	.	O
1	Two	O
2	US	O
3	commercial	O
4	cultivars	O
5	(	O
6	Tehama	O
7	and	O
8	Vina	O
9	),	O
10	three	O
11	European	O
12	commercial	O
13	cultivars	O
14	(	O
15	Esterhazy	O
16	,	O
17	139	O
18	,	O
19	G120	O
20	)	O
21	and	O
22	five	O
23	New	O
24	Zealand	O
25	selections	O
26	(	O
27	Rex	O
28	,	O
29	Dublin	O
30	'	O
31	s	O
32	Glory	O
33	,	O
34	Meyric	O
35	,	O
36	McKinster	O
37	,	O
38	Stanley	O
39	)	O
40	were	O
41	evaluated	O
42	.	O
1	Anatomy	O
2	of	O
3	the	O
4	uterine	O
5	artery	O
6	.	O
1	However	O
2	,	O
3	activation	O
4	of	O
5	the	O
6	cAMP	O
7	pathway	O
8	,	O
9	which	O
10	is	O
11	known	O
12	to	O
13	regulate	O
14	inhibin	O
15	alpha	B
16	expression	O
17	,	O
18	greatly	O
19	enhanced	O
20	the	O
21	actions	O
22	of	O
23	SF	O
24	-	O
25	1	O
26	.	O
1	The	O
2	single	O
3	strandedness	O
4	is	O
5	manifested	O
6	as	O
7	a	O
8	terminal	O
9	extension	O
10	of	O
11	the	O
12	G	O
13	-	O
14	rich	O
15	strand	O
16	(	O
17	G	O
18	tails	O
19	)	O
20	that	O
21	can	O
22	occur	O
23	independently	O
24	of	O
25	telomerase	O
26	,	O
27	suggesting	O
28	that	O
29	cdc17	O
30	/	O
31	pol1	O
32	mutants	O
33	exhibit	O
34	defects	O
35	in	O
36	telomeric	O
37	lagging	O
38	-	O
39	strand	O
40	synthesis	O
41	.	O
1	However	O
2	,	O
3	calphostin	O
4	C	O
5	,	O
6	a	O
7	specific	O
8	inhibitor	O
9	of	O
10	PKC	B
11	,	O
12	abolished	O
13	the	O
14	TPA	O
15	-	O
16	induced	O
17	increase	O
18	in	O
19	CFI	O
20	mRNA	O
21	levels	O
22	.	O
1	Following	O
2	conditioning	O
3	,	O
4	a	O
5	single	O
6	coat	O
7	of	O
8	adhesive	O
9	was	O
10	applied	O
11	and	O
12	light	O
13	-	O
14	cured	O
15	.	O
1	Induced	O
2	expression	O
3	of	O
4	c	B
5	-	O
6	myc	O
7	is	O
8	likely	O
9	to	O
10	contribute	O
11	to	O
12	the	O
13	proliferation	O
14	of	O
15	Stat1	O
16	-	O
17	null	O
18	cells	O
19	in	O
20	response	O
21	to	O
22	IFNs	O
23	.	O
1	NDRF	O
2	/	O
3	NeuroD2	O
4	was	O
5	co	O
6	-	O
7	precipitated	O
8	with	O
9	PKN	O
10	from	O
11	the	O
12	lysate	O
13	of	O
14	COS	O
15	-	O
16	7	O
17	cells	O
18	transfected	O
19	with	O
20	both	O
21	expression	O
22	constructs	O
23	for	O
24	NDRF	O
25	/	O
26	NeuroD2	O
27	and	O
28	PKN	O
29	.	O
1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	P19	O
6	cells	O
7	revealed	O
8	that	O
9	expression	O
10	of	O
11	NDRF	O
12	/	O
13	NeuroD2	O
14	increased	O
15	the	O
16	transactivation	O
17	of	O
18	the	O
19	rat	O
20	insulin	B
21	promoter	O
22	element	O
23	3	O
24	(	O
25	RIPE3	O
26	)	O
27	enhancer	O
28	up	O
29	to	O
30	approximately	O
31	12	O
32	-	O
33	fold	O
34	and	O
35	that	O
36	co	O
37	-	O
38	expression	O
39	of	O
40	catalytically	O
41	active	O
42	form	O
43	of	O
44	PKN	O
45	,	O
46	but	O
47	not	O
48	kinase	B
49	-	O
50	deficient	O
51	derivative	O
52	,	O
53	resulted	O
54	in	O
55	a	O
56	further	O
57	threefold	O
58	increase	O
59	of	O
60	NDRF	O
61	/	O
62	NeuroD2	O
63	-	O
64	mediated	O
65	transcription	O
66	.	O
1	AF154055	O
2	.	O
1	Sequence	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	upstream	O
11	to	O
12	the	O
13	ATG	O
14	codon	O
15	did	O
16	not	O
17	contain	O
18	a	O
19	conventional	O
20	TATA	O
21	box	O
22	.	O
1	BACKGROUND	O
2	:	O
3	Left	O
4	ventricular	O
5	hypertrophy	O
6	is	O
7	a	O
8	heterogeneous	O
9	disorder	O
10	with	O
11	distinct	O
12	morphologies	O
13	.	O
1	Neuronal	O
2	signaling	O
3	properties	O
4	are	O
5	largely	O
6	determined	O
7	by	O
8	the	O
9	quantity	O
10	and	O
11	combination	O
12	of	O
13	ion	O
14	channels	O
15	expressed	O
16	.	O
1	Copyright	O
2	2000	O
3	The	O
4	Royal	O
5	College	O
6	of	O
7	Radiologists	O
8	.	O
1	Two	O
2	estrogen	O
3	receptor	B
4	(	O
5	ER	O
6	)	O
7	isoforms	O
8	with	O
9	different	O
10	estrogen	O
11	dependencies	O
12	are	O
13	generated	O
14	from	O
15	the	O
16	trout	O
17	ER	O
18	gene	O
19	.	O
1	Electron	O
2	microscopic	O
3	and	O
4	enzymatic	O
5	analyses	O
6	revealed	O
7	that	O
8	the	O
9	A118	O
10	genome	O
11	is	O
12	a	O
13	linear	O
14	,	O
15	circularly	O
16	permuted	O
17	,	O
18	terminally	O
19	redundant	O
20	collection	O
21	of	O
22	double	O
23	-	O
24	stranded	O
25	DNA	O
26	molecules	O
27	.	O
1	All	O
2	four	O
3	domains	O
4	were	O
5	linked	O
6	via	O
7	proline	O
8	-	O
9	threonine	O
10	-	O
11	rich	O
12	peptides	O
13	.	O
1	We	O
2	critically	O
3	assess	O
4	current	O
5	systematic	O
6	uncertainties	O
7	and	O
8	determine	O
9	the	O
10	primordial	O
11	Li	O
12	abundance	O
13	within	O
14	new	O
15	,	O
16	much	O
17	tighter	O
18	limits	O
19	:	O
20	&	O
21	amp	O
22	;	O
23	parl0	O
24	;	O
25	Li	O
26	&	O
27	amp	O
28	;	O
29	solm0	O
30	;	O
31	H	O
32	&	O
33	amp	O
34	;	O
35	parr0	O
36	;	O
37	p	O
38	=	O
39	1	O
40	.	O
41	23	O
42	+	O
43	0	O
44	.	O
45	68	O
46	-	O
47	0	O
48	.	O
49	32x10	O
50	-	O
51	10	O
52	.	O
1	Further	O
2	studies	O
3	in	O
4	T	O
5	-	O
6	24	O
7	cells	O
8	demonstrated	O
9	that	O
10	HA	O
11	fragments	O
12	also	O
13	induced	O
14	I	O
15	kappa	B
16	B	O
17	alpha	B
18	phosphorylation	O
19	and	O
20	degradation	O
21	,	O
22	kappa	B
23	B	O
24	-	O
25	linked	O
26	reporter	O
27	gene	O
28	expression	O
29	,	O
30	and	O
31	ICAM	O
32	-	O
33	1	O
34	promoter	O
35	activity	O
36	in	O
37	an	O
38	NF	B
39	-	O
40	kappa	B
41	B	O
42	-	O
43	dependent	O
44	manner	O
45	.	O
1	The	O
2	two	O
3	-	O
4	hybrid	O
5	assay	O
6	was	O
7	then	O
8	performed	O
9	using	O
10	full	O
11	-	O
12	length	O
13	genes	O
14	of	O
15	CI	O
16	,	O
17	HC	O
18	-	O
19	Pro	O
20	,	O
21	P1	O
22	,	O
23	P3	O
24	,	O
25	and	O
26	CP	O
27	,	O
28	but	O
29	no	O
30	heterologous	O
31	interactions	O
32	were	O
33	detected	O
34	.	O
1	Patch	O
2	test	O
3	results	O
4	obtained	O
5	with	O
6	corticosteroid	O
7	allergic	O
8	patients	O
9	tested	O
10	with	O
11	a	O
12	large	O
13	corticosteroid	O
14	series	O
15	validated	O
16	the	O
17	earlier	O
18	classification	O
19	of	O
20	corticosteroid	O
21	molecules	O
22	in	O
23	four	O
24	groups	O
25	of	O
26	cross	O
27	-	O
28	reacting	O
29	molecules	O
30	:	O
31	i	O
32	.	O
33	e	O
34	.,	O
35	group	O
36	A	O
37	(	O
38	hydrocortisone	O
39	type	O
40	),	O
41	group	O
42	B	O
43	(	O
44	acetonides	O
45	),	O
46	group	O
47	C	O
48	(	O
49	betamethasone	O
50	type	O
51	-	O
52	non	O
53	esterified	O
54	)	O
55	and	O
56	group	O
57	D	O
58	(	O
59	esters	O
60	).	O
1	Mechanisms	O
2	of	O
3	tachyphylaxis	O
4	in	O
5	regional	O
6	anesthesia	O
7	of	O
8	long	O
9	duration	O
1	We	O
2	show	O
3	that	O
4	stabilization	O
5	of	O
6	the	O
7	hairpin	O
8	reduced	O
9	the	O
10	amount	O
11	of	O
12	tRNA	O
13	primer	O
14	that	O
15	is	O
16	annealed	O
17	to	O
18	the	O
19	PBS	O
20	.	O
1	Ischemia	O
2	-	O
3	induced	O
4	biphasic	O
5	arrhythmias	O
6	were	O
7	suppressed	O
8	in	O
9	both	O
10	zatebradine	O
11	and	O
12	propranolol	O
13	groups	O
14	.	O
1	No	O
2	definite	O
3	conclusions	O
4	are	O
5	possible	O
6	because	O
7	of	O
8	the	O
9	small	O
10	number	O
11	of	O
12	patients	O
13	involved	O
14	in	O
15	this	O
16	phase	O
17	II	O
18	trial	O
19	.	O
1	Two	O
2	distinct	O
3	Salmonella	O
4	fimbrins	O
5	,	O
6	AgfA	O
7	and	O
8	SefA	O
9	,	O
10	comprising	O
11	thin	O
12	aggregative	O
13	fimbriae	O
14	SEF17	O
15	and	O
16	SEF14	O
17	,	O
18	respectively	O
19	,	O
20	were	O
21	each	O
22	genetically	O
23	engineered	O
24	to	O
25	carry	O
26	PT3	O
27	,	O
28	an	O
29	alpha	B
30	-	O
31	helical	O
32	16	O
33	-	O
34	amino	O
35	acid	O
36	Leishmania	O
37	T	O
38	-	O
39	cell	O
40	epitope	O
41	derived	O
42	from	O
43	the	O
44	metalloprotease	O
45	gp63	O
46	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	novel	O
6	human	O
7	I	O
8	-	O
9	mfa	O
10	domain	O
11	-	O
12	containing	O
13	protein	O
14	that	O
15	differently	O
16	regulates	O
17	human	O
18	T	O
19	-	O
20	cell	O
21	leukemia	O
22	virus	O
23	type	O
24	I	O
25	and	O
26	HIV	O
27	-	O
28	1	O
29	expression	O
30	.	O
1	With	O
2	chemical	O
3	shift	O
4	imaging	O
5	,	O
6	the	O
7	signal	O
8	intensity	O
9	decreased	O
10	on	O
11	the	O
12	out	O
13	-	O
14	of	O
15	-	O
16	phase	O
17	images	O
18	in	O
19	six	O
20	of	O
21	seven	O
22	(	O
23	86	O
24	%)	O
25	patients	O
26	with	O
27	APA	O
28	and	O
29	in	O
30	eight	O
31	of	O
32	nine	O
33	(	O
34	89	O
35	%)	O
36	patients	O
37	with	O
38	BAH	O
39	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	combined	O
6	lesions	O
7	of	O
8	cholinergic	O
9	and	O
10	serotonergic	O
11	neurons	O
12	in	O
13	the	O
14	rat	O
15	brain	O
16	do	O
17	not	O
18	alter	O
19	olfactory	O
20	perception	O
21	or	O
22	olfactory	O
23	short	O
24	-	O
25	term	O
26	memory	O
27	.	O
1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	O
6	Src	O
7	activated	O
8	by	O
9	isoproterenol	O
10	led	O
11	to	O
12	tyrosine	O
13	phosphorylation	O
14	of	O
15	Shc	O
16	and	O
17	subsequent	O
18	Erk	O
19	activation	O
20	,	O
21	but	O
22	not	O
23	tyrosine	O
24	phosphorylation	O
25	of	O
26	cortactin	O
27	or	O
28	Stat3	O
29	.	O
1	Structural	O
2	changes	O
3	in	O
4	the	O
5	kinetically	O
6	more	O
7	damaged	O
8	E44D	O
9	mutant	O
10	detected	O
11	in	O
12	(	O
13	1	O
14	)	O
15	H	O
16	-(	O
17	15	O
18	)	O
19	N	O
20	HSQC	O
21	spectra	O
22	were	O
23	largely	O
24	limited	O
25	to	O
26	the	O
27	loop	O
28	I	O
29	-	O
30	helix	O
31	I	O
32	motif	O
33	,	O
34	suggesting	O
35	that	O
36	Glu	O
37	-	O
38	44	O
39	stabilizes	O
40	the	O
41	active	O
42	site	O
43	region	O
44	.	O
1	Immunity	O
2	acquired	O
3	by	O
4	mice	O
5	during	O
6	I	O
7	.	O
8	scapularis	O
9	nymphal	O
10	activity	O
11	in	O
12	early	O
13	summer	O
14	may	O
15	exclude	O
16	a	O
17	large	O
18	proportion	O
19	of	O
20	the	O
21	mouse	O
22	population	O
23	from	O
24	maintaining	O
25	E	O
26	.	O
27	phagocytophila	O
28	during	O
29	the	O
30	period	O
31	of	O
32	larval	O
33	activity	O
34	later	O
35	in	O
36	the	O
37	season	O
38	.	O
1	Activation	O
2	of	O
3	a	O
4	CRE	O
5	-	O
6	dependent	O
7	junB	O
8	promoter	O
9	/	O
10	chloramphenicol	O
11	acetyltransferase	O
12	(	O
13	CAT	O
14	)	O
15	reporter	O
16	gene	O
17	by	O
18	the	O
19	BCR	O
20	was	O
21	also	O
22	blocked	O
23	by	O
24	SB203580	O
25	.	O
1	As	O
2	no	O
3	complete	O
4	PPARgamma	O
5	antagonists	O
6	have	O
7	been	O
8	described	O
9	hitherto	O
10	,	O
11	we	O
12	have	O
13	constructed	O
14	a	O
15	dominant	O
16	-	O
17	negative	O
18	mutant	O
19	receptor	B
20	to	O
21	inhibit	O
22	wild	O
23	-	O
24	type	O
25	PPARgamma	O
26	action	O
27	.	O
1	Despite	O
2	resolution	O
3	of	O
4	the	O
5	solid	O
6	portion	O
7	of	O
8	the	O
9	tumor	O
10	,	O
11	serial	O
12	MRI	O
13	showed	O
14	enlargement	O
15	of	O
16	a	O
17	bilobar	O
18	tumor	O
19	cyst	O
20	3	O
21	years	O
22	after	O
23	the	O
24	original	O
25	diagnosis	O
26	.	O
1	After	O
2	nitric	O
3	oxide	O
4	inhalation	O
5	,	O
6	the	O
7	results	O
8	showed	O
9	moderate	O
10	increases	O
11	in	O
12	PaO2	O
13	and	O
14	SaO2	O
15	(	O
16	P	O
17	>	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	Qs	O
28	/	O
29	Q	O
30	tau	O
31	ratio	O
32	(	O
33	P	O
34	<	O
35	0	O
36	.	O
37	01	O
38	).	O
1	Covalent	O
2	modification	O
3	of	O
4	the	O
5	transactivator	O
6	protein	O
7	IE2	O
8	-	O
9	p86	O
10	of	O
11	human	O
12	cytomegalovirus	O
13	by	O
14	conjugation	O
15	to	O
16	the	O
17	ubiquitin	O
18	-	O
19	homologous	O
20	proteins	O
21	SUMO	O
22	-	O
23	1	O
24	and	O
25	hSMT3b	O
26	.	O
1	National	O
2	abortion	O
3	laws	O
4	usually	O
5	do	O
6	not	O
7	allow	O
8	abortion	O
9	when	O
10	a	O
11	foetus	O
12	is	O
13	independently	O
14	viable	O
15	,	O
16	i	O
17	.	O
18	e	O
19	.	O
20	from	O
21	a	O
22	gestational	O
23	age	O
24	of	O
25	about	O
26	24	O
27	weeks	O
28	.	O
1	Deglutition	O
2	is	O
3	considered	O
4	to	O
5	be	O
6	immature	O
7	in	O
8	infants	O
9	and	O
10	to	O
11	mature	O
12	postnatally	O
13	.	O
1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'-	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	human	O
11	multidrug	O
12	resistance	O
13	protein	O
14	2	O
15	(	O
16	MRP2	O
17	)	O
18	gene	O
19	and	O
20	its	O
21	regulation	O
22	in	O
23	comparison	O
24	withthe	O
25	multidrug	O
26	resistance	O
27	protein	O
28	3	O
29	(	O
30	MRP3	O
31	)	O
32	gene	O
33	.	O
1	In	O
2	two	O
3	-	O
4	field	O
5	nodal	O
6	dissection	O
7	,	O
8	two	O
9	components	O
10	are	O
11	included	O
12	with	O
13	(	O
14	modern	O
15	two	O
16	-	O
17	field	O
18	)	O
19	or	O
20	without	O
21	(	O
22	traditional	O
23	two	O
24	-	O
25	field	O
26	)	O
27	nodal	O
28	dissection	O
29	around	O
30	both	O
31	recurrent	O
32	laryngeal	O
33	nerve	O
34	chains	O
35	in	O
36	the	O
37	upper	O
38	mediastinum	O
39	.	O
1	Static	O
2	and	O
3	dynamic	O
4	compliance	O
5	was	O
6	measured	O
7	after	O
8	induction	O
9	of	O
10	anesthesia	O
11	,	O
12	before	O
13	and	O
14	immediately	O
15	after	O
16	filtration	O
17	in	O
18	the	O
19	operating	O
20	theater	O
21	,	O
22	1	O
23	hour	O
24	after	O
25	return	O
26	to	O
27	the	O
28	pediatric	O
29	intensive	O
30	care	O
31	unit	O
32	,	O
33	and	O
34	24	O
35	hours	O
36	after	O
37	the	O
38	operation	O
39	.	O
1	Alternatively	O
2	,	O
3	PC12	O
4	-	O
5	E2	O
6	cells	O
7	were	O
8	submitted	O
9	to	O
10	treatment	O
11	with	O
12	antibodies	O
13	to	O
14	the	O
15	fibroblast	O
16	growth	O
17	factor	O
18	(	O
19	FGF	O
20	)	O
21	receptor	B
22	,	O
23	inhibitors	O
24	of	O
25	the	O
26	nonreceptor	O
27	tyrosine	O
28	kinase	B
29	p59	O
30	(	O
31	fyn	O
32	),	O
33	PLC	O
34	,	O
35	PKC	B
36	and	O
37	MEK	O
38	and	O
39	an	O
40	activator	O
41	of	O
42	PKC	B
43	,	O
44	phorbol	O
45	-	O
46	12	O
47	-	O
48	myristate	O
49	-	O
50	13	O
51	-	O
52	acetate	O
53	(	O
54	PMA	O
55	).	O
1	As	O
2	assessed	O
3	by	O
4	a	O
5	genetic	O
6	assay	O
7	that	O
8	measures	O
9	AAI	O
10	-	O
11	dependent	O
12	DNA	O
13	binding	O
14	,	O
15	TraM	O
16	inhibited	O
17	TraR	O
18	function	O
19	before	O
20	and	O
21	after	O
22	the	O
23	transcription	O
24	factor	O
25	had	O
26	bound	O
27	to	O
28	its	O
29	DNA	O
30	recognition	O
31	site	O
32	.	O
1	D	O
2	-	O
3	cyclin	B
4	-	O
5	cdk	O
6	activity	O
7	is	O
8	required	O
9	for	O
10	Rb	O
11	phosphorylation	O
12	in	O
13	v	O
14	-	O
15	Jun	O
16	-	O
17	transformed	O
18	cells	O
19	,	O
20	since	O
21	ectopic	O
22	expression	O
23	of	O
24	the	O
25	cdk4	O
26	-	O
27	and	O
28	cdk6	O
29	-	O
30	specific	O
31	inhibitor	O
32	p16	O
33	(	O
34	INK4A	O
35	)	O
36	inhibits	O
37	both	O
38	DNA	O
39	synthesis	O
40	and	O
41	cell	O
42	proliferation	O
43	.	O
1	3	O
2	'	O
3	RNA	O
4	boundary	O
5	experiments	O
6	indicate	O
7	that	O
8	the	O
9	5	O
10	'	O
11	structure	O
12	reduces	O
13	the	O
14	number	O
15	of	O
16	(	O
17	G	O
18	/	O
19	U	O
20	)	O
21	AG	O
22	repeats	O
23	required	O
24	for	O
25	stable	O
26	TRAP	O
27	-	O
28	trp	O
29	leader	O
30	RNA	O
31	association	O
32	.	O
1	Gene	O
2	silencing	O
3	associated	O
4	with	O
5	repeated	O
6	DNA	O
7	sequences	O
8	has	O
9	been	O
10	reported	O
11	for	O
12	many	O
13	eukaryotes	O
14	,	O
15	including	O
16	plants	O
17	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	mouse	O
5	thioredoxin	O
6	reductases	O
7	.	O
1	Molecule	O
2	(	O
3	s	O
4	)	O
5	secreted	O
6	by	O
7	neuronal	O
8	cultures	O
9	contribute	O
10	to	O
11	this	O
12	induction	O
13	of	O
14	GLT	O
15	-	O
16	1	O
17	,	O
18	but	O
19	little	O
20	is	O
21	known	O
22	about	O
23	the	O
24	signaling	O
25	pathways	O
26	mediating	O
27	this	O
28	regulation	O
29	.	O
1	The	O
2	asymmetric	O
3	methylation	O
4	was	O
5	associated	O
6	with	O
7	tissue	O
8	-	O
9	specific	O
10	disruption	O
11	of	O
12	H19	O
13	genomic	O
14	imprinting	O
15	in	O
16	fetal	O
17	brain	O
18	.	O
1	Early	O
2	treatment	O
3	mechanics	O
4	of	O
5	the	O
6	Class	O
7	II	O
8	division	O
9	2	O
10	malocclusion	O
11	.	O
1	The	O
2	consensus	O
3	highlights	O
4	the	O
5	importance	O
6	of	O
7	residues	O
8	other	O
9	than	O
10	the	O
11	eight	O
12	motifs	O
13	that	O
14	are	O
15	often	O
16	associated	O
17	with	O
18	DEAD	O
19	-	O
20	box	O
21	RNA	O
22	helicases	O
23	,	O
24	as	O
25	well	O
26	as	O
27	de	O
28	-	O
29	emphasising	O
30	the	O
31	importance	O
32	of	O
33	the	O
34	""""	O
35	A	O
36	""""	O
37	residue	O
38	within	O
39	the	O
40	""""	O
41	DEAD	O
42	""""	O
43	motif	O
44	.	O
1	They	O
2	share	O
3	many	O
4	downstream	O
5	targets	O
6	,	O
7	including	O
8	remodeling	O
9	of	O
10	the	O
11	actin	O
12	cytoskeleton	O
13	,	O
14	activation	O
15	of	O
16	p70	O
17	(	O
18	S6	O
19	)	O
20	kinase	B
21	and	O
22	c	B
23	-	O
24	jun	O
25	N	O
26	-	O
27	terminal	O
28	kinase	B
29	(	O
30	JNK	O
31	),	O
32	and	O
33	regulation	O
34	of	O
35	transcription	O
36	and	O
37	cell	O
38	proliferation	O
39	.	O
1	Southern	O
2	blotting	O
3	and	O
4	single	O
5	strand	O
6	conformation	O
7	polymorphism	O
8	analyses	O
9	did	O
10	not	O
11	show	O
12	tumor	O
13	-	O
14	specific	O
15	alterations	O
16	of	O
17	this	O
18	gene	O
19	in	O
20	gliomas	O
21	and	O
22	RT	O
23	-	O
24	PCR	O
25	studies	O
26	showed	O
27	expression	O
28	in	O
29	glioma	O
30	cell	O
31	lines	O
32	,	O
33	suggesting	O
34	that	O
35	ANOVA	O
36	is	O
37	not	O
38	the	O
39	chromosome	O
40	19q	O
41	glioma	O
42	tumor	O
43	suppressor	O
44	gene	O
45	.	O
1	Molecular	O
2	mimicry	O
3	of	O
4	human	O
5	cytokine	O
6	and	O
7	cytokine	O
8	response	O
9	pathway	O
10	genes	O
11	by	O
12	KSHV	O
13	.	O
1	Proteolysis	O
2	of	O
3	Mbp1	O
4	and	O
5	Swi4	O
6	DNA	O
7	-	O
8	protein	O
9	complexes	O
10	has	O
11	revealed	O
12	the	O
13	extent	O
14	of	O
15	these	O
16	sequences	O
17	,	O
18	and	O
19	C	O
20	-	O
21	terminally	O
22	extended	O
23	molecules	O
24	with	O
25	substantially	O
26	enhanced	O
27	DNA	O
28	binding	O
29	activity	O
30	compared	O
31	to	O
32	the	O
33	core	O
34	domains	O
35	alone	O
36	have	O
37	been	O
38	produced	O
39	.	O
1	(	O
2	1998	O
3	)	O
4	J	O
5	.	O
1	The	O
2	prevalence	O
3	of	O
4	malnutrition	O
5	was	O
6	30	O
7	%	O
8	in	O
9	the	O
10	47	O
11	patients	O
12	without	O
13	CVD	O
14	and	O
15	was	O
16	significantly	O
17	higher	O
18	(	O
19	70	O
20	%,	O
21	P	O
22	<	O
23	0	O
24	.	O
25	001	O
26	)	O
27	in	O
28	the	O
29	70	O
30	patients	O
31	with	O
32	CVD	O
33	,	O
34	who	O
35	also	O
36	had	O
37	lower	O
38	tHcy	O
39	,	O
40	SAlb	O
41	,	O
42	plasma	O
43	IGF	O
44	-	O
45	1	O
46	,	O
47	serum	O
48	creatinine	O
49	(	O
50	SCr	O
51	),	O
52	and	O
53	blood	O
54	hemoglobin	O
55	.	O
1	The	O
2	second	O
3	functional	O
4	pair	O
5	of	O
6	CreA	O
7	sites	O
8	is	O
9	located	O
10	between	O
11	the	O
12	two	O
13	transcription	O
14	initiation	O
15	sites	O
16	.	O
1	After	O
2	phosphorylation	O
3	,	O
4	STAT	O
5	proteins	O
6	are	O
7	transported	O
8	into	O
9	the	O
10	nucleus	O
11	and	O
12	exhibit	O
13	transcriptional	O
14	activity	O
15	.	O
1	Application	O
2	of	O
3	the	O
4	method	O
5	to	O
6	a	O
7	representative	O
8	set	O
9	of	O
10	50	O
11	known	O
12	genes	O
13	from	O
14	Arabidopsis	O
15	thaliana	O
16	showed	O
17	significant	O
18	improvement	O
19	in	O
20	prediction	O
21	accuracy	O
22	compared	O
23	to	O
24	previous	O
25	spliced	O
26	alignment	O
27	methods	O
28	.	O
1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	alpha	B
7	-	O
8	helix	O
9	domain	O
10	of	O
11	p57	O
12	(	O
13	Kip2	O
14	),	O
15	which	O
16	is	O
17	conserved	O
18	in	O
19	the	O
20	Cip	O
21	/	O
22	Kip	O
23	proteins	O
24	,	O
25	is	O
26	implicated	O
27	in	O
28	protein	O
29	-	O
30	protein	O
31	interaction	O
32	and	O
33	confers	O
34	a	O
35	specific	O
36	regulatory	O
37	mechanism	O
38	,	O
39	outside	O
40	of	O
41	their	O
42	Cdk	O
43	-	O
44	inhibitory	O
45	activity	O
46	,	O
47	by	O
48	which	O
49	the	O
50	p57	O
51	(	O
52	Kip2	O
53	)	O
54	family	O
55	members	O
56	positively	O
57	act	O
58	on	O
59	myogenic	O
60	differentiation	O
61	.	O
1	A	O
2	cause	O
3	of	O
4	increase	O
5	of	O
6	alkaline	O
7	phosphatase	B
8	in	O
9	children	O
1	Ab	O
2	-	O
3	MLV	O
4	strains	O
5	expressing	O
6	P70	O
7	/	O
8	S2	O
9	failed	O
10	to	O
11	transform	O
12	NIH	O
13	3T3	O
14	cells	O
15	and	O
16	demonstrated	O
17	a	O
18	greatly	O
19	reduced	O
20	capacity	O
21	to	O
22	mediate	O
23	signaling	O
24	events	O
25	associated	O
26	with	O
27	the	O
28	Ras	B
29	-	O
30	dependent	O
31	mitogen	O
32	-	O
33	activated	O
34	protein	O
35	(	O
36	MAP	O
37	)	O
38	kinase	B
39	pathway	O
40	.	O
1	We	O
2	conclude	O
3	that	O
4	,	O
5	both	O
6	in	O
7	atrial	O
8	myocytes	O
9	and	O
10	in	O
11	Xenopus	O
12	oocytes	O
13	,	O
14	beta	B
15	-	O
16	adrenergic	O
17	stimulation	O
18	potentiates	O
19	the	O
20	ACh	O
21	-	O
22	evoked	O
23	GIRK	O
24	channels	O
25	via	O
26	a	O
27	pathway	O
28	that	O
29	involves	O
30	PKA	O
31	-	O
32	catalyzed	O
33	phosphorylation	O
34	downstream	O
35	from	O
36	beta	B
37	(	O
38	2	O
39	)	O
40	AR	O
41	.	O
1	Slap	O
2	negatively	O
3	regulates	O
4	Src	O
5	mitogenic	O
6	function	O
7	but	O
8	does	O
9	not	O
10	revert	O
11	Src	O
12	-	O
13	induced	O
14	cell	O
15	morphology	O
16	changes	O
17	.	O
1	Kaposi	O
2	'	O
3	s	O
4	sarcoma	O
5	-	O
6	associated	O
7	herpesvirus	O
8	viral	O
9	interferon	O
10	regulatory	O
11	factor	O
12	confers	O
13	resistance	O
14	to	O
15	the	O
16	antiproliferative	O
17	effect	O
18	of	O
19	interferon	O
20	-	O
21	alpha	B
22	.	O
1	Comparison	O
2	of	O
3	sequences	O
4	from	O
5	-	O
6	215	O
7	to	O
8	+	O
9	1	O
10	bp	O
11	identified	O
12	consensus	O
13	binding	O
14	sites	O
15	for	O
16	the	O
17	homeodomain	O
18	transcription	O
19	factor	O
20	thyroid	O
21	transcription	O
22	factor	O
23	-	O
24	1	O
25	(	O
26	TTF	O
27	-	O
28	1	O
29	).	O
1	An	O
2	analysis	O
3	of	O
4	synthetic	O
5	peptides	O
6	revealed	O
7	a	O
8	minimal	O
9	CTD	O
10	sequence	O
11	that	O
12	is	O
13	sufficient	O
14	to	O
15	bind	O
16	to	O
17	the	O
18	second	O
19	Rsp5	O
20	WW	O
21	domain	O
22	(	O
23	Rsp5	O
24	WW2	O
25	)	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	yeast	O
31	two	O
32	-	O
33	hybrid	O
34	assays	O
35	.	O
1	T1	O
2	-	O
3	weighted	O
4	MRI	O
5	on	O
6	the	O
7	49th	O
8	postoperative	O
9	day	O
10	demonstrated	O
11	bilateral	O
12	and	O
13	symmetrical	O
14	hyperintense	O
15	lesions	O
16	in	O
17	the	O
18	globus	O
19	pallidus	O
20	.	O
1	The	O
2	interaction	O
3	does	O
4	not	O
5	depend	O
6	on	O
7	the	O
8	presence	O
9	of	O
10	the	O
11	correct	O
12	amino	O
13	-	O
14	terminal	O
15	DNA	O
16	binding	O
17	domain	O
18	or	O
19	the	O
20	amino	O
21	acid	O
22	sequences	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	and	O
29	the	O
30	last	O
31	ten	O
32	amino	O
33	acids	O
34	.	O
1	CONCLUSION	O
2	:	O
3	The	O
4	probability	O
5	of	O
6	cardiopulmonary	O
7	complications	O
8	increases	O
9	significantly	O
10	when	O
11	patients	O
12	develop	O
13	class	O
14	1	O
15	HELLP	O
16	syndrome	O
17	.	O
1	This	O
2	tendency	O
3	is	O
4	likely	O
5	due	O
6	to	O
7	the	O
8	biased	O
9	nucleotide	O
10	composition	O
11	of	O
12	the	O
13	asparagus	O
14	genome	O
15	,	O
16	rather	O
17	than	O
18	to	O
19	the	O
20	translational	O
21	selection	O
22	for	O
23	specific	O
24	codons	O
25	.	O
1	SELECTION	O
2	CRITERIA	O
3	:	O
4	Randomised	O
5	trials	O
6	comparing	O
7	children	O
8	undergoing	O
9	systematic	O
10	therapy	O
11	focusing	O
12	on	O
13	the	O
14	family	O
15	in	O
16	conjunction	O
17	with	O
18	asthma	O
19	medication	O
20	,	O
21	with	O
22	children	O
23	taking	O
24	asthma	O
25	medication	O
26	only	O
27	.	O
1	Jkappa	O
2	DNA	O
3	-	O
4	binding	O
5	sites	O
6	were	O
7	not	O
8	required	O
9	for	O
10	this	O
11	activation	O
12	,	O
13	and	O
14	a	O
15	mutant	O
16	EBNA	O
17	-	O
18	3C	O
19	protein	O
20	unable	O
21	to	O
22	bind	O
23	Jkappa	O
24	activated	O
25	transcription	O
26	as	O
27	efficiently	O
28	as	O
29	wild	O
30	-	O
31	type	O
32	EBNA	O
33	-	O
34	3C	O
35	,	O
36	indicating	O
37	that	O
38	EBNA	O
39	-	O
40	3C	O
41	can	O
42	regulate	O
43	transcription	O
44	through	O
45	a	O
46	mechanism	O
47	that	O
48	is	O
49	independent	O
50	of	O
51	Jkappa	O
52	.	O
1	Finally	O
2	,	O
3	Cas	O
4	existed	O
5	mainly	O
6	in	O
7	cytosol	O
8	and	O
9	membrane	O
10	cytoskeleton	O
11	fractions	O
12	in	O
13	the	O
14	resting	O
15	state	O
16	,	O
17	and	O
18	remained	O
19	unchanged	O
20	during	O
21	platelet	O
22	aggregation	O
23	,	O
24	when	O
25	FAK	O
26	translocated	O
27	to	O
28	the	O
29	cytoskeletal	O
30	fraction	O
31	.	O
1	Our	O
2	data	O
3	provide	O
4	a	O
5	biochemical	O
6	explanation	O
7	for	O
8	the	O
9	similarity	O
10	in	O
11	phenotype	O
12	between	O
13	A	O
14	-	O
15	T	O
16	and	O
17	NBS	O
18	.	O
1	PATIENTS	O
2	OR	O
3	OTHER	O
4	PARTICIPANTS	O
5	:	O
6	Twenty	O
7	children	O
8	met	O
9	the	O
10	criteria	O
11	for	O
12	being	O
13	learning	O
14	disabled	O
15	.	O
1	In	O
2	the	O
3	study	O
4	on	O
5	PCI	O
6	mRNA	O
7	expression	O
8	in	O
9	the	O
10	reproductive	O
11	organs	O
12	,	O
13	we	O
14	first	O
15	cloned	O
16	rat	O
17	PCI	O
18	cDNA	O
19	and	O
20	then	O
21	evaluated	O
22	the	O
23	effect	O
24	of	O
25	androgen	O
26	on	O
27	the	O
28	PCI	O
29	mRNA	O
30	expression	O
31	.	O
1	The	O
2	stoichiometry	O
3	of	O
4	the	O
5	complexes	O
6	formed	O
7	with	O
8	the	O
9	dodeca	O
10	-	O
11	satellite	O
12	C	O
13	strand	O
14	suggests	O
15	that	O
16	,	O
17	in	O
18	DDP1	O
19	,	O
20	the	O
21	15	O
22	consecutive	O
23	KH	O
24	domains	O
25	are	O
26	organized	O
27	such	O
28	that	O
29	they	O
30	define	O
31	two	O
32	nucleic	O
33	acid	O
34	binding	O
35	surfaces	O
36	.	O
1	In	O
2	contrast	O
3	,	O
4	mutations	O
5	affecting	O
6	the	O
7	other	O
8	two	O
9	Nim1p	O
10	-	O
11	related	O
12	kinases	B
13	in	O
14	S	O
15	.	O
16	cerevisiae	O
17	,	O
18	Hsl1p	O
19	and	O
20	Kcc4p	O
21	,	O
22	produce	O
23	no	O
24	detectable	O
25	effect	O
26	on	O
27	septin	O
28	organization	O
29	.	O
1	Modeling	O
2	also	O
3	revealed	O
4	a	O
5	very	O
6	hydrophobic	O
7	surface	O
8	due	O
9	to	O
10	the	O
11	absence	O
12	of	O
13	H12	O
14	,	O
15	exposing	O
16	residues	O
17	from	O
18	H3	O
19	,	O
20	loop	O
21	3	O
22	-	O
23	4	O
24	,	O
25	H4	O
26	,	O
27	and	O
28	H11	O
29	.	O
1	In	O
2	the	O
3	SPP2	O
4	screening	O
5	test	O
6	,	O
7	a	O
8	few	O
9	plates	O
10	were	O
11	not	O
12	seen	O
13	in	O
14	both	O
15	groups	O
16	.	O
1	These	O
2	natural	O
3	antisense	O
4	S	O
5	transcripts	O
6	co	O
7	-	O
8	exist	O
9	with	O
10	several	O
11	less	O
12	abundant	O
13	sense	O
14	S	O
15	transcripts	O
16	.	O
1	The	O
2	data	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	YLL031c	O
10	transfers	O
11	the	O
12	ethanolaminephosphate	O
13	to	O
14	the	O
15	inner	O
16	alpha1	O
17	-	O
18	2	O
19	-	O
20	linked	O
21	mannose	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	the	O
28	group	O
29	that	O
30	links	O
31	the	O
32	GPI	O
33	lipid	O
34	anchor	O
35	to	O
36	proteins	O
37	,	O
38	whereas	O
39	Mcd4p	O
40	and	O
41	Gpi7p	O
42	transfer	O
43	ethanolaminephosphate	O
44	onto	O
45	the	O
46	alpha1	O
47	-	O
48	4	O
49	-	O
50	and	O
51	alpha1	O
52	-	O
53	6	O
54	-	O
55	linked	O
56	mannoses	O
57	of	O
58	the	O
59	GPI	O
60	anchor	O
61	,	O
62	respectively	O
63	.	O
1	The	O
2	patients	O
3	who	O
4	presented	O
5	with	O
6	mucocutaneous	O
7	disease	O
8	also	O
9	had	O
10	low	O
11	CD4	O
12	+	O
13	T	O
14	lymphocyte	O
15	counts	O
16	,	O
17	and	O
18	most	O
19	of	O
20	them	O
21	had	O
22	AIDS	O
23	defining	O
24	illnesses	O
25	.	O
1	The	O
2	gene	O
3	amplification	O
4	model	O
5	of	O
6	Coquelle	O
7	et	O
8	al	O
9	.	O
1	Double	O
2	-	O
3	blind	O
4	,	O
5	placebo	O
6	-	O
7	controlled	O
8	trial	O
9	.	O
1	Here	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	TAFII250	O
8	,	O
9	the	O
10	largest	O
11	subunit	O
12	of	O
13	TFIID	O
14	,	O
15	contains	O
16	two	O
17	tandem	O
18	bromodomain	O
19	modules	O
20	that	O
21	bind	O
22	selectively	O
23	to	O
24	multiply	O
25	acetylated	O
26	histone	O
27	H4	O
28	peptides	O
29	.	O
1	Therefore	O
2	,	O
3	analogs	O
4	of	O
5	vitamin	O
6	D3	O
7	have	O
8	been	O
9	investigated	O
10	in	O
11	a	O
12	number	O
13	of	O
14	trials	O
15	showing	O
16	improvement	O
17	of	O
18	psoriasis	O
19	.	O
1	The	O
2	real	O
3	challenge	O
4	for	O
5	the	O
6	future	O
7	will	O
8	be	O
9	the	O
10	management	O
11	of	O
12	patients	O
13	who	O
14	do	O
15	not	O
16	respond	O
17	to	O
18	first	O
19	-	O
20	line	O
21	treatment	O
22	.	O
1	CONCLUSION	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	endometriosis	O
8	increases	O
9	soluble	O
10	CD23	O
11	levels	O
12	,	O
13	which	O
14	can	O
15	be	O
16	suppressed	O
17	with	O
18	either	O
19	danazol	O
20	or	O
21	leuprolide	O
22	acetate	O
23	injection	O
24	.	O
1	Up	O
2	to	O
3	95	O
4	%	O
5	of	O
6	the	O
7	total	O
8	UV	O
9	exposure	O
10	received	O
11	is	O
12	in	O
13	the	O
14	UV	O
15	-	O
16	A	O
17	waveband	O
18	(	O
19	320	O
20	-	O
21	400	O
22	nm	O
23	).	O
1	Similarly	O
2	,	O
3	comparison	O
4	of	O
5	percentage	O
6	reductions	O
7	of	O
8	heart	O
9	rate	O
10	at	O
11	supine	O
12	,	O
13	sitting	O
14	and	O
15	exercise	O
16	by	O
17	repeated	O
18	measure	O
19	analysis	O
20	showed	O
21	the	O
22	Malays	O
23	to	O
24	have	O
25	significantly	O
26	higher	O
27	change	O
28	compared	O
29	to	O
30	the	O
31	Chinese	O
32	(	O
33	p	O
34	=	O
35	0	O
36	.	O
37	040	O
38	).	O
1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	amphotericin	O
11	B	O
12	oral	O
13	suspension	O
14	(	O
15	ABOS	O
16	)	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	fluconazole	O
22	refractory	O
23	oral	O
24	candidiasis	O
25	in	O
26	persons	O
27	with	O
28	HIV	O
29	infection	O
30	.	O
1	Paper	O
2	alert	O
3	.	O
1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	was	O
6	conducted	O
7	to	O
8	assess	O
9	the	O
10	relative	O
11	roles	O
12	of	O
13	99mTc	O
14	-	O
15	sestamibi	O
16	scintimammography	O
17	and	O
18	sonography	O
19	in	O
20	the	O
21	evaluation	O
22	of	O
23	breast	O
24	lesions	O
25	that	O
26	are	O
27	indeterminate	O
28	or	O
29	suspicious	O
30	on	O
31	mammography	O
32	or	O
33	clinical	O
34	examination	O
35	.	O
1	The	O
2	relationships	O
3	among	O
4	blood	O
5	concentrations	O
6	of	O
7	thyroid	O
8	hormones	O
9	and	O
10	selenium	O
11	,	O
12	zinc	O
13	,	O
14	retinol	O
15	,	O
16	and	O
17	alpha	B
18	-	O
19	tocopherol	O
20	were	O
21	studied	O
22	in	O
23	44	O
24	healthy	O
25	Northern	O
26	Italian	O
27	oldest	O
28	-	O
29	old	O
30	subjects	O
31	(	O
32	age	O
33	range	O
34	,	O
35	90	O
36	-	O
37	107	O
38	yr	O
39	),	O
40	selected	O
41	by	O
42	the	O
43	criteria	O
44	of	O
45	the	O
46	SENIEUR	O
47	protocol	O
48	.	O
1	Investigations	O
2	using	O
3	hippocampal	O
4	slices	O
5	maintained	O
6	in	O
7	vitro	O
8	have	O
9	demonstrated	O
10	that	O
11	bursts	O
12	of	O
13	oscillatory	O
14	field	O
15	potentials	O
16	in	O
17	the	O
18	gamma	B
19	frequency	O
20	range	O
21	(	O
22	30	O
23	-	O
24	80	O
25	Hz	O
26	)	O
27	are	O
28	followed	O
29	by	O
30	a	O
31	slower	O
32	oscillation	O
33	in	O
34	the	O
35	beta	B
36	1	O
37	range	O
38	(	O
39	12	O
40	-	O
41	20	O
42	Hz	O
43	).	O
1	Urinary	O
2	LTE4	O
3	increased	O
4	after	O
5	both	O
6	challenges	O
7	the	O
8	rise	O
9	being	O
10	higher	O
11	following	O
12	oral	O
13	as	O
14	compared	O
15	to	O
16	inhalation	O
17	provocation	O
18	(	O
19	p	O
20	=	O
21	0	O
22	.	O
23	0001	O
24	).	O
1	Transfection	O
2	of	O
3	cDNAs	O
4	for	O
5	three	O
6	mutant	O
7	enzymes	O
8	into	O
9	FPGS	O
10	-	O
11	null	O
12	Chinese	O
13	hamster	O
14	ovary	O
15	cells	O
16	restored	O
17	a	O
18	reduced	O
19	level	O
20	of	O
21	clonal	O
22	growth	O
23	,	O
24	whereas	O
25	a	O
26	T339I	O
27	mutant	O
28	supported	O
29	growth	O
30	at	O
31	a	O
32	level	O
33	comparable	O
34	to	O
35	that	O
36	of	O
37	the	O
38	wild	O
39	-	O
40	type	O
41	enzyme	O
42	.	O
1	The	O
2	Menopause	O
3	-	O
4	Rating	O
5	-	O
6	Scale	O
7	(	O
8	MRS	O
9	I	O
10	)	O
11	was	O
12	used	O
13	in	O
14	clinical	O
15	practice	O
16	since	O
17	1992	O
18	.	O
1	ECP	O
2	and	O
3	tryptase	O
4	levels	O
5	in	O
6	serum	O
7	were	O
8	measured	O
9	before	O
10	and	O
11	after	O
12	the	O
13	last	O
14	oral	O
15	challenge	O
16	.	O
1	Functional	O
2	studies	O
3	which	O
4	introduced	O
5	a	O
6	mutation	O
7	in	O
8	the	O
9	AP2	O
10	core	O
11	binding	O
12	region	O
13	as	O
14	well	O
15	as	O
16	cotransfection	O
17	experiments	O
18	using	O
19	an	O
20	AP2	O
21	expression	O
22	vector	O
23	revealed	O
24	that	O
25	AP2	O
26	exerts	O
27	a	O
28	repressive	O
29	role	O
30	on	O
31	the	O
32	HGF	O
33	gene	O
34	promoter	O
35	activity	O
36	.	O
1	(	O
2	GUT	O
3	)	O
4	Sera	O
5	of	O
6	30	O
7	montoux	O
8	negative	O
9	healthy	O
10	adults	O
11	(	O
12	age	O
13	/	O
14	sex	O
15	matched	O
16	)	O
17	were	O
18	taken	O
19	as	O
20	control	O
21	by	O
22	detecting	O
23	IgG	O
24	anti	B
25	bodies	O
26	to	O
27	A60	O
28	antigen	B
29	.	O
1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	role	O
7	of	O
8	S	O
9	.	O
10	argyrostoma	O
11	in	O
12	the	O
13	dissemination	O
14	of	O
15	Trichinella	O
16	larvae	O
17	in	O
18	nature	O
19	is	O
20	limited	O
21	in	O
22	comparison	O
23	to	O
24	the	O
25	role	O
26	played	O
27	by	O
28	mammals	O
29	with	O
30	scavenger	O
31	and	O
32	cannibalistic	O
33	behavior	O
34	.	O
1	RESULTS	O
2	:	O
3	The	O
4	introduction	O
5	of	O
6	the	O
7	PAIP	O
8	resulted	O
9	in	O
10	a	O
11	significant	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	reduction	O
20	in	O
21	contaminating	O
22	WBCs	O
23	(	O
24	median	O
25	,	O
26	30	O
27	,	O
28	000	O
29	)	O
30	from	O
31	the	O
32	numbers	O
33	seen	O
34	with	O
35	FIP	O
36	(	O
37	median	O
38	,	O
39	2	O
40	,	O
41	300	O
42	,	O
43	000	O
44	)	O
45	while	O
46	maintaining	O
47	the	O
48	separation	O
49	efficacy	O
50	(	O
51	47	O
52	%)	O
53	and	O
54	separation	O
55	time	O
56	.	O
1	Phd	O
2	antibody	O
3	-	O
4	immunoreactive	O
5	peptides	O
6	are	O
7	seen	O
8	in	O
9	light	O
10	-	O
11	adapted	O
12	mouse	O
13	retinal	O
14	cytosolic	O
15	and	O
16	nuclear	O
17	extracts	O
18	.	O
1	These	O
2	results	O
3	support	O
4	the	O
5	hypothesis	O
6	that	O
7	in	O
8	the	O
9	presence	O
10	of	O
11	tryptophan	O
12	the	O
13	ribosome	O
14	translating	O
15	tnaC	O
16	blocks	O
17	Rho	O
18	'	O
19	s	O
20	access	O
21	to	O
22	the	O
23	boxA	O
24	and	O
25	rut	O
26	sites	O
27	,	O
28	thereby	O
29	preventing	O
30	transcription	O
31	termination	O
32	.	O
1	In	O
2	situ	O
3	hybridization	O
4	with	O
5	the	O
6	antisense	O
7	RNA	O
8	probes	O
9	further	O
10	supported	O
11	the	O
12	expression	O
13	changes	O
14	of	O
15	these	O
16	six	O
17	clones	O
18	and	O
19	localized	O
20	the	O
21	changes	O
22	in	O
23	multiple	O
24	germ	O
25	cell	O
26	stages	O
27	as	O
28	well	O
29	as	O
30	other	O
31	cell	O
32	types	O
33	(	O
34	Sertoli	O
35	,	O
36	interstitial	O
37	and	O
38	peritubular	O
39	cells	O
40	).	O
1	This	O
2	study	O
3	shows	O
4	that	O
5	C	O
6	/	O
7	EBPbeta	O
8	is	O
9	the	O
10	predominant	O
11	C	O
12	/	O
13	EBP	O
14	isoform	O
15	found	O
16	in	O
17	activated	O
18	stellate	O
19	cells	O
20	and	O
21	that	O
22	increased	O
23	C	O
24	/	O
25	EBPbeta	O
26	protein	O
27	and	O
28	C	O
29	/	O
30	EBPbeta	O
31	binding	O
32	to	O
33	a	O
34	proximal	O
35	C	O
36	/	O
37	EBP	O
38	binding	O
39	site	O
40	in	O
41	the	O
42	promoter	O
43	mediates	O
44	the	O
45	activating	O
46	effect	O
47	of	O
48	acetaldehyde	O
49	.	O
1	As	O
2	with	O
3	VP16	O
4	,	O
5	the	O
6	transactivation	O
7	function	O
8	of	O
9	Luman	O
10	is	O
11	also	O
12	regulated	O
13	by	O
14	HCF	O
15	.	O
1	The	O
2	duration	O
3	of	O
4	reactive	O
5	hyperemia	O
6	decreased	O
7	with	O
8	aging	O
9	,	O
10	but	O
11	the	O
12	difference	O
13	between	O
14	males	O
15	and	O
16	females	O
17	was	O
18	not	O
19	significant	O
20	at	O
21	any	O
22	age	O
23	.	O
1	Furthermore	O
2	,	O
3	this	O
4	study	O
5	looks	O
6	at	O
7	the	O
8	impact	O
9	of	O
10	synthesis	O
11	conditions	O
12	on	O
13	block	O
14	length	O
15	and	O
16	crystallinity	O
17	,	O
18	and	O
19	the	O
20	impact	O
21	of	O
22	the	O
23	blocking	O
24	on	O
25	both	O
26	,	O
27	crystallinity	O
28	and	O
29	solubility	O
30	of	O
31	the	O
32	polymers	O
33	.	O
1	Both	O
2	the	O
3	MVBF	O
4	and	O
5	the	O
6	maximum	O
7	EMG	O
8	activity	O
9	in	O
10	the	O
11	right	O
12	masseter	O
13	and	O
14	the	O
15	left	O
16	anterior	O
17	temporalis	O
18	muscles	O
19	were	O
20	significantly	O
21	decreased	O
22	during	O
23	muscle	O
24	pain	O
25	when	O
26	the	O
27	subjects	O
28	bit	O
29	on	O
30	the	O
31	painful	O
32	side	O
33	.	O
1	The	O
2	detection	O
3	success	O
4	rate	O
5	was	O
6	determined	O
7	for	O
8	different	O
9	markers	O
10	using	O
11	this	O
12	MEK	O
13	.	O
1	We	O
2	have	O
3	shown	O
4	that	O
5	the	O
6	epidural	O
7	(	O
8	EPI	O
9	)	O
10	delivery	O
11	of	O
12	morphine	O
13	encapsulated	O
14	in	O
15	multivesicular	O
16	liposomes	O
17	(	O
18	DepoFoam	O
19	drug	O
20	delivery	O
21	system	O
22	)	O
23	produces	O
24	a	O
25	sustained	O
26	clearance	O
27	of	O
28	morphine	O
29	and	O
30	a	O
31	prolonged	O
32	analgesia	O
33	.	O
1	Methyllevamisole	O
2	was	O
3	used	O
4	as	O
5	the	O
6	internal	O
7	standard	O
8	.	O
1	Biochemical	O
2	examinations	O
3	of	O
4	calcium	O
5	-	O
6	phosphorus	O
7	metabolism	O
8	included	O
9	ions	O
10	and	O
11	PTH	O
12	concentrations	O
13	in	O
14	blood	O
15	serum	O
16	,	O
17	and	O
18	the	O
19	activity	O
20	of	O
21	bone	O
22	isoenzyme	O
23	of	O
24	AP	B
25	.	O
1	Pharmacoeconomic	O
2	assessment	O
3	of	O
4	HMG	O
5	-	O
6	CoA	O
7	reductase	O
8	inhibitor	O
9	therapy	O
10	:	O
11	an	O
12	analysis	O
13	based	O
14	on	O
15	the	O
16	CURVES	O
17	study	O
18	.	O
1	SELECTION	O
2	CRITERIA	O
3	:	O
4	All	O
5	controlled	O
6	trials	O
7	where	O
8	adults	O
9	with	O
10	schizophrenia	O
11	or	O
12	similar	O
13	illnesses	O
14	were	O
15	randomised	O
16	to	O
17	quetiapine	O
18	,	O
19	placebo	O
20	or	O
21	other	O
22	neuroleptic	O
23	drugs	O
24	and	O
25	where	O
26	clinically	O
27	relevant	O
28	outcomes	O
29	were	O
30	reported	O
31	.	O
1	CONCLUSIONS	O
2	:	O
3	In	O
4	essential	O
5	hypertension	O
6	an	O
7	acute	O
8	protein	O
9	load	O
10	induces	O
11	a	O
12	decrease	O
13	in	O
14	GFR	O
15	that	O
16	may	O
17	normalize	O
18	under	O
19	antihypertensive	O
20	treatment	O
21	.	O
1	This	O
2	finding	O
3	suggested	O
4	that	O
5	the	O
6	PI3K	O
7	-	O
8	Akt	O
9	activation	O
10	pathway	O
11	plays	O
12	some	O
13	role	O
14	in	O
15	the	O
16	antiapoptotic	O
17	effect	O
18	of	O
19	EPO	O
20	.	O
1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	proline	O
6	-	O
7	rich	O
8	domain	O
9	of	O
10	SOS1	O
11	is	O
12	involved	O
13	in	O
14	the	O
15	interaction	O
16	with	O
17	the	O
18	PLC	O
19	-	O
20	gamma1	O
21	SH3	O
22	domain	O
23	.	O
1	A	O
2	2	O
3	kb	O
4	transcript	O
5	was	O
6	isolated	O
7	from	O
8	brain	O
9	that	O
10	encodes	O
11	a	O
12	approximately	O
13	57	O
14	kDa	O
15	protein	O
16	;	O
17	the	O
18	predicted	O
19	protein	O
20	contains	O
21	the	O
22	known	O
23	N	O
24	-	O
25	terminal	O
26	Ets	O
27	domain	O
28	of	O
29	PE1	O
30	and	O
31	a	O
32	novel	O
33	C	O
34	-	O
35	terminal	O
36	domain	O
37	with	O
38	signficant	O
39	homology	O
40	to	O
41	murine	O
42	ERF	O
43	.	O
1	Wnt	O
2	-	O
3	1	O
4	overexpression	O
5	in	O
6	mammary	O
7	epithelial	O
8	cells	O
9	induced	O
10	cyclin	B
11	D1	O
12	mRNA	O
13	and	O
14	targeted	O
15	overexpression	O
16	of	O
17	Wnt	O
18	-	O
19	1	O
20	in	O
21	the	O
22	mammary	O
23	gland	O
24	of	O
25	transgenic	O
26	mice	O
27	increased	O
28	both	O
29	ILK	O
30	activity	O
31	and	O
32	cyclin	B
33	D1	O
34	levels	O
35	.	O
1	In	O
2	contrast	O
3	to	O
4	full	O
5	-	O
6	length	O
7	E2F	O
8	-	O
9	3	O
10	,	O
11	which	O
12	is	O
13	expressed	O
14	only	O
15	at	O
16	the	O
17	G1	O
18	/	O
19	S	O
20	boundary	O
21	,	O
22	E2F	O
23	-	O
24	3B	O
25	is	O
26	detected	O
27	throughout	O
28	the	O
29	cell	O
30	cycle	O
31	with	O
32	peak	O
33	levels	O
34	in	O
35	GO	O
36	where	O
37	it	O
38	is	O
39	associated	O
40	with	O
41	Rb	O
42	.	O
1	CONCLUSION	O
2	:	O
3	The	O
4	authors	O
5	emphasize	O
6	that	O
7	the	O
8	initial	O
9	management	O
10	of	O
11	primary	O
12	STS	O
13	should	O
14	be	O
15	adequate	O
16	and	O
17	suggest	O
18	that	O
19	safty	O
20	margin	O
21	of	O
22	>	O
23	or	O
24	=	O
25	2	O
26	cm	O
27	should	O
28	be	O
29	adhered	O
30	to	O
31	.	O
1	To	O
2	analyze	O
3	the	O
4	regulatory	O
5	activity	O
6	of	O
7	Gtx	O
8	,	O
9	we	O
10	first	O
11	identified	O
12	the	O
13	optimal	O
14	Gtx	O
15	-	O
16	binding	O
17	sequence	O
18	using	O
19	an	O
20	in	O
21	vitro	O
22	DNA	O
23	-	O
24	binding	O
25	assay	O
26	.	O
1	These	O
2	results	O
3	further	O
4	support	O
5	an	O
6	important	O
7	role	O
8	for	O
9	CBF2	O
10	in	O
11	mediating	O
12	EBNA2	O
13	transactivation	O
14	;	O
15	they	O
16	identify	O
17	the	O
18	hnRNP	O
19	protein	O
20	AUF1	O
21	as	O
22	a	O
23	major	O
24	component	O
25	of	O
26	CBF2	O
27	and	O
28	are	O
29	also	O
30	the	O
31	first	O
32	evidence	O
33	of	O
34	a	O
35	cis	O
36	-	O
37	acting	O
38	sequence	O
39	other	O
40	than	O
41	a	O
42	CBF1	O
43	binding	O
44	element	O
45	that	O
46	is	O
47	able	O
48	to	O
49	confer	O
50	responsiveness	O
51	to	O
52	EBNA2	O
53	.	O
1	However	O
2	,	O
3	it	O
4	is	O
5	not	O
6	known	O
7	whether	O
8	the	O
9	recently	O
10	identified	O
11	isoforms	O
12	Vav2	O
13	and	O
14	Vav3	O
15	,	O
16	which	O
17	are	O
18	broadly	O
19	expressed	O
20	,	O
21	can	O
22	couple	O
23	with	O
24	similar	O
25	classes	O
26	of	O
27	receptors	O
28	,	O
29	nor	O
30	is	O
31	it	O
32	known	O
33	whether	O
34	all	O
35	Vav	O
36	isoforms	O
37	possess	O
38	identical	O
39	functional	O
40	activities	O
41	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	ketamine	O
6	-	O
7	treated	O
8	rats	O
9	had	O
10	more	O
11	neurons	O
12	and	O
13	glial	O
14	cells	O
15	surrounding	O
16	the	O
17	ventricles	O
18	.	O
1	During	O
2	treatment	O
3	,	O
4	the	O
5	phosphorylation	O
6	state	O
7	of	O
8	Rb	O
9	shifted	O
10	to	O
11	a	O
12	hypophosphorylated	O
13	form	O
14	.	O
15	mRNA	O
16	for	O
17	the	O
18	HPV	O
19	E6	O
20	/	O
21	E7	O
22	genes	O
23	decreased	O
24	;	O
25	however	O
26	,	O
27	significant	O
28	changes	O
29	in	O
30	the	O
31	E7	O
32	protein	O
33	were	O
34	not	O
35	observed	O
36	,	O
37	while	O
38	increased	O
39	levels	O
40	of	O
41	Rb	O
42	immunoprecipitated	O
43	with	O
44	anti	B
45	-	O
46	E7	O
47	antibodies	O
48	were	O
49	observed	O
50	.	O
1	Further	O
2	characterization	O
3	of	O
4	these	O
5	putative	O
6	Hoxa	O
7	-	O
8	1	O
9	target	O
10	genes	O
11	will	O
12	aid	O
13	in	O
14	delineating	O
15	the	O
16	functions	O
17	of	O
18	the	O
19	Hoxa	O
20	-	O
21	1	O
22	protein	O
23	in	O
24	the	O
25	differentiation	O
26	processes	O
27	which	O
28	occur	O
29	during	O
30	embryogenesis	O
31	.	O
1	The	O
2	ability	O
3	of	O
4	U6	O
5	-	O
6	U57	O
7	mutants	O
8	to	O
9	influence	O
10	the	O
11	fidelity	O
12	of	O
13	both	O
14	branch	O
15	site	O
16	and	O
17	3	O
18	'	O
19	splice	O
20	site	O
21	recognition	O
22	suggests	O
23	that	O
24	this	O
25	nucleotide	O
26	may	O
27	participate	O
28	in	O
29	the	O
30	formation	O
31	of	O
32	the	O
33	active	O
34	site	O
35	(	O
36	s	O
37	)	O
38	of	O
39	the	O
40	spliceosome	O
41	.	O
1	The	O
2	therapy	O
3	time	O
4	to	O
5	deliver	O
6	the	O
7	NCS	O
8	therapeutic	O
9	dose	O
10	of	O
11	10000	O
12	RBE	O
13	-	O
14	cGy	O
15	,	O
16	is	O
17	27	O
18	times	O
19	longer	O
20	when	O
21	157Gd	O
22	is	O
23	used	O
24	instead	O
25	of	O
26	10B	O
27	.	O
1	To	O
2	facilitate	O
3	manipulation	O
4	of	O
5	large	O
6	genomic	O
7	sequences	O
8	,	O
9	we	O
10	developed	O
11	a	O
12	method	O
13	of	O
14	converting	O
15	Escherichia	O
16	coli	O
17	P1	O
18	artificial	O
19	chromosomes	O
20	(	O
21	PACs	O
22	)	O
23	into	O
24	yeast	O
25	artificial	O
26	chromosomes	O
27	(	O
28	YACs	O
29	).	O
1	The	O
2	manifestations	O
3	often	O
4	include	O
5	a	O
6	moderate	O
7	thrombocytopenia	O
8	and	O
9	,	O
10	less	O
11	commonly	O
12	,	O
13	hemolysis	O
14	.	O
1	Consciousness	O
2	is	O
3	connected	O
4	with	O
5	attention	O
6	,	O
7	working	O
8	memory	O
9	and	O
10	perception	O
11	.	O
1	Multiparity	O
2	had	O
3	a	O
4	protective	O
5	effect	O
6	with	O
7	0	O
8	.	O
9	66	O
10	less	O
11	risk	O
12	(	O
13	95	O
14	%	O
15	CI	O
16	0	O
17	.	O
18	44	O
19	-	O
20	0	O
21	.	O
22	99	O
23	).	O
1	Picture	O
2	the	O
3	smell	O
4	.	O
1	Because	O
2	GH	O
3	-	O
4	induced	O
5	Akt	O
6	activation	O
7	was	O
8	completely	O
9	inhibited	O
10	in	O
11	both	O
12	cells	O
13	by	O
14	the	O
15	same	O
16	concentration	O
17	of	O
18	LY294002	O
19	,	O
20	these	O
21	findings	O
22	indicate	O
23	that	O
24	the	O
25	wortmannin	O
26	sensitivity	O
27	of	O
28	both	O
29	the	O
30	IRS	O
31	-	O
32	1	O
33	-	O
34	independent	O
35	and	O
36	-	O
37	dependent	O
38	GH	O
39	-	O
40	induced	O
41	MAP	O
42	kinase	B
43	activation	O
44	may	O
45	reflect	O
46	the	O
47	activity	O
48	of	O
49	another	O
50	wortmannin	O
51	-	O
52	sensitive	O
53	target	O
54	(	O
55	s	O
56	)	O
57	in	O
58	addition	O
59	to	O
60	PI3K	O
61	in	O
62	mediation	O
63	of	O
64	GH	O
65	-	O
66	induced	O
67	MAP	O
68	kinase	B
69	activation	O
70	in	O
71	these	O
72	cells	O
73	.	O
1	Insulin	O
2	receptor	B
3	substrate	O
4	-	O
5	1	O
6	-	O
7	mediated	O
8	enhancement	O
9	of	O
10	growth	O
11	hormone	O
12	-	O
13	induced	O
14	mitogen	O
15	-	O
16	activated	O
17	protein	O
18	kinase	B
19	activation	O
20	.	O
1	Functional	O
2	magnetic	O
3	resonance	O
4	imaging	O
5	(	O
6	fMRI	O
7	)	O
8	has	O
9	been	O
10	increasingly	O
11	used	O
12	in	O
13	studying	O
14	human	O
15	brain	O
16	function	O
17	given	O
18	its	O
19	non	O
20	-	O
21	invasive	O
22	feature	O
23	and	O
24	good	O
25	spatial	O
26	resolution	O
27	.	O
1	Cytogenetic	O
2	analysis	O
3	of	O
4	LOH	O
5	mutants	O
6	by	O
7	chromosome	O
8	painting	O
9	indicated	O
10	a	O
11	mosaic	O
12	of	O
13	chromosomal	O
14	aberrations	O
15	involving	O
16	chromosome	O
17	17	O
18	,	O
19	in	O
20	which	O
21	partial	O
22	chromosome	O
23	deletions	O
24	,	O
25	amplifications	O
26	,	O
27	and	O
28	multiple	O
29	translocations	O
30	appeared	O
31	heterogeneously	O
32	in	O
33	a	O
34	single	O
35	mutant	O
36	.	O
1	RESULTS	O
2	:	O
3	No	O
4	significant	O
5	deformation	O
6	in	O
7	vertebral	O
8	artery	O
9	flow	O
10	was	O
11	noted	O
12	in	O
13	the	O
14	flexion	O
15	-	O
16	distraction	O
17	Stage	O
18	I	O
19	injuries	O
20	within	O
21	the	O
22	physiologic	O
23	range	O
24	of	O
25	cervical	O
26	flexion	O
27	.	O
1	Linking	O
2	continuous	O
3	community	O
4	-	O
5	based	O
6	morbidity	O
7	recording	O
8	of	O
9	influenza	O
10	-	O
11	like	O
12	illness	O
13	(	O
14	ILI	O
15	)	O
16	with	O
17	virological	O
18	sampling	O
19	has	O
20	consistently	O
21	proved	O
22	its	O
23	value	O
24	as	O
25	one	O
26	of	O
27	the	O
28	earliest	O
29	indicators	O
30	of	O
31	circulating	O
32	influenza	O
33	activity	O
34	.	O
1	Functional	O
2	recognition	O
3	of	O
4	5	O
5	'	O
6	splice	O
7	site	O
8	by	O
9	U4	O
10	/	O
11	U6	O
12	.	O
13	U5	O
14	tri	O
15	-	O
16	snRNP	O
17	defines	O
18	a	O
19	novel	O
20	ATP	O
21	-	O
22	dependent	O
23	step	O
24	in	O
25	early	O
26	spliceosome	O
27	assembly	O
28	.	O
1	As	O
2	in	O
3	the	O
4	other	O
5	three	O
6	members	O
7	whose	O
8	gene	O
9	expression	O
10	is	O
11	altered	O
12	during	O
13	tumorigenesis	O
14	,	O
15	PI12	O
16	expression	O
17	was	O
18	found	O
19	to	O
20	be	O
21	down	O
22	-	O
23	regulated	O
24	in	O
25	tumor	O
26	brain	O
27	tissues	O
28	and	O
29	in	O
30	two	O
31	brain	O
32	cancer	O
33	cell	O
34	lines	O
35	:	O
36	U	O
37	-	O
38	87	O
39	MG	O
40	and	O
41	H4	O
42	.	O
1	In	O
2	the	O
3	TLE	O
4	patients	O
5	the	O
6	NAA	O
7	:	O
8	Cr	O
9	ratios	O
10	were	O
11	reduced	O
12	in	O
13	the	O
14	seizure	O
15	focus	O
16	,	O
17	while	O
18	in	O
19	the	O
20	FLE	O
21	patients	O
22	they	O
23	were	O
24	not	O
25	always	O
26	reduced	O
27	in	O
28	the	O
29	seizure	O
30	focus	O
31	.	O
1	The	O
2	Spo0F	O
3	residues	O
4	making	O
5	up	O
6	the	O
7	hydrophobic	O
8	patch	O
9	are	O
10	very	O
11	similar	O
12	in	O
13	all	O
14	response	O
15	regulators	O
16	suggesting	O
17	that	O
18	the	O
19	binding	O
20	is	O
21	initiated	O
22	through	O
23	the	O
24	same	O
25	residues	O
26	in	O
27	all	O
28	interacting	O
29	response	O
30	regulator	O
31	-	O
32	kinase	B
33	pairs	O
34	.	O
1	We	O
2	found	O
3	that	O
4	the	O
5	amplitude	O
6	of	O
7	the	O
8	cortical	O
9	evoked	O
10	potentials	O
11	(	O
12	amplitude	O
13	of	O
14	the	O
15	N2	O
16	/	O
17	P2	O
18	peak	O
19	)	O
20	increased	O
21	from	O
22	5	O
23	.	O
24	1	O
25	+/-	O
26	0	O
27	.	O
28	7	O
29	microV	O
30	at	O
31	5	O
32	mA	O
33	to	O
34	16	O
35	.	O
36	3	O
37	+/-	O
38	1	O
39	.	O
40	1	O
41	microV	O
42	at	O
43	20	O
44	mA	O
45	.	O
1	Deletion	O
2	of	O
3	an	O
4	intergenic	O
5	DNA	O
6	-	O
7	binding	O
8	site	O
9	for	O
10	this	O
11	complex	O
12	from	O
13	a	O
14	human	O
15	beta	B
16	-	O
17	globin	O
18	locus	O
19	construct	O
20	results	O
21	in	O
22	delayed	O
23	human	O
24	gamma	B
25	-	O
26	to	O
27	beta	B
28	-	O
29	globin	O
30	switching	O
31	in	O
32	transgenic	O
33	mice	O
34	,	O
35	suggesting	O
36	that	O
37	the	O
38	PYR	O
39	complex	O
40	acts	O
41	to	O
42	facilitate	O
43	the	O
44	switch	O
45	.	O
1	Three	O
2	cDNAs	O
3	encoding	O
4	basic	O
5	leucine	O
6	zipper	O
7	(	O
8	bZIP	O
9	)-	O
10	type	O
11	ABRE	O
12	-	O
13	binding	O
14	proteins	O
15	were	O
16	isolated	O
17	by	O
18	using	O
19	the	O
20	yeast	O
21	one	O
22	-	O
23	hybrid	O
24	system	O
25	and	O
26	were	O
27	designated	O
28	AREB1	O
29	,	O
30	AREB2	O
31	,	O
32	and	O
33	AREB3	O
34	(	O
35	ABA	O
36	-	O
37	responsive	O
38	element	O
39	binding	O
40	protein	O
41	).	O
1	Recombinant	O
2	AROM	O
3	-	O
4	p64	O
5	displayed	O
6	high	O
7	binding	O
8	to	O
9	single	O
10	-	O
11	stranded	O
12	DNA	O
13	and	O
14	poly	O
15	(	O
16	A	O
17	)	O
18	homopolymers	O
19	suggesting	O
20	that	O
21	this	O
22	protein	O
23	could	O
24	play	O
25	a	O
26	role	O
27	in	O
28	mRNA	O
29	maturation	O
30	/	O
31	metabolism	O
32	.	O
1	It	O
2	is	O
3	now	O
4	estimated	O
5	that	O
6	inactivation	O
7	mutants	O
8	of	O
9	PTEN	O
10	exist	O
11	in	O
12	60	O
13	%	O
14	of	O
15	all	O
16	forms	O
17	of	O
18	solid	O
19	tumors	O
20	.	O
1	The	O
2	detector	O
3	has	O
4	the	O
5	advantage	O
6	of	O
7	finding	O
8	both	O
9	ST	O
10	segment	O
11	deviations	O
12	and	O
13	entire	O
14	ST	O
15	-	O
16	T	O
17	complex	O
18	changes	O
19	thereby	O
20	providing	O
21	a	O
22	wider	O
23	characterization	O
24	of	O
25	the	O
26	potential	O
27	ischemic	O
28	events	O
29	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	noncanonical	O
6	C	O
7	/	O
8	EBP	O
9	-	O
10	binding	O
11	site	O
12	within	O
13	the	O
14	Gadd45gamma	O
15	promoter	O
16	where	O
17	C	O
18	/	O
19	EBPbeta	O
20	and	O
21	C	O
22	/	O
23	EBPdelta	O
24	could	O
25	bind	O
26	,	O
27	was	O
28	identified	O
29	by	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assay	O
34	(	O
35	EMSA	O
36	)	O
37	and	O
38	reporter	O
39	gene	O
40	analysis	O
41	.	O
1	L	O
2	/	O
3	H	O
4	>	O
5	0	O
6	.	O
7	61	O
8	(	O
9	chi	O
10	(	O
11	2	O
12	)=	O
13	10	O
14	.	O
15	8	O
16	;	O
17	P	O
18	:<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	and	O
24	a	O
25	restrictive	O
26	filling	O
27	pattern	O
28	(	O
29	chi	O
30	(	O
31	2	O
32	)=	O
33	3	O
34	.	O
35	6	O
36	;	O
37	P	O
38	:<	O
39	0	O
40	.	O
41	05	O
42	)	O
43	were	O
44	independent	O
45	predictors	O
46	of	O
47	events	O
48	.	O
1	Nature	O
2	398	O
3	,	O
4	828	O
5	-	O
6	830	O
7	)	O
8	that	O
9	the	O
10	amino	O
11	acid	O
12	sequences	O
13	of	O
14	peptide	O
15	fragments	O
16	obtained	O
17	from	O
18	a	O
19	polypeptide	O
20	found	O
21	in	O
22	a	O
23	complex	O
24	of	O
25	proteins	O
26	that	O
27	alters	O
28	chromatin	O
29	structure	O
30	(	O
31	ARC	O
32	)	O
33	are	O
34	identical	O
35	to	O
36	portions	O
37	of	O
38	the	O
39	deduced	O
40	open	O
41	reading	O
42	frame	O
43	of	O
44	TIG	O
45	-	O
46	1	O
47	mRNA	O
48	.	O
1	Polysome	O
2	and	O
3	40S	O
4	ribosome	O
5	fractions	O
6	were	O
7	severely	O
8	decreased	O
9	in	O
10	the	O
11	krr1	O
12	mutant	O
13	and	O
14	Kri1p	O
15	-	O
16	depleted	O
17	cells	O
18	.	O
1	Diary	O
2	.	O
1	Mn2	O
2	+	O
3	increased	O
4	both	O
5	the	O
6	junction	O
7	binding	O
8	and	O
9	cleaving	O
10	activities	O
11	of	O
12	the	O
13	mutant	O
14	proteins	O
15	.	O
1	In	O
2	transient	O
3	analysis	O
4	using	O
5	particle	O
6	bombardment	O
7	of	O
8	tobacco	O
9	leaf	O
10	sections	O
11	,	O
12	a	O
13	tetramer	O
14	of	O
15	the	O
16	distB	O
17	ABRE	O
18	(	O
19	abscisic	O
20	acid	O
21	-	O
22	responsive	O
23	element	O
24	)	O
25	mediated	O
26	transactivation	O
27	by	O
28	ABI3	O
29	and	O
30	ABI3	O
31	-	O
32	dependent	O
33	response	O
34	to	O
35	ABA	O
36	,	O
37	whereas	O
38	a	O
39	tetramer	O
40	of	O
41	the	O
42	composite	O
43	RY	O
44	/	O
45	G	O
46	complex	O
47	,	O
48	containing	O
49	RY	O
50	repeats	O
51	and	O
52	a	O
53	G	O
54	-	O
55	box	O
56	,	O
57	mediated	O
58	only	O
59	ABA	O
60	-	O
61	independent	O
62	transactivation	O
63	by	O
64	ABI3	O
65	.	O
1	The	O
2	LMW	O
3	FGF	O
4	-	O
5	2	O
6	up	O
7	-	O
8	regulated	O
9	the	O
10	PKC	B
11	epsilon	O
12	levels	O
13	by	O
14	1	O
15	.	O
16	6	O
17	-	O
18	fold	O
19	;	O
20	by	O
21	contrast	O
22	the	O
23	HMW	O
24	isoform	O
25	down	O
26	-	O
27	regulated	O
28	the	O
29	level	O
30	of	O
31	this	O
32	PKC	B
33	isotype	O
34	by	O
35	about	O
36	3	O
37	-	O
38	fold	O
39	and	O
40	increased	O
41	the	O
42	amount	O
43	of	O
44	PKC	B
45	delta	I
46	by	O
47	1	O
48	.	O
49	7	O
50	-	O
51	fold	O
52	.	O
1	Prominent	O
2	findings	O
3	were	O
4	chronic	O
5	pancreatitis	O
6	with	O
7	acinar	O
8	and	O
9	ductal	O
10	plugs	O
11	,	O
12	granulomatous	O
13	and	O
14	necrotizing	O
15	peripancreatic	O
16	steatitis	O
17	,	O
18	degenerative	O
19	myopathy	O
20	,	O
21	testicular	O
22	atrophy	O
23	,	O
24	candidiasis	O
25	and	O
26	bacterial	O
27	necrotizing	O
28	glossitis	O
29	.	O
1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	indicate	O
7	that	O
8	multiple	O
9	survival	O
10	pathways	O
11	are	O
12	triggered	O
13	via	O
14	this	O
15	receptor	B
16	,	O
17	whereas	O
18	NF	B
19	-	O
20	kappaB	O
21	/	O
22	Rel	O
23	and	O
24	PI	O
25	-	O
26	3K	O
27	are	O
28	crucial	O
29	for	O
30	CD40	O
31	-	O
32	induced	O
33	proliferation	O
34	.	O
1	We	O
2	conclude	O
3	from	O
4	this	O
5	study	O
6	that	O
7	Arix	O
8	and	O
9	NBPhox	O
10	exhibit	O
11	indistinguishable	O
12	and	O
13	independent	O
14	transcriptional	O
15	regulatory	O
16	properties	O
17	on	O
18	the	O
19	DBH	O
20	promoter	O
21	.	O
1	An	O
2	increase	O
3	in	O
4	hypothalamic	O
5	expression	O
6	of	O
7	at	O
8	least	O
9	two	O
10	of	O
11	the	O
12	erbB	O
13	receptors	O
14	is	O
15	initiated	O
16	before	O
17	the	O
18	pubertal	O
19	augmentation	O
20	of	O
21	gonadal	O
22	steroid	O
23	secretion	O
24	and	O
25	is	O
26	completed	O
27	on	O
28	the	O
29	day	O
30	of	O
31	the	O
32	first	O
33	preovulatory	O
34	surge	O
35	of	O
36	gonadotropins	O
37	.	O
1	Furthermore	O
2	,	O
3	loss	O
4	of	O
5	methylation	O
6	also	O
7	greatly	O
8	reduced	O
9	the	O
10	association	O
11	of	O
12	another	O
13	yeast	O
14	B	O
15	-	O
16	type	O
17	subunit	O
18	,	O
19	Rts1p	O
20	.	O
1	The	O
2	authors	O
3	present	O
4	the	O
5	only	O
6	two	O
7	studies	O
8	that	O
9	have	O
10	proved	O
11	successful	O
12	in	O
13	treating	O
14	animal	O
15	models	O
16	of	O
17	osteoarthritis	O
18	using	O
19	gene	O
20	therapy	O
21	,	O
22	and	O
23	propose	O
24	an	O
25	overview	O
26	of	O
27	several	O
28	strategies	O
29	for	O
30	the	O
31	development	O
32	of	O
33	gene	O
34	therapy	O
35	in	O
36	osteoarthritis	O
37	treatment	O
38	in	O
39	the	O
40	future	O
41	.	O
1	Together	O
2	,	O
3	these	O
4	results	O
5	indicate	O
6	that	O
7	IL	B
8	-	O
9	1	O
10	beta	B
11	induces	O
12	VEGF	O
13	gene	O
14	expression	O
15	at	O
16	both	O
17	transcriptional	O
18	and	O
19	post	O
20	-	O
21	transcriptional	O
22	levels	O
23	,	O
24	and	O
25	IL	B
26	-	O
27	1	O
28	beta	B
29	evokes	O
30	p38	O
31	MAPK	O
32	and	O
33	JNK	O
34	signalings	O
35	,	O
36	which	O
37	in	O
38	turn	O
39	stimulate	O
40	the	O
41	transcription	O
42	of	O
43	the	O
44	VEGF	O
45	gene	O
46	through	O
47	Sp1	B
48	-	O
49	binding	O
50	sites	O
51	.	O
1	Binding	O
2	of	O
3	NusA	O
4	to	O
5	RNA	O
6	in	O
7	the	O
8	presence	O
9	of	O
10	alpha	B
11	or	O
12	N	O
13	involves	O
14	an	O
15	amino	O
16	-	O
17	terminal	O
18	S1	O
19	homology	O
20	region	O
21	that	O
22	is	O
23	otherwise	O
24	inactive	O
25	in	O
26	full	O
27	-	O
28	length	O
29	NusA	O
30	.	O
1	Elevation	O
2	of	O
3	intracellular	O
4	Ca	O
5	(	O
6	2	O
7	+)	O
8	levels	O
9	are	O
10	also	O
11	involved	O
12	because	O
13	treatment	O
14	with	O
15	receptor	B
16	-	O
17	associated	O
18	protein	O
19	,	O
20	nifedipine	O
21	,	O
22	MK801	O
23	,	O
24	removal	O
25	of	O
26	Ca	O
27	(	O
28	2	O
29	+)	O
30	from	O
31	the	O
32	medium	O
33	and	O
34	dantrolene	O
35	all	O
36	served	O
37	to	O
38	inhibit	O
39	calcium	O
40	elevation	O
41	and	O
42	attenuate	O
43	the	O
44	activation	O
45	of	O
46	CREB	O
47	.	O
1	When	O
2	BFDS	O
3	was	O
4	taken	O
5	as	O
6	the	O
7	reference	O
8	,	O
9	W	O
10	/	O
11	A	O
12	Z	O
13	scores	O
14	showed	O
15	consistent	O
16	positive	O
17	increments	O
18	,	O
19	from	O
20	birth	O
21	in	O
22	girls	O
23	and	O
24	1	O
25	mo	O
26	in	O
27	boys	O
28	.	O
1	Expression	O
2	of	O
3	a	O
4	hybrid	O
5	protein	O
6	containing	O
7	the	O
8	cytoplasmic	O
9	C	O
10	-	O
11	terminal	O
12	half	O
13	of	O
14	UhpB	O
15	fused	O
16	to	O
17	glutathione	O
18	S	O
19	-	O
20	transferase	O
21	(	O
22	GST	O
23	)	O
24	also	O
25	interfered	O
26	with	O
27	Uhp	O
28	signaling	O
29	.	O
1	RESULTS	O
2	:	O
3	Glaucoma	O
4	suspects	O
5	were	O
6	divided	O
7	into	O
8	two	O
9	groups	O
10	according	O
11	to	O
12	their	O
13	SWAP	O
14	results	O
15	:	O
16	high	O
17	risk	O
18	(	O
19	with	O
20	SWAP	O
21	abnormalities	O
22	)	O
23	and	O
24	low	O
25	risk	O
26	(	O
27	with	O
28	normal	O
29	SWAP	O
30	result	O
31	).	O
1	Tobramycin	O
2	-	O
3	loaded	O
4	SLN	O
5	administered	O
6	i	O
7	.	O
8	v	O
9	.	O
10	showed	O
11	a	O
12	prolonged	O
13	circulation	O
14	time	O
15	compared	O
16	to	O
17	the	O
18	i	O
19	.	O
20	v	O
21	.	O
22	administered	O
23	tobramycin	O
24	solution	O
25	.	O
1	Epidermal	O
2	growth	O
3	factor	O
4	receptor	B
5	transcriptionally	O
6	up	O
7	-	O
8	regulates	O
9	vascular	O
10	endothelial	O
11	growth	O
12	factor	O
13	expression	O
14	in	O
15	human	O
16	glioblastoma	O
17	cells	O
18	via	O
19	a	O
20	pathway	O
21	involving	O
22	phosphatidylinositol	O
23	3	O
24	'-	O
25	kinase	B
26	and	O
27	distinct	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	hypoxia	O
33	.	O
1	To	O
2	begin	O
3	to	O
4	understand	O
5	this	O
6	role	O
7	,	O
8	we	O
9	overexpressed	O
10	ATF	O
11	-	O
12	2	O
13	in	O
14	a	O
15	human	O
16	cancer	O
17	cell	O
18	line	O
19	.	O
1	Exon	O
2	A	O
3	is	O
4	located	O
5	approximately	O
6	7	O
7	kb	O
8	5	O
9	'	O
10	to	O
11	the	O
12	HSL	O
13	translation	O
14	start	O
15	site	O
16	.	O
1	Cardiovascular	O
2	risk	O
3	factors	O
4	and	O
5	antihypertensive	O
6	treatment	O
7	.	O
1	Characterization	O
2	of	O
3	a	O
4	Xenopus	O
5	laevis	O
6	CXC	O
7	chemokine	O
8	receptor	B
9	4	O
10	:	O
11	implications	O
12	for	O
13	hematopoietic	O
14	cell	O
15	development	O
16	in	O
17	the	O
18	vertebrate	O
19	embryo	O
20	.	O
1	Of	O
2	208	O
3	eligible	O
4	subjects	O
5	,	O
6	82	O
7	received	O
8	supervised	O
9	IPT	O
10	at	O
11	a	O
12	dose	O
13	of	O
14	900	O
15	mg	O
16	twice	O
17	weekly	O
18	for	O
19	6	O
20	mo	O
21	(	O
22	Regimen	O
23	A	O
24	),	O
25	73	O
26	received	O
27	unsupervised	O
28	IPT	O
29	900	O
30	mg	O
31	twice	O
32	weekly	O
33	for	O
34	6	O
35	mo	O
36	(	O
37	Regimen	O
38	B	O
39	),	O
40	and	O
41	53	O
42	received	O
43	unsupervised	O
44	IPT	O
45	300	O
46	mg	O
47	daily	O
48	for	O
49	6	O
50	mo	O
51	(	O
52	Regimen	O
53	C	O
54	).	O
1	The	O
2	wavenumbers	O
3	corresponding	O
4	to	O
5	the	O
6	normal	O
7	modes	O
8	of	O
9	vibration	O
10	were	O
11	calculated	O
12	using	O
13	the	O
14	DFT	O
15	(	O
16	B3LYP	O
17	/	O
18	6	O
19	-	O
20	31G	O
21	**)	O
22	approximation	O
23	and	O
24	their	O
25	agreement	O
26	with	O
27	the	O
28	measured	O
29	values	O
30	improved	O
31	after	O
32	scaling	O
33	of	O
34	the	O
35	associated	O
36	force	O
37	field	O
38	.	O
1	The	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	ThlA	O
8	is	O
9	involved	O
10	in	O
11	the	O
12	metabolism	O
13	of	O
14	both	O
15	acid	O
16	and	O
17	solvent	O
18	formation	O
19	,	O
20	whereas	O
21	the	O
22	physiological	O
23	function	O
24	of	O
25	ThlB	O
26	has	O
27	yet	O
28	to	O
29	be	O
30	elucidated	O
31	.	O
1	Interestingly	O
2	,	O
3	this	O
4	mutant	O
5	cell	O
6	line	O
7	lacks	O
8	expression	O
9	of	O
10	the	O
11	IKK	O
12	regulatory	O
13	protein	O
14	,	O
15	IKKgamma	O
16	.	O
1	In	O
2	addition	O
3	,	O
4	we	O
5	identified	O
6	a	O
7	novel	O
8	type	O
9	of	O
10	inhibitory	O
11	domain	O
12	in	O
13	the	O
14	N	O
15	-	O
16	terminal	O
17	60	O
18	amino	O
19	acids	O
20	of	O
21	IRF	O
22	-	O
23	1	O
24	which	O
25	strongly	O
26	inhibits	O
27	its	O
28	transcriptional	O
29	activity	O
30	.	O
1	The	O
2	swa2	O
3	-	O
4	1	O
5	allele	O
6	recovered	O
7	from	O
8	the	O
9	original	O
10	screen	O
11	carries	O
12	a	O
13	point	O
14	mutation	O
15	in	O
16	its	O
17	tetratricopeptide	O
18	repeat	O
19	(	O
20	TPR	O
21	)	O
22	domain	O
23	,	O
24	a	O
25	motif	O
26	not	O
27	found	O
28	in	O
29	auxilin	O
30	but	O
31	known	O
32	in	O
33	other	O
34	proteins	O
35	to	O
36	mediate	O
37	interaction	O
38	with	O
39	heat	O
40	-	O
41	shock	O
42	proteins	O
43	.	O
1	Association	O
2	of	O
3	stress	O
4	during	O
5	delivery	O
6	with	O
7	increased	O
8	numbers	O
9	of	O
10	nucleated	O
11	cells	O
12	and	O
13	hematopoietic	O
14	progenitor	O
15	cells	O
16	in	O
17	umbilical	O
18	cord	O
19	blood	O
20	.	O
1	The	O
2	authors	O
3	proposed	O
4	that	O
5	the	O
6	highly	O
7	convergent	O
8	inputs	O
9	to	O
10	the	O
11	entorhinal	O
12	cortex	O
13	indicate	O
14	this	O
15	region	O
16	may	O
17	be	O
18	particularly	O
19	important	O
20	for	O
21	selecting	O
22	or	O
23	compressing	O
24	information	O
25	.	O
1	Influence	O
2	of	O
3	oil	O
4	emulsions	O
5	and	O
6	diphenyl	O
7	on	O
8	post	O
9	-	O
10	harvest	O
11	physiconutritional	O
12	changes	O
13	in	O
14	Kagzi	O
15	limes	O
16	(	O
17	Citrus	O
18	aurantifolia	O
19	)	O
20	was	O
21	studied	O
22	.	O
1	The	O
2	extraction	O
3	was	O
4	subsequently	O
5	rated	O
6	as	O
7	'	O
8	easy	O
9	'	O
10	or	O
11	'	O
12	difficult	O
13	'.	O
14	Taking	O
15	Pell	O
16	-	O
17	Gregory	O
18	class	O
19	C	O
20	as	O
21	a	O
22	predictor	O
23	of	O
24	a	O
25	'	O
26	difficult	O
27	'	O
28	extraction	O
29	,	O
30	specificity	O
31	was	O
32	88	O
33	%	O
34	but	O
35	sensitivity	O
36	was	O
37	low	O
38	at	O
39	15	O
40	%.	O
1	In	O
2	addition	O
3	,	O
4	our	O
5	results	O
6	show	O
7	that	O
8	ERKs	O
9	and	O
10	PI3Ks	O
11	can	O
12	synergise	O
13	to	O
14	convert	O
15	ectoderm	O
16	into	O
17	mesoderm	O
18	.	O
1	Based	O
2	on	O
3	16S	O
4	rRNA	O
5	gene	O
6	sequence	O
7	analysis	O
8	,	O
9	the	O
10	11	O
11	species	O
12	having	O
13	two	O
14	tuf	O
15	genes	O
16	all	O
17	have	O
18	a	O
19	common	O
20	ancestor	O
21	,	O
22	while	O
23	the	O
24	six	O
25	species	O
26	having	O
27	only	O
28	one	O
29	copy	O
30	diverged	O
31	from	O
32	the	O
33	enterococcal	O
34	lineage	O
35	before	O
36	that	O
37	common	O
38	ancestor	O
39	.	O
1	Another	O
2	putative	O
3	HNF3	O
4	site	O
5	in	O
6	close	O
7	apposition	O
8	to	O
9	a	O
10	NF1	O
11	/	O
12	CTF	O
13	site	O
14	was	O
15	localized	O
16	upstream	O
17	of	O
18	the	O
19	silencer	O
20	-	O
21	like	O
22	element	O
23	.	O
1	DNase	O
2	I	O
3	genomic	O
4	footprinting	O
5	revealed	O
6	that	O
7	the	O
8	c	B
9	-	O
10	Myb	O
11	site	O
12	is	O
13	occupied	O
14	in	O
15	a	O
16	tissue	O
17	-	O
18	specific	O
19	fashion	O
20	in	O
21	vivo	O
22	.	O
1	Subsequently	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	reexpression	O
8	of	O
9	the	O
10	r	O
11	-	O
12	PTPeta	O
13	gene	O
14	in	O
15	highly	O
16	malignant	O
17	rat	O
18	thyroid	O
19	cells	O
20	transformed	O
21	by	O
22	retroviruses	O
23	carrying	O
24	the	O
25	v	O
26	-	O
27	mos	O
28	and	O
29	v	O
30	-	O
31	ras	O
32	-	O
33	Ki	O
34	oncogenes	O
35	suppresses	O
36	their	O
37	malignant	O
38	phenotype	O
39	.	O
1	Unlike	O
2	the	O
3	mammalian	O
4	proteins	O
5	,	O
6	XFGF3	O
7	is	O
8	efficiently	O
9	secreted	O
10	as	O
11	a	O
12	Mr	O
13	31	O
14	,	O
15	000	O
16	glycoprotein	O
17	,	O
18	gp31	O
19	,	O
20	which	O
21	undergoes	O
22	proteolytic	O
23	cleavage	O
24	to	O
25	produce	O
26	an	O
27	NH2	O
28	-	O
29	terminally	O
30	truncated	O
31	product	O
32	,	O
33	gp27	O
34	.	O
1	The	O
2	objectives	O
3	of	O
4	the	O
5	present	O
6	study	O
7	were	O
8	to	O
9	evaluate	O
10	the	O
11	effects	O
12	of	O
13	adding	O
14	Equex	O
15	to	O
16	a	O
17	TRIS	O
18	-	O
19	extender	O
20	,	O
21	diluting	O
22	the	O
23	semen	O
24	in	O
25	1	O
26	or	O
27	2	O
28	steps	O
29	,	O
30	freezing	O
31	according	O
32	to	O
33	2	O
34	methods	O
35	,	O
36	thawing	O
37	at	O
38	2	O
39	rates	O
40	,	O
41	and	O
42	the	O
43	interactions	O
44	between	O
45	these	O
46	treatments	O
47	,	O
48	on	O
49	the	O
50	post	O
51	-	O
52	thaw	O
53	survival	O
54	of	O
55	dog	O
56	spermatozoa	O
57	at	O
58	38	O
59	degrees	O
60	C	O
61	.	O
1	Psychiatric	O
2	disorders	O
3	in	O
4	children	O
5	and	O
6	adolescents	O
7	carry	O
8	considerable	O
9	morbidity	O
10	,	O
11	impede	O
12	development	O
13	,	O
14	and	O
15	carry	O
16	a	O
17	significant	O
18	mortality	O
19	by	O
20	suicide	O
21	.	O
1	Children	O
2	with	O
3	ADD	O
4	showed	O
5	an	O
6	attenuated	O
7	frontal	O
8	CNV	O
9	-	O
10	1	O
11	amplitude	O
12	and	O
13	a	O
14	trend	O
15	towards	O
16	increased	O
17	CNV	O
18	-	O
19	1	O
20	and	O
21	CNV	O
22	-	O
23	2	O
24	occipital	O
25	amplitudes	O
26	.	O
1	Where	O
2	UMDNJ	O
3	is	O
4	headed	O
5	.	O
1	CONCLUSION	O
2	:	O
3	Our	O
4	results	O
5	suggest	O
6	that	O
7	AIF	O
8	peak	O
9	saturation	O
10	leads	O
11	to	O
12	a	O
13	significant	O
14	systematic	O
15	error	O
16	in	O
17	the	O
18	determination	O
19	of	O
20	CBV	O
21	and	O
22	CBF	O
23	values	O
24	and	O
25	has	O
26	necessarily	O
27	to	O
28	be	O
29	taken	O
30	into	O
31	account	O
32	for	O
33	dynamic	O
34	contrast	O
35	-	O
36	enhanced	O
37	MR	O
38	perfusion	O
39	studies	O
40	.	O
1	Furthermore	O
2	,	O
3	transfection	O
4	of	O
5	cells	O
6	with	O
7	the	O
8	spacer	O
9	-	O
10	RING	O
11	domain	O
12	alone	O
13	suppressed	O
14	the	O
15	antiapoptotic	O
16	function	O
17	of	O
18	the	O
19	N	O
20	-	O
21	terminal	O
22	BIR	O
23	domain	O
24	of	O
25	c	B
26	-	O
27	IAP1	O
28	and	O
29	induced	O
30	apoptosis	O
31	.	O
1	S6K2	O
2	is	O
3	highly	O
4	homologous	O
5	to	O
6	S6K1	O
7	in	O
8	the	O
9	core	O
10	kinase	B
11	and	O
12	linker	O
13	regulatory	O
14	domains	O
15	but	O
16	differs	O
17	from	O
18	S6K1	O
19	in	O
20	the	O
21	N	O
22	-	O
23	and	O
24	C	O
25	-	O
26	terminal	O
27	regions	O
28	and	O
29	is	O
30	differently	O
31	localized	O
32	primarily	O
33	to	O
34	the	O
35	nucleus	O
36	because	O
37	of	O
38	a	O
39	C	O
40	-	O
41	terminal	O
42	nuclear	O
43	localization	O
44	signal	O
45	unique	O
46	to	O
47	S6K2	O
48	.	O
1	Ketanserin	O
2	,	O
3	a	O
4	hypotensive	O
5	drug	O
6	with	O
7	5	O
8	-	O
9	HT2	O
10	receptor	B
11	antagonism	O
12	,	O
13	when	O
14	administered	O
15	by	O
16	topical	O
17	infusion	O
18	of	O
19	a	O
20	0	O
21	.	O
22	25	O
23	%	O
24	w	O
25	/	O
26	v	O
27	solution	O
28	by	O
29	corneal	O
30	and	O
31	scleral	O
32	applications	O
33	,	O
34	was	O
35	found	O
36	to	O
37	lower	O
38	intraocular	O
39	pressure	O
40	with	O
41	four	O
42	times	O
43	more	O
44	activity	O
45	than	O
46	its	O
47	metabolite	O
48	,	O
49	ketanserinol	O
50	.	O
1	Characterization	O
2	of	O
3	the	O
4	microtubule	O
5	binding	O
6	domain	O
7	of	O
8	microtubule	O
9	actin	O
10	crosslinking	O
11	factor	O
12	(	O
13	MACF	O
14	):	O
15	identification	O
16	of	O
17	a	O
18	novel	O
19	group	O
20	of	O
21	microtubule	O
22	associated	O
23	proteins	O
24	.	O
1	These	O
2	results	O
3	also	O
4	suggest	O
5	the	O
6	involvement	O
7	of	O
8	additional	O
9	elements	O
10	in	O
11	the	O
12	UPR	O
13	.	O
1	Here	O
2	we	O
3	show	O
4	in	O
5	mouse	O
6	fibroblasts	O
7	stably	O
8	transformed	O
9	by	O
10	v	O
11	-	O
12	Src	O
13	that	O
14	mRNA	O
15	and	O
16	protein	O
17	levels	O
18	of	O
19	p21	O
20	(	O
21	WAF1	O
22	/	O
23	CIP1	O
24	),	O
25	cyclin	B
26	D1	O
27	,	O
28	and	O
29	cyclin	B
30	E	O
31	are	O
32	elevated	O
33	.	O
1	Among	O
2	eight	O
3	graminaceous	O
4	species	O
5	tested	O
6	,	O
7	Ids3	O
8	expression	O
9	was	O
10	observed	O
11	only	O
12	in	O
13	Fe	O
14	-	O
15	deficient	O
16	roots	O
17	of	O
18	H	O
19	.	O
20	vulgare	O
21	and	O
22	Secale	O
23	cereale	O
24	.	O
25	which	O
26	not	O
27	only	O
28	secrete	O
29	2	O
30	'-	O
31	deoxymugineic	O
32	acid	O
33	(	O
34	DMA	O
35	),	O
36	but	O
37	also	O
38	mugineic	O
39	acid	O
40	(	O
41	MA	O
42	)	O
43	and	O
44	3	O
45	-	O
46	epihydroxymugineic	O
47	acid	O
48	(	O
49	epiHMA	O
50	,	O
51	H	O
52	.	O
53	vulgare	O
54	),	O
55	and	O
56	3	O
57	-	O
58	hydroxymugineic	O
59	acid	O
60	(	O
61	HMA	O
62	,	O
63	S	O
64	.	O
65	cereale	O
66	).	O
1	The	O
2	present	O
3	findings	O
4	revealed	O
5	that	O
6	the	O
7	rib	O
8	-	O
9	2	O
10	protein	O
11	was	O
12	a	O
13	unique	O
14	alpha1	O
15	,	O
16	4	O
17	-	O
18	N	O
19	-	O
20	acetylglucosaminyltransferase	O
21	involved	O
22	in	O
23	the	O
24	biosynthetic	O
25	initiation	O
26	and	O
27	elongation	O
28	of	O
29	heparan	O
30	sulfate	O
31	.	O
1	Current	O
2	evidence	O
3	for	O
4	this	O
5	type	O
6	of	O
7	DNA	O
8	supercoiling	O
9	-	O
10	dependent	O
11	transcriptional	O
12	coupling	O
13	,	O
14	based	O
15	largely	O
16	on	O
17	the	O
18	in	O
19	vivo	O
20	activities	O
21	of	O
22	promoters	O
23	contained	O
24	in	O
25	engineered	O
26	DNA	O
27	constructs	O
28	,	O
29	suggests	O
30	that	O
31	the	O
32	transcription	O
33	complex	O
34	must	O
35	be	O
36	physically	O
37	hindered	O
38	to	O
39	generate	O
40	DNA	O
41	supercoils	O
42	and	O
43	to	O
44	prevent	O
45	their	O
46	diffusion	O
47	throughout	O
48	the	O
49	DNA	O
50	duplex	O
51	.	O
1	Bupropion	O
2	to	O
3	aid	O
4	smoking	O
5	cessation	O
6	.	O
1	Using	O
2	a	O
3	natural	O
4	dominant	O
5	negative	O
6	for	O
7	AP	B
8	-	O
9	1	O
10	transcriptional	O
11	activity	O
12	in	O
13	ROS	O
14	17	O
15	/	O
16	2	O
17	.	O
18	8	O
19	cells	O
20	,	O
21	we	O
22	then	O
23	showed	O
24	that	O
25	AP	B
26	-	O
27	1	O
28	transcription	O
29	factors	O
30	mediated	O
31	TGF	O
32	-	O
33	beta1	O
34	-	O
35	and	O
36	BMP	O
37	-	O
38	2	O
39	-	O
40	regulated	O
41	expression	O
42	of	O
43	the	O
44	(	O
45	alpha1	O
46	)	O
47	collagen	O
48	I	O
49	gene	O
50	as	O
51	well	O
52	as	O
53	TGF	O
54	-	O
55	beta1	O
56	-	O
57	regulated	O
58	expression	O
59	of	O
60	the	O
61	parathyroid	O
62	hormone	O
63	(	O
64	PTH	O
65	)/	O
66	PTH	O
67	-	O
68	related	O
69	peptide	O
70	(	O
71	PTHrP	O
72	)	O
73	receptor	B
74	.	O
1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	O
13	interleukin	O
14	-	O
15	6	O
16	(	O
17	IL	B
18	-	O
19	6	O
20	)	O
21	levels	O
22	in	O
23	gingival	O
24	crevicular	O
25	fluid	O
26	(	O
27	GCF	O
28	)	O
29	and	O
30	clinical	O
31	periodontal	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	periodontitis	O
44	(	O
45	AP	B
46	).	O
1	The	O
2	murine	O
3	int	O
4	-	O
5	6	O
6	locus	O
7	,	O
8	identified	O
9	as	O
10	a	O
11	frequent	O
12	integration	O
13	site	O
14	of	O
15	mouse	O
16	mammary	O
17	tumor	O
18	viruses	O
19	,	O
20	encodes	O
21	the	O
22	48	O
23	-	O
24	kDa	O
25	eIF3e	O
26	subunit	O
27	of	O
28	translation	O
29	initiation	O
30	factor	O
31	eIF3	O
32	.	O
1	PFK	O
2	-	O
3	A	O
4	mRNA	O
5	was	O
6	more	O
7	abundantly	O
8	expressed	O
9	in	O
10	all	O
11	tissues	O
12	than	O
13	were	O
14	the	O
15	PFK	O
16	-	O
17	B	O
18	and	O
19	PFK	O
20	-	O
21	C	O
22	genes	O
23	.	O
1	The	O
2	molecular	O
3	associations	O
4	dictating	O
5	INCENP	O
6	behavior	O
7	during	O
8	mitosis	O
9	are	O
10	currently	O
11	unknown	O
12	.	O
1	Because	O
2	the	O
3	high	O
4	-	O
5	density	O
6	lipoprotein	O
7	receptor	B
8	(	O
9	HDL	O
10	-	O
11	R	O
12	)	O
13	is	O
14	a	O
15	key	O
16	element	O
17	in	O
18	cholesterol	O
19	homeostasis	O
20	and	O
21	a	O
22	potential	O
23	therapeutic	O
24	target	O
25	for	O
26	hypercholesterolemic	O
27	drugs	O
28	,	O
29	an	O
30	understanding	O
31	of	O
32	HDL	O
33	-	O
34	R	O
35	regulation	O
36	is	O
37	essential	O
38	.	O
1	We	O
2	have	O
3	therefore	O
4	studied	O
5	the	O
6	molecular	O
7	mechanisms	O
8	of	O
9	TGF	O
10	-	O
11	beta1	O
12	action	O
13	on	O
14	thyroglobulin	O
15	(	O
16	TG	O
17	)	O
18	gene	O
19	expression	O
20	by	O
21	focusing	O
22	our	O
23	attention	O
24	on	O
25	TGF	O
26	-	O
27	beta1	O
28	regulation	O
29	of	O
30	thyroid	O
31	-	O
32	specific	O
33	transcription	O
34	factors	O
35	.	O
